The	O
pharmacologic	O
and	O
behavioral	O
characteristics	O
that	O
determine	O
tobacco	O
addiction	O
are	O
similar	O
to	O
those	O
drugs	O
such	O
as	O
heroin	B-Drug
cocaine.	O
cocaine	B-Drug

Diclazepam	B-Drug
(Ro5-3448),	O
also	O
known	O
as	O
chlorodiazepam	O
and	O
2'-chloro-diazepam,	O
is	O
a	O
benzodiazepine	O
functional	O
analog	O
of	O
diazepam.	O
diazepam	B-Drug

This	O
is	O
almost	O
always	O
in	O
ester	O
form;	O
for	O
instance,	O
the	O
case	O
of	O
nandrolone,	O
as	O
nandrolone	B-Drug
decanoate	I-Drug
or	O
phenylpropionate.	O
phenylpropionate	I-Drug

In	O
addition	O
to	O
opium,	O
Afghanistan	O
is	O
also	O
the	O
world's	O
leading	O
producer	O
of	O
hashish.	O
opium	B-Drug
hashish	B-Drug

Yopo	O
snuff	B-Drug
is	O
usually	O
blown	O
into	O
the	O
user's	O
nostrils	O
by	O
another	O
person	O
through	O
bamboo	O
tubes	O
or	O
sometimes	O
snuffed	O
user	O
using	O
bird	O
bone	O
tubes.	O

There	O
is	O
some	O
evidence	O
clozapine	B-Drug
may	O
reduce	O
propensity	O
for	O
substance	O
abuse	O
in	O
schizophrenic	O
patients.	O

Although	O
the	O
CYP2D6	O
genotype	O
and	O
route	O
of	O
administration	O
result	O
in	O
differential	O
rates	O
oxymorphone	B-Drug
formation,	O
unchanged	O
parent	O
compound	O
remains	O
major	O
contributor	O
to	O
overall	O
analgesic	O
effect	O
oxycodone.	O
oxycodone	B-Drug

cocaine,	O
cannabis	O
Something	O
Weird	O
(1967)	O
cocaine	B-Drug

FDA-approved	O
and	O
commercially	O
available	O
bupropion	B-Drug
is	O
racemic.	O

As	O
with	O
other	O
pure-opioid	O
agonists,	O
fentanyl	B-Drug
can	O
be	O
associated	O
dysphoria	O
in	O
both	O
dogs	O
and	O
cats.	O

In	O
1964,	O
the	O
Brain	O
Committee	O
recommended	O
that	O
only	O
selected	O
approved	O
doctors	O
working	O
at	O
specialized	O
centres	O
be	O
allowed	O
to	O
prescribe	O
diamorphine	B-Drug
and	O
cocaine	B-Drug
users.	O

No	O
significant	O
drug	O
interactions	O
have	O
been	O
observed	O
between	O
finasteride	B-Drug
and	O
a	O
limited	O
selection	O
of	O
medications.	O

In	O
2011,	O
21,649	O
emergency	O
room	O
visits	O
in	O
the	O
United	O
States	O
were	O
related	O
to	O
tramadol.	O
tramadol	B-Drug

Neulastim	O
(pegfilgrastim),	O
for	O
neutropenia.	O
pegfilgrastim	B-Drug

Evidently,	O
resorting	O
to	O
this	O
means	O
of	O
gaining	O
income	O
gave	O
France	O
a	O
vested	O
interest	O
in	O
the	O
continuation	O
opium	B-Drug
use	O
among	O
population	O
Indochina.	O

In	O
some	O
countries	O
such	O
as	O
the	O
United	O
States,	O
Australia,	O
and	O
New	O
Zealand,	O
all	O
of	O
these	O
compounds	O
would	O
be	O
considered	O
controlled	O
substance	O
analogs	O
PCP	B-Drug
under	O
Federal	O
Analog	O
Act	O
are	O
hence	O
illegal	O
drugs	O
if	O
sold	O
for	O
human	O
consumption.	O

The	O
main	O
pharmacological	O
effects	O
of	O
triazolam	B-Drug
are	O
the	O
enhancement	O
neurotransmitter	O
GABA	O
at	O
GABAA	O
receptor.	O

While	O
the	O
synthetic	O
anabolic	O
steroid	O
testosterone	O
cypionate	O
was	O
found	O
in	O
his	O
urine,	O
there	O
no	O
evidence	O
of	O
GHB	B-Drug
contrary	O
to	O
speculation.	O

There	O
has	O
been	O
differential	O
reporting	O
on	O
how	O
white	O
suburban	O
or	O
rural	O
addicts	O
of	O
opioids	O
are	O
portrayed	O
compared	O
to	O
black	O
and	O
Hispanic	O
urban	O
addicts,	O
often	O
heroin,	O
reinforcing	O
stereotypes	O
drug	O
users	O
drug-using	O
offenders.	O
heroin	B-Drug

Approved	O
for	O
medical	O
use	O
in	O
the	O
United	O
States	O
2004,	O
eszopiclone	B-Drug
is	O
available	O
as	O
generic	O
medication.	O

For	O
this	O
reason,	O
shorter	O
acting	O
agents	O
such	O
as	O
alfentanyl	O
or	O
remifentanil	B-Drug
may	O
be	O
more	O
suitable	O
in	O
the	O
context	O
of	O
inducing	O
general	O
anaesthesia.	O

Drug	O
rash	O
and	O
drug-induced	O
eosinophilia	O
with	O
systemic	O
symptoms	O
is	O
a	O
known	O
complication	O
of	O
tetrazepam	B-Drug
exposure.	O

In	O
1964,	O
Israeli	O
physician	O
Jacob	O
Sheskin	O
administered	O
thalidomide	B-Drug
to	O
a	O
patient	O
critically	O
ill	O
with	O
leprosy.	O

Oxycodone	B-Drug
(dihydrohydroxycodeinone)	O
Oxymorphone	B-Drug
(dihydrohydroxymorphinone)	O

Trials	O
in	O
emergency	O
department	O
settings	O
support	O
the	O
use	O
of	O
ondansetron	B-Drug
to	O
reduce	O
vomiting	O
associated	O
with	O
gastroenteritis	O
and	O
dehydration.	O

According	O
to	O
an	O
Associated	O
Press	O
article	O
from	O
2016,	O
"Chemical	O
weapon	O
for	O
sale:	O
China's	O
unregulated	O
narcotic",	O
fentanyl,	O
carfentanil	B-Drug
and	O
other	O
highly	O
potent	O
derivatives	O
of	O
fentanyl	B-Drug
were	O
actively	O
marketed	O
by	O
several	O
Chinese	O
chemical	O
companies.	O

Isoquinolines	O
such	O
as	O
papaverine	B-Drug
and	O
noscapine	B-Drug
have	O
no	O
significant	O
central	O
nervous	O
system	O
effects.	O

Less	O
common	O
analogs	O
include	O
3-HO-PCP,	O
3-MeO-PCMo,	O
and	O
3-MeO-PCP.	O
3-HO-PCP	B-Drug
3-MeO-PCMo	B-Drug
3-MeO-PCP	B-Drug

Selegiline	B-Drug
itself	O
has	O
neuroprotective	O
and	O
neuro-rescuing	O
effects,	O
but	O
concern	O
over	O
the	O
resulting	O
levomethamphetamine's	O
neurotoxicity	O
led	O
to	O
development	O
of	O
alternative	O
MAOB	O
inhibitors,	O
such	O
as	O
rasagiline,	O
that	O
do	O
not	O
produce	O
toxic	O
metabolites.	O
levomethamphetamine	B-Drug
rasagiline	B-Drug

Primarily,	O
fentanyl	B-Drug
provides	O
the	O
relief	O
of	O
pain	O
by	O
acting	O
on	O
brain	O
and	O
spinal	O
-receptors.	O

In	O
2014	O
actress	O
Skye	O
McCole	O
Bartusiak	O
died	O
of	O
an	O
overdose	O
due	O
to	O
the	O
combined	O
effects	O
carisoprodol,	O
hydrocodone	B-Drug
and	O
difluoroethane.	O
carisoprodol	B-Drug

Trimethoprim	B-Drug
has	O
been	O
used	O
in	O
trials	O
to	O
treat	O
retinitis.	O

Clomifene	B-Drug
is	O
a	O
prodrug	O
being	O
activated	O
via	O
similar	O
metabolic	O
pathways	O
as	O
the	O
related	O
triphenylethylene	O
SERMs	O
tamoxifen	B-Drug
and	O
toremifene.	O

According	O
to	O
the	O
U.S.	O
Drug	O
Enforcement	O
Administration	O
(DEA),	O
suvorexant	B-Drug
produces	O
similar	O
reinforcing	O
effects	O
those	O
of	O
zolpidem	B-Drug
and	O
thus	O
may	O
have	O
a	O
abuse	O
liability.	O

Other	O
GABAA	O
NAMs,	O
mostly	O
non-selective,	O
include	O
amentoflavone,	O
bemegride,	O
bilobalide,	O
cicutoxin,	O
dieldrin,	O
FG-7142,	O
fipronil,	O
flurothyl,	O
iomazenil,	O
laudanosine,	O
lindane,	O
oenanthotoxin,	O
pentylenetetrazol,	O
phenylsilatrane,	O
picrotoxin,	O
radequinil,	O
Ro15-4513,	O
sarmazenil,	O
suritozole,	O
terbequinil,	O
tetramethylenedisulfotetramine	O
(TETS),	O
and	O
ZK-93426	O
as	O
well	O
the	O
endogenous	O
neurosteroids	O
dehydroepiandrosterone	O
sulfate	O
(DHEA-S),	O
pregnenolone	O
sulfate,	O
epipregnanolone,	O
isopregnanolone.	O
bemegride	B-Drug

Vinylbital	B-Drug
(	O

Monoamine	O
oxidase	O
inhibitors	O
(MAOIs)	O
and	O
thiazide	O
diuretics	O
may	O
also	O
accentuate	O
the	O
orthostatic	O
hypotension	O
experienced	O
by	O
those	O
receiving	O
chlorpromazine	B-Drug
treatment.	O

Dextroamphetamine	B-Drug
sulfate	O
is	O
the	O
most	O
common	O
enantiopure	O
salt.	O

As	O
such,	O
finasteride	B-Drug
is	O
a	O
type	O
of	O
antiandrogen,	O
or	O
more	O
specifically,	O
an	O
androgen	O
synthesis	O
inhibitor.	O

Excessive	O
doses	O
of	O
methylphenidate,	O
above	O
the	O
therapeutic	O
range,	O
can	O
interfere	O
with	O
working	O
memory	O
and	O
cognitive	O
control.	O
methylphenidate	B-Drug

MDMA	B-Drug
is	O
unpredictable	O
and	O
produces	O
different	O
responses	O
in	O
people.	O

However,	O
the	O
long	O
term	O
side	O
effects	O
common	O
with	O
oral	O
contraceptives	O
such	O
as	O
arterial	O
disease	O
are	O
lower	O
levonorgestrel	B-Drug
than	O
in	O
combination	O
pills.	O

inhibitors	O
will	O
prolong	O
the	O
elimination	O
half-life	O
of	O
methamphetamine.	O
methamphetamine	B-Drug

Ketamine	B-Drug
can	O
be	O
absorbed	O
by	O
many	O
different	O
routes	O
due	O
to	O
both	O
its	O
water	O
and	O
lipid	O
solubility.	O

Apalutamide	B-Drug
acts	O
as	O
a	O
selective	O
competitive	O
silent	O
antagonist	O
of	O
the	O
androgen	O
receptor	O
(AR),	O
via	O
ligand-binding	O
domain,	O
and	O
hence	O
is	O
an	O
antiandrogen.	O

In	O
2009,	O
one	O
case	O
of	O
sympathomimetic	O
toxicity	O
was	O
reported	O
in	O
the	O
UK	O
after	O
a	O
person	O
took	O
0.2	O
g	O
mephedrone	B-Drug
orally,	O
and	O
this	O
did	O
not	O
achieve	O
desired	O
effect,	O
subcutaneously	O
injected	O
3.8	O
mixed	O
with	O
water	O
into	O
his	O
thighs.	O

JWH-018	B-Drug
has	O
an	O
EC50	O
of	O
102	O
nM	O
for	O
human	O
CB1	O
receptors,	O
and	O
133	O
CB2	O
receptors.	O

Finasteride	B-Drug
is	O
marketed	O
primarily	O
under	O
the	O
brand	O
names	O
Propecia,	O
for	O
pattern	O
hair	O
loss,	O
and	O
Proscar,	O
BPH,	O
both	O
of	O
which	O
are	O
products	O
Merck	O
&	O
Propecia	B-Drug
Proscar	B-Drug

On	O
January	O
19,	O
2018,	O
the	O
medical	O
examiner-coroner	O
for	O
county	O
of	O
Los	O
Angeles	O
said	O
musician	O
Tom	O
Petty	O
died	O
from	O
an	O
accidental	O
drug	O
overdose	O
as	O
a	O
result	O
mixing	O
medications	O
that	O
included	O
fentanyl,	O
acetyl	O
fentanyl	B-Drug
and	O
despropionyl	O
(among	O
others).	O

In	O
combination	O
with	O
Clidinium	O
as	O
NORMAXIN-CC	O
and	O
in	O
dicyclomine	B-Drug
NORMAXIN	O
for	O
IBS,	O
the	O
anti-depressant	O
Amitriptyline	B-Drug
Limbitrol.	O
Limbitrol	B-Drug

At	O
therapeutic	O
doses,	O
amphetamine	B-Drug
causes	O
emotional	O
and	O
cognitive	O
effects	O
such	O
as	O
euphoria,	O
change	O
in	O
desire	O
for	O
sex,	O
increased	O
wakefulness,	O
improved	O
control.	O

It	O
includes	O
heroin,	O
cannabis,	O
psilocybin,	O
khat,	O
LSD,	O
ecstasy	B-Drug
and	O
other	O
ecstasy-related	O
substances.	O
heroin	B-Drug
LSD	B-Drug

NMDA	O
receptor	O
antagonists	O
such	O
as	O
ketamine	B-Drug
SNRIs	O
milnacipran	B-Drug
Anticonvulsants	O
gabapentin	B-Drug
or	O
pregabalin	B-Drug
Clinical	O
studies	O
have	O
consistently	O
associated	O
medical	O
and	O
recreational	O
opioid	O
use	O
with	O
hypogonadism	O
(low	O
sex	O
hormone	O
levels)	O
in	O
different	O
sexes.	O

That	O
problem,	O
however	O
serious,	O
therefore	O
does	O
not	O
'warrant'	O
the	O
placing	O
of	O
tobacco	B-Drug
'under	O
international'	O
control,	O
i.e.	O
under	O
Vienna	O
Convention.	O

The	O
physical	O
dependence	O
and	O
withdrawal	O
syndrome	O
of	O
Nimetazepam	B-Drug
also	O
adds	O
to	O
the	O
addictive	O
nature	O
Nimetazepam.	O

A	O
massive	O
destruction	O
of	O
opium	B-Drug
by	O
an	O
emissary	O
the	O
Chinese	O
Daoguang	O
Emperor	O
in	O
attempt	O
to	O
stop	O
smuggling	O
led	O
First	O
Opium	O
War	O
(18391842),	O
which	O
Britain	O
defeated	O
China.	O

In	O
spite	O
of	O
this,	O
salbutamol	B-Drug
required	O
"a	O
declaration	O
Use	O
in	O
accordance	O
with	O
the	O
International	O
Standard	O
for	O
Therapeutic	O
Exemptions"	O
under	O
2010	O
WADA	O
prohibited	O
list.	O

On	O
June	O
10,	O
2014	O
the	O
UK	O
Advisory	O
Council	O
on	O
Misuse	O
of	O
Drugs	O
(ACMD)	O
recommended	O
that	O
PRO-LAD	B-Drug
be	O
specifically	O
named	O
in	O
Act	O
as	O
a	O
class	O
A	O
drug	O
despite	O
not	O
identifying	O
it	O
ever	O
having	O
been	O
sold	O
or	O
any	O
harm	O
associated	O
with	O
its	O
use.	O

Oxycodone	B-Drug
and/or	O
its	O
major	O
metabolites	O
may	O
be	O
measured	O
in	O
blood	O
or	O
urine	O
to	O
monitor	O
for	O
clearance,	O
abuse,	O
confirm	O
a	O
diagnosis	O
of	O
poisoning,	O
assist	O
medicolegal	O
death	O
investigation.	O

The	O
U.S.	O
Central	O
Intelligence	O
Agency	O
(CIA)	O
became	O
interested	O
in	O
LSD	B-Drug
when	O
they	O
read	O
reports	O
alleging	O
that	O
American	O
prisoners	O
during	O
the	O
Korean	O
War	O
were	O
being	O
brainwashed	O
with	O
use	O
of	O
some	O
sort	O
drug	O
or	O
lie	O
serum.	O

FDU-PB-22	B-Drug
acts	O
as	O
a	O
full	O
agonist	O
with	O
binding	O
affinity	O
of	O
1.19nM	O
at	O
CB1	O
and	O
2.43nM	O
CB2	O
cannabinoid	O
receptors.	O

Methyltestosterone	B-Drug
should	O
be	O
used	O
with	O
caution	O
in	O
women	O
and	O
children,	O
as	O
it	O
can	O
cause	O
irreversible	O
virilization.	O

Also,	O
cross-sensitization	O
is	O
not	O
unique	O
to	O
marijuana.	O
marijuana	B-Drug

Believing	O
MDMA	B-Drug
allowed	O
users	O
to	O
strip	O
away	O
habits	O
and	O
perceive	O
the	O
world	O
clearly,	O
Shulgin	O
called	O
drug	O
window.	O

Carisoprodol	B-Drug
was	O
a	O
modification	O
of	O
meprobamate,	O
intended	O
to	O
have	O
better	O
muscle	O
relaxing	O
properties,	O
less	O
potential	O
for	O
abuse,	O
and	O
risk	O
overdose.	O
meprobamate	B-Drug

In	O
Canada,	O
fentanyl	B-Drug
is	O
considered	O
a	O
Schedule	O
I	O
drug	O
as	O
listed	O
in	O
Canada's	O
Controlled	O
Drugs	O
and	O
Substances	O
Act.	O

Use	O
of	O
alcohol	O
or	O
other	O
CNS	O
depressants	O
while	O
taking	O
clonazepam	B-Drug
greatly	O
intensifies	O
the	O
effects	O
(and	O
side	O
effects)	O
drug.	O

Among	O
this	O
group,	O
the	O
most	O
closely	O
related	O
compounds	O
are	O
phenethylamine,	O
parent	O
compound	O
of	O
amphetamine,	O
and	O
N-methylphenethylamine,	O
an	O
isomer	O
amphetamine	B-Drug
(i.e.,	O
it	O
has	O
identical	O
molecular	O
formula).	O
phenethylamine	B-Drug

At	O
sub-anesthetic	O
doses,	O
dissociatives	O
alter	O
many	O
of	O
the	O
same	O
cognitive	O
and	O
perceptual	O
processes	O
affected	O
by	O
other	O
hallucinogenic	O
drugs	O
such	O
as	O
mescaline,	O
LSD,	O
psilocybin;	O
hence	O
they	O
are	O
also	O
considered	O
hallucinogenic,	O
psychedelic.	O
mescaline	B-Drug
LSD	B-Drug

The	O
topical	O
use	O
of	O
higher	O
concentration	O
(1020%)	O
benzocaine	B-Drug
products	O
applied	O
to	O
the	O
mouth	O
or	O
mucous	O
membranes	O
has	O
been	O
found	O
be	O
a	O
cause	O
methemoglobinemia,	O
disorder	O
in	O
which	O
amount	O
oxygen	O
carried	O
by	O
blood	O
is	O
greatly	O
reduced.	O

ETH-LAD	B-Drug
is	O
a	O
psychedelic	O
drug	O
similar	O
to	O
LSD,	O
and	O
slightly	O
more	O
potent	O
than	O
LSD	B-Drug
itself,	O
with	O
an	O
active	O
dose	O
reported	O
at	O
between	O
20	O
150	O
micrograms.	O

Vicoprofen	O
combines	O
the	O
analgesic	O
and	O
antitussive	O
properties	O
of	O
hydrocodone	B-Drug
with	O
analgesic,	O
anti-inflammatory,	O
antipyretic	O
ibuprofen.	O
ibuprofen	B-Drug

Epidural	O
diamorphine	B-Drug
(2.55	O
mg)	O
is	O
a	O
suitable	O
alternative.	O

Claims	O
of	O
subjective	O
differences	O
in	O
effects	O
between	O
the	O
acetylated	O
and	O
non-acetylated	O
forms	O
psilocin	B-Drug
vary:	O
some	O
users	O
report	O
that	O
O-acetylpsilocin	B-Drug
lasts	O
slightly	O
longer,	O
whilst	O
others	O
it	O
for	O
a	O
considerably	O
shorter	O
time.	O

The	O
term	O
was	O
introduced	O
by	O
David	O
F.	O
Duncan	O
and	O
Robert	O
S.	O
Gold	O
to	O
distinguish	O
these	O
drugs	O
from	O
psychedelics	O
dissociatives,	O
such	O
as	O
LSD	B-Drug
ketamine	B-Drug
respectively,	O
due	O
their	O
primary	O
effect	O
of	O
causing	O
delirium,	O
opposed	O
the	O
more	O
lucid	O
states	O
produced	O
other	O
hallucinogens.	O

The	O
level	O
of	O
needle	O
sharing	O
among	O
methamphetamine	B-Drug
users	O
is	O
similar	O
to	O
that	O
other	O
drug	O
injection	O
users.	O

Fentanyl	B-Drug
analogs	O
have	O
killed	O
hundreds	O
of	O
people	O
throughout	O
Europe	O
and	O
the	O
former	O
Soviet	O
republics	O
since	O
most	O
recent	O
resurgence	O
in	O
use	O
began	O
Estonia	O
early	O
2000s,	O
novel	O
derivatives	O
continue	O
to	O
appear.	O

Metenolone	O
enanthate,	O
or	O
methenolone	B-Drug
sold	O
under	O
the	O
brand	O
names	O
Primobolan	O
Depot	O
and	O
Nibal	O
Injection,	O
is	O
an	O
androgen	O
anabolic	O
steroid	O
(AAS)	O
medication	O
which	O
used	O
mainly	O
in	O
treatment	O
of	O
anemia	O
due	O
to	O
bone	O
marrow	O
failure.	O

A	O
fentanyl	B-Drug
patient-controlled	O
transdermal	O
system	O
(PCTS)	O
is	O
under	O
development,	O
which	O
aims	O
to	O
allow	O
patients	O
control	O
administration	O
of	O
through	O
the	O
skin	O
treat	O
postoperative	O
pain.	O

This	O
adverse	O
effect	O
is	O
not	O
unique	O
to	O
zolpidem,	O
but	O
also	O
occurs	O
with	O
other	O
hypnotic	O
drugs.	O
zolpidem	B-Drug

The	O
product	O
came	O
in	O
1.5ml	O
ampoules	O
consisting	O
of	O
76.2mg	O
Trenbolone	B-Drug
hexahydrobenzylcaronate	O
and	O
made	O
by	O
Negma	O
Pharmaceuticals	O
France.	O

Ibuprofen	B-Drug
is	O
also	O
an	O
extremely	O
rare	O
cause	O
of	O
toxic	O
epidermal	O
necrolysis.	O

A	O
few	O
of	O
the	O
metabolites	O
oxycodone	B-Drug
have	O
also	O
been	O
found	O
to	O
be	O
active	O
as	O
MOR	O
agonists,	O
some	O
which	O
notably	O
much	O
higher	O
affinity	O
for	O
(as	O
well	O
efficacy	O
at)	O
in	O
comparison.	O

is	O
therefore	O
no	O
longer	O
preferred;	O
phenothiazines	O
are	O
particularly	O
risky,	O
as	O
they	O
may	O
lower	O
the	O
seizure	O
threshold,	O
worsen	O
hyperthermia,	O
and	O
boost	O
anticholinergic	O
effects	O
of	O
PCP.	O
PCP	B-Drug

According	O
to	O
the	O
Victorian	O
Premier's	O
Drug	O
Advisory	O
Council	O
in	O
1899,	O
there	O
were	O
three	O
main	O
"classes"	O
of	O
opium	B-Drug
users.	O

Other	O
phenethylamines	O
that	O
share	O
this	O
structure	O
include	O
the	O
stimulants	O
methcathinone,	O
MDPV,	O
mephedrone	B-Drug
and	O
antidepressant	O
bupropion.	O
methcathinone	B-Drug
MDPV	B-Drug
bupropion	B-Drug

The	O
antidote	O
for	O
belladonna	O
poisoning	O
is	O
an	O
anticholinesterase	O
(such	O
as	O
physostigmine	B-Drug
or	O
pilocarpine),	O
the	O
same	O
atropine.	O
pilocarpine	B-Drug

The	O
FSA	O
further	O
recommended	O
that	O
healthy	O
adults	O
should	O
not	O
consume	O
more	O
than	O
70	O
mg	O
CBD	B-Drug
per	O
day.	O

In	O
December	O
2002,	O
a	O
study	O
by	O
RAND	O
investigating	O
whether	O
cannabis	O
use	O
results	O
in	O
the	O
subsequent	O
of	O
cocaine	B-Drug
and	O
heroin	B-Drug
was	O
published	O
British	O
Journal	O
Addiction.	O

The	O
officers	O
said	O
the	O
cups	O
and	O
bottle	O
all	O
emitted	O
"strong	O
odors	O
of	O
codeine"	O
even	O
though	O
codeine	B-Drug
is	O
odorless	O
according	O
to	O
National	O
Institutes	O
Health.	O

Moreover,	O
spirorenone	O
itself	O
has	O
virtually	O
no	O
affinity	O
for	O
the	O
androgen	O
receptor	O
while	O
its	O
progestogenic	O
activity	O
shows	O
species	O
differences,	O
being	O
somewhat	O
greater	O
than	O
that	O
of	O
spironolactone	B-Drug
in	O
rabbits	O
but	O
absent	O
mice	O
and	O
rats.	O

The	O
problem	O
was	O
that	O
amphetamine	B-Drug
leads	O
to	O
a	O
lack	O
of	O
judgement	O
and	O
willingness	O
take	O
risks,	O
which	O
in	O
sport	O
could	O
lead	O
better	O
performances	O
but	O
fighters	O
bombers	O
led	O
more	O
crash	O
landings	O
than	O
the	O
RAF	O
tolerate.	O

Furthermore,	O
both	O
psychostimulants,	O
MDPV	B-Drug
and	O
cocaine,	O
restore	O
drug-seeking	O
behavior	O
with	O
respect	O
to	O
each	O
other,	O
although	O
relapse	O
into	O
drug-taking	O
cocaine	B-Drug

Due	O
to	O
its	O
potency	O
and	O
much	O
lower	O
cost	O
than	O
so-called	O
classical	O
or	O
traditional	O
psychedelics,	O
25I-NBOMe	B-Drug
blotters	O
are	O
sometimes	O
misrepresented	O
as,	O
mistaken	O
for,	O
LSD	B-Drug
blotters.	O

Side	O
effects	O
of	O
triamcinolone	B-Drug
are	O
similar	O
to	O
other	O
corticoids.	O

Moreover,	O
in	O
spite	O
of	O
being	O
off-patent,	O
bicalutamide	B-Drug
was	O
said	O
to	O
still	O
generate	O
a	O
few	O
hundred	O
million	O
dollars	O
sales	O
per	O
year	O
for	O
AstraZeneca.	O

It	O
is	O
a	O
selective	O
androgen	O
receptor	O
antagonist	O
with	O
reduced	O
brain	O
distribution	O
compared	O
to	O
the	O
structurally	O
related	O
nonsteroidal	O
antiandrogen	O
enzalutamide.	O
enzalutamide	B-Drug

Norgestrel,	O
sold	O
under	O
the	O
brand	O
name	O
Ovral	O
among	O
others,	O
is	O
a	O
progestin	O
medication	O
which	O
used	O
in	O
birth	O
control	O
pills	O
and	O
menopausal	O
hormone	O
therapy.	O
Norgestrel	B-Drug

They	O
described	O
a	O
patient	O
whose	O
delusion	O
was	O
thought	O
to	O
be	O
caused	O
by	O
an	O
altered	O
state	O
of	O
consciousness	O
"brought	O
on	O
LSD	B-Drug
and	O
strychnine	O
continued	O
casual	O
marijuana	O
use.	O

The	O
absorption	O
of	O
cathinone	B-Drug
has	O
two	O
phases:	O
one	O
in	O
the	O
buccal	O
mucosa	O
and	O
stomach	O
small	O
intestine.	O

Cannabidiol	B-Drug
is	O
not	O
scheduled	O
under	O
the	O
Convention	O
on	O
Psychotropic	O
Substances	O
or	O
any	O
other	O
UN	O
drug	O
treaties.	O

Fentanyl	B-Drug
analogs	O
have	O
killed	O
hundreds	O
of	O
people	O
throughout	O
Europe	O
and	O
the	O
former	O
Soviet	O
republics	O
since	O
most	O
recent	O
resurgence	O
in	O
use	O
began	O
Estonia	O
early	O
2000s,	O
novel	O
derivatives	O
continue	O
to	O
appear.	O

Ivacaftor	B-Drug
is	O
extensively	O
metabolised	O
in	O
humans.	O

Methylphenidate	B-Drug
has	O
the	O
potential	O
to	O
induce	O
euphoria	O
due	O
its	O
pharmacodynamic	O
effect	O
(i.e.,	O
dopamine	O
reuptake	O
inhibition)	O
in	O
brain's	O
reward	O
system.	O

It	O
is	O
also	O
available	O
as	O
the	O
combination	O
naproxen/esomeprazole	B-Drug
magnesium	I-Drug
in	O
delayed	O
release	O
tablets	O
under	O
brand	O
name	O
Vimovo.	O

After	O
the	O
withdrawal	O
of	O
rofecoxib	O
from	O
market	O
in	O
September	O
2004,	O
celecoxib	B-Drug
enjoyed	O
a	O
robust	O
increase	O
sales.	O

Psilocybin	O
(O-phosphoryl-4-hydroxy-N,N-dimethyltryptamine,	O
4-PO-Psilocin,	O
or	O
4-PO-HO-DMT)	O
is	O
a	O
prodrug	O
that	O
converted	O
into	O
the	O
pharmacologically	O
active	O
compound	O
psilocin	B-Drug
in	O
body	O
by	O
dephosphorylation	O
reaction.	O

In	O
2018	O
the	O
federal	O
farm	O
bill	O
was	O
passed	O
allowing	O
any	O
hemp	O
derived	O
product	O
not	O
exceeding	O
0.3%	O
-9	O
THC	B-Drug
to	O
be	O
sold	O
legally.	O

Clomifene	B-Drug
activates	O
the	O
ER	O
in	O
setting	O
of	O
low	O
baseline	O
estrogen	O
levels	O
and	O
partially	O
blocks	O
receptor	O
context	O
high	O
levels.	O

Many	O
overdose	O
experiences	O
are	O
reported	O
in	O
the	O
medical	O
literature,	O
although	O
frequency	O
of	O
life-threatening	O
complications	O
from	O
ibuprofen	B-Drug
is	O
low.	O

Oxycodone,	O
like	O
other	O
opioid	O
analgesics,	O
tends	O
to	O
induce	O
feelings	O
of	O
euphoria,	O
relaxation	O
and	O
reduced	O
anxiety	O
in	O
those	O
who	O
are	O
occasional	O
users.	O
Oxycodone	B-Drug

At	O
steady-state	O
with	O
1	O
mg/day	O
finasteride,	O
mean	O
peak	O
concentrations	O
of	O
finasteride	B-Drug
were	O
9.2	O
ng/mL	O
(25	O
nmol/L).	O

Only	O
six	O
formal	O
studies	O
on	O
the	O
applications	O
of	O
LSD	B-Drug
occurred	O
between	O
1990	O
and	O
2017.	O

Much	O
of	O
the	O
cocaine	B-Drug
is	O
smuggled	O
from	O
Colombia	O
and	O
Mexico	O
via	O
Jamaica.	O

Schultes	O
and	O
colleges	O
(1977)	O
examined	O
a	O
120-year-old	O
bean	O
collection	O
found	O
0.6%	O
bufotenin	B-Drug
with	O
no	O
DMT	O
or	O
5-MeO-DMT	B-Drug
present	O
at	O
all.	O

Relative	O
to	O
inhaled	O
consumption,	O
peak	O
concentration	O
of	O
oral	O
THC	B-Drug
is	O
delayed,	O
and	O
it	O
may	O
be	O
difficult	O
determine	O
optimal	O
dosage	O
because	O
variability	O
in	O
patient	O
absorption.	O

MDMA	B-Drug
is	O
often	O
considered	O
the	O
drug	O
of	O
choice	O
within	O
rave	O
culture	O
and	O
also	O
used	O
at	O
clubs,	O
festivals,	O
house	O
parties.	O

The	O
elimination	O
half-life	O
of	O
metandienone	B-Drug
is	O
about	O
3	O
to	O
6	O
hours.	O

Supplemental	O
magnesium	O
treatment	O
has	O
been	O
shown	O
to	O
reduce	O
amphetamine	B-Drug
self-administration	O
(i.e.,	O
doses	O
given	O
oneself)	O
in	O
humans,	O
but	O
it	O
is	O
not	O
an	O
effective	O
monotherapy	O
for	O
addiction.	O

Like	O
its	O
naturally	O
secreted	O
counterpart,	O
levothyroxine	B-Drug
is	O
a	O
chiral	O
compound	O
in	O
the	O
L-form.	O

presumably	O
exhibits	O
functional	O
selectivity	O
at	O
the	O
5HT2A	O
receptor	O
similar	O
to	O
other	O
phenethylamine	B-Drug
hallucinogens,	O
activating	O
Phospholipase	O
A2	O
signal	O
cascade,	O
which	O
is	O
responsible	O
for	O
release	O
of	O
Thromboxane	O
A2,	O
triggering	O
blood	O
platelet	O
aggregation.	O

Through	O
the	O
Beckley	O
Foundation,	O
Feilding	O
initiates,	O
directs,	O
and	O
supports	O
scientific	O
research	O
investigating	O
psychoactive	O
substances,	O
such	O
as	O
cannabis	O
other	O
psychedelics	O
(LSD,	O
psilocybin,	O
ayahuasca,	O
DMT,	O
5-MeO-DMT	B-Drug
MDMA,	O
commonly	O
known	O
Ecstasy).Considered	O
one	O
of	O
pioneers	O
renaissance	O
psychedelic	O
research,	O
with	O
New	O
Scientist	O
calling	O
her	O
"Queen	O
Consciousness",	O
she	O
has	O
initiated	O
several	O
ground-breaking	O
projects.	O
LSD	B-Drug
MDMA	B-Drug

The	O
dose	O
of	O
THC	B-Drug
needed	O
to	O
kill	O
50%	O
tested	O
rodents	O
is	O
extremely	O
high.	O

Triamcinolone	B-Drug
is	O
a	O
glucocorticoid	O
used	O
to	O
treat	O
certain	O
skin	O
diseases,	O
allergies,	O
and	O
rheumatic	O
disorders	O
among	O
others.	O

One	O
of	O
the	O
earlier	O
alkaloids	O
isolated	O
from	O
plant	O
sources,	O
hyoscine	B-Drug
has	O
been	O
in	O
use	O
its	O
purified	O
forms	O
(such	O
as	O
various	O
salts,	O
including	O
hydrochloride,	O
hydrobromide,	O
hydroiodide,	O
and	O
sulfate),	O
since	O
isolation	O
by	O
German	O
scientist	O
Albert	O
Ladenburg	O
1880,	O
preparations	O
plant-based	O
form	O
antiquity	O
perhaps	O
prehistoric	O
times.	O

Mesuximide.	O
Mesuximide	B-Drug

In	O
April	O
2011,	O
Icelandic	O
media	O
reported	O
the	O
death	O
of	O
a	O
young	O
woman	O
that	O
may	O
have	O
been	O
connected	O
to	O
PMMA.In	O
four	O
deaths	O
were	O
recorded	O
in	O
Scotland	O
as	O
result	O
ecstasy	B-Drug
tablets	O
which	O
also	O
contained	O
January	O
2012,	O
number	O
ecstasy-related	O
Canada	O
previous	O
year	O
linked	O
PMMA	B-Drug
overdoses.	O

According	O
to	O
Heads:	O
A	O
Biography	O
of	O
Psychedelic	O
America,	O
additional	O
factors	O
included	O
the	O
1996	O
arrest	O
longtime	O
LSD	B-Drug
chemist	O
Nicholas	O
Sand	O
and	O
death	O
a	O
man	O
involved	O
in	O
illicit	O
sale	O
precursor	O
materials.	O

The	O
symptoms	O
of	O
oxycodone	B-Drug
withdrawal,	O
as	O
with	O
other	O
opioids,	O
may	O
include	O
"anxiety,	O
panic	O
attack,	O
nausea,	O
insomnia,	O
muscle	O
pain,	O
weakness,	O
fevers,	O
and	O
flu-like	O
symptoms".	O

In	O
contrast	O
to	O
ibogaine	B-Drug
and	O
other	O
iboga	O
alkaloids,	O
coronaridine	O
does	O
not	O
bind	O
either	O
the	O
1	O
or	O
2	O
receptor.	O

Any	O
damage	O
to	O
the	O
inside	O
of	O
nose	O
is	O
because	O
cocaine	B-Drug
highly	O
constricts	O
blood	O
vessels	O
and	O
therefore	O
oxygen/nutrient	O
flow	O
that	O
area.	O

The	O
effects	O
of	O
hyoscine	B-Drug
were	O
studied	O
for	O
use	O
as	O
a	O
truth	O
serum	O
in	O
interrogations	O
the	O
early	O
20th	O
century,	O
but	O
because	O
side	O
effects,	O
investigations	O
dropped.	O

While	O
this	O
nomenclature	O
has	O
not	O
caught	O
on	O
because	O
the	O
name	O
"methylone"	O
became	O
widely	O
used	O
before	O
conflicting	O
Methylone	B-Drug
trademark	O
was	O
noticed,	O
analogous	O
names	O
for	O
related	O
chemicals	O
k-MDEA	O
and	O
k-MBDB	O
have	O
become	O
established	O
those	O
substances.	O
methylone	B-Drug

In	O
vivo,	O
an	O
equimolar	O
dose	O
of	O
1-testosterone	B-Drug
has	O
the	O
same	O
potency	O
to	O
stimulate	O
growth	O
prostate,	O
seminal	O
vesicles	O
and	O
androgen-sensitive	O
levator	O
ani	O
muscle	O
as	O
reference	O
anabolic	O
steroid	O
testosterone	B-Drug
propionate,	O
but,	O
unlike	O
also	O
increases	O
liver	O
weight.	O
propionate	I-Drug

Topical	O
formulations	O
of	O
haloperidol	B-Drug
should	O
not	O
be	O
used	O
as	O
treatment	O
for	O
nausea	O
because	O
research	O
does	O
indicate	O
this	O
therapy	O
is	O
more	O
effective	O
than	O
alternatives.	O

From	O
his	O
books,	O
it	O
is	O
clear	O
that	O
MDMA	B-Drug
or	O
Ecstasy	O
was	O
the	O
drug	O
he	O
found	O
to	O
be	O
most	O
compelling	O
(although	O
asserts	O
in	O
book	O
Total	O
Synthesis	O
II	O
MDA	O
preferable	O
MDMA):	O
II,	O
describes	O
as	O
"the	O
benign	O
[I	O
have]	O
ever	O
encountered.	O

Buprenorphine	B-Drug
is	O
a	O
partial	O
opioid	O
receptor	O
agonist.	O

As	O
of	O
December	O
2009,	O
Endo,	O
Novartis,	O
and	O
the	O
US	O
FDA	O
notified	O
healthcare	O
professionals	O
to	O
add	O
new	O
warnings	O
precautions	O
about	O
potential	O
for	O
elevation	O
in	O
liver	O
function	O
tests	O
during	O
treatment	O
with	O
all	O
products	O
containing	O
diclofenac	B-Drug
sodium.	O
sodium	I-Drug

Nichols'	O
laboratory	O
had	O
published	O
that	O
the	O
rats	O
experienced	O
same	O
euphoric	O
effects	O
as	O
ecstasy,	O
which	O
was	O
probably	O
motivation	O
for	O
its	O
production	O
and	O
distribution	O
to	O
humans.	O
ecstasy	B-Drug

Suvorexant	B-Drug
is	O
not	O
recommended	O
in	O
people	O
with	O
liver	O
impairment.	O

According	O
to	O
the	O
Royal	O
Canadian	O
Mounted	O
Police,	O
90%	O
of	O
heroin	B-Drug
seized	O
in	O
Canada	O
(where	O
origin	O
was	O
known)	O
came	O
from	O
Afghanistan.	O

In	O
2009,	O
the	O
FDA	O
approved	O
bevacizumab	B-Drug
for	O
use	O
in	O
metastatic	O
renal	O
cell	O
cancer	O
(a	O
form	O
of	O
kidney	O
cancer).	O

Medical	O
marijuana	O
refers	O
to	O
the	O
use	O
of	O
Cannabis	O
plant	O
as	O
a	O
physician-recommended	O
herbal	O
therapy	O
well	O
synthetic	O
THC	B-Drug
and	O
cannabinoids.	O

One	O
new	O
process	O
can	O
detect	O
a	O
2	O
mg	O
dose	O
of	O
Rohypnol	B-Drug
for	O
up	O
to	O
28	O
days	O
post-ingestion.	O

80%	O
to	O
90%	O
of	O
systemically	O
available	O
alvimopan	B-Drug
is	O
bound	O
plasma	O
protein.	O

The	O
unique	O
80	O
mg	O
dosage	O
of	O
bicalutamide	B-Drug
used	O
in	O
Japan	O
was	O
selected	O
for	O
development	O
this	O
country	O
on	O
the	O
basis	O
observed	O
pharmacokinetic	O
differences	O
with	O
Japanese	O
men.	O

Dick	O
Hebdige	O
argues	O
that	O
mods	O
used	O
amphetamines	B-Drug
to	O
extend	O
their	O
leisure	O
time	O
into	O
the	O
early	O
hours	O
of	O
morning	O
and	O
as	O
a	O
way	O
bridging	O
gap	O
between	O
hostile	O
daunting	O
everyday	O
work	O
lives	O
"inner	O
world"	O
dancing	O
dressing-up	O
in	O
off-hours.	O

Amgen's	O
competing	O
drugs	O
having	O
sales	O
of	O
$3B	O
per	O
year,	O
and	O
other	O
competitors	O
dividing	O
the	O
remaining	O
$4B,	O
based	O
on	O
estimates	O
an	O
annual	O
price	O
for	O
alirocumab	B-Drug
$10,000	O
year.	O

Cutting	O
Ring	O
B	O
produces	O
secosteroids	O
one	O
of	O
which	O
is	O
vitamin	B-Drug
D3.	O
D3	I-Drug

By	O
the	O
mid-1980s,	O
MDMA	B-Drug
use	O
had	O
spread	O
to	O
colleges	O
around	O
United	O
States.	O

Phenylpiperidine	O
derivative	O
opioids:	O
meperidine/pethidine,	O
tramadol,	O
methadone,	O
fentanyl,	O
dextropropoxyphene,	O
propoxyphene.	O
meperidine	B-Drug
pethidine	B-Drug
tramadol	B-Drug
methadone	B-Drug
fentanyl	B-Drug
dextropropoxyphene	B-Drug
propoxyphene	B-Drug

As	O
early	O
as	O
1996,	O
dextromethorphan	B-Drug
hydrobromide	O
powder	O
could	O
be	O
purchased	O
in	O
bulk	O
from	O
online	O
retailers,	O
allowing	O
users	O
to	O
avoid	O
consuming	O
syrup	O
preparations.	O

Since	O
the	O
mid-1990s,	O
MDMA	B-Drug
has	O
become	O
most	O
widely	O
used	O
amphetamine-type	O
drug	O
by	O
college	O
students	O
and	O
teenagers.	O

This	O
may	O
be	O
illusory	O
due	O
to	O
the	O
metabolism-dependent	O
effects	O
of	O
tramadol.	O
tramadol	B-Drug

UR-144	B-Drug
is	O
banned	O
in	O
the	O
Czech	O
Republic.	O

This	O
property	O
allows	O
buprenorphine	B-Drug
to	O
act	O
similarly	O
full	O
opioid	O
agonists	O
at	O
lower	O
doses	O
(mainly	O
in	O
intolerant	O
individuals),	O
reaching	O
a	O
ceiling/plateau	O
higher	O
after	O
which	O
no	O
further	O
increase	O
typical	O
effects	O
(therapeutic	O
or	O
recreational)	O
occurs.	O

As	O
such,	O
norgestrel	B-Drug
is	O
identical	O
in	O
its	O
hormonal	O
activity	O
to	O
levonorgestrel	B-Drug
except	O
that	O
it	O
half	O
as	O
potent	O
by	O
weight.	O

On	O
17	O
October	O
2018	O
police	O
in	O
Genoa	O
Italy,	O
discovered	O
270	O
kg	O
of	O
heroin	B-Drug
hidden	O
a	O
ship	O
coming	O
from	O
the	O
Iranian	O
southern	O
port	O
Bandar	O
Abbas.	O

It	O
is	O
closely	O
related	O
to	O
stanozolol,	O
differing	O
only	O
in	O
having	O
an	O
isoxazole	O
instead	O
of	O
pyrazole	O
ring	O
fused	O
the	O
A	O
ring,	O
and	O
also	O
furazabol,	O
prostanozol,	O
danazol.	O
stanozolol	B-Drug
furazabol	B-Drug
danazol	B-Drug

Nitrazepam	B-Drug
is	O
largely	O
bound	O
to	O
plasma	O
proteins.	O

A	O
small	O
amount	O
of	O
amphetamine	B-Drug
is	O
also	O
produced	O
from	O
metabolism	O
methamphetamine,	O
but	O
does	O
not	O
cause	O
any	O
significant	O
clinical	O
effect.	O
methamphetamine	B-Drug

Consequently,	O
high	O
daily	O
exposure	O
(possibly	O
excluding	O
oral	O
route)	O
to	O
nicotine	B-Drug
can	O
cause	O
FosB	O
overexpression	O
in	O
the	O
nucleus	O
accumbens,	O
resulting	O
addiction.	O

Compared	O
with	O
amphetamine,	O
MDMA	B-Drug
and	O
its	O
metabolite	O
MDA	O
are	O
less	O
reinforcing.	O
amphetamine	B-Drug

(Phenazepam)	O
tablets	O
0.25,	O
0.5	O
and	O
1	O
mg,	O
solution	O
for	O
intramuscular	O
intravenous	O
injection	O
mg	O
Phenazepam	B-Drug

Since	O
1994,	O
the	O
production,	O
dispensing,	O
and	O
prescription	O
of	O
thalidomide	B-Drug
have	O
been	O
strictly	O
controlled,	O
requiring	O
women	O
to	O
use	O
two	O
forms	O
birth	O
control	O
submit	O
regular	O
pregnancy	O
tests.	O

PCP	B-Drug
is	O
notably	O
a	O
high-affinity	O
ligand	O
of	O
the	O
site	O
2	O
(Ki	O
=	O
154	O
nM),	O
not-well-characterized	O
associated	O
with	O
monoamine	O
reuptake	O
inhibition.	O

Milnacipran	B-Drug
is	O
structurally	O
different	O
from	O
other	O
SNRIs.	O

"	O
This	O
legend	O
was	O
made	O
famous	O
at	O
the	O
1969	O
Woodstock	O
festival,	O
when	O
concert-goers	O
were	O
warned	O
to	O
stay	O
away	O
from	O
"the	O
brown	O
acid",	O
which	O
allegedly	O
bad.	O
acid	B-Drug

Antiandrogens	O
like	O
cyproterone	O
acetate,	O
spironolactone,	O
and	O
bicalutamide	B-Drug
can	O
block	O
the	O
androgenic	O
anabolic	O
effects	O
of	O
testosterone.	O
spironolactone	B-Drug

In	O
1746,	O
diascordium	O
was	O
offered	O
in	O
two	O
forms:	O
with	O
or	O
without	O
opium.	O
opium	B-Drug

Blood	O
or	O
plasma	O
alprazolam	B-Drug
concentrations	O
are	O
usually	O
in	O
a	O
range	O
of	O
10100	O
g/L	O
persons	O
receiving	O
the	O
drug	O
therapeutically,	O
100300	O
those	O
arrested	O
for	O
impaired	O
driving,	O
and	O
3002000	O
victims	O
acute	O
overdosage.	O

Chlorpromazine	B-Drug
is	O
a	O
very	O
effective	O
antagonist	O
of	O
D2	O
dopamine	O
receptors	O
and	O
similar	O
receptors,	O
such	O
as	O
D3	O
D5.	O

The	O
production,	O
distribution,	O
and	O
sale	O
of	O
cocaine	B-Drug
products	O
is	O
restricted	O
(and	O
illegal	O
in	O
most	O
contexts)	O
countries	O
as	O
regulated	O
by	O
the	O
Single	O
Convention	O
on	O
Narcotic	O
Drugs,	O
United	O
Nations	O
Against	O
Illicit	O
Traffic	O
Drugs	O
Psychotropic	O
Substances.	O

Millennial	O
writers,	O
such	O
as	O
Tao	O
Lin	O
and	O
Megan	O
Boyle,	O
have	O
used	O
amphetamines	O
in	O
the	O
form	O
of	O
Adderall	B-Drug
heavily.	O

Naloxone	B-Drug
kits	O
are	O
recommended	O
for	O
laypersons	O
who	O
may	O
witness	O
an	O
opioid	O
overdose,	O
individuals	O
with	O
large	O
prescriptions	O
opioids,	O
those	O
in	O
substance	O
use	O
treatment	O
programs,	O
or	O
have	O
been	O
recently	O
released	O
from	O
incarceration.	O

However,	O
due	O
to	O
its	O
low	O
lipophilicity,	O
pregabalin	B-Drug
requires	O
active	O
transport	O
across	O
the	O
bloodbrain	O
barrier.	O

Specifically,	O
25I-NBOMe	B-Drug
is	O
an	O
N-benzyl	O
derivative	O
of	O
the	O
phenethylamine	B-Drug
molecule	O
2C-I,	O
formed	O
by	O
adding	O
a	O
2-methoxybenzyl	O
(BnOMe)	O
onto	O
nitrogen	O
(N)	O
backbone.	O

25I-NBOMe	B-Drug
(2C-I-NBOMe,	O
Cimbi-5,	O
also	O
shortened	O
to	O
"25I")	O
is	O
a	O
synthetic	O
hallucinogen	O
that	O
used	O
in	O
biochemistry	O
research	O
for	O
mapping	O
the	O
brain's	O
usage	O
of	O
type	O
2A	O
serotonin	O
receptor;	O
it	O
sometimes	O
recreational	O
purposes.	O
2C-I-NBOMe	B-Drug

MDMA	B-Drug
and	O
metabolites	O
are	O
primarily	O
excreted	O
as	O
conjugates,	O
such	O
sulfates	O
glucuronides.	O

Epilim	B-Drug
by	O
Sanofi-Aventis	O
Intravenous	O
injection	O

crack	O
cocaine,	O
heroin	B-Drug
Thumbsucker	O
(2005)	O

Phencyclidine	B-Drug
is	O
an	O
NMDA	O
receptor	O
antagonist	O
that	O
blocks	O
the	O
activity	O
of	O
to	O
cause	O
anaesthesia	O
and	O
analgesia	O
without	O
causing	O
cardiorespiratory	O
depression.	O

Cannabidiol	B-Drug
(CBD)	O
is	O
a	O
phytocannabinoid	O
discovered	O
in	O
1940.	O
CBD	B-Drug

CBD	B-Drug
is	O
a	O
5-HT1A	O
receptor	O
agonist,	O
which	O
under	O
laboratory	O
research	O
to	O
determine	O
if	O
it	O
has	O
an	O
anxiolytic	O
effect.	O

Unlike	O
testosterone	O
and	O
certain	O
other	O
AAS,	O
nandrolone	B-Drug
is	O
not	O
potentiated	O
in	O
androgenic	O
tissues	O
like	O
the	O
scalp,	O
skin,	O
prostate,	O
hence	O
deleterious	O
effects	O
these	O
are	O
lessened.	O

Diazepam	B-Drug
gel	O
was	O
better	O
than	O
placebo	O
in	O
reducing	O
the	O
risk	O
of	O
non-cessation	O
seizures.	O

Oxandrolone	B-Drug
improves	O
both	O
short-term	O
and	O
long-term	O
outcomes	O
in	O
people	O
recovering	O
from	O
severe	O
burns	O
is	O
well-established	O
as	O
a	O
safe	O
treatment	O
for	O
this	O
indication.	O

Chlorpromazine	B-Drug
is	O
an	O
antagonist	O
to	O
H1	O
receptors	O
(provoking	O
antiallergic	O
effects),	O
H2	O
(reduction	O
of	O
forming	O
gastric	O
juice),	O
M1	O
and	O
M2	O
(dry	O
mouth,	O
reduction	O
in	O
juice)	O
some	O
5-HT	O
(different	O
anti-allergic/gastrointestinal	O
actions).	O

So	O
the	O
best	O
thing	O
to	O
do	O
is	O
offer	O
something	O
that	O
seems	O
ambiguousthat	O
on	O
study	O
or	O
reflection	O
actually	O
can	O
be	O
seen	O
"anti"which	O
song	O
"Cocaine"	O
an	O
anti-cocaine	O
song.	O
Cocaine	B-Drug

As	O
such,	O
domperidone	B-Drug
with	O
ketoconazole	B-Drug
or	O
other	O
CYP3A4	O
inhibitors	O
is	O
a	O
potentially	O
dangerous	O
combination.	O

MDA	O
methylamine	O
methamphetamine	B-Drug
N-methylephedrine	O
and	O
N-methylpseudoephedrine	O

Contains	O
17	O
positions,	O
specific	O
generalization	O
for	O
tetrahydrocannabinol	B-Drug
stereochemical	O
variants	O
and	O
common	O
clause	O
salts.	O

Due	O
to	O
the	O
fact	O
that	O
memories	O
and	O
their	O
emotional	O
content	O
are	O
reconsolidated	O
in	O
hours	O
after	O
they	O
recalled/re-experienced,	O
propranolol	B-Drug
can	O
also	O
diminish	O
impact	O
of	O
already	O
formed	O
memories;	O
for	O
this	O
reason,	O
it	O
is	O
being	O
studied	O
treatment	O
specific	O
phobias,	O
such	O
as	O
arachnophobia,	O
dental	O
fear,	O
social	O
phobia.	O

A	O
clinical	O
trial	O
studying	O
the	O
use	O
of	O
thalidomide	B-Drug
in	O
leprosy	O
soon	O
followed.	O

DOET	B-Drug
is	O
considered	O
a	O
Schedule	O
9	O
prohibited	O
substance	O
in	O
Australia	O
under	O
the	O
Poisons	O
Standard	O
(October	O
2015).	O

In	O
the	O
United	O
States,	O
AMB-FUBINACA	B-Drug
is	O
a	O
Schedule	O

Use	O
of	O
diclofenac	B-Drug
for	O
animals	O
is	O
controversial	O
due	O
to	O
toxicity	O
when	O
eaten	O
by	O
scavenging	O
birds	O
that	O
eat	O
dead	O
animals;	O
the	O
medication	O
has	O
been	O
banned	O
veterinary	O
use	O
in	O
many	O
countries.	O

This	O
implies	O
that	O
trenbolone	B-Drug
leaves	O
the	O
body	O
as	O
beta-glucuronides	O
or	O
sulfates.	O

In	O
the	O
case	O
of	O
R	O
v	O
Hardison,	O
defendant,	O
charged	O
with	O
eight	O
counts	O
under	O
Misuse	O
Drugs	O
Act	O
1971	O
(MDA),	O
including	O
production	O
DMT	O
and	O
LSD,	O
claimed	O
that	O
cognitive	O
liberty	O
was	O
safeguarded	O
by	O
Article	O
9	O
European	O
Convention	O
on	O
Human	O
Rights.	O
LSD	B-Drug

Another	O
medically-utilized	O
name	O
is	O
diethylpropion	B-Drug
(BAN	O
and	O
AAN).	O

His	O
first	O
arrest	O
for	O
manufacturing	O
LSD	B-Drug
came	O
on	O
December	O
28,	O
1988	O
in	O
Mountain	O
View,	O
California.	O

Efavirenz	B-Drug
will	O
lower	O
the	O
blood	O
levels	O
of	O
most	O
protease	O
inhibitors,	O
including	O
aprenavir,	O
atazanavir,	O
and	O
indinavir.	O
atazanavir	B-Drug

Participants	O
were	O
administered	O
either	O
5,	O
10	O
or	O
20	O
g	O
of	O
LSD	B-Drug
and	O
assessed	O
using	O
a	O
temporal	O
reproduction	O
task	O
self-report	O
measures.	O

Androstenedione	B-Drug
has	O
been	O
found	O
to	O
possess	O
some	O
estrogenic	O
activity,	O
similarly	O
other	O
DHEA	O
metabolites.	O

During	O
this	O
period	O
Jacques-Joseph	O
Moreau,	O
who	O
specialized	O
in	O
the	O
sociological	O
concept	O
of	O
social	O
alienation,	O
studied	O
effects	O
regularly	O
consuming	O
hashish.	O
hashish	B-Drug

Dienogest	B-Drug
is	O
marketed	O
in	O
combination	O
with	O
estradiol	O
valerate	O
as	O
a	O
birth	O
control	O
pill	O
primarily	O
under	O
the	O
brand	O
names	O
Natazia	B-Drug
and	O
Qlaira	O
ethinylestradiol	O
name	O
Valette,	O
although	O
these	O
combinations	O
are	O
numerous	O
other	O
well.	O

L-Theanine	B-Drug

The	O
results	O
of	O
that	O
trial	O
were	O
published	O
in	O
the	O
New	O
England	O
Journal	O
Medicine	O
1999.After	O
further	O
work	O
was	O
done	O
by	O
Celgene	O
and	O
others,	O
2006	O
U.S.	O
Food	O
Drug	O
Administration	O
granted	O
accelerated	O
approval	O
for	O
thalidomide	B-Drug
combination	O
with	O
dexamethasone	B-Drug
treatment	O
newly	O
diagnosed	O
multiple	O
myeloma	O
patients.	O

Notorious	O
cocaine	B-Drug
cartels	O
such	O
as	O
Medellin	O
cartel	O
and	O
Cali	O
have	O
both	O
dominated	O
the	O
illicit	O
trade	O
well	O
their	O
country	O
of	O
Colombia.	O

A	O
total	O
of	O
72	O
people	O
in	O
central	O
Henan	O
Province,	O
where	O
Shuanghui	O
is	O
based,	O
were	O
taken	O
into	O
police	O
custody	O
for	O
allegedly	O
producing,	O
selling,	O
or	O
using	O
clenbuterol.	O
clenbuterol	B-Drug

In	O
2006,	O
illegally	O
manufactured,	O
non-pharmaceutical	O
fentanyl	B-Drug
often	O
mixed	O
with	O
cocaine	B-Drug
or	O
heroin	B-Drug
caused	O
an	O
outbreak	O
of	O
overdose	O
deaths	O
in	O
the	O
United	O
States	O
and	O
Canada,	O
heavily	O
concentrated	O
cities	O
Dayton,	O
Ohio;	O
Chicago;	O
Detroit;	O
Philadelphia.	O

Amphetamine	B-Drug
exerts	O
its	O
behavioral	O
effects	O
by	O
altering	O
the	O
use	O
of	O
monoamines	O
as	O
neuronal	O
signals	O
in	O
brain,	O
primarily	O
catecholamine	O
neurons	O
reward	O
and	O
executive	O
function	O
pathways	O
brain.	O

Cannabis	O
dependence	O
develops	O
in	O
about	O
9%	O
of	O
users,	O
significantly	O
less	O
than	O
that	O
heroin,	O
cocaine,	O
alcohol,	O
and	O
prescribed	O
anxiolytics,	O
but	O
slightly	O
higher	O
for	O
psilocybin,	O
mescaline,	O
or	O
LSD.	O
heroin	B-Drug
cocaine	B-Drug
mescaline	B-Drug
LSD	B-Drug

Some	O
authors	O
classify	O
as	O
pseudoalkaloids	O
such	O
compounds	O
ephedrine	B-Drug
and	O
cathinone.	O
cathinone	B-Drug

A	O
study	O
throughout	O
the	O
entire	O
United	O
States	O
has	O
reported	O
that	O
around	O
48	O
percent	O
of	O
people	O
who	O
graduated	O
from	O
high	O
school	O
in	O
1979	O
have	O
used	O
cocaine	B-Drug
recreationally	O
during	O
some	O
point	O
their	O
lifetime,	O
compared	O
to	O
approximately	O
20	O
students	O
between	O
years	O
1980	O
and	O
1995.	O

The	O
average	O
THC	B-Drug
level	O
in	O
coffee	O
shops	O
the	O
Netherlands	O
is	O
about	O
1819%.The	O
levels	O
of	O
cannabis	O
sold	O
United	O
States	O
rose	O
dramatically	O
between	O
1970s	O
and	O
2000.	O

Cocaine	B-Drug
and	O
its	O
major	O
metabolites	O
may	O
be	O
quantified	O
in	O
blood,	O
plasma,	O
or	O
urine	O
to	O
monitor	O
for	O
use,	O
confirm	O
a	O
diagnosis	O
of	O
poisoning,	O
assist	O
the	O
forensic	O
investigation	O
traffic	O
other	O
criminal	O
violation	O
sudden	O
death.	O

Ro5-4864	B-Drug
was	O
found	O
to	O
be	O
a	O
potent	O
ligand	O
for	O
the	O
"peripheral	O
benzodiazepine	O
receptor",	O
later	O
renamed	O
mitochondrial	O
translocator	O
protein	O
18kDa	O
(TSPO).	O

Morphine	B-Drug
is	O
the	O
predominant	O
alkaloid	O
found	O
in	O
cultivated	O
varieties	O
of	O
opium	B-Drug
poppy	O
that	O
are	O
used	O
for	O
production.	O

Due	O
to	O
its	O
progestogenic	O
activity,	O
desogestrel	B-Drug
has	O
potent	O
functional	O
antiestrogenic	O
effects	O
in	O
certain	O
tissues.	O

PCP	B-Drug
is	O
an	O
arylcyclohexylamine.	O

In	O
2011,	O
researchers	O
at	O
John	O
Jay	O
College	O
of	O
Criminal	O
Justice	O
reported	O
that	O
dietary	O
zinc	O
supplements	O
can	O
mask	O
the	O
presence	O
THC	B-Drug
and	O
other	O
drugs	O
in	O
urine.	O

Even	O
relatively	O
safe	O
and	O
well	O
understood	O
OTC	O
drugs	O
such	O
as	O
aspirin	B-Drug

Despite	O
its	O
reported	O
psychedelic	O
activity,	O
binding	O
studies	O
in	O
vitro	O
showed	O
3C-DFE	O
to	O
have	O
a	O
surprisingly	O
weak	O
affinity	O
of	O
2695	O
nM	O
at	O
5-HT2A	O
with	O
negligible	O
5-HT2C,	O
making	O
it	O
only	O
slightly	O
higher	O
than	O
mescaline,	O
despite	O
potency	O
vivo.	O
mescaline	B-Drug

Lorcaserin	B-Drug
has	O
shown	O
100x	O
selectivity	O
for	O
5-HT2C	O
versus	O
the	O
closely	O
related	O
5-HT2B	O
receptor,	O
and	O
17x	O
over	O
5-HT2A	O
receptor.	O

In	O
2012	O
heroin	B-Drug
was	O
responsible	O
for	O
147	O
deaths,	O
and	O
the	O
leading	O
cause	O
of	O
overdose	O
deaths	O
in	O
state.	O

Phenethylamine	B-Drug
in	O
leaf	O
and	O
seeds	O
Acacia	O
cuthbertsonii,	O
Psychoactive	O
decurrens,	O
Psychoactive,	O
but	O
less	O
than	O
0.02%	O
alkaloids	O
delibrata,	O
falcata,	O
0.2-0.3%	O
farnesiana,	O
Traces	O
of	O
5-MeO-DMT	B-Drug
fruit.	O

In	O
veterinary	O
anaesthesia,	O
ketamine	B-Drug
is	O
often	O
used	O
for	O
its	O
anaesthetic	O
and	O
analgesic	O
effects	O
on	O
cats,	O
dogs,	O
rabbits,	O
rats,	O
other	O
small	O
animals.	O

In	O
1986	O
Dyazide	B-Drug
was	O
the	O
most	O
prescribed	O
drug	O
in	O
US	O
and	O
had	O
$325	O
million	O
sales,	O
making	O
it	O
SmithKline	O
Beckman's	O
second-biggest	O
seller	O
behind	O
Tagamet.	O
Tagamet	B-Drug

In	O
the	O
United	O
States,	O
development	O
of	O
"crack"	O
cocaine	B-Drug
introduced	O
substance	O
to	O
a	O
generally	O
poorer	O
inner-city	O
market.	O

The	O
UK	O
has	O
a	O
significant	O
black	O
market	O
for	O
tobacco,	O
and	O
it	O
been	O
estimated	O
by	O
the	O
tobacco	B-Drug
industry	O
that	O
27%	O
of	O
cigarette	O
68%	O
handrolling	O
consumption	O
is	O
non-UK	O
duty	O
paid	O
(	O

Urine	O
was	O
collected	O
for	O
24	O
hours,	O
followed	O
by	O
extraction	O
of	O
JWH-018	B-Drug
metabolites	O
using	O
both	O
liquid-liquid	O
and	O
solid-phase	O
extraction.	O

A	O
2009	O
study	O
of	O
rats	O
that	O
involved	O
injecting	O
them	O
with	O
large	O
quantities	O
THC	B-Drug
(equivalent	O
to	O
5-10	O
joints	O
per	O
day	O
in	O
humans)	O
each	O
for	O
ten	O
days	O
straight,	O
then	O
subjecting	O
simulated	O
severe	O
stress	O
or	O
food	O
deprivation	O
led	O
double	O
the	O
blood	O
levels	O
THC-COOH	O
two	O
after	O
last	O
exposure	O
compared	O
were	O
neither	O
stressed	O
nor	O
deprived	O
food.	O

cannabis,	O
cocaine	B-Drug
Clean	O
and	O
Sober	O
(1988)	O

Examples	O
of	O
such	O
compounds	O
include	O
nalorphine	B-Drug
and	O
levallorphan.	O

In	O
humans,	O
the	O
only	O
post-synaptic	O
receptor	O
at	O
which	O
amphetamine	B-Drug
is	O
known	O
to	O
bind	O
5-HT1A	O
receptor,	O
where	O
it	O
acts	O
as	O
an	O
agonist	O
with	O
low	O
micromolar	O
affinity.	O

(non-selective;	O
discontinued)	O
Levofenfluramine	O
(enantiomer	O
of	O
fenfluramine)	O
fenfluramine	B-Drug

A	O
Senate	O
investigation	O
found	O
out	O
that	O
P648	O
million	O
worth	O
of	O
seized	O
shabu	B-Drug
from	O
the	O
November	O
2013	O
raid	O
was	O
not	O
declared	O
by	O
Pampanga	O
police.	O

In	O
2018,	O
the	O
Massachusetts	O
Supreme	O
Judicial	O
Court	O
found	O
that	O
a	O
probationer	O
with	O
opioid	O
use	O
disorder	O
could	O
be	O
detained	O
for	O
parole	O
violation	O
after	O
she	O
tested	O
positive	O
fentanyl.	O
fentanyl	B-Drug

Meprobamate	B-Drug
was	O
found	O
to	O
help	O
in	O
the	O
treatment	O
of	O
alcoholics	O
by	O
1956.	O

Any	O
psychoactive	O
marijuana,	O
regardless	O
of	O
its	O
CBD	B-Drug
content,	O
is	O
derived	O
from	O
the	O
flower	O
(or	O
bud)	O
genus	O
Cannabis.	O

It	O
is	O
therefore	O
not	O
scheduled	O
at	O
the	O
federal	O
level	O
in	O
United	O
States,	O
but	O
it	O
possible	O
that	O
HU-243	O
could	O
legally	O
be	O
considered	O
an	O
analog	O
of	O
THC	B-Drug
(which	O
one	O
substances	O
controlled	O
Schedule	O
I	O
as	O
"tetrahydrocannabinols")	O
or	O
another	O
synthetic	O

In	O
many	O
areas	O
the	O
U.S.	O
government	O
and	O
military	O
has	O
forced	O
eradication	O
of	O
coca	B-Drug
without	O
providing	O
for	O
any	O
meaningful	O
alternative	O
crop	O
farmers,	O
additionally	O
destroyed	O
their	O
food	O
or	O
market	O
crops,	O
leaving	O
them	O
starving	O
destitute.	O

The	O
recent	O
formulations	O
of	O
oxycodone,	O
particularly	O
Purdue	O
Pharma's	O
crush-,	O
chew-,	O
injection-	O
and	O
dissolve-resistant	O
OxyNEO	O
which	O
replaced	O
the	O
banned	O
OxyContin	B-Drug
product	O
in	O
Canada	O
early	O
2012,	O
have	O
led	O
to	O
a	O
decline	O
abuse	O
this	O
opiate	O
but	O
increased	O
more	O
potent	O
drug	O
fentanyl.	O
oxycodone	B-Drug
fentanyl	B-Drug

19-Nortestosterone	B-Drug
derivatives	O
like	O
nandrolone	B-Drug
can	O
be	O
metabolized	O
by	O
5-reductase	O
similarly	O
to	O
testosterone,	O
but	O
5-reduced	O
metabolites	O
of	O
19-nortestosterone	B-Drug
(e.g.,	O
5-dihydronandrolone)	O
tend	O
have	O
reduced	O
activity	O
as	O
AR	O
agonists,	O
resulting	O
in	O
androgenic	O
tissues	O
that	O
express	O
5-reductase.	O

The	O
ACMD	O
report	O
on	O
ecstasy,	O
based	O
a	O
12-month	O
study	O
of	O
4,000	O
academic	O
papers,	O
concluded	O
that	O
it	O
is	O
not	O
as	O
dangerous	O
other	O
class	O
ecstasy	B-Drug

Importantly,	O
this	O
study	O
will	O
also	O
evaluate	O
the	O
safety	O
and	O
tolerability	O
of	O
repeated	O
microdoses	O
LSD,	O
via	O
measures	O
LSD	B-Drug
pharmacokinetics	O
pharmacodynamics,	O
including	O
physiological	O
markers	O
inflammation	O
neurogenesis.	O

According	O
to	O
an	O
October	O
2013	O
Esquire	O
magazine	O
article,	O
"Between	O
1982	O
and	O
1989,	O
federal	O
prosecutors	O
estimated,	O
Ross	O
bought	O
resold	O
several	O
metric	O
tons	O
of	O
cocaine,"	O
with	O
Ross'	O
gross	O
revenue	O
claimed	O
be	O
more	O
than	O
$900	O
million	O
(equivalent	O
$2.7	O
billion	O
in	O
2019)	O
profits	O
almost	O
$300	O
($900	O
2019).	O
cocaine	B-Drug

One	O
gram	O
of	O
poppy	O
seeds	O
contains	O
up	O
to	O
33	O
micrograms	O
morphine	B-Drug
and	O
14	O
codeine,	O
the	O
Substance	O
Abuse	O
Mental	O
Health	O
Services	O
Administration	O
in	O
United	O
States	O
formerly	O
mandated	O
that	O
all	O
drug	O
screening	O
laboratories	O
use	O
a	O
standard	O
cutoff	O
300	O
nanograms	O
per	O
milliliter	O
urine	O
samples.	O
codeine	B-Drug

While	O
other	O
opioids	O
of	O
recreational	O
use	O
produce	O
only	O
morphine,	O
heroin	B-Drug
also	O
leaves	O
6-MAM,	O
a	O
psycho-active	O
metabolite.	O
morphine	B-Drug

LSD	B-Drug
currently	O
has	O
no	O
approved	O
uses	O
in	O
medicine.	O

However,	O
at	O
most,	O
only	O
7%	O
of	O
the	O
ingested	O
cathinone	B-Drug
is	O
recovered	O
in	O
urine.	O

Additionally	O
in	O
2018,	O
American	O
rapper	O
Mac	O
Miller	O
died	O
from	O
an	O
accidental	O
overdose	O
of	O
fentanyl,	O
cocaine	B-Drug
and	O
alcohol.	O
fentanyl	B-Drug

His	O
sister's	O
boyfriend,	O
Calvin,	O
is	O
a	O
successful	O
cocaine	B-Drug
dealer	O
while	O
Ace's	O
close	O
friend	O
Mitch	O
flashy,	O
popular	O
drug	O
dealer.	O

Unlike	O
albuterol,	O
salmeterol	B-Drug
becomes	O
dissolved	O
in	O
the	O
lipid	O
bilayer	O
of	O
cell	O
membrane,	O
and	O
its	O
gradual	O
dissociation	O
from	O
membrane	O
provides	O
beta-2	O
adrenoceptors	O
with	O
a	O
supply	O
agonist	O
for	O
an	O
extended	O
period	O
time.	O
albuterol	B-Drug

Possibly	O
by	O
promoting	O
sodium	O
efflux	O
from	O
neurons,	O
phenytoin	B-Drug
tends	O
to	O
stabilize	O
the	O
threshold	O
against	O
hyperexcitability	O
caused	O
excessive	O
stimulation	O
or	O
environmental	O
changes	O
capable	O
of	O
reducing	O
membrane	O
gradient.	O

After	O
World	O
War	O
II,	O
the	O
Andean	O
countries	O
saw	O
an	O
expansion	O
of	O
trade,	O
specifically	O
with	O
cocaine.	O
cocaine	B-Drug

N-Methyl-N-isopropyltryptamine	B-Drug
(MiPT)	O
is	O
a	O
psychedelic	O
tryptamine,	O
closely	O
related	O
to	O
DMT,	O
DiPT	B-Drug
and	O
Miprocin.	O
MiPT	B-Drug

In	O
the	O
1880s,	O
Knorr	O
was	O
trying	O
to	O
make	O
quinine	B-Drug
derivatives	O
from	O
phenylhydrazine,	O
and	O
instead	O
made	O
a	O
pyrazole	O
derivative,	O
which	O
after	O
methylation,	O
he	O
into	O
phenazone,	O
also	O
called	O
antipyrine,	O
has	O
been	O
"the	O
'mother'	O
of	O
all	O
modern	O
antipyretic	O
analgesics."	O

Zopiclone	B-Drug
has	O
crosstolerance	O
with	O
barbiturates	O
and	O
is	O
able	O
to	O
suppress	O
barbiturate	O
withdrawal	O
signs.	O

A	O
2009	O
Cochrane	O
review	O
found	O
methadone	B-Drug
was	O
effective	O
in	O
retaining	O
people	O
treatment	O
and	O
the	O
reduction	O
or	O
cessation	O
of	O
heroin	B-Drug
use	O
as	O
measured	O
by	O
self-report	O
urine/hair	O
analysis	O
but	O
did	O
not	O
affect	O
criminal	O
activity	O
risk	O
death.	O

The	O
pharmacological	O
effects	O
of	O
opium	B-Drug
tincture	O
are	O
due	O
principally	O
to	O
its	O
morphine	B-Drug
content.	O

According	O
to	O
the	O
UNODC,	O
opium	B-Drug
situation	O
in	O
southern	O
provinces	O
is	O
"out	O
of	O
control."	O

Cephalon	O
has	O
sued	O
Apotex	O
in	O
the	O
US	O
to	O
prevent	O
it	O
from	O
releasing	O
a	O
genericized	O
armodafinil	B-Drug
(Nuvigil).	O
Nuvigil	B-Drug

Levi-Montalcini	O
and	O
coworkers	O
presented	O
evidence	O
in	O
1993	O
that	O
lipid	O
amides	O
of	O
the	O
N-acylethanolamine	O
type,	O
such	O
as	O
PEA,	O
are	O
potential	O
prototypes	O
naturally	O
occurring	O
molecules	O
capable	O
modulating	O
mast	O
cell	O
activation,	O
her	O
group	O
used	O
acronym	O
ALIA	O
report.	O
PEA	B-Drug

Long	O
half-life	O
benzodiazepines	O
like	O
diazepam	B-Drug
or	O
chlordiazepoxide	B-Drug
are	O
preferred	O
to	O
minimize	O
rebound	O
effects	O
and	O
available	O
in	O
low	O
dose	O
forms.	O

John	O
Belushi	O
Ken	O
Caminiti	O
Chris	O
Farley,	O
died	O
of	O
cocaine	B-Drug
and	O
morphine	B-Drug
sulfate	I-Drug
overdose,	O
similar	O
to	O
Belushi.	O

Depending	O
on	O
the	O
amount	O
administered,	O
it	O
can	O
reverse	O
respiratory	O
depression	O
and,	O
if	O
enough	O
is	O
completely	O
effects	O
of	O
sufentanil.	O
sufentanil	B-Drug

DMT	O
is	O
produced	O
in	O
many	O
species	O
of	O
plants	O
often	O
conjunction	O
with	O
its	O
close	O
chemical	O
relatives	O
5-methoxy-N,N-dimethyltryptamine	B-Drug
(5-MeO-DMT)	O
and	O
bufotenin	B-Drug
(5-OH-DMT).	O
5-MeO-DMT	B-Drug
5-OH-DMT	B-Drug

Australia's	O
National	O
Cannabis	O
Prevention	O
and	O
Information	O
Centre	O
(NCPIC)	O
states	O
that	O
the	O
buds	O
(infructescences)	O
of	O
female	O
cannabis	O
plant	O
contain	O
highest	O
concentration	O
THC,	O
followed	O
by	O
leaves.	O
THC	B-Drug

Where	O
it	O
is	O
used,	O
levomethadone	B-Drug
used	O
for	O
narcotic	O
maintenance	O
in	O
place	O
of,	O
or	O
some	O
cases	O
alongside	O
as	O
an	O
alternative,	O
to	O
racemic	O
methadone,	O
owing	O
concern	O
about	O
the	O
cardiotoxic	O
and	O
QT-prolonging	O
action	O
of	O
methadone	B-Drug
being	O
exclusively	O
caused	O
by	O
dextrorotatory	O
enantiomer,	O
dextromethadone.	O

In	O
contrast,	O
inhalation	O
of	O
cocaine	B-Drug
leads	O
to	O
the	O
shortest	O
duration	O
its	O
effects	O
(515	O
minutes).	O

A	O
wide	O
variety	O
of	O
drugs	O
are	O
injected,	O
often	O
opioids:	O
these	O
may	O
include	O
legally	O
prescribed	O
medicines	O
and	O
medication	O
such	O
as	O
morphine,	O
well	O
stronger	O
compounds	O
favored	O
in	O
recreational	O
drug	O
use,	O
which	O
illegal.	O
morphine	B-Drug

Usually,	O
in	O
its	O
oral	O
formulations,	O
it	O
is	O
combined	O
with	O
naloxone	B-Drug
so	O
as	O
to	O
prevent	O
people	O
from	O
crushing	O
the	O
tablets,	O
dissolving	O
them	O
a	O
solvent	O
(like	O
water)	O
and	O
injecting	O
for	O
high	O
(as	O
orally	O
administered	O
produces	O
no	O
opioid-negating	O
effects.	O

Crack	O
cocaine	B-Drug
is	O
a	O
smokeable	O
form	O
of	O
made	O
into	O
small	O
"rocks"	O
by	O
processing	O
with	O
sodium	O
bicarbonate	O
(baking	O
soda)	O
and	O
water.	O

methylphenidate	B-Drug
(	O

The	O
medication	O
is	O
a	O
prodrug	O
of	O
etonogestrel	B-Drug
(3-ketodesogestrel)	O
in	O
the	O
body.	O

Norethandrolone	B-Drug
was	O
discovered	O
in	O
1953	O
and	O
introduced	O
for	O
medical	O
use	O
1956.	O

As	O
another	O
example,	O
the	O
ratio	O
of	O
dextromethorphan	B-Drug
(a	O
drug	O
that	O
is	O
mainly	O
metabolized	O
by	O
CYP2D6)	O
to	O
its	O
major	O
metabolite	O
dextrorphan	B-Drug
increased	O
approximately	O
35-fold	O
when	O
it	O
was	O
administered	O
people	O
being	O
treated	O
with	O
300	O
mg/day	O
bupropion,	O
indicative	O
a	O
interaction	O
common	O
over-the-counter	O
medicine.	O
bupropion	B-Drug

Medroxyprogesterone	B-Drug
acetate	I-Drug
Insulin	B-Drug
injection	I-Drug
(soluble)	I-Drug
Intermediate-acting	B-Drug
insulin	I-Drug
Gliclazide	B-Drug
Metformin	B-Drug
Glucagon	O
Diazoxide	B-Drug
Levothyroxine	B-Drug
Potassium	B-Drug
iodide	I-Drug

A	O
2014	O
SIGAR	O
report	O
claimed	O
levels	O
of	O
cultivation	O
have	O
risen	O
by	O
more	O
than	O
200,000	O
hectares...	O
since	O
2001	O
and	O
that	O
opium-poppy	O
are	O
at	O
another	O
all-time	O
high,	O
despite	O
$7.8	O
billion	O
obligated	O
for	O
counternarcotics	O
efforts,	O
concluding	O
that:counternarcotics	O
appears	O
to	O
fallen	O
off	O
the	O
agenda	O
both	O
U.S.	O
government	O
international	O
community,	O
fact	O
it	O
is	O
impossible	O
develop	O
a	O
coherent	O
effective	O
strategy	O
post-2014	O
Afghanistan	O
without	O
taking	O
full	O
account	O
opium	B-Drug
economy.	O

Nalmefene	B-Drug
is	O
extensively	O
metabolized	O
in	O
the	O
liver,	O
mainly	O
by	O
conjugation	O
with	O
glucuronic	O
acid	O
and	O
also	O
N-dealkylation.	O

Moreover,	O
no	O
difference	O
was	O
observed	O
between	O
spironolactone	B-Drug
and	O
placebo	O
with	O
regard	O
to	O
volume	O
of	O
residual	O
urine	O
or	O
prostate	O
size.	O

A	O
1960	O
Polish	O
paper	O
by	O
Biniecki	O
and	O
Krajewski	O
describing	O
the	O
synthesis	O
of	O
MDMA	B-Drug
as	O
an	O
intermediate	O
was	O
first	O
published	O
scientific	O
on	O
substance.	O

Pomalidomide	B-Drug
was	O
approved	O
in	O
February	O
2013	O
by	O
the	O
U.S.	O
Food	O
and	O
Drug	O
Administration	O
(FDA)	O
as	O
a	O
treatment	O
for	O
relapsed	O
refractory	O
multiple	O
myeloma.	O

To	O
be	O
initiated	O
under	O
a	O
guru,	O
one	O
must	O
have	O
had	O
no	O
caffeine,	O
alcohol,	O
nicotine	B-Drug
or	O
other	O
drugs,	O
for	O
at	O
least	O
year.	O

GPCRs	O
include	O
one	O
or	O
more	O
receptors	O
for	O
the	O
following	O
ligands:	O
sensory	O
signal	O
mediators	O
(e.g.,	O
light	O
and	O
olfactory	O
stimulatory	O
molecules);	O
adenosine,	O
bombesin,	O
bradykinin,	O
endothelin,	O
-aminobutyric	O
acid	O
(GABA),	O
hepatocyte	O
growth	O
factor	O
(HGF),	O
melanocortins,	O
neuropeptide	O
Y,	O
opioid	O
peptides,	O
opsins,	O
somatostatin,	O
GH,	O
tachykinins,	O
members	O
of	O
vasoactive	O
intestinal	O
peptide	O
family,	O
vasopressin;	O
biogenic	O
amines	O
dopamine,	O
epinephrine,	O
norepinephrine,	O
histamine,	O
serotonin,	O
melatonin);	O
glutamate	O
(metabotropic	O
effect);	O
glucagon;	O
acetylcholine	O
(muscarinic	O
chemokines;	O
lipid	O
inflammation	O
prostaglandins,	O
prostanoids,	O
platelet-activating	O
factor,	O
leukotrienes);	O
hormones	O
calcitonin,	O
C5a	O
anaphylatoxin,	O
follicle-stimulating	O
hormone	O
[FSH],	O
gonadotropin-releasing	O
[GnRH],	O
neurokinin,	O
thyrotropin-releasing	O
[TRH],	O
oxytocin);	O
endocannabinoids.	O
melatonin	B-Drug

DMT	O
is	O
generally	O
not	O
active	O
orally	O
unless	O
it	O
combined	O
with	O
a	O
monoamine	O
oxidase	O
inhibitor	O
(MAOI)	O
such	O
as	O
reversible	O
of	O
A	O
(RIMA),	O
for	O
example,	O
harmaline.	O
harmaline	B-Drug

Heroin,	O
also	O
known	O
as	O
diacetylmorphine	B-Drug
and	O
diamorphine	B-Drug
among	O
other	O
names,	O
is	O
an	O
opioid	O
used	O
a	O
recreational	O
drug	O
for	O
its	O
euphoric	O
effects.	O
Heroin	B-Drug

Current	O
recommendations	O
from	O
the	O
American	O
Heart	O
Association	O
are	O
to	O
use	O
spironolactone	B-Drug
in	O
patients	O
with	O
NYHA	O
Class	O
II-IV	O
heart	O
failure	O
who	O
have	O
a	O
left	O
ventricular	O
ejection	O
fraction	O
of	O
less	O
than	O
35%.In	O
randomized	O
evaluation	O
which	O
studied	O
people	O
severe	O
congestive	O
failure,	O
treated	O
were	O
found	O
relative	O
risk	O
death	O
0.70	O
or	O
an	O
overall	O
30%	O
reduction	O
compared	O
placebo	O
group,	O
indicating	O
significant	O
and	O
morbidity	O
benefit	O
medication.	O

Examples	O
include	O
the	O
CYP17A1	O
inhibitors	O
ketoconazole,	O
abiraterone	O
acetate,	O
and	O
seviteronel,	O
CYP11A1	O
(P450scc)	O
inhibitor	O
aminoglutethimide,	O
5-reductase	O
finasteride,	O
dutasteride,	O
epristeride,	O
alfatradiol,	O
saw	O
palmetto	O
extract	O
(Serenoa	O
repens).	O
ketoconazole	B-Drug
finasteride	B-Drug
dutasteride	B-Drug
alfatradiol	B-Drug

Illicit	O
use	O
of	O
pharmaceutical	O
fentanyl	B-Drug
and	O
its	O
analogues	O
first	O
appeared	O
in	O
the	O
mid-1970s	O
medical	O
community	O
continues	O
present.	O

The	O
package	O
insert	O
for	O
Dianabol,	O
a	O
common	O
anabolic	O
steroid	O
used	O
at	O
the	O
time,	O
stated,	O
"Anabolic	O
steroids	O
do	O
not	O
enhance	O
athletic	O
ability."	O
Dianabol	B-Drug

Clonazepam	B-Drug

Serum	O
JWH-018	B-Drug
concentrations	O
are	O
generally	O
in	O
the	O
110	O
g/L	O
range	O
during	O
first	O
few	O
hours	O
after	O
recreational	O
usage.	O

The	O
synthesis	O
of	O
cannabidiol	B-Drug
has	O
been	O
accomplished	O
by	O
several	O
research	O
groups.	O

The	O
withdrawal	O
of	O
chlordiazepoxide	B-Drug
during	O
pregnancy	O
and	O
breast	O
feeding	O
is	O
recommended,	O
as	O
rapidly	O
crosses	O
the	O
placenta	O
also	O
excreted	O
in	O
milk.	O

Aurorix	O
(moclobemide),	O
for	O
depression.	O
moclobemide	B-Drug

The	O
study	O
was	O
a	O
"double-blind,	O
placebo-controlled,	O
randomized",	O
24-week	O
trial	O
running	O
"from	O
July	O
3,	O
2008,	O
through	O
October	O
5,	O
2009"	O
with	O
"250	O
patients	O
opioid	O
dependence	O
disorder"	O
at	O
"13	O
clinical	O
sites	O
in	O
Russia"	O
on	O
the	O
use	O
of	O
injectable	O
naltrexone	B-Drug
(XR-NTX)	O
for	O
dependence.	O

Many	O
addicts	O
seeking	O
treatment	O
usually	O
avoid	O
methadone,	O
or	O
see	O
it	O
as	O
a	O
last	O
resort,	O
specifically	O
because	O
they	O
do	O
not	O
want	O
to	O
have	O
go	O
clinic	O
every	O
day	O
receive	O
their	O
medication.	O
methadone	B-Drug

Rock	O
music	O
and	O
its	O
related	O
subgenres	O
have	O
featured	O
a	O
number	O
of	O
warning	O
songs	O
such	O
as	O
Neil	O
Young's	O
"The	O
Needle	O
the	O
Damage	O
Done"	O
J.J.	O
Cale's	O
"Cocaine",	O
latter	O
composition	O
being	O
best	O
known	O
for	O
Eric	O
Clapton	O
versions.	O
Cocaine	B-Drug

Some	O
strategies	O
aim	O
to	O
reduce	O
drug	O
use	O
and	O
lead	O
abstinence	O
from	O
opioids,	O
while	O
others	O
attempt	O
stabilize	O
on	O
prescribed	O
methadone	B-Drug
or	O
buprenorphine	B-Drug
with	O
continued	O
replacement	O
therapy	O
indefinitely.	O

Half	O
lives	O
of	O
the	O
metabolites	O
were	O
315	O
minutes	O
for	O
nicotinoyl	O
metabolite,	O
and	O
135190	O
morphine.	O
morphine	B-Drug

One	O
in	O
a	O
hundred	O
Australians	O
has	O
used	O
ketamine	B-Drug
at	O
least	O
once	O
their	O
lives	O
and	O
one	O
five	O
over	O
the	O
past	O
12	O
months.	O

Oxymorphazone	O
is	O
an	O
opioid	O
analgesic	O
drug	O
related	O
to	O
oxymorphone.	O
oxymorphone	B-Drug

Elevated	O
blood	O
pressure	O
has	O
been	O
reported	O
when	O
buspirone	B-Drug
administered	O
to	O
patients	O
taking	O
monoamine	O
oxidase	O
inhibitors	O
(MAOIs).	O

PCP	B-Drug
is	O
classified	O
as	O
a	O
schedule	O
II	O
drug	O
in	O
the	O
United	O
States.	O

Norethisterone	B-Drug
was	O
patented	O
in	O
1951	O
and	O
came	O
into	O
medical	O
use	O
1957.	O

Ibuprofen	B-Drug
and	O
diclofenac	B-Drug
have	O
short	O
half-lives	O
(23	O
hours).	O

Hemp	O
has	O
lower	O
concentrations	O
of	O
THC	B-Drug
and	O
higher	O
CBD,	O
which	O
gives	O
lesser	O
psychoactive	O
effects.	O
CBD	B-Drug

Phenobarbital	B-Drug
is	O
used	O
as	O
a	O
secondary	O
agent	O
to	O
treat	O
newborns	O
with	O
neonatal	O
abstinence	O
syndrome,	O
condition	O
of	O
withdrawal	O
symptoms	O
from	O
exposure	O
opioid	O
drugs	O
in	O
utero.	O

A	O
heroin	B-Drug
overdose	O
may	O
be	O
treated	O
with	O
naloxone.	O
naloxone	B-Drug

As	O
of	O
2017,	O
the	O
therapeutic	O
mechanism	O
action	O
modafinil	B-Drug
for	O
narcolepsy	O
and	O
sleep-wake	O
disorders	O
remains	O
precisely	O
unknown.	O

This	O
final	O
intermediate	O
is	O
then	O
heated	O
in	O
decalin	O
or	O
another	O
suitable	O
high-boiling	O
solvent,	O
upon	O
which	O
a	O
ring-expansion	O
rearrangement	O
occurs,	O
forming	O
ketamine.	O
ketamine	B-Drug

Glaxo	O
refined	O
the	O
model	O
further,	O
by	O
replacing	O
imidazole	O
ring	O
of	O
cimetidine	B-Drug
with	O
a	O
furan	O
nitrogen-containing	O
substituent,	O
and	O
in	O
doing	O
so	O
developed	O
ranitidine.	O
ranitidine	B-Drug

There	O
is	O
also	O
a	O
case	O
report	O
of	O
fosphenytoin,	O
CYP3A4	O
inducer,	O
dramatically	O
reducing	O
the	O
analgesic	O
effects	O
oxycodone	B-Drug
in	O
chronic	O
pain	O
patient.	O

In	O
one	O
study,	O
after	O
a	O
single	O
50	O
mg	O
dose	O
of	O
clomifene,	O
the	O
half-life	O
clomifene	B-Drug
was	O
128	O
hours	O
(5.3	O
days),	O
4-hydroxyclomifene	O
13	O
hours,	O
and	O

Dexamethasone	B-Drug
is	O
a	O
synthetic	O
pregnane	O
corticosteroid	O
and	O
derivative	O
of	O
cortisol	O
(hydrocortisone)	O
also	O
known	O
as	O
1-dehydro-9-fluoro-16-methylhydrocortisone	O
or	O
9-fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione.	O

Since	O
then	O
fentanyl	B-Drug
is	O
a	O
more	O
common	O
cause	O
of	O
drug	O
related	O
deaths.	O

That	O
patent,	O
along	O
with	O
others,	O
was	O
challenged	O
by	O
generic	O
manufacturers	O
and	O
upheld	O
in	O
2014,	O
giving	O
Pfizer	O
exclusivity	O
for	O
Lyrica	B-Drug
the	O
US	O
until	O
2018.As	O
of	O
October	O
2017,	O
pregabalin	B-Drug
marketed	O
under	O
many	O
brand	O
names	O
other	O
countries:	O
Algerika,	O
Alivax,	O
Alyse,	O
Alzain,	O
Andogablin,	O
Aprion,	O
Averopreg,	O
Axual,	O
Balifibro,	O
Brieka,	O
Clasica,	O
Convugabalin,	O
Dapapalin,	O
Dismedox,	O
Dolgenal,	O
Dolica,	O
Dragonor,	O
Ecubalin,	O
Epica,	O
Epiron,	O
Gaba-P,	O
Gabanext,	O
Gabarol,	O
Gabica,	O
Gablin,	O
Gablovac,	O
Gabrika,	O
Gavin,	O
Gialtyn,	O
Glonervya,	O
Helimon,	O
Hexgabalin,	O
Irenypathic,	O
Kabian,	O
Kemirica,	O
Kineptia,	O
Lecaent,	O
Lingabat,	O
Linprel,	O
Lyric,	O
Lyrica,	O
Lyrineur,	O
Lyrolin,	O
Lyzalon,	O
Martesia,	O
Maxgalin,	O
Mystika,	O
Neuragabalin,	O
Neugaba,	O
Neurega,	O
Neurica,	O
Neuristan,	O
Neurolin,	O
Neurovan,	O
Neurum,	O
Newrica,	O
Nuramed,	O
Paden,	O
Pagadin,	O
Pagamax,	O
Painica,	O
Pevesca,	O
PG,	O
Plenica,	O
Pragiola,	O
Prebalin,	O
Prebanal,	O
Prebel,	O
Prebictal,	O
Prebien,	O
Prefaxil,	O
Pregaba,	O
Pregabalin,	O
Pregabalina,	O
Pregabaline,	O
Prgabaline,	O
Pregabalinum,	O
Pregabateg,	O
Pregaben,	O
Pregabid,	O
Pregabin,	O
Pregacent,	O
Pregadel,	O
Pregagamma,	O
Pregalex,	O
Pregalin,	O
Pregamid,	O
Pregan,	O
Preganerve,	O
Pregastar,	O
Pregatrend,	O
Pregavalex,	O
Pregdin	O
Apex,	O
Pregeb,	O
Pregobin,	O
Prejunate,	O
Prelin,	O
Preludyo,	O
Prelyx,	O
Premilin,	O
Preneurolin,	O
Prestat,	O
Pretor,	O
Priga,	O
Provelyn,	O
Regapen,	O
Resenz,	O
Rewisca,	O
Serigabtin,	O
Symra,	O
Vronogabic,	O
Xablin,	O
Xil.	O
Pregabalin	B-Drug

And	O
through	O
further	O
advances,	O
Janssen	O
created	O
fentanyl	B-Drug
in	O
1960,	O
which	O
proved	O
to	O
be	O
ten	O
times	O
more	O
potent	O
than	O
phenoperidine.	O
phenoperidine	B-Drug

The	O
paper	O
displayed	O
fluorescence	O
when	O
irradiated	O
at	O
365	O
nanometers;	O
however,	O
color	O
testing	O
for	O
LSD	B-Drug
with	O
para-dimethylaminobenzaldehyde	O
(Ehrlich's	O
reagent)	O
was	O
negative.	O

Metandienone	B-Drug
was	O
first	O
described	O
in	O
1955.	O

Animal	O
studies	O
in	O
FDA	O
files	O
for	O
zolpidem	B-Drug
showed	O
a	O
dose	O
dependent	O
increase	O
some	O
types	O
of	O
tumors,	O
although	O
the	O
were	O
too	O
small	O
to	O
reach	O
statistical	O
significance.	O

Only	O
of	O
a	O
few	O
these	O
compounds	O
were	O
widely	O
used	O
including	O
rolicyclidine	B-Drug
(PCPy),	O
eticyclidine	B-Drug
(PCE),	O
and	O
tenocyclidine	B-Drug
(TCP).	O
PCE	B-Drug
TCP	B-Drug

Desipramine	B-Drug
has	O
more	O
affinity	O
to	O
norepinephrine	O
transporter	O
than	O
imipramine.	O
imipramine	B-Drug

Naloxone	B-Drug
was	O
patented	O
in	O
1961	O
by	O
Mozes	O
J.	O
Lewenstein,	O
Jack	O
Fishman,	O
and	O
the	O
company	O
Sankyo.	O

The	O
advantage	O
of	O
switching	O
to	O
diazepam	B-Drug
is	O
that	O
dose	O
reductions	O
are	O
felt	O
less	O
acutely,	O
because	O
the	O
longer	O
half-lives	O
(20200	O
hours)	O
and	O
its	O
active	O
metabolites.	O

By	O
weight,	O
dimenhydrinate	B-Drug
is	O
between	O
53%	O
to	O
55.5%	O
diphenhydramine.	O
diphenhydramine	B-Drug

Morphine	B-Drug
sales	O
began	O
in	O
1827,	O
by	O
Heinrich	O
Emanuel	O
Merck	O
of	O
Darmstadt,	O
and	O
helped	O
him	O
expand	O
his	O
family	O
pharmacy	O
into	O
the	O
KGaA	O
pharmaceutical	O
company.	O

For	O
those	O
reasons,	O
DMT	O
was	O
known	O
as	O
the	O
"business	O
trip"	O
during	O
1960s	O
in	O
United	O
States,	O
a	O
user	O
could	O
access	O
full	O
depth	O
of	O
psychedelic	O
experience	O
considerably	O
less	O
time	O
than	O
with	O
other	O
substances	O
such	O
LSD	B-Drug
or	O
magic	O
mushrooms.	O

In	O
2016,	O
deaths	O
from	O
fatal	O
fentanyl	B-Drug
overdoses	O
in	O
the	O
province	O
of	O
British	O
Columbia	O
averaged	O
two	O
persons	O
per	O
day.	O

Sulpiride	B-Drug
is	O
found	O
in	O
the	O
milk	O
of	O
lactating	O
women.	O

JWH-073,	O
a	O
synthetic	O
cannabinoid,	O
is	O
an	O
analgesic	O
chemical	O
from	O
the	O
naphthoylindole	O
family	O
that	O
acts	O
as	O
partial	O
agonist	O
at	O
both	O
CB1	O
and	O
CB2	O
cannabinoid	O
receptors.	O
JWH-073	B-Drug

The	O
authors	O
suggest	O
that	O
where	O
preferred	O
non-pharmacological	O
treatment	O
strategies	O
have	O
been	O
exhausted,	O
eszopiclone	B-Drug
provides	O
an	O
efficient	O
for	O
insomnia.	O

For	O
example,	O
SNRIs	O
such	O
as	O
venlafaxine	B-Drug
are	O
commonly	O
prescribed	O
to	O
treat	O
depression,	O
and	O
the	O
5-HT1A	O
agonist	O
buspirone	B-Drug
is	O
primarily	O
for	O
treatment	O
of	O
anxiety.	O

Shortly	O
after	O
the	O
teratogenic	O
properties	O
of	O
thalidomide	B-Drug
were	O
recognized	O
in	O
mid-1960s,	O
its	O
anti-cancer	O
potential	O
was	O
explored	O
and	O
two	O
clinical	O
trials	O
conducted	O
people	O
with	O
advanced	O
cancer,	O
including	O
some	O
multiple	O
myeloma;	O
inconclusive.	O

Nalmefene	B-Drug
was	O
first	O
reported	O
in	O
a	O
patent	O
1974.	O

It	O
was	O
also	O
reported	O
in	O
Joliet,	O
Illinois	O
and	O
McHenry,	O
October	O
2013,	O
but	O
no	O
laboratory	O
tests	O
have	O
confirmed	O
that	O
desomorphine	B-Drug
present	O
the	O
blood,	O
urine	O
or	O
tissues	O
of	O
hospitalized	O
krokodil	O
patients.	O

Thus,	O
with	O
both	O
higher	O
the	O
dosage	O
of	O
heroin	B-Drug
used	O
and	O
faster	O
route	O
administration	O
used,	O
potential	O
risk	O
for	O
psychological	O
dependence/addiction.	O

Ibuprofen	B-Drug
is	O
sometimes	O
used	O
for	O
the	O
treatment	O
of	O
acne	O
because	O
its	O
anti-inflammatory	O
properties,	O
and	O
has	O
been	O
sold	O
in	O
Japan	O
topical	O
form	O
adult	O
acne.	O

Conversely,	O
this	O
is	O
not	O
the	O
case	O
for	O
pregabalin,	O
which	O
shows	O
linear	O
pharmacokinetics	O
and	O
no	O
saturation	O
of	O
absorption.	O
pregabalin	B-Drug

Flumazenil	B-Drug
was	O
found	O
to	O
be	O
more	O
effective	O
than	O
placebo	O
in	O
reducing	O
feelings	O
of	O
hostility	O
and	O
aggression	O
patients	O
who	O
had	O
been	O
free	O
benzodiazepines	O
for	O
4266	O
weeks.	O

The	O
CAS	O
number	O
of	O
naloxone	B-Drug
is	O
465-65-6;	O
the	O
anhydrous	O
hydrochloride	O
salt	O
has	O
357-08-4	O
and	O
with	O
2	O
molecules	O
water,	O
dihydrate,	O
51481-60-8	O

Nortriptyline	B-Drug
is	O
used	O
to	O
treat	O
depression.	O

In	O
2020,	O
the	O
US	O
state	O
of	O
Oregon	O
would	O
become	O
first	O
to	O
decriminalize	O
use	O
heroin	B-Drug
after	O
voters	O
passed	O
Ballot	O
Measure	O
110.	O

Research	O
by	O
the	O
Multidisciplinary	O
Association	O
for	O
Psychedelic	O
Studies	O
(MAPS)	O
has	O
provided	O
evidence	O
that	O
MDMA	B-Drug
can	O
help	O
address	O
trauma-related	O
disease,	O
in	O
particular	O
post-traumatic	O
stress	O
disorder.	O

These	O
drugs	O
have	O
largely	O
been	O
replaced	O
by	O
second-generation	O
(atypical)	O
antipsychotics	O
such	O
as	O
clozapine	B-Drug
and	O
paliperidone.	O
paliperidone	B-Drug

This	O
suggests	O
that	O
medical	O
use	O
of	O
amphetamine	B-Drug
does	O
not	O
significantly	O
affect	O
gene	O
regulation.	O

In	O
Great	O
Britain	O
and	O
Sweden,	O
mifepristone	B-Drug
is	O
licensed	O
for	O
use	O
with	O
vaginal	O
gemeprost	B-Drug
or	O
oral	O
misoprostol.	O
misoprostol	B-Drug

5-DHNET	O
is	O
formed	O
from	O
norethisterone	B-Drug
by	O
5-reductase	O
in	O
the	O
liver	O
and	O
other	O
tissues.	O

Thalidomide	B-Drug
was	O
first	O
marketed	O
in	O
1957	O
West	O
Germany,	O
where	O
it	O
available	O
over	O
the	O
counter.	O

Pickard	O
was	O
charged	O
with	O
manufacturing	O
LSD	B-Drug
and	O
served	O
five	O
years	O
in	O
prison.	O

Other	O
examples	O
include	O
phenylephrine,	O
isoproterenol,	O
and	O
dobutamine.	O
phenylephrine	B-Drug

methandrostenolone	B-Drug
(Dianabol)	O
boldenone	B-Drug
(Equipose)	O
fluoxymesterone	B-Drug
Dianabol	B-Drug

Both	O
norethisterone	B-Drug
and	O
NETA	O
are	O
also	O
available	O
in	O
the	O
United	O
States	O
as	O
contraceptives.	O

Amiloride's	O
pKa	O
is	O
8.67,	O
which	O
due	O
to	O
the	O
guanidinium	O
group.	O
Amiloride	B-Drug

Outside	O
of	O
Merck,	O
other	O
researchers	O
began	O
to	O
investigate	O
MDMA.	O
MDMA	B-Drug

Chinese	O
triad	O
gangs	O
eventually	O
came	O
to	O
play	O
a	O
major	O
role	O
in	O
the	O
illicit	O
heroin	B-Drug
trade.	O

Chloromorphide	O
does	O
not	O
appear	O
specifically	O
in	O
the	O
Controlled	O
Substances	O
Act	O
1970	O
United	O
States,	O
but	O
is	O
presumably	O
Schedule	O
II	O
controlled	O
substance	O
as	O
a	O
form	O
of	O
morphine	B-Drug
or	O
an	O
analogue	O
morphinan.	O

Vaccine	O
development	O
continued	O
to	O
accelerate,	O
with	O
the	O
most	O
notable	O
achievement	O
of	O
period	O
being	O
Jonas	O
Salk's	O
1954	O
polio	B-Drug
vaccine	I-Drug
under	O
funding	O
non-profit	O
National	O
Foundation	O
for	O
Infantile	O
Paralysis.	O

Phenethylamine	B-Drug
is	O
a	O
primary	O
amine,	O
the	O
amino-group	O
being	O
attached	O
to	O
benzene	O
ring	O
through	O
two-carbon,	O
or	O
ethyl	O
group.	O

Heroin	B-Drug
purity	O
has	O
been	O
classified	O
into	O
four	O
grades.	O

It	O
may	O
also	O
be	O
mixed	O
with	O
cannabis	O
or	O
tobacco.	O
tobacco	B-Drug

The	O
method	O
is	O
suitable	O
for	O
such	O
small	O
batches	O
that	O
pseudoephedrine	B-Drug
restrictions	O
are	O
less	O
effective,	O
it	O
uses	O
chemicals	O
easier	O
to	O
obtain	O
(though	O
no	O
dangerous	O
than	O
traditional	O
methods),	O
and	O
so	O
easy	O
carry	O
out	O
some	O
addicts	O
have	O
made	O
the	O
drug	O
while	O
driving.	O

Side	O
effects	O
of	O
nalbuphine	B-Drug
include	O
sedation,	O
sweatiness,	O
clamminess,	O
nausea,	O
vomiting,	O
dizziness,	O
vertigo,	O
dry	O
mouth,	O
and	O
headache.	O

On	O
more	O
degradation	O
CBN	B-Drug
is	O
formed.	O

FUB-APINACA	B-Drug
FUB-JWH-018	B-Drug

Despite	O
the	O
fact	O
that	O
gabapentinoids	O
are	O
GABA	O
analogues,	O
gabapentin	B-Drug
and	O
pregabalin	B-Drug
do	O
not	O
bind	O
to	O
receptors,	O
convert	O
into	O
or	O
receptor	O
agonists	O
in	O
vivo,	O
modulate	O
transport	O
metabolism.	O

These	O
mortality-related	O
effects	O
are	O
thought	O
to	O
be	O
a	O
consequence	O
of	O
androgen	O
deprivation,	O
rather	O
than	O
specific	O
drug-related	O
toxicity	O
bicalutamide.	O
bicalutamide	B-Drug

Methadone	B-Drug
and	O
its	O
two	O
main	O
metabolites	O
The	O
most	O
common	O
route	O
of	O
administration	O
at	O
a	O
methadone	O
clinic	O
is	O
in	O
racemic	O
oral	O
solution,	O
though	O
Germany,	O
only	O
the	O
R	O
enantiomer	O
(the	O
L	O
optical	O
isomer)	O
has	O
traditionally	O
been	O
used,	O
as	O
it	O
responsible	O
for	O
desired	O
opioid	O
effects.	O

In	O
a	O
study	O
of	O
cocaine	B-Drug
users,	O
the	O
average	O
time	O
taken	O
to	O
reach	O
peak	O
subjective	O
effects	O
was	O
14.6	O
minutes.	O

In	O
India,	O
methylphenidate	B-Drug
is	O
a	O
schedule	O
X	O
drug	O
and	O
controlled	O
by	O
the	O
Drugs	O
Cosmetics	O
Rule,	O
1945.	O

In	O
terms	O
of	O
benzodiazepine	O
receptor	O
binding	O
and	O
relevant	O
potency,	O
3	O
mg	O
eszopiclone	B-Drug
is	O
equivalent	O
to	O
10	O
diazepam.	O
diazepam	B-Drug

Cardiac	O
arrest	O
may	O
occur	O
in	O
propranolol	B-Drug
overdose	O
due	O
to	O
sudden	O
ventricular	O
arrhythmias,	O
or	O
cardiogenic	O
shock	O
which	O
ultimately	O
culminate	O
bradycardic	O
PEA.	O

As	O
such,	O
PCP	B-Drug
is	O
an	O
NMDA	O
receptor	O
antagonist.	O

Olanzapine	B-Drug
binds	O
all	O
receptors	O
and	O
is	O
used	O
to	O
treat	O
the	O
positive	O
negative	O
symptoms	O
of	O
schizophrenia	O
as	O
well	O
bipolar	O
disorder	O
depression.	O

4-substitution	O
(e.g.,	O
clostebol,	O
oxabolone),	O
and	O
various	O
other	O
modifications.	O
clostebol	B-Drug

In	O
2017,	O
fluticasone	B-Drug
was	O
the	O
15th	O
most	O
commonly	O
prescribed	O
medication	O
in	O
United	O
States,	O
with	O
more	O
than	O
32	O
million	O
prescriptions	O
(up	O
from	O
16th	O
place	O
&	O
29	O
2016).	O

Barbital	B-Drug
was	O
prepared	O
by	O
condensing	O
diethylmalonic	O
ester	O
with	O
urea	O
in	O
the	O
presence	O
of	O
sodium	O
ethoxide,	O
or	O
adding	O
at	O
least	O
two	O
molar	O
equivalents	O
ethyl	O
iodide	O
to	O
silver	O
salt	O
malonylurea	O
(barbituric	O
acid)	O
possibly	O
a	O
basic	O
solution	O
acid.	O

A	O
2015	O
meta-analysis	O
found	O
that	O
modafinil	B-Drug
and	O
armodafinil	B-Drug
may	O
slightly	O
reduce	O
negative	O
symptoms	O
in	O
people	O
with	O
acute	O
schizophrenia,	O
though	O
it	O
does	O
not	O
appear	O
useful	O
for	O
the	O
condition	O
who	O
are	O
stable,	O
high	O
symptom	O
scores.	O

4-MTA	B-Drug
was	O
developed	O
by	O
the	O
research	O
team	O
led	O
David	O
E.	O
Nichols	O
but	O
intended	O
to	O
be	O
used	O
only	O
as	O
an	O
agent	O
for	O
laboratory	O
into	O
serotonin	O
transporter	O
protein.	O

Analogues	O
of	O
mirtazapine	B-Drug
include	O
mianserin,	O
setiptiline,	O
and	O
aptazapine.	O
mianserin	B-Drug

In	O
1997,	O
a	O
group	O
of	O
Australian	O
researchers	O
proposed	O
(based	O
on	O
study	O
in	O
rats)	O
that	O
oxycodone	B-Drug
acts	O
KORs,	O
unlike	O
morphine,	O
which	O
upon	O
MORs.	O
morphine	B-Drug

At	O
normal	O
therapeutic	O
doses,	O
the	O
most	O
common	O
psychological	O
side	O
effects	O
of	O
amphetamine	B-Drug
include	O
increased	O
alertness,	O
apprehension,	O
concentration,	O
initiative,	O
self-confidence	O
and	O
sociability,	O
mood	O
swings	O
(	O

PCP	B-Drug
has	O
also	O
been	O
shown	O
to	O
cause	O
schizophrenia-like	O
changes	O
in	O
N-acetylaspartate	O
and	O
N-acetylaspartylglutamate	O
levels	O
the	O
rat	O
brain,	O
which	O
are	O
detectable	O
both	O
living	O
rats	O
upon	O
necropsy	O
examination	O
of	O
brain	O
tissue.	O

People	O
with	O
the	O
disorder	O
known	O
as	O
succinic	O
semialdehyde	O
dehydrogenase	O
deficiency,	O
also	O
-hydroxybutyric	O
aciduria,	O
have	O
elevated	O
levels	O
of	O
GHB	B-Drug
in	O
their	O
urine,	O
blood	O
plasma	O
and	O
cerebrospinal	O
fluid.	O

It	O
may	O
be	O
sold	O
in	O
combination	O
with	O
paracetamol	B-Drug
(acetaminophen)	O
or	O
as	O
longer-acting	O
formulations.	O
acetaminophen	B-Drug

THG	B-Drug
was	O
the	O
main	O
steroid	O
distributed	O
by	O
BALCO,	O
with	O
other	O
products	O
more	O
of	O
a	O
regimen	O
to	O
heighten	O
its	O
effects	O
in	O
accordance	O
an	O
individual	O
athlete's	O
requirements.	O

In	O
response,	O
New	O
Zealand	O
experts	O
called	O
for	O
wider	O
availability	O
of	O
naloxone.	O
naloxone	B-Drug

Diazepam	B-Drug
inhibits	O
acetylcholine	O
release	O
in	O
mouse	O
hippocampal	O
synaptosomes.	O

Spironolactone	B-Drug
may	O
put	O
people	O
at	O
a	O
heightened	O
risk	O
for	O
gastrointestinal	O
issues	O
like	O
nausea,	O
vomiting,	O
diarrhea,	O
cramping,	O
and	O
gastritis.	O

In	O
October	O
2019,	O
Sanofi	O
recalled	O
all	O
over-the-counter	O
Zantac	B-Drug
in	O
the	O
United	O
States	O
and	O
Canada,	O
Perrigo	O
issued	O
a	O
worldwide	O
recall	O
of	O
ranitidine,	O
Dr.	O
Reddy's	O
ranitidine	B-Drug
products	O
States,	O
Novitium	O
Pharma	O
hydrochloride	O
capsules	O
U.S.In	O
November	O
Aurobindo	O
Pharma,	O
Amneal	O
Pharmaceuticals,	O
American	O
Health	O
Packaging,	O
Golden	O
State	O
Medical	O
Supply,	O
Precision	O
Dose	O
some	O
lots	O
tablets,	O
capsules,	O
syrup.	O

De	O
Quincey	O
writes	O
about	O
the	O
great	O
English	O
Romantic	O
poet,	O
Samuel	O
Taylor	O
Coleridge	O
(17721834),	O
whose	O
"Kubla	O
Khan"	O
is	O
also	O
widely	O
considered	O
to	O
be	O
a	O
poem	O
of	O
opium	B-Drug
experience.	O

cocaine,	O
heroin,	O
cannabis	O
Punisher	O
War	O
Zone	O
(2008)	O
cocaine	B-Drug
heroin	B-Drug

LSD	B-Drug
may	O
trigger	O
panic	O
attacks	O
or	O
feelings	O
of	O
extreme	O
anxiety,	O
known	O
familiarly	O
as	O
a	O
"bad	O
trip."	O

Adinazolam	B-Drug
was	O
never	O
FDA	O
approved	O
and	O
made	O
available	O
to	O
the	O
public	O
market,	O
however	O
it	O
has	O
been	O
sold	O
as	O
a	O
designer	O
drug.	O

All	O
SSRIs	O
and	O
SNRIs	O
are	O
Category	O
C,	O
except	O
paroxetine,	O
which	O
is	O
D	O
since	O
it	O
has	O
shown	O
association	O
with	O
congenital	O
heart	O
disorders.	O
paroxetine	B-Drug

Oral	O
methylprednisolone	B-Drug
has	O
a	O
moderate	O
distribution	O
into	O
tissue	O
at	O
1.38L/kg.	O

The	O
Colombian	O
government	O
announced	O
that	O
it	O
eradicated	O
around	O
73,000	O
coca	B-Drug
hectares	O
during	O
2006	O
which,	O
according	O
to	O
it,	O
would	O
be	O
above	O
all	O
local	O
records	O
in	O
plant	O
destruction.	O

It	O
does	O
not	O
produce	O
any	O
significant	O
numbing	O
of	O
the	O
mouth	O
nor	O
it	O
give	O
a	O
rush	O
like	O
snorting	O
cocaine.	O
cocaine	B-Drug

Dienogest	B-Drug
is	O
metabolized	O
mainly	O
by	O
the	O
cytochrome	O
P450	O
enzyme	O
CYP3A4,	O
and	O
for	O
this	O
reason,	O
inhibitors	O
inducers	O
of	O
CYP3A4	O
can	O
alter	O
amount	O
exposure	O
to	O
dienogest	B-Drug
when	O
administered	O
concomitantly	O
with	O
it.	O

Along	O
with	O
other	O
calcium	O
channel	O
blockers,	O
verapamil	B-Drug
is	O
known	O
to	O
induce	O
gingival	O
enlargement.	O

This	O
means	O
that	O
although	O
recreational	O
marijuana	O
is	O
legal	O
in	O
the	O
state,	O
CBD	B-Drug
cannot	O
legally	O
be	O
sold	O
food	O
or	O
as	O
a	O
dietary	O
supplement	O
under	O
state	O
law.	O

(5th	O
ed.,	O
abbreviated	O
DSM-5),	O
classifies	O
problematic	O
cocaine	B-Drug
use	O
as	O
a	O
"Stimulant	O
disorder".	O

e.g.	O
whether	O
pure	O
or	O
in	O
conjunction	O
with	O
tobacco	B-Drug
and	O
how	O
much	O
is	O
smoked.	O

Experimentation	O
with	O
LSD,	O
peyote,	O
psilocybin	O
mushrooms,	O
MDA,	O
marijuana,	O
and	O
other	O
psychedelic	O
drugs	O
became	O
a	O
major	O
component	O
of	O
1960s	O
counterculture,	O
influencing	O
philosophy,	O
art,	O
music	O
styles	O
dress.	O
LSD	B-Drug

The	O
company	O
generates	O
more	O
than	O
50	O
percent	O
of	O
its	O
income	O
with	O
pain	O
medications	O
such	O
as	O
the	O
drug	O
Tramadol.	O
Tramadol	B-Drug

The	O
four	O
variations	O
of	O
laudanum	B-Drug
listed	O
here	O
were	O
used	O
in	O
the	O
United	O
States	O
during	O
late	O
19th	O
century.	O

After	O
August	O
21st,	O
2020,	O
all	O
forms	O
of	O
THC	B-Drug
were	O
deemed	O
illegal	O
above	O
0.3%	O
under	O
the	O
CSA	O
(Controlled	O
Substances	O
Act),	O
according	O
to	O
DEA.	O

Indometacin,	O
a	O
non-steroidal	O
anti-inflammatory	O
drug	O
(NSAID),	O
has	O
similar	O
mode	O
of	O
action	O
when	O
compared	O
to	O
other	O
drugs	O
in	O
this	O
group.	O
Indometacin	B-Drug

5-APB	B-Drug
is	O
commonly	O
found	O
as	O
the	O
succinate	O
and	O
hydrochloride	O
salt.	O

"A	O
2012	O
review	O
found	O
that	O
the	O
THC	B-Drug
content	O
in	O
marijuana	O
had	O
increased	O
worldwide	O
from	O
1970	O
to	O
2009.	O

marijuana	B-Drug

In	O
Ireland,	O
temazepam	B-Drug
is	O
a	O
Schedule	O
3	O
controlled	O
substance	O
with	O
strict	O
restrictions.	O

In	O
the	O
treatment	O
of	O
prostate	O
cancer,	O
initial	O
increase	O
in	O
testosterone	O
levels	O
associated	O
with	O
initiation	O
leuprorelin	B-Drug
therapy	O
is	O
counterproductive	O
to	O
goals.	O

Distillers	O
Co.	O
Ltd	O
(now	O
part	O
of	O
Diageo	O
plc),	O
marketed	O
thalidomide	B-Drug
throughout	O
the	O
UK,	O
Australia	O
and	O
New	O
Zealand,	O
under	O
brand	O
name	O
Distaval,	O
as	O
a	O
remedy	O
for	O
morning	O
sickness.	O

The	O
desired	O
short-term	O
psychoactive	O
effects	O
of	O
MDMA	B-Drug
have	O
been	O
reported	O
to	O
include:	O

This	O
receptor	O
was	O
first	O
noted	O
for	O
its	O
importance	O
as	O
a	O
target	O
of	O
serotonergic	O
psychedelic	O
drugs	O
such	O
LSD	B-Drug
and	O
psilocybin	O
mushrooms.	O

MDMA	B-Drug
(called	O
methylsafrylamin,	O
safrylmethylamin	O
or	O
N-Methyl-a-Methylhomopiperonylamin	O
in	O
Merck	O
laboratory	O
reports)	O
was	O
an	O
intermediate	O
compound	O
the	O
synthesis	O
of	O
methylhydrastinine.	O

THC	B-Drug
and	O
its	O
major	O
(inactive)	O
metabolite,	O
THC-COOH,	O
can	O
be	O
measured	O
in	O
blood,	O
urine,	O
hair,	O
oral	O
fluid	O
or	O
sweat	O
using	O
chromatographic	O
techniques	O
as	O
part	O
of	O
a	O
drug	O
use	O
testing	O
program	O
forensic	O
investigation	O
traffic	O
other	O
criminal	O
offense.	O

Provitamin	O
D2	I-Drug
spontaneously	O
forms	O
vitamin	B-Drug
D2.	O

In	O
2015,	O
Yankees	O
minor-league	O
pitching	O
prospect	O
Moises	O
Cedeno	O
tested	O
positive	O
for	O
clenbuterol	B-Drug
and	O
was	O
suspended	O
72	O
games.	O

THC	B-Drug
has	O
been	O
shown	O
to	O
inhibit	O
GABA	O
receptor	O
neurotransmission	O
in	O
the	O
brain	O
via	O
several	O
pathways.	O

It	O
has	O
been	O
found	O
to	O
possess	O
30%	O
of	O
the	O
affinity	O
corticosteroid	O
dexamethasone	B-Drug
for	O
this	O
receptor.	O

Due	O
to	O
its	O
similarity	O
in	O
effects	O
PCP,	O
PCE	B-Drug
was	O
placed	O
into	O
the	O
Schedule	O
1	O
list	O
of	O
illegal	O
drugs	O
1970s,	O
although	O
it	O
only	O
briefly	O
abused	O
1970s	O
and	O
1980s	O
is	O
now	O
little	O
known.	O
PCP	B-Drug

Wide	O
variance	O
in	O
the	O
measured	O
rate	O
of	O
deaths	O
caused	O
by	O
drugs	O
such	O
as	O
ecstasy	B-Drug
across	O
countries	O
suggest	O
that	O
user	O
and	O
societal/environmental	O
factors	O
may	O
also	O
affect	O
lethality	O
club	O
drugs.	O

Naltrexone	B-Drug
is	O
or	O
has	O
been	O
marketed	O
under	O
a	O
variety	O
of	O
brand	O
names,	O
including	O
Adepend,	O
Antaxone,	O
Celupan,	O
Depade,	O
Nalorex,	O
Narcoral,	O
Nemexin,	O
Nodict,	O
Revia/ReVia,	O
Trexan,	O
and	O
Vivitrol.	O
ReVia	B-Drug

MDMA	B-Drug
was	O
openly	O
distributed	O
in	O
Austin	O
and	O
DallasFort	O
Worth	O
area	O
bars	O
nightclubs,	O
becoming	O
popular	O
with	O
yuppies,	O
college	O
students,	O
gays.	O

Bicalutamide	B-Drug
is	O
a	O
member	O
of	O
the	O
nonsteroidal	O
antiandrogen	O
(NSAA)	O
group	O
medications.	O

In	O
2008,	O
recreational	O
use	O
of	O
oxycodone	B-Drug
and	O
hydrocodone	B-Drug
were	O
involved	O
in	O
14,800	O
deaths.	O

It	O
can	O
be	O
particularly	O
unsafe,	O
in	O
comparison	O
to	O
LSD,	O
for	O
those	O
suffering	O
from	O
hypertension,	O
as	O
amphetamine	B-Drug
compounds	O
are	O
known	O
cause	O
sharp	O
increases	O
systolic	O
blood	O
pressure.	O
LSD	B-Drug

This	O
rescheduling	O
constituted	O
part	O
of	O
the	O
argument	O
for	O
a	O
2002	O
petition	O
removal	O
cannabis	O
from	O
Schedule	O
I	O
Controlled	O
Substances	O
Act,	O
in	O
which	O
petitioner	O
Jon	O
Gettman	O
noted,	O
"Cannabis	O
is	O
natural	O
source	O
dronabinol	O
(THC),	O
ingredient	O
Marinol,	O
III	O
drug.	O
THC	B-Drug

Those	O
charged	O
with	O
ketamine	B-Drug
possession	O
will	O
in	O
most	O
cases	O
be	O
given	O
an	O
opportunity	O
to	O
plead	O
guilty	O
and	O
receive	O
no	O
jail	O
time	O
under	O
PC	O
1000,	O
Prop	O
36,	O
or	O
felony	O
supervised	O
probation.	O

It	O
is	O
likely	O
that	O
the	O
higher	O
THC	B-Drug
content	O
allows	O
people	O
to	O
ingest	O
less	O
tar.	O

0.05%	O
Moderate	O
(225	O
times	O
as	O
potent	O
hydrocortisone)	O
hydrocortisone	B-Drug

Health	O
Canada	O
gave	O
approval	O
to	O
mifepristone	B-Drug
in	O
July	O
2015.	O

A	O
forensic	O
standard	O
of	O
UR-144	B-Drug
is	O
available,	O
and	O
the	O
compound	O
has	O
been	O
posted	O
on	O
Forendex	O
website	O
potential	O
drugs	O
abuse.	O

PCP	B-Drug
is	O
notably	O
a	O
high-affinity	O
ligand	O
of	O
the	O
site	O
2	O
(Ki	O
=	O
154	O
nM),	O
not-well-characterized	O
associated	O
with	O
monoamine	O
reuptake	O
inhibition.	O

Placidyl	B-Drug
was	O
available	O
in	O
200	O
mg,	O
500	O
and	O
750	O
mg	O
strength	O
gel	O
filled	O
capsules.	O

At	O
this	O
period,	O
thirty	O
cases	O
of	O
acute	O
dysentery	O
also	O
occurred	O
amongst	O
them	O
and	O
although	O
nineteen	O
the	O
number	O
were	O
men	O
who	O
arrived	O
in	O
island	O
from	O
Europe	O
on	O
1st	O
12th	O
June,	O
yet,	O
symptoms	O
even	O
equally	O
as	O
mild	O
assimilated	O
soldier,	O
disease	O
yielded	O
to	O
common	O
remedies	O
viz	O
bleeding	O
when	O
state	O
vascular	O
system	O
appeared	O
indicate	O
use	O
it,	O
but	O
general,	O
saline	O
purgatives	O
small	O
repeated	O
quantities	O
only	O
necessary	O
with	O
doses	O
at	O
bed	O
time,	O
calomel	O
opium,	O
infusion	O
ipecacuanha	O
or	O
Dovers	O
powder,	O
tonics,	O
moderate	O
port	O
wine	O
a	O
light	O
farinaceous	O
diet	O
generally	O
speedily	O
accomplished	O
perfect	O
case.	O
opium	B-Drug

Amphetamine	B-Drug
is	O
used	O
by	O
some	O
athletes	O
for	O
its	O
psychological	O
and	O
athletic	O
performance-enhancing	O
effects,	O
such	O
as	O
increased	O
endurance	O
alertness;	O
however,	O
non-medical	O
amphetamine	B-Drug
use	O
prohibited	O
at	O
sporting	O
events	O
that	O
are	O
regulated	O
collegiate,	O
national,	O
international	O
anti-doping	O
agencies.	O

(levamisole)	O
Daktarin	B-Drug
(miconazole)	O
Vermox	O
(mebendazole)	O
levamisole	B-Drug
miconazole	B-Drug
mebendazole	B-Drug

In	O
the	O
United	O
States,	O
domperidone	B-Drug
is	O
not	O
currently	O
a	O
legally	O
marketed	O
human	O
drug	O
and	O
it	O
approved	O
for	O
sale	O
in	O
U.S.	O

As	O
of	O
October	O
31,	O
2016;	O
25I-NBOMe	B-Drug
is	O
a	O
controlled	O
substance	O
(Schedule	O
III)	O
in	O
Canada.	O

Like	O
other	O
2C-X-NBOMe	O
molecules,	O
25I-NBOMe	B-Drug
is	O
a	O
derivative	O
of	O
the	O
2C	O
family	O
phenethylamines	O
described	O
by	O
chemist	O
Alexander	O
Shulgin	O
in	O
his	O
book	O
PiHKAL.	O

Studies	O
have	O
found	O
that	O
combined	O
birth	O
control	O
pills	O
containing	O
newer-generation	O
progestins	O
such	O
as	O
desogestrel,	O
gestodene,	O
norgestimate,	O
drospirenone,	O
and	O
cyproterone	O
acetate	O
are	O
associated	O
with	O
a	O
1.5-	O
to	O
3-fold	O
higher	O
risk	O
of	O
VTE	O
than	O
first-generation	O
levonorgestrel	B-Drug
norethisterone.	O
desogestrel	B-Drug
norgestimate	B-Drug
norethisterone	B-Drug

DJ	O
Screw's	O
invoking	O
lean	O
in	O
his	O
lyrics	O
and	O
use	O
of	O
slow	O
tempos	O
had	O
caused	O
style	O
to	O
be	O
characterized	O
"[a]s	O
if	O
the	O
song	O
itself	O
has	O
taken	O
too	O
much	O
codeine	B-Drug
promethazine".	O
promethazine	B-Drug

One	O
of	O
his	O
preparations,	O
a	O
pill	O
which	O
he	O
extolled	O
as	O
"archanum"	O
or	O
"laudanum",	O
may	O
have	O
contained	O
opium.	O
laudanum	B-Drug
opium	B-Drug

Cannabis	O
tea,	O
which	O
contains	O
relatively	O
small	O
concentrations	O
of	O
THC	B-Drug
because	O
is	O
an	O
oil	O
(lipophilic)	O
and	O
only	O
slightly	O
water-soluble	O
(with	O
a	O
solubility	O
2.8	O
mg	O
per	O
liter).	O

Methadone	B-Drug
substitution	O
as	O
a	O
treatment	O
of	O
opioid	O
addiction	O
has	O
been	O
criticized	O
in	O
the	O
social	O
sciences	O
for	O
its	O
role	O
control	O
addicts.	O

Once	O
ingested,	O
psilocybin	O
is	O
rapidly	O
metabolized	O
to	O
psilocin,	O
which	O
then	O
acts	O
on	O
serotonin	O
receptors	O
in	O
the	O
brain.	O
psilocin	B-Drug

PCP	B-Drug
has	O
been	O
shown	O
to	O
produce	O
conditioned	O
place	O
aversion	O
and	O
preference	O
in	O
animal	O
studies.	O

Laudanum	B-Drug
was	O
historically	O
used	O
to	O
treat	O
a	O
variety	O
of	O
conditions,	O
but	O
its	O
principal	O
use	O
as	O
pain	O
medication	O
and	O
cough	O
suppressant.	O

Uniquely	O
among	O
17-alkylated	O
AAS,	O
oxandrolone	B-Drug
shows	O
little	O
to	O
no	O
hepatotoxicity,	O
even	O
at	O
high	O
doses.	O

Cases	O
of	O
life-threatening	O
or	O
fatal	O
hyponatremia	O
(excessively	O
low	O
sodium	O
concentration	O
in	O
the	O
blood)	O
have	O
developed	O
MDMA	B-Drug
users	O
attempting	O
to	O
prevent	O
dehydration	O
by	O
consuming	O
excessive	O
amounts	O
water	O
without	O
replenishing	O
electrolytes.	O

Methylprednisolone	B-Drug
undergoes	O
renal	O
excretion	O
of	O
hydrophilic	O
inactive	O
metabolites,	O
including	O
20-carboxymelthylprednisolone	O
and	O
6[beta]-hydroxy-20[alpha]-hydroxymethylprednisolone.	O

Reproductive	O
and	O
developmental	O
studies	O
of	O
acetaminophen	B-Drug
in	O
rats	O
mice	O
have	O
shown	O
fetotoxicity,	O
necrosis	O
the	O
liver	O
kidney	O
pregnant	O
rat	O
fetus,	O
retarded	O
growth	O
decreased	O
reproductive	O
capacity	O
offspring.	O

Topiramate	B-Drug
(1995).	O

Hash	B-Drug
oil	I-Drug
is	O
a	O
resinous	O
matrix	O
of	O
cannabinoids	O
obtained	O
from	O
the	O
Cannabis	O
plant	O
by	O
solvent	O
extraction,	O
formed	O
into	O
hardened	O
or	O
viscous	O
mass.	O

2Benzyl	O
alcohol	O
should	O
not	O
to	O
be	O
used	O
on	O
neonates	O
3Preservative	O
free	O
formulation	O
Methylprednisolone	B-Drug
taken	O
orally	O
by	O
people	O
who	O
have	O
systemic	O
fungal	O
infections,	O
with	O
the	O
exception	O
of	O
Depo-Medrol	O
when	O
administered	O
as	O
an	O
intra-articular	O
injection	O
for	O
localized	O
joint	O
conditions.	O

THC	B-Drug
increases	O
appetite	O
(aka	O
"the	O
munchies")	O
by	O
acting	O
as	O
a	O
CB1	O
agonist.	O

Bevacizumab	B-Drug
was	O
approved	O
in	O
the	O
United	O
States	O
February	O
2004,	O
for	O
use	O
metastatic	O
colorectal	O
cancer	O
when	O
used	O
with	O
standard	O
chemotherapy	O
treatment	O
(as	O
first-line	O
treatment).	O

At	O
normal	O
urine	O
pH,	O
the	O
half-lives	O
of	O
dextroamphetamine	B-Drug
and	O
levoamphetamine	O
are	O
911	O
hours	O
1114	O
hours,	O
respectively.	O

Combination	O
of	O
alprazolam	B-Drug
with	O
the	O
herb	O
kava	O
can	O
result	O
in	O
development	O
a	O
semi-comatose	O
state.	O

Bupivacaine,	O
marketed	O
under	O
the	O
brand	O
name	O
Marcaine	O
among	O
others,	O
is	O
a	O
medication	O
used	O
to	O
decrease	O
feeling	O
in	O
specific	O
area.	O
Bupivacaine	B-Drug

In	O
fact,	O
TFMPP	B-Drug
reduces	O
locomotor	O
activity	O
and	O
produces	O
aversive	O
effects	O
in	O
animals	O
rather	O
than	O
self-administration,	O
which	O
may	O
explain	O
the	O
decision	O
of	O
DEA	O
not	O
to	O
permanently	O
make	O
a	O
controlled	O
substance.	O

4-HO-MET	O
is	O
not	O
scheduled	O
at	O
the	O
federal	O
level	O
in	O
United	O
States,	O
but	O
it	O
possible	O
that	O
could	O
be	O
considered	O
an	O
analog	O
of	O
psilocin,	O
which	O
case	O
purchase,	O
sale,	O
or	O
possession	O
prosecuted	O
under	O
Federal	O
Analog	O
Act.	O
psilocin	B-Drug

Compared	O
to	O
heroin,	O
it	O
is	O
more	O
potent,	O
has	O
higher	O
profit	O
margins	O
and,	O
because	O
compact,	O
simpler	O
logistics.	O
heroin	B-Drug

Spironolactone	B-Drug
is	O
available	O
in	O
the	O
form	O
of	O
tablets	O
(25	O
mg,	O
50	O
100	O
mg;	O
brand	O
name	O
Aldactone,	O
others)	O
and	O
suspensions	O
mg/5	O
mL;	O
CaroSpir)	O
for	O
use	O
by	O
mouth.	O

Since	O
heroin	B-Drug
can	O
cause	O
nausea	O
and	O
vomiting,	O
a	O
significant	O
number	O
of	O
deaths	O
attributed	O
to	O
overdose	O
are	O
caused	O
by	O
aspiration	O
vomit	O
an	O
unconscious	O
person.	O

A	O
generic	O
version	O
of	O
gabapentin	B-Drug
first	O
became	O
available	O
in	O
the	O
United	O
States	O
2004.	O

Aspirin,	O
however,	O
is	O
used	O
together	O
with	O
heparin	B-Drug
in	O
pregnant	O
women	O
antiphospholipid	O
syndrome.	O
Aspirin	B-Drug

Purdue	O
Pharma	O
a	O
privately	O
held	O
company	O
based	O
in	O
Stamford,	O
Connecticut,	O
developed	O
the	O
prescription	O
painkiller	O
OxyContin.	O
OxyContin	B-Drug

In	O
2009,	O
the	O
Czechoslovak	O
state	O
security	O
secret	O
police	O
were	O
proven	O
to	O
have	O
used	O
hyoscine	B-Drug
at	O
least	O
three	O
times	O
obtain	O
confessions	O
from	O
alleged	O
antistate	O
dissidents.	O

Hematological:	O
agranulocytosis,	O
thrombocytopenia,	O
eosinophilia,	O
leukopenia	O
Skin:	O
rash,	O
urticaria,	O
diaphoresis,	O
pruritus,	O
photosensitivity	O
Imipramine	B-Drug
affects	O
numerous	O
neurotransmitter	O
systems	O
known	O
to	O
be	O
involved	O
in	O
the	O
etiology	O
of	O
depression,	O
anxiety,	O
attention-deficit	O
hyperactivity	O
disorder	O
(ADHD),	O
enuresis	O
and	O
other	O
mental	O
physical	O
conditions.	O

Cocaine	B-Drug
use	O
leads	O
to	O
an	O
increased	O
risk	O
of	O
hemorrhagic	O
and	O
ischemic	O
strokes.	O

Intravenous	O
salbutamol	B-Drug
can	O
be	O
used	O
as	O
a	O
tocolytic	O
to	O
relax	O
the	O
uterine	O
smooth	O
muscle	O
delay	O
premature	O
labor.	O

Trimethoprim	B-Drug
and	O
sulfamethoxazole	B-Drug
are	O
commonly	O
used	O
in	O
combination	O
due	O
to	O
possible	O
synergistic	O
effects,	O
reduced	O
development	O
of	O
resistance.	O

The	O
opioid	O
medication	O
tapentadol	B-Drug
was	O
developed	O
to	O
mimic	O
the	O
actions	O
of	O
desmetramadol	O
in	O
order	O
create	O
a	O
weak-moderate	O
analgesic	O
which	O
is	O
not	O
dependent	O
on	O
metabolic	O
activation.	O

The	O
Arme	O
d'Orient,	O
along	O
with	O
a	O
contingent	O
of	O
151	O
scientists	O
and	O
anthropologists	O
from	O
the	O
Commission	O
des	O
Sciences	O
et	O
Arts,	O
brought	O
quantities	O
hashish	B-Drug
home	O
them	O
Napoleon's	O
expedition	O
to	O
Egypt.	O

DMT	O
is	O
found	O
as	O
a	O
minor	O
alkaloid	O
in	O
snuff	B-Drug
made	O
from	O
Virola	O
bark	O
resin	O
which	O
5-MeO-DMT	B-Drug
the	O
main	O
active	O
alkaloid.	O

In	O
India	O
(except	O
the	O
state	O
of	O
Punjab),	O
multiple	O
brands	O
Tapentadol	B-Drug
remain	O
available	O
over	O
counter.	O

In	O
2004,	O
according	O
to	O
the	O
United	O
Nations,	O
589	O
tonnes	O
of	O
cocaine	B-Drug
were	O
seized	O
globally	O
by	O
law	O
enforcement	O
authorities.	O

One	O
of	O
the	O
main	O
advantages	O
fenethylline	B-Drug
was	O
that	O
it	O
does	O
not	O
increase	O
blood	O
pressure	O
to	O
same	O
extent	O
as	O
an	O
equivalent	O
dose	O
amphetamine	B-Drug
and	O
so	O
could	O
be	O
used	O
in	O
patients	O
with	O
cardiovascular	O
conditions.	O

UR-144	B-Drug
produces	O
bradycardia	O
and	O
hypothermia	O
in	O
rats	O
at	O
a	O
dose	O
of	O
10	O
mg/kg,	O
suggesting	O
weak	O
cannabinoid-like	O
activity.	O

As	O
an	O
AAS,	O
metenolone	B-Drug
enanthate	O
is	O
antigonadotropic	O
and	O
can	O
suppress	O
the	O
hypothalamicpituitarygonadal	O
axis	O
produce	O
reversible	O
hypogonadism	O
infertility.	O

However	O
the	O
same	O
change	O
made	O
to	O
more	O
potent	O
analogue	O
carfentanil	B-Drug
retained	O
reasonable	O
opioid	O
receptor	O
activity,	O
reflecting	O
higher	O
binding	O
affinity	O
produced	O
by	O
4-carbomethoxy	O
group.	O

Nitrazepam	B-Drug
may	O
promote	O
the	O
development	O
of	O
parasympathetic	O
overactivity	O
or	O
vagotonia,	O
leading	O
to	O
potentially	O
fatal	O
respiratory	O
distress	O
in	O
children.	O

SERT	O
3)	O
desipramine	B-Drug
@	O

Pregabalin's	O
use	O
in	O
cancer-associated	O
neuropathic	O
pain	O
is	O
controversial;	O
though	O
such	O
common.	O
Pregabalin	B-Drug

Between	O
January	O
2007	O
and	O
December	O
2009	O
(a	O
period	O
of	O
three	O
years),	O
1,232,143	O
prescriptions	O
bicalutamide	B-Drug
were	O
dispensed	O
in	O
the	O
U.S.,	O
or	O
about	O
400,000	O
per	O
year.	O

Streptomycin,	O
discovered	O
during	O
a	O
Merck-funded	O
research	O
program	O
in	O
Selman	O
Waksman's	O
laboratory	O
at	O
Rutgers	O
1943,	O
became	O
the	O
first	O
effective	O
treatment	O
for	O
tuberculosis.	O
Streptomycin	B-Drug

UR-144	B-Drug
has	O
high	O
affinity	O
for	O
the	O
CB2	O
receptor	O
with	O
a	O
Ki	O
of	O
1.8	O
nM	O

The	O
opium	B-Drug
trade	O
incurred	O
intense	O
enmity	O
from	O
the	O
later	O
British	O
Prime	O
Minister	O
William	O
Ewart	O
Gladstone.	O

However,	O
structural	O
changes	O
observed	O
over	O
time	O
in	O
the	O
brains	O
of	O
methamphetamine	B-Drug
users,	O
and	O
various	O
other	O
substances	O
(e.g.,	O
neurotoxins),	O
though	O
not	O
'holes'	O
any	O
manner,	O
can	O
still	O
be	O
significantly	O
damaging.	O

Orally	O
administered	O
cocaine	B-Drug
takes	O
approximately	O
30	O
minutes	O
to	O
enter	O
the	O
bloodstream.	O

Following	O
the	O
discovery	O
at	O
a	O
Jordanian	O
airport	O
of	O
toner	O
cartridge	O
that	O
had	O
been	O
modified	O
into	O
an	O
improvised	O
explosive	O
device,	O
resultant	O
increased	O
level	O
airfreight	O
scrutiny	O
led	O
to	O
major	O
shortage	O
(drought)	O
heroin	B-Drug
from	O
October	O
2010	O
until	O
April	O
2011.	O

The	O
dextro	O
isomer,	O
d-alphacetylmethadol	O
(d--acetylmethadol),	O
is	O
more	O
potent	O
but	O
shorter	O
acting.	O
acetylmethadol	B-Drug

It	O
has	O
recently	O
been	O
discovered	O
that	O
most	O
or	O
all	O
of	O
the	O
therapeutic	O
efficacy	O
paracetamol	B-Drug
is	O
due	O
to	O
a	O
metabolite,	O
AM404,	O
which	O
enhances	O
release	O
serotonin	O
and	O
inhibits	O
uptake	O
anandamide.	O

Patients	O
dependent	O
on	O
clonazepam	B-Drug
should	O
be	O
slowly	O
titrated	O
off	O
under	O
the	O
supervision	O
of	O
a	O
qualified	O
healthcare	O
professional	O
to	O
reduce	O
intensity	O
withdrawal	O
or	O
rebound	O
symptoms.	O

A	O
2007	O
UK	O
study	O
ranked	O
MDMA	B-Drug
18th	O
in	O
harmfulness	O
out	O
of	O
20	O
recreational	O
drugs.	O

Although	O
said	O
to	O
be	O
only	O
slightly	O
androgenic,	O
nandrolone	B-Drug
decanoate	I-Drug
may	O
still	O
occasionally	O
cause	O
virilization	O
at	O
recommended	O
dosages	O
in	O
women,	O
especially	O
with	O
long-term	O
treatment.	O

The	O
dextro	O
isomer,	O
d-alphacetylmethadol	O
(d--acetylmethadol),	O
is	O
more	O
potent	O
but	O
shorter	O
acting.	O
acetylmethadol	B-Drug

Cocaine	B-Drug
is	O
addictive	O
due	O
to	O
its	O
effect	O
on	O
the	O
reward	O
pathway	O
in	O
brain.	O

My	O
feelings	O
about	O
LSD	B-Drug
are	O
mixed.	O

A	O
chemist	O
named	O
Angelo	O
Mariani	O
who	O
read	O
Mantegazza's	O
paper	O
became	O
immediately	O
intrigued	O
with	O
coca	B-Drug
and	O
its	O
economic	O
potential.	O

Because	O
the	O
lethal	O
dose	O
of	O
heroin	B-Drug
was	O
viewed	O
as	O
a	O
hundred	O
times	O
greater	O
than	O
its	O
effective	O
dose,	O
advertised	O
safer	O
alternative	O
to	O
other	O
opioids.	O

phenibut	B-Drug
propofol	B-Drug
(Diprivan)	O
theanine	B-Drug
(found	O
in	O
Camellia	O
sinensis,	O
the	O
tea	O
plant)	O
valerian	O
(from	O
Valeriana	O
officinalis)	O
Diprivan	B-Drug

PCP	B-Drug
may	O
induce	O
feelings	O
of	O
strength,	O
power,	O
and	O
invulnerability	O
as	O
well	O
a	O
numbing	O
effect	O
on	O
the	O
mind.	O

Metabolism	O
of	O
JWH-018	B-Drug
was	O
assessed	O
using	O
Wistar	O
rats	O
which	O
had	O
been	O
administered	O
an	O
ethanolic	O
extract	O
containing	O
JWH-018.	O

The	O
beta	O
blocker	O
atenolol	B-Drug
is	O
an	O
anti-hypertensive	O
medication	O
that	O
shown	O
to	O
more	O
significantly	O
lower	O
the	O
blood	O
pressure	O
of	O
Caucasian	O
patients	O
than	O
African	O
American	O
in	O
United	O
States.	O

A	O
forensic	O
standard	O
of	O
UR-144	B-Drug
is	O
available,	O
and	O
the	O
compound	O
has	O
been	O
posted	O
on	O
Forendex	O
website	O
potential	O
drugs	O
abuse.	O

The	O
widespread	O
use	O
of	O
fentanyl	B-Drug
triggered	O
the	O
production	O
citrate	O
(the	O
salt	O
formed	O
by	O
combining	O
and	O
citric	O
acid	O
in	O
a	O
1:1	O
stoichiometric	O
ratio).	O

By	O
treating	O
normal	O
and	O
knockout	O
mice	O
lacking	O
the	O
serotonin	O
transporter	O
with	O
fluoxetine	B-Drug
scientists	O
showed	O
that	O
emotional	O
reactions	O
in	O
adulthood,	O
like	O
a	O
short	O
latency	O
to	O
escape	O
foot	O
shocks	O
inclination	O
explore	O
new	O
environments	O
were	O
dependent	O
on	O
active	O
transporters	O
during	O
neonatal	O
period.	O

Lorazepam's	O
anticonvulsant	O
properties	O
and	O
pharmacokinetic	O
profile	O
make	O
intravenous	O
use	O
reliable	O
for	O
terminating	O
acute	O
seizures,	O
but	O
induce	O
prolonged	O
sedation.	O
Lorazepam	B-Drug

Claims	O
of	O
subjective	O
differences	O
in	O
effects	O
between	O
the	O
acetylated	O
and	O
non-acetylated	O
forms	O
psilocin	B-Drug
vary:	O
some	O
users	O
report	O
that	O
O-acetylpsilocin	B-Drug
lasts	O
slightly	O
longer,	O
whilst	O
others	O
it	O
for	O
a	O
considerably	O
shorter	O
time.	O

Phentermine	B-Drug
may	O
also	O
trigger	O
the	O
release	O
of	O
monoamines	O
from	O
VMAT2,	O
which	O
is	O
a	O
common	O
pharmacodynamic	O
effect	O
among	O
substituted	O
amphetamines.	O

The	O
first	O
by	O
the	O
Egyptians	O
is	O
called	O
Assis	O
(Hashish	O
(Arab.)),	O
which	O
poulder	O
of	O
Hemp,	O
or	O
Hemp	O
leaves,	O
water	O
made	O
in	O
paste	O
dough,	O
they	O
would	O
eat	O
five	O
pieces,	O
(each)	O
as	O
big	O
a	O
Chestnut	O
(or	O
larger);	O
This	O
used	O
common	O
people,	O
because	O
it	O
small	O
price,	O
and	O
no	O
wonder,	O
that	O
such	O
vertue	O
proceedeth	O
from	O
Hempe,	O
for	O
according	O
to	O
Galens	O
opinion,	O
Hempe	O
excessively	O
filleth	O
head.	O
Hashish	B-Drug

The	O
pharmaceutical	O
company	O
Rexar	O
reformulated	O
their	O
popular	O
weight	O
loss	O
drug	O
Obetrol	B-Drug
following	O
its	O
mandatory	O
withdrawal	O
from	O
the	O
market	O
in	O
1973	O
under	O
Kefauver	O
Harris	O
Amendment	O
to	O
Federal	O
Food,	O
Drug,	O
and	O
Cosmetic	O
Act	O
due	O
results	O
of	O
Drug	O
Efficacy	O
Study	O
Implementation	O
(DESI)	O
program	O
(which	O
indicated	O
a	O
lack	O
efficacy).	O

Michael	O
Cera	O
used	O
real	O
mescaline	B-Drug
for	O
the	O
movie	O
Crystal	O
Fairy	O
&	O
Magical	O
Cactus,	O
as	O
expressed	O
in	O
an	O
interview.	O

A	O
medical	O
doctor	O
even	O
wrote	O
cocaine	B-Drug
is	O
often	O
the	O
direct	O
incentive	O
to	O
crime	O
of	O
rape	O
by	O
negroes.	O

In	O
the	O
UK,	O
alprazolam	B-Drug
is	O
recommended	O
for	O
short-term	O
treatment	O
(24	O
weeks)	O
of	O
severe	O
acute	O
anxiety.	O

In	O
Hong	O
Kong,	O
etorphine	B-Drug
is	O
regulated	O
under	O
Schedule	O
1	O
of	O
Kong's	O
Chapter	O
134	O
Dangerous	O
Drugs	O
Ordinance.	O

Methadone,	O
or	O
buprenorphine	B-Drug
alone,	O
are	O
generally	O
preferred	O
when	O
treatment	O
is	O
required	O
during	O
pregnancy.	O
Methadone	B-Drug

Clonazepam	B-Drug
was	O
the	O
second	O
most	O
frequently	O
implicated	O
benzodiazepine	O
in	O
ED	O
visits.	O

Diprenorphine	O
(Revivon)	O
is	O
an	O
opioid	O
receptor	O
antagonist	O
that	O
can	O
be	O
administered	O
in	O
proportion	O
to	O
the	O
amount	O
of	O
etorphine	B-Drug
used	O
(1.3	O
times)	O
reverse	O
its	O
effects.	O

Psilocybin	O
is	O
rapidly	O
dephosphorylated	O
in	O
the	O
body	O
to	O
psilocin,	O
which	O
an	O
agonist	O
for	O
several	O
serotonin	O
receptors,	O
are	O
also	O
known	O
as	O
5-hydroxytryptamine	O
(5-HT)	O
receptors.	O
psilocin	B-Drug

Therefore,	O
succinylcholine	B-Drug
dose	O
reduction	O
is	O
not	O
needed	O
for	O
Lambert	O
Eaton	O
syndrome.	O

By	O
the	O
mid-1950s,	O
14	O
pharmaceutical	O
companies	O
were	O
marketing	O
thalidomide	B-Drug
in	O
46	O
countries	O
under	O
at	O
least	O
37	O
different	O
trade	O
names.	O

Over	O
200	O
naloxone	B-Drug
distribution	O
programs	O
utilize	O
licensed	O
prescribers	O
to	O
distribute	O
the	O
drug,	O
often	O
through	O
use	O
of	O
standing	O
medication	O
orders	O
whereby	O
is	O
distributed	O
under	O
medical	O
authority	O
a	O
physician	O
or	O
other	O
prescriber	O
(such	O
as	O
pharmacist	O
California's	O
AB1535).	O

Such	O
is	O
the	O
case	O
for	O
cannabis	O
and	O
resin	O
which	O
are	O
classified	O
with	O
heroin	B-Drug
in	O
group	O
IV	O
sole	O
reason	O
that	O
they	O
lack	O
therapeutic	O
value.	O

In	O
combined	O
injectable	O
contraceptives:	O
Estradiol	B-Drug
undecylate/norethisterone	I-Drug
enanthate	I-Drug
valerate/methenmadinone	O
caproate	O

studies	O
of	O
alcoholics	O
who	O
underwent	O
LSD	B-Drug
treatment	O
reported	O
a	O
50%	O
success	O
rate	O
after	O
single	O
high-dose	O
session.	O

The	O
opium	B-Drug
poppy,	O
as	O
its	O
name	O
indicates,	O
is	O
the	O
principal	O
source	O
of	O
opium,	O
dried	O
latex	O
produced	O
by	O
seed	O
pods.	O

In	O
September	O
2020,	O
the	O
EMA	O
received	O
an	O
application	O
for	O
marketing	O
authorization	O
of	O
dexamethasone	B-Drug
COVID19.	O

In	O
New	O
Zealand,	O
Sativex	B-Drug
is	O
"approved	O
for	O
use	O
as	O
an	O
add-on	O
treatment	O
symptom	O
improvement	O
in	O
people	O
with	O
moderate	O
to	O
severe	O
spasticity	O
due	O
multiple	O
sclerosis	O
who	O
have	O
not	O
responded	O
adequately	O
other	O
anti-spasticity	O
medication.	O

However,	O
in	O
one	O
study	O
escitalopram	B-Drug
had	O
a	O
superior	O
efficacy	O
profile	O
to	O
venlafaxine.	O
venlafaxine	B-Drug

health	O
ministry	O
Statens	O
folkhlsoinstitut	O
classified	O
MBDB	B-Drug
as	O
"health	O
hazard"	O
under	O
the	O
act	O
Lagen	O
om	O
frbud	O
mot	O
vissa	O
hlsofarliga	O
varor	O
(translated	O
Act	O
on	O
Prohibition	O
of	O
Certain	O
Goods	O
Dangerous	O
to	O
Health)	O
Feb	O
25,	O
1999,	O
in	O
their	O
regulation	O
SFS	O
1999:58	O
listed	O
"2-metylamino-1-(3,4-metylendioxifenyl)-butan	O
(MBDB)",	O
making	O
it	O
illegal	O
sell	O
or	O
possess.	O

In	O
North	O
America,	O
there	O
are	O
now	O
fewer	O
deaths	O
involving	O
heroin	B-Drug
than	O
either	O
meth	B-Drug
or	O
cocaine,	O
a	O
striking	O
change	O
that	O
has	O
taken	O
place	O
over	O
the	O
last	O
two	O
years	O
as	O
all	O
but	O
disappeared	O
from	O
some	O
regions.	O
cocaine	B-Drug

Carbamazepine	B-Drug
(Equetro,	O
Epitol,	O
and	O
many	O
other	O
variations)	O
Epitol	B-Drug

Cocaine	B-Drug
can	O
be	O
snorted,	O
swallowed,	O
injected,	O
or	O
smoked.	O

A	O
2006	O
review	O
paper	O
summarized	O
several	O
studies	O
that	O
examined	O
the	O
effect	O
of	O
androstenedione	B-Drug
on	O
strength	O
training.	O

In	O
1970,	O
the	O
US	O
adopted	O
Uniform	O
Controlled	O
Substances	O
Act,	O
which	O
regulated	O
opium	B-Drug
tincture	O
(Laudanum)	O
as	O
a	O
Schedule	O
II	O
substance	O
(currently	O
DEA	O
#9630),	O
placing	O
even	O
tighter	O
controls	O
on	O
drug.	O
Laudanum	B-Drug

It	O
contains	O
1%	O
of	O
anhydrous	O
morphine.	O
morphine	B-Drug

Ondansetron	B-Drug
is	O
one	O
of	O
several	O
antiemetic	O
drugs	O
used	O
during	O
the	O
vomiting	O
phase	O
cyclic	O
syndrome.	O

Zolpidem	B-Drug
can	O
typically	O
be	O
detected	O
in	O
bodily	O
fluids	O
for	O
36	O
hours,	O
though	O
it	O
may	O
possible	O
to	O
detect	O
by	O
hair	O
testing	O
much	O
later,	O
which	O
is	O
due	O
the	O
short	O
elimination	O
half-life	O
of	O
2.53	O
hours.	O

In	O
the	O
horror	O
video-game	O
Amnesia:	O
The	O
Dark	O
Descent	O
(2010),	O
laudanum	B-Drug
can	O
be	O
found	O
at	O
several	O
places	O
in	O
castle,	O
and	O
used	O
to	O
regain	O
health.	O

Mesterolone	B-Drug
is	O
marketed	O
mainly	O
under	O
the	O
brand	O
name	O
Proviron.	O

Later	O
he	O
recruited	O
Bolivian	O
coca	B-Drug
producers	O
into	O
his	O
company	O
"La	O
Corporacin"	O
(transl.the	O
corporation).	O

Apalutamide	B-Drug
is	O
available	O
in	O
the	O
United	O
States,	O
Canada,	O
European	O
Union,	O
and	O
Australia.	O

"	O
The	O
case	O
was	O
settled	O
in	O
2014	O
for	O
$325M.Controversy	O
arose	O
over	O
the	O
drug	O
"Celebrex".	O
Celebrex	B-Drug

Ranitidine	B-Drug
was	O
originally	O
administered	O
long-term	O
for	O
acid-reflux	O
treatment,	O
sometimes	O
indefinitely.	O

CBD	B-Drug
shares	O
a	O
precursor	O
with	O
THC	B-Drug
and	O
is	O
the	O
main	O
cannabinoid	O
in	O
CBD-dominant	O
Cannabis	O
strains.	O

Extracellular	O
levels	O
of	O
glutamate,	O
the	O
primary	O
excitatory	O
neurotransmitter	O
in	O
brain,	O
have	O
been	O
shown	O
to	O
increase	O
striatum	O
following	O
exposure	O
amphetamine.	O
amphetamine	B-Drug

5-MeO-MiPT	B-Drug
causes	O
the	O
ehrlich	O
reagent	O
to	O
turn	O
purple	O
then	O
fade	O
faint	O
blue.	O

Neither	O
zaleplon,	O
nor	O
any	O
nonbenzodiazepine	O
hypnotic	O
class	O
medication	O
should	O
be	O
combined	O
with	O
alcohol,	O
as	O
both	O
modulate	O
GABAA	O
receptor	O
sites,	O
and	O
in	O
a	O
synergistic	O
manner	O
increase	O
the	O
chances	O
of	O
fatal	O
respiratory	O
depression	O
asphyxiation	O
from	O
vomiting.	O
zaleplon	B-Drug

While	O
somewhat	O
more	O
biologically	O
plausible	O
than	O
the	O
discredited	O
LSD	B-Drug
legend	O
due	O
to	O
fat-solubility	O
of	O
THC,	O
this	O
phenomenon	O
remains	O
scientifically	O
unproven.	O
THC	B-Drug

The	O
venom	O
of	O
the	O
Colorado	O
River	O
toad,	O
Bufo	O
alvarius,	O
may	O
have	O
used	O
as	O
a	O
psychedelic	O
drug,	O
its	O
active	O
constituents	O
being	O
5-MeO-DMT	B-Drug
and	O
bufotenin.	O
bufotenin	B-Drug

"	O
Morphine	B-Drug
was	O
the	O
first	O
pharmaceutical	O
isolated	O
from	O
a	O
natural	O
product,	O
and	O
this	O
success	O
encouraged	O
isolation	O
of	O
other	O
alkaloids:	O
by	O
1820,	O
isolations	O
noscapine,	O
strychnine,	O
veratrine,	O
colchicine,	O
caffeine,	O
quinine	B-Drug
were	O
reported.	O
noscapine	B-Drug
colchicine	B-Drug

In	O
the	O
1920s,	O
nightlife	O
of	O
city	O
was	O
dominated	O
by	O
party	O
drugs	O
such	O
as	O
cocaine.	O
cocaine	B-Drug

Exogenous	O
infusion	O
of	O
melatonin,	O
replicating	O
endogenous	O
levels	O
in	O
the	O
bright-light	O
condition	O
(in	O
which	O
melatonin	B-Drug
was	O
suppressed)	O
reestablished	O
normal	O
core	O
body	O
temperature	O
trough.	O

Alprazolam	B-Drug
overdoses	O
cause	O
excess	O
central	O
nervous	O
system	O
(CNS)	O
depression	O
and	O
may	O
include	O
one	O
or	O
more	O
of	O
the	O
following	O
symptoms:	O
Coma	O
death	O
if	O
alprazolam	B-Drug
is	O
combined	O
with	O
other	O
substances.	O

The	O
recreational	O
use	O
is	O
not	O
particularly	O
widespread	O
in	O
the	O
EU	O
with	O
exception	O
of	O
Tallinn,	O
Estonia,	O
where	O
it	O
has	O
largely	O
replaced	O
heroin.	O
heroin	B-Drug

In	O
1964,	O
Israeli	O
physician	O
Jacob	O
Sheskin	O
administered	O
thalidomide	B-Drug
to	O
a	O
patient	O
critically	O
ill	O
with	O
leprosy.	O

Fentanyl,	O
also	O
spelled	O
fentanil,	O
is	O
an	O
opioid	O
used	O
as	O
a	O
pain	O
medication	O
and	O
together	O
with	O
other	O
medications	O
for	O
anesthesia.	O
Fentanyl	B-Drug

Butorphanol	B-Drug
was	O
originally	O
in	O
Schedule	O
II	O
and	O
at	O
one	O
point	O
it	O
decontrolled.	O

Gloria	O
Discerni,	O
18,	O
died	O
after	O
overdosing	O
on	O
a	O
drug	O
initially	O
believed	O
to	O
be	O
LSD.	O
LSD	B-Drug

Common	O
corticosteroids	O
include	O
dexamethasone	B-Drug
and	O
betamethasone.	O
betamethasone	B-Drug

Nonetheless,	O
while	O
the	O
ratio	O
of	O
anabolic	O
to	O
androgenic	O
activity	O
metandienone	B-Drug
is	O
improved	O
relative	O
that	O
testosterone,	O
drug	O
does	O
still	O
possess	O
moderate	O
and	O
capable	O
producing	O
severe	O
virilization	O
in	O
women	O
children.	O

5F-EMB-PINACA	B-Drug
5F-NNE1	B-Drug
5F-	O

Experts	O
estimate	O
that	O
were	O
thalidomide	B-Drug
led	O
to	O
the	O
death	O
of	O
approximately	O
2,000	O
children	O
and	O
serious	O
birth	O
defects	O
in	O
more	O
than	O
10,000	O
children,	O
about	O
5,000	O
them	O
West	O
Germany.	O

It	O
is	O
a	O
substituted	O
methamphetamine	B-Drug
and	O
homolog	O
of	O
2,5-dimethoxy-4-methylamphetamine	O
(DOM).	O

Nicotine	B-Drug
in	O
any	O
form	O
is	O
contraindicated	O
individuals	O
with	O
a	O
known	O
hypersensitivity	O
to	O
nicotine.	O
nicotine	B-Drug

The	O
company's	O
first	O
product	O
is	O
the	O
QuickNic	O
Nicotine	B-Drug
Inhaler.	O

The	O
commercial	O
product	O
contains	O
no	O
codeine	B-Drug
or	O
promethazine,	O
but	O
claims	O
to	O
"Slow	O
Your	O
Roll"	O
with	O
a	O
combination	O
of	O
herbal	O
ingredients	O
such	O
as	O
valerian	O
root	O
and	O
rose	O
hips	O
well	O
the	O
hormone	O
melatonin.	O
promethazine	B-Drug
melatonin	B-Drug

In	O
October	O
1988,	O
China	O
became	O
the	O
first	O
country	O
in	O
world	O
to	O
approve	O
mifepristone.	O
mifepristone	B-Drug

alcohol	O
dependence,	O
withdrawal,	O
delirium	O
tremens)	O
barbiturates	O
such	O
as	O
phenobarbital,	O
sodium	B-Drug
thiopental	I-Drug
and	O
secobarbital	B-Drug
benzodiazepines	O
diazepam	B-Drug
(Valium),	O
lorazepam	B-Drug
(Ativan),	O
alprazolam	B-Drug
(Xanax)	O
(see	O
benzodiazepine	O
dependence	O
withdrawal	O
syndrome)	O
phenobarbital	B-Drug
Valium	B-Drug
Ativan	B-Drug
Xanax	B-Drug

Bromazepam	B-Drug
(7-bromo-1,3-dihydro-5-(2-pyridyl)-2H-1,	O
4-benzodiazepin-2-one)	O

In	O
1934,	O
Smith,	O
Kline	O
&	O
French	O
made	O
the	O
first	O
amphetamine	B-Drug
pharmaceutical	O
when	O
they	O
began	O
selling	O
a	O
decongestant	O
inhaler	O
containing	O
volatile	O
free	O
base	O
under	O
trade	O
name	O
Benzedrine.	O

Some	O
evidence	O
indicates	O
that	O
NDMA	O
may	O
form	O
from	O
the	O
degradation	O
of	O
ranitidine	B-Drug
itself	O
with	O
increasing	O
levels	O
seen	O
over	O
its	O
shelf	O
life.	O

It	O
is	O
generally	O
less	O
expensive	O
than	O
other	O
forms	O
of	O
heroin.	O
heroin	B-Drug

Salvinorin	B-Drug
A	I-Drug
can	O
be	O
synthesized	O
from	O
salvinorin	O
B	O
by	O
acetylation,	O
and	O

Levothyroxine	B-Drug
absorption	O
is	O
increased	O
by	O
fasting	O
and	O
decreased	O
in	O
certain	O
malabsorption	O
syndromes,	O
foods,	O
with	O
age.	O

Inactive	O
ingredients	O
in	O
alprazolam	B-Drug
tablets	O
and	O
solutions	O
include	O
microcrystalline	O
cellulose,	O
corn	O
starch,	O
docusate	B-Drug
sodium,	O
povidone,	O
sodium	I-Drug
starch	O
glycollate,	O
lactose	O
monohydrate,	O
magnesium	O
stearate,	O
colloidal	O
silicon	O
dioxide,	O
benzoate.	O

The	O
decision	O
of	O
the	O
United	O
States	O
Congress	O
to	O
pass	O
Marihuana	B-Drug
Tax	O
Act	O
1937	O
was	O
based	O
on	O
poorly	O
attended	O
hearings	O
and	O
reports	O
questionable	O
studies.	O

On	O
December	O
22,	O
2008,	O
the	O
United	O
States	O
Food	O
and	O
Drug	O
Administration	O
issued	O
an	O
alert	O
to	O
consumers	O
naming	O
27	O
different	O
products	O
marketed	O
as	O
dietary	O
supplements	O
for	O
weight	O
loss,	O
that	O
illegally	O
contain	O
undisclosed	O
amounts	O
of	O
sibutramine.	O
sibutramine	B-Drug

However,	O
multiple	O
other	O
NMDA	O
receptor	O
antagonists,	O
including	O
memantine,	O
lanicemine,	O
rislenemdaz,	O
rapastinel,	O
and	O
4-chlorokynurenine,	O
have	O
thus	O
far	O
failed	O
to	O
demonstrate	O
sufficient	O
effectiveness	O
for	O
depression.	O
memantine	B-Drug
rapastinel	B-Drug
4-chlorokynurenine	B-Drug

Examples	O
of	O
known	O
interactions	O
include	O
bupropion,	O
caffeine,	O
mephenytoin,	O
midazolam,	O
nicotine,	O
nifedipine,	O
omeprazole,	O
propranolol,	O
proguanil,	O
selegiline,	O
theophylline,	O
and	O
tizanidine.	O
bupropion	B-Drug
midazolam	B-Drug
nicotine	B-Drug
omeprazole	B-Drug
propranolol	B-Drug
selegiline	B-Drug
theophylline	B-Drug
tizanidine	B-Drug

The	O
results	O
of	O
the	O
study	O
support	O
idea	O
that	O
serotonin	O
damage	O
due	O
to	O
MDMA	B-Drug
use	O
causes	O
lateral	O
inhibition	O
diminish	O
amongst	O
orientation	O
sensitive	O
neurons	O
in	O
occipital	O
lobe.	O

Ketamine	B-Drug
infusions	O
are	O
used	O
for	O
the	O
acute	O
pain	O
treatment	O
in	O
emergency	O
departments	O
and	O
perioperative	O
period	O
individuals	O
with	O
refractory	O
pain.	O

Tramadol,	O
which	O
lacks	O
the	O
cardiotoxicity,	O
has	O
been	O
recommended	O
instead	O
of	O
propoxyphene,	O
as	O
it	O
is	O
also	O
indicated	O
for	O
mild	O
to	O
moderate	O
pain,	O
and	O
less	O
likely	O
be	O
misused	O
or	O
cause	O
addiction	O
than	O
other	O
opioids.	O
Tramadol	B-Drug
propoxyphene	B-Drug

Teriflunomide	B-Drug
prevents	O
the	O
expansion	O
of	O
activated	O
and	O
autoimmune	O
lymphocytes	O
by	O
interfering	O
with	O
their	O
cell	O
cycle	O
progression	O
while	O
nonlymphoid	O
cells	O
are	O
able	O
to	O
use	O
another	O
pathway	O
make	O
ribonucleotides	O
salvage	O
pyrimidine	O
pathway,	O
which	O
makes	O
them	O
less	O
dependent	O
on	O
de	O
novo	O
synthesis.	O

There	O
was	O
a	O
minimum	O
of	O
49,000	O
seizures	O
resulting	O
in	O
the	O
interception	O
an	O
estimated	O
19.4	O
metric	O
tons	O
(19.1	O
long	O
tons;	O
21.4	O
short	O
tons)	O
heroin.	O
heroin	B-Drug

The	O
cloud	O
is	O
made	O
up	O
of	O
one	O
or	O
more	O
independent	O
machines	O
that	O
have	O
the	O
Cocaine	B-Drug
server	O
(Cocained)	O
installed.	O

In	O
general,	O
tobacco	B-Drug
companies	O
have	O
continued	O
to	O
focus	O
on	O
questioning	O
the	O
methodology	O
of	O
studies	O
showing	O
that	O
secondhand	O
smoke	O
is	O
harmful.	O

As	O
of	O
October	O
2015,	O
phenazepam	B-Drug
is	O
a	O
controlled	O
substance	O
in	O
China.	O

It	O
involves	O
"treatment	O
of	O
racemic	O
methadone	B-Drug
base	O
with	O
d-(+)-tartaric	O
acid	O
in	O
an	O
acetone/water	O
mixture	O
[which]	O
precipitates	O
almost	O
solely	O
the	O
dextro-methadone	O
levo-tartrate,	O
and	O
more	O
potent	O
levo-methadone	O
can	O
easily	O
be	O
retrieved	O
from	O
mother	O
liquor	O
a	O
high	O
state	O
optical	O
purity	O

Methylone	B-Drug
has	O
been	O
sold	O
for	O
recreational	O
use,	O
taking	O
advantage	O
of	O
the	O
absence	O
legal	O
prohibition	O
this	O
compound	O
in	O
many	O
countries.	O

hash	B-Drug
Shortened	O
name	O
for	O
hashish.	O
hashish	B-Drug

The	O
Mafia	O
took	O
advantage	O
of	O
Sicily's	O
location	O
along	O
the	O
historic	O
route	O
opium	B-Drug
westward	O
into	O
Europe	O
and	O
United	O
States.	O

Although	O
prescriptions	O
for	O
nimetazepam	B-Drug
have	O
decreased,	O
abuse	O
of	O
the	O
drug	O
is	O
still	O
significant	O
in	O
Brunei,	O
Singapore,	O
Malaysia,	O
and	O
Philippines.	O

Procaine	B-Drug
benzylpenicillin	I-Drug
Spectinomycin	O
Sulfamethoxazole/trimethoprim	B-Drug
Azithromycin	B-Drug
Cefixime	B-Drug
Cefotaxime	B-Drug
Ceftriaxone	B-Drug
Cefuroxime	B-Drug
Ciprofloxacin	B-Drug
Clarithromycin	O
Piperacillin/tazobactam	O
Vancomycin	B-Drug
Ceftazidime	B-Drug
Meropenem	B-Drug
Ceftazidime/avibactam	B-Drug

Other	O
NMDA	O
receptor	O
antagonists	O
include	O
ketamine,	O
tiletamine,	O
dextromethorphan,	O
nitrous	O
oxide,	O
and	O
dizocilpine	O
(MK-801).	O
ketamine	B-Drug
tiletamine	B-Drug
dextromethorphan	B-Drug

Fospropofol	O
is	O
a	O
prodrug	O
of	O
propofol;	O
it	O
metabolized	O
by	O
alkaline	O
phosphatases	O
to	O
an	O
active	O
metabolite,	O
propofol.	O
propofol	B-Drug

This	O
means	O
that	O
the	O
risk	O
of	O
a	O
hypertensive	O
crisis,	O
dangerous	O
high	O
blood	O
pressure	O
crisis	O
from	O
eating	O
tyramine-rich	O
foods	O
such	O
as	O
cheese,	O
is	O
likely	O
lower	O
with	O
harmaline	B-Drug
than	O
irreversible	O
MAOIs	O
phenelzine.	O
phenelzine	B-Drug

Acetaminophen	B-Drug
is	O
metabolized	O
in	O
the	O
liver	O
via	O
glucuronide	O
conjugation,	O
sulfate	O
conjugation	O
or	O
oxidation.	O

Extracts	O
such	O
as	O
hashish	B-Drug
and	O
hash	B-Drug
oil	I-Drug
typically	O
contain	O
more	O
THC	B-Drug
than	O
high	O
potency	O
cannabis	O
infructescences.	O

Television	O
series	O
about	O
cannabis	O
Cannabis	O
exploitation	O
films:	O
Assassin	O
of	O
Youth	O
Marihuana	B-Drug
Reefer	O
Madness	O

The	O
maximum	O
plasma	O
concentration	O
of	O
morphine	B-Drug
following	O
oral	O
administration	O
heroin	B-Drug
was	O
around	O
twice	O
as	O
much	O
that	O
morphine.	O

All	O
methoxyphenyl	O
regioisomers,	O
and	O
N-butyl	O
homologues	O
of	O
RCS-4	B-Drug
its	O
regioisomers	O
also	O
display	O
potent	O
agonist	O
activities	O
at	O
CB1	O
CB2	O
receptors.	O

studies	O
suggest	O
that	O
long-term	O
treatment	O
with	O
amphetamine	B-Drug
decreases	O
abnormalities	O
in	O
brain	O
structure	O
and	O
function	O
found	O
subjects	O
ADHD,	O
improves	O
several	O
parts	O
of	O
the	O
brain,	O
such	O
as	O
right	O
caudate	O
nucleus	O
basal	O
ganglia.	O

The	O
South	O
China	O
Morning	O
Post	O
reports	O
the	O
rise	O
in	O
use	O
of	O
ketamine,	O
easy	O
to	O
mass-produce	O
illicit	O
labs	O
southern	O
China,	O
particularly	O
among	O
young.	O
ketamine	B-Drug

5-MeO-MiPT	B-Drug
causes	O
the	O
ehrlich	O
reagent	O
to	O
turn	O
purple	O
then	O
fade	O
faint	O
blue.	O

A	O
single	O
case	O
of	O
desomorphine	B-Drug
use	O
was	O
reported	O
in	O
Spain	O
2014,	O
with	O
the	O
drug	O
consumed	O
orally	O
rather	O
than	O
by	O
injection.	O

Stimulants	O
and	O
cocaine-related	O
alkaloids:	O
Cocaine,	O
from	O
coca	B-Drug
plant	O
(Erythroxylum	O
coca)	O
Ecgonine,	O
a	O
precursor	O
metabolite	B-Drug
of	O
cocaine	B-Drug
Benzoylecgonine,	O
Hydroxytropacocaine,	O
Cocaine	B-Drug

He	O
began	O
working	O
on	O
LSD	B-Drug
in	O
the	O
1950s.	O

While	O
strong	O
opiates	O
are	O
heavily	O
regulated	O
within	O
the	O
European	O
Union,	O
there	O
is	O
a	O
"hidden	O
addiction"	O
with	O
codeine.	O
codeine	B-Drug

Salbutamol,	O
also	O
known	O
as	O
albuterol	B-Drug
and	O
marketed	O
Ventolin	B-Drug
among	O
other	O
brand	O
names,	O
is	O
a	O
medication	O
that	O
opens	O
up	O
the	O
medium	O
large	O
airways	O
in	O
lungs.	O
Salbutamol	B-Drug

Subsequently,	O
gabapentin	B-Drug
was	O
approved	O
in	O
the	O
United	O
States	O
for	O
treatment	O
of	O
postherpetic	O
neuralgia	O
May	O
2002.	O

In	O
many	O
national,	O
state,	O
and	O
provincial	O
drug	O
laws,	O
there	O
is	O
a	O
great	O
deal	O
of	O
ambiguity	O
about	O
the	O
legal	O
status	O
psilocybin	O
mushrooms,	O
as	O
well	O
strong	O
element	O
selective	O
enforcement	O
in	O
some	O
places,	O
since	O
psilocin	B-Drug
are	O
deemed	O
illegal	O
to	O
possess	O
without	O
license	O
substances,	O
but	O
mushrooms	O
themselves	O
not	O
mentioned	O
these	O
laws.	O

During	O
the	O
selective	O
breeding	O
process	O
for	O
medical	O
marijuana,	O
THC:CBD	O
ratios	O
are	O
accounted	O
and	O
accommodated	O
to	O
needs	O
of	O
client's	O
preference/illness.	O
THC	B-Drug
CBD	B-Drug

Laboratory	O
tests	O
assessing	O
the	O
toxicity	O
of	O
chlordiazepoxide,	O
nitrazepam	B-Drug
and	O
diazepam	B-Drug
on	O
mice	O
spermatozoa	O
found	O
that	O
chlordiazepoxide	B-Drug
produced	O
toxicities	O
in	O
sperm	O
including	O
abnormalities	O
involving	O
both	O
shape	O
size	O
head.	O

Domperidone	B-Drug
marketed	O
under	O
trade	O
name	O
"Motilium"	O
in	O
Switzerland	O
and	O
(Western)	O
Germany.	O

,	O
hyoscine	B-Drug
can	O
cause	O
significant	O
unwanted	O
side	O
effects	O
when	O
taken	O
with	O
other	O
medications.	O

In	O
the	O
US,	O
immediate-release	O
injectable	O
nalmefene	B-Drug
was	O
approved	O
in	O
1995	O
as	O
an	O
antidote	O
for	O
opioid	O
overdose.	O

Flurazepam,	O
developed	O
by	O
Roche	O
Pharmaceuticals	O
was	O
one	O
of	O
the	O
first	O
benzo	O
hypnotics	O
(sleeping	O
pills)	O
to	O
be	O
marketed.	O
Flurazepam	B-Drug

Fentanyl	B-Drug
patches	O
for	O
cancer	O
pain	O
are	O
on	O
the	O
World	O
Health	O
Organization's	O
List	O
of	O
Essential	O
Medicines.	O

Alprazolam	B-Drug
and	O
other	O
triazolobenzodiazepines	O
such	O
as	O
triazolam	B-Drug
that	O
have	O
a	O
triazole	O
ring	O
fused	O
to	O
their	O
diazepine	O
appear	O
antidepressant	O
properties.	O

In	O
California	O
methadone	B-Drug
maintenance	O
treatment	O
is	O
covered	O
under	O
the	O
medical	O
benefit.	O

hash	B-Drug
oil	I-Drug
A	O
resin	O
extracted	O
from	O
cannabis	O
or	O
hashish.	O
hashish	B-Drug

(Bulstrode	O
reflecting):	O
"The	O
thought	O
was,	O
that	O
he	O
had	O
not	O
told	O
Mrs	O
Abel	O
when	O
the	O
dose	O
of	O
opium	B-Drug
must	O
cease.	O
...	O

A	O
review	O
in	O
2015	O
summarized	O
a	O
number	O
of	O
studies	O
involving	O
chronic	O
methamphetamine	B-Drug
use	O
rodents.	O

Side	O
effects	O
of	O
fentanyl	B-Drug
analogs	O
are	O
similar	O
to	O
those	O
itself,	O
which	O
include	O
itching,	O
nausea,	O
and	O
potentially	O
serious	O
respiratory	O
depression	O
can	O
be	O
life-threatening.	O

Methylisopropyllysergamide	B-Drug
is	O
a	O
structural	O
isomer	O
of	O
LSD,	O
with	O
the	O
alkyl	O
groups	O
on	O
amide	O
nitrogen	O
having	O
been	O
subjected	O
to	O
methylene	O
shuffle.	O
LSD	B-Drug

The	O
duration	O
of	O
action	O
is	O
2	O
to	O
4	O
hours	O
and	O
7.5	O
10	O
mg	O
via	O
the	O
subcutaneous	O
route	O
most	O
common	O
starting	O
dose,	O
being	O
equal	O
80	O
100	O
pethidine,	O
40	O
60	O
alphaprodine	B-Drug
morphine.	O
pethidine	B-Drug
morphine	B-Drug

Briefly	O
used	O
by	O
some	O
psychotherapists	O
as	O
an	O
adjunct	O
to	O
therapy,	O
the	O
drug	O
became	O
popular	O
recreationally	O
and	O
DEA	O
listed	O
MDMA	B-Drug
a	O
Schedule	O

Increased	O
plasma	O
levels	O
of	O
haloperidol	B-Drug
Carbamazepine:	O
Carbamazepine	B-Drug

With	O
the	O
street	O
price	O
for	O
heroin	B-Drug
or	O
oxycodone	B-Drug
much	O
higher	O
than	O
cost	O
of	O
codeine	B-Drug
and	O
chemicals,	O
users	O
manufacture	O
krokodil	O
a	O
cheaper,	O
comparable	O
high.	O

Medical	O
examiners	O
concluded	O
that	O
musician	O
Prince	O
died	O
on	O
April	O
21,	O
2016,	O
from	O
an	O
accidental	O
fentanyl	B-Drug
overdose.	O

Chlordiazepoxide	B-Drug
(Librium),	O
a	O
long-acting	O
benzodiazepine,	O
is	O
gaining	O
attention	O
as	O
an	O
alternative	O
to	O
diazepam	B-Drug
in	O
substance	O
abusers	O
dependent	O
on	O
benzodiazepines	O
due	O
its	O
decreased	O
abuse	O
potential.	O
Librium	B-Drug

Acetylfentanyl	B-Drug
has	O
been	O
analytically	O
confirmed	O
in	O
32	O
fatalities	O
four	O
European	O
member	O
states	O
between	O
2013	O
and	O
August	O
2015,	O
Germany	O
(2),	O
Poland	O
(1),	O
Sweden	O
(27)	O
the	O
United	O
Kingdom	O
(2).	O

These	O
effects	O
were	O
not	O
noted	O
in	O
its	O
medicinal	O
use	O
the	O
1950s	O
and	O
1960s	O
however,	O
reports	O
of	O
physical	O
violence	O
on	O
PCP	B-Drug
have	O
often	O
been	O
shown	O
to	O
be	O
unfounded.	O

As	O
of	O
17	O
October	O
2018	O
when	O
recreational	O
use	O
cannabis	O
was	O
legalized	O
in	O
Canada,	O
dietary	O
supplements	O
for	O
human	O
and	O
veterinary	O
health	O
products	O
containing	O
not	O
more	O
than	O
10	O
parts	O
per	O
million	O
THC	B-Drug
extract	O
were	O
approved	O
marketing;	O
Nabiximols	B-Drug
(as	O
Sativex)	O
is	O
used	O
as	O
a	O
prescription	O
drug	O
Canada.	O
Sativex	B-Drug

In	O
one	O
laboratory	O
study	O
in	O
a	O
rat	O
model	O
2016,	O
alkaloid-containing	O
extracts	O
of	O
kratom	B-Drug
gave	O
evidence	O
inducing	O
naloxone-reversible	O
antinociceptive	O
effects	O
hotplate	O
and	O
tail-flick	O
tests	O
to	O
level	O
comparable	O
oxycodone.	O
oxycodone	B-Drug

The	O
muscle	O
relaxant	O
properties	O
of	O
tetrazepam	B-Drug
are	O
most	O
likely	O
due	O
to	O
a	O
reduction	O
calcium	O
influx.	O

Methadone	B-Drug
maintenance	O
treatment	O

In	O
2003,	O
70%	O
of	O
Europe's	O
hashish	B-Drug
consumed	O
was	O
produced	O
in	O
Morocco.	O

The	O
FDA	O
required	O
that	O
Celgene	O
Corporation,	O
which	O
planned	O
to	O
market	O
thalidomide	B-Drug
under	O
the	O
brand	O
name	O
Thalomid,	O
establish	O
a	O
system	O
for	O
education	O
and	O
prescribing	O
safety	O
(STEPS)	O
oversight	O
program.	O
Thalomid	B-Drug

For	O
instance,	O
the	O
CYP3A4	O
inducers	O
rifampicin	B-Drug
and	O
bosentan	B-Drug
have	O
been	O
found	O
to	O
decrease	O
norethisterone	B-Drug
exposure	O
by	O
42%	O
23%,	O
respectively,	O
carbamazepine	B-Drug
St.	O
John's	O
wort	O
also	O
accelerate	O
clearance.	O

"The	O
addition	O
of	O
tobacco	B-Drug
leaf	O
to	O
the	O
chewing	O
mixture	O
is	O
a	O
relatively	O
recent	O
innovation,	O
as	O
was	O
not	O
introduced	O
from	O
American	O
continent	O
until	O
colonial	O
era.	O

Bromazepam	B-Drug
binds	O
to	O
the	O
GABA	O
receptor	O
GABAA,	O
causing	O
a	O
conformational	O
change	O
and	O
increasing	O
inhibitory	O
effects	O
of	O
GABA.	O

Convulsions	O
from	O
GHB	B-Drug
can	O
be	O
treated	O
with	O
the	O
benzodiazepines	O
diazepam	B-Drug
or	O
lorazepam.	O
lorazepam	B-Drug

Metenolone	O
acetate	O
is	O
taken	O
by	O
mouth,	O
while	O
metenolone	B-Drug
enanthate	O
given	O
injection	O
into	O
muscle.	O

Now	O
a	O
free	O
man,	O
Plinston	O
gave	O
Marks	O
job	O
transporting	O
hashish	B-Drug
in	O
Frankfurt;	O
turn	O
hired	O
New	O
Zealand	O
smuggler	O
named	O
Lang	O
as	O
his	O
driver.	O

DMT	O
is	O
a	O
functional	O
analog	O
and	O
structural	O
of	O
other	O
psychedelic	O
tryptamines	O
such	O
as	O
O-acetylpsilocin	B-Drug
(4-AcO-DMT),	O
5-MeO-DMT,	O
psilocybin	O
(4-PO-DMT),	O
psilocin	B-Drug
(4-HO-DMT),	O
bufotenin	B-Drug
(5-HO-DMT).	O
4-AcO-DMT	B-Drug
5-MeO-DMT	B-Drug

In	O
Thai	O
varieties,	O
mitragynine	B-Drug
is	O
the	O
most	O
abundant	O
component	O
(up	O
to	O
66%	O
of	O
total	O
alkaloids)	O
while	O
7-hydroxymitragynine	O
a	O
minor	O
constituent	O
2%	O
alkaloid	O
content).	O

Estonia	O
in	O
known	O
to	O
have	O
been	O
home	O
the	O
world's	O
longest	O
documented	O
fentanyl	B-Drug
epidemic,	O
especially	O
following	O
Taliban	O
ban	O
on	O
opium	O
poppy	O
cultivation	O
Afghanistan.	O

Various	O
surveys	O
conducted	O
between	O
2015	O
and	O
2019	O
found	O
that	O
many	O
users	O
of	O
cannabis	O
substitute	O
it	O
for	O
prescription	O
drugs	O
(including	O
opioids),	O
alcohol,	O
tobacco;	O
most	O
those	O
who	O
used	O
in	O
place	O
alcohol	O
or	O
tobacco	B-Drug
either	O
reduced	O
stopped	O
their	O
intake	O
the	O
latter	O
substances.	O

It	O
is	O
unclear	O
if	O
fentanyl	B-Drug
gives	O
long-term	O
pain	O
relief	O
to	O
people	O
with	O
neuropathic	O
pain.	O

The	O
available	O
data	O
was	O
determined	O
to	O
be	O
insufficient	O
allow	O
reliable	O
conclusions	O
drawn	O
regarding	O
the	O
effectiveness	O
of	O
oral	O
cannabis	O
extract	O
or	O
THC	B-Drug
in	O
controlling	O
tics.	O

The	O
"China	O
White"	O
form	O
of	O
fentanyl	B-Drug
refers	O
to	O
any	O
a	O
number	O
clandestinely	O
produced	O
analogues,	O
especially	O
-methylfentanyl	O
(AMF).	O

This	O
article	O
pertains	O
to	O
steroidal	O
androgens;	O
nonsteroidal	O
androgens	O
like	O
the	O
selective	O
androgen	O
receptor	O
modulators	O
(SARMs)	O
andarine	B-Drug
and	O
enobosarm	B-Drug
(ostarine)	O
are	O
not	O
included	O
here.	O
ostarine	B-Drug

Potential	O
drug	O
interactions	O
involving	O
at	O
least	O
one	O
CNS	O
depressant	O
were	O
observed	O
for	O
84%	O
of	O
midazolam	B-Drug
users	O
who	O
subsequently	O
required	O
to	O
receive	O
the	O
benzodiazepine	O
antagonist	O
flumazenil.	O
flumazenil	B-Drug

Examples	O
of	O
classical	O
psychedelics	O
include	O
DMT,	O
LSD,	O
mescaline,	O
and	O
psilocybin.	O
LSD	B-Drug
mescaline	B-Drug

However,	O
later	O
studies	O
by	O
different	O
researchers	O
found	O
the	O
affinity	O
of	O
ketamine	B-Drug
>10	O
M	O
for	O
regular	O
human	O
and	O
rat	O
D2	O
receptors,	O
Moreover,	O
whereas	O
receptor	O
agonists	O
like	O
bromocriptine	B-Drug
are	O
able	O
to	O
rapidly	O
powerfully	O
suppress	O
prolactin	O
secretion,	O
subanesthetic	O
doses	O
have	O
not	O
been	O
do	O
this	O
in	O
humans	O
fact	O
dose-dependently	O
increase	O
levels.	O

For	O
example,	O
ketoprofen's	O
effects	O
have	O
been	O
studied	O
in	O
horses	O
more	O
than	O
ruminants	O
but,	O
due	O
to	O
controversy	O
over	O
its	O
use	O
racehorses,	O
veterinarians	O
who	O
treat	O
livestock	O
the	O
United	O
States	O
commonly	O
prescribe	O
flunixin	O
meglumine,	O
which,	O
while	O
labeled	O
for	O
such	O
animals,	O
is	O
not	O
indicated	O
post-operative	O
pain.	O
ketoprofen	B-Drug

Cyclization	O
of	O
N-phthaloyl-L-glutamine	O
occurs	O
using	O
carbonyldiimidazole,	O
which	O
then	O
yields	O
thalidomide	B-Drug
(3).	O

Reports	O
of	O
deaths	O
and	O
significant	O
injuries	O
have	O
been	O
attributed	O
to	O
the	O
use	O
25I-NBOMe,	O
prompting	O
some	O
governments	O
control	O
its	O
possession,	O
production,	O
sale.	O
25I-NBOMe	B-Drug

In	O
1956,	O
researchers	O
at	O
SKF	O
involved	O
in	O
clinical	O
trials,	O
noted	O
that	O
even	O
when	O
used	O
very	O
high	O
doses,	O
thalidomide	B-Drug
could	O
not	O
induce	O
sleep	O
mice.	O

Spironolactone	B-Drug
is	O
dethioacetylated	O
into	O
canrenone.	O

It	O
is	O
also	O
contraindicated	O
in	O
HIV	O
positive	O
patients	O
taking	O
protease	O
inhibitors,	O
delavirdine	B-Drug
and	O
efavirenz	B-Drug
(which	O
an	O
agonist	O
at	O
the	O
5HT2A-mGlu2	O
receptor	O
protomer	O
increases	O
chances	O
of	O
a	O
patient	O
experiencing	O
hallucinations	O
during	O
methylergometrine	O
therapy).	O

The	O
antidote	O
for	O
belladonna	O
poisoning	O
is	O
physostigmine	B-Drug
or	O
pilocarpine,	O
the	O
same	O
as	O
atropine.	O
pilocarpine	B-Drug

World	O
annual	O
cocaine	B-Drug
consumption,	O
as	O
of	O
2000,	O
stood	O
at	O
around	O
600	O
tonnes,	O
with	O
the	O
United	O
States	O
consuming	O
300	O
t,	O
50%	O
total,	O
Europe	O
about	O
150	O
25%	O
and	O
rest	O
world	O
remaining	O
t	O
or	O
25%.	O

The	O
disposition	O
of	O
MDMA	B-Drug
may	O
also	O
be	O
stereoselective,	O
with	O
the	O
S-enantiomer	O
having	O
a	O
shorter	O
elimination	O
half-life	O
and	O
greater	O
excretion	O
than	O
R-enantiomer.	O

The	O
Harrison	O
Act	O
left	O
manufacturers	O
of	O
cocaine	B-Drug
untouched	O
so	O
long	O
as	O
they	O
met	O
certain	O
purity	O
and	O
labeling	O
standards.	O

As	O
of	O
August	O
2015,	O
25I-NBOMe	B-Drug
has	O
reportedly	O
led	O
to	O
at	O
least	O
19	O
overdose	O
deaths	O
in	O
the	O
United	O
States.	O

In	O
humans,	O
MDMA	B-Drug
increases	O
the	O
amount	O
of	O
serotonin	O
in	O
synaptic	O
clefts	O
serotonergic	O
neurons	O
by	O
inhibiting	O
its	O
uptake	O
into	O
and	O
directly	O
releasing	O
it	O
from	O
neurons.	O

Alvimopan	B-Drug
undergoes	O
no	O
significant	O
hepatic	O
metabolism,	O
but	O
is	O
metabolized	O
by	O
intestinal	O
flora.	O

R-MDMA	O
has	O
notable	O
agonism	O
towards	O
5-HT2AR,	O
which	O
supposedly	O
contributes	O
to	O
the	O
mild	O
psychedelic	O
hallucinations	O
induced	O
by	O
high	O
doses	O
of	O
MDMA	B-Drug
in	O
humans.	O

A	O
mixture	O
of	O
mannitol	B-Drug
and	O
fentanyl	B-Drug
(or	O
analogs)	O
in	O
ratio	O
1:10	O
is	O
labeled	O
sold	O
as	O
"China	O
white",	O
a	O
popular	O
heroin	B-Drug
substitute.	O

Thalidomide	B-Drug
may	O
interfere	O
with	O
various	O
contraceptives,	O
and	O
hence	O
it	O
is	O
advised	O
that	O
women	O
of	O
reproductive	O
age	O
use	O
at	O
least	O
two	O
different	O
means	O
contraception	O
to	O
ensure	O
no	O
child	O
will	O
be	O
conceived	O
while	O
they	O
are	O
taking	O
thalidomide.	O
thalidomide	B-Drug

hydromorphone's	O
having	O
a	O
more	O
rapid	O
onset	O
of	O
action	O
and	O
alterations	O
to	O
the	O
overall	O
absorption,	O
distribution,	O
metabolism,	O
elimination	O
profile	O
as	O
well	O
side	O
effect	O
(in	O
general,	O
less	O
nausea	O
itching)	O
versus	O
that	O
morphine.	O
hydromorphone	B-Drug
morphine	B-Drug

NMT	O
is	O
in	O
turn	O
transmethylated	O
by	O
the	O
same	O
process	O
(step	O
3)	O
to	O
form	O
end	O
product	O
N,N-dimethyltryptamine.	O
N,N-dimethyltryptamine	B-Drug

Hyoscine	B-Drug
use	O
should	O
be	O
avoided	O
in	O
this	O
age	O
group	O
because	O
of	O
these	O
potent	O
anticholinergic	O
adverse	O
effects,	O
which	O
have	O
also	O
been	O
linked	O
to	O
an	O
increased	O
risk	O
for	O
dementia.	O

Midazolam	B-Drug
is	O
sometimes	O
used	O
in	O
neonatal	O
intensive	O
care	O
units.	O

Phencyclidine	B-Drug
is	O
used	O
for	O
its	O
ability	O
to	O
induce	O
a	O
dissociative	O
state.	O

The	O
rapid	O
rise	O
and	O
subsequent	O
fall	O
of	O
DA	O
levels	O
could	O
explain	O
some	O
the	O
addictive	O
properties	O
mephedrone	B-Drug
displays	O
in	O
users.	O

MDMA	B-Drug
makes	O
it	O
easier	O
for	O
a	O
patient	O
to	O
stay	O
in	O
the	O
optimal	O
arousal	O
zone	O
by	O
decreasing	O
feelings	O
of	O
anxiety	O
and	O
defensiveness	O
when	O
revisiting	O
traumatic	O
memories.	O

An	O
individual	O
who	O
has	O
consumed	O
too	O
much	O
diazepam	B-Drug
typically	O
displays	O
one	O
or	O
more	O
of	O
these	O
symptoms	O
in	O
a	O
period	O
approximately	O
four	O
hours	O
immediately	O
following	O
suspected	O
overdose:	O
Drowsiness	O
Mental	O
confusion	O
Hypotension	O
Impaired	O
motor	O
functions	O
reflexes	O

During	O
the	O
1990s,	O
Parke-Davis,	O
a	O
subsidiary	O
of	O
Pfizer,	O
used	O
number	O
illegal	O
techniques	O
to	O
encourage	O
physicians	O
in	O
United	O
States	O
prescribe	O
gabapentin	B-Drug
for	O
unapproved	O
uses.	O

The	O
morphine	B-Drug
base	O
is	O
then	O
reacted	O
with	O
acetic	O
anhydride,	O
which	O
forms	O
heroin.	O
heroin	B-Drug

In	O
2001,	O
Genelabs	O
submitted	O
a	O
New	O
Drug	O
Application	O
of	O
prasterone	B-Drug
for	O
the	O
treatment	O
systemic	O
lupus	O
erythematosus	O
(SLE)	O
to	O
FDA.	O

Hence,	O
as	O
a	O
prodrug	O
of	O
norethisterone,	O
NETE	O
has	O
essentially	O
the	O
same	O
effects	O
acting	O
potent	O
progestogen	O
with	O
additional	O
weak	O
androgenic	O
and	O
estrogenic	O
activity	O
(the	O
latter	O
via	O
its	O
metabolite	O
ethinylestradiol).	O
norethisterone	B-Drug

Consequently,	O
laudanum	B-Drug
became	O
mostly	O
obsolete	O
as	O
an	O
analgesic,	O
since	O
its	O
principal	O
ingredient	O
is	O
morphine,	O
which	O
can	O
be	O
prescribed	O
by	O
itself	O
to	O
treat	O
pain.	O
morphine	B-Drug

Studies	O
show	O
that	O
antidepressants	O
like	O
fluoxetine,	O
imipramine	B-Drug
and	O
desipramine	B-Drug
have	O
very	O
limited	O
effects	O
for	O
ATS	O
abuse	O
since	O
they	O
may	O
reduce	O
craving	O
or	O
increase	O
period	O
of	O
adherence	O
to	O
short-to-medium-term	O
treatments.	O
fluoxetine	B-Drug

Heroin	O
overdose	O
is	O
usually	O
treated	O
with	O
the	O
opioid	O
antagonist,	O
naloxone.	O
naloxone	B-Drug

The	O
U.S.	O
Food	O
and	O
Drug	O
Administration	O
(FDA)	O
approved	O
tramadol	B-Drug
in	O
March	O
1995,	O
an	O
extended-release	O
(ER)	O
formulation	O
September	O
2005.	O

Rather,	O
aspirin	B-Drug
is	O
the	O
only	O
NSAID	O
that	O
irreversibly	O
inhibits	O
COX-1.	O

Benzhydrocodone/APAP	O
contains	O
acetaminophen,	O
which	O
can	O
cause	O
acute	O
liver	O
failure	O
at	O
high	O
doses	O
(	O
acetaminophen	B-Drug

Bolenol	O
(INN,	O
USAN),	O
also	O
known	O
as	O
17-ethyl-19-norandrost-5-en-17-ol	O
(ethylnorandrostenol),	O
is	O
a	O
synthetic,	O
orally	O
active	O
anabolic-androgenic	O
steroid	O
(AAS)	O
and	O
17-alkylated	O
derivative	O
of	O
19-nortestosterone	B-Drug
(nandrolone)	O
that	O
was	O
never	O
marketed.	O
nandrolone	B-Drug

An	O
example	O
is	O
through	O
the	O
nicotinic	O
acetylcholine	O
receptor	O
(nAchRs),	O
which	O
a	O
commonly	O
found	O
along	O
surfaces	O
of	O
cells	O
that	O
respond	O
to	O
nicotine	B-Drug
stimulation,	O
turning	O
them	O
on	O
or	O
off.	O

Fruit,	O
especially	O
bananas,	O
a	O
common	O
Latin	O
American	O
export,	O
is	O
the	O
most	O
method	O
seen	O
to	O
smuggle	O
cocaine	B-Drug
into	O
Europe.	O

Indeed,	O
the	O
androgenic	O
effects	O
of	O
tibolone	B-Drug
have	O
been	O
ranked	O
as	O
stronger	O
than	O
those	O
all	O
other	O
commonly	O
used	O
19-nortestosterone	B-Drug
progestins	O
(e.g.,	O
norethisterone,	O
levonorgestrel,	O
others).The	O
norethisterone	B-Drug
levonorgestrel	B-Drug

At	O
least	O
17	O
other	O
people	O
have	O
had	O
medical	O
treatment	O
after	O
taking	O
the	O
white	O
heroin.	O
heroin	B-Drug

5-MAPB	B-Drug

According	O
to	O
Cocaine's	O
official	O
website,	O
the	O
drink	O
is	O
now	O
being	O
sold	O
in	O
three	O
varieties:	O
one	O
Original,	O
"Cut"	O
(which	O
lacks	O
purported	O
"throat-burning"	O
sensation	O
of	O
Original),	O
and	O
"Free",	O
which	O
contains	O
no	O
sugar.	O
Cocaine	B-Drug

Some	O
of	O
the	O
available	O
data	O
also	O
suggested	O
that	O
lorazepam	B-Drug
and	O
alprazolam	B-Drug
are	O
more	O
diazepam-like	O
in	O
having	O
relatively	O
high	O
abuse	O
liability,	O
while	O
oxazepam,	O
halazepam,	O
possibly	O
chlordiazepoxide,	O
low	O
this	O
regard.	O
oxazepam	B-Drug
halazepam	B-Drug
chlordiazepoxide	B-Drug

In	O
the	O
United	O
States	O
in	O
1937,	O
Marihuana	B-Drug
Tax	O
Act	O
was	O
passed,	O
and	O
prohibited	O
production	O
of	O
hemp	O
addition	O
to	O
cannabis.	O

When	O
given	O
by	O
injection	O
into	O
a	O
vein,	O
heroin	B-Drug
has	O
two	O
to	O
three	O
times	O
the	O
effect	O
of	O
similar	O
dose	O
morphine.	O
morphine	B-Drug

Diphenoxylate	B-Drug
and	O
atropine	O
have	O
been	O
studied	O
in	O
small	O
trials	O
as	O
a	O
treatment	O
for	O
fecal	O
incontinence;	O
it	O
appears	O
to	O
be	O
less	O
efficacious	O
more	O
adverse	O
effects	O
when	O
compared	O
with	O
loperamide	B-Drug
or	O
codeine.	O
codeine	B-Drug

They	O
have	O
reclassified	O
CBD	B-Drug
as	O
a	O
Schedule	O
4	O
substance	O
or	O
0	O
under	O
certain	O
criteria.	O

cannabis	O
Stoned:	O
In	O
The	O
Beginning	O
(2010)	O
cannabis,	O
LSD,	O
cocaine,	O
sleeping	O
pills,	O
crack	O
Strange	O
Days	O
(1995)	O
LSD	B-Drug
cocaine	B-Drug

In	O
July	O
2014,	O
the	O
Medicines	O
and	O
Healthcare	O
products	O
Regulatory	O
Agency	O
(MHRA)	O
of	O
UK	O
issued	O
a	O
warning	O
about	O
potential	O
for	O
life-threatening	O
harm	O
from	O
accidental	O
exposure	O
to	O
transdermal	O
fentanyl	B-Drug
patches,	O
particularly	O
in	O
children,	O
advised	O
that	O
they	O
should	O
be	O
folded,	O
with	O
adhesive	O
side	O
in,	O
before	O
being	O
discarded.	O

The	O
active	O
substances	O
of	O
khat	O
are	O
cathinone	B-Drug
and,	O
to	O
a	O
lesser	O
extent,	O
cathine.	O
cathine	B-Drug

Phenazepam	B-Drug
should	O
not	O
be	O
used	O
therapeutically	O
for	O
periods	O
of	O
longer	O
than	O
one	O
month	O
including	O
tapering	O
on	O
and	O
off	O
the	O
drug	O
as	O
recommended	O
any	O
benzodiazepine	O
in	O
British	O
national	O
formulary.	O

Hyponatremia	O
(low	O
blood	O
sodium)	O
occurred	O
in	O
4.1%	O
of	O
subjects	O
randomized	O
to	O
chlortalidone	B-Drug
the	O
Systolic	O
Hypertension	O
Elderly	O
Trial,	O
compared	O
1.3%	O
control	O
subjects.	O

A	O
series	O
of	O
Class	O
II	O
recalls	O
was	O
initiated	O
in	O
March	O
2004,	O
and	O
February	O
2008	O
ALZA	O
Corporation	O
recalled	O
their	O
25	O
g/h	O
Duragesic	B-Drug
patches	O
due	O
to	O
a	O
concern	O
that	O
small	O
cuts	O
the	O
gel	O
reservoir	O
could	O
result	O
accidental	O
exposure	O
patients	O
or	O
health	O
care	O
providers	O
fentanyl	B-Drug
gel.	O

Combustion	O
products	O
are	O
not	O
present	O
when	O
using	O
a	O
vaporizer,	O
consuming	O
THC	B-Drug
in	O
pill	O
form,	O
or	O
cannabis	O
foods.	O

Dependence	O
liability	O
is	O
similar	O
to	O
morphine,	O
but	O
with	O
a	O
less	O
severe	O
withdrawal	O
syndrome.	O
morphine	B-Drug

Cocaine	B-Drug
is	O
the	O
second	O
most	O
popular	O
illegal	O
recreational	O
drug	O
in	O
Europe	O
(behind	O
cannabis).	O

In	O
2006,	O
the	O
MLB	O
banned	O
use	O
of	O
amphetamine.	O
amphetamine	B-Drug

Studies	O
on	O
rats	O
indicate	O
that	O
PCP	B-Drug
interacts	O
indirectly	O
with	O
opioid	O
receptors	O
(endorphin	O
and	O
enkephalin)	O
to	O
produce	O
analgesia.	O

The	O
Harrison	O
Narcotics	O
Act	O
of	O
1914	O
restricted	O
the	O
manufacture	O
and	O
distribution	O
opiates,	O
including	O
laudanum,	O
coca	B-Drug
derivatives	O
in	O
United	O
States;	O
this	O
was	O
followed	O
by	O
France's	O
Loi	O
des	O
stupefiants	O
1916,	O
Britain's	O
Dangerous	O
Drugs	O
1920.In	O
States,	O
regulated	O
"opium	O
or	O
leaves,	O
any	O
compound,	O
manufacture,	O
salt,	O
derivative	O
preparation	O
laudanum	B-Drug
opium	B-Drug

The	O
unapproved	O
use	O
of	O
these	O
compounds	O
in	O
herbal	O
smoking	O
blends	O
has	O
led	O
to	O
a	O
resurgence	O
legitimate	O
scientific	O
research	O
into	O
their	O
use,	O
and	O
consequently	O
the	O
C8	O
homologue	O
CP	B-Drug
47,497	I-Drug
been	O
assigned	O
proper	O
name,	O
cannabicyclohexanol.	O
cannabicyclohexanol	B-Drug

Prior	O
to	O
the	O
introduction	O
of	O
paracetamol,	O
Percodan	B-Drug
was	O
mainstay	O
in	O
post-operative	O
oral	O
pain	O
treatment	O
due	O
potency	O
and	O
long	O
half-life	O
oxycodone.	O
paracetamol	B-Drug
oxycodone	B-Drug

It	O
was	O
found	O
to	O
be	O
superior	O
triazolam	B-Drug
in	O
side	O
effect	O
profile	O
preoperative	O
patients	O
a	O
trial.	O

In	O
Ireland,	O
alprazolam	B-Drug
is	O
a	O
Schedule	O
4	O
medicine.	O

Designed	O
to	O
regulate	O
amphetamines,	O
barbiturates,	O
and	O
other	O
synthetics,	O
the	O
34th	O
version	O
of	O
treaty,	O
as	O
25	O
January	O
2014,	O
regulates	O
secobarbital	B-Drug
schedule	O
II,	O
amobarbital,	O
butalbital,	O
cyclobarbital,	O
pentobarbital	B-Drug
III,	O
allobarbital,	O
barbital,	O
butobarbital,	O
mephobarbital,	O
phenobarbital,	O
butabarbital,	O
vinylbital	B-Drug
IV	O
on	O
its	O
"Green	O
List".	O
amphetamines	B-Drug
amobarbital	B-Drug
butalbital	B-Drug
cyclobarbital	B-Drug
allobarbital	B-Drug
barbital	B-Drug
butobarbital	B-Drug
mephobarbital	B-Drug
phenobarbital	B-Drug
butabarbital	B-Drug

Androstenedione,	O
or	O
4-androstenedione	B-Drug
(abbreviated	O
as	O
A4	O
4-dione),	O
also	O
known	O
androst-4-ene-3,17-dione,	O
is	O
an	O
endogenous	O
weak	O
androgen	O
steroid	O
hormone	O
and	O
intermediate	O
in	O
the	O
biosynthesis	O
of	O
estrone	O
testosterone	O
from	O
dehydroepiandrosterone	O
(DHEA).	O
Androstenedione	B-Drug
androst-4-ene-3,17-dione	B-Drug

LSD,	O
cocaine,	O
heroin,	O
cannabis,	O
peyote	O
Dope	O
Sick	O
Love	O
(2005)	O
LSD	B-Drug
cocaine	B-Drug
heroin	B-Drug

Doctors	O
also	O
prescribed	O
heroin	B-Drug
for	O
irritable	O
babies,	O
bronchitis,	O
insomnia,	O
"nervous	O
conditions,"	O
hysteria,	O
menstrual	O
cramps,	O
and	O
"vapors",	O
leading	O
to	O
mass	O
addiction.	O

Nialamide	B-Drug
(Niamid)	O

Nicotine	B-Drug
constitutes	O
approximately	O
0.63.0%	O
of	O
the	O
dry	O
weight	O
tobacco.	O
tobacco	B-Drug

Fentanyl's	O
most	O
common	O
side	O
effects,	O
which	O
affect	O
more	O
than	O
10%	O
of	O
people,	O
include	O
diarrhea,	O
nausea,	O
constipation,	O
dry	O
mouth,	O
somnolence,	O
confusion,	O
asthenia	O
(weakness),	O
sweating.	O
Fentanyl	B-Drug

LSD	B-Drug
is	O
not	O
believed	O
to	O
have	O
been	O
manufactured	O
locally	O
in	O
a	O
significant	O
quantity	O
(if	O
at	O
all)	O
and	O
most	O
if	O
all	O
supplies	O
were	O
sourced	O
from	O
overseas.	O

Possession	O
of	O
diamorphine	B-Drug
for	O
the	O
purpose	O
trafficking	O
is	O
an	O
indictable	O
offense	O
and	O
subject	O
to	O
imprisonment	O
life.	O

Diazepam	B-Drug
when	O
taken	O
late	O
in	O
pregnancy,	O
during	O
the	O
third	O
trimester,	O
causes	O
a	O
definite	O
risk	O
of	O
severe	O
benzodiazepine	O
withdrawal	O
syndrome	O
neonate	O
with	O
symptoms	O
including	O
hypotonia,	O
and	O
reluctance	O
to	O
suck,	O
apnoeic	O
spells,	O
cyanosis,	O
impaired	O
metabolic	O
responses	O
cold	O
stress.	O

The	O
hallucinogen	O
LSD	B-Drug
is	O
a	O
psychoactive	O
drug	O
commonly	O
used	O
as	O
recreational	O
drug.	O

This	O
is	O
an	O
analogue	O
of	O
the	O
more	O
popular	O
drug	O
5-MeO-DiPT	B-Drug
(nicknamed	O
"foxy	O
methoxy")	O
and	O
has	O
nickname	O
"moxy".	O

Opioid	O
drugs	O
include	O
partial	O
agonists,	O
like	O
the	O
anti-diarrhea	O
drug	O
loperamide	B-Drug
and	O
antagonists	O
naloxegol	B-Drug
for	O
opioid-induced	O
constipation.	O

Like	O
other	O
androgens,	O
oxandrolone	B-Drug
can	O
cause	O
or	O
worsen	O
acne	O
and	O
priapism	O
(unwanted	O
prolonged	O
erections).	O

MDMA	B-Drug
tablets	O
typically	O
have	O
low	O
purity	O
due	O
to	O
bulking	O
agents	O
that	O
are	O
added	O
dilute	O
the	O
drug	O
and	O
increase	O
profits	O
(notably	O
lactose)	O
binding	O
agents.	O

The	O
latest	O
estimate	O
provided	O
by	O
the	O
U.S.	O
authorities	O
on	O
annual	O
production	O
of	O
cocaine	B-Drug
in	O
Colombia	O
refers	O
to	O
290	O
metric	O
tons.	O

In	O
1985,	O
another	O
Contra	O
leader	O
"told	O
U.S.	O
authorities	O
that	O
his	O
group	O
was	O
being	O
paid	O
$50,000	O
by	O
Colombian	O
traffickers	O
for	O
help	O
with	O
a	O
100-kilo	O
cocaine	B-Drug
shipment	O
and	O
the	O
money	O
would	O
go	O
'for	O
cause'	O
of	O
fighting	O
Nicaraguan	O
government."	O

Patients	O
with	O
variant	O
forms	O
of	O
the	O
gene	O
CYP2D6	O
may	O
not	O
receive	O
full	O
benefit	O
from	O
tamoxifen	B-Drug
because	O
too	O
slow	O
metabolism	O
prodrug	O
into	O
its	O
active	O
metabolites.	O

Because	O
norpropoxyphene	O
has	O
a	O
long	O
half-life	O
in	O
the	O
body	O
of	O
up	O
to	O
36	O
hours	O
(compared	O
around	O
612	O
for	O
dextropropoxyphene),	O
it	O
can	O
accumulate	O
tissues	O
during	O
chronic	O
use	O
dextropropoxyphene-containing	O
medications,	O
especially	O
people	O
whose	O
excretion	O
drugs	O
is	O
slower	O
than	O
normal	O
such	O
as	O
young	O
children,	O
elderly,	O
and	O
individuals	O
with	O
reduced	O
kidney	O
or	O
liver	O
function,	O
so	O
side	O
effects	O
including	O
serious	O
adverse	O
events	O
are	O
more	O
common	O
these	O
groups	O
dextropropoxyphene	B-Drug
should	O
be	O
avoided	O
where	O
possible.	O

Thin	O
boiled	O
starch,	O
2	O
ounces;	O
Laudanum,	O
20	O
drops;	O
"Use	O
as	O
an	O
injection	O
[meaning	O
enema]	O
every	O
six	O
to	O
twelve	O
hours";	O
(2)	O
Tincture	O
rhubarb,	O
1	O
ounce;	O
Laudanum	B-Drug
4	O
drachms;	O
"Dose:	O
One	O
teaspoonful	O
three	O
hours."	O

Ropivacaine	B-Drug
(rINN)	O
is	O
a	O
local	O
anaesthetic	O
drug	O
belonging	O
to	O
the	O
amino	O
amide	O
group.	O

He	O
worked	O
in	O
the	O
film	O
industry	O
and	O
saw	O
a	O
number	O
of	O
people	O
who	O
had	O
difficulty	O
finding	O
help	O
from	O
anyone	O
knowledgeable	O
about	O
special	O
difficulties	O
presented	O
by	O
cocaine	B-Drug
addiction.	O

Skin:	O
itching,	O
depigmentation,	O
rash,	O
urticaria,	O
edema,	O
angioedema,	O
bruising,	O
inflammation	O
of	O
the	O
vein	O
at	O
injection	O
site,	O
irritation	O
skin	O
when	O
applied	O
topically	O
Blood:	O
methemoglobinemia	O
AllergyADRs	O
associated	O
with	O
use	O
intravenous	O
lidocaine	B-Drug
are	O
similar	O
to	O
toxic	O
effects	O
from	O
systemic	O
exposure	O
above.	O

While	O
Epidiolex	B-Drug
treatment	O
is	O
generally	O
well	O
tolerated,	O
it	O
associated	O
with	O
minor	O
adverse	O
effects,	O
such	O
as	O
gastrointestinal	O
upset,	O
decreased	O
appetite,	O
lethargy,	O
sleepiness	O
and	O
poor	O
sleep	O
quality.	O

Because	O
of	O
their	O
identical	O
molecular	O
weight	O
and	O
similar	O
fragmentation	O
patterns,	O
JWH-302	B-Drug

Opana	B-Drug
ER	I-Drug
(extended-release	O
tablet):	O

Halothane	O
was	O
the	O
first	O
such	O
anesthetic	O
developed	O
and	O
other	O
currently	O
used	O
inhaled	O
anesthetics,	O
as	O
isoflurane,	O
desflurane,	O
sevoflurane,	O
are	O
halogenated	O
ethers.	O
isoflurane	B-Drug
desflurane	B-Drug
sevoflurane	B-Drug

The	O
anti	O
convulsion	O
drug	O
Lamotrigine	B-Drug
has	O
shown	O
some	O
success	O
in	O
treating	O
symptoms	O
of	O
depersonalization,	O
often	O
combination	O
with	O
a	O
Selective	O
serotonin	O
reuptake	O
inhibitor	O
and	O
is	O
the	O
first	O
choice	O
at	O
depersonalisation	O
research	O
unit	O
King's	O
College	O
London.	O

baeocystin	B-Drug
alone	O
would	O
likely	O
not	O
induce	O
hallucinogenic	O
effects	O
in	O
vivo".	O

Experts	O
in	O
the	O
UK	O
have	O
suggested	O
that	O
some	O
drugs	O
may	O
be	O
causing	O
less	O
harm,	O
to	O
fewer	O
users	O
(although	O
they	O
are	O
also	O
used	O
frequently	O
first	O
place),	O
include	O
cannabis,	O
psilocybin	O
mushrooms,	O
LSD,	O
and	O
ecstasy.	O
LSD	B-Drug
ecstasy	B-Drug

The	O
blue-staining	O
species	O
of	O
Psilocybe	O
are	O
characterized	O
by	O
the	O
presence	O
psilocin	B-Drug
and	O
psilocybin.	O

Alphaprodine	B-Drug
was	O
sold	O
under	O
several	O
brand	O
names,	O
mainly	O
Nisentil	O
and	O
Prisilidine.	O

Oral	O
dosage	O
forms	O
of	O
methaqualone	B-Drug
hydrochloride	O
were	O
manufactured	O
as	O
capsules,	O
whereas	O
oral	O
free-base	O
tablets.	O

The	O
amine	O
is	O
often	O
an	O
alkaloid,	O
such	O
as	O
nicotine,	O
cocaine,	O
morphine,	O
and	O
ephedrine,	O
or	O
derivatives	O
thereof.	O
nicotine	B-Drug
cocaine	B-Drug
morphine	B-Drug
ephedrine	B-Drug

In	O
June	O
2013,	O
the	O
United	O
States	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
(CDC)	O
issued	O
a	O
health	O
advisory	O
to	O
emergency	O
departments	O
alerting	O
14	O
overdose	O
deaths	O
among	O
intravenous	O
drug	O
users	O
in	O
Rhode	O
Island	O
associated	O
with	O
acetylfentanyl,	O
synthetic	O
opioid	O
analog	O
of	O
fentanyl	B-Drug
that	O
has	O
never	O
been	O
licensed	O
medical	O
use.	O

Chemical	O
syntheses	O
of	O
norethandrolone	B-Drug
have	O
been	O
published.	O

Many	O
choose	O
mixtures	O
that	O
are	O
made	O
without	O
propylene	O
glycol	O
and	O
nicotine,	O
but	O
use	O
higher	O
amounts	O
of	O
glycerin	O
to	O
produce	O
larger	O
plumes	O
vapor.	O
nicotine	B-Drug

The	O
two	O
main	O
ways	O
cocaine	B-Drug
is	O
smoked	O
are	O
freebasing	O
and	O
by	O
using	O
which	O
has	O
been	O
converted	O
to	O
smokable	O
"crack	O
cocaine".	O

The	O
alpha-2	O
agonist	O
dexmedetomidine	B-Drug
may	O
also	O
be	O
useful	O
for	O
agitation,	O
but	O
effects	O
on	O
heart	O
rate	O
and	O
blood	O
pressure	O
are	O
variable	O
based	O
several	O
studies	O
case	O
reports.	O

Pickard	O
was	O
charged	O
with	O
manufacturing	O
LSD	B-Drug
and	O
served	O
five	O
years	O
in	O
prison.	O

Phentermine	B-Drug
was	O
approved	O
for	O
medical	O
use	O
in	O
the	O
United	O
States	O
1959.	O

The	O
absorption	O
rate	O
of	O
zaleplon	B-Drug
is	O
rapid	O
and	O
the	O
onset	O
therapeutic	O
effects	O
typically	O
breached	O
within	O
515	O
minutes	O
following	O
ingestion.	O

Higher	O
demand	O
for	O
cocaine	B-Drug
in	O
Western	O
Europe	O
addition	O
to	O
North	O
American	O
interdiction	O
campaigns	O
has	O
led	O
dramatically	O
increased	O
trafficking	O
the	O
region:	O
nearly	O
50%	O
of	O
all	O
non-U.S.	O
bound	O
cocaine,	O
or	O
about	O
13%	O
global	O
flows,	O
is	O
now	O
smuggled	O
through	O
West	O
Africa.	O

In	O
multiple	O
clinical	O
trials,	O
ketamine	B-Drug
infusions	O
delivered	O
short-term	O
pain	O
relief	O
in	O
neuropathic	O
diagnoses,	O
after	O
traumatic	O
spine	O
injury,	O
fibromyalgia,	O
and	O
complex	O
regional	O
syndrome	O
(CRPS).	O

There	O
were	O
only	O
seven	O
methamphetamine	B-Drug
lab	O
incidents	O
reported	O
in	O
Hawaii	O
2004,	O
though	O
nearly	O
59	O
percent	O
of	O
substance	O
abuse	O
treatment	O
admissions	O
(excluding	O
alcohol)	O
for	O
primary	O
during	O
the	O
first	O
six	O
months	O
2004.	O

According	O
to	O
the	O
United	O
Nations	O
Office	O
on	O
Drugs	O
and	O
Crime	O
(UNODC),	O
"the	O
amount	O
of	O
THC	B-Drug
present	O
in	O
a	O
cannabis	O
sample	O
is	O
generally	O
used	O
as	O
measure	O
potency.	O

The	O
biological	O
half-life	O
from	O
the	O
plasma	O
is	O
200	O
to	O
300	O
minutes;	O
due	O
stable	O
complexes	O
of	O
triamcinolone	B-Drug
and	O
its	O
receptor	O
in	O
intracellular	O
fluid,	O
total	O
significantly	O
longer	O
at	O
about	O
36	O
hours.	O

Following	O
the	O
patch,	O
a	O
flavoured	O
lollipop	O
of	O
fentanyl	B-Drug
citrate	O
mixed	O
with	O
inert	O
fillers	O
was	O
introduced	O
in	O
1998	O
under	O
brand	O
name	O
Actiq,	O
becoming	O
first	O
quick-acting	O
formation	O
for	O
use	O
chronic	O
breakthrough	O
pain.	O
Actiq	B-Drug

Medical	O
marijuana	O
refers	O
to	O
the	O
use	O
of	O
Cannabis	O
plant	O
as	O
a	O
physician-recommended	O
herbal	O
therapy	O
well	O
synthetic	O
THC	B-Drug
and	O
cannabinoids.	O

Alectinib	B-Drug
was	O
approved	O
in	O
Japan	O
July	O
2014	O
for	O
the	O
treatment	O
of	O
ALK	O
fusion-gene	O
positive,	O
unresectable,	O
advanced	O
or	O
recurrent	O
non-small-cell	O
lung	O
cancer	O
(NSCLC).It	O
granted	O
an	O
accelerated	O
approval	O
by	O
US	O
Food	O
and	O
Drug	O
Administration	O
(FDA)	O
December	O
2015	O
to	O
treat	O
patients	O
with	O
ALK-positive	O
NSCLC	O
whose	O
disease	O
worsened	O
after,	O
who	O
could	O
not	O
tolerate,	O
crizotinib	B-Drug
(Xalkori).	O

As	O
of	O
October	O
2015,	O
5-MeO-DMT	B-Drug
is	O
a	O
controlled	O
substance	O
in	O
China.	O

It	O
is	O
an	O
active	O
analgesic	O
in	O
vivo,	O
more	O
potent	O
than	O
codeine	B-Drug
or	O
pethidine	B-Drug
but	O
slightly	O
less	O
morphine,	O
and	O
produces	O
similar	O
effects	O
to	O
morphine	B-Drug
animals	O
with	O
sedation	O

Mecloqualone	B-Drug
(Nubarene,	O
Casfen)	O
is	O
a	O
Quinazolinone-class	O
GABAergic	O
and	O
an	O
analogue	O
of	O
methaqualone	B-Drug
that	O
was	O
first	O
made	O
in	O
1960	O
marketed	O
mainly	O
France	O
some	O
other	O
European	O
countries.	O

that	O
JWH-018	B-Drug
was	O
found	O
as	O
one	O
of	O
the	O
active	O
components	O
in	O
at	O
least	O
three	O
versions	O
grey	O
market	O
drug	O
Spice,	O
which	O
has	O
been	O
sold	O
an	O
incense	O
a	O
number	O
countries	O
around	O
world	O
since	O
2002.	O

Researchers	O
confirmed	O
that	O
THC	B-Drug
exerts	O
its	O
most	O
prominent	O
effects	O
via	O
actions	O
on	O
two	O
types	O
of	O
cannabinoid	O
receptors,	O
the	O
CB1	O
receptor	O
and	O
CB2	O
receptor,	O
both	O
which	O
are	O
G	O
protein-coupled	O
receptors.	O

As	O
of	O
December	O
2019,	O
there	O
is	O
no	O
effective	O
pharmacotherapy	O
for	O
amphetamine	B-Drug
addiction.	O

The	O
labs	O
manufacture	O
temazepam	B-Drug
by	O
chemically	O
altering	O
diazepam,	O
oxazepam	B-Drug
or	O
lorazepam.	O
"	O
diazepam	B-Drug
lorazepam	B-Drug

Their	O
paper	O
in	O
the	O
Multidisciplinary	O
Association	O
for	O
Psychedelic	O
Studies	O
journal	O
demonstrated	O
that	O
administration	O
of	O
low	O
"maintenance"	O
doses	O
ibogaine	B-Drug
HCl	O
with	O
opioids	O
decreases	O
tolerance,	O
but	O
noted	O
ibogaine's	O
potentiating	O
action	O
could	O
make	O
this	O
a	O
risky	O
procedure.	O

Before	O
the	O
1990s,	O
harvesting	O
coca	B-Drug
leaves	O
had	O
been	O
a	O
relatively	O
small-scale	O
business	O
in	O
Colombia.	O

For	O
women	O
who	O
have	O
had	O
intrathecal	O
opioids,	O
there	O
should	O
be	O
a	O
minimum	O
hourly	O
observation	O
of	O
respiratory	O
rate,	O
sedation	O
and	O
pain	O
scores	O
for	O
at	O
least	O
12	O
hours	O
diamorphine	B-Drug
24	O
morphine.	O
morphine	B-Drug

In	O
the	O
US,	O
dihydrocodeine	B-Drug
is	O
a	O
DEA	O
Schedule	O
II	O
substance,	O
although	O
preparations	O
containing	O
small	O
amounts	O
of	O
are	O
classified	O
as	O
III	O
or	O
V,	O
depending	O
on	O
concentration	O
relative	O
to	O
other	O
active	O
constituents,	O
such	O
paracetamol	B-Drug
(acetaminophen).	O
acetaminophen	B-Drug

If	O
ipratropium	B-Drug
is	O
inhaled,	O
side	O
effects	O
resembling	O
those	O
of	O
other	O
anticholinergics	O
are	O
minimal.	O

It	O
evokes	O
robust	O
hyperthermia	O
in	O
rodents	O
while	O
producing	O
only	O
modest	O
hyperactivity	O
and	O
serotonergic	O
neurotoxicity,	O
substantially	O
lower	O
than	O
that	O
caused	O
by	O
MDMA,	O
at	O
very	O
high	O
doses.	O
MDMA	B-Drug

Ibogaine	B-Drug
is	O
metabolized	O
in	O
the	O
human	O
body	O
by	O
cytochrome	O
P450	O
2D6	O
into	O
noribogaine	B-Drug
(more	O
correctly,	O
O-desmethylibogaine	O
or	O
12-hydroxyibogamine).	O

Through	O
his	O
work	O
he	O
had	O
become	O
known	O
as	O
one	O
of	O
the	O
leading	O
experts	O
in	O
LSD	B-Drug
research.	O

Ketoprofen,	O
when	O
administered	O
intravenously,	O
is	O
recommended	O
for	O
a	O
maximum	O
of	O
five	O
days	O
use.	O
Ketoprofen	B-Drug

The	O
majority	O
of	O
ibuprofen	B-Drug
is	O
metabolised	O
and	O
eliminated	O
within	O
24	O
hours	O
in	O
the	O
urine;	O
however,	O
1%	O
unchanged	O
drug	O
removed	O
through	O
biliary	O
excretion.	O

Fentanyl	B-Drug
was	O
first	O
synthesized	O
in	O
Belgium	O
by	O
Paul	O
Janssen	O
under	O
the	O
label	O
of	O
his	O
relatively	O
newly	O
formed	O
Pharmaceutica	O
1959.	O

Phenazepam	B-Drug
should	O
not	O
be	O
taken	O
with	O
alcohol	O
or	O
any	O
other	O
CNS	O
depressants.	O

Clomifene	B-Drug
and	O
its	O
metabolites	O
are	O
excreted	O
primarily	O
through	O
feces	O
(42%),	O
excretion	O
can	O
occur	O
up	O
to	O
6	O
weeks	O
after	O
discontinuation.	O

Typically	O
abusers	O
would	O
ingest	O
the	O
blue	O
half	O
containing	O
methamphetamine	B-Drug
for	O
stimulation	O
and	O
wakefulness,	O
followed	O
by	O
future	O
ingestion	O
of	O
yellow	O
pentobarbital	B-Drug
as	O
a	O
hypnotic	O
counteracting	O
stimulant-induced	O
insomnia	O
whenever	O
sleep	O
was	O
desired.	O

Sofosbuvir	B-Drug
is	O
only	O
administered	O
orally.	O

PCP	B-Drug
was	O
initially	O
made	O
in	O
1926	O
and	O
brought	O
to	O
market	O
as	O
an	O
anesthetic	O
medication	O
the	O
1950s.	O

It	O
was	O
later	O
determined	O
that	O
SV40	O
present	O
as	O
a	O
contaminant	O
in	O
polio	B-Drug
vaccine	I-Drug
lots	O
had	O
been	O
administered	O
to	O
90%	O
of	O
the	O
children	O
United	O
States.	O

the	O
following	O
phenethylamine	B-Drug
derivatives,	O
namely:	O
(c)	O

The	O
report	O
also	O
stated	O
that	O
cocaine	B-Drug
use	O
had	O
increased	O
over	O
the	O
four	O
years	O
leading	O
up	O
to	O
2012.	O

Thalidomide	B-Drug
has	O
several	O
cardiovascular	O
adverse	O
effects,	O
including	O
risk	O
of	O
heart	O
attacks,	O
pulmonary	O
hypertension,	O
and	O
changes	O
in	O
rhythm	O
syncope,	O
bradycardia,	O
atrioventricular	O
block.	O

Diazepam	B-Drug
undergoes	O
oxidative	O
metabolism	O
by	O
demethylation	O
(CYP	O
2C9,	O
2C19,	O
2B6,	O
3A4,	O
and	O
3A5),	O
hydroxylation	O
3A4	O
2C19)	O
glucuronidation	O
in	O
the	O
liver	O
as	O
part	O
of	O
cytochrome	O
P450	O
enzyme	O
system.	O

Plants	O
in	O
the	O
genus	O
Hypericum	O
(including	O
St.	O
John's	O
wort)	O
conversely	O
can	O
lower	O
plasma	O
levels	O
of	O
alprazolam	B-Drug
and	O
reduce	O
its	O
therapeutic	O
effect.	O

Thalidomide	B-Drug
was	O
first	O
marketed	O
in	O
1957	O
West	O
Germany,	O
where	O
it	O
available	O
over	O
the	O
counter.	O

Trenbolone	B-Drug
increases	O
an	O
inflammatory	O
mediator	O
peptide	O
called	O
bradykinin	O
which	O
facilitates	O
the	O
dilation	O
of	O
blood	O
vessels.	O

The	O
Drug	O
Equality	O
Alliance	O
(DEA)	O
has	O
launched	O
legal	O
actions	O
against	O
the	O
UK	O
Government's	O
partial	O
and	O
unequal	O
administration	O
of	O
Act's	O
discretionary	O
powers,	O
making	O
particular	O
reference	O
to	O
arbitrary	O
exclusion	O
alcohol	O
tobacco	B-Drug
on	O
subjective	O
grounds	O
historical	O
cultural	O
precedents	O
contrary	O
policy	O
objects.	O

The	O
mixing	O
ratio	O
with	O
naloxone	B-Drug
is	O
chosen	O
so	O
that	O
the	O
analgesic	O
effect	O
of	O
tilidine	B-Drug
not	O
impaired.	O

The	O
committee	O
concluded	O
that	O
breast	O
cancer	O
clinical	O
studies	O
of	O
patients	O
taking	O
Avastin	B-Drug
have	O
shown	O
no	O
advantage	O
in	O
survival	O
rates,	O
improvement	O
quality	O
life,	O
and	O
significant	O
side	O
effects.	O

Estonia	O
has	O
the	O
highest	O
rate	O
of	O
3-methylfentanyl	B-Drug
overdose	O
deaths	O
in	O
EU,	O
due	O
to	O
its	O
high	O
recreational	O
use.	O

Desogestrel	B-Drug
is	O
available	O
alone	O
in	O
the	O
form	O
of	O
75	O
g	O
oral	O
tablets	O
and	O
at	O
a	O
dose	O
150	O
combination	O
with	O
20	O
or	O
30	O
ethinylestradiol	O
tablets.	O

It	O
is	O
a	O
benzylpiperidine	O
and	O
phenethylamine	B-Drug
derivative	O
which	O
also	O
shares	O
part	O
of	O
its	O
basic	O
structure	O
with	O
catecholamines.	O

The	O
13th-century	O
Ibn	O
Taymiyyah	O
prohibited	O
the	O
use	O
of	O
hashish;	O
he	O
mentioned	O
that	O
it	O
was	O
introduced	O
to	O
Levant	O
with	O
Mongol	O
invasion	O
(throughout	O
13th	O
century).	O
hashish	B-Drug

A	O
second	O
process	O
is	O
required	O
to	O
convert	O
the	O
cocaine	B-Drug
base	O
into	O
powdered	O
hydrochloride.	O

Any	O
stereoisomeric	O
form	O
of	O
a	O
substance	O
for	O
the	O
time	O
being	O
specified	O
in	O
paragraph	O
1	O
this	O
Part	O
Schedule	O
[not	O
phenylpropanolamine.]	O
phenylpropanolamine	B-Drug

Cocaine's	O
desired	O
euphoric	O
effects	O
are	O
delayed	O
when	O
snorted	O
through	O
the	O
nose	O
by	O
about	O
five	O
minutes.	O
Cocaine	B-Drug

One	O
death	O
through	O
coronary	O
arterial	O
thrombosis	O
has	O
been	O
linked	O
to	O
ADB-FUBINACA	B-Drug
intoxication.	O

As	O
an	O
example,	O
the	O
17-alkylated	O
AAS	O
methyltestosterone	B-Drug
and	O
metandienone	B-Drug
are	O
converted	O
by	O
aromatase	O
into	O
methylestradiol.	O

It	O
is	O
also	O
used	O
in	O
surgery	O
and	O
post	O
operative	O
pain	O
control	O
patients	O
that	O
are	O
taking	O
high	O
dose	O
buprenorphine	B-Drug
for	O
chronic	O
because	O
it	O
the	O
only	O
opioid	O
has	O
a	O
potency	O
binding	O
affinity	O
strong	O
enough	O
to	O
displace	O
from	O
receptors	O
central	O
nervous	O
system	O
provide	O
analgesia.	O

Richard	O
Davenport-Hines,	O
in	O
his	O
book	O
The	O
Pursuit	O
of	O
Oblivion,	O
criticized	O
the	O
efficacy	O
War	O
on	O
Drugs	O
by	O
pointing	O
out	O
that	O
1015%	O
illicit	O
heroin	B-Drug
and	O
30%	O
cocaine	B-Drug
is	O
intercepted.	O

Under	O
normal	O
physiological	O
conditions,	O
the	O
concentration	O
of	O
GHB	B-Drug
in	O
body	O
is	O
rather	O
low,	O
and	O
pathways	O
would	O
run	O
reverse	O
direction	O
to	O
what	O
shown	O
here	O
produce	O
endogenous	O
GHB.	O

Due	O
to	O
its	O
weak	O
androgenic	O
activity,	O
norethisterone	B-Drug
can	O
produce	O
side	O
effects	O
such	O
as	O
acne,	O
hirsutism,	O
and	O
voice	O
changes	O
of	O
slight	O
severity	O
in	O
some	O
women	O
at	O
high	O
dosages	O
(e.g.,	O
10	O
40	O
mg/day).	O

The	O
clearance	O
of	O
oxycodone	B-Drug
is	O
0.8	O
L/min.	O

It	O
was	O
concluded	O
that	O
BZP	B-Drug
appears	O
to	O
induce	O
toxic	O
seizures	O
in	O
neurologically	O
normal	O
subjects.	O

All	O
SSRIs	O
and	O
SNRIs	O
are	O
Category	O
C,	O
except	O
paroxetine,	O
which	O
is	O
D	O
since	O
it	O
has	O
shown	O
association	O
with	O
congenital	O
heart	O
disorders.	O
paroxetine	B-Drug

Traces	O
of	O
the	O
drug	O
have	O
also	O
been	O
found	O
in	O
other	O
recreational	O
drugs	O
including	O
cocaine,	O
MDMA,	O
and	O
heroin.	O
cocaine	B-Drug
MDMA	B-Drug
heroin	B-Drug

One	O
example	O
is	O
the	O
case	O
of	O
Big	O
Lurch,	O
a	O
former	O
rapper	O
with	O
history	O
violent	O
crime,	O
who	O
was	O
convicted	O
murdering	O
and	O
cannibalizing	O
his	O
roommate	O
while	O
under	O
influence	O
PCP.	O
PCP	B-Drug

Desonide	B-Drug
0.05%	O

Because	O
the	O
masses	O
involved	O
are	O
so	O
small,	O
concealing	O
and	O
transporting	O
illicit	O
LSD	B-Drug
is	O
much	O
easier	O
than	O
smuggling	O
cocaine,	O
cannabis,	O
or	O
other	O
illegal	O
drugs.	O
cocaine	B-Drug

Such	O
is	O
the	O
case	O
with	O
Suboxone	B-Drug
in	O
context	O
of	O
opioid	O
dependence.	O

The	O
variation	O
of	O
reported	O
half-lifes	O
are	O
attributed	O
to	O
differences	O
in	O
nordazepam	B-Drug
metabolism	O
and	O
that	O
its	O
metabolites	O
as	O
is	O
hydroxylated	O
active	O
such	O
oxazepam,	O
before	O
finally	O
being	O
glucuronidated	O
excreted	O
the	O
urine.	O
oxazepam	B-Drug

The	O
mechanism	O
that	O
produces	O
the	O
purported	O
hallucinogenic	O
and	O
entheogenic	O
effects	O
of	O
5-MeO-DiPT	B-Drug
is	O
thought	O
to	O
result	O
primarily	O
from	O
5-HT2A	O
receptor	O
agonism,	O
although	O
additional	O
mechanisms	O
action	O
such	O
as	O
monoamine	O
oxidase	O
inhibition	O
(MAOI)	O
may	O
be	O
involved	O
also.	O

In	O
the	O
case	O
of	O
antiandrogen	O
monotherapy	O
for	O
prostate	O
cancer,	O
rates	O
diarrhea	O
are	O
5	O
to	O
20%	O
flutamide,	O
2	O
5%	O
bicalutamide,	O
and	O
4%	O
nilutamide.	O
bicalutamide	B-Drug

The	O
DEA	O
classifies	O
trenbolone	B-Drug
and	O
its	O
esters	O
as	O
Schedule	O
III	O
controlled	O
substances	O
under	O
the	O
Controlled	O
Substances	O
Act.	O

Many	O
drugs	O
can	O
produce	O
a	O
sedative	O
effect	O
including	O
benzodiazepines,	O
propofol,	O
thiopental,	O
ketamine	B-Drug
and	O
inhaled	O
general	O
anesthetics.	O
propofol	B-Drug
thiopental	B-Drug

However,	O
norethisterone	B-Drug
has	O
been	O
found	O
to	O
be	O
a	O
substrate	O
for	O
aromatase	O
and	O
is	O
converted	O
in	O
the	O
liver	O
small	O
extent	O
(0.35%)	O
highly	O
potent	O
estrogen	O
EE,	O
this	O
reason,	O
unlike	O
most	O
other	O
progestins,	O
some	O
estrogenic	O
activity.	O

Usually,	O
in	O
its	O
oral	O
formulations,	O
it	O
is	O
combined	O
with	O
naloxone	B-Drug
so	O
as	O
to	O
prevent	O
people	O
from	O
crushing	O
the	O
tablets,	O
dissolving	O
them	O
a	O
solvent	O
(like	O
water)	O
and	O
injecting	O
for	O
high	O
(as	O
orally	O
administered	O
produces	O
no	O
opioid-negating	O
effects.	O

Russian	O
Spetsnaz	O
security	O
forces	O
used	O
a	O
fentanyl	B-Drug
analogue	O
or	O
derivative	O
to	O
incapacitate	O
people	O
rapidly	O
in	O
the	O
Moscow	O
theater	O
hostage	O
crisis	O
2002.	O

Side	O
effects	O
typical	O
of	O
KOR	O
activation	O
such	O
as	O
hallucinations	O
and	O
dissociation	O
have	O
also	O
been	O
observed	O
with	O
nalmefene	B-Drug
in	O
human	O
studies.	O

According	O
to	O
the	O
International	O
Agency	O
for	O
Research	O
on	O
Cancer,	O
"nicotine	O
is	O
not	O
generally	O
considered	O
be	O
a	O
carcinogen."	O
nicotine	B-Drug

The	O
main	O
challenge	O
with	O
ketamine	B-Drug
treatment	O
is	O
what	O
to	O
do	O
when	O
the	O
anti-depressive	O
action	O
expires.	O

At	O
normal	O
urine	O
pH,	O
the	O
half-lives	O
of	O
dextroamphetamine	B-Drug
and	O
levoamphetamine	O
are	O
911	O
hours	O
1114	O
hours,	O
respectively.	O

They	O
found	O
no	O
fentanyl,	O
but	O
did	O
find	O
two	O
other,	O
much	O
more	O
potent	O
and	O
potentially	O
toxic	O
drugs,	O
carfentanil	B-Drug
remifentanil.	O
fentanyl	B-Drug
remifentanil	B-Drug

JWH-149	B-Drug
is	O
a	O
synthetic	O
cannabimimetic	O
that	O
was	O
discovered	O
by	O
John	O
W.	O
Huffman.	O

One	O
potential	O
cause	O
of	O
death	O
from	O
GHB	B-Drug
consumption	O
is	O
polydrug	O
toxicity.	O

However,	O
its	O
high	O
potency,	O
combined	O
with	O
the	O
rapid	O
action	O
of	O
both	O
etorphine	B-Drug
and	O
antagonist,	O
diprenorphine,	O
means	O
that	O
it	O
has	O
found	O
a	O
place	O
for	O
use	O
in	O
capture	O
large	O
mammals	O
such	O
as	O
rhinoceroses	O
elephants,	O
where	O
onset	O
recovery	O
are	O
very	O
important.	O

A	O
common	O
problem	O
is	O
that	O
GHB	B-Drug
does	O
not	O
leave	O
traces	O
in	O
the	O
body	O
after	O
a	O
short	O
period	O
of	O
time,	O
complicating	O
diagnosis	O
and	O
research.	O

Androstenedione	B-Drug
was	O
manufactured	O
as	O
a	O
dietary	O
supplement,	O
often	O
called	O
andro	O
or	O
andros	O
for	O
short.	O

It	O
is	O
also	O
the	O
N,N-dimethyl	O
analog	O
of	O
3,4-methylenedioxyamphetamine	B-Drug
(MDA).	O

JWH-018	B-Drug
produces	O
bradycardia	O
and	O
hypothermia	O
in	O
rats	O
at	O
doses	O
of	O
0.33	O
mg/kg,	O
suggesting	O
potent	O
cannabinoid-like	O
activity.	O

the	O
following	O
phenethylamine	B-Drug
derivatives,	O
namely:	O
(c)	O

Magnetic	O
resonance	O
imaging	O
studies	O
on	O
human	O
methamphetamine	B-Drug
users	O
have	O
also	O
found	O
evidence	O
of	O
neurodegeneration,	O
or	O
adverse	O
neuroplastic	O
changes	O
in	O
brain	O
structure	O
and	O
function.	O

Most	O
of	O
the	O
side	O
effects	O
spironolactone	B-Drug
are	O
dose-dependent.	O

Analogues	O
of	O
PCP	B-Drug
exhibit	O
varying	O
potency	O
at	O
nACh	O
receptors	O
and	O
NMDA	O
receptors.	O

Fencamfamin	B-Drug
(INN),	O
also	O
known	O
as	O
fencamfamine	B-Drug
or	O
by	O
the	O
brand	O
names	O
Glucoenergan	O
and	O
Reactivan,	O
is	O
a	O
stimulant	O
which	O
was	O
developed	O
Merck	O
in	O
1960s.	O
Reactivan	B-Drug

(JWH-081)	O
JWH-081	B-Drug

Although	O
nicotine	B-Drug
itself	O
does	O
not	O
cause	O
cancer	O
in	O
humans,	O
it	O
is	O
unclear	O
whether	O
functions	O
as	O
a	O
tumor	O
promoter	O
of	O
2012.	O

Australia's	O
National	O
Cannabis	O
Prevention	O
and	O
Information	O
Centre	O
(NCPIC)	O
states	O
that	O
the	O
buds	O
(infructescences)	O
of	O
female	O
cannabis	O
plant	O
contain	O
highest	O
concentration	O
THC,	O
followed	O
by	O
leaves.	O
THC	B-Drug

As	O
such,	O
PCP	B-Drug
is	O
an	O
NMDA	O
receptor	O
antagonist.	O

5F-ADB	B-Drug
was	O
first	O
identified	O
in	O
November	O
2014	O
from	O
post-mortem	O
samples	O
taken	O
an	O
individual	O
who	O
had	O
died	O
after	O
using	O
a	O
product	O
containing	O
this	O
substance.	O

Lorazepam	B-Drug
is	O
sometimes	O
used	O
as	O
an	O
alternative	O
to	O
midazolam	B-Drug
in	O
palliative	O
sedation.	O

Acetylfentanyl	B-Drug
was	O
discovered	O
at	O
the	O
same	O
time	O
as	O
fentanyl	B-Drug
itself	O
and	O
had	O
only	O
rarely	O
been	O
encountered	O
on	O
illicit	O
market	O
in	O
late	O
1980s.	O

Lubiprostone	B-Drug
is	O
used	O
in	O
the	O
management	O
of	O
chronic	O
idiopathic	O
constipation	O
and	O
irritable	O
bowel	O
syndrome.	O

The	O
dosages	O
of	O
methyltestosterone	B-Drug
used	O
are	O
10	O
to	O
50	O
mg/day	O
in	O
men	O
for	O
common	O
medical	O
uses	O
like	O
hypogonadism	O
and	O
delayed	O
puberty	O
as	O
well	O
physique-	O
performance-enhancing	O
purposes	O
2.5	O
women	O
menopausal	O
symptoms.	O

However,	O
PCP	B-Drug
has	O
little	O
affinity	O
for	O
the	O
human	O
monoamine	O
transporters,	O
including	O
dopamine	O
transporter	O
(DAT).	O

Nalbuphine	B-Drug
binds	O
with	O
high	O
affinity	O
to	O
the	O
MOR	O
and	O
KOR,	O
has	O
relatively	O
low	O
for	O
DOR.	O

This	O
means	O
that	O
detriments	O
to	O
the	O
fetus	O
have	O
been	O
observed	O
in	O
animal	O
studies	O
and	O
adequate	O
human	O
not	O
conducted;	O
amphetamine	B-Drug
may	O
still	O
be	O
prescribed	O
pregnant	O
women	O
if	O
potential	O
benefits	O
outweigh	O
risks.	O

In	O
the	O
UK,	O
its	O
highly	O
likely	O
that	O
this	O
compound	O
would	O
be	O
covered	O
by	O
"phenylethylamine	O
amendment"	O
to	O
misuse	O
of	O
drugs	O
act	O
rendering	O
it	O
a	O
Class	O
A	O
controlled	O
drug.	O
phenylethylamine	B-Drug

A	O
cultivar	O
for	O
opium	B-Drug
production,	O
Papaver	O
somniferum	O
L.	O
elite,	O
contains	O
91.2	O
percent	O
morphine,	O
codeine,	O
and	O
thebaine	O
in	O
its	O
latex	O
alkaloids,	O
whereas	O
the	O
of	O
condiment	O
"Marianne",	O
these	O
three	O
alkaloids	O
total	O
only	O
14.0	O
percent.	O
morphine	B-Drug
codeine	B-Drug

Fodiss	O
(fluoxetine)	O
-	O
an	O
antidepressant	O
of	O
the	O
SSRI	O
class.	O
fluoxetine	B-Drug

Etizolam	B-Drug
is	O
licensed	O
for	O
the	O
treatment	O
of	O
anxiety,	O
insomnia	O
and	O
neurosis	O
as	O
a	O
prescription-only	O
medication.	O

It	O
was	O
introduced	O
to	O
replace	O
pentobarbital	B-Drug
after	O
the	O
latter's	O
manufacturer	O
disallowed	O
that	O
drug's	O
use	O
for	O
executions.	O

The	O
long	O
half-lives	O
of	O
tamoxifen	B-Drug
and	O
afimoxifene	O
are	O
attributed	O
to	O
their	O
high	O
plasma	O
protein	O
binding	O
as	O
well	O
enterohepatic	O
recirculation.	O

A	O
seizure	O
of	O
a	O
record	O
amount	O
fentanyl	B-Drug
occurred	O
on	O
February	O
2,	O
2019,	O
by	O
U.S.	O
Customs	O
and	O
Border	O
Protection	O
in	O
Nogales,	O
Arizona.	O

In	O
the	O
West,	O
cocaine	B-Drug
usage	O
was	O
lower,	O
which	O
thought	O
to	O
be	O
due	O
a	O
switch	O
methamphetamine	B-Drug
among	O
some	O
users;	O
is	O
cheaper,	O
three	O
and	O
half	O
times	O
more	O
powerful,	O
lasts	O
1224	O
longer	O
with	O
each	O
dose.	O

At	O
very	O
high	O
doses	O
(e.g.,	O
240	O
mg,	O
or	O
between	O
200600	O
mg),	O
fenfluramine	B-Drug
induces	O
a	O
psychedelic	O
state	O
resembling	O
that	O
produced	O
by	O
lysergic	O
acid	B-Drug
diethylamide	O
(LSD).	O
LSD	B-Drug

The	O
CIA's	O
own	O
internal	O
investigation	O
concluded	O
that	O
the	O
head	O
of	O
MKUltra,	O
CIA	O
chemist	O
Sidney	O
Gottlieb,	O
had	O
conducted	O
LSD	B-Drug
experiment	O
with	O
Olson's	O
prior	O
knowledge,	O
although	O
neither	O
Olson	O
nor	O
other	O
men	O
taking	O
part	O
in	O
were	O
informed	O
as	O
to	O
exact	O
nature	O
drug	O
until	O
some	O
20	O
minutes	O
after	O
its	O
ingestion.	O

Amcinonide	B-Drug
0.05%	O
(Cyclocort)	O

cannabis,	O
LSD,	O
methamphetamine	B-Drug
The	O
Business	O
(2005)	O
LSD	B-Drug

Ken	O
Kesey	O
was	O
also	O
said	O
to	O
have	O
experimented	O
with	O
LSD	B-Drug
Ringo	O
Starr	O
in	O
1965	O
and	O
that	O
he	O
influenced	O
the	O
setup	O
for	O
future	O
performances	O
The	O
Beatles	O
UK.In	O

Van	O
Urk	O
reagent	O
turns	O
blue-purple	O
when	O
in	O
the	O
presence	O
of	O
LSD.	O
LSD	B-Drug

Chlorpromazine	B-Drug
is	O
classified	O
as	O
a	O
low-potency	O
typical	O
antipsychotic	O
and	O
used	O
in	O
the	O
treatment	O
of	O
both	O
acute	O
chronic	O
psychoses,	O
including	O
schizophrenia	O
manic	O
phase	O
bipolar	O
disorder,	O
well	O
amphetamine-induced	O
psychosis.	O

It	O
contained	O
6	O
mg	O
cocaine	B-Drug
per	O
ounce	O
of	O
wine,	O
but	O
Vin	O
Mariani	O
which	O
was	O
to	O
be	O
exported	O
7.2	O
ounce,	O
compete	O
with	O
the	O
higher	O
content	O
similar	O
drinks	O
in	O
United	O
States.	O

Also,	O
cross-sensitization	O
is	O
not	O
unique	O
to	O
marijuana.	O
marijuana	B-Drug

Beginning	O
in	O
2015,	O
Canada	O
has	O
seen	O
a	O
number	O
of	O
fentanyl	B-Drug
overdoses.	O

For	O
example,	O
the	O
drug	O
methotrexate	B-Drug
is	O
a	O
competitive	O
inhibitor	O
of	O
enzyme	O
dihydrofolate	O
reductase,	O
which	O
catalyzes	O
reduction	O
to	O
tetrahydrofolate.	O

Additionally,	O
nociceptin	O
may	O
have	O
lower	O
tolerance	O
development	O
than	O
drugs	O
such	O
as	O
morphine.	O
morphine	B-Drug

Ogata's	O
synthesis	O
of	O
methamphetamine	B-Drug
replaced	O
much	O
more	O
complicated	O
earlier	O
syntheses,	O
and	O
continues	O
to	O
be	O
used	O
as	O
the	O
basis	O
for	O
modern	O
production	O
usage	O
drug.	O

Diethylthiambutene	B-Drug
has	O
been	O
the	O
most	O
widely	O
used,	O
mainly	O
in	O
veterinary	O
medicine.	O

)	O
*"opium	O
derivative"	O
means:	O
opium	B-Drug

Respiratory	O
depression	O
is	O
a	O
potentially	O
serious	O
or	O
fatal	O
adverse	O
drug	O
reaction	O
associated	O
with	O
the	O
use	O
of	O
codeine,	O
but	O
mainly	O
danger	O
lies	O
in	O
much	O
more	O
potent	O
and	O
CNS-depressing	O
phenothiazine-related	O
antihistamine	O
promethazine.	O
codeine	B-Drug
promethazine	B-Drug

As	O
of	O
2018	O
fentanyl	B-Drug
was	O
the	O
most	O
commonly	O
listed	O
opioid	O
in	O
overdose	O
drug	O
deaths,	O
surpassing	O
heroin.	O
heroin	B-Drug

For	O
example,	O
neuronal	O
nAChR	O
channels	O
are	O
blocked	O
by	O
clinically	O
relevant	O
anaesthetic	O
concentrations	O
of	O
both	O
thiopental	B-Drug
and	O
pentobarbital.	O
pentobarbital	B-Drug

WIN	B-Drug
55,212-2	I-Drug
is	O
a	O
potent	O
cannabinoid	O
receptor	O
agonist	O
that	O
has	O
been	O
found	O
to	O
be	O
analgesic	O
in	O
rat	O
model	O
of	O
neuropathic	O
pain.	O

People	O
who	O
take	O
PMA	B-Drug
are	O
often	O
mistaken	O
for	O
it	O
being	O
identified	O
as	O
MDMA.MDMA	O
is	O
occasionally	O
known	O
taken	O
in	O
conjunction	O
with	O
psychedelic	O
drugs.	O

Since	O
it	O
is	O
not	O
aromatized	O
(and	O
hence	O
cannot	O
be	O
transformed	O
into	O
an	O
estrogenic	O
metabolite),	O
unlike	O
norethisterone,	O
norethisterone	B-Drug

THG	B-Drug
was	O
developed	O
by	O
Patrick	O
Arnold	O
for	O
the	O
Bay	O
Area	O
Laboratory	O
Co-operative	O
(BALCO),	O
which	O
claimed	O
to	O
be	O
a	O
nutritional	O
supplement	O
company.	O

There	O
is	O
no	O
specific	O
recommended	O
antidote	O
for	O
finasteride	B-Drug
overdose.	O

This	O
is	O
usually	O
done	O
with	O
off-label	O
fentanyl	B-Drug
patches	O
manufactured	O
for	O
humans	O
chronic	O
pain.	O

For	O
use	O
against	O
pain,	O
dihydrocodeine	B-Drug
is	O
usually	O
formulated	O
as	O
tablets	O
or	O
capsules	O
containing	O
1516	O
mg	O
3032	O
with	O
without	O
other	O
active	O
ingredients	O
such	O
aspirin,	O
paracetamol	B-Drug
(acetaminophen),	O
ibuprofen,	O
others.	O
aspirin	B-Drug
acetaminophen	B-Drug
ibuprofen	B-Drug

Fentanyl	B-Drug
is	O
sometimes	O
given	O
intrathecally	O
as	O
part	O
of	O
spinal	O
anesthesia	O
or	O
epidurally	O
for	O
epidural	O
anaesthesia	O
and	O
analgesia.	O

The	O
medication	O
has	O
largely	O
been	O
replaced	O
by	O
newer	O
and	O
improved	O
NSAAs,	O
namely	O
bicalutamide	B-Drug
enzalutamide,	O
due	O
to	O
their	O
better	O
efficacy,	O
tolerability,	O
safety,	O
dosing	O
frequency	O
(once	O
per	O
day),	O
is	O
now	O
relatively	O
little-used.	O
enzalutamide	B-Drug

It	O
is	O
also	O
often	O
combined	O
with	O
lidocaine	B-Drug
as	O
a	O
topical	O
preparation	O
for	O
dermal	O
anesthesia	O
(lidocaine/prilocaine	O
or	O
EMLA),	O
treatment	O
of	O
conditions	O
like	O
paresthesia.	O
lidocaine/prilocaine	B-Drug
EMLA	B-Drug

In	O
addition	O
to	O
the	O
amounts	O
previously	O
mentioned,	O
cocaine	B-Drug
can	O
be	O
sold	O
in	O
"bill	O
sizes":	O

Bupivacaine	B-Drug
(Posimir)	O
is	O
indicated	O
in	O
adults	O
for	O
administration	O
into	O
the	O
subacromial	O
space	O
under	O
direct	O
arthroscopic	O
visualization	O
to	O
produce	O
post-surgical	O
analgesia	O
up	O
72	O
hours	O
following	O
decompression.	O

Pentetrazol	O
Phentermine	B-Drug
Phenpromethamine	B-Drug
Prenylamine	O
Prolintane	O
Phendimetrazine	B-Drug
(phenmetrazine)	O
phenmetrazine	B-Drug

From	O
October	O
2017	O
to	O
February	O
2018	O
in	O
the	O
United	O
States,	O
28	O
people	O
20	O
different	O
states	O
were	O
infected	O
with	O
salmonella,	O
an	O
outbreak	O
occurring	O
from	O
consumption	O
of	O
contaminated	O
pills,	O
powder,	O
tea	O
or	O
unidentified	O
sources	O
kratom.	O
kratom	B-Drug

Oxycodone/aspirin	B-Drug
(trade	O
name	O
Percodan)	O
is	O
a	O
combination	O
drug	O
marketed	O
by	O
Endo	O
Pharmaceuticals.	O
Percodan	B-Drug

In	O
a	O
double-blind,	O
placebo-controlled	O
trial	O
of	O
326	O
people,	O
4	O
people	O
had	O
serious	O
adverse	O
events	O
and	O
61%	O
became	O
resedated	O
following	O
the	O
use	O
flumazenil.	O
flumazenil	B-Drug

A	O
cross-tolerance	O
can	O
develop	O
between	O
psilocybin	O
and	O
the	O
pharmacologically	O
similar	O
LSD,	O
phenethylamines	O
such	O
as	O
mescaline	B-Drug
DOM.Repeated	O
use	O
of	O
does	O
not	O
lead	O
to	O
physical	O
dependence.	O
LSD	B-Drug

Valdecoxib	B-Drug
was	O
also	O
used	O
off-label	O
for	O
controlling	O
acute	O
pain	O
and	O
various	O
types	O
of	O
surgical	O
pain.	O

Such	O
damage	O
is	O
much	O
more	O
likely	O
to	O
be	O
related	O
the	O
toxic	O
chemicals	O
used	O
in	O
crude	O
at-home	O
synthesis	O
than	O
desomorphine	B-Drug
itself.	O

NM-2201	B-Drug

A	O
19992005	O
Australian	O
police	O
survey	O
of	O
detainees	O
reported	O
preliminary	O
findings	O
that	O
self-reported	O
users	O
benzodiazepines	O
were	O
less	O
likely	O
than	O
non-user	O
to	O
work	O
full-time	O
and	O
more	O
receive	O
government	O
benefits,	O
use	O
methamphetamine	B-Drug
or	O
heroin,	O
be	O
arrested	O
imprisoned.	O
heroin	B-Drug

Hyoscine	B-Drug
use	O
should	O
be	O
avoided	O
in	O
this	O
age	O
group	O
because	O
of	O
these	O
potent	O
anticholinergic	O
adverse	O
effects,	O
which	O
have	O
also	O
been	O
linked	O
to	O
an	O
increased	O
risk	O
for	O
dementia.	O

Both	O
ibogaine	B-Drug
and	O
LSD	B-Drug
appear	O
to	O
be	O
effective	O
for	O
encouraging	O
introspection	O
giving	O
the	O
user	O
occasion	O
reflect	O
on	O
sources	O
of	O
their	O
addiction,	O
while	O
also	O
producing	O
an	O
intense,	O
transformative	O
experience	O
that	O
can	O
put	O
established	O
patterns	O
behavior	O
into	O
perspective;	O
has	O
added	O
benefit	O
preventing	O
withdrawal	O
effects.	O

Presently,	O
nalbuphine	B-Drug
is	O
not	O
a	O
controlled	O
substance	O
under	O
the	O
CSA.	O

Israel	O
banned	O
25I-NBOMe	B-Drug
in	O
2013.	O

Cocaine	B-Drug
may	O
be	O
detected	O
by	O
law	O
enforcement	O
using	O
the	O
Scott	O
reagent.	O

As	O
an	O
AAS,	O
methyltestosterone	B-Drug
is	O
agonist	O
of	O
the	O
androgen	O
receptor	O
(AR),	O
similarly	O
to	O
androgens	O
like	O
testosterone	O
and	O
dihydrotestosterone	O
(DHT).	O

Mayo	O
termed	O
his	O
use	O
of	O
prasterone	B-Drug
as	O
"an	O
honest	O
mistake,"	O
saying	O
the	O
was	O
in	O
an	O
over-the-counter	O
supplement	O
and	O
that	O
he	O
unaware	O
banned	O
by	O
NBA.	O

Animal	O
studies	O
have	O
found	O
prazepam	B-Drug
taken	O
during	O
pregnancy	O
results	O
in	O
delayed	O
growth	O
and	O
causes	O
reproductive	O
abnormalities.	O

Like	O
all	O
benzodiazepines,	O
clonazepam	B-Drug
is	O
a	O
GABA-positive	O
allosteric	O
modulator.	O

The	O
mechanism	O
of	O
action	O
zopiclone	B-Drug
is	O
similar	O
to	O
benzodiazepines,	O
with	O
effects	O
on	O
locomotor	O
activity	O
and	O
dopamine	O
serotonin	O
turnover.	O

Hydromorphone	B-Drug
is	O
known	O
in	O
various	O
countries	O
around	O
the	O
world	O
by	O
brand	O
names	O
Hydal,	O
Dimorphone,	O
Exalgo,	O
Sophidone	O
LP,	O
Dilaudid,	O
Hydrostat,	O
Hydromorfan,	O
Hydromorphan,	O
Hymorphan,	O
Laudicon,	O
Opidol,	O
Palladone,	O
Hydromorph	O
Contin,	O
and	O
others.	O
Dilaudid	B-Drug
Palladone	B-Drug

Sleep	O
medicine	O
physicians	O
sometimes	O
prescribe	O
tramadol	B-Drug
(or	O
other	O
opiate	O
medications)	O
for	O
refractory	O
restless	O
legs	O
syndrome	O
(RLS);	O
that	O
is,	O
RLS	O
does	O
not	O
respond	O
adequately	O
to	O
treatment	O
with	O
first-line	O
medications	O
such	O
as	O
dopamine	O
agonists	O
(like	O
pramipexole)	O
or	O
alpha-2-delta	O
(2)	O
ligands	O
(gabapentinoids),	O
often	O
due	O
augmentation.	O
pramipexole	B-Drug

However,	O
most	O
opioid	O
tests	O
will	O
not	O
reliably	O
detect	O
oxycodone,	O
oxymorphone,	O
meperidine,	O
or	O
fentanyl.	O
oxycodone	B-Drug
oxymorphone	B-Drug
meperidine	B-Drug
fentanyl	B-Drug

The	O
list	O
includes	O
other	O
potassium-sparing	O
diuretics,	O
such	O
as	O
triamterene	B-Drug
and	O
spironolactone.	O
spironolactone	B-Drug

Fentanyl	B-Drug
is	O
used	O
orally,	O
smoked,	O
snorted,	O
or	O
injected.	O

Estonia	O
in	O
known	O
to	O
have	O
been	O
home	O
the	O
world's	O
longest	O
documented	O
fentanyl	B-Drug
epidemic,	O
especially	O
following	O
Taliban	O
ban	O
on	O
opium	O
poppy	O
cultivation	O
Afghanistan.	O

Research	O
in	O
these	O
events	O
is	O
complicated	O
because	O
cannabis	O
often	O
used	O
conjunction	O
with	O
tobacco,	O
and	O
drugs	O
such	O
as	O
alcohol	O
cocaine.	O
tobacco	B-Drug
cocaine	B-Drug

slightly	O
chemically	O
altered	O
but	O
more	O
natural	O
than	O
the	O
semi-synthetics,	O
as	O
most	O
are	O
morphine	B-Drug
prodrugs,	O
diacetylmorphine	B-Drug
(morphine	O
diacetate;	O
heroin),	O
nicomorphine	B-Drug
dinicotinate),	O
dipropanoylmorphine	B-Drug
dipropionate),	O
heroin	B-Drug
dinicotinate	B-Drug

In	O
the	O
adaptation	O
Interview	O
with	O
Vampire	O
(film)	O
(1994),	O
which	O
was	O
based	O
on	O
1976	O
novel	O
same	O
name,	O
Claudia	O
uses	O
laudanum	B-Drug
to	O
try	O
and	O
dispose	O
of	O
Lestat:	O

Foods	O
that	O
alkalinize	O
the	O
urine	O
can	O
lead	O
to	O
slower	O
absorption	O
and	O
elimination	O
of	O
diazepam,	O
increasing	O
drug	O
levels	O
activity.	O
diazepam	B-Drug

Meanwhile,	O
a	O
member	O
of	O
his	O
lab,	O
Robert	O
D'Amato,	O
who	O
was	O
looking	O
for	O
angiogenesis	O
inhibitors,	O
discovered	O
in	O
1994	O
that	O
thalidomide	B-Drug
inhibited	O
and	O
effective	O
suppressing	O
tumor	O
growth	O
rabbits.	O

The	O
approximate	O
cost	O
of	O
a	O
1	O
ml	O
ampoule	O
naloxone	B-Drug
in	O
the	O
US	O
is	O
estimated	O
to	O
be	O
significantly	O
higher	O
than	O
most	O
Western	O
countries.	O

Similarly,	O
benzodiazepine	O
overdoses	O
may	O
be	O
effectively	O
reversed	O
with	O
flumazenil.	O
flumazenil	B-Drug

A	O
water	O
filter	O
modified	O
for	O
vaporizing	O
hash	B-Drug
oil.	O
oil	I-Drug

In	O
the	O
U.S.,	O
fentanyl	B-Drug
is	O
a	O
Schedule	O
II	O
controlled	O
substance	O
per	O
Controlled	O
Substance	O
Act.	O

Stanozolol	B-Drug
Stenbolone	O
Testosterone	O
Tetrahydrogestrinone	B-Drug
Tibolone	B-Drug
Trenbolone	B-Drug
Zeranol	O
Zilpaterol	O

Meperidine	B-Drug
is	O
a	O
fully	O
synthetic	O
opioid,	O
and	O
other	O
members	O
of	O
the	O
phenylpiperidine	O
family	O
like	O
alfentanil	B-Drug
sufentanil	B-Drug
are	O
complex	O
versions	O
this	O
structure.	O

From	O
2013	O
until	O
2016,	O
overdose	O
deaths	O
involving	O
fentanyl	B-Drug
increased	O
113%	O
per	O
year.	O

It	O
was	O
developed	O
during	O
the	O
course	O
of	O
research	O
that	O
ultimately	O
resulted	O
in	O
super-potent	O
opioid	O
derivatives	O
such	O
as	O
carfentanil,	O
though	O
it	O
is	O
a	O
substantially	O
less	O
potent	O
analogue.	O
carfentanil	B-Drug

Cannabidiol	B-Drug
(CBD)	O
is	O
under	O
preliminary	O
research	O
for	O
its	O
potential	O
to	O
modify	O
the	O
effects	O
of	O
THC,	O
possibly	O
mitigating	O
some	O
negative,	O
psychosis-like	O
THC.	O
CBD	B-Drug
THC	B-Drug

BZP	B-Drug
is	O
banned	O
in	O
all	O
Australian	O
states.	O

On	O
June	O
11,	O
2013,	O
just	O
days	O
after	O
being	O
robbed	O
at	O
gunpoint	O
in	O
San	O
Francisco,	O
rapper	O
2	O
Chainz	O
was	O
arrested	O
Los	O
Angeles	O
International	O
Airport	O
on	O
charges	O
of	O
possessing	O
promethazine	B-Drug
and	O
codeine	B-Drug
(the	O
primary	O
ingredients	O
lean)	O
along	O
with	O
marijuana.	O

As	O
obstacles	O
to	O
manual	O
eradication	O
the	O
US	O
Department	O
of	O
State	O
listed	O
local	O
level	O
protests	O
blocking	O
access	O
roads	O
coca	B-Drug
fields,	O
and	O
security	O
concerns	O
on	O
Ecuador-Colombia	O
border	O
in	O
Catatumbo	O
region	O
near	O
Venezuela-Colombia	O
border.	O

Although	O
poisoning	O
by	O
hyoscine	B-Drug
appears	O
quite	O
often	O
in	O
the	O
media	O
as	O
an	O
aid	O
for	O
raping,	O
kidnapping,	O
killing,	O
or	O
robbery,	O
effects	O
of	O
this	O
drug	O
and	O
way	O
it	O
is	O
applied	O
criminals	O
(transdermal	O
injection,	O
on	O
playing	O
cards	O
papers,	O
etc.)	O
are	O
exaggerated,	O
especially	O
skin	O
exposure,	O
dose	O
that	O
can	O
be	O
absorbed	O
too	O
low	O
to	O
have	O
any	O
effect.	O

There	O
was	O
an	O
extensive	O
and	O
complicated	O
system	O
of	O
BEIC	O
agencies	O
involved	O
in	O
the	O
supervision	O
management	O
opium	B-Drug
production	O
distribution	O
India.	O

The	O
dose	O
of	O
oxycodone	B-Drug
must	O
be	O
reduced	O
in	O
patients	O
with	O
liver	O
function.	O

Norethisterone	B-Drug
and	O
its	O
metabolites	O
have	O
negligible	O
affinity	O
for	O
the	O
glucocorticoid	O
receptor	O
(GR)	O
mineralocorticoid	O
(MR)	O
hence	O
no	O
glucocorticoid,	O
antiglucocorticoid,	O
mineralocorticoid,	O
or	O
antimineralocorticoid	O
activity.	O

Under	O
the	O
Drug	O
Addiction	O
Treatment	O
Act	O
of	O
2000,	O
physicians	O
can	O
obtain	O
an	O
"X-waiver"	O
to	O
prescribe	O
buprenorphine.	O
buprenorphine	B-Drug

These	O
monoamines	O
can	O
then	O
be	O
released	O
via	O
monoamine	O
transporters,	O
which	O
have	O
been	O
reversed	O
by	O
MDMA	B-Drug
(see	O
below).Intracellular	O
also	O
bind	O
to	O
oxidase	O
A	O
(MAO-A)	O
as	O
an	O
inhibitor,	O
and	O
thus	O
prevent	O
it	O
from	O
breaking	O
down	O
cytosolic	O
serotonin.	O

A	O
high	O
dosage	O
of	O
1,600	O
mg/day	O
prasterone	B-Drug
in	O
men	O
for	O
4	O
weeks	O
was	O
found	O
to	O
increase	O
DHEA	O
and	O
androstenedione	B-Drug
levels	O
but	O
did	O
not	O
significantly	O
affect	O
testosterone	O
levels.	O

Stanozolol	B-Drug
has	O
high	O
oral	O
bioavailability,	O
due	O
to	O
the	O
presence	O
of	O
its	O
C17	O
alkyl	O
group	O
and	O
resistance	O
gastrointestinal	O
liver	O
metabolism	O
that	O
it	O
results	O
in.	O

It	O
is	O
possible	O
that	O
the	O
action	O
of	O
ibogaine	B-Drug
at	O
kappa	O
opioid	O
receptor	O
may	O
indeed	O
contribute	O
significantly	O
to	O
psychoactive	O
effects	O
attributed	O
ingestion;	O
Salvia	O
divinorum,	O
another	O
plant	O
recognized	O
for	O
its	O
strong	O
hallucinogenic	O
properties,	O
contains	O
chemical	O
salvinorin	B-Drug
A,	O
which	O
a	O
highly	O
selective	O
agonist.	O
A	I-Drug

danazol,	O
ethisterone,	O
gestrinone,	O
normethandrone,	O
norvinisterone	O
High:	O
levonorgestrel,	O
norgestrel,	O
norgestrienone,	O
danazol	B-Drug
levonorgestrel	B-Drug
norgestrel	B-Drug

To	O
satisfy	O
the	O
UN	O
Narcotics	O
Convention,	O
some	O
cannabis	O
strains	O
have	O
been	O
bred	O
to	O
produce	O
minimal	O
levels	O
of	O
tetrahydrocannabinol	B-Drug
(THC),	O
principal	O
psychoactive	O
constituent.	O
THC	B-Drug

In	O
the	O
UK,	O
flubromazolam	B-Drug
has	O
been	O
classified	O
as	O
a	O
Class	O
C	O
drug	O
by	O
May	O
2017	O
amendment	O
to	O
The	O
Misuse	O
of	O
Drugs	O
Act	O
1971	O
along	O
with	O
several	O
other	O
designer	O
benzodiazepine	O
drugs.	O

Vaporizer,	O
which	O
heats	O
any	O
form	O
of	O
cannabis	O
to	O
165190	O
C	O
(329374	O
F),	O
causing	O
the	O
active	O
ingredients	O
evaporate	O
into	O
vapor	O
without	O
burning	O
plant	O
material	O
(the	O
boiling	O
point	O
THC	B-Drug
is	O
157	O
(315	O
F)	O
at	O
atmospheric	O
pressure).	O

Tobacco	O
smoking	O
is	O
the	O
practice	O
of	O
burning	O
tobacco	B-Drug
and	O
ingesting	O
smoke	O
that	O
produced.	O

7-Hydroxymitragynine	O
is	O
a	O
terpenoid	O
indole	O
alkaloid	O
from	O
the	O
plant	O
Mitragyna	B-Drug
speciosa,	O
commonly	O
known	O
as	O
Kratom.	O
speciosa	I-Drug
Kratom	B-Drug

It	O
produces	O
effects	O
in	O
animals	O
similar	O
to	O
those	O
of	O
tetrahydrocannabinol	B-Drug
(THC),	O
a	O
cannabinoid	O
naturally	O
present	O
cannabis,	O
leading	O
its	O
use	O
synthetic	O
cannabis	O
products	O
that	O
some	O
countries	O
are	O
sold	O
legally	O
as	O
"incense	O
blends".	O
THC	B-Drug

A	O
study	O
of	O
the	O
United	O
Kingdom	O
General	O
Practice	O
Research	O
Database,	O
which	O
contains	O
over	O
80,000	O
men,	O
found	O
that	O
relative	O
risk	O
gynecomastia	O
in	O
cimetidine	B-Drug
users	O
was	O
7.2	O
to	O
non-users.	O

In	O
Russia	O
versions	O
of	O
sumatriptan,	O
which	O
are	O
not	O
registered	O
in	O
the	O
National	O
registry	O
medications,	O
may	O
be	O
regarded	O
as	O
narcotic	O
drugs	O
(derivatives	O
dimethyltriptamine).	O
sumatriptan	B-Drug
dimethyltriptamine	B-Drug

Efavirenz	B-Drug
is	O
not	O
effective	O
against	O
HIV-2,	O
as	O
the	O
pocket	O
of	O
HIV-2	O
reverse	O
transcriptase	O
has	O
a	O
different	O
structure,	O
which	O
confers	O
intrinsic	O
resistance	O
to	O
NNRTI	O
class.	O

It	O
is	O
an	O
acetyl	O
derivative	O
of	O
oxymorphone	B-Drug
and	O
intermediate	O
in	O
the	O
synthesis	O
several	O
related	O
drugs.	O

When	O
tobacco	B-Drug
is	O
smoked,	O
most	O
of	O
the	O
nicotine	B-Drug
pyrolyzed.	O

It	O
is	O
one	O
of	O
only	O
three	O
androgens	O
approved	O
for	O
androgen	O
replacement	O
in	O
postmenopausal	O
women,	O
the	O
others	O
being	O
testosterone	O
(and	O
esters)	O
and	O
methyltestosterone.	O
methyltestosterone	B-Drug

In	O
2019,	O
Australian	O
swimmer	O
Shayna	O
Jack	O
tested	O
positive	O
for	O
ligandrol.	O
ligandrol	B-Drug

Urine	O
was	O
collected	O
for	O
24	O
hours,	O
followed	O
by	O
extraction	O
of	O
JWH-018	B-Drug
metabolites	O
using	O
both	O
liquid-liquid	O
and	O
solid-phase	O
extraction.	O

In	O
cats,	O
gabapentin	B-Drug
can	O
be	O
used	O
as	O
an	O
analgesic	O
in	O
multi-modal	O
pain	O
management.	O

In	O
one	O
case,	O
the	O
patient	O
was	O
a	O
teenage	O
girl	O
described	O
as	O
having	O
"hysterical	O
personality"	O
who	O
heard	O
warnings	O
about	O
staring	O
at	O
sun	O
under	O
LSD	B-Drug
in	O
school	O
anti-drug	O
lecture	O
and	O
thought	O
this	O
"would	O
be	O
neat	O
thing,"	O
another	O
case	O
had	O
paranoid	O
schizophrenia.	O

In	O
the	O
US,	O
etorphine	B-Drug
is	O
listed	O
as	O
a	O
Schedule	O
I	O
drug	O
with	O
an	O
ACSCN	O
of	O
9056,	O
although	O
its	O
hydrochloride	O
salt	O
classified	O
II	O
9059.	O

"A	O
2012	O
review	O
found	O
that	O
the	O
THC	B-Drug
content	O
in	O
marijuana	O
had	O
increased	O
worldwide	O
from	O
1970	O
to	O
2009.	O

Alprazolam	B-Drug
may	O
be	O
used	O
in	O
combination	O
with	O
other	O
medications	O
for	O
chemotherapy-induced	O
nausea	O
and	O
vomiting.	O

Flagyl	B-Drug
(metronidazole)	O
is	O
a	O
nitroimidazole	O
antibiotic	O
medication	O
used	O
particularly	O
for	O
anaerobic	O
bacteria	O
and	O
protozoa.	O
metronidazole	B-Drug

Therefore,	O
oxycodone	B-Drug
accumulates	O
in	O
patients	O
with	O
kidney	O
impairment.	O

Modafinil	B-Drug
is	O
currently	O
classified	O
as	O
a	O
Schedule	O
IV	O
controlled	O
substance	O
under	O
United	O
States	O
federal	O
law;	O
it	O
illegal	O
to	O
import	O
by	O
anyone	O
other	O
than	O
DEA-registered	O
importer	O
without	O
prescription.	O

Following	O
absorption,	O
amphetamine	B-Drug
readily	O
distributes	O
into	O
most	O
tissues	O
in	O
the	O
body,	O
with	O
high	O
concentrations	O
occurring	O
cerebrospinal	O
fluid	O
and	O
brain	O
tissue.	O

In	O
the	O
1950s	O
and	O
1960s	O
LSD	B-Drug
was	O
used	O
in	O
psychiatry	O
to	O
enhance	O
psychotherapy	O
known	O
as	O
psychedelic	O
therapy.	O

The	O
metabolites	O
of	O
cathinone,	O
cathine	B-Drug
and	O
norephedrine,	O
also	O
possess	O
CNS	O
stimulation,	O
but	O
create	O
much	O
weaker	O
effects.	O
cathinone	B-Drug
norephedrine	B-Drug

It	O
is	O
unclear	O
if	O
fentanyl	B-Drug
gives	O
long-term	O
pain	O
relief	O
to	O
people	O
with	O
neuropathic	O
pain.	O

As	O
with	O
other	O
psychedelics	O
such	O
as	O
LSD,	O
the	O
experience,	O
or	O
'trip',	O
is	O
strongly	O
dependent	O
upon	O
set	O
and	O
setting.	O
LSD	B-Drug

,	O
Stockholm	O
had	O
probably	O
one	O
of	O
the	O
highest	O
rates	O
cannabis	O
use	O
in	O
Europe;	O
1971,	O
3035%	O
16-year-old	O
students	O
replied	O
that	O
they	O
smoked	O
hashish	B-Drug
or	O
marijuana	O
Jonas	O
Hartelius,	O
scientific	O
adviser	O
to	O
Swedish	O
Carnegie	O
Institute,	O
stated	O
another	O
factor	O
which	O
a	O
significant	O
impact	O
on	O
drug	O
policy	O
from	O
1960s	O
and	O
onwards	O
was	O
an	O
"Independent	O
debate	O
outside	O
establishment,	O
mobilizing	O
public	O
opinion	O
against	O
drugs	O
have	O
been	O
crucial	O
importance	O
for	O
development	O
control	O
narcotic	O
drugs.	O

In	O
the	O
United	O
States,	O
in	O
2003,	O
a	O
17	O
year	O
old	O
who,	O
according	O
to	O
his	O
parents,	O
was	O
self-treating	O
anxiety	O
with	O
home-brewed	O
poppy	O
seed	O
tea,	O
died	O
of	O
pulmonary	O
edema	O
caused	O
by	O
acute	O
morphine	B-Drug
and	O
codeine	B-Drug
intoxication.	O

Risperidone	B-Drug
has	O
not	O
demonstrated	O
a	O
benefit	O
in	O
the	O
treatment	O
of	O
eating	O
disorders	O
or	O
personality	O
disorders.	O

On	O
1	O
July	O
2020,	O
an	O
anti-drug	O
operation	O
coordinated	O
in	O
Italy	O
by	O
the	O
Italian	O
Guardia	O
di	O
Finanza	O
and	O
Customs	O
Monopolies	O
Agency	O
seized	O
14	O
tonnes	O
of	O
amphetamines,	O
labeled	O
as	O
Captagon,	O
smuggled	O
from	O
Syria	O
initially	O
hypothesized	O
authorities	O
to	O
have	O
been	O
produced	O
ISIS,	O
which	O
were	O
found	O
three	O
shipping	O
containers	O
filled	O
with	O
around	O
84	O
million	O
pills,	O
southern	O
port	O
Salerno.	O
amphetamines	B-Drug
Captagon	B-Drug

In	O
October	O
2018,	O
cannabidiol	B-Drug
became	O
legal	O
for	O
recreational	O
and	O
medical	O
use	O
by	O
the	O
federal	O
Cannabis	O
Act.	O

Nicocodeine	B-Drug
is	O
almost	O
always	O
used	O
as	O
the	O
hydrochloride	O
salt,	O
which	O
has	O
a	O
free	O
base	O
conversion	O
ratio	O
of	O
.917.	O

Several	O
large	O
quantities	O
of	O
illicitly	O
produced	O
fentanyl	B-Drug
have	O
been	O
seized	O
by	O
U.S.	O
law	O
enforcement	O
agencies.	O

Children	O
who	O
had	O
been	O
exposed	O
to	O
high	O
levels	O
of	O
cocaine	B-Drug
in	O
utero	O
show	O
poorer	O
behavioral	O
inhibition	O
than	O
those	O
with	O
lower	O
exposure	O
or	O
unexposed	O
children.	O

cocaine	B-Drug
Iowa	O
(2005)	O

Amodiaquine	O
Artemether	B-Drug
Artemether/lumefantrine	O
Artesunate	B-Drug
Artesunate/amodiaquine	O
Artesunate/mefloquine	B-Drug
Artesunate/pyronaridine	O
tetraphosphate	O

By	O
2013,	O
case	O
reports	O
of	O
25I-NBOMe	B-Drug
intoxication,	O
with	O
and	O
without	O
analytic	O
confirmation	O
the	O
drug	O
in	O
body,	O
were	O
becoming	O
increasingly	O
common	O
medical	O
literature.25I-NBOMe	O
is	O
widely	O
rumored	O
to	O
be	O
orally	O
inactive;	O
however,	O
apparent	O
overdoses	O
have	O
occurred	O
via	O
oral	O
administration.	O

One	O
brand	O
was	O
withdrawn	O
from	O
the	O
market	O
in	O
2013.In	O
Hong	O
Kong,	O
temazepam	B-Drug
is	O
regulated	O
under	O
Schedule	O
1	O
of	O
Kong's	O
Chapter	O
134	O
Dangerous	O
Drugs	O
Ordinance.	O

Analogues	O
of	O
PCP	B-Drug
exhibit	O
varying	O
potency	O
at	O
nACh	O
receptors	O
and	O
NMDA	O
receptors.	O

Phentermine	B-Drug
was	O
marketed	O
with	O
fenfluramine	B-Drug
or	O
dexfenfluramine	B-Drug
as	O
a	O
combination	O
appetite	O
suppressant	O
and	O
fat	O
burning	O
agent	O
under	O
the	O
popular	O
name	O
fen-phen.	O
fen-phen	B-Drug

AM-1714	O
AM-2201	B-Drug
AM-2232	B-Drug

While	O
not	O
finding	O
his	O
own	O
experiences	O
with	O
MDMA	B-Drug
particularly	O
powerful,	O
Shulgin	O
was	O
impressed	O
the	O
drug's	O
disinhibiting	O
effects	O
and	O
thought	O
it	O
could	O
be	O
useful	O
in	O
therapy.	O

The	O
act	O
of	O
prescribing	O
naloxone	B-Drug
along	O
with	O
opioid	O
prescriptions	O
is	O
called	O
co-prescribing.	O

The	O
effect	O
was	O
also	O
used	O
clinically,	O
including	O
some	O
research	O
in	O
the	O
1970s	O
various	O
countries	O
of	O
using	O
it	O
under	O
carefully	O
monitored	O
circumstances	O
as	O
a	O
form	O
oral	O
opioid	O
agonist	O
substitution	O
therapy,	O
e.g.	O
Substitutionmittel	O
that	O
may	O
be	O
useful	O
alternative	O
to	O
methadone.	O
methadone	B-Drug

The	O
concentration	O
of	O
alprazolam	B-Drug
peaks	O
after	O
one	O
to	O
two	O
hours.	O

In	O
May	O
2020,	O
Gilead	O
announced	O
that	O
it	O
would	O
provide	O
the	O
first	O
940,000	O
doses	O
of	O
remdesivir	B-Drug
to	O
federal	O
government	O
free	O
charge.	O

Brand	O
names	O
include	O
Thorazine,	O
Largactil,	O
Hibernal,	O
and	O
Megaphen	O
(sold	O
by	O
Bayer	O
in	O
West-Germany	O
since	O
July	O
1953).	O
Thorazine	B-Drug
Largactil	B-Drug

In	O
espresso,	O
however,	O
likely	O
due	O
to	O
its	O
higher	O
amount	O
of	O
suspended	O
solids,	O
there	O
are	O
significant	O
contents	O
magnesium,	O
the	O
B	O
vitamins,	O
niacin	B-Drug
and	O
riboflavin,	O
212	O
mg	O
caffeine	O
per	O
100	O
grams	O
grounds.	O

Illicitly	O
synthesized	O
fentanyl	B-Drug
powder	O
has	O
also	O
appeared	O
on	O
the	O
United	O
States	O
market.	O

This	O
site	O
has	O
been	O
referred	O
to	O
as	O
the	O
gabapentin	B-Drug
receptor	O
(2	O
subunit),	O
it	O
is	O
target	O
of	O
drugs	O
and	O
pregabalin.	O
pregabalin	B-Drug

Those	O
with	O
THC	B-Drug
in	O
their	O
system	O
are	O
from	O
three	O
to	O
seven	O
times	O
more	O
likely	O
be	O
the	O
cause	O
of	O
accident	O
than	O
those	O
who	O
had	O
not	O
used	O
either	O
cannabis	O
or	O
alcohol,	O
although	O
its	O
role	O
is	O
necessarily	O
causal	O
because	O
stays	O
bloodstream	O
for	O
days	O
weeks	O
after	O
intoxication.	O

Fentanyl	B-Drug
patches	O
for	O
cancer	O
pain	O
are	O
on	O
the	O
World	O
Health	O
Organization's	O
List	O
of	O
Essential	O
Medicines.	O

An	O
association	O
exists	O
between	O
paracetamol	B-Drug
use	O
and	O
asthma,	O
but	O
whether	O
this	O
is	O
causal	O
still	O
debated	O
as	O
of	O
2017.	O

In	O
addition,	O
propylhexedrine	B-Drug
products	O
are	O
manufactured	O
using	O
delivery	O
devices	O
(such	O
as	O
sub-recreational-dosage	O
inhalers)	O
that	O
difficult	O
(or	O
nearly	O
impossible)	O
to	O
consume	O
effectively	O
(at	O
recreational	O
doses)	O
via	O
non-oral	O
routes	O
of	O
administration,	O
further	O
limiting	O
its	O
ability	O
match	O
or	O
replace	O
other	O
amphetamine-related	O
stimulants	O
for	O
use.	O

Acute	O
kidney	O
injury	O
tubular	O
necrosis	O
Renal	O
papillary	O
necrosisNSAIDs	O
in	O
combination	O
with	O
excessive	O
use	O
of	O
phenacetin	O
or	O
paracetamol	B-Drug
(acetaminophen)	O
may	O
lead	O
to	O
analgesic	O
nephropathy.	O
acetaminophen	B-Drug

Distillers	O
Co.	O
Ltd	O
(now	O
part	O
of	O
Diageo	O
plc),	O
marketed	O
thalidomide	B-Drug
throughout	O
the	O
UK,	O
Australia	O
and	O
New	O
Zealand,	O
under	O
brand	O
name	O
Distaval,	O
as	O
a	O
remedy	O
for	O
morning	O
sickness.	O

As	O
a	O
structural	O
analog	O
of	O
N,N-dimethyltryptamine	B-Drug
(DMT),	O
5-MeO-DMT	B-Drug
is	O
Schedule	O
9	O
prohibited	O
substance	O
under	O
the	O
Poisons	O
Standard.	O

Other	O
heroin	B-Drug
droughts	O
(shortages)	O
have	O
been	O
attributed	O
to	O
cartels	O
restricting	O
supply	O
in	O
order	O
force	O
a	O
price	O
increase	O
and	O
also	O
fungus	O
that	O
attacked	O
the	O
opium	B-Drug
crop	O
of	O
2009.	O

In	O
McCune-Albright	O
syndrome	O
(MAS)	O
tamoxifen	B-Drug
has	O
been	O
used	O
to	O
treat	O
premature	O
puberty	O
and	O
the	O
consequences	O
of	O
puberty.	O

Zaleplon	B-Drug
has	O
a	O
pharmacological	O
profile	O
similar	O
to	O
benzodiazepines,	O
characterized	O
by	O
an	O
increase	O
in	O
slow	O
wave	O
deep	O
sleep	O
(SWDS)	O
with	O
rapid	O
onset	O
of	O
hypnotic	O
action.	O

Methylphenidate	B-Drug
is	O
not	O
approved	O
for	O
children	O
under	O
six	O
years	O
of	O
age.	O

Zyprexa	B-Drug
(olanzapine)	I-Drug

The	O
pharmacological	O
effects	O
of	O
tetrazepam	B-Drug
are	O
significantly	O
less	O
potent	O
when	O
compared	O
against	O
diazepam,	O
in	O
animal	O
studies.	O
diazepam	B-Drug

In	O
the	O
autobiographical	O
novel	O
Rush	O
by	O
Kim	O
Wozencraft,	O
intravenous	O
phenmetrazine	B-Drug
is	O
described	O
as	O
most	O
euphoric	O
and	O
pro-sexual	O
of	O
stimulants	O
author	O
used.	O

Hyoscine	B-Drug
was	O
first	O
written	O
about	O
in	O
1881	O
and	O
started	O
to	O
be	O
used	O
for	O
anesthesia	O
around	O
1900.	O

A	O
kilogram	O
of	O
heroin	B-Drug
laced	O
with	O
fentanyl	B-Drug
may	O
sell	O
for	O
more	O
than	O
US$100,000,	O
but	O
the	O
itself	O
be	O
produced	O
far	O
cheaply	O
about	O
US$6,000	O
per	O
kilogram.	O

USFDA-commissioned	O
studies	O
from	O
2011	O
indicate	O
that	O
in	O
children,	O
young	O
adults,	O
and	O
adults	O
there	O
is	O
no	O
association	O
between	O
serious	O
adverse	O
cardiovascular	O
events	O
(sudden	O
death,	O
heart	O
attack,	O
stroke)	O
the	O
medical	O
use	O
of	O
methylphenidate	B-Drug
or	O
other	O
ADHD	O
stimulants.	O

After	O
restricting	O
its	O
manufacture	O
and	O
distribution	O
in	O
1965,	O
the	O
US	O
government	O
fully	O
criminalized	O
LSD	B-Drug
1968,	O
after	O
which	O
European	O
nations	O
hosted	O
psychedelic	O
research	O
followed	O
suit.	O

The	O
term	O
empathogen,	O
meaning	O
"generating	O
a	O
state	O
of	O
empathy",	O
was	O
coined	O
in	O
198384	O
independently	O
by	O
Ralph	O
Metzner	O
and	O
David	O
E.	O
Nichols	O
as	O
to	O
denote	O
therapeutic	O
class	O
drugs	O
that	O
includes	O
MDMA	B-Drug
phenethylamine	O
relatives.	O

DJ	O
Screw's	O
invoking	O
lean	O
in	O
his	O
lyrics	O
and	O
use	O
of	O
slow	O
tempos	O
had	O
caused	O
style	O
to	O
be	O
characterized	O
"[a]s	O
if	O
the	O
song	O
itself	O
has	O
taken	O
too	O
much	O
codeine	B-Drug
promethazine".	O
promethazine	B-Drug

litorale	O
Delosperma	O
lydenbergense,	O
DMT,	O
5-MeO-DMT	B-Drug
nubigenum,	O
pageanum,	O
pergamentaceum,	O
Traces	O
of	O
DMT	O
tradescantioides,	O
Prestonia	O
amazonica:	O

Much	O
is	O
still	O
not	O
known	O
about	O
what	O
factors	O
may	O
exist	O
to	O
aid	O
children	O
who	O
were	O
exposed	O
cocaine	B-Drug
in	O
utero.	O

In	O
1981	O
dried	O
capsules	O
were	O
found	O
being	O
sold	O
for	O
decoration	O
in	O
Sweden,	O
that	O
had	O
been	O
lanced	O
2	O
to	O
5	O
times	O
with	O
a	O
tool	O
having	O
3	O
4	O
blades	O
and	O
the	O
opium	B-Drug
scraped	O
off.	O

Side	O
effects	O
of	O
mesterolone	B-Drug
include	O
symptoms	O
masculinization	O
like	O
acne,	O
increased	O
hair	O
growth,	O
voice	O
changes,	O
and	O
sexual	O
desire.	O

heroin	B-Drug
Lammbock	O
(2001)	O

Cognitive	O
deficits	O
as	O
well	O
increased	O
dissociation	O
and	O
delusion	O
symptoms	O
were	O
observed	O
in	O
frequent	O
recreational	O
users	O
of	O
ketamine.	O
ketamine	B-Drug

A	O
consumer	O
report	O
noted	O
that	O
ibuprofen,	O
naproxen,	O
and	O
salsalate	B-Drug
are	O
less	O
expensive	O
than	O
other	O
NSAIDs,	O
essentially	O
as	O
effective	O
safe	O
when	O
used	O
appropriately	O
to	O
treat	O
osteoarthritis	O
pain.	O
ibuprofen	B-Drug
naproxen	B-Drug

This	O
is	O
despite	O
the	O
evidence	O
that	O
paracetamol	B-Drug
and	O
NSAIDs	O
have	O
some	O
similar	O
pharmacological	O
activity.	O

2C-G	O
and	O
all	O
of	O
its	O
homologs	O
are	O
unscheduled	O
in	O
the	O
United	O
States,	O
but	O
possession	O
sales	O
might	O
be	O
prosecuted	O
under	O
Federal	O
Analog	O
Act	O
because	O
their	O
close	O
structural	O
similarities	O
to	O
2C-B,	O
which	O
is	O
a	O
Schedule	O
2C-B	B-Drug

This	O
makes	O
it	O
approximately	O
one	O
fifth	O
as	O
potent	O
fentanyl.	O
fentanyl	B-Drug

Tramadol	B-Drug
is	O
demethylated	O
by	O
the	O
liver	O
enzyme	O
CYP2D6	O
in	O
same	O
way	O
as	O
codeine,	O
and	O
so	O
similarly	O
to	O
variation	O
effects	O
seen	O
with	O
individuals	O
who	O
have	O
a	O
less	O
active	O
form	O
of	O
("poor	O
metabolizers")	O
will	O
tend	O
get	O
reduced	O
analgesic	O
from	O
tramadol.	O
codeine	B-Drug
tramadol	B-Drug

Acetylmethadol	B-Drug
has	O
an	O
ACSCN	O
of	O
9601.	O

SHBG	O
levels	O
with	O
birth	O
control	O
pills	O
containing	O
different	O
progestins	O
are	O
increased	O
by	O
1.5	O
to	O
2-fold	O
levonorgestrel,	O
2.5-	O
4-fold	O
desogestrel	B-Drug
and	O
gestodene,	O
3.5-	O
drospirenone	O
dienogest,	O
4-	O
5-fold	O
cyproterone	O
acetate.	O
levonorgestrel	B-Drug
dienogest	B-Drug

In	O
Canada,	O
mescaline	B-Drug
is	O
listed	O
as	O
prohibited	O
under	O
schedule	O
III	O
of	O
the	O
Controlled	O
Drugs	O
and	O
Substances	O
Acts,	O
but	O
peyote	O
specifically	O
exempt	O
legally	O
available.	O

Only	O
of	O
a	O
few	O
these	O
compounds	O
were	O
widely	O
used	O
including	O
rolicyclidine	B-Drug
(PCPy),	O
eticyclidine	B-Drug
(PCE),	O
and	O
tenocyclidine	B-Drug
(TCP).	O
PCE	B-Drug
TCP	B-Drug

Smoking	O
or	O
vaporizing	O
hash	B-Drug
oil	I-Drug
is	O
known	O
colloquially	O
as	O
"dabbing",	O
from	O
the	O
English	O
verb	O
to	O
daub	O
(Dutch	O
dabben,	O
French	O
dauber),	O
"to	O
smear	O
with	O
something	O
adhesive".	O

Ketamine	B-Drug
has	O
similar	O
efficacy	O
to	O
opioids	O
in	O
a	O
hospital	O
emergency	O
department	O
setting	O
for	O
management	O
of	O
acute	O
pain	O
and	O
control	O
procedural	O
pain.	O

Buspar	B-Drug
(buspirone)	O
an	O
anxiolytic	O
used	O
to	O
treat	O
generalized	O
anxiety	O
disorder.	O
buspirone	B-Drug

Compared	O
to	O
heroin,	O
it	O
is	O
more	O
potent,	O
has	O
higher	O
profit	O
margins	O
and,	O
because	O
compact,	O
simpler	O
logistics.	O
heroin	B-Drug

It	O
has	O
only	O
around	O
half	O
the	O
potency	O
of	O
etonitazene	B-Drug
in	O
animal	O
studies,	O
but	O
it	O
is	O
likely	O
less	O
potent	O
humans	O
as	O
was	O
seen	O
with	O
(	O

The	O
artists	O
almost	O
unanimously	O
reported	O
LSD	B-Drug
to	O
be	O
an	O
enhancement	O
their	O
creativity.	O

Pantopon,	O
also	O
known	O
as	O
Opium	O
Alkaloids	O
Hydrochlorides,	O
is	O
a	O
preparation	O
of	O
opiates	B-Drug
made	O
up	O
all	O
the	O
alkaloids	O
present	O
in	O
opium	B-Drug
their	O
natural	O
proportions	O
hydrochlorides	O
salts.	O

The	O
weak	O
opioid	O
codeine,	O
in	O
low	O
doses	O
and	O
combined	O
with	O
one	O
or	O
more	O
other	O
drugs,	O
is	O
commonly	O
available	O
without	O
a	O
prescription	O
can	O
be	O
used	O
to	O
treat	O
mild	O
pain.	O
codeine	B-Drug

It	O
is	O
based	O
on	O
the	O
book	O
of	O
same	O
name	O
by	O
Roberto	O
Saviano,	O
a	O
study	O
business	O
around	O
drug	O
cocaine,	O
covering	O
its	O
movement	O
across	O
continents.	O
cocaine	B-Drug

The	O
tests	O
are	O
used	O
for	O
general	O
screening	O
purposes,	O
offering	O
a	O
generic	O
result	O
the	O
presence	O
of	O
wide	O
range	O
drugs,	O
including	O
Heroin,	O
Cocaine,	O
Methamphetamine,	O
Amphetamine,	O
Ecstasy/MDMA,	O
Methadone,	O
Ketamine,	O
PCP,	O
PMA,	O
DMT,	O
MDPV,	O
and	O
may	O
detect	O
rapidly	O
evolving	O
synthetic	O
designer	O
drugs.	O
Heroin	B-Drug
Cocaine	B-Drug
Methamphetamine	B-Drug
Amphetamine	B-Drug
MDMA	B-Drug
Methadone	B-Drug
Ketamine	B-Drug
PCP	B-Drug
PMA	B-Drug
MDPV	B-Drug

Upon	O
oral	O
ingestion,	O
it	O
is	O
rapidly	O
converted	O
into	O
norethisterone	B-Drug
by	O
esterases	O
during	O
intestinal	O
and	O
first-pass	O
hepatic	O
metabolism.	O

It	O
is	O
moderately	O
effective:	O
about	O
30-40%	O
of	O
those	O
given	O
gabapentin	B-Drug
for	O
diabetic	O
neuropathy	O
or	O
postherpetic	O
neuralgia	O
have	O
a	O
meaningful	O
benefit.	O

The	O
agency	O
cited	O
increased	O
distribution	O
in	O
Texas,	O
escalating	O
street	O
use,	O
and	O
new	O
evidence	O
of	O
MDA	O
(an	O
analog	O
MDMA)	O
neurotoxicity	O
as	O
reasons	O
for	O
the	O
emergency	O
measure.	O
MDMA	B-Drug

Efavirenz	B-Drug
is	O
safe	O
to	O
use	O
during	O
the	O
first	O
trimester	O
of	O
pregnancy.	O

In	O
the	O
1970s,	O
synthetic	O
THC	B-Drug
was	O
created	O
to	O
be	O
administered	O
as	O
drug	O
Marinol	O
in	O
a	O
capsule.	O

These	O
side	O
effects	O
tend	O
to	O
be	O
significantly	O
worsened	O
when	O
the	O
BZP/TFMPP	O
mix	O
is	O
consumed	O
alongside	O
alcohol,	O
especially	O
headache,	O
nausea,	O
and	O
hangover.	O
BZP	B-Drug
TFMPP	B-Drug

Meprobamate	B-Drug
is	O
a	O
Schedule	O
IV	O
drug	O
(US)	O

Hence	O
the	O
finding	O
that	O
patient	O
outcomes	O
are	O
not	O
improved	O
with	O
use	O
of	O
spironolactone.	O
spironolactone	B-Drug

The	O
contributions	O
of	O
these	O
metabolites	O
to	O
the	O
psychoactive	O
and	O
toxic	O
effects	O
MDMA	B-Drug
are	O
an	O
area	O
active	O
research.	O

Propylhexedrine	B-Drug
can	O
also	O
cause	O
swelling,	O
dryness	O
and	O
irritation	O
of	O
mucous	O
membranes.	O

Since	O
April	O
2006,	O
all	O
products,	O
including	O
plant	O
parts,	O
that	O
contain	O
ephedrine	B-Drug
are	O
only	O
available	O
with	O
a	O
prescription.	O

There	O
is	O
also	O
evidence	O
that	O
these	O
cultures	O
used	O
a	O
mixture	O
of	O
coca	B-Drug
leaves	O
and	O
saliva	O
as	O
an	O
anesthetic	O
for	O
the	O
performance	O
trepanation.	O

Cathinone	B-Drug
and	O
methcathinone	B-Drug
are	O
listed	O
in	O
separate	O
sections	O
of	O
Schedule	O
III,	O
while	O
diethylpropion	B-Drug
pyrovalerone	B-Drug
(also	O
cathinones),	O
IV,	O
each	O
without	O
language	O
to	O
capture	O
analogues,	O
isomers,	O
etc.	O

The	O
results	O
of	O
that	O
trial	O
were	O
published	O
in	O
the	O
New	O
England	O
Journal	O
Medicine	O
1999.After	O
further	O
work	O
was	O
done	O
by	O
Celgene	O
and	O
others,	O
2006	O
U.S.	O
Food	O
Drug	O
Administration	O
granted	O
accelerated	O
approval	O
for	O
thalidomide	B-Drug
combination	O
with	O
dexamethasone	B-Drug
treatment	O
newly	O
diagnosed	O
multiple	O
myeloma	O
patients.	O

Buspirone	B-Drug
is	O
a	O
member	O
of	O
the	O
azapirone	O
chemical	O
class,	O
and	O
consists	O
azaspirodecanedione	O
pyrimidinylpiperazine	O
components	O
linked	O
together	O
by	O
butyl	O
chain.	O

Lidocaine	B-Drug
and	O
intravenous	O
lipid	O
emulsion	O
have	O
been	O
successfully	O
used	O
for	O
serious	O
ventricular	O
tachyarrhythmias	O
in	O
several	O
case	O
reports.	O

Similar	O
to	O
many	O
psychoactive	O
herbs,	O
Salvia	O
divinorum	O
synthesizes	O
and	O
excretes	O
its	O
active	O
constituent	O
(salvinorin	O
A)	O
via	O
trichomes,	O
of	O
the	O
peltate-glandular	O
morphology,	O
located	O
just	O
beneath	O
cuticle	O
(subcuticular)	O
layer.	O
salvinorin	B-Drug
A	I-Drug

This	O
drew	O
strong	O
protests	O
among	O
those	O
using	O
kratom	B-Drug
to	O
deal	O
with	O
chronic	O
pain	O
or	O
wean	O
themselves	O
off	O
opioids	O
alcohol.	O

Studies	O
have	O
subsequently	O
distinguished	O
between	O
enkephalins,	O
endorphins,	O
and	O
endogenously-produced	O
morphine,	O
which	O
is	O
not	O
a	O
peptide.	O
morphine	B-Drug

This	O
may	O
be	O
due	O
to	O
increased	O
seizures	O
during	O
use	O
and	O
decreased	O
production	O
of	O
the	O
precursor	O
chemicals	O
used	O
manufacture	O
MDMA.	O
MDMA	B-Drug

About	O
1	O
percent	O
of	O
the	O
responders	O
to	O
an	O
internet	O
poll	O
and	O
22	O
those	O
attending	O
addiction	O
facilities	O
had	O
a	O
history	O
abuse	O
gabapentin.	O
gabapentin	B-Drug

heroin,	O
methadone,	O
cannabis	O
The	O
Skeleton	O
Twins	O
(2014)	O
heroin	B-Drug
methadone	B-Drug

It	O
had	O
been	O
developed	O
by	O
Frank	O
Berger	O
at	O
Wallace	O
Laboratories	O
and	O
was	O
named	O
carisoprodol.	O
carisoprodol	B-Drug

Buspirone	B-Drug
was	O
first	O
made	O
in	O
1968	O
and	O
approved	O
for	O
medical	O
use	O
the	O
United	O
States	O
1986.	O

Mirtazapine	B-Drug
has	O
been	O
shown	O
to	O
lower	O
drug	O
seeking	O
behaviour	O
in	O
various	O
human	O
and	O
animal	O
studies.	O

PCP	B-Drug
and	O
ketamine	B-Drug
are	O
known	O
to	O
better	O
resemble	O
endogenous	O
psychoses	O
because	O
they	O
reproduce	O
both	O
positive	O
negative	O
symptoms	O
of	O
psychoses,	O
while	O
psilocybin	O
related	O
hallucinogens	O
typically	O
produce	O
effects	O
resembling	O
only	O
the	O
schizophrenia.	O

The	O
French	O
Poet	O
Baudelaire	O
wrote	O
about	O
the	O
effects	O
of	O
Hashish	B-Drug
and	O
Opium	O
in	O
Les	O
Paradis	O
artificiels	O
(1860)	O
theorized	O
how	O
they	O
could	O
be	O
used	O
to	O
allow	O
individual	O
reach	O
"ideal"	O
states	O
mind.	O

Estan,	O
Lucidon)	O
Dienestrol	O
diacetate/methyltestosterone	O
(Farmatest)	O
Diethylstilbestrol/methyltestosterone	O
(Tylosterone)	O
Esterified	B-Drug
estrogens/methyltestosterone	I-Drug
(Covaryx,	O
Eemt,	O
Essian,	O
Estratest,	O
Menogen,	O
Syntest)	O
Ethinylestradiol/methyltestosterone	O
(Climatone,	O
Dumone,	O
Duotrone,	O
Estandron,	O
Femandren,	O
Femovirin,	O
Gynetone,	O
Lynandron,	O
Mepilin,	O
Mixogen,	O
Primodian)	O
methyltestosterone	B-Drug
Estratest	B-Drug

The	O
toxicity	O
of	O
5-MeO-MiPT	B-Drug
is	O
not	O
known	O
but	O
as	O
with	O
all	O
research	O
chemicals	O
doses	O
should	O
be	O
carefully	O
weighed	O
on	O
an	O
accurate	O
milligram	O
scale	O
and	O
users	O
take	O
caution	O
because	O
overdoses	O
are	O
listed.	O

Psilocybin	O
is	O
about	O
100	O
times	O
less	O
potent	O
than	O
LSD	B-Drug
on	O
a	O
weight	O
per	O
basis,	O
and	O
the	O
physiological	O
effects	O
last	O
half	O
as	O
long.	O

The	O
absorption	O
of	O
clozapine	B-Drug
is	O
almost	O
complete	O
following	O
oral	O
administration,	O
but	O
the	O
bioavailability	O
only	O
60	O
to	O
70%	O
due	O
first-pass	O
metabolism.	O

As	O
of	O
2011	O
there	O
was	O
no	O
evidence	O
that	O
an	O
increase	O
in	O
physical	O
performance	O
occurs	O
after	O
inhaling	O
salbutamol,	O
but	O
are	O
various	O
reports	O
for	O
benefit	O
when	O
delivered	O
orally	O
or	O
intravenously.	O
salbutamol	B-Drug

Degarelix	B-Drug
is	O
a	O
GnRH	O
antagonist	O
that	O
approved	O
for	O
use	O
in	O
patients	O
with	O
advanced	O
hormone-sensitive	O
prostate	O
cancer	O
throughout	O
Europe	O
and	O
also	O
the	O
United	O
States.	O

For	O
sublingual	O
and	O
buccal	O
administration,	O
25I-NBOMe	B-Drug
is	O
often	O
applied	O
to	O
sheets	O
of	O
blotter	O
paper	O
which	O
small	O
portions	O
(tabs)	O
are	O
held	O
in	O
the	O
mouth	O
allow	O
absorption	O
through	O
oral	O
mucosa.	O

Cocaine	B-Drug
increases	O
alertness,	O
feelings	O
of	O
well-being,	O
euphoria,	O
energy,	O
competence,	O
sociability,	O
and	O
sexuality.	O

Combination	O
of	O
NSAIDs	O
with	O
pregabalin	B-Drug
as	O
preemptive	O
analgesia	O
has	O
shown	O
promising	O
results	O
for	O
decreasing	O
post	O
operative	O
pain	O
intensity.	O

Ciclosporin,	O
also	O
spelled	O
cyclosporine	B-Drug
and	O
cyclosporin,	O
is	O
a	O
calcineurin	O
inhibitor,	O
used	O
as	O
an	O
immunosuppressant	O
medication.	O
Ciclosporin	B-Drug
cyclosporin	B-Drug

Phenelzine	B-Drug
(Nardil)	O
an	O
antidepressant	O
of	O
the	O
MAOI	O
class	O
used	O
to	O
depression.	O
Nardil	B-Drug

O-Acetylpsilocin,	O
being	O
an	O
ester	O
of	O
psilocin,	O
is	O
a	O
Class	O
A	O
drug	O
in	O
the	O
UK	O
under	O
Misuse	O
Drugs	O
Act	O
1971.	O
O-Acetylpsilocin	B-Drug
psilocin	B-Drug

Phencyclidine	B-Drug
enters	O
the	O
ion	O
channel	O
and	O
binds,	O
reversibly	O
non-competitively,	O
inside	O
pore	O
to	O
block	O
entry	O
of	O
positive	O
ions	O
cell,	O
thereby	O
inhibiting	O
cell	O
depolarisation.	O

Testosterone	O
enanthate	O
was	O
described	O
as	O
early	O
1952	O
and	O
first	O
introduced	O
for	O
medical	O
use	O
in	O
the	O
United	O
States	O
1954	O
under	O
brand	O
name	O
Delatestryl.	O
Delatestryl	B-Drug

It	O
is	O
used	O
under	O
the	O
brand	O
name	O
Klimonorm	O
as	O
a	O
combined	O
oral	O
tablet	O
with	O
estradiol	O
valerate	O
and	O
Climara	B-Drug
Pro	O
transdermal	O
patch	O
estradiol.	O

In	O
April	O
2008	O
the	O
United	O
States	O
Drug	O
Enforcement	O
Administration	O
published	O
an	O
"Initial	O
Notice	O
of	O
Proposed	O
Rulemaking"	O
concerning	O
scheduling	O
three	O
anabolic	O
substances:	O
boldione,	O
desoxymethyltestosterone,	O
and	O
dienedione.	O
desoxymethyltestosterone	B-Drug
dienedione	B-Drug

Exceptions	O
include	O
scopolamine	B-Drug
hydrobromide,	O
which	O
is	O
soluble	O
in	O
organic	O
solvents,	O
and	O
the	O
water-soluble	O
quinine	B-Drug
sulfate.	O

Cocaine	B-Drug
overdose	O
may	O
result	O
in	O
cardiovascular	O
and	O
brain	O
damage,	O
such	O
as:	O
constricting	O
blood	O
vessels	O
the	O
brain,	O
causing	O
strokes	O
arteries	O
heart;	O
heart	O
attacks.	O

Lorazepam	B-Drug
has	O
particularly	O
marked	O
amnesic	O
properties	O
that	O
may	O
make	O
it	O
more	O
effective	O
when	O
amnesia	O
is	O
the	O
desired	O
effect.	O

The	O
authors	O
point	O
out	O
that	O
the	O
nalbuphine	B-Drug
moiety	O
is	O
approximately	O
ten	O
times	O
more	O
pharmacologically	O
potent	O
than	O
mixed	O
opioid	O
agonist/antagonist	O
butorphanol	B-Drug
on	O
an	O
"antagonist	O
index"	O
scale	O
which	O
quantitates	O
drug's	O
ability	O
to	O
act	O
both	O
as	O
analgesic	O
(via	O
KOR	O
agonism)	O
well	O
a	O
MOR	O
antagonist.	O

Phencyclidine	B-Drug
(PCP)	O
is	O
believed	O
to	O
be	O
the	O
first	O
arylcyclohexylamine	O
with	O
recognized	O
anesthetic	O
properties,	O
but	O
several	O
arylcyclohexylamines	O
were	O
described	O
before	O
PCP	B-Drug
in	O
scientific	O
literature,	O
beginning	O
PCA	O
(1-phenylcyclohexan-1-amine)	O

Fentanyl	B-Drug
analogs	O
have	O
killed	O
hundreds	O
of	O
people	O
throughout	O
Europe	O
and	O
the	O
former	O
Soviet	O
republics	O
since	O
most	O
recent	O
resurgence	O
in	O
use	O
began	O
Estonia	O
early	O
2000s,	O
novel	O
derivatives	O
continue	O
to	O
appear.	O

There	O
are	O
a	O
number	O
of	O
broad	O
classes	O
opioids:	O
Natural	O
opiates:	O
alkaloids	O
contained	O
in	O
the	O
resin	B-Drug
opium	O
poppy,	O
primarily	O
morphine,	O
codeine,	O
and	O
thebaine,	O
but	O
not	O
papaverine	B-Drug
noscapine	B-Drug
which	O
have	O
different	O
mechanism	O
action;	O
morphine	B-Drug
codeine	B-Drug

Cases	O
of	O
etizolam	B-Drug
dependence	O
have	O
been	O
documented	O
in	O
the	O
medical	O
literature.	O

As	O
for	O
all	O
other	O
opioid-based	O
medications,	O
naloxone	B-Drug
(trade	O
name	O
Narcan)	O
is	O
the	O
definitive	O
antidote	O
overdose.	O
Narcan	B-Drug

In	O
the	O
United	O
States,	O
JWH-081	B-Drug
is	O
a	O
Schedule	O
I	O
Controlled	O
Substance.	O

Among	O
adolescent	O
users	O
in	O
the	O
United	O
States	O
between	O
1999	O
and	O
2008,	O
girls	O
were	O
more	O
likely	O
to	O
use	O
MDMA	B-Drug
than	O
boys.	O

The	O
antipsychotic	O
effects	O
of	O
chlorpromazine	B-Drug
were	O
discovered	O
in	O
1952,	O
and	O
imipramine	B-Drug
was	O
then	O
developed	O
studied	O
as	O
an	O
for	O
use	O
patients	O
with	O
schizophrenia.	O

Aminorex	B-Drug
(Menocil,	O
Apiquel,	O
aminoxaphen,	O
aminoxafen,	O
McN-742)	O
is	O
a	O
weight	O
loss	O
(anorectic)	O
stimulant	O
drug.	O

This	O
is	O
in	O
contradiction	O
with	O
widespread	O
statements	O
that	O
spironolactone	B-Drug
increases	O
free	O
estradiol	O
levels	O
by	O
displacing	O
from	O
SHBG.Spironolactone	O
appears	O
to	O
cross	O
the	O
bloodbrain	O
barrier.	O

Recent	O
reports	O
demonstrated	O
that	O
KORs	O
are	O
required	O
for	O
stress-induced	O
reinstatement	O
of	O
cocaine	B-Drug
seeking.	O

O-Demethylation	O
to	O
oxymorphone	B-Drug
predominantly	O
via	O
CYP2D6	O

Although	O
they	O
are	O
still	O
considered	O
to	O
be	O
highly	O
effective,	O
have	O
been	O
increasingly	O
replaced	O
by	O
antidepressants	O
with	O
an	O
improved	O
safety	O
and	O
side	O
effect	O
profile,	O
such	O
as	O
the	O
SSRIs	O
other	O
newer	O
novel	O
reversible	O
MAOI	O
moclobemide.	O
moclobemide	B-Drug

Later	O
writers	O
have	O
asserted	O
that	O
Paracelsus'	O
recipe	O
for	O
laudanum	B-Drug
contained	O
opium,	O
but	O
its	O
composition	O
remains	O
unknown.	O
opium	B-Drug

Diclofenac	B-Drug
has	O
been	O
shown	O
also	O
to	O
harm	O
freshwater	O
fish	O
species	O
such	O
as	O
rainbow	O
trout.	O

On	O
August	O
30,	O
2016,	O
the	O
Drug	O
Enforcement	O
Administration	O
(DEA)	O
announced	O
its	O
intention	O
to	O
place	O
active	O
materials	O
in	O
kratom	B-Drug
plant	O
into	O
Schedule	O
I	O
of	O
Controlled	O
Substances	O
Act	O
as	O
a	O
warning	O
about	O
an	O
imminent	O
hazard	O
public	O
safety,	O
citing	O
over	O
600	O
calls	O
poison	O
control	O
centers	O
between	O
2010	O
and	O
2015	O
15	O
kratom-related	O
deaths	O
2014	O
2016.	O

The	O
combination	O
medicine	O
dextromethorphan/bupropion	O
is	O
in	O
clinical	O
trials	O
by	O
Axsome	O
Therapeutics	O
for	O
major	O
depressive	O
disorder,	O
with	O
fast	O
track	O
designation	O
granted	O
the	O
FDA	O
2017.	O
dextromethorphan	B-Drug
bupropion	B-Drug

5-APB	B-Drug
is	O
a	O
potent	O
agonist	O
for	O
the	O
5-HT2A	O
and	O
5-HT2B	O
receptors	O
(Ki	O
of	O
14	O
nmol/L	O
at	O
with	O
an	O
efficacy	O
0.924).	O

cannabis,	O
cocaine,	O
heroin	B-Drug
(smoked)	O
Blood	O
In	O
Out	O
(1993)	O
cocaine	B-Drug

Because	O
it	O
is	O
5-reduced,	O
oxandrolone	B-Drug
not	O
a	O
substrate	O
for	O
aromatase,	O
hence	O
cannot	O
be	O
aromatized	O
into	O
metabolites	O
with	O
estrogenic	O
activity.	O

It	O
is	O
estimated	O
that	O
almost	O
half	O
of	O
these	O
users	O
take	O
drugs	O
most	O
days,	O
with	O
many	O
taking	O
heroin	B-Drug
multiple	O
times	O
a	O
day.	O

As	O
of	O
2017	O
in	O
the	O
United	O
States	O
about	O
1%	O
people	O
grade	O
12	O
reported	O
using	O
PCP	B-Drug
prior	O
year	O
while	O
2.9%	O
those	O
over	O
age	O
25	O
it	O
at	O
some	O
point	O
their	O
lives.	O

This	O
changed	O
in	O
1927	O
when	O
Jnos	O
Kabay	O
developed	O
a	O
chemical	O
process	O
to	O
extract	O
morphine	B-Drug
from	O
the	O
crushed	O
capsule.	O

Most	O
serotonergic	O
psychedelics	O
are	O
not	O
significantly	O
dopaminergic,	O
and	O
LSD	B-Drug
is	O
therefore	O
atypical	O
in	O
this	O
regard.	O

Tarceva	B-Drug
(erlotinib),	O
for	O
various	O
cancers.	O
erlotinib	B-Drug

While	O
ketoconazole	B-Drug
blocks	O
the	O
synthesis	O
of	O
sterol	O
ergosterol	O
in	O
fungi,	O
humans,	O
at	O
high	O
dosages	O
(>800	O
mg/day),	O
it	O
potently	O
inhibits	O
activity	O
several	O
enzymes	O
necessary	O
for	O
conversion	O
cholesterol	O
to	O
steroid	O
hormones	O
such	O
as	O
testosterone	O
and	O
cortisol.	O

Ciclosporin	B-Drug
exhibits	O
very	O
poor	O
solubility	O
in	O
water,	O
and,	O
as	O
a	O
consequence,	O
suspension	O
and	O
emulsion	O
forms	O
of	O
the	O
medication	O
have	O
been	O
developed	O
for	O
oral	O
administration	O
injection.	O

At	O
above	O
optimal	O
doses,	O
methylphenidate	B-Drug
has	O
offtarget	O
effects	O
that	O
decrease	O
learning.	O

The	O
effect	O
of	O
MDMA	B-Drug
increasing	O
sociability	O
is	O
consistent,	O
while	O
its	O
effects	O
on	O
empathy	O
have	O
been	O
more	O
mixed.	O

Cocaine	B-Drug
is	O
the	O
second	O
most	O
popular	O
illegal	O
recreational	O
drug	O
in	O
Europe	O
(behind	O
cannabis).	O

Some	O
examples	O
include:	O
Amfepramone	B-Drug
(2-(Diethylamino)	O
propiophenone)	O

The	O
254	O
pounds	O
(115	O
kg)	O
of	O
fentanyl,	O
which	O
was	O
estimated	O
to	O
be	O
worth	O
US$3.5M,	O
concealed	O
in	O
a	O
compartment	O
under	O
false	O
floor	O
truck	O
transporting	O
cucumbers.	O
fentanyl	B-Drug

These	O
compounds	O
may	O
produce	O
positive	O
results	O
for	O
amphetamine	B-Drug
on	O
drug	O
tests.	O

Acetorphine	B-Drug
was	O
developed	O
in	O
1966	O
by	O
the	O
Reckitt	O
research	O
group	O
that	O
etorphine.	O
etorphine	B-Drug

In	O
2016,	O
deaths	O
from	O
fatal	O
fentanyl	B-Drug
overdoses	O
in	O
the	O
province	O
of	O
British	O
Columbia	O
averaged	O
two	O
persons	O
per	O
day.	O

A	O
kilogram	O
of	O
heroin	B-Drug
laced	O
with	O
fentanyl	B-Drug
may	O
sell	O
for	O
more	O
than	O
US$100,000,	O
but	O
the	O
itself	O
be	O
produced	O
far	O
cheaply	O
about	O
US$6,000	O
per	O
kilogram.	O

It	O
is	O
this	O
property	O
of	O
buprenorphine	B-Drug
that	O
can	O
induce	O
acute	O
withdrawal	O
when	O
administered	O
before	O
other	O
opioids	O
have	O
left	O
the	O
body.	O

The	O
amount	O
of	O
transfer	O
oxymorphone	B-Drug
into	O
the	O
breast	O
milk	O
is	O
not	O
known	O
and	O
women	O
are	O
cautioned	O
to	O
weigh	O
risks	O
benefits	O
before	O
breastfeeding	O
while	O
on	O
this	O
medication.	O

In	O
the	O
second,	O
Justice	O
Department	O
joined	O
a	O
qui	O
tam,	O
or	O
whistleblower,	O
lawsuit	O
brought	O
by	O
former	O
sales	O
rep	O
over	O
off-label	O
marketing	O
of	O
three	O
drugs:	O
Lotrel	O
and	O
Valturna	O
(both	O
hypertension	O
drugs),	O
diabetes	B-Drug
drug,	O
Starlix.	O
Starlix	B-Drug

Like	O
MDMA,	O
MPPP	B-Drug
is	O
a	O
designer	O
drug,	O
but	O
its	O
effects	O
are	O
more	O
akin	O
to	O
morphine	B-Drug
or	O
other	O
opiates.	O
MDMA	B-Drug

One	O
US	O
Department	O
of	O
Justice	O
publication	O
lists	O
"China	O
White"	O
as	O
a	O
synonym	O
for	O
number	O
fentanyl	B-Drug
analogues,	O
including	O
3-methylfentanyl	B-Drug
and	O
-methylfentanyl,	O
which	O
today	O
are	O
classified	O
Schedule	O
I	O
drugs	O
in	O
the	O
United	O
States.	O

Thus,	O
high	O
extracellular	O
MDMA	B-Drug
can	O
reverse	O
the	O
transport.	O

However,	O
they	O
claim	O
normally	O
produced	O
up	O
to	O
a	O
kilogram	O
of	O
LSD	B-Drug
every	O
five	O
weeks.	O

Commercial	O
cannabinoid	O
immunoassays,	O
often	O
employed	O
as	O
the	O
initial	O
screening	O
method	O
when	O
testing	O
physiological	O
specimens	O
for	O
marijuana	O
presence,	O
have	O
different	O
degrees	O
of	O
cross-reactivity	O
with	O
THC	B-Drug
and	O
its	O
metabolites.	O

In	O
2016,	O
about	O
21	O
million	O
people	O
between	O
the	O
ages	O
of	O
15	O
and	O
64	O
used	O
ecstasy	B-Drug
(0.3%	O
world	O
population).	O

The	O
availability	O
of	O
oxymetholone	B-Drug
is	O
fairly	O
limited	O
and	O
seems	O
to	O
be	O
scattered	O
into	O
isolated	O
markets	O
in	O
Europe,	O
Asia,	O
North	O
South	O
America.	O

Finasteride	B-Drug
is	O
indicated	O
for	O
the	O
treatment	O
of	O
symptomatic	O
benign	O
prostatic	O
hyperplasia	O
(BPH)	O
in	O
men	O
with	O
an	O
enlarged	O
prostate	O
and	O
male	O
pattern	O
hair	O
loss	O
(androgenetic	O
alopecia)	O
men.	O

Currently	O
metopon,	O
which	O
has	O
a	O
DEA	O
ACSCN	O
of	O
9260,	O
does	O
not	O
have	O
an	O
annual	O
manufacturing	O
quota	O
listed	O
in	O
the	O
Federal	O
Register	O
and	O
bulk	O
research	O
on	O
drug	O
at	O
this	O
time	O
is	O
taking	O
place	O
Germany,	O
Switzerland,	O
Austria.	O
metopon	B-Drug

According	O
to	O
Chong,	O
the	O
DEA	O
agents	O
questioned	O
him	O
and	O
told	O
that	O
he	O
could	O
go	O
home,	O
one	O
even	O
offering	O
a	O
ride	O
but	O
instead	O
was	O
transferred	O
holding	O
cell	O
confined	O
for	O
five	O
days	O
without	O
any	O
food	O
or	O
water,	O
although	O
Chong	O
said	O
ingested	O
powdery	O
substance	O
left	O
him,	O
which	O
later	O
found	O
be	O
methamphetamine.	O
methamphetamine	B-Drug

PCP	B-Drug
was	O
initially	O
made	O
in	O
1926	O
and	O
brought	O
to	O
market	O
as	O
an	O
anesthetic	O
medication	O
the	O
1950s.	O

In	O
2005,	O
the	O
European	O
Senlis	O
Council	O
began	O
developing	O
a	O
programme	O
which	O
hopes	O
to	O
solve	O
problems	O
caused	O
by	O
large	O
quantity	O
of	O
opium	O
produced	O
illegally	O
in	O
Afghanistan,	O
most	O
is	O
converted	O
heroin	B-Drug
and	O
smuggled	O
for	O
sale	O
Europe	O
United	O
States.	O

Participants	O
applied	O
clascoterone	B-Drug
or	O
vehicle	O
(placebo)	O
cream	O
twice	O
daily	O
for	O
12	O
weeks.	O

Recent	O
reports	O
demonstrated	O
that	O
KORs	O
are	O
required	O
for	O
stress-induced	O
reinstatement	O
of	O
cocaine	B-Drug
seeking.	O

Mescaline	B-Drug
is	O
produced	O
when	O
products	O
of	O
natural	O
mammalian	O
catecholamine-based	O
neuronal	O
signaling	O
such	O
as	O
dopamine	O
and	O
noradrenaline	O
are	O
subjected	O
to	O
additional	O
metabolism	O
via	O
methylation,	O
mescaline's	O
hallucinogenic	O
properties	O
stem	O
from	O
its	O
structural	O
similarities	O
with	O
these	O
two	O
neurotransmitters.	O
mescaline	B-Drug

Prednisone	B-Drug
also	O
results	O
in	O
leukocytosis.	O

Currently	O
sufentanil	B-Drug
is	O
the	O
most	O
potent	O
opioid	O
painkiller	O
available	O
for	O
use	O
in	O
humans.	O

The	O
drug	O
acts	O
as	O
a	O
long-lasting	O
prodrug	O
of	O
trenbolone	B-Drug
when	O
administered	O
via	O
intramuscular	O
injection.	O

Diampromide	B-Drug
is	O
in	O
Schedule	O
I	O
of	O
the	O
Controlled	O
Substances	O
Act	O
1970	O
United	O
States	O
as	O
a	O
Narcotic	O
with	O
ACSCN	O
9615	O
zero	O
aggregate	O
manufacturing	O
quota	O
2014.	O

Thalidomide	B-Drug
may	O
interfere	O
with	O
various	O
contraceptives,	O
and	O
hence	O
it	O
is	O
advised	O
that	O
women	O
of	O
reproductive	O
age	O
use	O
at	O
least	O
two	O
different	O
means	O
contraception	O
to	O
ensure	O
no	O
child	O
will	O
be	O
conceived	O
while	O
they	O
are	O
taking	O
thalidomide.	O
thalidomide	B-Drug

However,	O
new	O
data	O
suggested	O
both	O
ropivacaine	B-Drug
(1.2-1.8	O
mg/kg	O
in	O
40ml)	O
and	O
levobupivacaine	B-Drug
(40	O
ml	O
of	O
0.125%	O
solution)	O
be	O
used,	O
because	O
they	O
have	O
less	O
cardiovascular	O
central	O
nervous	O
system	O
toxicity	O
than	O
racemic	O
bupivacaine.	O
bupivacaine	B-Drug

Turner	O
died	O
prematurely	O
due	O
to	O
drowning	O
during	O
presumed	O
unsupervised	O
ketamine	B-Drug
use.	O

Other	O
synonyms	O
for	O
heroin	B-Drug
include:	O
diacetylmorphine,	O
and	O
morphine	B-Drug
diacetate.	O
diacetylmorphine	B-Drug

Diazepam	B-Drug
is	O
highly	O
protein-bound,	O
with	O
96	O
to	O
99%	O
of	O
the	O
absorbed	O
drug	O
being	O
protein-bound.	O

Opioids	O
are	O
a	O
diverse	O
class	O
of	O
moderately	O
strong,	O
addictive,	O
and	O
inexpensive	O
drugs,	O
which	O
include	O
opiates	O
(i.e.,	O
morphine	B-Drug
codeine),	O
oxycodone	B-Drug
(OxyContin,	O
Percocet),	O
hydrocodone	B-Drug
(Vicodin,	O
Norco),	O
fentanyl.	O
codeine	B-Drug
OxyContin	B-Drug
Percocet	B-Drug
Vicodin	B-Drug
Norco	B-Drug
fentanyl	B-Drug

Budesonide	B-Drug
is	O
given	O
by	O
metered-dose	O
inhaler	O
or	O
nebulizer	O
for	O
maintenance	O
and	O
prophylactic	O
treatment	O
of	O
asthma,	O
including	O
patients	O
who	O
require	O
oral	O
corticosteroids	O
those	O
may	O
benefit	O
from	O
a	O
systemic	O
dose	O
reduction.	O

chloral	O
hydrate	O
and	O
some	O
histamine	O
H1	O
antagonists,	O
common	O
recreational	O
drugs	O
such	O
as	O
ethanol,	O
cocaine,	O
less	O
anticholinergics,	O
barbiturates,	O
opioids,	O
PCP,	O
scopolamine,	O
nasal	O
spray	O
ingredient	O
oxymetazoline,	O
certain	O
GABAergics	O
like	O
GHB	B-Drug
Researchers	O
agree	O
that	O
the	O
drug	O
most	O
commonly	O
involved	O
in	O
drug-facilitated	O
sexual	O
assaults	O
is	O
alcohol,	O
which	O
victim	O
has	O
consumed	O
voluntarily	O
cases.	O
cocaine	B-Drug
PCP	B-Drug
scopolamine	B-Drug
oxymetazoline	B-Drug

An	O
additional	O
three	O
hundred	O
civilian	O
personnel	O
were	O
allowed	O
to	O
assist	O
in	O
the	O
eradication	O
of	O
coca.	O
coca	B-Drug

In	O
June	O
2020,	O
the	O
Australian	O
Therapeutic	O
Goods	O
Administration	O
(TGA)	O
published	O
a	O
consultation	O
on	O
proposal	O
to	O
pave	O
way	O
make	O
"low	O
dose"	O
CBD	B-Drug
available	O
consumer/patients	O
via	O
pharmacists	O
only	O
through	O
moving	O
products	O
from	O
Schedule	O
4	O
3.	O

Hyoscine	B-Drug
has	O
been	O
used	O
to	O
model	O
the	O
defects	O
in	O
cholinergic	O
function	O
for	O
models	O
of	O
Alzheimer's,	O
dementia,	O
fragile	O
X	O
syndrome,	O
and	O
Down	O
syndrome.	O

By	O
December	O
2009	O
mephedrone	B-Drug
was	O
available	O
on	O
at	O
least	O
31	O
websites	O
based	O
in	O
the	O
UK	O
and	O
by	O
March	O
2010	O
there	O
were	O
78	O
online	O
shops,	O
half	O
of	O
which	O
sold	O
amounts	O
less	O
than	O
200	O
grams	O
that	O
also	O
bulk	O
quantities.	O

A	O
notable	O
exception	O
is	O
thebaine,	O
which	O
present	O
in	O
far	O
larger	O
fractions	O
opium	B-Drug
than	O
poppy	O
straw.	O

Esbriet	O
(pirfenidone),	O
for	O
idiopathic	O
pulmonary	O
fibrosis.	O
pirfenidone	B-Drug

Hyoscine	B-Drug
enters	O
breast	O
milk	O
by	O
secretion.	O

The	O
only	O
ATS	O
in	O
this	O
category	O
is	O
cathine.	O
cathine	B-Drug

Nandrolone	B-Drug
esters	O
are	O
used	O
clinically,	O
although	O
increasingly	O
rarely,	O
for	O
people	O
in	O
catabolic	O
states	O
with	O
major	O
burns,	O
cancer,	O
and	O
AIDS,	O
an	O
ophthalmological	O
formulation	O
was	O
available	O
to	O
support	O
cornea	O
healing.	O

And	O
the	O
following	O
have	O
not	O
been	O
marketed:	O
Mesabolone	O
17-(1-methyloxycyclohexyl)	O
ether	O
of	O
1-testosterone	B-Drug

Ketoprofen	B-Drug
is	O
generally	O
prescribed	O
for	O
arthritis-related	O
inflammatory	O
pains	O
or	O
severe	O
toothaches	O
that	O
result	O
in	O
the	O
inflammation	O
of	O
gums.	O

Early	O
medical	O
trials	O
of	O
humans	O
taking	O
desomorphine	B-Drug
have	O
resulted	O
in	O
the	O
finding	O
that	O
like	O
morphine	B-Drug
and	O
most	O
other	O
analgesics	O
type,	O
small	O
amounts	O
are	O
highly	O
addictive	O
tolerance	O
to	O
drug	O
develops	O
quickly.	O

However,	O
they	O
are	O
still	O
less	O
when	O
AG	O
is	O
combined	O
with	O
hydrocortisone,	O
and	O
so	O
generally	O
a	O
corticosteroid	O
even	O
at	O
this	O
lower	O
dosage.	O
hydrocortisone	B-Drug

It	O
was	O
developed	O
in	O
the	O
1950s	O
during	O
research	O
into	O
analogues	O
of	O
pethidine	B-Drug
and	O
assessed	O
by	O
United	O
Nations	O
Office	O
on	O
Drugs	O
Crime	O
but	O
not	O
included	O
list	O
drugs	O
under	O
international	O
control,	O
probably	O
because	O
it	O
used	O
medicine	O
or	O
widely	O
available.	O

Dehydrogenation	O
using	O
DDQ	O
forms	O
boldenone.	O
boldenone	B-Drug

There	O
are	O
multiple	O
indications	O
that	O
paradoxical	O
reactions	O
upon	O
for	O
example	O
benzodiazepines,	O
barbiturates,	O
inhalational	O
anesthetics,	O
propofol,	O
neurosteroids,	O
and	O
alcohol	O
associated	O
with	O
structural	O
deviations	O
of	O
GABAA	O
receptors.	O
propofol	B-Drug

The	O
dopamine	O
reuptake	O
inhibition	O
produced	O
by	O
4-FA	O
is	O
stronger	O
than	O
that	O
of	O
either	O
4-CA	B-Drug
or	O
4-IA.	O

In	O
2018	O
the	O
federal	O
farm	O
bill	O
was	O
passed	O
allowing	O
any	O
hemp	O
derived	O
product	O
not	O
exceeding	O
0.3%	O
-9	O
THC	B-Drug
to	O
be	O
sold	O
legally.	O

Holding	O
the	O
belief	O
that	O
MDMA	B-Drug
had	O
unique	O
potential	O
both	O
to	O
aid	O
psychotherapy	O
and	O
eventually	O
become	O
a	O
prescription	O
medicine,	O
Rick	O
Doblin	O
sought	O
gain	O
incorporation	O
for	O
MAPS	O
as	O
501(c)(3)	O
nonprofit	O
research	O
educational	O
organization.	O

4-hydroxytamoxifen),	O
a	O
major	O
active	O
metabolite	O
of	O
tamoxifen,	O
show	O
89251%	O
and	O
41246%	O
the	O
affinity	O
estradiol	O
for	O
ER	O
in	O
human	O
MCF-7	O
breast	O
cancer	O
cells,	O
respectively.	O
tamoxifen	B-Drug

Ultimately	O
public	O
opinion	O
rested	O
against	O
the	O
cocaine	B-Drug
user.	O

Hydrocodone	B-Drug
causes	O
respiratory	O
depression	O
and	O
miosis.	O

Use	O
of	O
another	O
illicit	O
drug,	O
hashish,	O
has	O
also	O
increased	O
in	O
Europe.	O
hashish	B-Drug

The	O
Qing	O
government	O
banned	O
opium	B-Drug
soon	O
afterward.	O

CBD	B-Drug
flowers,	O
although	O
openly	O
sold	O
online	O
and	O
in	O
some	O
retails	O
store,	O
are	O
not	O
legal	O
the	O
United	O
Kingdom	O
as	O
confirmed	O
an	O
email	O
from	O
Senior	O
Compliance	O
Officer	O
of	O
Home	O
Office	O
Drugs	O
&	O
Firearms	O
Licensing	O
Unit.	O

However,	O
single	O
very	O
high	O
doses	O
of	O
diazepam	B-Drug
have	O
been	O
found	O
to	O
cause	O
lifelong	O
immunosuppression	O
in	O
neonatal	O
rats.	O

The	O
two	O
main	O
ways	O
cocaine	B-Drug
is	O
smoked	O
are	O
freebasing	O
and	O
by	O
using	O
which	O
has	O
been	O
converted	O
to	O
smokable	O
"crack	O
cocaine".	O

Phencyclidine	B-Drug
or	O
phenylcyclohexyl	O
piperidine	O
(PCP),	O
also	O
known	O
as	O
angel	B-Drug
dust	I-Drug
among	O
other	O
names,	O
is	O
a	O
drug	O
used	O
for	O
its	O
mind-altering	O
effects.	O
PCP	B-Drug

Concerns	O
for	O
liver	O
toxicity	O
initially	O
arose	O
from	O
a	O
study	O
of	O
nonaddicted	O
obese	O
patients	O
receiving	O
300	O
mg	O
naltrexone.	O
naltrexone	B-Drug

Phencyclidine	B-Drug
is	O
an	O
NMDA	O
receptor	O
antagonist	O
that	O
blocks	O
the	O
activity	O
of	O
to	O
cause	O
anaesthesia	O
and	O
analgesia	O
without	O
causing	O
cardiorespiratory	O
depression.	O

Mifepristone	B-Drug
as	O
a	O
regular	O
contraceptive	O
at	O
2	O
mg	O
daily	O
prevents	O
ovulation	O
(1	O
does	O
not).	O

This	O
strategy	O
was	O
outlined	O
at	O
an	O
international	O
meeting	O
of	O
tobacco	B-Drug
companies	O
in	O
1988,	O
which	O
Philip	O
Morris	O
proposed	O
to	O
set	O
up	O
a	O
team	O
scientists,	O
organized	O
by	O
company	O
lawyers,	O
"carry	O
out	O
work	O
on	O
ETS	O
keep	O
the	O
controversy	O
alive.	O

The	O
medicinal	O
chemistry	O
work	O
turned	O
to	O
improving	O
the	O
lead	O
compound	O
into	O
a	O
suitable	O
drug:	O
result	O
was	O
thalidomide.	O
thalidomide	B-Drug

The	O
name	O
"scopolamine"	O
is	O
derived	O
from	O
one	O
type	O
of	O
nightshade	O
known	O
as	O
Scopolia,	O
while	O
the	O
"hyoscine"	O
another	O
Hyoscyamus	O
niger.	O
scopolamine	B-Drug
hyoscine	B-Drug

In	O
April	O
2019,	O
the	O
FDA	O
issued	O
a	O
statement	O
declaring	O
that	O
kratom	B-Drug
was	O
not	O
approved	O
for	O
any	O
medical	O
use,	O
potentially	O
unsafe	O
in	O
commercial	O
products	O
available	O
United	O
States,	O
and	O
remained	O
on	O
an	O
import	O
alert	O
where	O
imported	O
supplies	O
would	O
be	O
confiscated.	O

Succinic	O
semialdehyde	O
dehydrogenase	O
deficiency	O
is	O
a	O
disease	O
that	O
causes	O
GHB	B-Drug
to	O
accumulate	O
in	O
the	O
blood.	O

Due	O
to	O
its	O
unique	O
mechanism	O
of	O
action,	O
EPI-001	O
type	O
compounds	O
may	O
prove	O
be	O
effective	O
in	O
the	O
treatment	O
advanced	O
prostate	O
cancer	O
resistant	O
conventional	O
antiandrogens	O
such	O
as	O
enzalutamide.	O
enzalutamide	B-Drug

Internationally,	O
benzodiazepines	O
are	O
categorized	O
as	O
Schedule	O
IV	O
controlled	O
drugs,	O
apart	O
from	O
flunitrazepam,	O
which	O
is	O
a	O
III	O
drug	O
under	O
the	O
Convention	O
on	O
Psychotropic	O
Substances.	O
flunitrazepam	B-Drug

Hash	O
pressing,	O
tours,	O
consumption	O
of	O
the	O
drug,	O
and	O
sales	O
are	O
still	O
illegal,	O
but	O
unofficially,	O
combination	O
these	O
services	O
has	O
made	O
North	O
African	O
region	O
one	O
largest	O
exporters	O
hashish,	O
which	O
is	O
a	O
produced	O
from	O
female	O
cannabis	O
plants	O
through	O
compression	O
heating	O
resin	B-Drug
glands	O
known	O
as	O
trichomes.	O
hashish	B-Drug

By	O
increasing	O
the	O
effects	O
of	O
norepinephrine	O
and	O
dopamine,	O
methylphenidate	B-Drug
increases	O
activity	O
central	O
nervous	O
system	O
produces	O
such	O
as	O
increased	O
alertness,	O
reduced	O
fatigue,	O
improved	O
attention.	O

Nalmefene	B-Drug
is	O
extensively	O
metabolized	O
in	O
the	O
liver,	O
mainly	O
by	O
conjugation	O
with	O
glucuronic	O
acid	O
and	O
also	O
N-dealkylation.	O

When	O
nonselective	O
COX-1/COX-2	O
inhibitors	O
(such	O
as	O
aspirin,	O
ibuprofen,	O
and	O
naproxen)	O
lower	O
stomach	O
prostaglandin	O
levels,	O
ulcers	O
of	O
the	O
or	O
duodenum	O
internal	O
bleeding	O
can	O
result.	O
aspirin	B-Drug
ibuprofen	B-Drug
naproxen	B-Drug

The	O
seizure	O
is	O
the	O
largest	O
cocaine	B-Drug
in	O
U.S.	O
Customs	O
and	O
Border	O
Protection's	O
230-year	O
history,	O
US	O
fourth	O
worldwide.	O

There	O
was	O
a	O
total	O
of	O
12.0	O
million	O
prescriptions	O
for	O
spironolactone	B-Drug
in	O
the	O
United	O
States	O
2016	O
alone.	O

Low-dose	O
spironolactone	B-Drug
is	O
generally	O
very	O
well	O
tolerated.	O

Its	O
DEA	O
Administrative	O
Controlled	O
Substances	O
Control	O
Number	O
is	O
9051	O
and	O
the	O
one	O
salt	O
in	O
use,	O
acetyldihydrocodeine	B-Drug
hydrochloride,	O
has	O
a	O
freebase	O
conversion	O
ratio	O
of	O
0.90.	O

DJ	O
Screw's	O
invoking	O
lean	O
in	O
his	O
lyrics	O
and	O
use	O
of	O
slow	O
tempos	O
had	O
caused	O
style	O
to	O
be	O
characterized	O
"[a]s	O
if	O
the	O
song	O
itself	O
has	O
taken	O
too	O
much	O
codeine	B-Drug
promethazine".	O
promethazine	B-Drug

Neither	O
the	O
crown	O
(fruit,	O
mescal	O
button)	O
of	O
Peyote	O
cactus	O
nor	O
roots	O
plant	O
Mimosa	O
hostilis	O
Psilocybe	O
mushrooms	O
themselves	O
are	O
included	O
in	O
Schedule	O
1,	O
but	O
only	O
their	O
respective	O
principles,	O
Mescaline,	O
DMT	O
and	O
Psilocybin.	O
Mescaline	B-Drug

cannabis	B-Drug
(drug)	I-Drug

Alprazolam,	O
like	O
other	O
benzodiazepines,	O
binds	O
to	O
specific	O
sites	O
on	O
the	O
GABAA	O
(gamma-aminobutyric	O
acid)	O
receptor.	O
Alprazolam	B-Drug

Overdose	O
of	O
flunitrazepam	B-Drug
may	O
result	O
in	O
excessive	O
sedation,	O
or	O
impairment	O
balance	O
speech.	O

On	O
October	O
15,	O
2011,	O
Anderson	O
County	O
coroner	O
Greg	O
Shore	O
attributed	O
the	O
death	O
of	O
a	O
South	O
Carolina	O
college	O
basketball	O
player	O
to	O
"drug	O
toxicity	O
and	O
organ	O
failure"	O
caused	O
by	O
JWH-018.	O
JWH-018	B-Drug

This	O
drug	O
mixture	O
has	O
slightly	O
stronger	O
CNS	O
effects	O
than	O
racemic	O
amphetamine	B-Drug
due	O
to	O
the	O
higher	O
proportion	O
of	O
dextroamphetamine.	O
dextroamphetamine	B-Drug

These	O
results	O
suggest	O
that	O
PCP	B-Drug
is	O
a	O
highly	O
selective	O
ligand	O
of	O
the	O
NMDAR	O
and	O
2	O
receptor.	O

Spironolactone	B-Drug
is	O
typically	O
used	O
at	O
a	O
low	O
dosage	O
of	O
25	O
to	O
50	O
mg/day	O
in	O
the	O
treatment	O
heart	O
failure,	O
while	O
it	O
high	O
dosages	O
200	O
essential	O
hypertension,	O
and	O
100	O
400	O
for	O
hyperaldosteronism	O
ascites	O
due	O
cirrhosis.	O

Dihydromorphine	B-Drug
is	O
a	O
moderately	O
strong	O
analgesic	O
and	O
used	O
clinically	O
in	O
the	O
treatment	O
of	O
pain	O
also	O
an	O
active	O
metabolite	O
opioid	O
drug	O
dihydrocodeine.	O
dihydrocodeine	B-Drug

Upon	O
ingestion	O
of	O
between	O
50	O
mg	O
and	O
200	O
BZP,	O
the	O
user	O
may	O
experience	O
any	O
or	O
all	O
following:	O
BZP	B-Drug

Most	O
heroin	B-Drug
deaths	O
result	O
not	O
from	O
overdose	O
per	O
se,	O
but	O
combination	O
with	O
other	O
depressant	O
drugs	O
such	O
as	O
alcohol	O
or	O
benzodiazepines.	O

Light	O
Sound	O
Dimension	O
(LSD)	O
was	O
possibly	O
the	O
first	O
psychedelic	O
lightshow	O
and	O
operated	O
by	O
Bill	O
Ham.	O
LSD	B-Drug

The	O
bill	O
includes	O
Medicare	O
and	O
Medicaid	O
reform	O
in	O
order	O
to	O
improve	O
treatment,	O
recovery,	O
prevention	O
efforts	O
while	O
also	O
strengthening	O
the	O
fight	O
against	O
synthetic	O
drugs	O
like	O
fentanyl.	O
fentanyl	B-Drug

Shortly	O
after	O
the	O
teratogenic	O
properties	O
of	O
thalidomide	B-Drug
were	O
recognized	O
in	O
mid-1960s,	O
its	O
anti-cancer	O
potential	O
was	O
explored	O
and	O
two	O
clinical	O
trials	O
conducted	O
people	O
with	O
advanced	O
cancer,	O
including	O
some	O
multiple	O
myeloma;	O
inconclusive.	O

Cocaine	B-Drug
is	O
a	O
Schedule	O
8	O
prohibited	O
substance	O
in	O
Australia	O
under	O
the	O
Poisons	O
Standard	O
(July	O
2016).	O

It	O
has	O
benefits	O
over	O
methadone	B-Drug
and	O
buprenorphine	B-Drug
in	O
that	O
it	O
is	O
not	O
a	O
restricted	O
medication.	O

According	O
to	O
IMS,	O
the	O
hydrocodone/ibuprofen	B-Drug
tablets	O
7.5	O
mg/200	O
mg,	O
had	O
an	O
estimated	O
market	O
size	O
of	O
$15.7	O
million	O
for	O
12	O
months	O
preceding	O
May	O
2016.	O

The	O
duration	O
of	O
action	O
MDMA	B-Drug
is	O
usually	O
four	O
to	O
six	O
hours,	O
after	O
which	O
serotonin	O
levels	O
in	O
the	O
brain	O
are	O
depleted.	O

However,	O
the	O
FDA	O
closely	O
monitors	O
labeling	O
of	O
opium	B-Drug
tincture.	O

The	O
estrogenic	O
effects	O
of	O
tibolone	B-Drug
may	O
show	O
tissue	O
selectivity	O
in	O
their	O
distribution.	O

Like	O
oxazepam,	O
it	O
does	O
not	O
require	O
liver	O
oxidation,	O
but	O
only	O
glucuronidation	O
into	O
lorazepam-glucuronide.	O
oxazepam	B-Drug

Desmethylprodine	B-Drug
was	O
first	O
synthesized	O
in	O
1947	O
at	O
Hoffman-LaRoche	O
Laboratories	O
by	O
Albert	O
Ziering	O
and	O
John	O
Lee.	O

Oldham	O
Kelsey	O
was	O
given	O
a	O
Presidential	O
award	O
for	O
distinguished	O
service	O
from	O
the	O
federal	O
government	O
not	O
allowing	O
thalidomide	B-Drug
to	O
be	O
approved	O
sale	O
in	O
US.In	O
Canada,	O
history	O
of	O
dates	O
back	O
April	O
1,	O
1961.	O

Deliriants	O
atropine	O
(alkaloid	O
found	O
in	O
plants	O
of	O
the	O
family	O
Solanaceae,	O
including	O
datura,	O
deadly	O
nightshade,	O
henbane	O
and	O
mandrake)	O
dimenhydrinate	B-Drug
(Dramamine,	O
an	O
antihistamine)	O
diphenhydramine	B-Drug
(Benadryl,	O
Unisom,	O
Nytol)	O
Dramamine	B-Drug
Nytol	B-Drug

Butane	O
and	O
supercritical	O
carbon	O
dioxide	O
hash	B-Drug
oil	I-Drug
have	O
become	O
popular	O
in	O
recent	O
years.	O

The	O
ergoline	O
antimigraine	O
agent	O
ergotamine	B-Drug
also	O
acts	O
on	O
this	O
receptor.	O

They	O
include	O
methylprednisolone	B-Drug
aceponate	O
(Advantan),	O
acetate	I-Drug
(Depo-Medrol),	O
succinate	O
(Solu-Medrol),	O
and	O
suleptanate	O
(Medrosol,	O
Promedrol).	O

However,	O
the	O
European	O
Medicines	O
Agency	O
has	O
recently	O
backed	O
agency's	O
decision,	O
and	O
recommended	O
in	O
June	O
2009	O
that	O
propoxyphene	B-Drug
preparations	O
be	O
withdrawn	O
across	O
Union.	O

A	O
forensic	O
standard	O
of	O
5-APB	B-Drug
is	O
available,	O
and	O
the	O
compound	O
has	O
been	O
posted	O
on	O
Forendex	O
website	O
potential	O
drugs	O
abuse.	O

Use	O
of	O
butalbital	B-Drug
and	O
alcohol,	O
benzodiazepines,	O
other	O
CNS-depressants	O
can	O
contribute	O
to	O
coma,	O
in	O
extreme	O
cases,	O
fatality.	O

Both	O
Avastin	B-Drug
and	O
Lucentis	B-Drug
were	O
created	O
by	O
Genentech	O
which	O
is	O
owned	O
Roche;	O

Sveriges	O
riksdag	O
added	O
25C-NBOMe	B-Drug
to	O
schedule	O
I	O
("substances,	O
plant	O
materials	O
and	O
fungi	O
which	O
normally	O
do	O
not	O
have	O
medical	O
use")	O
as	O
narcotics	O
in	O
Sweden	O
of	O
Aug	O
1,	O
2013,	O
published	O
by	O
Medical	O
Products	O
Agency	O
their	O
regulation	O
LVFS	O
2013:15	O
listed	O
2-(4-kloro-2,5-dimetoxifenyl)-N-(2-metoxibensyl)etanamin.	O

Historically,	O
pyridine	O
was	O
produced	O
from	O
coal	B-Drug
tar.	O
tar	I-Drug

Nitrazepam's	O
half-life	O
in	O
the	O
cerebrospinal	O
fluid,	O
68	O
hours,	O
indicates	O
that	O
nitrazepam	B-Drug
is	O
eliminated	O
extremely	O
slowly	O
from	O
fluid.	O
Nitrazepam	B-Drug

In	O
the	O
US,	O
fentanyl	B-Drug
and	O
analogs	O
caused	O
over	O
29,000	O
deaths	O
in	O
2017,	O
a	O
large	O
increase	O
previous	O
four	O
years.	O

Fentanyl	B-Drug
-	O
It	O
is	O
a	O
synthetic,	O
centrally-acting	O
opioid.	O

Chlordiazepoxide	B-Drug
overdose	O
is	O
considered	O
a	O
medical	O
emergency	O
and,	O
in	O
general,	O
requires	O
the	O
immediate	O
attention	O
of	O
personnel.	O

In	O
the	O
US,	O
FDA	O
has	O
approved	O
two	O
oral	O
cannabinoids	O
for	O
use	O
as	O
medicine:	O
dronabinol	O
and	O
nabilone.	O
nabilone	B-Drug

Enzyme	O
inducers	O
All	O
drugs	O
that	O
fall	O
within	O
the	O
class	O
of	O
enzyme	O
increase	O
clearance	O
and	O
decrease	O
half-life	O
methylprednisolone	B-Drug
when	O
co-administered.	O

It	O
has	O
been	O
estimated	O
that	O
therapeutic	O
levels	O
of	O
danazol,	O
methyltestosterone,	O
fluoxymesterone,	O
levonorgestrel,	O
and	O
norethisterone	B-Drug
would	O
respectively	O
occupy	O
or	O
displace	O
from	O
testosterone	O
8397%,	O
4869%,	O
4264%,	O
1647%,	O
439%	O
SHBG	O
binding	O
sites,	O
while	O
others	O
with	O
low	O
affinity	O
for	O
such	O
as	O
ethinylestradiol,	O
cyproterone	O
acetate,	O
medroxyprogesterone	B-Drug
acetate	I-Drug
1%	O
fewer	O
sites.	O
danazol	B-Drug
methyltestosterone	B-Drug
fluoxymesterone	B-Drug
levonorgestrel	B-Drug

Thalidomide	B-Drug
was	O
first	O
marketed	O
in	O
1957	O
West	O
Germany,	O
where	O
it	O
available	O
over	O
the	O
counter.	O

In	O
April	O
2012,	O
after	O
failing	O
to	O
persuade	O
the	O
trusts	O
that	O
it	O
was	O
uncertain	O
whether	O
Avastin	B-Drug
as	O
safe	O
and	O
effective	O
Lucentis,	O
in	O
order	O
retain	O
market	O
for	O
Novartis	O
announced	O
would	O
sue	O
trusts.	O
Lucentis	B-Drug

According	O
to	O
the	O
Royal	O
Canadian	O
Mounted	O
Police,	O
90%	O
of	O
heroin	B-Drug
seized	O
in	O
Canada	O
(where	O
origin	O
was	O
known)	O
came	O
from	O
Afghanistan.	O

Cloforex	O
(Oberex)	O
(prodrug	O
of	O
chlorphentermine)	O
chlorphentermine	B-Drug

In	O
2014,	O
despite	O
the	O
introduction	O
of	O
abiraterone	O
acetate	O
in	O
2011	O
and	O
enzalutamide	B-Drug
2012,	O
bicalutamide	B-Drug
was	O
still	O
most	O
commonly	O
prescribed	O
drug	O
treatment	O
metastatic	O
castration-resistant	O
prostate	O
cancer	O
(mCRPC).	O

Four	O
postmortem	O
cases	O
linked	O
to	O
the	O
synthetic	O
cannabinoids	O
5F-PB-22	B-Drug
have	O
been	O
reviewed.	O

Therefore,	O
efforts	O
directed	O
toward	O
monitoring	O
drug	O
interactions	O
and	O
preventing	O
injuries	O
from	O
midazolam	B-Drug
administration	O
are	O
expected	O
to	O
have	O
a	O
substantial	O
impact	O
on	O
the	O
safe	O
use	O
of	O
this	O
drug.	O

Concurrent	O
use	O
of	O
MDMA	B-Drug
high	O
dosages	O
with	O
another	O
serotonergic	O
drug	O
can	O
result	O
in	O
a	O
life-threatening	O
condition	O
called	O
serotonin	O
syndrome.	O

Atypicals	O
salvinorin	B-Drug
A	I-Drug
(found	O
in	O
Salvia	O
divinorum,	O
a	O
trans-neoclerodane	O
diterpenoid	O
("Diviner's	O
Sage",	O
"Lady	O
Salvia",	O
"Salvinorin"))	O

Enzalutamide	B-Drug
monotherapy	O
is	O
regarded	O
as	O
having	O
a	O
moderate	O
negative	O
effect	O
on	O
sexual	O
function	O
and	O
activity,	O
significantly	O
less	O
than	O
that	O
of	O
GnRH	O
analogues	O
but	O
similar	O
to	O
other	O
NSAAs	O
such	O
bicalutamide.	O
bicalutamide	B-Drug

Oxycodone	B-Drug
has	O
a	O
7,8-dihydro	O
feature.	O

A	O
1985	O
study	O
found	O
that	O
triazolam	B-Drug
and	O
temazepam	B-Drug
maintained	O
higher	O
rates	O
of	O
self-injection	O
in	O
both	O
human	O
animal	O
subjects	O
compared	O
to	O
a	O
variety	O
other	O
benzodiazepines	O
(others	O
examined:	O
diazepam,	O
lorazepam,	O
oxazepam,	O
flurazepam,	O
alprazolam,	O
chlordiazepoxide,	O
clonazepam,	O
nitrazepam,	O
flunitrazepam,	O
bromazepam,	O
clorazepate).	O
diazepam	B-Drug
lorazepam	B-Drug
oxazepam	B-Drug
flurazepam	B-Drug
alprazolam	B-Drug
chlordiazepoxide	B-Drug
clonazepam	B-Drug
nitrazepam	B-Drug
flunitrazepam	B-Drug
bromazepam	B-Drug
clorazepate	B-Drug

By	O
using	O
the	O
technique	O
of	O
functional	O
neurochemical	O
assay	O
chlorpromazine	B-Drug
and	O
phenothiazine	O
derivatives	O
have	O
been	O
shown	O
to	O
inhibitory	O
effects	O
on	O
NMDA	O
receptors	O
that	O
appeared	O
be	O
mediated	O
by	O
action	O
at	O
Zn	O
site.	O

If	O
naloxegol	B-Drug
is	O
coadministered	O
with	O
other	O
opioid	O
antagonists,	O
there	O
a	O
potential	O
for	O
additive	O
effect	O
and	O
increased	O
risk	O
of	O
withdrawal.	O

They	O
found	O
that	O
the	O
psychoactive	O
chemicals	O
psilocybin	O
and	O
psilocin	B-Drug
exhibited	O
serotonin-like	O
effects,	O
however	O
as	O
dosage	O
increased,	O
these	O
compounds	O
acted	O
serotonin	O
antagonists,	O
being	O
comparable	O
to	O
most	O
potent	O
antagonist	O
yet	O
discovered.	O

Propylhexedrine	B-Drug
should	O
not	O
be	O
used	O
if	O
an	O
MAOI	O
has	O
been	O
in	O
the	O
past	O
14	O
days,	O
or	O
is	O
being	O
currently	O
used,	O
as	O
this	O
can	O
lead	O
to	O
a	O
hypertensive	O
crisis.	O

In	O
particular,	O
methamphetamine	B-Drug
appears	O
to	O
cause	O
hyperintensity	O
and	O
hypertrophy	O
of	O
white	O
matter,	O
marked	O
shrinkage	O
hippocampi,	O
reduced	O
gray	O
matter	O
in	O
the	O
cingulate	O
cortex,	O
limbic	O
paralimbic	O
cortex	O
recreational	O
users.	O

Ergine,	O
also	O
known	O
as	O
d-lysergic	O
acid	B-Drug
amide	O
(LSA)	O
and	O
d-lysergamide,	O
is	O
an	O
ergoline	O
alkaloid	O
that	O
occurs	O
in	O
various	O
species	O
of	O
vines	O
the	O
Convolvulaceae	O
some	O
fungi.	O
Ergine	B-Drug

Soft	O
drugs	O
include	O
hash,	O
marijuana,	O
sleeping	O
pills	O
and	O
sedatives,	O
while	O
hard	O
heroin,	O
cocaine,	O
amphetamine,	O
LSD	B-Drug
ecstasy.	O
hash	B-Drug
heroin	B-Drug
cocaine	B-Drug
amphetamine	B-Drug
ecstasy	B-Drug

The	O
Riksdag	O
added	O
25I-NBOMe	B-Drug
to	O
Narcotic	O
Drugs	O
Punishments	O
Act	O
under	O
Swedish	O
schedule	O

After	O
paying	O
Marks	O
5,000	O
for	O
his	O
work	O
in	O
Frankfurt,	O
Plinston	O
then	O
sold	O
hashish	B-Drug
on	O
to	O
and	O
three	O
friends	O
(Radcliffe,	O
Weatherly	O
Jarvis)	O
London;	O
selling	O
650	O
kilos	O
within	O
a	O
week,	O
the	O
four	O
men	O
made	O
profit	O
of	O
20,000.	O

However,	O
Danish	O
addicts	O
would	O
only	O
be	O
able	O
to	O
inject	O
heroin	B-Drug
according	O
the	O
policy	O
set	O
by	O
National	O
Board	O
of	O
Health.	O

Many	O
people	O
who	O
smoke	O
cannabis	O
also	O
tobacco.	O
tobacco	B-Drug

However,	O
thalidomide	B-Drug
is	O
a	O
teratogenic	O
substance,	O
and	O
proportion	O
of	O
children	O
born	O
during	O
the	O
1960s	O
were	O
afflicted	O
with	O
syndrome	O
known	O
as	O
embryopathy	O
(TE).	O

Like	O
many	O
other	O
drugs,	O
PCP	B-Drug
has	O
been	O
known	O
to	O
alter	O
mood	O
states	O
in	O
an	O
unpredictable	O
fashion,	O
causing	O
some	O
individuals	O
become	O
detached,	O
and	O
others	O
animated.	O

Due	O
to	O
amphetamines	O
addiction	O
liability	O
in	O
some	O
people,	O
newer	O
wakefulness-promoting	O
drugs	O
such	O
as	O
modafinil	B-Drug
have	O
been	O
seen	O
possible	O
safer	O
alternatives	O
for	O
military	O
use	O
countries,	O
including	O
the	O
United	O
States.	O

A	O
reversal	O
agent	O
for	O
benzodiazepines	O
exists,	O
flumazenil	B-Drug
(Anexate).	O
Anexate	B-Drug

With	O
a	O
farm	O
gate	O
price	O
of	O
approximately	O
$125	O
per	O
kilogram	O
for	O
dry	O
opium,	O
an	O
Afghan	O
farmer	O
can	O
make	O
17	O
times	O
more	O
profit	O
growing	O
opium	B-Drug
poppy	O
($4,622	O
hectare),	O
than	O
by	O
wheat	O
($266	O
hectare).	O

The	O
proposed	O
changes	O
included	O
other	O
similar	O
blanket	O
bans	O
for	O
substances,	O
such	O
as	O
a	O
ban	O
on	O
any	O
and	O
all	O
plants	O
containing	O
Mescaline	B-Drug
or	O
Ephedrine.	O
Ephedrine	B-Drug

It	O
contains	O
salts	O
of	O
various	O
alkaloids,	O
and	O
can	O
range	O
from	O
nine	O
to	O
30	O
times	O
the	O
morphine	B-Drug
concentration	O
poppy	O
straw.	O

It	O
has	O
been	O
shown	O
to	O
be	O
a	O
potentiator	O
of	O
analgesia	O
induced	O
by	O
morphine,	O
but	O
not	O
endogenous	O
opioids,	O
in	O
rats.	O
morphine	B-Drug

Two	O
days	O
later,	O
the	O
French	O
government	O
ordered	O
Roussel-Uclaf	O
to	O
distribute	O
mifepristone	B-Drug
in	O
interests	O
of	O
public	O
health.	O

Elagolix	B-Drug
is	O
indicated	O
for	O
the	O
treatment	O
of	O
moderate	O
to	O
severe	O
endometriosis	O
pain	O
and	O
relugolix	O
uterine	O
fibroids.	O

Cocaine	B-Drug
is	O
also	O
carried	O
in	O
small,	O
concealed,	O
kilogram	O
quantities	O
across	O
the	O
border	O
by	O
couriers	O
known	O
as	O
"mules"	O
(or	O
"mulas"),	O
who	O
cross	O
a	O
either	O
legally,	O
for	O
example,	O
through	O
port	O
or	O
airport,	O
illegally	O
elsewhere.	O

Another	O
more	O
potent	O
analog,	O
pomalidomide,	O
is	O
now	O
FDA	O
approved.	O
pomalidomide	B-Drug

Phentermine	B-Drug
Phenylpropanolamine	B-Drug

Death	O
from	O
fentanyl	B-Drug
overdose	O
continues	O
to	O
be	O
a	O
public	O
health	O
of	O
national	O
concern	O
in	O
Canada	O
since	O
September	O
2015.	O

Following	O
the	O
use	O
of	O
nasal	O
spray	O
device	O
by	O
police	O
officers	O
on	O
Staten	O
Island	O
in	O
New	O
York,	O
an	O
additional	O
20,000	O
will	O
begin	O
carrying	O
naloxone	B-Drug
mid-2014.	O

Nandrolone	B-Drug
theoretically	O
may	O
produce	O
erectile	O
dysfunction	O
as	O
a	O
side	O
effect,	O
although	O
there	O
is	O
no	O
clinical	O
evidence	O
to	O
support	O
this	O
notion	O
at	O
present.	O

Tabernanthine	O
persistently	O
reduced	O
the	O
self-administration	O
of	O
cocaine	B-Drug
and	O
morphine	B-Drug
in	O
rats.	O

Ropivacaine	B-Drug
was	O
found	O
to	O
have	O
less	O
cardiotoxicity	O
than	O
bupivacaine	B-Drug
in	O
animal	O
models.	O

Diazepam	B-Drug
is	O
therefore	O
only	O
recommended	O
for	O
short-term	O
therapy	O
at	O
the	O
lowest	O
possible	O
dose	O
owing	O
to	O
risks	O
of	O
severe	O
withdrawal	O
problems	O
from	O
low	O
doses	O
even	O
after	O
gradual	O
reduction.	O

Cocaine	B-Drug
is	O
the	O
second	O
most	O
frequently	O
used	O
illegal	O
drug	O
globally,	O
after	O
cannabis.	O

Although	O
the	O
therapeutic	O
effects	O
of	O
empathogens	O
may	O
be	O
promising,	O
drugs	O
such	O
as	O
MDMA	B-Drug
have	O
potential	O
for	O
negative	O
that	O
are	O
counter	O
productive	O
in	O
a	O
therapy	O
setting.	O

The	O
Church	O
of	O
the	O
Tree	O
Life,	O
founded	O
in	O
California	O
1971	O
by	O
John	O
Mann	O
but	O
now	O
defunct,	O
declared	O
use	O
5-MeO-DMT	B-Drug
to	O
be	O
a	O
sacrament.	O

In	O
an	O
early	O
media	O
report	O
on	O
MDMA	B-Drug
published	O
in	O
1982,	O
a	O
Drug	O
Enforcement	O
Administration	O
(DEA)	O
spokesman	O
stated	O
the	O
agency	O
would	O
ban	O
drug	O
if	O
enough	O
evidence	O
for	O
abuse	O
could	O
be	O
found.	O

In	O
2011,	O
researchers	O
at	O
John	O
Jay	O
College	O
of	O
Criminal	O
Justice	O
reported	O
that	O
dietary	O
zinc	O
supplements	O
can	O
mask	O
the	O
presence	O
cocaine	B-Drug
and	O
other	O
drugs	O
in	O
urine.	O

Coadministration	O
with	O
modafinil	B-Drug
alongside	O
opioids	O
such	O
as	O
hydrocodone,	O
oxycodone,	O
and	O
fentanyl,	O
well	O
various	O
other	O
drugs,	O
may	O
experience	O
a	O
drop	O
in	O
plasma	O
concentrations.	O
hydrocodone	B-Drug
oxycodone	B-Drug
fentanyl	B-Drug

Increased	O
brain-derived	O
neurotrophic	O
factor	O
(BDNF)	O
signaling	O
in	O
the	O
ventral	O
tegmental	O
area	O
(VTA)	O
has	O
been	O
shown	O
to	O
mediate	O
opioid-induced	O
withdrawal	O
symptoms	O
via	O
downregulation	O
of	O
insulin	O
receptor	O
substrate	O
2	O
(IRS2),	O
protein	O
kinase	O
B	O
(AKT),	O
and	O
mechanistic	O
target	O
rapamycin	B-Drug
complex	O
(mTORC2).	O

Alcohol	O
and	O
nicotine	B-Drug
also	O
prime	O
the	O
brain	O
for	O
a	O
heightened	O
response	O
to	O
other	O
drugs	O
are,	O
like	O
marijuana,	O
typically	O
used	O
before	O
person	O
progresses	O
other,	O
more	O
harmful	O
substances.	O

Flunitrazepam	B-Drug
impairs	O
cognitive	O
functions.	O

It	O
is	O
being	O
investigated	O
as	O
a	O
potential	O
treatment	O
for	O
nicotine	B-Drug
addiction,	O
to	O
assist	O
smoking	O
cessation.	O

(or	O
possibly	O
JWH-302,	O
isomer	O
not	O
determined),	O
JWH-203,	O
JWH-302	B-Drug
JWH-203	B-Drug

Tramadol	B-Drug
is	O
marketed	O
as	O
a	O
racemic	O
mixture	O
of	O
both	O
R-	O
and	O
S-stereoisomers,	O
because	O
the	O
two	O
isomers	O
complement	O
each	O
other's	O
analgesic	O
activities.	O

Side	O
effects	O
of	O
laudanum	B-Drug
are	O
generally	O
the	O
same	O
as	O
with	O
morphine,	O
and	O
include	O
euphoria,	O
dysphoria,	O
pruritus,	O
sedation,	O
constipation,	O
reduced	O
tidal	O
volume,	O
respiratory	O
depression,	O
well	O
psychological	O
dependence,	O
physical	O
miosis,	O
xerostomia.	O
morphine	B-Drug

Pethidinic	O
acid	O
(meperidinic	O
acid,	O
pethidine	B-Drug
intermediate	I-Drug
C)	O
is	O
a	O
4-phenylpiperidine	O
derivative	O
that	O
both	O
metabolite	O
of	O
and	O
precursor	O
to	O
(meperidine).	O
C	I-Drug
meperidine	B-Drug

Opioids	O
are	O
substances	O
that,	O
when	O
reaching	O
opioid	O
receptors,	O
have	O
effects	O
similar	O
to	O
those	O
of	O
morphine.	O
morphine	B-Drug

In	O
Canada,	O
ergine	B-Drug
is	O
not	O
illegal	O
to	O
possess	O
as	O
it	O
listed	O
under	O
Canada's	O
Controlled	O
Drugs	O
and	O
Substances	O
Act,	O
though	O
likely	O
sell	O
for	O
human	O
consumption.	O

PMMA	B-Drug
and	O
PMEA	O
are	O
anecdotally	O
weaker,	O
more	O
"ecstasy-like"	O
somewhat	O
less	O
dangerous	O
than	O
PMA	B-Drug
itself,	O
but	O
can	O
still	O
produce	O
nausea	O
hyperthermia	O
similar	O
to	O
that	O
produced	O
by	O
PMA,	O
albeit	O
at	O
slightly	O
higher	O
doses.	O

It	O
may	O
be	O
useful	O
for	O
treating	O
scalp	O
hair	O
loss	O
or	O
in	O
those	O
who	O
have	O
issues	O
tolerating	O
spironolactone.	O
spironolactone	B-Drug

Whereas	O
cocaine	B-Drug
hydrochloride	O
cannot	O
be	O
smoked	O
(burns	O
with	O
no	O
effect),	O
crack	O
when	O
allows	O
for	O
quick	O
absorption	O
into	O
the	O
blood	O
stream,	O
and	O
reaches	O
brain	O
in	O
eight	O
seconds.	O

In	O
animal	O
studies	O
it	O
has	O
proved	O
to	O
be	O
effective	O
at	O
reducing	O
self-administration	O
of	O
morphine,	O
cocaine,	O
methamphetamine,	O
nicotine	B-Drug
and	O
sucrose.	O
morphine	B-Drug
cocaine	B-Drug
methamphetamine	B-Drug

MDMA	B-Drug
Amants	O
rguliers,	O
Les	O
(2005)	O

Ethylestrenol	B-Drug
has	O
been	O
used	O
for	O
a	O
variety	O
of	O
indications	O
including:	O
To	O
promote	O
weight	O
gain	O
and	O
muscle	O
growth	O
As	O
an	O
adjunct	O
in	O
the	O
treatment	O
bone	O
pain	O
decreased	O
strength	O
associated	O
with	O
osteoporosis	O
catabolic	O
states	O
such	O
as	O
corticosteroid	O
therapy	O
convalescence	O
chronic	O
infections,	O
extensive	O
surgery,	O
severe	O
trauma	O
treat	O
treatment-refractory	O
anemias	O
(via	O
stimulation	O
erythropoiesis)	O
acquired	O
congenital	O
aplastic	O
anemia	O
kidney	O
disease	O
to	O
improve	O
well-being	O
arthritis	O
short	O
stature	O
youth	O
should	O
not	O
be	O
taken	O
by	O
pregnant	O
women	O
it	O
can	O
masculinize	O
female	O
fetuses.	O

It	O
is	O
not	O
publicly	O
known	O
where	O
Pickard	O
initially	O
produced	O
LSD.	O
LSD	B-Drug

Evidence	O
provides	O
support	O
for	O
a	O
small	O
or	O
modest	O
improvement	O
with	O
sertraline,	O
fluoxetine,	O
paroxetine,	O
and	O
venlafaxine.	O
sertraline	B-Drug
fluoxetine	B-Drug
paroxetine	B-Drug
venlafaxine	B-Drug

As	O
of	O
August	O
2016	O
perampanel	B-Drug
had	O
been	O
studied	O
and	O
development	O
discontinued	O
in	O
migraine,	O
multiple	O
sclerosis,	O
neuropathic	O
pain,	O
Parkinson's	O
disease.	O

in	O
order	O
to	O
be	O
bioactivated;	O
this	O
makes	O
6-MAM	O
somewhat	O
more	O
potent	O
than	O
heroin.	O
heroin	B-Drug

The	O
plasma	O
protein	O
binding	O
of	O
apalutamide	B-Drug
is	O
96%,	O
while	O
that	O
its	O
major	O
metabolite	O
N-desmethylapalutamide	O
95%,	O
both	O
irrespective	O
concentration.	O

In	O
terms	O
of	O
purity	O
data	O
for	O
Australian	O
MDMA,	O
the	O
average	O
is	O
around	O
34%,	O
ranging	O
from	O
less	O
than	O
1%	O
to	O
about	O
85%.	O
MDMA	B-Drug

Jean-Paul	O
Sartre	O
took	O
mescaline	B-Drug
shortly	O
before	O
the	O
publication	O
of	O
his	O
first	O
book,	O
L'Imaginaire;	O
he	O
had	O
a	O
bad	O
trip	O
during	O
which	O
imagined	O
that	O
was	O
menaced	O
by	O
sea	O
creatures.	O

Phenobarbital	B-Drug
is	O
used	O
in	O
cases	O
of	O
drug	O
withdrawal	O
syndromes.	O

It	O
differs	O
from	O
many	O
dissociatives	O
such	O
as	O
ketamine	B-Drug
and	O
phencyclidine	B-Drug
(PCP)	O
that	O
were	O
developed	O
pharmaceutical	O
drugs	O
for	O
use	O
general	O
anesthetics	O
in	O
it	O
was	O
designed	O
grey	O
market	O
distribution.	O
PCP	B-Drug

The	O
ibogaine	B-Drug
assertion,	O
which	O
was	O
completely	O
unfounded,	O
did	O
significant	O
damage	O
to	O
Muskie's	O
reputation,	O
and	O
cited	O
as	O
a	O
factor	O
in	O
his	O
loss	O
of	O
the	O
nomination	O
George	O
McGovern.	O

For	O
over	O
a	O
thousand	O
years	O
South	O
American	O
indigenous	O
peoples	O
have	O
chewed	O
the	O
leaves	O
of	O
Erythroxylon	O
coca,	O
plant	O
that	O
contains	O
vital	O
nutrients	O
as	O
well	O
numerous	O
alkaloids,	O
including	O
cocaine.	O
coca	B-Drug
cocaine	B-Drug

Compared	O
to	O
other	O
local	O
anaesthetics,	O
bupivacaine	B-Drug
is	O
markedly	O
cardiotoxic.	O

25B-NBOMe	B-Drug
(NBOMe-2C-B,	O
Cimbi-36,	O
Nova,	O
BOM	O
2-CB)	O
is	O
a	O
derivative	O
of	O
the	O
phenethylamine	B-Drug
psychedelic	O
2C-B,	O
discovered	O
in	O
2004	O
by	O
Ralf	O
Heim	O
at	O
Free	O
University	O
Berlin.	O
NBOMe-2C-B	B-Drug
2C-B	B-Drug

Chlorpromazine	B-Drug
tends	O
to	O
have	O
greater	O
effect	O
at	O
serotonin	O
receptors	O
than	O
D2	O
receptors,	O
which	O
is	O
notably	O
the	O
opposite	O
of	O
other	O
typical	O
antipsychotics.	O

Fluconazole	B-Drug
is	O
on	O
the	O
World	O
Health	O
Organization's	O
List	O
of	O
Essential	O
Medicines.	O

The	O
project	O
studied	O
the	O
effects	O
on	O
patients	O
of	O
psychoactive	O
drugs,	O
particularly	O
LSD,	O
psilocybin,	O
mescaline,	O
cocaine,	O
AMT,	O
and	O
DMT.	O
LSD	B-Drug
mescaline	B-Drug
AMT	B-Drug

When	O
questioned	O
about	O
the	O
essence	O
of	O
cocaine	B-Drug
business,	O
Escobar	O
replied	O
with	O
"[the	O
business	O
is]	O
simple:	O
you	O
bribe	O
someone	O
here,	O
there,	O
and	O
pay	O
a	O
friendly	O
banker	O
to	O
help	O
bring	O
money	O
back."	O

As	O
with	O
other	O
opioids,	O
the	O
most	O
common	O
side	O
effects	O
of	O
oliceridine	B-Drug
are	O
nausea,	O
vomiting,	O
dizziness,	O
headache	O
and	O
constipation.	O

Desogestrel	B-Drug
can	O
also	O
cause	O
changes	O
in	O
total,	O
LDL,	O
and	O
HDL	O
cholesterol.	O

Buprenorphine	B-Drug
is	O
a	O
semisynthetic	O
analogue	O
of	O
thebaine,	O
and	O
fairly	O
soluble	O
in	O
water,	O
as	O
its	O
hydrochloride	O
salt.	O

The	O
first	O
objective,	O
placebo-controlled	O
evidence	O
of	O
ibogaine's	O
ability	O
to	O
attenuate	O
opioid	O
withdrawal	O
in	O
rats	O
was	O
published	O
by	O
Dzoljic	O
et	O
al.	O
ibogaine	B-Drug

As	O
an	O
analog	O
of	O
fentanyl,	O
acetylfentanyl	O
is	O
a	O
Schedule	O
I	O
controlled	O
drug.	O
fentanyl	B-Drug

Because	O
of	O
the	O
latter,	O
flunitrazepam	B-Drug
is	O
commonly	O
used	O
in	O
suicide.	O

In	O
general	O
there	O
are	O
far	O
lower	O
risks	O
of	O
pulmonary	O
complications	O
for	O
regular	O
cannabis	O
smokers	O
when	O
compared	O
with	O
those	O
tobacco.	O
tobacco	B-Drug

The	O
most	O
important	O
urinary	O
metabolite	O
is	O
conjugated	O
morphine,	O
which	O
may	O
be	O
detectable	O
for	O
days	O
or	O
weeks	O
after	O
the	O
last	O
dose.	O
morphine	B-Drug

Since	O
nordazepam	B-Drug
and	O
other	O
benzodiazepines	O
are	O
excreted	O
in	O
breast	O
milk,	O
the	O
substance	O
should	O
not	O
be	O
administered	O
to	O
mothers	O
who	O
breastfeeding.	O

When	O
smoked,	O
cocaine	B-Drug
is	O
sometimes	O
combined	O
with	O
other	O
drugs,	O
such	O
as	O
cannabis,	O
often	O
rolled	O
into	O
a	O
joint	O
or	O
blunt.	O

Upon	O
intramuscular	O
injection	O
in	O
oil,	O
which	O
results	O
the	O
formation	O
of	O
a	O
long-lasting	O
depot	O
muscle,	O
nandrolone	B-Drug
decanoate	I-Drug
is	O
stored	O
unchanged	O
and	O
slowly	O
absorbed	O
into	O
body.	O

The	O
most	O
common	O
salt	O
of	O
MDMA	B-Drug
is	O
the	O
hydrochloride	O
salt;	O
pure	O
water-soluble	O
and	O
appears	O
as	O
a	O
white	O
or	O
off-white	O
powder	O
crystal.	O

Because	O
of	O
its	O
relatively	O
long	O
duration	O
action,	O
and	O
evidence	O
safety	O
efficacy,	O
diazepam	B-Drug
is	O
preferred	O
over	O
other	O
benzodiazepines	O
for	O
treatment	O
persons	O
experiencing	O
moderate	O
to	O
severe	O
alcohol	O
withdrawal.	O

Because	O
mesterolone	B-Drug
is	O
not	O
17-alkylated,	O
it	O
has	O
little	O
or	O
no	O
potential	O
for	O
hepatotoxicity.	O

The	O
alpha1	O
antagonist	O
prazosin	B-Drug
could	O
be	O
effective	O
for	O
PTSD	O

In	O
June	O
2012,	O
two	O
teens	O
in	O
Grand	O
Forks,	O
North	O
Dakota	O
and	O
East	O
Minnesota	O
fatally	O
overdosed	O
on	O
a	O
substance	O
that	O
was	O
allegedly	O
25I-NBOMe,	O
resulting	O
lengthy	O
sentences	O
for	O
of	O
the	O
parties	O
involved	O
Federal	O
indictment	O
against	O
Texas-based	O
online	O
vendor.	O
25I-NBOMe	B-Drug

Patients	O
are	O
then	O
able	O
to	O
trust	O
themselves	O
and	O
their	O
therapist	O
engage	O
with	O
traumatic	O
memories	O
under	O
the	O
influence	O
of	O
MDMA.	O
MDMA	B-Drug

While	O
the	O
price	O
of	O
cocaine	B-Drug
is	O
higher	O
in	O
Chile	O
than	O
Peru	O
and	O
Bolivia,	O
final	O
destination	O
usually	O
Europe,	O
especially	O
Spain	O
where	O
drug	O
dealing	O
networks	O
exist	O
among	O
South	O
American	O
immigrants.	O

Depression	O
from	O
methamphetamine	B-Drug
withdrawal	O
lasts	O
longer	O
and	O
is	O
more	O
severe	O
than	O
that	O
of	O
cocaine	O
withdrawal.	O

"	O
With	O
respect	O
to	O
mirtazapine,	O
it	O
found:	O
"There	O
is	O
no	O
difference	O
between	O
mirtazapine	B-Drug
and	O
other	O
antidepressants	O
on	O
any	O
efficacy	O
measure,	O
although	O
in	O
terms	O
of	O
achieving	O
remission	O
appears	O
have	O
a	O
statistical	O
though	O
not	O
clinical	O
advantage.	O

Buprenorphine	B-Drug
may	O
also	O
be	O
used	O
recreationally	O
by	O
injection	O
or	O
in	O
the	O
nose	O
for	O
high	O
it	O
produces.	O

It	O
is	O
recommended	O
that,	O
to	O
avoid	O
becoming	O
a	O
victim	O
of	O
hyoscine,	O
person	O
should	O
never	O
accept	O
food	O
or	O
beverages	O
offered	O
by	O
strangers	O
new	O
acquaintances,	O
nor	O
leave	O
unattended	O
in	O
their	O
presence.	O
hyoscine	B-Drug

After	O
a	O
single	O
dose	O
of	O
apalutamide,	O
its	O
clearance	O
rate	O
(CL/F)	O
was	O
1.3	O
L/h,	O
while	O
increased	O
to	O
2.0	O
L/h	O
at	O
steady-state.	O
apalutamide	B-Drug

Within	O
2	O
years	O
of	O
its	O
approval	O
(and	O
that	O
ritonavir	B-Drug
4	O
months	O
later)	O
annual	O
deaths	O
from	O
AIDS	O
in	O
the	O
United	O
States	O
fell	O
over	O
50,000	O
to	O
approximately	O
18,000	O
On	O
28	O
April	O
1995	O
Hoffmann-La	O
Roche	O
sold	O
Biomedical	O
Laboratories,	O
Inc.	O

A	O
number	O
of	O
derivatives	O
PCP	B-Drug
have	O
been	O
sold	O
for	O
recreational	O
and	O
non-medical	O
use.	O

The	O
LD50	O
in	O
humans	O
is	O
30	O
g	O
which	O
led	O
to	O
the	O
requirement	O
that	O
medicine	O
include	O
an	O
equal	O
dose	O
of	O
antidote,	O
diprenorphine	O
or	O
naloxone.	O
naloxone	B-Drug

At	O
the	O
same	O
time,	O
CBD	B-Drug
levels	O
in	O
seized	O
samples	O
have	O
lowered,	O
part	O
because	O
of	O
desire	O
to	O
produce	O
higher	O
THC	B-Drug
and	O
more	O
illegal	O
growers	O
cultivate	O
indoors	O
using	O
artificial	O
lights.	O

A	O
number	O
of	O
derivatives	O
18-MC	B-Drug
have	O
been	O
developed,	O
with	O
several	O
them	O
being	O
superior	O
to	O
itself,	O
the	O
methoxyethyl	O
congener	O
ME-18-MC	O
more	O
potent	O
than	O
similar	O
efficacy,	O
and	O
methylamino	O
analogue	O
18-MAC	O
effective	O
around	O
same	O
potency.	O

Methyldihydromorphine	B-Drug
is	O
a	O
semi-synthetic	O
opioid	O
originally	O
developed	O
in	O
Germany	O
1936,	O
controlled	O
under	O
both	O
domestic	O
law	O
and	O
UN	O
conventions	O
because	O
of	O
its	O
possible	O
potential	O
for	O
abuse.	O

The	O
FDA	O
states	O
that	O
individuals	O
who	O
have	O
experienced	O
hypersensitivity	O
reactions	O
to	O
other	O
stimulants	O
in	O
the	O
past	O
or	O
are	O
currently	O
taking	O
monoamine	O
oxidase	O
inhibitors	O
should	O
not	O
take	O
methamphetamine.	O
methamphetamine	B-Drug

Jean-Michel	O
Basquiat,	O
though	O
some	O
sources	O
list	O
his	O
death	O
as	O
heroin	B-Drug
overdose	O
only.	O

Amiloride	B-Drug
was	O
approved	O
by	O
the	O
U.S.	O
Food	O
and	O
Drug	O
Administration	O
(FDA)	O
on	O
October	O
5,	O
1981.	O

Among	O
other	O
achievements,	O
Szra	O
and	O
his	O
colleagues	O
characterized	O
the	O
biochemistry	O
of	O
first	O
three	O
psychedelic	O
cogeners	O
tryptamine:	O
dimethyl-,	O
diethyl-,	O
dipropyl-tryptamine	O
(DMT,	O
DET,	O
DPT),	O
describing	O
their	O
pharmacokinetics	O
effects.	O
DPT	B-Drug

In	O
the	O
US,	O
fentanyl	B-Drug
and	O
analogs	O
caused	O
over	O
29,000	O
deaths	O
in	O
2017,	O
a	O
large	O
increase	O
previous	O
four	O
years.	O

Racemic	O
methamphetamine	B-Drug
may	O
be	O
prepared	O
starting	O
from	O
phenylacetone	O
by	O
either	O
the	O
Leuckart	O
or	O
reductive	O
amination	O
methods.	O

Notably,	O
amphetamine	B-Drug
and	O
trace	O
amines	O
possess	O
high	O
binding	O
affinities	O
for	O
TAAR1,	O
but	O
not	O
monoamine	O
autoreceptors.	O

While	O
O-acetylpsilocin	B-Drug
is	O
not	O
well	O
researched	O
(sometimes	O
viewed	O
negatively	O
as	O
a	O
research	O
chemical,	O
opposed	O
to	O
psilocin	B-Drug
and	O
psilocybin),	O
it	O
difficult	O
psilocybin	O
synthesize.	O

Anthropologist	O
Michael	O
Agar	O
once	O
described	O
heroin	B-Drug
as	O
"the	O
perfect	O
whatever	O
drug."	O

Transdermal	O
fentanyl	B-Drug
has	O
also	O
been	O
used	O
for	O
many	O
years	O
in	O
dogs	O
and	O
cats	O
post-operative	O
analgesia.	O

Methamphetamine	B-Drug
in	O
soils	O
has	O
shown	O
to	O
be	O
a	O
persistent	O
pollutant.	O

Continual	O
daily	O
doses	O
of	O
diazepam	B-Drug
quickly	O
build	O
to	O
a	O
high	O
concentration	O
in	O
the	O
body	O
(mainly	O
adipose	O
tissue),	O
far	O
excess	O
actual	O
dose	O
for	O
any	O
given	O
day.	O

Cocaine	B-Drug
is	O
addictive	O
due	O
to	O
its	O
effect	O
on	O
the	O
reward	O
pathway	O
in	O
brain.	O

In	O
addition,	O
due	O
to	O
its	O
5-reduced	O
nature,	O
stanozolol	B-Drug
is	O
non-aromatizable,	O
and	O
hence	O
has	O
no	O
propensity	O
for	O
producing	O
estrogenic	O
effects	O
such	O
as	O
gynecomastia	O
or	O
fluid	O
retention.	O

In	O
the	O
case	O
of	O
diamorphine,	O
this	O
includes	O
promoting	O
safer	O
means	O
taking	O
drug,	O
such	O
as	O
smoking,	O
nasal	O
use,	O
oral	O
or	O
rectal	O
insertion.	O
diamorphine	B-Drug

Its	O
toxin,	O
as	O
an	O
exudate	O
of	O
glands	O
within	O
the	O
skin,	O
contains	O
5-MeO-DMT	B-Drug
and	O
bufotenin.	O
bufotenin	B-Drug

Severe	O
overdose	O
resulting	O
in	O
death	O
has	O
also	O
been	O
reported	O
people	O
who	O
took	O
MDMA	B-Drug
combination	O
with	O
certain	O
monoamine	O
oxidase	O
inhibitors,	O
such	O
as	O
phenelzine	B-Drug
(Nardil),	O
tranylcypromine	B-Drug
(Parnate),	O
or	O
moclobemide	B-Drug
(Aurorix,	O
Manerix).	O
Nardil	B-Drug
Parnate	B-Drug

cocaine	B-Drug
Horrible	O
Bosses	O
(2011)	O

In	O
addition	O
to	O
actions	O
at	O
receptors,	O
Semax,	O
as	O
well	O
a	O
related	O
peptide	O
drug,	O
Selank,	O
have	O
been	O
found	O
inhibit	O
enzymes	O
involved	O
in	O
the	O
degradation	O
of	O
enkephalins	O
and	O
other	O
endogenous	O
regulatory	O
peptides	O
(IC50	O
Pharmacokinetics	O
Chemistry	O
==	O
Semax	B-Drug

During	O
the	O
early	O
1950s	O
and	O
1960s	O
National	O
Institute	O
of	O
Mental	O
Health	O
sponsored	O
study	O
psychedelic	O
drugs	O
such	O
as	O
psilocybin	O
LSD	B-Drug
to	O
alleviate	O
debilitating	O
anxiety	O
depression	O
patients	O
with	O
terminal	O
diagnoses	O
may	O
feel.	O

Pantera	O
frontman,	O
Phil	O
Anselmo,	O
turned	O
to	O
heroin	B-Drug
while	O
touring	O
during	O
the	O
1990s	O
cope	O
with	O
his	O
back	O
pain.	O

For	O
example,	O
a	O
1985	O
study	O
that	O
showed	O
harmful	O
effects	O
of	O
cocaine	B-Drug
use	O
during	O
pregnancy	O
created	O
huge	O
media	O
buzz.	O

Struggling	O
with	O
the	O
pain	O
of	O
prostatic	O
cancer	O
that	O
had	O
metastasized	O
to	O
his	O
bones,	O
man	O
was	O
now	O
declining	O
morphine	B-Drug
he	O
required	O
for	O
analgesia	O
because	O
constipation.	O

Adinazolam	B-Drug
binds	O
to	O
peripheral-type	O
benzodiazepine	O
receptors	O
that	O
interact	O
allosterically	O
with	O
GABA	O
as	O
an	O
agonist	O
produce	O
inhibitory	O
effects.	O

Drug	O
tolerance	O
may	O
also	O
develop	O
to	O
infusions	O
of	O
diazepam	B-Drug
if	O
it	O
is	O
given	O
for	O
longer	O
than	O
24	O
hours.	O

Programs	O
training	O
police	O
and	O
fire	O
personnel	O
in	O
opioid	O
overdose	O
response	O
using	O
naloxone	B-Drug
have	O
also	O
shown	O
promise	O
the	O
US,	O
effort	O
is	O
increasing	O
to	O
integrate	O
fatality	O
prevention	O
overall	O
crisis.	O

Clinical	O
trials	O
studied	O
single	O
dose	O
experimental	O
oral	O
immediate	O
release	O
nalbuphine	B-Drug
tablets	O
for	O
analgesic	O
efficacy	O
over	O
a	O
four-	O
to	O
six-hour	O
time	O
period	O
following	O
administration.	O

Many	O
cacti	O
are	O
known	O
to	O
be	O
psychoactive,	O
containing	O
phenethylamine	B-Drug
alkaloids	O
such	O
as	O
mescaline.	O
mescaline	B-Drug

As	O
of	O
2017	O
in	O
the	O
United	O
States	O
about	O
1%	O
people	O
grade	O
12	O
reported	O
using	O
PCP	B-Drug
prior	O
year	O
while	O
2.9%	O
those	O
over	O
age	O
25	O
it	O
at	O
some	O
point	O
their	O
lives.	O

Veterinary	O
researchers	O
at	O
Colorado	O
State	O
University	O
are	O
researching	O
a	O
number	O
of	O
factors	O
and	O
illnesses	O
relevant	O
to	O
both	O
humans	O
animals:	O
pharmacokinetics,	O
safety,	O
different	O
methods	O
CBD	B-Drug
dosing,	O
idiopathic	O
epilepsy,	O
osteoarthritis,	O
certain	O
types	O
cancers.	O

Nalbuphine	B-Drug
was	O
initially	O
designated	O
as	O
a	O
Schedule	O
II	O
controlled	O
substance	O
in	O
the	O
United	O
States	O
along	O
with	O
other	O
opioids	O
upon	O
introduction	O
of	O
1970	O
Controlled	O
Substances	O
Act.	O

In	O
the	O
case	O
of	O
dienogest	B-Drug
and	O
estradiol	O
valerate	O
birth	O
control	O
pill,	O
these	O
other	O
brand	O
names	O
include	O
Gianda	O
Klaira.	O

In	O
chemical	O
terms,	O
it	O
is	O
an	O
alkaloid	O
with	O
a	O
phenethylamine	B-Drug
skeleton	O
found	O
in	O
various	O
plants	O
the	O
genus	O
Ephedra	O
(family	O
Ephedraceae).	O

On	O
July	O
5,	O
2010,	O
former	O
Oakland	O
Raiders	O
quarterback	O
JaMarcus	O
Russell	O
was	O
arrested	O
at	O
his	O
home	O
in	O
Mobile,	O
Alabama,	O
for	O
possession	O
of	O
codeine	B-Drug
syrup	O
without	O
a	O
prescription.	O

Pure	O
lorazepam	B-Drug
is	O
an	O
almost	O
white	O
powder	O
that	O
nearly	O
insoluble	O
in	O
water	O
and	O
oil.	O

Treatment	O
to	O
address	O
an	O
ibuprofen	B-Drug
overdose	O
is	O
based	O
on	O
how	O
the	O
symptoms	O
present.	O

Ibuprofen	B-Drug
is	O
practically	O
insoluble	O
in	O
water,	O
but	O
very	O
soluble	O
most	O
organic	O
solvents	O
like	O
ethanol	O
(66.18	O
g/100mL	O
at	O
40	O
C	O
for	O
90%	O
EtOH),	O
methanol,	O
acetone	O
and	O
dichloromethane.	O

MDMA	B-Drug
is	O
often	O
considered	O
the	O
drug	O
of	O
choice	O
within	O
rave	O
culture	O
and	O
also	O
used	O
at	O
clubs,	O
festivals,	O
house	O
parties.	O

Ott	O
concluded	O
that	O
free	O
base	O
bufotenin	B-Drug
taken	O
intranasally	O
and	O
sublingually	O
produced	O
effects	O
similar	O
to	O
those	O
of	O
Yopo	O
without	O
the	O
toxic	O
peripheral	O
symptoms,	O
such	O
as	O
facial	O
flushing,	O
observed	O
in	O
other	O
studies	O
which	O
drug	O
was	O
administered	O
intravenously.	O

Buprenorphine	B-Drug
works	O
as	O
a	O
partial	O
opioid	O
agonist.	O

clobazam	B-Drug
(Frisium,	O
Onfi,	O
Tapclob,	O
Urbanol)	O
a	O
benzodiazepine	O
that	O
has	O
been	O
marketed	O
as	O
an	O
anxiolytic	O
since	O
1975	O
and	O
anticonvulsant	O
1984.	O

In	O
1976,	O
it	O
began	O
to	O
appear	O
mixed	O
with	O
"china	O
white"	O
heroin	B-Drug
as	O
an	O
additive.	O

In	O
2007,	O
the	O
Medicines	O
and	O
Healthcare	O
products	O
Regulatory	O
Agency	O
removed	O
licence	O
for	O
co-proxamol,	O
also	O
called	O
distalgesic.	O
co-proxamol	B-Drug

Apalutamide	B-Drug
was	O
originated	O
by	O
the	O
University	O
of	O
California	O
system	O
and	O
developed	O
primarily	O
Janssen	O
Research	O
&	O
Development,	O
a	O
division	O
Johnson	O
Johnson.	O

Consumption	O
of	O
androstendione	B-Drug
products	O
contaminated	O
with	O
traces	O
bolandione	B-Drug
may	O
also	O
result	O
in	O
testing	O
positive	O
for	O
nandrolone.	O
nandrolone	B-Drug

For	O
example,	O
in	O
an	O
MDMA	B-Drug
(ecstasy)	O
comedown,	O
if	O
the	O
user	O
experiences	O
severe,	O
persisting	O
emotional	O
distress,	O
such	O
as	O
panic	O
attacks,	O
severe	O
generalized	O
anxiety,	O
or	O
insomnia	O
following	O
session,	O
a	O
physician	O
may	O
prescribe	O
benzodiazepine	O
(specifically,	O
lorazepam)	O
and/or	O
sleep	O
aid	O
(e.g.,	O
zolpidem),	O
to	O
alleviate	O
those	O
effects.	O
ecstasy	B-Drug
lorazepam	B-Drug
zolpidem	B-Drug

2	O
x	O
the	O
broncho-dilating	O
power	O
of	O
amphetamine	B-Drug
(as	O
measured	O
using	O
isolated	O
rabbit	O
lung),	O
and	O
an	O
LD50	O
50	O
mg/kg	O
(rat,	O
i.v.).	O

The	O
chemical	O
structure	O
of	O
ostarine	B-Drug
has	O
not	O
been	O
publicly	O
disclosed.	O

For	O
example,	O
the	O
equivalent	O
dose	O
of	O
diazepam	B-Drug
in	O
an	O
elderly	O
individual	O
on	O
lorazepam	B-Drug
may	O
be	O
half	O
what	O
would	O
expected	O
a	O
younger	O
individual.	O

A	O
2015	O
review	O
noted	O
that	O
stimulation	O
of	O
the	O
42	O
nicotinic	O
receptor	O
is	O
responsible	O
for	O
certain	O
improvements	O
in	O
attentional	O
performance;	O
among	O
subtypes,	O
nicotine	B-Drug
has	O
highest	O
binding	O
affinity	O
at	O
(	O

Overapplication	O
of	O
oral	O
anesthetics	O
such	O
as	O
benzocaine	B-Drug
can	O
increase	O
the	O
risk	O
pulmonary	O
aspiration	O
by	O
relaxing	O
gag-reflex	O
and	O
allowing	O
regurgitated	O
stomach	O
contents	O
or	O
secretions	O
to	O
enter	O
airway.	O

Lycette	O
told	O
the	O
hearing	O
that	O
his	O
death	O
could	O
not	O
have	O
been	O
caused	O
by	O
cannabis,	O
and	O
Lee	O
had	O
died	O
from	O
an	O
edema	O
a	O
reaction	O
to	O
one	O
or	O
both	O
of	O
ingredients	O
in	O
equagesic.	O
equagesic	B-Drug

A	O
subsequent	O
trial	O
in	O
Europe	O
failed	O
to	O
show	O
a	O
risk	O
infants	O
of	O
mothers	O
receiving	O
ketoconazole.	O
ketoconazole	B-Drug

Many	O
of	O
the	O
deaths	O
from	O
using	O
cannabis,	O
other	O
than	O
car	O
accidents	O
while	O
intoxicated	O
or	O
violence	O
and	O
aggression,	O
are	O
more	O
likely	O
to	O
figure	O
in	O
longer	O
term,	O
just	O
as	O
with	O
tobacco,	O
where	O
both	O
nicotine	B-Drug
overdose	O
cannabis	O
extremely	O
rare	O
nonexistent.	O
tobacco	B-Drug

Abiraterone	O
acetate	O
is	O
used	O
in	O
combination	O
with	O
prednisone,	O
a	O
corticosteroid,	O
as	O
treatment	O
for	O
mCRPC	O
(previously	O
called	O
hormone-resistant	O
or	O
hormone-refractory	O
prostate	O
cancer).	O
prednisone	B-Drug

Allyltestosterone	O
is	O
the	O
parent	O
structure	O
of	O
two	O
marketed	O
19-nortestosterone	B-Drug
progestins,	O
allylestrenol	O
and	O
altrenogest.	O

The	O
study	O
explored	O
other	O
reasons	O
why	O
crack	O
is	O
viewed	O
as	O
more	O
addictive	O
and	O
theorized,	O
"a	O
accurate	O
interpretation	O
of	O
existing	O
evidence	O
that	O
already	O
abuse-prone	O
cocaine	B-Drug
users	O
are	O
most	O
likely	O
to	O
move	O
toward	O
a	O
efficient	O
mode	O
ingestion	O
they	O
escalate	O
their	O
use.	O

Smoking	O
is	O
associated	O
with	O
a	O
decreased	O
risk	O
of	O
Parkinson's	O
Disease;	O
however,	O
it	O
unknown	O
whether	O
this	O
due	O
to	O
people	O
healthier	O
brain	O
dopaminergic	O
reward	O
centers	O
(the	O
area	O
the	O
affected	O
by	O
Parkinson's)	O
being	O
more	O
likely	O
enjoy	O
smoking	O
and	O
thus	O
pick	O
up	O
habit,	O
nicotine	B-Drug
directly	O
acting	O
as	O
neuroprotective	O
agent,	O
or	O
other	O
compounds	O
in	O
cigarette	O
smoke	O
agents.	O

methamphetamine	B-Drug

Given	O
the	O
known	O
metabolic	O
liberation	O
(and	O
presence	O
as	O
an	O
impurity)	O
of	O
amantadine	B-Drug
in	O
related	O
compound	O
APINACA,	O
it	O
is	O
suspected	O
that	O
hydrolysis	O
amide	O
group	O
Adamantyl-THPINACA	B-Drug
may	O
also	O
release	O
amantadine.	O
APINACA	B-Drug

According	O
to	O
the	O
United	O
Nations	O
Office	O
on	O
Drugs	O
and	O
Crime	O
(UNODC),	O
"the	O
amount	O
of	O
THC	B-Drug
present	O
in	O
a	O
cannabis	O
sample	O
is	O
generally	O
used	O
as	O
measure	O
potency.	O

THC	B-Drug
is	O
the	O
principal	O
psychoactive	O
constituent	O
of	O
cannabis.	O

It	O
was	O
developed	O
in	O
the	O
early	O
1900s	O
after	O
first	O
having	O
been	O
synthesised	O
1875	O
UK	O
by	O
CR	O
Alders	O
Wright	O
organisation	O
at	O
Bayer,	O
along	O
with	O
various	O
other	O
esters	O
of	O
morphine,	O
but	O
never	O
used	O
medically,	O
instead	O
being	O
widely	O
sold	O
as	O
one	O
"designer	O
drugs"	O
for	O
around	O
five	O
years	O
following	O
introduction	O
international	O
restrictions	O
on	O
sale	O
heroin	B-Drug
1925.	O
morphine	B-Drug

A	O
2016	O
meta-analysis	O
found	O
that	O
bupropion	B-Drug
therapy	O
for	O
depression	O
is	O
superior	O
to	O
placebo.	O

According	O
to	O
DSM-V	O
criteria,	O
9%	O
of	O
those	O
who	O
are	O
exposed	O
cannabis	O
develop	O
use	O
disorder,	O
compared	O
20%	O
for	O
cocaine,	O
23%	O
alcohol	O
and	O
68%	O
nicotine.	O
cocaine	B-Drug
nicotine	B-Drug

Modafinil	B-Drug
was	O
added	O
to	O
the	O
World	O
Anti-Doping	O
Agency	O
"Prohibited	O
List"	O
in	O
2004	O
as	O
a	O
prohibited	O
stimulant	O
(see	O
Legal	O
Status).	O

In	O
accordance,	O
50	O
mg/day	O
bicalutamide	B-Drug
has	O
been	O
found	O
to	O
possess	O
equivalent	O
or	O
superior	O
effectiveness	O
750	O
flutamide	O
in	O
a	O
large	O
clinical	O
trial	O
for	O
prostate	O
cancer.	O

Cocaine	B-Drug
became	O
popular	O
in	O
America	O
again	O
the	O
1960s,	O
undergoing	O
a	O
re-emergence	O
of	O
kind.	O

It	O
takes	O
15	O
to	O
60	O
minutes	O
for	O
the	O
effects	O
of	O
PCP	B-Drug
manifest.	O

As	O
the	O
sodium	O
salt	O
of	O
prasterone	B-Drug
sulfate	O
(brand	O
names	O
Astenile,	O
Mylis,	O
Teloin),	O
an	O
ester	O
prodrug	O
prasterone,	O
is	O
used	O
in	O
Japan	O
as	O
injection	O
for	O
treatment	O
insufficient	O
cervical	O
ripening	O
and	O
dilation	O
during	O
childbirth.	O

it	O
enables	O
the	O
body	O
to	O
convert	O
higher	O
amounts	O
of	O
codeine	B-Drug
morphine.	O
morphine	B-Drug

Propranolol	B-Drug
was	O
patented	O
in	O
1962	O
and	O
approved	O
for	O
medical	O
use	O
1964.	O

The	O
QPC	O
said	O
the	O
system	O
had	O
also	O
fuelled	O
an	O
illegal	O
market,	O
particularly	O
for	O
methamphetamine.	O
methamphetamine	B-Drug

Internationally,	O
chlordiazepoxide	B-Drug
is	O
a	O
Schedule	O
IV	O
controlled	O
drug	O
under	O
the	O
Convention	O
on	O
Psychotropic	O
Substances.	O

The	O
"Classical"	O
psychedelics,	O
the	O
psychedelics	O
with	O
largest	O
scientific	O
and	O
cultural	O
influence,	O
are	O
mescaline,	O
LSD,	O
psilocybin,	O
DMT.	O
mescaline	B-Drug
LSD	B-Drug

In	O
November	O
2009,	O
the	O
tabloid	O
newspaper,	O
The	O
Sun	O
published	O
a	O
story	O
stating	O
that	O
man	O
had	O
ripped	O
off	O
his	O
own	O
scrotum	O
whilst	O
using	O
mephedrone.	O
mephedrone	B-Drug

Ephedrine	B-Drug
is	O
the	O
precursor	O
of	O
synthetic	O
amphetamines.	O

The	O
acute	O
effect	O
of	O
amphetamine	B-Drug
use	O
manifests	O
itself	O
in	O
euphoria,	O
intensification	O
the	O
train	O
thought,	O
speech	O
and	O
motoricity	O
an	O
increase	O
initiative	O
urge	O
to	O
move.	O

PCP	B-Drug
not	O
only	O
produced	O
symptoms	O
similar	O
to	O
schizophrenia,	O
it	O
also	O
yielded	O
electroencephalogram	O
changes	O
in	O
the	O
thalamocortical	O
pathway	O
(increased	O
delta	O
decreased	O
alpha)	O
and	O
hippocampus	O
(increase	O
theta	O
bursts)	O
that	O
were	O
those	O
schizophrenia.	O

However,	O
the	O
use	O
of	O
stimulants	O
such	O
as	O
methylphenidate	B-Drug
in	O
cases	O
treatment-resistant	O
depression	O
is	O
controversial.	O

Doxorubicin,	O
like	O
other	O
anticancer	O
quinones,	O
was	O
used	O
for	O
chemotherapy	O
in	O
human	O
cancers	O
many	O
years.	O
Doxorubicin	B-Drug

Roche	O
markets	O
Avastin	B-Drug
worldwide,	O
and	O
also	O
Lucentis	B-Drug
in	O
the	O
US.	O

Internationally,	O
amphetamine	B-Drug
is	O
in	O
Schedule	O
II	O
of	O
the	O
Convention	O
on	O
Psychotropic	O
Substances.	O

Spironolactone	B-Drug
was	O
discovered	O
in	O
1957,	O
and	O
introduced	O
1959.	O

Nevertheless,	O
androstenedione	B-Drug
is	O
the	O
principal	O
steroid	O
produced	O
by	O
postmenopausal	O
ovary.	O

In	O
1971,	O
congressmen	O
released	O
an	O
explosive	O
report	O
on	O
the	O
growing	O
heroin	B-Drug
epidemic	O
among	O
US	O
servicemen	O
in	O
Vietnam,	O
finding	O
that	O
ten	O
to	O
fifteen	O
percent	O
were	O
addicted	O
heroin.	O
"	O

Many	O
fentanyl	B-Drug
overdoses	O
are	O
initially	O
classified	O
as	O
heroin	B-Drug
overdoses.	O

As	O
of	O
December	O
2019,	O
there	O
is	O
no	O
effective	O
pharmacotherapy	O
for	O
methamphetamine	B-Drug
addiction.	O

Combustion	O
products	O
are	O
not	O
present	O
when	O
using	O
a	O
vaporizer,	O
consuming	O
THC	B-Drug
in	O
pill	O
form,	O
or	O
cannabis	O
foods.	O

This	O
intervention	O
has	O
demonstrated	O
success	O
in	O
many	O
psychiatric	O
conditions	O
(e.g.,	O
depression)	O
and	O
substance	O
use	O
disorders	O
tobacco).	O
tobacco	B-Drug

In	O
Japan,	O
bicalutamide	B-Drug
is	O
licensed	O
at	O
a	O
dosage	O
of	O
80	O
mg/day	O
alone	O
or	O
in	O
combination	O
with	O
GnRH	O
analogue	O
for	O
prostate	O
cancer.	O

Many	O
people	O
who	O
smoke	O
cannabis	O
also	O
tobacco.	O
tobacco	B-Drug

The	O
same	O
motif	O
can	O
be	O
found	O
in	O
reboxetine	B-Drug
where	O
it	O
is	O
constrained	O
a	O
morpholine	O
ring	O
system.	O

In	O
January	O
2013,	O
an	O
18-year-old	O
in	O
Scottsdale,	O
Arizona,	O
died	O
after	O
consuming	O
25I-NBOMe	B-Drug
sold	O
as	O
LSD;	O
a	O
toxicology	O
screening	O
found	O
no	O
other	O
drugs	O
the	O
person's	O
system.	O
LSD	B-Drug

Recreationally,	O
methamphetamine	B-Drug
is	O
used	O
to	O
increase	O
sexual	O
desire,	O
lift	O
the	O
mood,	O
and	O
energy,	O
allowing	O
some	O
users	O
engage	O
in	O
activity	O
continuously	O
for	O
several	O
days	O
straight.	O

Kratom	B-Drug
is	O
scheduled	O
to	O
become	O
an	O
illegal	O
substance	O
in	O
Indonesia	O
at	O
the	O
beginning	O
of	O
2022	O
once	O
new	O
regulations	O
from	O
Indonesian	O
National	O
Narcotics	O
Agency	O
(BNN)	O
go	O
into	O
effect.	O

Inc.	O
The	O
drug	O
name	O
"Quaalude"	O
combined	O
the	O
words	O
"quiet	O
interlude"	O
and	O
shared	O
a	O
stylistic	O
reference	O
to	O
another	O
marketed	O
by	O
firm,	O
Maalox.	O
Quaalude	B-Drug

PCP	B-Drug
hydrochloride	O
can	O
be	O
insufflated	O
(snorted),	O
depending	O
upon	O
the	O
purity.	O

Ketamine	B-Drug
may	O
be	O
quantitated	O
in	O
blood	O
or	O
plasma	O
to	O
confirm	O
a	O
diagnosis	O
of	O
poisoning	O
hospitalized	O
patients,	O
provide	O
evidence	O
an	O
impaired	O
driving	O
arrest	O
assist	O
medicolegal	O
death	O
investigation.	O

Aspirin	B-Drug
is	O
used	O
in	O
the	O
case	O
of	O
Synalgos	O
DC.	O

There	O
is	O
also	O
evidence	O
that	O
this	O
type	O
of	O
treatment	O
works	O
with	O
LSD,	O
which	O
has	O
been	O
shown	O
to	O
have	O
a	O
therapeutic	O
effect	O
on	O
alcoholism.	O
LSD	B-Drug

Temazepam,	O
similar	O
to	O
other	O
benzodiazepines	O
and	O
nonbenzodiazepine	O
hypnotic	O
drugs,	O
causes	O
impairments	O
in	O
body	O
balance	O
standing	O
steadiness	O
individuals	O
who	O
wake	O
up	O
at	O
night	O
or	O
the	O
next	O
morning.	O
Temazepam	B-Drug

In	O
surveys,	O
the	O
number	O
of	O
high	O
school	O
students	O
admitting	O
to	O
trying	O
PCP	B-Drug
at	O
least	O
once	O
fell	O
from	O
13%	O
in	O
1979	O
less	O
than	O
3%	O
1990.	O

However,	O
most	O
men	O
have	O
preserved	O
sexual	O
function	O
with	O
bicalutamide	B-Drug
monotherapy.	O

However,	O
fluoxymesterone	B-Drug
is	O
nonetheless	O
proportionally	O
less	O
androgenic	O
and	O
more	O
anabolic	O
than	O
methyltestosterone	B-Drug
testosterone.	O

This	O
is	O
a	O
characteristic	O
that	O
it	O
shares	O
with	O
other	O
NMDA	O
receptor	O
antagonists,	O
including	O
ketamine,	O
PCP,	O
and	O
dizocilpine	O
(MK-801).	O
ketamine	B-Drug
PCP	B-Drug

In	O
2013,	O
researchers	O
reported	O
that	O
tramadol	B-Drug
was	O
found	O
in	O
relatively	O
high	O
concentrations	O
(1%+)	O
the	O
roots	O
of	O
African	O
pin	O
cushion	O
tree	O
(Nauclea	O
latifolia).	O

The	O
authors	O
did	O
not	O
evaluate	O
or	O
rate	O
the	O
negative	O
impact	O
of	O
ecstasy	B-Drug
on	O
cognitive	O
health	O
users	O
(e.g.	O
impaired	O
memory	O
and	O
concentration).	O

It	O
increased	O
international	O
production	O
of	O
heroin	B-Drug
at	O
lower	O
prices	O
in	O
the	O
1980s.	O

More	O
than	O
12	O
different	O
analogues	O
of	O
fentanyl,	O
all	O
unapproved	O
and	O
clandestinely	O
produced,	O
have	O
been	O
identified	O
in	O
the	O
U.S.	O
drug	O
traffic.	O
fentanyl	B-Drug

Most	O
clomifene	B-Drug
metabolism	O
occurs	O
in	O
the	O
liver,	O
where	O
it	O
undergoes	O
enterohepatic	O
recirculation.	O

If	O
an	O
overdose	O
occurs,	O
a	O
narcotic	O
antagonist,	O
such	O
as	O
naloxone,	O
may	O
be	O
given.	O
naloxone	B-Drug

Ethisterone	O
is	O
a	O
major	O
active	O
metabolite	O
of	O
danazol	B-Drug
(2,3-isoxazolethisterone),	O
and	O
thought	O
to	O
contribute	O
importantly	O
its	O
effects.	O

Naltrexone,	O
as	O
naltrexone/bupropion,	O
is	O
also	O
used	O
to	O
treat	O
obesity.	O
Naltrexone	B-Drug
naltrexone	B-Drug
bupropion	B-Drug

Amphetamine	B-Drug
is	O
classified	O
in	O
US	O
pregnancy	O
category	O
C.	O

There	O
is	O
no	O
evidence	O
that	O
the	O
effects	O
of	O
mifepristone	B-Drug
can	O
be	O
reversed,	O
although	O
some	O
anti-abortion	O
groups	O
claim	O
it	O
reversed	O
by	O
giving	O
progesterone.	O

According	O
to	O
the	O
USCDC,	O
methadone	B-Drug
was	O
involved	O
in	O
31%	O
of	O
opioid	O
related	O
deaths	O
US	O
between	O
19992010	O
and	O
40%	O
as	O
sole	O
drug	O
involved,	O
far	O
higher	O
than	O
other	O
opioids.	O

This	O
causes	O
increased	O
release	O
of	O
dopamine	O
in	O
the	O
brain	O
which	O
is	O
reason	O
for	O
euphoric	O
and	O
rewarding	O
effects	O
heroin.	O
heroin	B-Drug

Naloxone	B-Drug
also	O
reduced	O
drinking.	O

Fenfluramine	B-Drug
was	O
approved	O
for	O
medical	O
use	O
in	O
the	O
European	O
Union	O
December	O
2020.	O

Pasta	O
di	O
coca	B-Drug
Base	O
Boccia	O
Cruda	O
Oxi	O
(abbr.	O

It	O
is	O
biotransformed	O
by	O
CYP3A4	O
and	O
CYP2B6	O
isoenzymes	O
into	O
norketamine,	O
which,	O
in	O
turn,	O
converted	O
CYP2A6	O
hydroxynorketamine	O
dehydronorketamine.	O
norketamine	B-Drug

Also	O
present	O
in	O
mupirocin	B-Drug
are	O
pseudomonic	O
acid	O
B	O
with	O
an	O
additional	O
hydroxyl	O
group	O
at	O
C8,	O
C	O
a	O
double	O
bond	O
between	O
C10	O
and	O
C11,	O
instead	O
of	O
the	O
epoxide	O
PA-A,	O
D	O
C4`	O
C5`	O
9-hydroxy-nonanoic	O
portion	O
mupirocin.	O

The	O
therapeutic	O
effect	O
of	O
naloxone	B-Drug
provides	O
evidence	O
for	O
the	O
role	O
endogenous	O
opioid	O
system	O
in	O
pathogenesis	O
depersonalization."	O

Saphris	B-Drug
(asenapine)	O
asenapine	B-Drug

This	O
activity	O
may	O
be	O
associated	O
with	O
some	O
of	O
the	O
other	O
more	O
psychotic	O
features	O
PCP	B-Drug
intoxication,	O
which	O
is	O
evidenced	O
by	O
successful	O
use	O
D2	O
receptor	O
antagonists	O
(such	O
as	O
haloperidol)	O
in	O
treatment	O
psychosis.	O
haloperidol	B-Drug

In	O
fact,	O
no	O
Shire	O
manufacturing	O
facility	O
(other	O
than	O
the	O
Rexar	O
it	O
had	O
acquired)	O
produced	O
immediate-release	O
Adderall	B-Drug
at	O
any	O
time.	O

Any	O
person	O
seeking	O
or	O
obtaining	O
diamorphine	B-Drug
without	O
disclosing	O
authorization	O
30	O
days	O
before	O
another	O
prescription	O
from	O
a	O
practitioner	O
is	O
guilty	O
of	O
an	O
indictable	O
offense	O
and	O
subject	O
to	O
imprisonment	O
for	O
term	O
not	O
exceeding	O
seven	O
years.	O

1-Phenylcyclohexylamine	O
or	O
any	O
compound	O
(not	O
being	O
ketamine,	O
tiletamine	B-Drug
a	O
for	O
the	O
time	O
specified	O
in	O
paragraph	O
1(a)	O
of	O
Part	O
1	O
this	O
Schedule)	O
structurally	O
derived	O
from	O
1-phenylcyclohexylamine	O
2-amino-2-phenylcyclohexanone	O
by	O
modification	O
following	O
ways,	O
that	O
is	O
to	O
say,	O
(i)	O
substitution	O
at	O
nitrogen	O
atom	O
extent	O
alkyl,	O
alkenyl	O
hydroxyalkyl	O
groups,	O
replacement	O
amino	O
group	O
with	O
1-piperidyl,	O
1-pyrrolidyl	O
1-azepyl	O
group,	O
whether	O
not	O
containing	O
ring	O
further	O
substituted	O
one	O
more	O
alkyl	O
groups;	O
ketamine	B-Drug

Paracetamol	B-Drug
is	O
also	O
used	O
for	O
severe	O
pain,	O
such	O
as	O
cancer	O
pain	O
and	O
after	O
surgery,	O
in	O
combination	O
with	O
opioid	O
medication.	O

After	O
training	O
the	O
patient	O
to	O
respond	O
hypnosis,	O
LSD	B-Drug
would	O
be	O
administered,	O
and	O
during	O
onset	O
phase	O
of	O
drug	O
placed	O
into	O
a	O
state	O
trance.	O

In	O
August	O
2017,	O
UFC	O
Light	O
Heavyweight	O
Champion	O
Jon	O
Jones	O
tested	O
positive	O
for	O
turinabol	B-Drug
in	O
a	O
drug	O
test	O
administered	O
by	O
USADA	O
following	O
his	O
victory	O
over	O
Daniel	O
Cormier	O
at	O
214	O
the	O
month	O
prior.	O

In	O
this	O
paper	O
he	O
declared	O
coca	B-Drug
and	O
cocaine	B-Drug
(at	O
the	O
time	O
they	O
were	O
assumed	O
to	O
be	O
same)	O
as	O
being	O
useful	O
medicinally,	O
in	O
treatment	O
of	O
"a	O
furred	O
tongue	O
morning,	O
flatulence,	O
whitening	O
teeth.	O

In	O
2004,	O
the	O
University	O
of	O
Texas	O
found	O
that	O
8.3%	O
secondary	O
school	O
students	O
in	O
had	O
taken	O
codeine	B-Drug
syrup	O
to	O
get	O
high.	O

Verapamil	B-Drug
is	O
also	O
a	O
Kv	O
voltage	O
gated	O
potassium	O
channel	O
blocker.	O

Naltrexone	B-Drug
is	O
the	O
generic	O
name	O
of	O
drug	O
and	O
its	O
INN,	O
USAN,	O
BAN,	O
DCF,	O
DCIT,	O
while	O
naltrexone	B-Drug
hydrochloride	I-Drug
USP	O
BANM.	O

Due	O
to	O
the	O
growing	O
British	O
demand	O
for	O
Chinese	O
tea	O
and	O
Emperor's	O
lack	O
of	O
interest	O
in	O
commodities	O
other	O
than	O
silver,	O
traders	O
resorted	O
trade	O
opium	B-Drug
as	O
a	O
high-value	O
commodity	O
which	O
China	O
was	O
not	O
self-sufficient.	O

Some	O
users	O
of	O
cocaine	B-Drug
report	O
feelings	O
restlessness,	O
irritability,	O
and	O
anxiety.	O

Amobarbital	B-Drug
was	O
once	O
manufactured	O
in	O
the	O
US	O
by	O
Eli	O
Lilly	O
Pharmaceuticals	O
under	O
brand	O
name	O
Amytal	O
capsule	O
form.	O

Allergic	O
reactions	O
can	O
develop	O
to	O
tetrazepam	B-Drug
and	O
it	O
is	O
considered	O
be	O
a	O
potential	O
allergen.	O

The	O
Colorado	O
Harm	O
Reduction	O
Substance	O
Use	O
Disorders	O
Law	O
requires	O
that	O
the	O
cost	O
of	O
opioid	O
antagonists	O
such	O
as	O
Narcan	B-Drug
and	O
Evzio	O
be	O
covered	O
by	O
health	O
insurance.	O

0.5	O
mg	O
was	O
shown	O
to	O
be	O
superior	O
flurazepam	B-Drug
30	O
mg,	O
but	O
inferior	O
temazepam	B-Drug
in	O
some	O
studies.	O

It	O
may	O
also	O
be	O
mixed	O
with	O
cannabis	O
or	O
tobacco.	O
tobacco	B-Drug

Phenibut	B-Drug
is	O
used	O
in	O
Eastern	O
Europe	O
for	O
alcohol	O
detoxification	O
as	O
it	O
has	O
sedative	O
and	O
anxiolytic	O
effects.	O

JWH-018	B-Drug
will	O
not	O
be	O
detected	O
by	O
older	O
methods	O
employed	O
for	O
detecting	O
THC	B-Drug
and	O
other	O
cannabis	O
terpenoids.	O

Psilocin	B-Drug
binds	O
with	O
high	O
affinity	O
to	O
5-HT2A	O
receptors	O
and	O
low	O
5-HT1	O
receptors,	O
including	O
5-HT1A	O
5-HT1D;	O
effects	O
are	O
also	O
mediated	O
via	O
5-HT2C	O
receptors.	O

Although	O
very	O
rare,	O
at	O
therapeutic	O
doses	O
these	O
events	O
appear	O
to	O
occur	O
in	O
approximately	O
0.1%	O
of	O
individuals	O
within	O
the	O
first	O
several	O
weeks	O
after	O
starting	O
amphetamine	B-Drug
therapy.	O

Alphaxolone	O
and	O
alfaxolone	B-Drug
are	O
additional	O
alternative	O
spellings.	O

The	O
Expert	O
Committee's	O
evaluation	O
of	O
MDMA	B-Drug
during	O
its	O
22nd	O
meeting	O
in	O
1985	O
was	O
marked	O
by	O
pleas	O
from	O
physicians	O
to	O
allow	O
further	O
research	O
into	O
the	O
drug's	O
therapeutic	O
uses.	O

In	O
one	O
clinical	O
trial	O
with	O
patients	O
who	O
had	O
prior	O
experience	O
older	O
hypnotics	O
temazepam	B-Drug
and	O
nitrazepam,	O
most	O
preferred	O
lormetazepam	B-Drug
due	O
to	O
less	O
heavy	O
sedation,	O
amnesia,	O
residual	O
effects.	O
nitrazepam	B-Drug

para-fluorofentanyl	B-Drug
thiofentanylSynthetic	O
4-phenylpiperidine	O
opioids	O

Axelopran	O
Bevenopran	O
Methylsamidorphan	O
Naldemedine	B-Drug
Buprenorphine	B-Drug
and	O
dezocine	O
are	O
partial	O
agonists	O
of	O
the	O
MOR	O
but	O
antagonists	O
KOR.	O

Metandienone	B-Drug
is	O
used	O
for	O
physique-	O
and	O
performance-enhancing	O
purposes	O
by	O
competitive	O
athletes,	O
bodybuilders,	O
powerlifters.	O

A	O
5%	O
emulsion	O
preparation,	O
containing	O
2.5%	O
each	O
of	O
lidocaine/prilocaine,	O
is	O
marketed	O
by	O
APP	O
Pharmaceuticals	O
under	O
the	O
trade	O
name	O
EMLA	B-Drug
(an	O
abbreviation	O
for	O
eutectic	O
mixture	O
local	O
anesthetics).	O
lidocaine/prilocaine	B-Drug

The	O
2012	O
clinical	O
practice	O
guidelines	O
by	O
the	O
American	O
Association	O
for	O
Study	O
of	O
Liver	O
Diseases	O
(AASLD)	O
states	O
that	O
amiloride	B-Drug
can	O
be	O
used	O
to	O
treat	O
ascites	O
in	O
place	O
spironolactone	B-Drug
if	O
it	O
isn't	O
tolerated	O
(e.g.	O
due	O
side	O
effect	O
gynecomastia),	O
though	O
a	O
preferred	O
drug	O
cost	O
and	O
lack	O
efficacy.	O

In	O
addition	O
to	O
the	O
conversion	O
of	O
ibuprofen	B-Drug
S-enantiomer,	O
body	O
can	O
metabolize	O
several	O
other	O
compounds,	O
including	O
numerous	O
hydroxyl,	O
carboxyl	O
and	O
glucuronyl	O
metabolites.	O

PCP	B-Drug
is	O
metabolized	O
into	O
PCHP,	O
PPC	O
and	O
PCAA.	O

In	O
the	O
United	O
Kingdom,	O
diamorphine	B-Drug
is	O
available	O
by	O
prescription,	O
though	O
it	O
a	O
restricted	O
Class	O
A	O
drug.	O

On	O
more	O
degradation	O
CBN	B-Drug
is	O
formed.	O

Each	O
mL	O
contains	O
10	O
mg	O
of	O
anhydrous	O
morphine	B-Drug
(the	O
equivalent	O
100	O
powdered	O
opium),	O
other	O
opium	B-Drug
alkaloids	O
(except	O
noscapine),	O
and	O
ethanol,	O
19%.	O
noscapine	B-Drug

Gabriel	O
G.	O
Nahas,	O
in	O
a	O
Bulletin	O
on	O
Narcotics	O
report,	O
noted:	O
Some	O
psychotropic	O
substances	O
such	O
as	O
nicotine,	O
myristicin,	O
ephedrine,	O
mitraginyne,	O
salvinorin	B-Drug
A,	O
arecoline,	O
theophylline,	O
theobromine,	O
kava,	O
khat,	O
tobacco,	O
L-theanine,	O
or	O
caffeine	O
(in	O
moderate	O
amounts)	O
and	O
responsible	O
consumption,	O
alcoholic	O
drinks	O
small	O
amounts	O
limited	O
consumption)	O
do	O
not	O
produce	O
any	O
measurable	O
symptoms	O
of	O
neuropsychological	O
toxicity,	O
main	O
physical	O
damage,	O
acute	O
damage	O
dependence	O
addiction,	O
also	O
side	O
effects	O
several	O
adverse	O
effects.	O
nicotine	B-Drug
ephedrine	B-Drug
A	I-Drug
theophylline	B-Drug
tobacco	B-Drug
L-theanine	B-Drug

Hashish	B-Drug
slabs	O
are	O
often	O
marked	O
with	O
a	O
signature	O
emblem	O
indicating	O
its	O
producer,	O
such	O
as	O
an	O
abstract	O
design,	O
number,	O
or	O
imitation	O
of	O
commercial	O
logo.	O

Conflict	O
is	O
usually	O
the	O
number	O
one	O
problem	O
between	O
family	O
members	O
and	O
people	O
abusing	O
heroin,	O
fighting	O
becomes	O
an	O
everyday	O
routine.	O
heroin	B-Drug

JWH-018	B-Drug
will	O
not	O
be	O
detected	O
by	O
older	O
methods	O
employed	O
for	O
detecting	O
THC	B-Drug
and	O
other	O
cannabis	O
terpenoids.	O

Litigation	O
over	O
the	O
same	O
issues	O
related	O
to	O
metoclopramide	B-Drug
also	O
reached	O
US	O
Supreme	O
Court	O
in	O
PLIVA,	O

These	O
effects	O
were	O
not	O
noted	O
in	O
its	O
medicinal	O
use	O
the	O
1950s	O
and	O
1960s	O
however,	O
reports	O
of	O
physical	O
violence	O
on	O
PCP	B-Drug
have	O
often	O
been	O
shown	O
to	O
be	O
unfounded.	O

Along	O
with	O
testosterone	B-Drug
enanthate,	O
cypionate,	O
and	O
propionate,	O
undecanoate	O
is	O
one	O
of	O
the	O
most	O
widely	O
used	O
esters.	O
propionate	I-Drug

25I-NBOMe	B-Drug
is	O
usually	O
synthesised	O
from	O
2C-I	O
and	O
2-methoxybenzaldehyde,	O
via	O
reductive	O
alkylation.	O

However,	O
the	O
British	O
government	O
is	O
again	O
moving	O
towards	O
a	O
consideration	O
of	O
heroin	B-Drug
prescription	O
as	O
legitimate	O
component	O
National	O
Health	O
Service	O
(NHS).	O

In	O
case	O
of	O
serious	O
medical	O
reasons,	O
nordazepam	B-Drug
can	O
be	O
given	O
in	O
late	O
pregnancy,	O
but	O
the	O
foetus,	O
due	O
to	O
pharmacological	O
action	O
drug,	O
may	O
experience	O
side	O
effects	O
such	O
as	O
hypothermia,	O
hypotonia,	O
and	O
sometimes	O
mild	O
respiratory	O
depression.	O

In	O
2020,	O
oxycodone	B-Drug
possession	O
was	O
decriminalized	O
in	O
the	O
U.S.	O
state	O
of	O
Oregon.	O

Because	O
it	O
is	O
an	O
antiandrogen,	O
however,	O
spironolactone	B-Drug
could	O
theoretically	O
have	O
the	O
potential	O
to	O
cause	O
feminization	O
of	O
male	O
fetuses	O
at	O
sufficient	O
doses.	O

Via	O
CB1	O
receptor	O
activation,	O
THC	B-Drug
indirectly	O
increases	O
dopamine	O
release	O
and	O
produces	O
psychotropic	O
effects.	O

Remifentanil	B-Drug
can	O
be	O
administered	O
as	O
part	O
of	O
an	O
anesthesia	O
technique	O
called	O
TIVA	O
(Total	O
Intravenous	O
Anesthesia)	O
using	O
computer	O
controlled	O
infusion	O
pumps	O
in	O
a	O
process	O
target	O
(TCI).	O

Epidiolex	B-Drug
documentation	O
lists	O
sleepiness,	O
insomnia	O
and	O
poor	O
quality	O
sleep,	O
decreased	O
appetite,	O
diarrhea,	O
fatigue.	O

During	O
the	O
Islamic	O
Golden	O
Age,	O
use	O
of	O
opium	B-Drug
was	O
discussed	O
in	O
detail	O
by	O
Avicenna	O
(c.980	O
June	O
1037	O
AD)	O
The	O
Canon	O
Medicine.	O

This	O
was	O
easily	O
accomplished	O
because	O
Flix	O
Gallardo	O
had	O
already	O
established	O
a	O
marijuana	O
trafficking	O
infrastructure	O
that	O
stood	O
ready	O
to	O
serve	O
the	O
Colombia-based	O
cocaine	B-Drug
traffickers.	O

Paracetamol	B-Drug
is	O
used	O
for	O
the	O
relief	O
of	O
mild	O
to	O
moderate	O
pain.	O

The	O
"digital	O
revolution"	O
was	O
indeed	O
heralded	O
early	O
on	O
as	O
the	O
"New	O
LSD"	O
by	O
none	O
other	O
than	O
Timothy	O
Leary.	O
LSD	B-Drug

Both	O
received	O
approval	O
for	O
sale	O
in	O
the	O
US	O
1985,	O
under	O
brand	O
names	O
Marinol	O
and	O
Cesamet.	O
Cesamet	B-Drug

Lorazepam	B-Drug
(7-chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one)	O
Lormetazepam	B-Drug
(7-chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-1-methyl-2H-1,4-benzodiazepin-2-one)	O

A	O
number	O
of	O
other	O
medications	O
may	O
be	O
used	O
if	O
these	O
are	O
not	O
effective	O
such	O
as	O
valproic	O
acid,	O
phenobarbital,	O
propofol,	O
or	O
ketamine.	O
phenobarbital	B-Drug
propofol	B-Drug
ketamine	B-Drug

Pristiq	B-Drug
(desvenlafaxine)	O
an	O
antidepressant	O
of	O
the	O
SNRI	O
class.	O
desvenlafaxine	B-Drug

Users	O
who	O
started	O
at	O
ages	O
12	O
or	O
13	O
were	O
four	O
times	O
as	O
likely	O
to	O
become	O
dependent	O
compared	O
those	O
between	O
18	O
and	O
20.However,	O
a	O
study	O
of	O
non-deviant	O
users	O
in	O
Amsterdam	O
found	O
"relative	O
absence	O
destructive	O
compulsive	O
use	O
patterns	O
over	O
ten	O
year	O
period"	O
concluded	O
that	O
cocaine	B-Drug
can	O
do	O
exercise	O
control.	O

The	O
Riksdag	O
added	O
25I-NBOMe	B-Drug
to	O
Narcotic	O
Drugs	O
Punishments	O
Act	O
under	O
Swedish	O
schedule	O

Furthermore,	O
enzalutamide	B-Drug
behaves	O
as	O
an	O
antagonist	O
of	O
the	O
W741C	O
mutant	O
AR	O
in	O
contrast	O
to	O
bicalutamide	B-Drug
which	O
a	O
pure	O
agonist	O
when	O
bound	O
mutant.	O

Therefore,	O
females	O
have	O
an	O
increased	O
biological	O
vulnerability	O
to	O
nicotine's	O
reinforcing	O
effects	O
compared	O
males	O
and	O
progesterone	O
may	O
be	O
used	O
counter	O
this	O
enhanced	O
vulnerability.	O
nicotine	B-Drug

Because	O
pruritus	O
is	O
due	O
to	O
excessive	O
serum	O
histamine	O
levels,	O
antihistamines	O
such	O
as	O
diphenhydramine	B-Drug
(Benadryl)	O
are	O
often	O
co-administered.	O

As	O
an	O
AAS,	O
stanozolol	B-Drug
is	O
agonist	O
of	O
the	O
androgen	O
receptor	O
(AR),	O
similarly	O
to	O
androgens	O
like	O
testosterone	O
and	O
DHT.	O

The	O
eszopiclone/zopiclone	O
difference	O
is	O
in	O
the	O
dosagethe	O
strongest	O
eszopiclone	B-Drug
dosage	O
contains	O
3	O
mg	O
of	O
therapeutic	O
stereoisomer,	O
whereas	O
highest	O
zopiclone	B-Drug
(10	O
mg)	O
5	O
active	O
stereoisomer.	O

Black	O
tar	O
as	O
a	O
type	O
holds	O
variable	O
admixture	O
morphine	B-Drug
derivativespredominantly	O
6-MAM	O
(6-monoacetylmorphine),	O
which	O
is	O
another	O
result	O
of	O
crude	O
acetylation.	O
6-monoacetylmorphine	B-Drug

However,	O
a	O
decision	O
by	O
an	O
American	O
representative	O
in	O
the	O
World	O
Health	O
Assembly	O
banned	O
publication	O
of	O
study,	O
because	O
it	O
seemed	O
to	O
make	O
case	O
for	O
positive	O
uses	O
cocaine.	O
cocaine	B-Drug

Alfaxalone	B-Drug
has	O
some	O
depressive	O
effects	O
on	O
the	O
central	O
nervous	O
system,	O
including	O
a	O
reduction	O
in	O
cerebral	O
blood	O
flow,	O
intracranial	O
pressure,	O
and	O
body	O
temperature.	O

Poppy	O
straw	O
is	O
then	O
processed	O
in	O
a	O
manner	O
similar	O
to	O
opium	B-Drug
extract	O
opiates	O
and	O
other	O
alkaloids	O
(see	O
Morphine).	O
Morphine	B-Drug

Low	O
doses	O
of	O
amitriptyline	B-Drug
moderately	O
improve	O
sleep	O
disturbances	O
and	O
reduce	O
pain	O
fatigue	O
associated	O
with	O
fibromyalgia.	O

These	O
results	O
indicate	O
that	O
when	O
administered	O
safely	O
in	O
a	O
methodologically	O
rigorous	O
medically	O
supervised	O
psychotherapeutic	O
setting,	O
LSD	B-Drug
can	O
reduce	O
anxiety,	O
the	O
study	O
concludes,	O
suggesting	O
larger	O
controlled	O
studies	O
are	O
warranted.	O

Alberto	O
Fujimori,	O
president	O
of	O
Peru	O
from	O
1990	O
to	O
2000,	O
described	O
U.S.	O
foreign	O
drug	O
policy	O
as	O
"failed"	O
on	O
grounds	O
that	O
for	O
10	O
years,	O
there	O
has	O
been	O
a	O
considerable	O
sum	O
invested	O
by	O
the	O
Peruvian	O
government	O
and	O
another	O
part	O
American	O
government,	O
this	O
not	O
led	O
reduction	O
in	O
supply	O
coca	B-Drug
leaf	O
offered	O
sale.	O

It	O
is	O
the	O
species	O
of	O
plant	O
from	O
which	O
both	O
opium	B-Drug
and	O
poppy	O
seeds	O
are	O
derived	O
also	O
a	O
valuable	O
ornamental	O
plant,	O
grown	O
in	O
gardens.	O

In	O
theory,	O
diprenorphine	O
could	O
also	O
be	O
used	O
as	O
an	O
antidote	O
for	O
treating	O
overdose	O
of	O
certain	O
opioid	O
derivatives	O
which	O
are	O
in	O
humans,	O
particularly	O
buprenorphine	B-Drug
the	O
binding	O
affinity	O
is	O
so	O
high	O
that	O
naloxone	B-Drug
does	O
not	O
reliably	O
reverse	O
narcotic	O
effects.	O

Amines	O
are	O
a	O
broad	O
class	O
of	O
compounds,	O
and	O
more	O
complex	O
members	O
the	O
can	O
be	O
extremely	O
bioactive,	O
for	O
example	O
strychnine	O
heroin.	O
heroin	B-Drug

Oxandrolone	B-Drug
greatly	O
increases	O
warfarin's	O
blood-thinning	O
effect,	O
sometimes	O
dangerously	O
so.	O
warfarin	B-Drug

Levomethorphan	B-Drug
is	O
listed	O
under	O
the	O
Single	O
Convention	O
on	O
Narcotic	O
Drugs	O
1961	O
and	O
regulated	O
like	O
morphine	B-Drug
in	O
most	O
countries.	O

Etomidate	B-Drug
has	O
minimal	O
cardiovascular	O
side	O
effects,	O
reduces	O
intracerebral	O
pressure	O
(by	O
reducing	O
cerebral	O
blood	O
flow),	O
and	O
does	O
not	O
cause	O
histamine	O
release.	O

Morphine	B-Drug
produces	O
a	O
dose-dependent	O
depressive	O
effect	O
on	O
the	O
respiratory	O
system,	O
which	O
can	O
lead	O
to	O
profound	O
depression,	O
hypoxia,	O
coma	O
and	O
finally	O
arrest	O
death.	O

PCP	B-Drug
has	O
been	O
shown	O
to	O
produce	O
conditioned	O
place	O
aversion	O
and	O
preference	O
in	O
animal	O
studies.	O

Oxandrolone	B-Drug
has	O
also	O
been	O
sold	O
under	O
the	O
brand	O
names	O
Antitriol	O
(Spain),	O
Anatrophill	O
(France),	O
Lipidex	O
(Brazil),	O
Lonavar	O
(Argentina,	O
Australia,	O
Italy),	O
Protivar,	O
and	O
Vasorome	O
(Japan),	O
among	O
others.	O

heroin	B-Drug
Shot	O
List	O
(2009)	O

Typical	O
antipsychotics	O
such	O
as	O
phenothiazines	O
and	O
haloperidol	B-Drug
have	O
been	O
used	O
to	O
control	O
psychotic	O
symptoms,	O
but	O
may	O
produce	O
many	O
undesirable	O
side	O
effects	O
dystonia	O
their	O
use	O

The	O
therapeutic	O
pharmacological	O
properties	O
of	O
zopiclone	B-Drug
include	O
hypnotic,	O
anxiolytic,	O
anticonvulsant,	O
and	O
myorelaxant	O
properties.	O

Opium	O
contains	O
a	O
class	O
of	O
naturally	O
occurring	O
alkaloids	O
known	O
as	O
opiates,	O
that	O
include	O
morphine,	O
codeine,	O
thebaine,	O
oripavine,	O
papaverine	B-Drug
and	O
noscapine.	O
morphine	B-Drug
codeine	B-Drug
noscapine	B-Drug

In	O
2016,	O
the	O
street	O
price	O
of	O
oxymorphone	B-Drug
was	O
reported	O
to	O
be	O

One	O
study	O
of	O
British	O
heroin	B-Drug
addicts	O
found	O
a	O
12-fold	O
excess	O
mortality	O
ratio	O
(1.8	O
percent	O
the	O
group	O
dying	O
per	O
year).	O

Adamantyl-THPINACA	B-Drug
(ATHPINACA,	O
AD-THPINACA)	O
is	O
an	O
indazole-based	O
synthetic	O
cannabinoid,	O
which	O
was	O
first	O
reported	O
to	O
Europol	O
in	O
Slovenia	O
January	O
2015.	O

The	O
Cochrane	O
reviews	O
on	O
the	O
treatment	O
of	O
ADHD	O
in	O
children,	O
adolescents,	O
and	O
adults	O
with	O
pharmaceutical	O
amphetamines	B-Drug
stated	O
that	O
short-term	O
studies	O
have	O
demonstrated	O
these	O
drugs	O
decrease	O
severity	O
symptoms,	O
but	O
they	O
higher	O
discontinuation	O
rates	O
than	O
non-stimulant	O
medications	O
due	O
to	O
their	O
adverse	O
side	O
effects.	O

When	O
used	O
at	O
anesthetic	O
doses,	O
ketamine	B-Drug
usually	O
stimulates	O
rather	O
than	O
depresses	O
the	O
circulatory	O
system.	O

Internationally,	O
DOET	B-Drug
is	O
a	O
Schedule	O

Triazolam	B-Drug
should	O
not	O
be	O
administered	O
to	O
patients	O
on	O
Atripla.	O
Atripla	B-Drug

Paracetamol	B-Drug
was	O
first	O
marketed	O
in	O
the	O
United	O
States	O
1950	O
under	O
name	O
Triagesic,	O
a	O
combination	O
of	O
paracetamol,	O
aspirin,	O
and	O
caffeine.	O
paracetamol	B-Drug
aspirin	B-Drug

Phencyclidine	B-Drug
is	O
an	O
NMDA	O
receptor	O
antagonist	O
that	O
blocks	O
the	O
activity	O
of	O
to	O
cause	O
anaesthesia	O
and	O
analgesia	O
without	O
causing	O
cardiorespiratory	O
depression.	O

A	O
common	O
example	O
of	O
an	O
irreversible	O
inhibitor	O
that	O
is	O
used	O
as	O
a	O
drug	O
aspirin,	O
which	O
inhibits	O
the	O
COX-1	O
and	O
COX-2	O
enzymes	O
produce	O
inflammation	O
messenger	O
prostaglandin.	O
aspirin	B-Drug

Shulgin	O
reports	O
that	O
MMDA-2	B-Drug
produces	O
effects	O
such	O
as	O
enhanced	O
awareness,	O
empathy,	O
and	O
visual	O
facilitation	O
distortion,	O
well	O
some	O
side	O
like	O
gastrointestinal	O
upset	O
appetite	O
loss.	O

The	O
androgen	O
synthesis	O
inhibitors	O
aminoglutethimide	O
and	O
ketoconazole	B-Drug
were	O
first	O
marketed	O
in	O
1960	O
1977,	O
respectively,	O
the	O
newer	O
drug	O
abiraterone	O
acetate	O
was	O
introduced	O
2011.	O

Cocaine's	O
binding	O
properties	O
are	O
such	O
that	O
it	O
attaches	O
so	O
this	O
hydrogen	O
bond	O
will	O
not	O
form	O
and	O
is	O
blocked	O
from	O
formation	O
due	O
to	O
the	O
tightly	O
locked	O
orientation	O
of	O
cocaine	B-Drug
molecule.	O
Cocaine	B-Drug

JWH-081	B-Drug

As	O
of	O
October	O
2015	O
25I-NBOMe	B-Drug
is	O
a	O
controlled	O
substance	O
in	O
China.	O

The	O
authors	O
investigated	O
the	O
relative	O
abilities	O
of	O
various	O
opioids	O
to	O
induce	O
histamine	O
release	O
mediated	O
increased	O
capillary	O
permeability	O
and	O
tissue	O
edema	O
(wheal	O
response	O
)	O
cutaneous	O
vasodilatation	O
local	O
redness	O
(flare	O
response)	O
when	O
subjects	O
were	O
intradermally	O
injected	O
with	O
0.02	O
ml	O
equimolar	O
concentrations	O
5	O
x	O
10-4	O
M.	O
Nalbuphine	B-Drug
did	O
not	O
produce	O
either	O
a	O
wheal	O
or	O
flare	O
response.	O

Cough	O
medicines	O
containing	O
dihydrocodeine	B-Drug
are	O
controlled	O
similarly	O
to	O
dextromethrophan	O
in	O
the	O
United	O
States,	O
that	O
its	O
sale	O
is	O
strictly	O
limited	O
by	O
purchase	O
quantity	O
and	O
restricted	O
persons	O
20	O
older	O
for	O
purchase.	O

Lormetazepam	B-Drug
is	O
considered	O
a	O
hypnotic	O
benzodiazepine	O
and	O
officially	O
indicated	O
for	O
moderate	O
to	O
severe	O
insomnia.	O

The	O
additional	O
carbon	O
atoms	O
required	O
for	O
the	O
synthesis	O
of	O
cocaine	B-Drug
are	O
derived	O
from	O
acetyl-CoA,	O
by	O
addition	O
two	O
acetyl-CoA	O
units	O
to	O
N-methyl-1-pyrrolinium	O
cation.	O

Meprobamate	B-Drug
is	O
available	O
in	O
200-	O
and	O
400-mg	O
tablets	O
for	O
oral	O
administration.	O

In	O
2003	O
the	O
International	O
Agency	O
for	O
Research	O
on	O
Cancer	O
(IARC),	O
a	O
World	O
Health	O
Organization	O
sponsored	O
group,	O
found	O
sufficient	O
evidence	O
that	O
habit	O
of	O
chewing	O
betel	O
quid,	O
with	O
or	O
without	O
tobacco,	O
causes	O
cancer	O
in	O
humans.	O
tobacco	B-Drug

The	O
cultivation	O
of	O
coca	B-Drug
has	O
become	O
an	O
attractive	O
economic	O
decision	O
for	O
many	O
growers	O
due	O
to	O
the	O
combination	O
several	O
factors,	O
including	O
lack	O
other	O
employment	O
alternatives,	O
lower	O
profitability	O
alternative	O
crops	O
in	O
official	O
crop	O
substitution	O
programs,	O
eradication-related	O
damages	O
non-drug	O
farms,	O
spread	O
new	O
strains	O
plant	O
persistent	O
worldwide	O
demand.	O

In	O
June	O
2020,	O
fenfluramine	B-Drug
was	O
approved	O
for	O
medical	O
use	O
in	O
the	O
United	O
States	O
with	O
an	O
indication	O
to	O
treat	O
Dravet	O
syndrome.	O

The	O
withdrawal	O
symptoms	O
of	O
cathinone	B-Drug
include,	O
hot	O
flashes,	O
lethargy	O
and	O
a	O
great	O
urge	O
to	O
use	O
the	O
drug	O
for	O
at	O
least	O
first	O
two	O
days.	O

These	O
combination	O
products	O
also	O
include	O
paracetamol	B-Drug
(acetaminophen)	O
and	O
caffeine.	O
acetaminophen	B-Drug

Salvinorin	B-Drug
A	I-Drug
is	O
the	O
first	O
documented	O
diterpene	O
hallucinogen.	O

Etizolam	B-Drug
therefore	O
has	O
a	O
reduced	O
liability	O
to	O
induce	O
tolerance,	O
and	O
dependence,	O
compared	O
with	O
classic	O
benzodiazepines.	O

Common	O
amphetamines	O
include	O
methamphetamine,	O
ephedrine,	O
MDMA,	O
as	O
well	O
substituted	O
cathinones	O
like	O
methcathinone,	O
MDPV,	O
and	O
mephedrone,	O
though	O
a	O
large	O
number	O
of	O
other	O
related	O
compounds	O
have	O
been	O
recently	O
synthesized.	O
methamphetamine	B-Drug
ephedrine	B-Drug
MDMA	B-Drug
methcathinone	B-Drug
MDPV	B-Drug
mephedrone	B-Drug

Psychological	O
dependence	O
is	O
more	O
common	O
in	O
those	O
who	O
abuse	O
carisoprodol	B-Drug
and	O
have	O
a	O
history	O
of	O
drug	O
(particularly	O
sedatives	O
or	O
alcohol).	O

Common	O
side	O
effects	O
of	O
nordazepam	B-Drug
include	O
somnolence,	O
which	O
is	O
more	O
common	O
in	O
elderly	O
patients	O
and/or	O
people	O
on	O
high-dose	O
regimens.	O

In	O
emergency	O
medicine,	O
safe	O
administration	O
of	O
intranasal	O
fentanyl	B-Drug
with	O
a	O
low	O
rate	O
side	O
effects	O
and	O
promising	O
pain	O
reducing	O
effect	O
was	O
demonstrated	O
in	O
prospective	O
observational	O
study	O
about	O
900	O
out-of-hospital	O
patients.	O

It	O
has	O
structural	O
and	O
pharmacodynamic	O
properties	O
similar	O
to	O
the	O
drugs	O
5-MeO-DiPT,	O
DiPT,	O
MiPT.	O
5-MeO-DiPT	B-Drug
DiPT	B-Drug
MiPT	B-Drug

PPD)	O
Antivenom	O
immunoglobulin	O
Diphtheria	O
antitoxin	O
Recommendations	O
for	O
all	O
BCG	B-Drug
vaccine	I-Drug
Haemophilus	O
influenzae	O
type	O
b	O

The	O
comic	O
features	O
31	O
underground	O
artists	O
contributing	O
mostly	O
one-pagers	O
about	O
drug	O
experiences	O
(primarily	O
LSD).	O
LSD	B-Drug

Analogues	O
of	O
PCP	B-Drug
exhibit	O
varying	O
potency	O
at	O
nACh	O
receptors	O
and	O
NMDA	O
receptors.	O

The	O
two	O
most	O
common	O
forms	O
of	O
narcotic	O
drugs	O
are	O
morphine	B-Drug
and	O
codeine.	O
codeine	B-Drug

The	O
latex	O
also	O
contains	O
the	O
closely	O
related	O
opiates	O
codeine	B-Drug
and	O
thebaine,	O
non-analgesic	O
alkaloids	O
such	O
as	O
papaverine	B-Drug
noscapine.	O
noscapine	B-Drug

Black	O
cocaine	B-Drug
(Spanish:	O
coca	B-Drug
negra)	O
is	O
a	O
mixture	O
of	O
regular	O
base	O
or	O
hydrochloride	O
with	O
various	O
other	O
substances.	O

dimethylamphetamine	B-Drug

The	O
sale	O
of	O
poppy	O
seeds	O
delivered	O
a	O
significant	O
proportion	O
the	O
income	O
from	O
licit	O
opium	B-Drug
crop.	O

Buspirone,	O
a	O
serotonin	O
1A	O
receptor	O
(5-HT1A)	O
agonist,	O
has	O
shown	O
limited	O
efficacy	O
for	O
treating	O
anxiety	O
in	O
people	O
with	O
cannabis	O
use	O
disorder,	O
though	O
there	O
may	O
be	O
better	O
males	O
than	O
females.	O
Buspirone	B-Drug

Walter	O
White	O
first	O
synthesizes	O
methamphetamine	B-Drug
through	O
the	O
Nagai	O
route,	O
using	O
red	O
phosphorus	O
and	O
iodine	O
to	O
reduce	O
pseudoephedrine.	O
pseudoephedrine	B-Drug

Drugs	O
that	O
acidify	O
the	O
urine,	O
such	O
as	O
ascorbic	O
acid,	O
increase	O
urinary	O
excretion	O
of	O
dextroamphetamine,	O
thus	O
decreasing	O
half-life	O
dextroamphetamine	B-Drug
in	O
body.	O

Buprenorphine	B-Drug
was	O
discovered	O
in	O
1972.The	O
first	O
fully	O
synthetic	O
opioid	O
meperidine	B-Drug
(later	O
demerol),	O
found	O
serendipitously	O
by	O
German	O
chemist	O
Otto	O
Eisleb	O
(or	O
Eislib)	O
at	O
IG	O
Farben	O
1932.	O
demerol	B-Drug

In	O
2005,	O
Celgene	O
received	O
FDA	O
approval	O
for	O
lenalidomide	B-Drug
(Revlimid)	O
as	O
the	O
first	O
commercially	O
useful	O
derivative.	O
Revlimid	B-Drug

The	O
original	O
speedball	O
used	O
cocaine	B-Drug
hydrochloride	O
mixed	O
with	O
morphine	B-Drug
sulfate,	O
as	O
opposed	O
to	O
heroin.	O
sulfate	I-Drug
heroin	B-Drug

The	O
combination	O
of	O
nabilone	B-Drug
and	O
zolpidem	B-Drug
has	O
been	O
shown	O
to	O
decrease	O
sleep-related	O
mood-related	O
symptoms	O
cannabis	O
withdrawal,	O
in	O
addition	O
decreasing	O
use.	O

Spark	O
has	O
an	O
already	O
approved	O
treatment	O
for	O
Lebers	O
congenital	O
amaurosis,	O
Luxturna	B-Drug
-	O
priced	O
at	O
US$850,000	O
per	O
patient.	O

is	O
therefore	O
no	O
longer	O
preferred;	O
phenothiazines	O
are	O
particularly	O
risky,	O
as	O
they	O
may	O
lower	O
the	O
seizure	O
threshold,	O
worsen	O
hyperthermia,	O
and	O
boost	O
anticholinergic	O
effects	O
of	O
PCP.	O
PCP	B-Drug

Diphenhydramine	B-Drug
also	O
acts	O
as	O
an	O
intracellular	O
sodium	O
channel	O
blocker,	O
which	O
is	O
responsible	O
for	O
its	O
actions	O
a	O
local	O
anesthetic.	O

When	O
political	O
pressure	O
was	O
brought	O
against	O
the	O
British	O
government's	O
involvement	O
in	O
Sino-Indian	O
opium	B-Drug
trade,	O
18931895	O
Royal	O
Commission	O
on	O
Opium	O
created	O
to	O
investigate	O
drug.	O

The	O
length	O
of	O
the	O
half	O
life	O
methadone	B-Drug
allows	O
for	O
exhibition	O
respiratory	O
depressant	O
effects	O
an	O
extended	O
duration	O
time	O
in	O
opioid-naive	O
people.	O

Studies	O
have	O
shown	O
that	O
alcohol	O
and	O
tobacco	B-Drug
may	O
additionally	O
be	O
regarded	O
as	O
gateway	O
drugs;	O
however,	O
a	O
more	O
parsimonious	O
explanation	O
could	O
cannabis	O
is	O
simply	O
readily	O
available	O
(and	O
at	O
an	O
earlier	O
age)	O
than	O
illegal	O
hard	O
drugs.	O

Lemborexant	B-Drug
was	O
approved	O
in	O
the	O
United	O
States	O
for	O
use	O
by	O
adults	O
with	O
insomnia	O
December	O
2019.	O

Carfentanil	B-Drug
is	O
classified	O
as	O
Schedule	O
II	O
under	O
the	O
Controlled	O
Substances	O
Act	O
in	O
United	O
States	O
with	O
a	O
DEA	O
ACSCN	O
of	O
9743	O
and	O
2016	O
annual	O
aggregate	O
manufacturing	O
quota	O
19	O
grams	O

5-MAPDB	B-Drug
6-MAPDB,	O
its	O
psychedelic	O
activity	O
is	O
disputed	O
6-MAPB	B-Drug
6-MAPDB	B-Drug

Mesterolone	B-Drug
cipionate	O
is	O
a	O
synthetic	O
anabolicandrogenic	O
steroid	O
and	O
an	O
androgen	O
ester	O
specifically,	O
the	O
C17	O
cypionate	O
of	O
mesterolone	B-Drug
which	O
was	O
never	O
marketed.	O

Pseudoephedrine	B-Drug
is	O
used	O
to	O
relieve	O
nasal	O
or	O
sinus	O
congestion	O
caused	O
by	O
the	O
common	O
cold,	O
sinusitis,	O
hay	O
fever	O
and	O
other	O
respiratory	O
allergies;	O
it	O
also	O
ear	O
inflammation	O
infection.	O

JWH-164	B-Drug
is	O
a	O
positional	O
isomer	O
of	O
the	O
related	O
compound	O
JWH-081,	O
but	O
with	O
methoxy	O
group	O
at	O
7-position	O
naphthyl	O
ring,	O
rather	O
than	O
JWH-081	B-Drug

Ketoconazole,	O
sold	O
under	O
the	O
brand	O
name	O
Nizoral	B-Drug
among	O
others,	O
is	O
an	O
antifungal	O
medication	O
used	O
to	O
treat	O
a	O
number	O
of	O
fungal	O
infections.	O
Ketoconazole	B-Drug

About	O
1	O
in	O
100	O
people	O
with	O
hypertension	O
have	O
elevated	O
levels	O
of	O
aldosterone;	O
these	O
people,	O
the	O
antihypertensive	O
effect	O
spironolactone	B-Drug
may	O
exceed	O
that	O
complex	O
combined	O
regimens	O
other	O
antihypertensives	O
since	O
it	O
targets	O
primary	O
cause	O
blood	O
pressure.	O

In	O
June	O
2017,	O
faced	O
with	O
the	O
public	O
health	O
crisis,	O
opioid	O
epidemic,	O
FDA	O
asked	O
Endo	O
Pharmaceuticals	O
to	O
"remove	O
its	O
pain	O
medication,	O
reformulated	O
Opana	B-Drug
ER	I-Drug
(oxymorphone	O
hydrochloride),	O
from	O
market".	O
oxymorphone	B-Drug
hydrochloride	I-Drug

Harmala	O
alkaloids	O
are	O
also	O
found	O
in	O
the	O
Banisteriopsis	O
caapi	O
vine,	O
key	O
plant	O
ingredient	O
sacramental	O
beverage	O
Ayahuasca,	O
concentrations	O
that	O
range	O
between	O
0.31	O
and	O
8.43%	O
for	O
harmine,	O
0.03-0.83%	O
harmaline	B-Drug
0.05-2.94%	O
tetrahydroharmine.	O

Starting	O
in	O
1927	O
with	O
Kurt	O
Beringer's	O
Der	O
Meskalinrausch	O
(The	O
Mescaline	B-Drug
Intoxication),	O
more	O
intensive	O
effort	O
began	O
to	O
be	O
focused	O
on	O
studies	O
of	O
psychoactive	O
plants.	O

As	O
the	O
serotonergic	O
system	O
may	O
be	O
involved	O
in	O
regulation	O
of	O
sleep,	O
mood,	O
and	O
anxiety,	O
stimulation	O
this	O
by	O
high	O
doses	O
GHB	B-Drug
certain	O
neuropharmacological	O
events	O
induced	O
administration.	O

They	O
had	O
also	O
studied	O
his	O
hospital	O
records,	O
which	O
included	O
two	O
admissions	O
for	O
drug	O
detoxification	O
and	O
methadone	B-Drug
treatments."	O

Although	O
millennia	O
older,	O
the	O
production	O
of	O
poppy	O
head	O
decoctions	O
can	O
be	O
seen	O
as	O
a	O
quick-and-dirty	O
variant	O
Kby	O
straw	O
process,	O
which	O
since	O
its	O
publication	O
in	O
1930	O
has	O
become	O
major	O
method	O
obtaining	O
licit	O
opium	B-Drug
alkaloids	O
worldwide,	O
discussed	O
Morphine.	O
Morphine	B-Drug

The	O
estrogenic	O
activity	O
of	O
norethisterone	B-Drug
at	O
high	O
doses	O
would	O
also	O
be	O
expected	O
to	O
contribute	O
its	O
antigonadotropic	O
effects.	O

Severe	O
overdose	O
resulting	O
in	O
death	O
has	O
also	O
been	O
reported	O
people	O
who	O
took	O
MDMA	B-Drug
combination	O
with	O
certain	O
monoamine	O
oxidase	O
inhibitors,	O
such	O
as	O
phenelzine	B-Drug
(Nardil),	O
tranylcypromine	B-Drug
(Parnate),	O
or	O
moclobemide	B-Drug
(Aurorix,	O
Manerix).	O
Nardil	B-Drug
Parnate	B-Drug

Individuals	O
who	O
are	O
prescribed	O
methadone	B-Drug
for	O
either	O
IV	O
or	O
IM	O
administration	O
cannot	O
drive	O
in	O
the	O
UK,	O
mainly	O
due	O
to	O
increased	O
sedation	O
effects	O
that	O
this	O
route	O
of	O
use	O
can	O
cause.	O

The	O
conversion	O
is	O
rate-limited	O
by	O
the	O
enzyme,	O
which	O
prevents	O
high	O
blood	O
concentrations	O
of	O
dextroamphetamine	B-Drug
and	O
reduces	O
lisdexamfetamine's	O
drug	O
liking	O
abuse	O
potential	O
at	O
clinical	O
doses.	O
lisdexamfetamine	B-Drug

Osilodrostat	B-Drug
was	O
investigated	O
for	O
the	O
treatment	O
of	O
hypertension,	O
heart	O
failure,	O
and	O
renal	O
disease,	O
but	O
development	O
these	O
indications	O
discontinued.	O

Quantification	O
of	O
alprazolam	B-Drug
in	O
blood	O
and	O
plasma	O
samples	O
may	O
be	O
necessary	O
to	O
confirm	O
a	O
diagnosis	O
intoxication	O
hospitalized	O
patients,	O
or	O
provide	O
evidence	O
the	O
case	O
crimes	O
e.g.,	O
impaired	O
driving	O
arrest,	O
assist	O
thorough	O
forensic	O
investigation,	O
medicolegal	O
death	O
investigation.	O

Eszopiclone	B-Drug
is	O
most	O
effective	O
if	O
it	O
not	O
taken	O
after	O
a	O
heavy	O
meal	O
with	O
high	O
fat	O
content.	O

(CP	O
55,940)	O
CP	B-Drug
55,940	I-Drug

In	O
January	O
2018,	O
Saudi	O
Arabia	O
seized	O
1.3	O
million	O
Captagon	B-Drug
pills	O
at	O
Al-Haditha	O
crossing	O
near	O
the	O
border	O
with	O
Jordan.	O

If	O
the	O
patient	O
responds	O
to	O
lorazepam	B-Drug
challenge,	O
then	O
can	O
be	O
scheduled	O
at	O
interval	O
doses	O
until	O
catatonia	O
resolves.	O

Psilocin	B-Drug
is	O
the	O
chemical	O
primarily	O
responsible	O
for	O
hallucinogenic	O
effects	O
of	O
Psilocybe.	O

Additionally,	O
apremilast	B-Drug
was	O
approved	O
by	O
the	O
FDA	O
in	O
March	O
2014.	O

In	O
a	O
clinical	O
study	O
of	O
enzalutamide	B-Drug
for	O
ER-positive	O
breast	O
cancer	O
in	O
women,	O
was	O
found	O
to	O
decrease	O
serum	O
concentrations	O
the	O
aromatase	O
inhibitors	O
anastrozole	B-Drug
and	O
exemestane	B-Drug
by	O
90%	O
50%,	O
respectively,	O
which	O
could	O
reduce	O
their	O
effectiveness.	O

Though	O
less	O
common	O
than	O
stimulant	O
psychosis,	O
stimulants	O
such	O
as	O
cocaine	B-Drug
and	O
amphetamines	O
well	O
the	O
dissociative	O
drug	O
phencyclidine	B-Drug
(PCP,	O
angel	B-Drug
dust)	O
may	O
also	O
cause	O
a	O
theorized	O
severe	O
life-threatening	O
condition	O
known	O
excited	O
delirium.	O
PCP	B-Drug
dust	I-Drug

Two	O
months	O
before,	O
the	O
FDA	O
had	O
approved	O
another	O
drug	O
for	O
HepC,	O
simeprevir.	O
simeprevir	B-Drug

In	O
August	O
2018,	O
Nebraska	O
used	O
diazepam	B-Drug
as	O
part	O
of	O
the	O
drug	O
combination	O
to	O
execute	O
Carey	O
Dean	O
Moore,	O
first	O
death	O
row	O
inmate	O
executed	O
in	O
over	O
21	O
years.	O

Cocaine	B-Drug
is	O
a	O
powerful	O
nervous	O
system	O
stimulant.	O

Fentanyl	B-Drug
produces	O
sleep	O
and	O
drowsiness,	O
as	O
dosage	O
is	O
increased,	O
can	O
produce	O
the	O
-waves	O
often	O
seen	O
in	O
natural	O
on	O
electroencephalogram.	O

Unlike	O
amphetamine,	O
propylhexedrine's	O
serotonin-releasing	O
properties	O
have	O
the	O
potential	O
to	O
cause	O
long	O
term	O
negative	O
side	O
effects	O
similar	O
MDMA	B-Drug
abuse,	O
though	O
degree	O
in	O
which	O
decreased	O
serotonergic	O
neurotransmission	O
occurs	O
as	O
a	O
result	O
of	O
recreational	O
propylhexedrine	B-Drug
usage	O
is	O
largely	O
unclear	O
relevant	O
literature.	O
amphetamine	B-Drug

tablets	O
came	O
"computer	O
acid"	O
or	O
"blotter	O
paper	O
LSD,"	O
typically	O
made	O
by	O
dipping	O
a	O
preprinted	O
sheet	O
of	O
blotting	O
into	O
an	O
LSD/water/alcohol	O
solution.	O
acid	B-Drug
LSD	B-Drug

Diazepam	B-Drug
should	O
be	O
stored	O
at	O
room	O
temperature	O
(1530	O
C).	O

Pharmacologically,	O
tramadol	B-Drug
is	O
similar	O
to	O
tapentadol	B-Drug
and	O
methadone	B-Drug
in	O
that	O
it	O
not	O
only	O
binds	O
the	O
MOR,	O
but	O
also	O
inhibits	O
reuptake	O
of	O
serotonin	O
norepinephrine	O
due	O
its	O
action	O
on	O
noradrenergic	O
serotonergic	O
systems,	O
such	O
as	O
"atypical"	O
opioid	O
activity.	O

PCP	B-Drug
hydrochloride	O
can	O
be	O
insufflated	O
(snorted),	O
depending	O
upon	O
the	O
purity.	O

Risperidone	B-Drug
undergoes	O
hepatic	O
metabolism	O
and	O
renal	O
excretion.	O

The	O
GR	O
has	O
contains	O
several	O
sites	O
for	O
phosphorylation,	O
sumoylation,	O
ubiquitination,	O
and	O
acetylation	O
that	O
primarily	O
occurs	O
after	O
intracellular	O
methylprednisolone	B-Drug
binding	O
to	O
the	O
GR.	O

JWH-018	B-Drug
has	O
an	O
EC50	O
of	O
102	O
nM	O
for	O
human	O
CB1	O
receptors,	O
and	O
133	O
CB2	O
receptors.	O

This	O
condition	O
resolved	O
after	O
discontinuing	O
valproate	B-Drug
therapy.	O

Phenytoin	B-Drug
(1938).	O

However,	O
the	O
effects	O
were	O
significantly	O
less	O
than	O
those	O
of	O
methyltestosterone.	O
methyltestosterone	B-Drug

In	O
one	O
2002	O
survey	O
of	O
53	O
women	O
who	O
used	O
Rohypnol	B-Drug
recreationally,	O
10%	O
said	O
they	O
were	O
physically	O
or	O
sexually	O
assaulted	O
while	O
under	O
its	O
influence.	O

MDMA	B-Drug
can	O
substitute	O
for	O
K+	O
in	O
this	O
transport.	O

Metoclopramide	B-Drug
also	O
treats	O
gastroparesis	O
Eticlopride	O
binds	O
D2	O
and	O
D3	O
with	O
high	O
affinity	O
but	O
D4	O
Nafadotride	O
Raclopride	O
can	O
be	O
radiolabeled	O
used	O
in	O
PET	O
imaging	O
to	O
identify	O
disease	O
progression	O
Huntington's	O
Disease	O

However,	O
as	O
of	O
June	O
2019,	O
FDA	O
continues	O
to	O
warn	O
consumers	O
not	O
use	O
Kratom	B-Drug
and,	O
at	O
the	O
same	O
time,	O
it	O
is	O
advocating	O
for	O
more	O
research	O
a	O
better	O
understanding	O
Kratoms	O
safety	O
profile.	O

In	O
the	O
United	O
States	O
where	O
patches	O
cannot	O
always	O
be	O
returned	O
through	O
a	O
medication	O
take-back	O
program,	O
flushing	O
is	O
recommended	O
for	O
fentanyl	B-Drug
because	O
it	O
fastest	O
and	O
surest	O
way	O
to	O
remove	O
them	O
from	O
home	O
prevent	O
ingestion	O
by	O
children,	O
pets	O
or	O
others	O
not	O
intended	O
use	O
them.	O

When	O
sold	O
online	O
it	O
may	O
be	O
called	O
the	O
alternative	O
name	O
doxylam,	O
not	O
to	O
confused	O
with	O
doxylamine.	O
doxylamine	B-Drug

It	O
is	O
thought	O
that	O
the	O
KOR	O
activation	O
of	O
nalmefene	B-Drug
might	O
produce	O
dysphoria	O
and	O
anxiety.	O

marijuana	B-Drug
Killing	O
Zoe	O
(1994)	O

Food	O
does	O
not	O
significantly	O
influence	O
the	O
oral	O
bioavailability	O
of	O
pregabalin.	O
pregabalin	B-Drug

In	O
the	O
adaptation	O
Interview	O
with	O
Vampire	O
(film)	O
(1994),	O
which	O
was	O
based	O
on	O
1976	O
novel	O
same	O
name,	O
Claudia	O
uses	O
laudanum	B-Drug
to	O
try	O
and	O
dispose	O
of	O
Lestat:	O

Administering	O
through	O
the	O
nasal	O
spray,	O
Narcan,	O
and	O
auto-injectable	O
device,	O
Evizio,	O
is	O
...easy	O
suitable	O
for	O
home	O
use.	O
Narcan	B-Drug

The	O
TMAs	O
are	O
analogs	O
of	O
the	O
phenethylamine	B-Drug
cactus	O
alkaloid	O
mescaline.	O
mescaline	B-Drug

Use	O
of	O
clostebol	B-Drug
has	O
led	O
to	O
the	O
suspension	O
a	O
number	O
athletes	O
in	O
various	O
sports	O
including	O
Freddy	O
Galvis	O
Philadelphia	O
Phillies	O
2012,	O
Dee	O
Gordon	O
Miami	O
Marlins	O
2016,	O
and	O
Olympic	O
athlete	O
Viktoria	O
Orsi	O
Toth	O
2016.In	O
urinalysis	O
resulted	O
Therese	O
Johaug	O
testing	O
positive	O
for	O
clostebol.	O

Dipropanoylmorphine	B-Drug
is	O
slightly	O
slower	O
acting	O
than	O
diamorphine	B-Drug
and	O
morphine,	O
but	O
longer	O
lasting,	O
more	O
potent	O
by	O
weight	O
due	O
to	O
its	O
higher	O
lipophilicity.	O
morphine	B-Drug

Nabiximols,	O
trade	O
name	O
Sativex,	O
a	O
cannabinoid	O
oromucosal	O
mouth	O
spray,	O
was	O
approved	O
in	O
December	O
2011,	O
for	O
multiple	O
sclerosis	O
(MS);	O
only	O
on	O
prescription	O
as	O
third	O
alternative	O
to	O
two	O
other	O
drugs	O
that	O
condition	O
patients	O
who	O
not	O
responded	O
adequately	O
medication	O
spasticity	O
and	O
show	O
clinically	O
relevant	O
improvement	O
of	O
symptoms	O
related	O
during	O
an	O
initial	O
trial	O
treatment.	O
Nabiximols	B-Drug
Sativex	B-Drug

She	O
began	O
her	O
sentence	O
on	O
March	O
7,	O
2008,	O
and	O
was	O
released	O
September	O
5,	O
2008.In	O
the	O
BALCO	O
case,	O
she	O
had	O
denied	O
to	O
federal	O
agents	O
use	O
of	O
steroid	O
Tetrahydrogestrinone,	O
known	O
as	O
"The	O
Clear",	O
or	O
"THG",	O
from	O
1999,	O
but	O
claimed	O
given	O
impression	O
taking	O
a	O
flaxseed	O
oil	O
supplement	O
for	O
two	O
years	O
while	O
coach	O
Trevor	O
Graham	O
supplied	O
with	O
substance.	O
Tetrahydrogestrinone	B-Drug
THG	B-Drug

Most	O
commercial	O
immunoassays	O
for	O
the	O
benzodiazepine	O
class	O
of	O
drugs	O
cross-react	O
with	O
diazepam,	O
but	O
confirmation	O
and	O
quantitation	O
are	O
usually	O
performed	O
using	O
chromatographic	O
techniques.	O
diazepam	B-Drug

The	O
2014	O
Farm	O
Bill	O
legalized	O
the	O
sale	O
of	O
"non-viable	O
hemp	O
material"	O
grown	O
within	O
states	O
participating	O
in	O
Hemp	O
Pilot	O
Program	O
which	O
defined	O
as	O
cannabis	O
containing	O
less	O
than	O
0.3%	O
THC.	O
THC	B-Drug

Gabapentin	B-Drug
and	O
opioids	O
are	O
commonly	O
prescribed	O
or	O
abused	O
together,	O
research	O
indicates	O
that	O
the	O
breathing	O
suppression	O
they	O
cause	O
is	O
additive.	O

Ketamine	B-Drug
is	O
likely	O
to	O
be	O
most	O
beneficial	O
for	O
surgical	O
patients	O
when	O
severe	O
post-operative	O
pain	O
expected	O
and	O
opioid-tolerant	O
patients.	O

Serotonin	O
syndrome	O
may	O
result	O
from	O
the	O
combined	O
use	O
of	O
dextromethorphan	B-Drug
and	O
serotonergic	O
antidepressants	O
such	O
as	O
SSRIs	O
or	O
MAOIs,	O
but	O
further	O
research	O
is	O
needed	O
to	O
determine	O
whether	O
doses	O
beyond	O
those	O
normally	O
used	O
therapeutically	O
are	O
produce	O
this	O
effect.	O

JWH-149	B-Drug

Tramadol	B-Drug
(a	O
schedule	O
IV	O
drug	O
in	O
the	O
US)	O
is	O
used	O
primarily	O
to	O
treat	O
mild	O
severe	O
pain,	O
both	O
acute	O
and	O
chronic.	O

Nabiximols,	O
a	O
combined	O
THC	B-Drug
and	O
cannabidiol	B-Drug
(CBD)	O
product	O
that	O
is	O
formulated	O
as	O
an	O
oral	O
(buccal)	O
spray,	O
has	O
been	O
shown	O
to	O
improve	O
withdrawal	O
symptoms	O
without	O
improving	O
abstinence	O
rates.	O
Nabiximols	B-Drug
CBD	B-Drug

JWH-018	B-Drug
has	O
been	O
shown	O
to	O
cause	O
profound	O
changes	O
in	O
CB1	O
receptor	O
density	O
following	O
administration,	O
causing	O
desensitization	O
its	O
effects	O
more	O
rapidly	O
than	O
related	O
cannabinoids.	O

Loperamide	B-Drug
can	O
be	O
present	O
in	O
breast	O
milk,	O
and	O
is	O
not	O
recommended	O
for	O
breast-feeding	O
mothers.	O

Mesterolone,	O
along	O
with	O
other	O
AAS,	O
is	O
a	O
schedule	O
III	O
controlled	O
substance	O
in	O
the	O
United	O
States	O
under	O
Controlled	O
Substances	O
Act	O
and	O
IV	O
Canada	O
Drugs	O
Act.	O
Mesterolone	B-Drug

Mercdes	O
Benegbi,	O
born	O
with	O
phocomelia	O
of	O
both	O
arms,	O
drove	O
the	O
successful	O
campaign	O
for	O
compensation	O
from	O
her	O
government	O
Canadians	O
who	O
were	O
affected	O
by	O
thalidomide.	O
thalidomide	B-Drug

A	O
drug	O
safety	O
communication	O
from	O
the	O
US	O
Food	O
and	O
Drug	O
Administration	O
(FDA),	O
in	O
January	O
2020,	O
stated	O
that	O
a	O
clinical	O
trial	O
demonstrated	O
possible	O
increased	O
risk	O
of	O
cancer	O
for	O
those	O
taking	O
lorcaserin.	O
lorcaserin	B-Drug

MDMA	B-Drug
racemate	O
is	O
a	O
partial	O
agonist	O
towards	O
human	O
TAAR1,	O
but	O
this	O
not	O
physiologically	O
relevant	O
due	O
to	O
low	O
EC50.	O

In	O
October	O
2016,	O
the	O
state	O
of	O
Ohio	O
announced	O
that	O
it	O
would	O
resume	O
executions	O
in	O
January	O
2017,	O
using	O
a	O
formulation	O
midazolam,	O
vecuronium	B-Drug
bromide,	O
potassium	O
chloride,	O
but	O
this	O
was	O
blocked	O
by	O
Federal	O
judge.	O
midazolam	B-Drug
bromide	I-Drug

Smoking	O
or	O
vaporizing	O
cocaine	B-Drug
and	O
inhaling	O
it	O
into	O
the	O
lungs	O
produces	O
an	O
almost	O
immediate	O
"high"	O
that	O
can	O
be	O
very	O
powerful	O
(and	O
addicting)	O
quite	O
rapidly	O
this	O
initial	O
crescendo	O
of	O
stimulation	O
is	O
known	O
as	O
a	O
"rush".	O

Closely	O
related	O
AAS	O
include	O
metenolone	B-Drug
and	O
its	O
esters	O
acetate	O
enanthate.	O

When	O
the	O
Controlled	O
Substances	O
Act	O
(CSA)	O
was	O
enacted	O
in	O
1971,	O
nalbuphine	B-Drug
placed	O
schedule	O
II.	O

Meprobamatemarketed	O
as	O
Miltown	B-Drug
by	O
Wallace	O
Laboratories	O
and	O
Equanil	B-Drug
Wyeth,	O
among	O
othersis	O
a	O
carbamate	O
derivative	O
used	O
an	O
anxiolytic	O
drug.	O

In	O
front-bridged	O
analogs	O
the	O
nitrogen	O
lone	O
pairings	O
rigid	O
fixity	O
makes	O
it	O
reside	O
in	O
an	O
equatorial	O
placing	O
for	O
piperidine	O
ring-part	O
of	O
tropane	O
nucleus,	O
pointing	O
to	O
two-carbon	O
&	O
three	O
methylene	O
unit	O
bridgehead;	O
giving	O
attested	O
cocaine	B-Drug
analogues	O
preference	O
SERT	O
over	O
DAT.	O

At	O
this	O
level	O
of	O
potency,	O
it	O
is	O
not	O
possible	O
to	O
accurately	O
measure	O
a	O
single	O
dose	O
25I-NBOMe	B-Drug
powder	O
without	O
an	O
analytical	O
balance,	O
and	O
attempting	O
do	O
so	O
may	O
put	O
the	O
user	O
at	O
significant	O
risk	O
overdose.	O

Androstenedione,	O
also	O
known	O
as	O
androst-4-ene-3,17-dione,	O
is	O
a	O
naturally	O
occurring	O
androstane	O
steroid	O
and	O
17-ketosteroid.	O
Androstenedione	B-Drug
androst-4-ene-3,17-dione	B-Drug

Revlimid	B-Drug
is	O
available	O
only	O
in	O
a	O
restricted	O
distribution	O
setting	O
to	O
avoid	O
its	O
use	O
during	O
pregnancy.	O

There	O
is	O
no	O
conclusive	O
evidence	O
that	O
thalidomide	B-Drug
or	O
lenalidomide	B-Drug
useful	O
to	O
bring	O
about	O
maintain	O
remission	O
in	O
Crohn's	O
disease.	O

PCP	B-Drug
not	O
only	O
produced	O
symptoms	O
similar	O
to	O
schizophrenia,	O
it	O
also	O
yielded	O
electroencephalogram	O
changes	O
in	O
the	O
thalamocortical	O
pathway	O
(increased	O
delta	O
decreased	O
alpha)	O
and	O
hippocampus	O
(increase	O
theta	O
bursts)	O
that	O
were	O
those	O
schizophrenia.	O

5F-ADB	B-Drug
was	O
also	O
identified	O
in	O
cannabidiol	B-Drug
(CBD)	O
products	O
from	O
a	O
US-based	O
CBD	B-Drug
manufacturer	O
2018.	O

The	O
first	O
nonsteroidal	O
androgens,	O
the	O
arylpropionamides,	O
were	O
discovered	O
via	O
structural	O
modification	O
of	O
bicalutamide.	O
bicalutamide	B-Drug

Benzylfentanyl	O
has	O
a	O
Ki	O
of	O
213	O
nM	O
at	O
the	O
mu	O
opioid	O
receptor,	O
binding	O
around	O
1/200	O
as	O
strong	O
fentanyl	B-Drug
itself,	O
though	O
it	O
is	O
still	O
slightly	O
more	O
potent	O
than	O
codeine.	O
codeine	B-Drug

There	O
is	O
a	O
risk	O
of	O
dangerously	O
low	O
blood	O
pressure	O
if	O
people	O
take	O
mianserin	B-Drug
along	O
with	O
diazoxide,	O
hydralazine,	O
or	O
nitroprusside.	O
diazoxide	B-Drug
hydralazine	B-Drug
nitroprusside	B-Drug

Metenolone	B-Drug
esters	O
are	O
androgen	O
and	O
prodrugs	O
of	O
metenolone	B-Drug
in	O
the	O
body.	O

For	O
withdrawal	O
purposes,	O
stabilisation	O
with	O
a	O
long-acting	O
agent	O
such	O
as	O
diazepam	B-Drug
is	O
recommended	O
before	O
commencing	O
withdrawal.	O

It	O
was	O
approved	O
in	O
Canada	O
under	O
the	O
Contrave	B-Drug
brand	O
name	O
2018.	O

Initial	O
trial	O
results	O
on	O
fospropofol	B-Drug
pharmacokinetics	O
were	O
retracted	O
by	O
the	O
investigators.	O

Evidence	O
of	O
effects	O
heroin	O
maintenance	O
compared	O
to	O
methadone	B-Drug
are	O
unclear	O
as	O
2010.	O

When	O
first	O
released,	O
thalidomide	B-Drug
was	O
promoted	O
for	O
anxiety,	O
trouble	O
sleeping,	O
"tension",	O
and	O
morning	O
sickness.	O

Forced	O
acid	O
diuresis	O
(with	O
ammonium	O
chloride	O
or,	O
more	O
safely,	O
ascorbic	O
acid)	O
may	O
increase	O
clearance	O
of	O
PCP	B-Drug
from	O
the	O
body,	O
and	O
was	O
somewhat	O
controversially	O
recommended	O
in	O
past	O
as	O
a	O
decontamination	O
measure.	O

Research	O
suggests	O
that	O
enzalutamide	B-Drug
may	O
be	O
effective	O
in	O
the	O
treatment	O
of	O
certain	O
types	O
breast	O
cancer	O
women.	O

Restless	O
legs	O
syndrome	O
can	O
be	O
treated	O
using	O
clonazepam	B-Drug
as	O
a	O
third-line	O
treatment	O
option	O
the	O
use	O
of	O
is	O
still	O
investigational.	O

This	O
product	O
then	O
undergoes	O
transamination	O
and	O
methylation	O
to	O
form	O
ephedrine	B-Drug
its	O
stereoisomer,	O
pseudoephedrine.	O
pseudoephedrine	B-Drug

Other	O
terms	O
are	O
"cocaine	O
baby"	O
and	O
"crack	O
kid".	O
cocaine	B-Drug

Studies	O
have	O
shown	O
that	O
alcohol	O
and	O
tobacco	B-Drug
may	O
additionally	O
be	O
regarded	O
as	O
gateway	O
drugs;	O
however,	O
a	O
more	O
parsimonious	O
explanation	O
could	O
cannabis	O
is	O
simply	O
readily	O
available	O
(and	O
at	O
an	O
earlier	O
age)	O
than	O
illegal	O
hard	O
drugs.	O

In	O
the	O
United	O
Kingdom,	O
bufotenin	B-Drug
is	O
a	O
Class	O
A	O
drug	O
under	O
1971	O
Misuse	O
of	O
Drugs	O
Act.	O

Adverse	O
interactions	O
may	O
occur	O
between	O
ibogaine	B-Drug
and	O
psychiatric	O
medications.	O

The	O
FDA	O
reported	O
in	O
April	O
2012	O
that	O
twelve	O
young	O
children	O
had	O
died	O
and	O
more	O
made	O
seriously	O
ill	O
from	O
separate	O
accidental	O
exposures	O
to	O
fentanyl	B-Drug
skin	O
patches.	O

At	O
the	O
same	O
time,	O
CBD	B-Drug
levels	O
in	O
seized	O
samples	O
have	O
lowered,	O
part	O
because	O
of	O
desire	O
to	O
produce	O
higher	O
THC	B-Drug
and	O
more	O
illegal	O
growers	O
cultivate	O
indoors	O
using	O
artificial	O
lights.	O

Disulfiram	B-Drug
produces	O
a	O
very	O
unpleasant	O
reaction	O
when	O
drinking	O
alcohol	O
that	O
includes	O
flushing,	O
nausea	O
and	O
palpitations.	O

Earlier	O
treaties	O
had	O
only	O
controlled	O
opium,	O
coca,	O
and	O
derivatives	O
such	O
as	O
morphine,	O
heroin	B-Drug
cocaine.	O
opium	B-Drug
coca	B-Drug
morphine	B-Drug
cocaine	B-Drug

Tibolone	B-Drug
reduces	O
hot	O
flashes,	O
prevents	O
bone	O
loss,	O
improves	O
vaginal	O
atrophy	O
and	O
urogenital	O
symptoms	O
(e.g.,	O
dryness,	O
dyspareunia),	O
has	O
positive	O
effects	O
on	O
mood	O
sexual	O
function.	O

China	O
not	O
only	O
continues	O
to	O
be	O
a	O
major	O
transit	O
route	O
for	O
Southeast	O
Asian	O
heroin	B-Drug
bound	O
international	O
drug	O
markets,	O
but	O
also	O
Southwest	O
entering	O
northwestern	O
from	O
Afghanistan,	O
Pakistan,	O
and	O
Tajikistan.	O

Early	O
and	O
persistent	O
use	O
of	O
cocaine	B-Drug
or	O
heroin	B-Drug
in	O
the	O
juvenile	O
years	O
is	O
an	O
indicator	O
serious,	O
criminal	O
behavior	O
adulthood.	O

A	O
2008	O
study	O
concluded	O
that,	O
based	O
on	O
US	O
data	O
from	O
the	O
period	O
20002002,	O
adolescent-onset	O
(defined	O
here	O
as	O
ages	O
1117)	O
usage	O
of	O
hallucinogenic	O
drugs	O
(including	O
psilocybin)	O
did	O
not	O
increase	O
risk	O
drug	O
dependence	O
in	O
adulthood;	O
this	O
was	O
contrast	O
to	O
adolescent	O
cannabis,	O
cocaine,	O
inhalants,	O
anxiolytic	O
medicines,	O
and	O
stimulants,	O
all	O
which	O
were	O
associated	O
with	O
"an	O
excess	O
developing	O
clinical	O
features	O
dependence".	O
cocaine	B-Drug

It	O
is	O
a	O
class-IV	O
antiarrhythmic	O
and	O
more	O
effective	O
than	O
digoxin	B-Drug
in	O
controlling	O
ventricular	O
rate.	O

Levetiracetam	B-Drug
(1999).	O

The	O
non-medical	O
use	O
of	O
oxycodone	B-Drug
existed	O
from	O
the	O
early	O
1970s,	O
but	O
by	O
2015,	O
91%	O
a	O
national	O
sample	O
injecting	O
drug	O
users	O
in	O
Australia	O
had	O
reported	O
using	O
oxycodone,	O
and	O
27%	O
injected	O
it	O
last	O
six	O
months.	O

GPO	O
will	O
devote	O
2.5	O
percent	O
of	O
its	O
manufacturing	O
capacity	O
to	O
make	O
42	O
million	O
efavirenz	B-Drug
pills	O
in	O
2018,	O
allowing	O
it	O
serve	O
export	O
markets	O
as	O
well	O
domestic.	O

Evidence	O
suggests	O
that	O
usage	O
of	O
triamcinolone	B-Drug
acetonide	O
or	O
other	O
steroids	O
to	O
treat	O
macular	O
edema	O
increases	O
the	O
risk	O
increasing	O
intraocular	O
pressure	O
in	O
patients.	O

In	O
surveys,	O
the	O
number	O
of	O
high	O
school	O
students	O
admitting	O
to	O
trying	O
PCP	B-Drug
at	O
least	O
once	O
fell	O
from	O
13%	O
in	O
1979	O
less	O
than	O
3%	O
1990.	O

Muscle	O
relaxants	O
(Baclofen,	O
phenibut,	O
carisoprodol,	O
cyclobenzaprine,	O
etc.)	O
Baclofen	B-Drug
phenibut	B-Drug
carisoprodol	B-Drug
cyclobenzaprine	B-Drug

According	O
to	O
the	O
50th	O
edition	O
of	O
British	O
National	O
Formulary	O
(BNF),	O
diamorphine	B-Drug
hydrochloride	O
may	O
be	O
used	O
in	O
treatment	O
acute	O
pain,	O
myocardial	O
infarction,	O
pulmonary	O
oedema,	O
and	O
chronic	O
pain.	O

Intranasal	O
fentanyl	B-Drug
appears	O
to	O
be	O
as	O
equally	O
effective	O
IV	O
morphine	B-Drug
and	O
superior	O
intramuscular	O
for	O
management	O
of	O
acute	O
hospital	O
pain.	O

In	O
Tiwanaku	O
culture,	O
a	O
snuff	B-Drug
tray	O
was	O
used	O
along	O
with	O
an	O
inhaling	O
tube.	O

N-Ethyl-1,3-benzodioxolylpentanamine	O
(EBDP;	O
Ethyl-K;	O
3,4-methylenedioxy-N-ethyl--propylphenethylamine)	O
is	O
a	O
psychoactive	O
drug	O
and	O
member	O
of	O
the	O
phenethylamine	B-Drug
chemical	O
class	O
which	O
acts	O
as	O
an	O
entactogen,	O
psychedelic,	O
stimulant.	O

There	O
is	O
probably	O
no	O
single	O
reference	O
that	O
lists	O
all	O
the	O
pharmaceutical	O
variations	O
of	O
laudanum	B-Drug
were	O
created	O
and	O
used	O
in	O
different	O
countries	O
during	O
centuries	O
since	O
it	O
was	O
initially	O
formulated.	O

Whole-cell	O
voltage	O
clamp	O
studies	O
have	O
demonstrated	O
that	O
perampanel	B-Drug
is	O
a	O
negative	O
allosteric	O
AMPA	O
receptor	O
antagonist.	O

is	O
a	O
structurally	O
constrained	O
derivative	O
of	O
25B-NBOMe,	O
which	O
acts	O
as	O
potent	O
partial	O
agonist	O
with	O
124x	O
selectivity	O
for	O
5-HT2A	O
over	O
5-HT2C,	O
making	O
it	O
the	O
most	O
selective	O
ligand	O
identified	O
to	O
date.	O
25B-NBOMe	B-Drug

Combustion	O
products	O
are	O
not	O
present	O
when	O
using	O
a	O
vaporizer,	O
consuming	O
THC	B-Drug
in	O
pill	O
form,	O
or	O
cannabis	O
foods.	O

Ipratropium	B-Drug
bromide,	O
sold	O
under	O
the	O
trade	O
name	O
Atrovent	B-Drug
among	O
others,	O
is	O
a	O
medication	O
which	O
opens	O
up	O
medium	O
and	O
large	O
airways	O
in	O
lungs.	O
bromide	I-Drug

Cocaine	B-Drug
is	O
available	O
throughout	O
Oregon,	O
and	O
crack	O
cocaine	O
in	O
some	O
urban	O
areas.	O

The	O
work	O
mentions	O
the	O
painkillers	O
willow	O
(leading	O
ultimately	O
to	O
aspirin,	O
she	O
writes),	O
autumn	O
crocus	O
and	O
opium,	O
which	O
however	O
is	O
also	O
narcotic.	O
aspirin	B-Drug
opium	B-Drug

In	O
the	O
US,	O
similar	O
descriptions	O
("bath	O
salts"	O
is	O
most	O
common)	O
have	O
been	O
used	O
to	O
describe	O
mephedrone	B-Drug
as	O
well	O
methylone	B-Drug
and	O
methylenedioxypyrovalerone	B-Drug
(MDPV).	O
MDPV	B-Drug

When	O
used	O
at	O
higher	O
doses,	O
the	O
drug	O
"can	O
produce	O
similar	O
effects	O
to	O
heroin."	O
heroin	B-Drug

In	O
2013,	O
a	O
CNN	O
program	O
that	O
featured	O
Charlotte's	O
Web	O
cannabis	O
brought	O
increased	O
attention	O
to	O
the	O
use	O
of	O
CBD	B-Drug
in	O
treatment	O
seizure	O
disorders.	O

Etoxeridine	B-Drug
was	O
developed	O
in	O
the	O
1950s	O
and	O
investigated	O
for	O
use	O
surgical	O
anesthesia,	O
however	O
it	O
never	O
commercialized	O
is	O
not	O
currently	O
used	O
medicine.	O

At	O
therapeutic	O
doses,	O
phenytoin	B-Drug
may	O
produce	O
nystagmus	O
on	O
lateral	O
gaze.	O

Dexamethasone	B-Drug
is	O
recommended	O
by	O
the	O
National	O
Health	O
Service	O
in	O
UK	O
and	O
Institutes	O
of	O
(NIH)	O
US	O
for	O
patients	O
with	O
COVID-19	O
who	O
need	O
either	O
mechanical	O
ventilation	O
or	O
supplemental	O
oxygen	O
(without	O
ventilation).	O

Following	O
the	O
popularisation	O
of	O
nightclubs	O
and	O
rave	O
culture	O
in	O
Hong	O
Kong,	O
abuse	O
party	O
drugs	O
such	O
as	O
ecstasy	B-Drug
ketamine	B-Drug
has	O
been	O
on	O
rise	O
since	O
2000.	O

The	O
abbreviation	O
"DTO,"	O
traditionally	O
used	O
to	O
refer	O
Deodorized	O
Tincture	O
of	O
Opium,	O
is	O
sometimes	O
also	O
erroneously	O
employed	O
abbreviate	O
"diluted	O
tincture	O
opium.	O
opium	B-Drug

There	O
are	O
many	O
social	O
services	O
groups,	O
like	O
Capital	O
Area	O
Human	O
Services,	O
providing	O
therapy	O
as	O
well	O
opioid-reversal	O
drugs;	O
and	O
No	O
Overdose	O
Baton	O
Rouge,	O
which	O
offers	O
clean	O
syringes,	O
the	O
opioid	O
antagonist	O
nasal	O
spray	O
Narcan,	O
sterile	O
smoking	O
devices,	O
attempting	O
to	O
help.	O
Narcan	B-Drug

Studies	O
have	O
shown	O
that	O
alcohol	O
and	O
tobacco	B-Drug
may	O
additionally	O
be	O
regarded	O
as	O
gateway	O
drugs;	O
however,	O
a	O
more	O
parsimonious	O
explanation	O
could	O
cannabis	O
is	O
simply	O
readily	O
available	O
(and	O
at	O
an	O
earlier	O
age)	O
than	O
illegal	O
hard	O
drugs.	O

Studies	O
on	O
rats	O
indicate	O
that	O
PCP	B-Drug
interacts	O
indirectly	O
with	O
opioid	O
receptors	O
(endorphin	O
and	O
enkephalin)	O
to	O
produce	O
analgesia.	O

Alprazolam	B-Drug
may	O
also	O
be	O
indicated	O
for	O
the	O
treatment	O
of	O
generalized	O
anxiety	O
disorder,	O
as	O
well	O
conditions	O
with	O
co-morbid	O
depression.	O

Today,	O
mestanolone	B-Drug
has	O
mostly	O
been	O
discontinued	O
in	O
medicine,	O
though	O
it	O
is	O
still	O
available	O
Japan.	O

An	O
unusual	O
but	O
unique	O
characteristic	O
of	O
mescaline	B-Drug
use	O
is	O
the	O
"geometricization"	O
three-dimensional	O
objects.	O

cannabidiol	B-Drug
A	O
non-psychotropic	O
chemical	O
compound	O
found	O
in	O
cannabis,	O
abbreviated	O
CBD.	O
CBD	B-Drug

Black	O
tar	O
as	O
a	O
type	O
holds	O
variable	O
admixture	O
morphine	B-Drug
derivativespredominantly	O
6-MAM	O
(6-monoacetylmorphine),	O
which	O
is	O
another	O
result	O
of	O
crude	O
acetylation.	O
6-monoacetylmorphine	B-Drug

In	O
September	O
2020,	O
the	O
EMA	O
received	O
an	O
application	O
for	O
marketing	O
authorization	O
of	O
dexamethasone	B-Drug
COVID19.	O

The	O
estimated	O
median	O
effective	O
dose	O
(ED50)	O
for	O
SERT	O
occupancy	O
hence	O
was	O
98.1	O
mg,	O
which	O
associated	O
with	O
a	O
plasma	O
tramadol	B-Drug
level	O
of	O
about	O
330	O
ng/ml	O
(1,300	O
nM).	O

Methyltestosterone	B-Drug
is	O
the	O
INN,	O
USAN,	O
USP,	O
BAN,	O
and	O
JAN	O
of	O
drug	O
its	O
generic	O
name	O
in	O
English	O
Japanese,	O
while	O
mthyltestostrone	O
DCF	O
French	O
metiltestosterone	O
DCIT	O
Italian	O
name.	O

Prolonged	O
use	O
of	O
bromazepam	B-Drug
can	O
cause	O
tolerance	O
and	O
may	O
lead	O
to	O
both	O
physical	O
psychological	O
dependence	O
on	O
the	O
drug,	O
as	O
a	O
result,	O
it	O
is	O
medication	O
which	O
controlled	O
by	O
international	O
law.	O

Studies	O
have	O
subsequently	O
distinguished	O
between	O
enkephalins,	O
endorphins,	O
and	O
endogenously-produced	O
morphine,	O
which	O
is	O
not	O
a	O
peptide.	O
morphine	B-Drug

Methamphetamine	B-Drug
is	O
also	O
well	O
absorbed	O
following	O
inhalation	O
and	O
intranasal	O
administration.	O

Fentanyl	B-Drug
in	O
injectable	O
formulation	O
is	O
commonly	O
used	O
for	O
analgesia	O
and	O
as	O
a	O
component	O
of	O
balanced	O
sedation	O
general	O
anesthesia	O
small	O
animal	O
patients.	O

Abuse	O
of	O
opium	B-Drug
in	O
the	O
United	O
States	O
began	O
late	O
19th	O
century	O
and	O
was	O
largely	O
associated	O
with	O
Chinese	O
immigrants.	O

Formal	O
research	O
on	O
this	O
chemical	O
was	O
first	O
conducted	O
in	O
2009,	O
when	O
it	O
shown	O
to	O
be	O
metabolised	O
a	O
similar	O
manner	O
related	O
drugs	O
like	O
methylone.	O
methylone	B-Drug

Racecadotril	B-Drug
is	O
rapidly	O
and	O
effectively	O
metabolized	O
to	O
the	O
moderately	O
active	O
S-acetylthiorphan	O
main	O
metabolite	O
thiorphan,	O
of	O
which	O
90%	O
are	O
bound	O
blood	O
plasma	O
proteins.	O

Oxandrolone	B-Drug
has,	O
therefore,	O
largely	O
been	O
replaced	O
by	O
growth	O
hormone	O
for	O
this	O
use.	O

'	O
Benzoxazines	O
(more	O
specifically	O
cyclopropylethynylated	O
benzoxazines)	O
Substituted	O
benzoxazines	O
Efavirenz,	O
the	O
active	O
constituent	O
of	O
Sustiva,	O
Stocrin,	O
and	O
Efavir	O
Efavirenz	B-Drug
Sustiva	B-Drug

Analogues	O
of	O
PCP	B-Drug
exhibit	O
varying	O
potency	O
at	O
nACh	O
receptors	O
and	O
NMDA	O
receptors.	O

This	O
finding	O
caused	O
scientists	O
to	O
speculate	O
about	O
whether	O
cathinone	B-Drug
was	O
the	O
true	O
active	O
ingredient	O
in	O
khat.	O

When	O
fermentation	O
begins	O
add	O
to	O
it	O
a	O
solution	O
of	O
4	O
ounces	O
selected	O
opium	B-Drug
in	O
12	O
water.	O

Not	O
all	O
cannabis	O
plants	O
are	O
created	O
equal,	O
for	O
example	O
Hemp	O
has	O
very	O
little	O
THC	B-Drug
but	O
a	O
large	O
amount	O
of	O
CBD.	O
CBD	B-Drug

Unlike	O
heparin,	O
this	O
class	O
of	O
drugs	O
may	O
be	O
used	O
for	O
months	O
or	O
years.	O
heparin	B-Drug

Prevnar	B-Drug
13	O
provides	O
coverage	O
of	O
bacterial	O
variants,	O
expanding	O
beyond	O
the	O
original	O
7-valent	O
version.	O

Bulk	O
cargo	O
ships	O
are	O
also	O
used	O
to	O
smuggle	O
cocaine	B-Drug
staging	O
sites	O
in	O
the	O
western	O
CaribbeanGulf	O
of	O
Mexico	O
area.	O

Research	O
suggests	O
that	O
when	O
methadone	B-Drug
is	O
used	O
long-term	O
it	O
can	O
build	O
up	O
unpredictably	O
in	O
the	O
body	O
and	O
lead	O
to	O
potentially	O
deadly	O
slowed	O
breathing.	O

In	O
addition,	O
it	O
has	O
been	O
stated	O
that	O
"the	O
subjective	O
effects	O
of	O
S.	O
divinorum	O
indicate	O
salvia	O
disrupts	O
certain	O
facets	O
consciousness	O
much	O
more	O
than	O
the	O
largely	O
serotonergic	O
hallucinogen	O
[LSD]",	O
and	O
postulated	O
inhibition	O
a	O
brain	O
area	O
is	O
apparently	O
as	O
fundamentally	O
involved	O
in	O
higher	O
cognitive	O
function	O
claustrum	O
may	O
explain	O
this.	O
LSD	B-Drug

In	O
rabbits	O
the	O
similarity	O
between	O
effects	O
of	O
new	O
alkaloid	O
and	O
ergometrine	B-Drug
were	O
particularly	O
striking,	O
but	O
was	O
less	O
toxic	O
to	O
(the	O
approximate	O
intravenous	O
LD50	O
3.5mg/kg).	O

The	O
conditions	O
required	O
under	O
the	O
program	O
include	O
limiting	O
prescription	O
and	O
dispensing	O
rights	O
to	O
authorized	O
prescribers	O
pharmacies	O
only,	O
keeping	O
a	O
registry	O
of	O
all	O
patients	O
prescribed	O
thalidomide,	O
providing	O
extensive	O
patient	O
education	O
about	O
risks	O
associated	O
with	O
drug,	O
periodic	O
pregnancy	O
tests	O
for	O
women	O
who	O
take	O
drug.	O
thalidomide	B-Drug

A	O
2019	O
review	O
found	O
that	O
the	O
transition	O
rate	O
from	O
a	O
diagnosis	O
of	O
hallucinogen-induced	O
psychosis	O
(which	O
included	O
PCP)	O
to	O
schizophrenia	O
was	O
26%.	O
PCP	B-Drug

Studies	O
and	O
clinical	O
trials	O
comparing	O
dipropanoylmorphine	B-Drug
to	O
morphine	B-Drug
have	O
produced	O
results	O
that	O
indicate	O
the	O
incidence	O
of	O
side-effects	O
are	O
far	O
more	O
common	O
with	O
morphine.	O

Dopaminergic	O
stimulants	O
such	O
as	O
amphetamine,	O
ephedrine,	O
and	O
propylhexedrine	B-Drug
work	O
by	O
causing	O
the	O
release	O
of	O
dopamine	O
norepinephrine,	O
along	O
with	O
(in	O
some	O
cases)	O
blocking	O
reuptake	O
these	O
neurotransmitters.	O
amphetamine	B-Drug
ephedrine	B-Drug

Meprobamate	B-Drug
and	O
other	O
muscle-relaxing	O
drugs	O
often	O
were	O
subjects	O
of	O
misuse	O
in	O
the	O
1950s	O
60s.	O

Norethandrolone	B-Drug
is	O
available	O
today	O
only	O
in	O
France.	O

Two	O
small,	O
placebo-controlled	O
trials	O
have	O
been	O
conducted	O
to	O
assess	O
the	O
efficacy	O
of	O
ondansetron	B-Drug
for	O
postanesthetic	O
shivering,	O
a	O
common	O
occurrence	O
after	O
surgery.	O

Cocaine	B-Drug
also	O
causes	O
vasoconstriction,	O
thus	O
reducing	O
bleeding	O
during	O
minor	O
surgical	O
procedures.	O

Danazol	B-Drug
has	O
a	O
complex	O
mechanism	O
of	O
action,	O
and	O
is	O
characterized	O
as	O
weak	O
androgen	O
anabolic	O
steroid,	O
progestogen,	O
antigonadotropin,	O
steroidogenesis	O
inhibitor,	O
functional	O
antiestrogen.	O

The	O
bioavailability	O
of	O
oral	O
administration	O
oxycodone	B-Drug
averages	O
within	O
a	O
range	O
60	O
to	O
87%,	O
with	O
rectal	O
yielding	O
the	O
same	O
results;	O
intranasal	O
varies	O
between	O
individuals	O
mean	O
46%.After	O
dose	O
conventional	O
(instant-release)	O
oxycodone,	O
onset	O
action	O
is	O
10	O
30	O
minutes,	O
and	O
peak	O
plasma	O
levels	O
drug	O
are	O
attained	O
roughly	O
minutes;	O
in	O
contrast,	O
after	O
OxyContin	B-Drug
(an	O
controlled-release	O
formulation),	O
occur	O
about	O
three	O
hours.	O

Infrequent	O
(0.11%	O
of	O
people	O
with	O
pregabalin):	O
depression,	O
lethargy,	O
agitation,	O
anorgasmia,	O
hallucinations,	O
myoclonus,	O
hypoaesthesia,	O
hyperaesthesia,	O
tachycardia,	O
excessive	O
salivation,	O
hypoglycaemia,	O
sweating,	O
flushing,	O
rash,	O
muscle	O
cramp,	O
myalgia,	O
arthralgia,	O
urinary	O
incontinence,	O
dysuria,	O
thrombocytopenia,	O
kidney	O
calculus	O
Rare	O
(<0.1%	O
neutropenia,	O
first	O
degree	O
heart	O
block,	O
hypotension,	O
hypertension,	O
pancreatitis,	O
dysphagia,	O
oliguria,	O
rhabdomyolysis,	O
suicidal	O
thoughts	O
or	O
behavior.	O
pregabalin	B-Drug

At	O
his	O
prime,	O
Surez	O
made	O
$400	O
million	O
annually,	O
was	O
one	O
of	O
the	O
major	O
suppliers	O
Medelln	O
Cartel	O
as	O
well	O
leader	O
largest	O
Bolivian	O
drug	O
empire,	O
and	O
considered	O
to	O
be	O
biggest	O
cocaine	B-Drug
producer	O
in	O
world.	O

Despite	O
that	O
cocaine	B-Drug
was	O
typically	O
illegal	O
to	O
sell	O
and	O
legal	O
outlets	O
were	O
rarer,	O
the	O
quantities	O
of	O
produced	O
declined	O
very	O
little.	O

Cocaine	B-Drug
sold	O
on	O
the	O
street	O
is	O
commonly	O
mixed	O
with	O
local	O
anesthetics,	O
cornstarch,	O
quinine,	O
or	O
sugar,	O
which	O
can	O
result	O
in	O
additional	O
toxicity.	O
quinine	B-Drug

Management	O
of	O
PCP	B-Drug
intoxication	O
mostly	O
consists	O
supportive	O
care	O
controlling	O
breathing,	O
circulation,	O
and	O
body	O
temperature	O
and,	O
in	O
the	O
early	O
stages,	O
treating	O
psychiatric	O
symptoms.	O

Butane	O
and	O
supercritical	O
carbon	O
dioxide	O
hash	B-Drug
oil	I-Drug
have	O
become	O
popular	O
in	O
recent	O
years.	O

Several	O
large	O
quantities	O
of	O
illicitly	O
produced	O
fentanyl	B-Drug
have	O
been	O
seized	O
by	O
U.S.	O
law	O
enforcement	O
agencies.	O

Tolerance	O
to	O
some	O
of	O
the	O
desired	O
and	O
adverse	O
effects	O
MDMA	B-Drug
is	O
expected	O
occur	O
with	O
consistent	O
use.	O

An	O
injected	O
mixture	O
of	O
cocaine	B-Drug
and	O
heroin,	O
known	O
as	O
"speedball"	O
is	O
a	O
particularly	O
dangerous	O
combination,	O
the	O
converse	O
effects	O
drugs	O
actually	O
complement	O
each	O
other,	O
but	O
may	O
also	O
mask	O
symptoms	O
an	O
overdose.	O
heroin	B-Drug

In	O
rats	O
tolerance	O
is	O
slower	O
to	O
develop	O
the	O
anticonvulsant	O
effects	O
compared	O
benzodiazepine	O
site	O
full	O
agonist	O
diazepam.	O
diazepam	B-Drug

Spironolactone	B-Drug
has	O
been	O
found	O
to	O
block	O
EpsteinBarr	O
virus	O
(EBV)	O
production	O
and	O
that	O
of	O
other	O
human	O
herpesviruses	O
by	O
inhibiting	O
the	O
function	O
an	O
EBV	O
protein	O
SM,	O
which	O
is	O
essential	O
for	O
infectious	O
production.	O

Powdered	O
hyoscine,	O
in	O
a	O
form	O
referred	O
to	O
as	O
"devil's	O
breath",	O
does	O
not	O
brainwash	O
or	O
control	O
people	O
into	O
being	O
defrauded	O
by	O
their	O
attackers;	O
these	O
alleged	O
effects	O
are	O
most	O
likely	O
urban	O
legends.	O
hyoscine	B-Drug

Trifluoperazine	B-Drug
has	O
central	O
antiadrenergic,	O
antidopaminergic,	O
and	O
minimal	O
anticholinergic	O
effects.	O

"Epidiolex	O
Epidiolex	B-Drug

The	O
psychoactive	O
substance	O
in	O
Cannabis,	O
THC,	O
is	O
unique	O
that	O
it	O
contains	O
no	O
nitrogen	O
and	O
not	O
an	O
indole,	O
tryptamine,	O
phenethylamine,	O
anticholinergic	O
(deliriant),	O
or	O
a	O
dissociative	O
drug.	O
THC	B-Drug
phenethylamine	B-Drug

100	O
mg/kg	O
Phenylpiracetam	B-Drug
performed	O
an	O
average	O
of	O
375%	O
as	O
much	O
work,	O
and	O
consumed	O
little	O
non-preferred	O
rat	O
chow.	O

The	O
effects	O
of	O
amphetamine	B-Drug
on	O
gene	O
regulation	O
are	O
both	O
dose-	O
and	O
route-dependent.	O

As	O
of	O
August	O
2015,	O
25I-NBOMe	B-Drug
has	O
reportedly	O
led	O
to	O
at	O
least	O
19	O
overdose	O
deaths	O
in	O
the	O
United	O
States.	O

Reaction	O
with	O
1,1-dimethoxycyclopentane	O
followed	O
by	O
heating	O
to	O
eliminate	O
methanol	O
gives	O
quinbolone.	O
quinbolone	B-Drug

Still	O
today,	O
the	O
kratom	B-Drug
leaf	O
is	O
reportedly	O
most	O
commonly	O
used	O
illicit	O
drug	O
in	O
Thailand	O
where	O
it	O
became	O
listed	O
as	O
a	O
controlled	O
substance	O
1943.	O

Harmal	O
alkaloids	O
are	O
antagonists	O
to	O
the	O
GABAA-receptor,	O
and	O
ibogaine	B-Drug
NMDA-receptors.	O

The	O
Cochrane	O
review	O
of	O
preoperative	O
analgesics	O
for	O
additional	O
pain	O
relief	O
in	O
children	O
and	O
adolescents	O
shows	O
no	O
evidence	O
benefit	O
taking	O
paracetamol	B-Drug
before	O
dental	O
treatment	O
to	O
help	O
reduce	O
after	O
procedures	O
under	O
local	O
anaesthetic,	O
but	O
the	O
quality	O
is	O
low.	O

There	O
are	O
two	O
antidotes	O
that	O
frequently	O
used	O
in	O
the	O
hospital	O
setting	O
and	O
these	O
naloxone	B-Drug
flumazenil.	O
flumazenil	B-Drug

-N-hydroxyamphetamine	O
(MDOH,	O
MDH,	O
N-hydroxytenamphetamine)	O
is	O
an	O
entactogen,	O
psychedelic,	O
and	O
stimulant	O
of	O
the	O
phenethylamine	O
amphetamine	O
chemical	O
classes.	O
MDOH	B-Drug

As	O
of	O
October	O
2015	O
Ocfentanil	B-Drug
is	O
a	O
controlled	O
substance	O
in	O
China.	O

Pentazocine	B-Drug
is	O
known	O
as	O
Talwin	B-Drug
(hence	O
"Ts"),	O
the	O
pentazocine/tripelennamine	O
combination	O
acquired	O
slang	O
name	O
Ts	O
and	O
blues.	O
pentazocine	B-Drug

Paracetamol	B-Drug
and	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
including	O
ibuprofen	B-Drug
naproxen	B-Drug
are	O
considered	O
safer	O
alternatives.	O

In	O
the	O
U.S.,	O
fentanyl	B-Drug
is	O
a	O
Schedule	O
II	O
controlled	O
substance	O
per	O
Controlled	O
Substance	O
Act.	O

Harold	O
Bornstein,	O
the	O
former	O
personal	O
physician	O
of	O
United	O
States	O
President	O
Donald	O
Trump,	O
stated	O
in	O
2017	O
that	O
Trump	O
was	O
taking	O
finasteride	B-Drug
to	O
promote	O
hair	O
growth.	O

A	O
2018	O
report	O
by	O
The	O
Guardian	O
indicated	O
that	O
many	O
major	O
drug	O
suppliers	O
on	O
the	O
dark	O
web	O
have	O
voluntarily	O
banned	O
trafficking	O
of	O
fentanyl.	O
fentanyl	B-Drug

It	O
is	O
biotransformed	O
by	O
CYP3A4	O
and	O
CYP2B6	O
isoenzymes	O
into	O
norketamine,	O
which,	O
in	O
turn,	O
converted	O
CYP2A6	O
hydroxynorketamine	O
dehydronorketamine.	O
norketamine	B-Drug

two	O
compounds	O
JWH-018	B-Drug

Nortriptyline,	O
sold	O
under	O
the	O
brand	O
name	O
Pamelor,	O
among	O
others,	O
is	O
a	O
medication	O
used	O
to	O
treat	O
depression,	O
neuropathic	O
pain,	O
attention	O
deficit	O
hyperactivity	O
disorder	O
(ADHD),	O
smoking	O
cessation	O
and	O
anxiety.	O
Nortriptyline	B-Drug
Pamelor	B-Drug

5	O
non-epileptic	O
subjects	O
were	O
given	O
slowly	O
increasing	O
doses	O
of	O
secobarbital,	O
pentobarbital,	O
or	O
amobarbital	B-Drug
to	O
a	O
point	O
obvious	O
intoxication	O
over	O
period	O
more	O
than	O
73	O
days.	O
secobarbital	B-Drug
pentobarbital	B-Drug

Some	O
club	O
drugs	O
are	O
almost	O
always	O
illegal,	O
such	O
as	O
cocaine.	O
cocaine	B-Drug

A	O
notable	O
exception	O
to	O
this	O
are	O
AAS	O
that	O
androgen	O
precursors	O
or	O
prohormones,	O
including	O
dehydroepiandrosterone	O
(DHEA),	O
androstenediol,	O
androstenedione,	O
boldione	O
(androstadienedione),	O
bolandiol	O
(norandrostenediol),	O
bolandione	B-Drug
(norandrostenedione),	O
dienedione,	O
mentabolan	O
(MENT	O
dione,	O
trestione),	O
and	O
methoxydienone	O
(methoxygonadiene)	O
(although	O
these	O
relatively	O
weak	O
AAS).	O
androstenedione	B-Drug
dienedione	B-Drug

Heroin	B-Drug
(illicit	O
opioid	O
drug)	O
and	O
other	O
narcotics	O
reduce	O
sexual	O
interest	O
decrease	O
the	O
sex	O
hormone	O
levels	O
in	O
humans.	O

In	O
addition,	O
oxycodone	B-Drug
is	O
subject	O
to	O
national	O
laws	O
that	O
differ	O
by	O
country.	O

By	O
the	O
mid-1920s,	O
heroin	B-Drug
production	O
had	O
been	O
made	O
illegal	O
in	O
many	O
parts	O
of	O
world.	O

Thalidomide	B-Drug
is	O
provided	O
as	O
a	O
racemic	O
mixture	O
of	O
two	O
enantiomers;	O
while	O
there	O
are	O
reports	O
that	O
only	O
one	O
the	O
enantiomers	O
may	O
cause	O
birth	O
defects,	O
body	O
converts	O
each	O
enantiomer	O
into	O
other	O
through	O
mechanisms	O
not	O
well	O
understood.	O

Norcodeine	B-Drug
(N-desmethylcodeine)	O
Normorphine	B-Drug
(N-desmethylmorphine)	O

Of	O
anticonvulsant	O
drugs,	O
behavioural	O
disturbances	O
occur	O
most	O
frequently	O
with	O
clonazepam	B-Drug
and	O
phenobarbital.	O
phenobarbital	B-Drug

It	O
is	O
thought	O
that	O
this	O
can	O
result	O
in	O
sustained	O
and	O
higher	O
concentrations	O
of	O
MDMA	B-Drug
if	O
the	O
user	O
takes	O
consecutive	O
doses	O
drug.	O

Propylhexedrine	B-Drug
is	O
not	O
an	O
amphetamine,	O
nor	O
even	O
a	O
phenethylamine,	O
but	O
instead	O
can	O
be	O
referred	O
to	O
as	O
cycloalkylamine,	O
or	O
more	O
specifically	O
cyclohexylethylamine	O
being	O
the	O
N,a-dimethyl	O
derivative	O
of	O
2-cyclohexylethylamine.	O
amphetamine	B-Drug
phenethylamine	B-Drug

Darolutamide	B-Drug
shows	O
some	O
advantages	O
in	O
comparison	O
to	O
enzalutamide	B-Drug
and	O
apalutamide,	O
two	O
other	O
second-generation	O
NSAAs.	O
apalutamide	B-Drug

Cimetidine,	O
fluvoxamine	B-Drug
and	O
propranolol	B-Drug
causes	O
a	O
marked	O
increase	O
in	O
the	O
elimination	O
half-life	O
of	O
bromazepam	B-Drug
leading	O
to	O
increased	O
accumulation	O
bromazepam.	O
Cimetidine	B-Drug

Canada	O
and	O
many	O
other	O
countries	O
prohibit	O
manufacturers	O
from	O
including	O
secondary	O
active	O
ingredients	O
for	O
the	O
above	O
reason;	O
their	O
Talwin	B-Drug
PX	O
does	O
not	O
contain	O
naloxone.	O
naloxone	B-Drug

Nortriptyline,	O
the	O
main	O
active	O
metabolite	O
of	O
amitriptyline,	O
is	O
an	O
antidepressant	O
on	O
its	O
own	O
right.	O
Nortriptyline	B-Drug
amitriptyline	B-Drug

Fentanyl	B-Drug
is	O
a	O
synthetic	O
opioid	O
in	O
the	O
phenylpiperidine	O
family,	O
which	O
includes	O
sufentanil,	O
alfentanil,	O
remifentanil,	O
and	O
carfentanil.	O
sufentanil	B-Drug
alfentanil	B-Drug
remifentanil	B-Drug
carfentanil	B-Drug

PCP	B-Drug
comes	O
in	O
both	O
powder	O
and	O
liquid	O
forms	O
(PCP	O
base	O
is	O
dissolved	O
most	O
often	O
ether),	O
but	O
typically	O
it	O
sprayed	O
onto	O
leafy	O
material	O
such	O
as	O
cannabis,	O
mint,	O
oregano,	O
tobacco,	O
parsley,	O
or	O
ginger	O
leaves,	O
then	O
smoked.	O
tobacco	B-Drug

Intramuscular	O
midazolam	B-Drug
appears	O
to	O
be	O
a	O
reasonable	O
option	O
especially	O
in	O
those	O
who	O
are	O
not	O
hospital.	O

Androstenedione	B-Drug
is	O
released	O
into	O
the	O
blood	O
by	O
theca	O
cells.	O

Griselda	O
Blanco	O
Restrepo	O
(February	O
15,	O
1943	O
September	O
3,	O
2012),	O
known	O
as	O
La	O
Madrina,	O
the	O
Black	O
Widow,	O
Cocaine	O
Godmother	O
and	O
Queen	O
of	O
Narco-Trafficking,	O
was	O
a	O
Colombian	O
drug	O
lord	O
Medelln	O
Cartel	O
pioneer	O
in	O
Miami-based	O
cocaine	B-Drug
trade	O
underworld	O
during	O
1980s	O
through	O
early	O
2000s.	O

In	O
the	O
United	O
States,	O
betacetylmethadol	B-Drug
is	O
a	O
Schedule	O

The	O
program	O
also	O
offered	O
a	O
treatment	O
for	O
heroin	B-Drug
addicts.	O

Meanwhile,	O
Mort	O
detects	O
the	O
symptoms	O
of	O
cocaine	B-Drug
abuse	O
and	O
confronts	O
his	O
friend,	O
but	O
Eddie	O
claims	O
to	O
be	O
nothing	O
more	O
than	O
a	O
casual	O
user.	O

Respiratory	O
depression	O
can	O
be	O
a	O
problem	O
with	O
alphaprodine	B-Drug
even	O
at	O
normal	O
therapeutic	O
doses.	O

Examples	O
of	O
drugs	O
with	O
different	O
levels	O
regulated	O
distribution	O
in	O
most	O
countries	O
include:	O
caffeine	O
(coffee,	O
tea),	O
nicotine	B-Drug
(tobacco),	O
ethyl	O
alcohol	O
(beer,	O
wine,	O
spirits),	O
and	O
antibiotics.	O
tobacco	B-Drug

This	O
is	O
in	O
part	O
due	O
to	O
the	O
high	O
ratio	O
of	O
anabolic	O
androgenic	O
effect	O
nandrolone	B-Drug
and	O
its	O
weak	O
propensity	O
for	O
estrogenic	O
side	O
effects.	O

On	O
March	O
13,	O
2003,	O
Caracol	O
pleaded	O
guilty	O
to	O
participating	O
in	O
a	O
narcotics	O
trafficking	O
conspiracy	O
that	O
smuggled	O
tens	O
of	O
thousands	O
kilograms	O
cocaine	B-Drug
into	O
New	O
York	O
and	O
other	O
cities.	O

The	O
estimated	O
U.S.	O
cocaine	B-Drug
market	O
exceeded	O
US$70	O
billion	O
in	O
street	O
value	O
for	O
the	O
year	O
2005,	O
exceeding	O
revenues	O
by	O
corporations	O
such	O
as	O
Starbucks.	O

A	O
clinical	O
trial	O
comparing	O
its	O
efficacy	O
and	O
tolerability	O
with	O
amitriptyline	B-Drug
in	O
the	O
treatment	O
of	O
irritable	O
bowel	O
syndrome	O
showed	O
that	O
tianeptine	O
was	O
at	O
least	O
as	O
effective	O
produced	O
less	O
prominent	O
adverse	O
effects	O
such	O
dry	O
mouth	O
constipation.	O

Buprenorphine	B-Drug
is	O
metabolized	O
by	O
the	O
liver,	O
via	O
CYP3A4	O

Many	O
were	O
based	O
on	O
fentanyl	B-Drug
or	O
meperidine.	O
meperidine	B-Drug

The	O
dose	O
of	O
THC	B-Drug
needed	O
to	O
kill	O
50%	O
tested	O
rodents	O
is	O
extremely	O
high.	O

The	O
pathologists	O
conducting	O
the	O
autopsy	O
thought	O
it	O
possible,	O
for	O
instance,	O
that	O
he	O
had	O
suffered	O
"anaphylactic	O
shock	O
brought	O
on	O
by	O
codeine	B-Drug
pills	O
gotten	O
from	O
his	O
dentist,	O
to	O
which	O
was	O
known	O
have	O
a	O
mild	O
allergy".	O

On	O
March	O
30,	O
2010,	O
the	O
FDA	O
declined	O
to	O
approve	O
use	O
of	O
Nuvigil	B-Drug
treat	O
jet	O
lag.	O

This	O
was	O
reported	O
in	O
most	O
of	O
mainland	O
Europe	O
and	O
the	O
UK	O
which	O
led	O
to	O
a	O
price	O
increase	O
approximately	O
30	O
percent	O
cost	O
street	O
heroin	B-Drug
increased	O
demand	O
for	O
diverted	O
methadone.	O
methadone	B-Drug

The	O
lethal	O
dose	O
is	O
highly	O
variable	O
among	O
different	O
members	O
of	O
the	O
class,	O
with	O
superpotent	O
barbiturates	O
such	O
as	O
pentobarbital	B-Drug
being	O
potentially	O
fatal	O
in	O
considerably	O
lower	O
doses	O
than	O
low-potency	O
butalbital.	O
butalbital	B-Drug

In	O
1676	O
Sydenham	O
published	O
a	O
seminal	O
work,	O
Medical	O
Observations	O
Concerning	O
the	O
History	O
and	O
Cure	O
of	O
Acute	O
Diseases,	O
in	O
which	O
he	O
promoted	O
his	O
brand	O
opium	B-Drug
tincture,	O
advocated	O
its	O
use	O
for	O
range	O
medical	O
conditions.	O

In	O
the	O
event	O
of	O
an	O
overdose,	O
a	O
site	O
may	O
also	O
provide	O
medications	O
such	O
as	O
naloxone,	O
used	O
antidote	O
in	O
opioid	O
overdose	O
situations,	O
or	O
other	O
antidotes	O
emergency	O
care.	O
naloxone	B-Drug

Enzyme	O
inducers	O
such	O
as	O
barbiturates,	O
phenylbutazone,	O
phenytoin,	O
ampicillin	B-Drug
or	O
tetracyclines	O
are	O
expected	O
to	O
reduce	O
plasma	O
concentrations	O
of	O
medrogestone,	O
but	O
no	O
systematic	O
research	O
has	O
been	O
done.	O
phenytoin	B-Drug

Combined	O
with	O
a	O
115-month	O
average	O
imprisonment	O
for	O
crack	O
offenses,	O
compared	O
an	O
of	O
87	O
months	O
cocaine	B-Drug
the	O
sentencing	O
disparity	O
results	O
in	O
more	O
African-Americans	O
spending	O
time	O
prison	O
system.	O

Pimozide	B-Drug
(Orap)	O
a	O
typical	O
antipsychotic	O
used	O
to	O
treat	O
tic	O
disorders.	O
Orap	B-Drug

Diazepam	B-Drug
may	O
impair	O
the	O
ability	O
to	O
drive	O
vehicles	O
or	O
operate	O
machinery.	O

Under	O
the	O
brand	O
name	O
"Sassyfras",	O
MDMA	B-Drug
tablets	O
were	O
sold	O
in	O
brown	O
bottles.	O

As	O
of	O
2017	O
in	O
the	O
United	O
States	O
about	O
1%	O
people	O
grade	O
12	O
reported	O
using	O
PCP	B-Drug
prior	O
year	O
while	O
2.9%	O
those	O
over	O
age	O
25	O
it	O
at	O
some	O
point	O
their	O
lives.	O

Aminorex	B-Drug
has	O
been	O
shown	O
to	O
have	O
locomotor	O
stimulant	O
effects,	O
lying	O
midway	O
between	O
dextroamphetamine	B-Drug
and	O
methamphetamine.	O
methamphetamine	B-Drug

Alprazolam	B-Drug
and	O
other	O
benzodiazepines	O
may	O
also	O
cause	O
the	O
development	O
of	O
physical	O
dependence,	O
tolerance,	O
benzodiazepine	O
withdrawal	O
symptoms	O
during	O
rapid	O
dose	O
reduction	O
or	O
cessation	O
therapy	O
after	O
long-term	O
treatment.	O

Hyoscyamine	B-Drug
is	O
an	O
antimuscarinic;	O
i.e.,	O
antagonist	O
of	O
muscarinic	O
acetylcholine	O
receptors.	O

Although	O
Skinner	O
and	O
Pickard	O
were	O
arrested	O
moving	O
the	O
laboratory	O
from	O
Atlas-E	O
silo	O
location,	O
they	O
never	O
actually	O
produced	O
LSD	B-Drug
at	O
this	O
site.	O

It	O
is	O
most	O
similar	O
to	O
the	O
highly	O
potent	O
opioid	O
carfentanil	B-Drug
(4-carbomethoxyfentanyl),	O
only	O
slightly	O
more	O
potent.	O

In	O
terminal	O
diseases,	O
there	O
is	O
no	O
ceiling	O
dose	O
for	O
opium	B-Drug
tincture;	O
the	O
increased	O
slowly	O
until	O
diarrhea	O
controlled.	O

PRO-LAD	B-Drug
is	O
an	O
analogue	O
of	O
LSD.	O
LSD	B-Drug

All	O
drugs	O
in	O
the	O
NBOMe	O
family,	O
including	O
25I-NBOMe,	O
are	O
illegal.	O
25I-NBOMe	B-Drug

Furanylfentanyl	B-Drug
may	O
be	O
measured	O
in	O
blood	O
or	O
urine	O
to	O
monitor	O
for	O
use,	O
confirm	O
a	O
diagnosis	O
of	O
poisoning,	O
assist	O
medicolegal	O
death	O
investigation.	O

Combination	O
of	O
levothyroxine	B-Drug
with	O
ketamine	B-Drug
may	O
cause	O
hypertension	O
and	O
tachycardia;	O
tricyclic	O
tetracyclic	O
antidepressants	O
increase	O
its	O
toxicity.	O

Dihydrocodeine	B-Drug
is	O
an	O
opioid	O
agonist.	O

It	O
is	O
also	O
spelled	O
phenethylline	O
and	O
fenetylline	B-Drug
(INN);	O
other	O
names	O
for	O
it	O
are	O
amphetaminoethyltheophylline	O
amfetyline.	O

If	O
lorazepam	B-Drug
is	O
not	O
available,	O
or	O
intravenous	O
access	O
possible,	O
then	O
diazepam	B-Drug
should	O
be	O
given.	O

In	O
the	O
absence	O
of	O
amphetamine,	O
VMAT2	O
will	O
normally	O
move	O
monoamines	O
(e.g.,	O
dopamine,	O
histamine,	O
serotonin,	O
norepinephrine,	O
etc.)	O
amphetamine	B-Drug

As	O
of	O
2013,	O
kratom	B-Drug
was	O
listed	O
by	O
ASEAN	O
in	O
its	O
annex	O
products	O
that	O
cannot	O
be	O
included	O
traditional	O
medicines	O
and	O
health	O
supplements	O
are	O
traded	O
across	O
nations.	O

The	O
interaction	O
between	O
sofosbuvir	B-Drug
and	O
a	O
number	O
of	O
other	O
drugs,	O
such	O
as	O
ciclosporin,	O
darunavir/ritonavir,	O
efavirenz,	O
emtricitabine,	O
methadone,	O
raltegravir,	O
rilpivirine,	O
tacrolimus,	O
or	O
tenofovir	B-Drug
disoproxil,	O
were	O
evaluated	O
in	O
clinical	O
trials	O
no	O
dose	O
adjustment	O
is	O
needed	O
for	O
any	O
these	O
drugs.	O
ciclosporin	B-Drug
darunavir	B-Drug
ritonavir	B-Drug
efavirenz	B-Drug
emtricitabine	B-Drug
methadone	B-Drug
raltegravir	B-Drug
rilpivirine	B-Drug
tacrolimus	B-Drug
disoproxil	I-Drug

The	O
Riksdag	O
added	O
25I-NBOMe	B-Drug
to	O
Narcotic	O
Drugs	O
Punishments	O
Act	O
under	O
Swedish	O
schedule	O

Niemann	O
described	O
every	O
step	O
he	O
took	O
to	O
isolate	O
cocaine	B-Drug
in	O
his	O
dissertation	O
titled	O
ber	O
eine	O
neue	O
organische	O
Base	O
den	O
Cocablttern	O

The	O
metabolites,	O
as	O
well	O
some	O
unmetabolized	O
alprazolam,	O
are	O
filtered	O
out	O
by	O
the	O
kidneys	O
and	O
excreted	O
in	O
urine.	O
alprazolam	B-Drug

"	O
The	O
three	O
main	O
forms	O
of	O
cannabis	O
products	O
are	O
the	O
flower/fruit,	O
resin	O
(hashish),	O
and	O
oil	I-Drug
(hash	O
oil).	O
hashish	B-Drug
hash	B-Drug

Even	O
small	O
quantities	O
of	O
25I-NBOMe	B-Drug
can	O
produce	O
a	O
large	O
number	O
blotters.	O

It	O
has	O
been	O
used	O
to	O
refer	O
opiates	O
since	O
at	O
least	O
1888,	O
and	O
this	O
usage	O
arose	O
because	O
opium,	O
when	O
prepared	O
for	O
smoking,	O
is	O
viscous.	O
opium	B-Drug

Although	O
deaths	O
from	O
methadone	B-Drug
are	O
on	O
the	O
rise,	O
methadone-associated	O
not	O
being	O
caused	O
primarily	O
by	O
intended	O
for	O
treatment	O
programs,	O
according	O
to	O
a	O
panel	O
of	O
experts	O
convened	O
Substance	O
Abuse	O
and	O
Mental	O
Health	O
Services	O
Administration,	O
which	O
released	O
report	O
titled	O
"Methadone-Associated	O
Mortality,	O
Report	O
National	O
Assessment".	O

The	O
combination	O
of	O
alcohol	O
and	O
zaleplon	B-Drug
can	O
result	O
in	O
fatal	O
respiratory	O
depression	O
asphyxiation	O
from	O
vomiting.	O

Quinidine	B-Drug
may	O
interact	O
with	O
chlorpromazine	B-Drug
to	O
increase	O
myocardialdepression.	O

cocaine,	O
MDMA,	O
LSD,	O
cannabis	O
Days	O
of	O
Wine	O
and	O
Roses	O
(film)	O
(1962)	O
cocaine	B-Drug
MDMA	B-Drug
LSD	B-Drug

Although	O
25I-NBOMe	B-Drug
was	O
discovered	O
in	O
2003,	O
it	O
did	O
not	O
emerge	O
as	O
a	O
common	O
recreational	O
drug	O
until	O
2010,	O
when	O
first	O
sold	O
by	O
vendors	O
specializing	O
the	O
supply	O
of	O
designer	O
drugs.	O

Neither	O
the	O
crown	O
(fruit,	O
mescal	O
button)	O
of	O
Peyote	O
cactus	O
nor	O
roots	O
plant	O
Mimosa	O
hostilis	O
Psilocybe	O
mushrooms	O
themselves	O
are	O
included	O
in	O
Schedule	O
1,	O
but	O
only	O
their	O
respective	O
principals,	O
mescaline,	O
DMT,	O
and	O
psilocin.	O
mescaline	B-Drug
psilocin	B-Drug

It	O
is	O
also	O
prohibited	O
to	O
grow	O
varieties	O
with	O
more	O
than	O
0.8%	O
of	O
morphine	B-Drug
in	O
dry	O
matter	O
their	O
capsules,	O
excluding	O
research	O
and	O
experimental	O
purposes	O
(24/1b/	O
the	O
act).	O

Metoclopramide	B-Drug
is	O
excreted	O
into	O
milk.	O

Elevated	O
concentrations	O
of	O
eluxadoline	O
were	O
observed	O
with	O
co-administration	O
inhibitors	O
the	O
transporter	O
protein	O
OATP1B1,	O
such	O
as:	O
Cyclosporine	B-Drug
Gemfibrozil	O
Certain	O
antiretrovirals	O
Rifampin	B-Drug
EltrombopagAlso,	O
concurrent	O
use	O
other	O
drugs	O
that	O
cause	O
constipation	O
is	O
not	O
preferred,	O
Opioids	O
Alosetron	B-Drug
Anticholinergics	O
Bismuth	B-Drug
subsalicylate,	O
potentially	O
dangerous	O
synergism.	O
subsalicylate	I-Drug

It	O
also	O
triggers	O
the	O
release	O
of	O
several	O
other	O
hormones	O
(e.g.,	O
epinephrine)	O
and	O
neurotransmitters	O
serotonin	O
histamine)	O
as	O
well	O
synthesis	O
certain	O
neuropeptides	O
cocaine	B-Drug
amphetamine	B-Drug
regulated	O
transcript	O
(CART)	O
peptides).	O

Painkillers	O
used	O
by	O
athletes	O
range	O
from	O
common	O
over-the-counter	O
medicines	O
such	O
as	O
NSAIDs	O
(such	O
ibuprofen)	O
to	O
powerful	O
prescription	O
narcotics.	O
ibuprofen	B-Drug

subsequently	O
gave	O
Huxley	O
a	O
dose	O
of	O
mescaline.	O
mescaline	B-Drug

MDMA	B-Drug
is	O
part	O
of	O
the	O
amphetamine	B-Drug
family	O
and	O
elicits	O
its	O
positive	O
effects	O
by	O
altering	O
brain	O
serotonin,	O
dopamine	O
norepinephrine	O
neurotransmitter	O
levels.	O

A	O
2019	O
systematic	O
review	O
and	O
meta-analysis	O
by	O
Murrie	O
et	O
al.	O
found	O
that	O
the	O
transition	O
rate	O
from	O
a	O
diagnosis	O
of	O
hallucinogen-induced	O
psychosis	O
to	O
schizophrenia	O
was	O
26%	O
(CI	O
14%-43%),	O
which	O
lower	O
than	O
cannabis-induced	O
(34%)	O
but	O
higher	O
amphetamine	B-Drug
(22%),	O
opioid	O
(12%),	O
alcohol	O
(10%)	O
sedative	O
(9%)	O
induced	O
psychoses.	O

Research	O
in	O
these	O
events	O
is	O
complicated	O
because	O
cannabis	O
often	O
used	O
conjunction	O
with	O
tobacco,	O
and	O
drugs	O
such	O
as	O
alcohol	O
cocaine.	O
tobacco	B-Drug
cocaine	B-Drug

It	O
is	O
the	O
species	O
of	O
plant	O
from	O
which	O
both	O
opium	B-Drug
and	O
poppy	O
seeds	O
are	O
derived	O
also	O
a	O
valuable	O
ornamental	O
plant,	O
grown	O
in	O
gardens.	O

More	O
than	O
12	O
different	O
analogues	O
of	O
fentanyl,	O
all	O
unapproved	O
and	O
clandestinely	O
produced,	O
have	O
been	O
identified	O
in	O
the	O
U.S.	O
drug	O
traffic.	O
fentanyl	B-Drug

Physicians	O
had	O
earlier	O
been	O
recommended	O
to	O
prescribe	O
products	O
with	O
only	O
dextropropoxyphene	B-Drug
and	O
not	O
patients	O
a	O
history	O
of	O
drug	O
abuse,	O
depression,	O
or	O
suicidal	O
tendencies.	O

For	O
reference,	O
circulating	O
concentrations	O
of	O
danazol	B-Drug
are	O
in	O
the	O
range	O
2	O
M	O
at	O
a	O
dosage	O
600	O
mg/day	O
women.	O

Fentanyl	B-Drug
in	O
injectable	O
formulation	O
is	O
commonly	O
used	O
for	O
analgesia	O
and	O
as	O
a	O
component	O
of	O
balanced	O
sedation	O
general	O
anesthesia	O
small	O
animal	O
patients.	O

However,	O
despite	O
the	O
greater	O
in	O
vitro	O
activity	O
of	O
some	O
its	O
metabolites,	O
it	O
has	O
been	O
determined	O
that	O
oxycodone	B-Drug
itself	O
is	O
responsible	O
for	O
83.0%	O
and	O
94.8%	O
analgesic	O
effect	O
following	O
oral	O
intravenous	O
administration,	O
respectively.	O

Triamcinolone	B-Drug
is	O
a	O
glucocorticoid	O
that	O
about	O
five	O
times	O
as	O
potent	O
cortisol,	O
but	O
has	O
very	O
little	O
mineralocorticoid	O
effects.	O

Due	O
to	O
its	O
short	O
half	O
life,	O
the	O
duration	O
of	O
action	O
flumazenil	B-Drug
is	O
usually	O
less	O
than	O
1	O
hour,	O
and	O
multiple	O
doses	O
may	O
be	O
needed.	O

Tamoxifen	B-Drug
causes	O
cells	O
to	O
remain	O
in	O
the	O
G0	O
and	O
G1	O
phases	O
of	O
cell	O
cycle.	O

Cocaine	B-Drug
hydrochloride	O
(Goprelto),	O
an	O
ester	O
local	O
anesthetic,	O
was	O
approved	O
for	O
medical	O
use	O
in	O
the	O
United	O
States	O
December	O
2017,	O
and	O
is	O
indicated	O
introduction	O
of	O
anesthesia	O
mucous	O
membranes	O
diagnostic	O
procedures	O
surgeries	O
on	O
or	O
through	O
nasal	O
cavities	O
adults.	O

For	O
example,	O
ketoprofen's	O
effects	O
have	O
been	O
studied	O
in	O
horses	O
more	O
than	O
ruminants	O
but,	O
due	O
to	O
controversy	O
over	O
its	O
use	O
racehorses,	O
veterinarians	O
who	O
treat	O
livestock	O
the	O
United	O
States	O
commonly	O
prescribe	O
flunixin	O
meglumine,	O
which,	O
while	O
labeled	O
for	O
such	O
animals,	O
is	O
not	O
indicated	O
post-operative	O
pain.	O
ketoprofen	B-Drug

In	O
Italy,	O
the	O
gold	O
standard	O
for	O
treatment	O
of	O
high-dose	O
benzodiazepine	O
dependency	O
is	O
810	O
days	O
low-dose,	O
slowly	O
infused	O
flumazenil.	O
flumazenil	B-Drug

This	O
indicates	O
that	O
acute	O
and	O
chronic	O
administration	O
of	O
both	O
domperidone	B-Drug
metoclopramide	B-Drug
is	O
effective	O
in	O
increasing	O
prolactin	O
levels,	O
but	O
there	O
are	O
differential	O
effects	O
on	O
the	O
secretion	O
with	O
treatment.	O

Conversely,	O
following	O
a	O
single	O
5	O
mg	O
dose	O
of	O
finasteride,	O
mean	O
peak	O
levels	O
finasteride	B-Drug
were	O
37	O
ng	O

There	O
is	O
no	O
evidence	O
prasterone	B-Drug
of	O
benefit	O
in	O
treating	O
or	O
preventing	O
cancer.	O

However,	O
sometimes	O
samples	O
containing	O
pure	O
enantiomers	O
may	O
be	O
made	O
and	O
sold	O
at	O
a	O
higher	O
cost	O
in	O
cases	O
where	O
the	O
use	O
requires	O
specifically	O
one	O
isomer	O
(e.g.,	O
for	O
stereospecific	O
reagent);	O
compare	O
omeprazole	B-Drug
esomeprazole.	O
esomeprazole	B-Drug

Hash	B-Drug
oil	I-Drug
can	O
be	O
the	O
most	O
potent	O
of	O
main	O
cannabis	O
products	O
because	O
its	O
high	O
level	O
psychoactive	O
compound	O
per	O
volume,	O
which	O
vary	O
depending	O
on	O
plant's	O
mix	O
essential	O
oils	O
and	O
compounds.	O

Clonazepam	B-Drug
is	O
prescribed	O
for	O
short	O
term	O
management	O
of	O
epilepsy	O
and	O
panic	O
disorder	O
with	O
or	O
without	O
agoraphobia.	O

Due	O
to	O
its	O
structural	O
similarity	O
the	O
schedule	O
I/III	O
drug	O
THC	B-Drug
it	O
can	O
be	O
treated	O
as	O
a	O
I	O
within	O
United	O
States	O
legal	O
system	O
under	O
Federal	O
Analogue	O
Act.	O

Because	O
of	O
its	O
short	O
elimination	O
half-life,	O
gabapentin	B-Drug
must	O
be	O
administered	O
3	O
to	O
4	O
times	O
per	O
day	O
maintain	O
therapeutic	O
levels.	O

Ephedrine	B-Drug
exhibits	O
optical	O
isomerism	O
and	O
has	O
two	O
chiral	O
centres,	O
giving	O
rise	O
to	O
four	O
stereoisomers.	O

Xofluza	B-Drug
(baloxavir	O
marboxil),	O
for	O
influenza	O
A	O
and	O
B	O
(both	O
treatment	O
prevention).	O
baloxavir	B-Drug
marboxil	I-Drug

Clonazepam	B-Drug
was	O
the	O
second	O
most	O
frequently	O
implicated	O
benzodiazepine	O
in	O
ED	O
visits.	O

In	O
2019,	O
Spanish	O
authorities	O
apprehended	O
a	O
20m	O
privately-owned	O
semi-submersible	O
off	O
Galicia,	O
Spain	O
containing	O
3,000	O
kg	O
of	O
cocaine,	O
in	O
the	O
first	O
known	O
incident	O
submarine	O
crossing	O
Atlantic	O
Ocean.	O
cocaine	B-Drug

Like	O
cocaine	B-Drug
in	O
other	O
forms,	O
crack	O
rock	O
acts	O
as	O
a	O
local	O
anesthetic,	O
numbing	O
the	O
tongue	O
or	O
mouth	O
only	O
where	O
directly	O
placed.	O

Between	O
400	O
and	O
1200	O
AD,	O
Arab	O
traders	O
introduced	O
opium	B-Drug
to	O
China,	O
India	O
by	O
700.	O

In	O
addition	O
to	O
low	O
NAcc	O
D2	O
binding,	O
cocaine	B-Drug
is	O
also	O
known	O
produce	O
a	O
variety	O
of	O
changes	O
the	O
primate	O
brain	O
such	O
as	O
increases	O
prodynorphin	O

Leuprorelin	B-Drug
may	O
be	O
used	O
in	O
the	O
treatment	O
of	O
hormone-responsive	O
cancers	O
such	O
as	O
prostate	O
cancer	O
and	O
breast	O
cancer.	O

Oxycodone's	O
chemical	O
name	O
is	O
derived	O
from	O
codeine.	O
Oxycodone	B-Drug
codeine	B-Drug

It	O
is	O
also	O
available	O
as	O
the	O
combination	O
phentermine/topiramate.	O
phentermine/topiramate	B-Drug

A	O
combination	O
of	O
naltrexone	B-Drug
with	O
buprenorphine	B-Drug
(buprenorphine/naltrexone)	O
has	O
been	O
developed,	O
but	O
not	O
marketed.	O
buprenorphine/naltrexone	B-Drug

The	O
3,6-diesters	O
of	O
morphine	B-Drug
are	O
drugs	O
with	O
more	O
rapid	O
and	O
complete	O
central	O
nervous	O
system	O
penetration	O
due	O
to	O
increased	O
lipid	O
solubility	O
other	O
structural	O
considerations.	O

Experimental	O
studies	O
attempted	O
to	O
measure	O
the	O
effect	O
of	O
LSD	B-Drug
on	O
creative	O
activity	O
and	O
aesthetic	O
appreciation.	O

MBDB's	O
dosage,	O
according	O
to	O
PiHKAL,	O
is	O
180210	O
mg;	O
the	O
proper	O
dosage	O
relative	O
body	O
mass	O
seems	O
unknown.	O
MBDB	B-Drug

trichomes	O
Structures	O
giving	O
the	O
cannabis	O
leaf	O
a	O
powdery	O
appearance	O
and	O
containing	O
most	O
of	O
THC.	O
THC	B-Drug

A	O
large-scale	O
trial	O
utilizing	O
cognitive	O
behavioral	O
therapy	O
in	O
chronic	O
users	O
of	O
sedative	O
hypnotics	O
including	O
nitrazepam,	O
temazepam,	O
and	O
zopiclone	B-Drug
found	O
CBT	O
to	O
be	O
a	O
significantly	O
more	O
effective	O
long-term	O
treatment	O
for	O
insomnia	O
than	O
hypnotic	O
drugs.	O
nitrazepam	B-Drug
temazepam	B-Drug

These	O
studies	O
test	O
broadly	O
for	O
a	O
number	O
of	O
phenotypes,	O
including	O
opioid	O
dependence,	O
cocaine	O
alcohol	O
methamphetamine	B-Drug
dependence/psychosis,	O
response	O
to	O
naltrexone	B-Drug
treatment,	O
personality	O
traits,	O
and	O
others.	O

Opponents	O
of	O
more	O
prohibitive	O
measures	O
against	O
salvia	O
argue	O
that	O
such	O
reactions	O
are	O
largely	O
due	O
to	O
an	O
inherent	O
prejudice	O
and	O
a	O
particular	O
cultural	O
bias	O
rather	O
than	O
any	O
actual	O
balance	O
evidence,	O
pointing	O
out	O
inconsistencies	O
in	O
attitudes	O
toward	O
other	O
toxic	O
addictive	O
drugs	O
as	O
alcohol	O
nicotine.	O
nicotine	B-Drug

In	O
1909,	O
Ernest	O
Shackleton	O
took	O
"Forced	O
March"	O
brand	O
cocaine	B-Drug
tablets	O
to	O
Antarctica,	O
as	O
did	O
Captain	O
Scott	O
a	O
year	O
later	O
on	O
his	O
ill-fated	O
journey	O
the	O
South	O
Pole.	O

Methamphetamine	B-Drug
may	O
be	O
sold	O
illicitly,	O
either	O
as	O
pure	O
dextromethamphetamine	B-Drug
or	O
in	O
an	O
equal	O
parts	O
mixture	O
of	O
the	O
right-	O
and	O
left-handed	O
molecules	O
(i.e.,	O
50%	O
levomethamphetamine	B-Drug
dextromethamphetamine).	O

co-codamol	B-Drug

Apparent	O
steady	O
state	O
for	O
armodafinil	B-Drug
was	O
reached	O
within	O
7	O
days	O
of	O
dosing.	O

Methadone	B-Drug
is	O
available	O
in	O
traditional	O
pill,	O
sublingual	O
tablet,	O
and	O
two	O
different	O
formulations	O
designed	O
for	O
the	O
person	O
to	O
drink.	O

Specifically,	O
nociceptin	O
acts	O
to	O
inhibit	O
neural	O
rewards	O
induced	O
by	O
drugs	O
such	O
as	O
amphetamines,	O
morphine,	O
cocaine,	O
and	O
especially	O
alcohol	O
in	O
animal	O
models,	O
though	O
the	O
exact	O
mechanism	O
of	O
this	O
has	O
not	O
yet	O
been	O
proven.	O
morphine	B-Drug
cocaine	B-Drug

This	O
may	O
be	O
illusory	O
due	O
to	O
the	O
metabolism-dependent	O
effects	O
of	O
tramadol.	O
tramadol	B-Drug

as	O
after	O
1991	O
the	O
availability	O
of	O
heroin	B-Drug
and	O
other	O
drugs	O
smuggled	O
into	O
those	O
countries	O
from	O
abroad	O
increased	O
enormously.	O

When	O
taken	O
by	O
mouth,	O
it	O
has	O
roughly	O
1.5	O
times	O
the	O
effect	O
of	O
equivalent	O
amount	O
morphine.	O
morphine	B-Drug

As	O
with	O
psilocybin,	O
miprocybin	O
and	O
metocybin,	O
ethocybin	B-Drug
is	O
a	O
prodrug	O
that	O
converted	O
into	O
the	O
pharmacologically	O
active	O
compound	O
ethocin	B-Drug
in	O
body	O
by	O
dephosphorylation.	O

Bicalutamide	B-Drug
monotherapy	O
seems	O
to	O
have	O
minimal	O
effect	O
on	O
testicular	O
spermatogenesis,	O
ultrastructure,	O
and	O
certain	O
aspects	O
of	O
male	O
fertility.	O

Some	O
countries,	O
such	O
as	O
Peru	O
and	O
Bolivia,	O
permit	O
the	O
cultivation	O
of	O
coca	B-Drug
leaf	O
for	O
traditional	O
consumption	O
by	O
local	O
indigenous	O
population,	O
but	O
nevertheless,	O
prohibit	O
production,	O
sale,	O
cocaine.	O
cocaine	B-Drug

Amphetamine,	O
discovered	O
before	O
methamphetamine,	O
was	O
first	O
synthesized	O
in	O
1887	O
Germany	O
by	O
Romanian	O
chemist	O
Lazr	O
Edeleanu	O
who	O
named	O
it	O
phenylisopropylamine.	O
Amphetamine	B-Drug
methamphetamine	B-Drug

Conversely,	O
unesterified	O
nandrolone	B-Drug
has	O
been	O
used	O
by	O
intramuscular	O
injection	O
once	O
daily.	O

Those	O
either	O
are	O
not	O
found	O
in	O
proteins	O
(for	O
example	O
carnitine,	O
GABA,	O
levothyroxine)	O
or	O
produced	O
directly	O
and	O
isolation	O
by	O
standard	O
cellular	O
machinery	O
example,	O
hydroxyproline	O
selenomethionine).	O
carnitine	B-Drug
levothyroxine	B-Drug

There	O
is	O
little	O
evidence	O
for	O
damage	O
to	O
the	O
organ	O
system,	O
only	O
due	O
consumption	O
in	O
combination	O
with	O
tobacco.	O
tobacco	B-Drug

Celgene	O
has	O
sponsored	O
numerous	O
clinical	O
trials	O
with	O
analogues	O
to	O
thalidomide,	O
such	O
as	O
lenalidomide,	O
that	O
are	O
substantially	O
more	O
powerful	O
and	O
have	O
fewer	O
side	O
effects	O
except	O
for	O
greater	O
myelosuppression.	O
thalidomide	B-Drug
lenalidomide	B-Drug

THC	B-Drug
also	O
potentiates	O
the	O
effects	O
of	O
glycine	O
receptors.	O

Androstenedione	B-Drug
was	O
manufactured	O
as	O
a	O
dietary	O
supplement,	O
often	O
called	O
andro	O
or	O
andros	O
for	O
short.	O

JWH-018,	O
CP	B-Drug
47,497	I-Drug
(and	O
its	O
homologues)	O
JWH-018	B-Drug

In	O
the	O
UK,	O
etizolam	B-Drug
has	O
been	O
classified	O
as	O
a	O
Class	O
C	O
drug	O
by	O
May	O
2017	O
amendment	O
to	O
The	O
Misuse	O
of	O
Drugs	O
Act	O
1971	O
along	O
with	O
several	O
other	O
designer	O
benzodiazepine	O
drugs.	O

This	O
is	O
because	O
LSD	B-Drug
almost	O
always	O
present	O
in	O
a	O
medium	O
(e.g.	O
blotter	O
or	O
neutral	O
liquid),	O
and	O
some	O
contexts,	O
the	O
amount	O
that	O
can	O
be	O
considered	O
with	O
respect	O
to	O
sentencing	O
total	O
mass	O
of	O
drug	O
its	O
medium.	O

Cocaine's	O
stimulant	O
effects	O
are	O
similar	O
to	O
that	O
of	O
amphetamine,	O
however,	O
these	O
tend	O
be	O
much	O
shorter	O
lasting	O
and	O
more	O
prominent.	O
Cocaine	B-Drug
amphetamine	B-Drug

Phenampromide	B-Drug
(N-(1-methyl-2-piperidino)	O
ethyl)	O

The	O
events	O
of	O
the	O
first	O
LSD	B-Drug
trip,	O
now	O
known	O
as	O
Bicycle	O
Day,	O
after	O
bicycle	O
ride	O
home,	O
proved	O
to	O
Hofmann	O
that	O
he	O
had	O
indeed	O
made	O
a	O
significant	O
discovery:	O
psychoactive	O
substance	O
with	O
extraordinary	O
potency,	O
capable	O
causing	O
shifts	O
consciousness	O
in	O
incredibly	O
low	O
doses.	O

Recreational	O
use	O
of	O
25I-NBOMe	B-Drug
carries	O
a	O
significant	O
risk	O
both	O
pharmacological	O
and	O
behavioral	O
toxicity.	O

In	O
Chile,	O
GHB	B-Drug
is	O
a	O
controlled	O
drug	O
under	O
the	O
law	O
Ley	O
de	O
substancias	O
psicotrpicas	O
y	O
estupefacientes	O
(psychotropic	O
substances	O
and	O
narcotics).	O

Danazol	B-Drug
is	O
lipophilic	O
and	O
can	O
partition	O
into	O
cell	O
membranes,	O
which	O
indicates	O
that	O
it	O
likely	O
to	O
distribute	O
deeply	O
tissue	O
compartments.	O

Medical	O
examiners	O
concluded	O
that	O
author	O
journalist	O
Michelle	O
McNamara	O
died	O
on	O
April	O
21,	O
2016,	O
from	O
an	O
accidental	O
overdose	O
where	O
Fentanyl	B-Drug
was	O
a	O
contributing	O
factor.	O

CBN	B-Drug
(cannabinol)	O
CBG	O
(cannabigerol)	O
CBC	O
(cannabichromene)	O
cannabinol	B-Drug

2C-B-FLY	B-Drug
is	O
a	O
psychedelic	O
phenethylamine	B-Drug
of	O
the	O
2C	O
family.	O

Nabilone	B-Drug
Any	O
compound	O
structurally	O
derived	O
from	O
3phenylacetylindole	O
by	O
substitution	O
at	O
the	O
nitrogen	O
atom	O
of	O
indole	O
ring	O
with	O
alkyl,	O
alkenyl,	O
cycloalkylmethyl,	O
cycloalkylethyl	O
or	O
2(4morpholinyl)ethyl,	O
whether	O
not	O
further	O
substituted	O
in	O
to	O
any	O
extent	O
and	O
phenyl	O
extent.	O

It	O
is	O
commonly	O
applied	O
to	O
any	O
drug	O
with	O
perception-altering	O
psychedelic	O
effects	O
such	O
as	O
LSD	B-Drug
and	O
other	O
ergotamine	B-Drug
derivatives,	O
DMT	O
tryptamines	O
including	O
the	O
alkaloids	O
of	O
Psilocybe	O
spp.	O

There	O
was	O
a	O
proposal	O
being	O
discussed	O
by	O
the	O
UN	O
Commission	O
on	O
Narcotic	O
Drugs	O
(CND)	O
to	O
include	O
butyrfentanyl	B-Drug
in	O
Schedule	O
1	O
of	O
1961	O
Single	O
Convention	O
which	O
passed	O
16	O
March	O
2017.	O

Specifically,	O
it	O
is	O
a	O
derivative	O
of	O
GABA	O
with	O
pentyl	O
disubstitution	O
at	O
3	O
position,	O
hence,	O
the	O
name	O
-	O
gabapentin,	O
in	O
such	O
way	O
as	O
to	O
form	O
six-membered	O
ring.	O
gabapentin	B-Drug

Cocaine	B-Drug
is	O
smoked	O
by	O
inhaling	O
the	O
vapor	O
produced	O
when	O
solid	O
cocaine	B-Drug
heated	O
to	O
point	O
that	O
it	O
sublimates.	O

Blood	O
or	O
plasma	O
ketamine	B-Drug
concentrations	O
are	O
usually	O
in	O
a	O
range	O
of	O
0.55.0	O

A	O
subsequent	O
inquest	O
determined	O
that	O
her	O
death	O
was	O
not	O
directly	O
caused	O
by	O
the	O
consumption	O
of	O
ecstasy,	O
but	O
rather	O
result	O
large	O
quantity	O
water	O
she	O
had	O
consumed.	O
ecstasy	B-Drug

The	O
U.S.	O
Food	O
and	O
Drug	O
Administration	O
(FDA)	O
fenfluramine	B-Drug
labeling	O
includes	O
a	O
boxed	O
warning	O
stating	O
the	O
drug	O
is	O
associated	O
with	O
valvular	O
heart	O
disease	O
(VHD)	O
pulmonary	O
arterial	O
hypertension	O
(PAH).	O

Clobazam	B-Drug
was	O
first	O
synthesized	O
in	O
1966	O
and	O
published	O
1969.	O

In	O
1994,	O
Zurich	O
started	O
a	O
pilot	O
project	O
using	O
prescription	O
heroin	B-Drug
in	O
heroin-assisted	O
treatment	O
(HAT)	O
which	O
allowed	O
users	O
to	O
obtain	O
and	O
inject	O
it	O
under	O
medical	O
supervision.	O

Breast	O
tenderness	O
(93%),	O
gynecomastia	O
(54%),	O
and	O
sexual	O
dysfunction	O
(60%)	O
were	O
all	O
reported	O
as	O
side	O
effects	O
of	O
bicalutamide	B-Drug
at	O
the	O
dosage	O
used	O
in	O
study,	O
although	O
no	O
treatment	O
discontinuations	O
due	O
to	O
adverse	O
occurred	O
functioning	O
was	O
maintained	O
75%	O
patients.	O

The	O
most	O
significant	O
difference	O
in	O
side	O
effects	O
of	O
loprazolam	B-Drug
and	O
diazepam	B-Drug
is	O
it	O
less	O
prone	O
to	O
day	O
time	O
sedation	O
as	O
the	O
half-life	O
considered	O
be	O
intermediate	O
whereas	O
has	O
a	O
very	O
long	O
half-life.	O

The	O
price	O
of	O
white	O
heroin	B-Drug
is	O
reported	O
only	O
by	O
a	O
few	O
European	O
countries	O
and	O
ranged	O
between	O
27	O
110	O
per	O
gram.	O

Women	O
should	O
be	O
offered	O
diamorphine	B-Drug
(0.30.4	O
mg	O
intrathecally)	O
for	O
intra-	O
and	O
postoperative	O
analgesia	O
because	O
it	O
reduces	O
the	O
need	O
supplemental	O
after	O
a	O
caesarean	O
section.	O

Primary	O
reports	O
also	O
have	O
provided	O
evidence	O
that	O
PEA	B-Drug
downregulates	O
hyperactive	O
mast	O
cells	O
in	O
a	O
dose-dependent	O
manner,	O
and	O
it	O
might	O
likewise	O
alleviate	O
pain	O
behaviors	O
elicited	O
mice-pain	O
models.	O

The	O
press	O
release	O
from	O
the	O
U.S.	O
Office	O
of	O
National	O
Drug	O
Control	O
Policy	O
stated	O
that	O
"coca	O
cultivation	O
declined	O
by	O
8	O
percent,	O
114,100	O
to	O
105,400	O
hectares,	O
when	O
those	O
areas	O
surveyed	O
US	O
government	O
in	O
2004	O
were	O
compared	O
with	O
same	O
2005".	O
coca	B-Drug

Black	O
tar	O
heroin	O
is	O
impure	O
diamorphine.	O
diamorphine	B-Drug

There	O
is	O
no	O
evidence	O
of	O
toxicity	O
from	O
contaminants	O
street	O
heroin	B-Drug
in	O
Australia."	O

Ranitidine	B-Drug
is	O
contraindicated	O
for	O
people	O
with	O
acute	O
porphyria	O
in	O
the	O
past,	O
because	O
links	O
may	O
exist	O
between	O
taking	O
ranitidine	B-Drug
and	O
porphyria.	O

+	O
and	O
NOS	O
results	O
in	O
the	O
formation	O
of	O
cofactor	O
tetrahydrobiopterin	B-Drug
(BH4),	O
which	O
then	O
moves	O
from	O
plasma	O
membrane	O
into	O
cytoplasm.	O
BH4	B-Drug

Stimulants	O
such	O
as	O
amphetamine	B-Drug
can	O
improve	O
performance	O
on	O
difficult	O
and	O
boring	O
tasks	O
are	O
used	O
by	O
some	O
students	O
a	O
study	O
test-taking	O
aid.	O

However,	O
some	O
sedating	O
antihistamines	O
such	O
as	O
orphenadrine	B-Drug
can	O
produce	O
a	O
synergistic	O
pain	O
relieving	O
effect	O
permitting	O
smaller	O
doses	O
of	O
opioids	O
be	O
used.	O

Congress	O
temporarily	O
placed	O
cannabis	O
in	O
Schedule	O
I,	O
the	O
most	O
restrictive	O
classification,	O
and	O
National	O
Commission	O
on	O
Marihuana	B-Drug
Drug	O
Abuse	O
or	O
Shafer	O
was	O
appointed	O
to	O
make	O
a	O
recommendation	O
for	O
its	O
permanent	O
placement.	O

As	O
an	O
N-ethyl	O
derivative	O
of	O
6-APB,	O
6-EAPB	B-Drug
fell	O
outside	O
the	O
scope	O
Temporary	O
Class	O
Drug	O
ban	O
issued	O
by	O
Home	O
Office	O
on	O
June	O
10,	O
2013.	O
6-APB	B-Drug

CP	B-Drug
47,497	I-Drug
and	O
its	O
C6,	O
C8,	O
C9	O
homologues	O
were	O
made	O
illegal	O
in	O
Latvia	O
on	O
28	O
November	O
2009.	O

In	O
a	O
study	O
of	O
89	O
women	O
with	O
hyperandrogenism	O
due	O
to	O
persistent	O
adrenarche	O
syndrome,	O
finasteride	B-Drug
produced	O
93%	O
reduction	O
in	O
facial	O
hirsutism	O
and	O
73%	O
bodily	O
after	O
2	O
years	O
treatment.	O

Desipramine	B-Drug
is	O
a	O
tricyclic	O
compound,	O
specifically	O
dibenzazepine,	O
and	O
possesses	O
three	O
rings	O
fused	O
together	O
with	O
side	O
chain	O
attached	O
in	O
its	O
chemical	O
structure.	O

Fewer	O
than	O
30	O
different	O
analogs	O
of	O
PCP	B-Drug
were	O
reported	O
as	O
being	O
used	O
on	O
the	O
street	O
during	O
1970s	O
and	O
1980s,	O
mainly	O
in	O
United	O
States.	O

Despite	O
the	O
side	O
effects,	O
thalidomide	B-Drug
was	O
sold	O
in	O
pharmacies	O
Canada	O
until	O
1962.	O

By	O
1984	O
the	O
DEA	O
had	O
announced	O
its	O
intention	O
to	O
designate	O
MDMA	B-Drug
as	O
a	O
Schedule	O

In	O
1995	O
the	O
World	O
Health	O
Organization	O
(WHO)	O
and	O
United	O
Nations	O
Interregional	O
Crime	O
Justice	O
Research	O
Institute	O
(UNICRI)	O
announced	O
in	O
a	O
press	O
release	O
publication	O
of	O
results	O
largest	O
global	O
study	O
on	O
cocaine	B-Drug
use	O
ever	O
undertaken.	O

Since	O
then,	O
scopolamine	B-Drug
has	O
become	O
a	O
standard	O
drug	O
for	O
experimentally	O
inducing	O
cognitive	O
defects	O
in	O
animals.	O

Methadone	B-Drug
was	O
developed	O
in	O
1937	O
Germany	O
by	O
scientists	O
working	O
for	O
I.G.	O
Farbenindustrie	O
AG	O
at	O
the	O
Farbwerke	O
Hoechst	O
who	O
were	O
looking	O
a	O
synthetic	O
opioid	O
that	O
could	O
be	O
created	O
with	O
readily	O
available	O
precursors,	O
to	O
solve	O
Germany's	O
opium	B-Drug
shortage	O
problem.	O

The	O
usual	O
means	O
of	O
protection	O
against	O
the	O
negative	O
effects	O
iodine-131	O
is	O
by	O
saturating	O
thyroid	O
gland	O
with	O
stable	O
iodine-127	O
in	O
form	O
potassium	B-Drug
iodide	I-Drug
tablets,	O
taken	O
daily	O
for	O
optimal	O
prophylaxis.	O

Therefore,	O
people	O
driving	O
or	O
conducting	O
activities	O
which	O
require	O
vigilance	O
should	O
exercise	O
caution	O
in	O
using	O
nitrazepam	B-Drug
possibly	O
avoid	O
it	O
altogether.	O

A	O
2018	O
report	O
by	O
The	O
Guardian	O
indicated	O
that	O
many	O
major	O
drug	O
suppliers	O
on	O
the	O
dark	O
web	O
have	O
voluntarily	O
banned	O
trafficking	O
of	O
fentanyl.	O
fentanyl	B-Drug

Dapsone's	O
anti-inflammatory	O
and	O
immunomodulatory	O
effects	O
are	O
thought	O
to	O
be	O
its	O
mechanism	O
of	O
action	O
in	O
treating	O
dermatitis	O
herpetiformis.	O
Dapsone	B-Drug

A	O
2017	O
survey	O
in	O
Utah	O
of	O
heroin	B-Drug
users	O
found	O
about	O
80	O
percent	O
started	O
with	O
prescription	O
drugs.	O

A	O
2015	O
study	O
has	O
investigated	O
the	O
interrelation	O
between	O
mephedrone	B-Drug
and	O
alcohol,	O
focusing	O
on	O
psychostimulant	O
rewarding	O
effects.	O

At	O
its	O
33rd	O
meeting,	O
in	O
2003,	O
the	O
World	O
Health	O
Organization	O
Expert	O
Committee	O
on	O
Drug	O
Dependence	O
recommended	O
transferring	O
THC	B-Drug
to	O
Schedule	O
IV	O
of	O
Convention,	O
citing	O
medical	O
uses	O
and	O
low	O
abuse	O
potential.	O

Kief	O
is	O
a	O
powder,	O
rich	O
in	O
trichomes,	O
which	O
can	O
be	O
sifted	O
from	O
the	O
leaves,	O
flowers	O
and	O
fruits	O
of	O
cannabis	O
plants	O
either	O
consumed	O
powder	O
form	O
or	O
compressed	O
to	O
produce	O
cakes	O
hashish.	O
hashish	B-Drug

With	O
the	O
establishment	O
of	O
poppy	O
straw	O
as	O
source	O
majority	O
natural	O
morphine	B-Drug
and	O
other	O
opiates,	O
much	O
world	O
production	O
opium	B-Drug
is	O
destined	O
for	O
illicit	O
uses.	O

In	O
June	O
2008,	O
more	O
than	O
20	O
people	O
were	O
hospitalized	O
with	O
psychosis	O
in	O
Norway	O
after	O
ingesting	O
counterfeit	O
rohypnol	B-Drug
tablets	O
containing	O
hyoscine.	O
hyoscine	B-Drug

This	O
group	O
also	O
includes	O
some	O
alkaloids	O
that	O
besides	O
the	O
nitrogen	O
heterocycle	O
contain	O
terpene	O
(e.g.,	O
evonine)	O
or	O
peptide	O
fragments	O
(e.g.	O
ergotamine).	O
ergotamine	B-Drug

Fentanyl	B-Drug
is	O
a	O
synthetic	O
opioid	O
in	O
the	O
phenylpiperidine	O
family,	O
which	O
includes	O
sufentanil,	O
alfentanil,	O
remifentanil,	O
and	O
carfentanil.	O
sufentanil	B-Drug
alfentanil	B-Drug
remifentanil	B-Drug
carfentanil	B-Drug

In	O
2006,	O
the	O
U.S.	O
Food	O
and	O
Drug	O
Administration	O
(FDA)	O
began	O
investigating	O
several	O
respiratory	O
deaths,	O
but	O
doctors	O
in	O
United	O
Kingdom	O
were	O
not	O
warned	O
of	O
risks	O
with	O
fentanyl	B-Drug
until	O
September	O
2008.	O

The	O
active	O
ingredients	O
are	O
morphine	B-Drug
sulfate	I-Drug
and	O
naltrexone	B-Drug
hydrochloride;	O
being	O
an	O
opioid	O
receptor	O
agonist	O
antagonist.	O
hydrochloride	I-Drug

An	O
additional	O
study,	O
in	O
which	O
at	O
least	O
one	O
of	O
the	O
authors	O
is	O
employed	O
by	O
multiple	O
drug	O
companies,	O
examined	O
efficacy	O
temazepam	B-Drug
treatment	O
on	O
chronic	O
insomnia	O
over	O
three	O
months,	O
and	O
saw	O
no	O
tolerance,	O
with	O
even	O
suggesting	O
might	O
become	O
more	O
effective	O
time.	O

Around	O
1970,	O
Shulgin	O
sent	O
instructions	O
for	O
N-methylated	O
MDA	O
(MDMA)	O
synthesis	O
to	O
the	O
founder	O
of	O
a	O
Los	O
Angeles	O
chemical	O
company	O
who	O
had	O
requested	O
them.	O
MDMA	B-Drug

When	O
compared	O
to	O
oral	O
AAS,	O
trenbolone	B-Drug
acetate	O
has	O
a	O
stronger	O
negative	O
effect	O
on	O
cholesterol	O
levels.	O

It	O
was	O
reported	O
that	O
ulcers	O
and	O
dermatologic	O
problems,	O
both	O
of	O
which	O
involved	O
emotional	O
factors,	O
were	O
reduced	O
by	O
chlordiazepoxide.	O
chlordiazepoxide	B-Drug

Researchers	O
confirmed	O
that	O
THC	B-Drug
exerts	O
its	O
most	O
prominent	O
effects	O
via	O
actions	O
on	O
two	O
types	O
of	O
cannabinoid	O
receptors,	O
the	O
CB1	O
receptor	O
and	O
CB2	O
receptor,	O
both	O
which	O
are	O
G	O
protein-coupled	O
receptors.	O

Fentanyl	B-Drug
has	O
a	O
therapeutic	O
index	O
of	O
270.	O

A	O
2019	O
review	O
found	O
that	O
pregabalin	B-Drug
reduces	O
symptoms,	O
and	O
was	O
generally	O
well	O
tolerated.	O

For	O
instance,	O
etorphine	B-Drug
and	O
acetorphine	B-Drug
were	O
considered	O
sufficiently	O
morphine-like	O
to	O
fall	O
under	O
the	O
treaty's	O
scope,	O
although	O
they	O
are	O
many	O
times	O
more	O
potent	O
than	O
morphine.	O
morphine	B-Drug

Her	O
physician	O
prescribed	O
codeine	B-Drug
for	O
post-caesarian	O
pain.	O

Rofecoxib	O
(Vioxx)	O
was	O
shown	O
to	O
produce	O
significantly	O
fewer	O
gastrointestinal	O
adverse	O
drug	O
reactions	O
(ADRs)	O
compared	O
with	O
naproxen.	O
naproxen	B-Drug

Methamphetamine	B-Drug
or	O
meth	B-Drug
is	O
a	O
synthetic	O
drug	O
which	O
can	O
be	O
produced	O
on	O
domestic	O
scale.	O

Outside	O
Europe,	O
the	O
illicit	O
market	O
for	O
amphetamine	B-Drug
is	O
much	O
smaller	O
than	O
methamphetamine	B-Drug
and	O
MDMA.	O
MDMA	B-Drug

From	O
2001	O
to	O
2003,	O
the	O
number	O
of	O
16-year-old	O
boys	O
who	O
had	O
used	O
illegal	O
drugs	O
in	O
past	O
month	O
fell	O
from	O
10%	O
7%.In	O
2005,	O
compliance	O
with	O
EU	O
rules,	O
cultivation	O
industrial	O
hemp	O
less	O
than	O
0.2%	O
THC	B-Drug
was	O
legalized	O
providing	O
farmer	O
followed	O
a	O
rules	O
such	O
as	O
yearly	O
registration	O
field.	O

At	O
lower	O
doses,	O
it	O
antagonizes	O
the	O
analgesic	O
effects	O
of	O
alfentanil	B-Drug
and	O
substitutes	O
for	O
naloxone	B-Drug
in	O
morphine-treated	O
monkeys;	O
however,	O
also	O
reverses	O
naloxone-precipitated	O
withdrawal	O
pigeons	O
trained	O
to	O
discriminate	O
morphine	B-Drug
from	O
naloxone.	O

The	O
newest	O
formulation	O
to	O
come	O
out	O
was	O
in	O
2014,	O
when	O
zohydro,	O
an	O
increased	O
dosage	O
formula	O
of	O
hydrocodone	B-Drug
released;	O
this	O
it	O
is	O
the	O
strongest	O
yet	O
created	O
for	O
pain	O
management,	O
on	O
par	O
with	O
moderate	O
dose	O
oxycodone	B-Drug
.	O

Methyltestosterone	B-Drug
is	O
highly	O
protein-bound,	O
by	O
approximately	O
98%.	O

The	O
authors	O
investigated	O
the	O
relative	O
abilities	O
of	O
various	O
opioids	O
to	O
induce	O
histamine	O
release	O
mediated	O
increased	O
capillary	O
permeability	O
and	O
tissue	O
edema	O
(wheal	O
response	O
)	O
cutaneous	O
vasodilatation	O
local	O
redness	O
(flare	O
response)	O
when	O
subjects	O
were	O
intradermally	O
injected	O
with	O
0.02	O
ml	O
equimolar	O
concentrations	O
5	O
x	O
10-4	O
M.	O
Nalbuphine	B-Drug
did	O
not	O
produce	O
either	O
a	O
wheal	O
or	O
flare	O
response.	O

PCP	B-Drug
may	O
cause	O
hallucinations,	O
distorted	O
perceptions	O
of	O
sounds,	O
and	O
violent	O
behavior.	O

Nevertheless,	O
cocaine	B-Drug
metabolites	O
can	O
be	O
detected	O
in	O
the	O
urine	O
of	O
subjects	O
that	O
have	O
sipped	O
even	O
one	O
cup	O
coca	B-Drug
leaf	O
infusion.	O

Former	O
senator	O
and	O
former	O
Vice	O
President	O
of	O
the	O
United	O
States	O
Joe	O
Biden	O
sponsored	O
Drug	O
Sentencing	O
Reform	O
Cocaine	B-Drug
Kingpin	O
Trafficking	O
Act	O
2007	O
(S.	O
1711),	O
which	O
would	O
have	O
completely	O
eliminated	O
disparity	O
by	O
increasing	O
amount	O
crack	O
cocaine	B-Drug
required	O
for	O
imposition	O
mandatory	O
minimum	O
prison	O
terms	O
to	O
those	O
powder	O
cocaine.	O

Therefore,	O
patients	O
receiving	O
an	O
opioid	O
analgesic,	O
general	O
anesthetics,	O
phenothiazines,	O
or	O
other	O
tranquilizers,	O
sedatives,	O
hypnotics,	O
CNS	O
depressants	O
(including	O
alcohol)	O
concomitantly	O
with	O
Nalbuphine	B-Drug
may	O
exhibit	O
additive	O
effect.	O

The	O
disintegration	O
of	O
these	O
top	O
cocaine	B-Drug
cartels	O
in	O
Colombia	O
the	O
late	O
1990s	O
have	O
paved	O
way	O
for	O
insurgent	O
groups	O
to	O
take	O
over.	O

A	O
typical	O
dose	O
of	O
harmaline	B-Drug
for	O
MAO	O
inhibition	O
is	O
150	O
mg,	O
higher	O
than	O
any	O
MT	O
so	O
MT's	O
MAOI	O
activity	O
at	O
doses	O
will	O
be	O
significant	O
but	O
not	O
total.	O

Moore	O
received	O
a	O
lethal	O
injection,	O
administered	O
as	O
an	O
intravenous	O
series	O
of	O
four	O
drugs	O
that	O
included	O
fentanyl	B-Drug
citrate	O
to	O
inhibit	O
breathing	O
and	O
render	O
the	O
subject	O
unconscious.	O

Methylone	B-Drug
was	O
first	O
synthesized	O
by	O
the	O
chemists	O
Peyton	O
Jacob	O
III	O
and	O
Alexander	O
Shulgin	O
in	O
1996	O
for	O
potential	O
use	O
as	O
an	O
antidepressant.	O

Another	O
form	O
of	O
fentanyl	B-Drug
that	O
has	O
appeared	O
on	O
the	O
streets	O
is	O
Actiq	B-Drug
lollipop	O
formulation.	O

Diazepam	B-Drug
is	O
the	O
drug	O
of	O
choice	O
for	O
treating	O
benzodiazepine	O
dependence	O
with	O
its	O
long	O
half-life	O
allowing	O
easier	O
dose	O
reduction.	O

Other	O
NMDA	O
receptor	O
antagonists	O
include	O
ketamine,	O
tiletamine,	O
dextromethorphan,	O
nitrous	O
oxide,	O
and	O
dizocilpine	O
(MK-801).	O
ketamine	B-Drug
tiletamine	B-Drug
dextromethorphan	B-Drug

Clozapine	B-Drug
is	O
a	O
dibenzodiazepine	O
that	O
structurally	O
related	O
to	O
loxapine.	O
loxapine	B-Drug

The	O
Riksdag	O
added	O
25I-NBOMe	B-Drug
to	O
Narcotic	O
Drugs	O
Punishments	O
Act	O
under	O
Swedish	O
schedule	O

Other	O
NMDA	O
receptor	O
antagonists	O
include	O
ketamine,	O
tiletamine,	O
dextromethorphan,	O
nitrous	O
oxide,	O
and	O
dizocilpine	O
(MK-801).	O
ketamine	B-Drug
tiletamine	B-Drug
dextromethorphan	B-Drug

Drostanolone	B-Drug
propionate	I-Drug
produces	O
considerably	O
less	O
virilization	O
in	O
women	O
compared	O
to	O
equal	O
doses	O
of	O
testosterone	B-Drug
propionate.	O

Studies	O
conducted	O
by	O
the	O
FDA	O
from	O
2014	O
through	O
2019	O
have	O
determined	O
that	O
a	O
majority	O
of	O
CBD	B-Drug
products	O
are	O
not	O
accurately	O
labeled	O
with	O
amount	O
they	O
contain.	O

In	O
addition	O
to	O
its	O
well	O
explored	O
interactions	O
with	O
NMDA	O
receptors,	O
PCP	B-Drug
has	O
also	O
been	O
shown	O
inhibit	O
dopamine	O
reuptake,	O
and	O
thereby	O
leads	O
increased	O
extracellular	O
levels	O
of	O
hence	O
dopaminergic	O
neurotransmission.	O

A	O
number	O
of	O
derivatives	O
PCP	B-Drug
have	O
been	O
sold	O
for	O
recreational	O
and	O
non-medical	O
use.	O

Hayes,	O
an	O
American	O
student,	O
was	O
caught	O
trying	O
to	O
smuggle	O
four	O
pounds	O
of	O
hashish	B-Drug
out	O
Turkey	O
on	O
October	O
7,	O
1970.	O

However,	O
trazodone	B-Drug
is	O
not	O
cross-tolerant	O
with	O
alcohol.	O

AM-1714	O
AM-2201	B-Drug
AM-2232	B-Drug

It	O
is	O
not	O
as	O
effective	O
trional.	O
trional	B-Drug

Norethisterone	B-Drug
(0.5	O
to	O
3	O
mg/day)	O
has	O
been	O
found	O
dose-dependently	O
decrease	O
circulating	O
SHBG	O
levels,	O
which	O
is	O
a	O
common	O
property	O
of	O
androgens	O
and	O
due	O
AR-mediated	O
suppression	O
hepatic	O
production.	O

Liquidliquid	O
extraction	O
(aka	O
solvent	O
extraction)	O
(see	O
also	O
Hash	B-Drug
oil)	O
oil	I-Drug

Nicodicodine	B-Drug
is	O
metabolised	O
in	O
the	O
liver	O
by	O
demethylation	O
to	O
produce	O
6-nicotinoyldihydromorphine,	O
and	O
subsequently	O
further	O
dihydromorphine.	O
dihydromorphine	B-Drug

Tamiflu	B-Drug
(oseltamivir),	O
for	O
influenza	O
A	O
and	O
B	O
(both	O
treatment	O
prevention).	O
oseltamivir	B-Drug

Later	O
in	O
the	O
20th	O
century,	O
addiction	O
to	O
opiates,	O
especially	O
heroin	B-Drug
young	O
people,	O
continued	O
rise	O
and	O
so	O
sale	O
prescription	O
of	O
opiates	O
was	O
limited	O
doctors	O
treatment	O
centers.	O

The	O
super-	O
or	O
subcritical	O
fluid	O
is	O
pumped	O
through	O
the	O
natural	O
product,	O
and	O
mostly	O
mannitol	B-Drug
product	O
easily	O
separated	O
from	O
solvent	O
minute	O
amount	O
of	O
byproduct.	O

However,	O
other	O
research	O
contradicts	O
this	O
hypothesis	O
and	O
has	O
suggested	O
that	O
spironolactone	B-Drug
might	O
actually	O
produce	O
antidepressant	O
effects,	O
for	O
instance	O
studies	O
showing	O
antidepressant-like	O
effects	O
of	O
in	O
animals.	O

Another	O
legend,	O
often	O
mentioned	O
together	O
with	O
the	O
"holes	O
in	O
brain"	O
myth	O
discussed	O
above,	O
is	O
that	O
MDMA	B-Drug
causes	O
Parkinson's	O
disease,	O
possibly	O
even	O
one	O
night	O
of	O
exposure.	O

At	O
its	O
height,	O
the	O
Medelln	O
Cartel	O
was	O
largest	O
drug	O
cartel	O
in	O
world	O
and	O
smuggled	O
three	O
times	O
as	O
much	O
cocaine	B-Drug
their	O
main	O
competitors,	O
Cali	O
Cartel,	O
an	O
international	O
drug-trafficking	O
organization	O
based	O
Valle	O
del	O
Cauca	O
department	O
of	O
Colombia.	O

Laudanosine	O
decreases	O
the	O
seizure	O
threshold,	O
and	O
thus	O
it	O
can	O
induce	O
seizures	O
if	O
present	O
at	O
sufficient	O
threshold	O
concentrations;	O
however	O
such	O
concentrations	O
are	O
unlikely	O
to	O
be	O
produced	O
consequent	O
chemodegradable	O
metabolism	O
of	O
clinically	O
administered	O
doses	O
cisatracurium	B-Drug
or	O
atracurium.	O

Methylnaltrexone	B-Drug
is	O
approved	O
for	O
the	O
treatment	O
of	O
opioid-induced	O
constipation	O
(OIC).	O

Thalidomide	B-Drug
is	O
provided	O
as	O
a	O
racemic	O
mixture	O
of	O
two	O
enantiomers;	O
while	O
there	O
are	O
reports	O
that	O
only	O
one	O
the	O
enantiomers	O
may	O
cause	O
birth	O
defects,	O
body	O
converts	O
each	O
enantiomer	O
into	O
other	O
through	O
mechanisms	O
not	O
well	O
understood.	O

Side	O
effects	O
of	O
fentanyl	B-Drug
analogs	O
are	O
similar	O
to	O
those	O
itself,	O
which	O
include	O
itching,	O
nausea	O
and	O
potentially	O
serious	O
respiratory	O
depression	O
(namely	O
with	O
overdoses	O
or	O
improper	O
drug-combinations,	O
such	O
as	O
benzodiazepines)	O
can	O
be	O
life-threatening.	O

While	O
thebaine	O
is	O
not	O
used	O
therapeutically,	O
it	O
the	O
main	O
alkaloid	O
extracted	O
from	O
Papaver	O
bracteatum	O
(Iranian	O
opium	O
/	O
Persian	O
poppy)	O
and	O
can	O
be	O
converted	O
industrially	O
into	O
a	O
variety	O
of	O
compounds,	O
including	O
hydrocodone,	O
hydromorphone,	O
oxycodone,	O
oxymorphone,	O
nalbuphine,	O
naloxone,	O
naltrexone,	O
buprenorphine	B-Drug
etorphine.	O
hydrocodone	B-Drug
hydromorphone	B-Drug
oxycodone	B-Drug
oxymorphone	B-Drug
nalbuphine	B-Drug
naloxone	B-Drug
naltrexone	B-Drug
etorphine	B-Drug

According	O
to	O
clinical	O
reviews,	O
a	O
kratom	B-Drug
overdose	O
can	O
cause	O
liver	O
toxicity,	O
seizures,	O
coma,	O
and	O
death,	O
especially	O
when	O
in	O
combination	O
with	O
alcohol	O
abuse.	O

As	O
such,	O
as	O
tramadol	B-Drug
is	O
related	O
to	O
venlafaxine,	O
the	O
same	O
conditions	O
apply.	O
venlafaxine	B-Drug

Desomorphine	B-Drug
Dextroamphetamine	B-Drug
Ecgonine	O
(any	O
derivative	O
of	O
ecgonine	O
which	O
is	O
convertible	O
to	O
or	O
cocaine)	O
cocaine	B-Drug

A	O
2018	O
report	O
by	O
the	O
National	O
Academies	O
of	O
Sciences,	O
Engineering,	O
and	O
Medicine	O
concludes,	O
"[w]hile	O
it	O
is	O
biologically	O
plausible	O
that	O
nicotine	B-Drug
can	O
act	O
as	O
a	O
tumor	O
promoter,	O
existing	O
body	O
evidence	O
indicates	O
this	O
unlikely	O
to	O
translate	O
into	O
increased	O
risk	O
human	O
cancer.	O

cocaine,	O
heroin,	O
pheniramine,	O
buprenorphine	B-Drug
(chaanf	O
in	O
Punjab)	O
Valley	O
of	O
the	O
Dolls	O
(1967)	O
cocaine	B-Drug
heroin	B-Drug

The	O
contribution	O
of	O
these	O
receptors	O
to	O
the	O
overall	O
pharmacology	O
heroin	B-Drug
remains	O
unknown.	O

After	O
an	O
intake	O
of	O
1.5	O
mg	O
levonorgestrel	B-Drug
in	O
clinical	O
trials,	O
very	O
common	O
side	O
effects	O
(reported	O
by	O
10%	O
or	O
more)	O
included:	O
hives,	O
dizziness,	O
hair-loss,	O
headache,	O
nausea,	O
abdominal	O
pain,	O
uterine	O
delayed	O
menstruation,	O
heavy	O
bleeding,	O
and	O
fatigue;	O
1%	O
to	O
10%)	O
included	O
diarrhea,	O
vomiting,	O
painful	O
menstruation;	O
these	O
usually	O
disappeared	O
within	O
48	O
hours.	O

25I-NBOMe	B-Drug
was	O
explicitly	O
scheduled	O
in	O
Queensland	O
drug	O
law	O
April	O
2012,	O
and	O
New	O
South	O
Wales	O
October	O
2013,	O
as	O
were	O
some	O
related	O
compounds	O
such	O
25B-NBOMe.	O
25B-NBOMe	B-Drug

This	O
activity	O
may	O
be	O
associated	O
with	O
some	O
of	O
the	O
other	O
more	O
psychotic	O
features	O
PCP	B-Drug
intoxication,	O
which	O
is	O
evidenced	O
by	O
successful	O
use	O
D2	O
receptor	O
antagonists	O
(such	O
as	O
haloperidol)	O
in	O
treatment	O
psychosis.	O
haloperidol	B-Drug

Many	O
fitness	O
models	O
and	O
bodybuilders	O
use	O
trenbolone	B-Drug
acetate,	O
particularly	O
when	O
preparing	O
to	O
compete	O
in	O
an	O
upcoming	O
bodybuilding	O
competition.	O

Cocaine	B-Drug
effects,	O
further,	O
are	O
shown	O
to	O
be	O
potentiated	O
for	O
the	O
user	O
when	O
used	O
in	O
conjunction	O
with	O
new	O
surroundings	O
and	O
stimuli,	O
otherwise	O
novel	O
environs.	O

For	O
instance,	O
at	O
its	O
33rd	O
meeting,	O
the	O
WHO	O
Expert	O
Committee	O
on	O
Drug	O
Dependence	O
recommended	O
transferring	O
tetrahydrocannabinol	B-Drug
to	O
Schedule	O
IV	O
of	O
Convention,	O
citing	O
medical	O
uses	O
and	O
low	O
abuse	O
potential.	O

One	O
example	O
is	O
the	O
case	O
of	O
Big	O
Lurch,	O
a	O
former	O
rapper	O
with	O
history	O
violent	O
crime,	O
who	O
was	O
convicted	O
murdering	O
and	O
cannibalizing	O
his	O
roommate	O
while	O
under	O
influence	O
PCP.	O
PCP	B-Drug

The	O
majority	O
of	O
research	O
shows	O
that	O
nicotine	B-Drug
reduces	O
body	O
weight,	O
but	O
some	O
researchers	O
have	O
found	O
may	O
result	O
in	O
weight	O
gain	O
under	O
specific	O
types	O
eating	O
habits	O
animal	O
models.	O

The	O
following	O
adverse	O
effects	O
have	O
been	O
reported	O
with	O
nalmefene:	O
nalmefene	B-Drug

Naproxen	B-Drug
may	O
cause	O
muscle	O
cramps	O
in	O
the	O
legs	O
3%	O
of	O
people.	O

Most	O
states	O
have	O
laws	O
that	O
give	O
explicit	O
protection	O
from	O
legal	O
liability	O
for	O
providers	O
who	O
prescribe	O
or	O
dispense	O
naloxone.	O
naloxone	B-Drug

Side	O
effects	O
of	O
oxymetholone	B-Drug
include	O
increased	O
sexual	O
desire	O
as	O
well	O
symptoms	O
masculinization	O
like	O
acne,	O
hair	O
growth,	O
and	O
voice	O
changes.	O

The	O
acid	O
dissociation	O
constant	O
(pKa')	O
of	O
bicalutamide	B-Drug
is	O
approximately	O
12.	O

Unlike	O
other	O
opioid	O
medications	O
used	O
to	O
treat	O
diarrhea,	O
which	O
reduce	O
intestinal	O
motility,	O
racecadotril	B-Drug
has	O
an	O
antisecretory	O
effect	O
it	O
reduces	O
the	O
secretion	O
of	O
water	O
and	O
electrolytes	O
into	O
intestine.	O

The	O
major	O
metabolites	O
of	O
diamorphine,	O
6-MAM,	O
morphine,	O
morphine-3-glucuronide,	O
and	O
morphine-6-glucuronide,	O
may	O
be	O
quantitated	O
in	O
blood,	O
plasma	O
or	O
urine	O
to	O
monitor	O
for	O
use,	O
confirm	O
a	O
diagnosis	O
poisoning,	O
assist	O
medicolegal	O
death	O
investigation.	O
diamorphine	B-Drug
morphine	B-Drug

Propranolol	B-Drug
may	O
cause	O
harmful	O
effects	O
in	O
the	O
baby	O
if	O
taken	O
during	O
pregnancy.	O

It	O
is	O
the	O
indazole	O
core	O
analogue	O
of	O
NNE1.	O
NNE1	B-Drug

Methylenedioxypyrovalerone	B-Drug
has	O
no	O
record	O
of	O
FDA	O
approved	O
medical	O
use.	O

Ma	O
Fuxiang	O
officially	O
prohibited	O
opium	B-Drug
and	O
made	O
it	O
illegal	O
in	O
Ningxia,	O
but	O
the	O
Guominjun	O
reversed	O
his	O
policy;	O
by	O
1933,	O
people	O
from	O
every	O
level	O
of	O
society	O
were	O
abusing	O
drug,	O
Ningxia	O
was	O
left	O
destitution.	O

When	O
enough	O
fentanyl	B-Drug
has	O
been	O
absorbed,	O
the	O
(sedated)	O
person	O
generally	O
lets	O
lollipop	O
fall	O
from	O
mouth,	O
indicating	O
sufficient	O
analgesia	O
and	O
somewhat	O
reducing	O
likelihood	O
of	O
overdose	O
associated	O
risks.	O

Ranitidine,	O
sold	O
under	O
the	O
brand	O
name	O
Zantac	B-Drug
among	O
others,	O
is	O
a	O
medication	O
that	O
decreases	O
stomach	O
acid	O
production.	O
Ranitidine	B-Drug

Common	O
side	O
effects	O
of	O
oxycodone	B-Drug
include	O
constipation	O
(23%),	O
nausea	O
vomiting	O
(12%),	O
somnolence	O
dizziness	O
(13%),	O
itching	O
dry	O
mouth	O
(6%),	O
and	O
sweating	O
(5%).	O

cannabis,	O
MDMA,	O
cocaine	B-Drug
Caddyshack	O
(1980)	O
MDMA	B-Drug

THG	B-Drug
was	O
banned	O
by	O
the	O
Food	O
and	O
Drug	O
Administration	O
(FDA)	O
in	O
2003.	O

But	O
at	O
doses	O
of	O
4-10	O
milligrams	O
users	O
find	O
5-MeO-MiPT	B-Drug
to	O
be	O
a	O
very	O
euphoric	O
and	O
tactile	O
chemical.	O

This	O
is	O
an	O
analogue	O
of	O
the	O
more	O
popular	O
drug	O
5-MeO-DiPT	B-Drug
(nicknamed	O
"foxy	O
methoxy")	O
and	O
has	O
nickname	O
"moxy".	O

Naltrexone	B-Drug
is	O
an	O
opioid	O
receptor	O
antagonist	O
used	O
for	O
the	O
treatment	O
of	O
addiction.	O

Bupropion	B-Drug
is	O
taken	O
in	O
tablet	O
form	O
and	O
available	O
only	O
by	O
prescription	O
industrialized	O
countries.	O

Niemann	O
described	O
every	O
step	O
he	O
took	O
to	O
isolate	O
cocaine	B-Drug
in	O
his	O
dissertation	O
titled	O
ber	O
eine	O
neue	O
organische	O
Base	O
den	O
Cocablttern	O

There	O
have	O
been	O
incidents	O
reported	O
where	O
desomorphine	B-Drug
had	O
supposedly	O
present	O
within	O
either	O
country,	O
but	O
no	O
confirmed	O
by	O
any	O
drug	O
testing	O
or	O
analytical	O
results,	O
and	O
use	O
in	O
North	O
America	O
is	O
still	O
considered	O
unconfirmed.	O

Citing	O
laboratory	O
tests	O
on	O
animals,	O
Hart	O
refuted	O
Duterte's	O
claim	O
that	O
methamphetamine	B-Drug
shrinks	O
people's	O
brains	O
and	O
causes	O
them	O
to	O
become	O
violent.	O

American	O
author	O
Daniel	O
Pinchbeck	O
wrote	O
about	O
his	O
own	O
experience	O
of	O
ibogaine	B-Drug
in	O
book	O
Breaking	O
Open	O
the	O
Head	O
(2002),	O
and	O
a	O
2003	O
article	O
for	O
The	O
Guardian	O
titled	O
"Ten	O
years	O
therapy	O
one	O
night".	O

Methylketobemidone	O
is	O
so	O
named	O
because	O
it	O
the	O
methyl	O
ketone	O
analogue	O
of	O
bemidone	B-Drug
(hydroxypethidine).	O
hydroxypethidine	B-Drug

This	O
was	O
lower	O
than	O
cannabis-induced	O
psychosis	O
(34%)	O
but	O
higher	O
amphetamine	B-Drug
(22%),	O
opioid	O
(12%),	O
alcohol	O
(10%)	O
and	O
sedative	O
(9%)	O
induced	O
psychoses.	O

Some	O
androstenedione	B-Drug
is	O
also	O
secreted	O
into	O
the	O
plasma,	O
and	O
may	O
be	O
converted	O
in	O
peripheral	O
tissues	O
to	O
testosterone	O
estrogens.	O

Zolpidem	B-Drug
is	O
a	O
Schedule	O
IV	O
controlled	O
substance	O
under	O
the	O
Controlled	O
Substances	O
Act	O
of	O
1970	O
(CSA).	O

cocaine,	O
heroin	B-Drug
New	O
Jack	O
City	O
(1991)	O
crack	O
cocaine	B-Drug

The	O
central	O
nervous	O
system	O
side	O
effects	O
of	O
AG	O
are	O
due	O
to	O
its	O
nature	O
as	O
an	O
anticonvulsant	O
and	O
relation	O
glutethimide.	O
glutethimide	B-Drug

Three	O
paths	O
were	O
found:	O
from	O
morphine	B-Drug
to	O
hydromorphone	B-Drug
with	O
dihydromorphine	B-Drug
as	O
the	O
penultimate	O
step,	O
morphinone	O
and	O
hydromorphinol	B-Drug
hydromorphone.	O

Dimethylheptylpyran	B-Drug
HU-210,	O
about	O
100	O
times	O
as	O
potent	O
THC	B-Drug
HU-331	O
a	O
potential	O
anti-cancer	O
drug	O
derived	O
from	O
cannabidiol	B-Drug
that	O
specifically	O
inhibits	O
topoisomerase	O
II.	O
HU-210	B-Drug

Sumatriptan	B-Drug
is	O
metabolised	O
primarily	O
by	O
monoamine	O
oxidase	O
A	O
into	O
2{5[(methylsulfamoyl)methyl]indole3yl}acetic	O
acid	O
which	O
then	O
conjugated	O
to	O
glucuronic	O
acid.	O

In	O
the	O
treatment	O
of	O
postpartum	O
major	O
depressive	O
disorders	O
and	O
other	O
unipolar	O
depressions	O
in	O
women	O
who	O
are	O
breastfeeding,	O
nortriptyline,	O
paroxetine	B-Drug
(Paxil),	O
sertraline	B-Drug
(Zoloft)	O
general	O
considered	O
to	O
be	O
preferred	O
medications.	O
nortriptyline	B-Drug
Paxil	B-Drug
Zoloft	B-Drug

JWH-210	B-Drug
may	O
be	O
neurotoxic	O
to	O
animals	O
when	O
administered	O
in	O
high	O
doses.	O

Oxycodone	B-Drug
has	O
a	O
half-life	O
of	O
4.5	O
hours.	O

In	O
April	O
2014	O
U.S.	O
House	O
Democrats	O
Henry	O
Waxman,	O
Frank	O
Pallone	O
Jr.,	O
and	O
Diana	O
DeGette	O
wrote	O
Gilead	O
Sciences	O
Inc.	O
questioning	O
the	O
$84,000	O
price	O
for	O
sofosbuvir.	O
sofosbuvir	B-Drug

The	O
other	O
drugs	O
included	O
diazepam	B-Drug
as	O
a	O
tranquilizer,	O
cisatracurium	B-Drug
besylate	O
muscle	O
relaxant,	O
and	O
potassium	O
chloride	O
to	O
stop	O
the	O
heart.	O

This	O
proposal	O
is	O
based	O
on	O
an	O
initial	O
literature	O
review	O
the	O
safety	O
of	O
low	O
dose	O
CBD	B-Drug
published	O
by	O
TGA	O
in	O
April	O
2020.	O

An	O
exception	O
is	O
medroxyprogesterone	B-Drug
acetate	I-Drug
as	O
a	O
progestogen-only	O
injectable	O
contraceptive,	O
which	O
has	O
been	O
associated	O
with	O
2-	O
to	O
4-fold	O
increase	O
in	O
risk	O
of	O
VTE	O
relative	O
other	O
progestogens	O
and	O
non-use.	O

The	O
UNODC	O
states	O
that	O
cannabis	O
often	O
contains	O
5%	O
THC	B-Drug
content,	O
resin	O
"can	O
contain	O
up	O
to	O
20%	O
content",	O
and	O
"Cannabis	O
oil	I-Drug
may	O
more	O
than	O
60%	O
content.	O
Cannabis	B-Drug

Women	O
who	O
take	O
oral	O
contraceptives	O
containing	O
gestodene	O
are	O
5.6	O
times	O
as	O
likely	O
to	O
develop	O
venous	O
thromboembolism	O
than	O
women	O
do	O
not	O
any	O
contraceptive	O
pill,	O
and	O
1.6	O
compared	O
taking	O
levonorgestrel.	O
levonorgestrel	B-Drug

Researchers	O
found	O
that	O
replacing	O
one	O
of	O
the	O
ethyl	O
groups	O
milnacipran	B-Drug
with	O
an	O
allyl	O
moiety	O
increases	O
norepinephrine	O
potency.	O

GHB	B-Drug
is	O
a	O
naturally	O
occurring	O
substance	O
that	O
acts	O
in	O
similar	O
fashion	O
to	O
some	O
neurotransmitters	O
the	O
mammalian	O
brain.	O

There	O
is	O
an	O
exception	O
however	O
for	O
"any	O
drug	O
product	O
approved	O
by	O
the	O
United	O
States	O
Food	O
and	O
Drug	O
Administration	O
which	O
contains	O
Salvinorin	B-Drug
A	I-Drug
or	O
its	O
isomers,	O
esters,	O
ethers,	O
salts,	O
salts	O
of	O
if	O
existence	O
such	O
possible	O
within	O
specific	O
chemical	O
designation."	O

This	O
difficulty	O
is	O
regularly	O
encountered	O
when	O
treating	O
overdoses	O
of	O
high-affinity	O
opioids	O
in	O
the	O
fentanyl	B-Drug
chemical	O
family	O
or	O
with	O
buprenorphine.	O
buprenorphine	B-Drug

Ketoconazole	B-Drug
HRA	O
was	O
approved	O
for	O
use	O
in	O
the	O
European	O
Union	O
treatment	O
of	O
Cushing's	O
syndrome	O
November	O
2014.As	O
March	O
2019,	O
oral	O
levoketoconazole	O
(developmental	O
code	O
name	O
COR-003,	O
tentative	O
brand	O
Recorlev)	O
is	O
phase	O
III	O
clinical	O
trials	O
syndrome.	O

PCP	B-Drug
has	O
also	O
been	O
shown	O
to	O
cause	O
schizophrenia-like	O
changes	O
in	O
N-acetylaspartate	O
and	O
N-acetylaspartylglutamate	O
levels	O
the	O
rat	O
brain,	O
which	O
are	O
detectable	O
both	O
living	O
rats	O
upon	O
necropsy	O
examination	O
of	O
brain	O
tissue.	O

cannabis,	O
Twelve	O
(fictional	O
drug	O
with	O
similar	O
effects	O
to	O
MDMA	B-Drug
and	O
cocaine),	O
many	O
drugs	O
referred	O
Twin	O
Peaks:	O
Fire	O
Walk	O
With	O
Me	O
(1992)	O
cocaine	B-Drug

Mometasone	B-Drug
is	O
used	O
to	O
alleviate	O
inflammation	O
and	O
itchiness	O
in	O
skin	O
conditions	O
that	O
respond	O
treatment	O
with	O
glucocorticoids	O
such	O
as	O
psoriasis	O
atopic	O
dermatitis.	O

Hash	B-Drug
oil	I-Drug
Fully	O
extracted	O
cannabis	O
(FECO)	O

Soon	O
after	O
the	O
Egyptian	O
government	O
issued	O
an	O
1884	O
ban	O
on	O
cultivation,	O
though	O
officials	O
were	O
permitted	O
to	O
confiscate	O
and	O
export	O
captured	O
hashish	B-Drug
rather	O
than	O
destroy	O
it.	O

5-MeO-DMT	B-Drug
(5-methoxy-N,N-dimethyltryptamine)	O
is	O
a	O
psychedelic	O
of	O
the	O
tryptamine	O
class.	O
5-methoxy-N,N-dimethyltryptamine	B-Drug

In	O
Australia,	O
which	O
has	O
had	O
the	O
highest	O
opioid	O
mortality	O
per	O
capita	O
in	O
OECD,	O
studies	O
found	O
that	O
"overdose	O
fatality	O
is	O
not	O
a	O
simple	O
function	O
of	O
heroin	B-Drug
dose	O
or	O
purity.	O

Bicalutamide	B-Drug
causes	O
elevated	O
liver	O
enzymes	O
in	O
around	O
1%	O
of	O
people.	O

PCP	B-Drug
can	O
be	O
ingested	O
through	O
smoking.	O

By	O
the	O
19th	O
century,	O
laudanum	B-Drug
was	O
used	O
in	O
many	O
patent	O
medicines	O
to	O
"relieve	O
pain	O
...	O
produce	O
sleep	O
allay	O
irritation	O
check	O
excessive	O
secretions	O
support	O
system	O
[and]	O
as	O
a	O
soporific".	O

It	O
inhibits	O
the	O
binding	O
of	O
glutamine	B-Drug
to	O
N-Methyl-D-aspartic	O
acid	O
(NMDA)	O
receptors	O
in	O
Thalamocortical	O
radiations	O
and	O
limbic	O
system,	O
causing	O
amnesia.	O

RU-56187	O
is	O
3-	O
to	O
10-fold	O
more	O
potent	O
as	O
an	O
antiandrogen	O
than	O
bicalutamide	B-Drug
or	O
nilutamide	O
in	O
animals.	O

UR-144	B-Drug
(TMCP-018,	O
KM-X1,	O

NBOMe-mescaline	B-Drug
is	O
not	O
listed	O
in	O
the	O
schedules	O
set	O
out	O
by	O
United	O
Nations'	O
Single	O
Convention	O
on	O
Narcotic	O
Drugs	O
from	O
1961	O
nor	O
their	O
Psychotropic	O
Substances	O
1971,	O
so	O
signatory	O
countries	O
to	O
these	O
international	O
drug	O
control	O
treaties	O
are	O
required	O
said	O
NBOMe-mescaline.	O

Norboletone	B-Drug
(INN)	O
(former	O
proposed	O
brand	O
name	O
Genabol),	O
or	O
norbolethone,	O
is	O
a	O
synthetic	O
and	O
orally	O
active	O
anabolicandrogenic	O
steroid	O
(AAS)	O
which	O
was	O
never	O
marketed.	O
norbolethone	B-Drug

With	O
further	O
processing,	O
crack	O
cocaine	B-Drug
can	O
be	O
produced	O
from	O
cocaine.	O

Despite	O
criticism	O
for	O
their	O
methodology,	O
the	O
DEA	O
contends	O
that	O
there	O
was	O
a	O
99.5%	O
drop	O
in	O
availability	O
of	O
LSD	B-Drug
US	O
two	O
years	O
following	O
arrest.	O

This	O
changed	O
in	O
1927	O
when	O
Jnos	O
Kabay	O
developed	O
a	O
chemical	O
process	O
to	O
extract	O
morphine	B-Drug
from	O
the	O
crushed	O
capsule.	O

Les	O
King,	O
a	O
former	O
member	O
of	O
the	O
ACMD,	O
has	O
stated	O
mephedrone	B-Drug
appears	O
to	O
be	O
less	O
potent	O
than	O
amphetamine	O
and	O
ecstasy,	O
but	O
that	O
any	O
benefit	O
associated	O
with	O
this	O
could	O
negated	O
by	O
users	O
taking	O
larger	O
amounts.	O
ecstasy	B-Drug

7-Hydroxymitragynine	O
is	O
a	O
terpenoid	O
indole	O
alkaloid	O
from	O
the	O
plant	O
Mitragyna	B-Drug
speciosa,	O
commonly	O
known	O
as	O
Kratom.	O
speciosa	I-Drug
Kratom	B-Drug

Certain	O
CYP2D6	O
variations	O
in	O
breast	O
cancer	O
patients	O
lead	O
to	O
a	O
worse	O
clinical	O
outcome	O
for	O
tamoxifen	B-Drug
treatment.	O

Methcathinone	B-Drug
is	O
a	O
beta-keto	O
N-methylamphetamine	O
and	O
closely	O
related	O
to	O
the	O
naturally	O
occurring	O
compounds,	O
cathinone	B-Drug
cathine.	O
cathine	B-Drug

LSD	B-Drug
has	O
also	O
been	O
studied	O
in	O
depression,	O
anxiety,	O
and	O
drug	O
dependence,	O
with	O
positive	O
preliminary	O
results.	O

Extracts	O
of	O
toad	O
secretion,	O
containing	O
bufotenin	B-Drug
and	O
other	O
bioactive	O
compounds,	O
have	O
been	O
used	O
in	O
some	O
traditional	O
medicines	O
such	O
as	O
chan	O
su	O
(probably	O
derived	O
from	O
Bufo	O
gargarizans),	O
which	O
has	O
medicinally	O
for	O
centuries	O
China.	O

Nitrazepam	B-Drug
increases	O
the	O
slow	O
wave	O
light	O
sleep	O
(SWLS)	O
in	O
a	O
dose-dependent	O
manner	O
whilst	O
suppressing	O
deep	O
stages.	O

I	O
narcotic,	O
including	O
its	O
derivatives	O
(see	O
sumatriptan	B-Drug
and	O
zolmitriptan).	O
zolmitriptan	B-Drug

Several	O
people	O
with	O
kidney	O
failure	O
developed	O
myoclonus	O
while	O
receiving	O
pregabalin,	O
apparently	O
as	O
a	O
result	O
of	O
gradual	O
accumulation	O
the	O
drug.	O
pregabalin	B-Drug

Smoking	O
freebase	B-Drug
cocaine	B-Drug
has	O
the	O
additional	O
effect	O
of	O
releasing	O
methylecgonidine	O
into	O
user's	O
system	O
due	O
to	O
pyrolysis	O
substance	O
(a	O
side	O
which	O
insufflating	O
or	O
injecting	O
powder	O
does	O
not	O
create).	O

Distillers	O
Co.	O
Ltd	O
(now	O
part	O
of	O
Diageo	O
plc),	O
marketed	O
thalidomide	B-Drug
throughout	O
the	O
UK,	O
Australia	O
and	O
New	O
Zealand,	O
under	O
brand	O
name	O
Distaval,	O
as	O
a	O
remedy	O
for	O
morning	O
sickness.	O

Efflux	O
by	O
P-glycoprotein	O
in	O
the	O
intestinal	O
wall	O
reduces	O
passage	O
of	O
loperamide,	O
and	O
fraction	O
drug	O
crossing	O
is	O
then	O
further	O
reduced	O
through	O
first-pass	O
metabolism	O
liver.	O
loperamide	B-Drug

LSD	B-Drug
is	O
an	O
ergoline	O
derivative.	O

As	O
of	O
2018,	O
cannabis	O
oil	O
is	O
legal	O
to	O
possess,	O
buy,	O
and	O
sell	O
in	O
the	O
UK,	O
providing	O
product	O
does	O
not	O
contain	O
more	O
than	O
1	O
milligram	O
THC	B-Drug
advertised	O
as	O
a	O
medicinal	O
benefit.	O

Piroxicam	B-Drug
is	O
one	O
of	O
the	O
few	O
NSAIDs	O
that	O
can	O
be	O
given	O
parenteral	O
routes.	O

Severe	O
injection	O
site	O
necrosis	O
and	O
sepsis	O
has	O
occurred	O
(sometimes	O
requiring	O
amputation	O
of	O
limb)	O
with	O
multiple	O
pentazocine	B-Drug
lactate.	O

Excessive	O
concentrations	O
of	O
TXA2	O
could	O
lead	O
to	O
thrombosis,	O
which	O
when	O
coupled	O
with	O
25I-NBOMe's	O
vasoconstrictive	O
effect,	O
is	O
a	O
major	O
risk	O
factor	O
for	O
cardiac	O
ischemia,	O
dangerous	O
condition	O
the	O
symptoms	O
are	O
present	O
in	O
several	O
toxicological	O
reports.	O
25I-NBOMe	B-Drug

Studies	O
have	O
shown	O
that	O
alcohol	O
and	O
tobacco	B-Drug
may	O
additionally	O
be	O
regarded	O
as	O
gateway	O
drugs;	O
however,	O
a	O
more	O
parsimonious	O
explanation	O
could	O
cannabis	O
is	O
simply	O
readily	O
available	O
(and	O
at	O
an	O
earlier	O
age)	O
than	O
illegal	O
hard	O
drugs.	O

Overall,	O
amitriptyline	B-Drug
is	O
recommended	O
for	O
tension	O
headache	O
prophylaxis,	O
along	O
with	O
lifestyle	O
advice,	O
which	O
should	O
include	O
avoidance	O
of	O
analgesia	O
and	O
caffeine.	O

In	O
1971,	O
Knoll	O
showed	O
that	O
selegiline	B-Drug
selectively	O
inhibits	O
the	O
B-isoform	O
of	O
monoamine	O
oxidase	O
(MAO-B)	O
and	O
proposed	O
it	O
is	O
unlikely	O
to	O
cause	O
infamous	O
"cheese	O
effect"	O
(hypertensive	O
crisis	O
resulting	O
from	O
consuming	O
foods	O
containing	O
tyramine)	O

For	O
this	O
reason,	O
shorter	O
acting	O
agents	O
such	O
as	O
alfentanyl	O
or	O
remifentanil	B-Drug
may	O
be	O
more	O
suitable	O
in	O
the	O
context	O
of	O
inducing	O
general	O
anaesthesia.	O

Mannitol	B-Drug
and	O
sorbitol	O
are	O
isomers,	O
the	O
only	O
difference	O
being	O
orientation	O
of	O
hydroxyl	O
group	O
on	O
carbon	O
2.	O

Achieving	O
acute	O
opioid	O
analgesia	O
is	O
difficult	O
in	O
persons	O
using	O
buprenorphine	B-Drug
for	O
replacement	O
therapy.	O

Any	O
GHB/GBL	O
overdose	O
is	O
a	O
medical	O
emergency	O
and	O
should	O
be	O
cared	O
for	O
by	O
appropriately	O
trained	O
personnel.	O
GHB	B-Drug

PCP's	O
rewarding	O
and	O
reinforcing	O
effects	O
are	O
at	O
least	O
partly	O
mediated	O
by	O
blocking	O
the	O
NMDA	O
receptors	O
in	O
glutamatergic	O
inputs	O
to	O
D1-type	O
medium	O
spiny	O
neurons	O
nucleus	O
accumbens.	O
PCP	B-Drug

The	O
products	O
had	O
names	O
such	O
as	O
Neodoves	O
pills,	O
but	O
the	O
range	O
was	O
discontinued	O
in	O
January	O
2008	O
after	O
Israeli	O
government	O
made	O
mephedrone	B-Drug
illegal.	O

Randomized	O
controlled	O
trials	O
have	O
found	O
benefit	O
from	O
atenolol	B-Drug
and	O
clonidine.	O
clonidine	B-Drug

Pharmaceutical	O
lisdexamfetamine	B-Drug
dimesylate	I-Drug
is	O
contraindicated	O
in	O
patients	O
with	O
hypersensitivity	O
to	O
amphetamine	B-Drug
products	O
or	O
any	O
of	O
the	O
formulation's	O
inactive	O
ingredients.	O

"A	O
2016,	O
the	O
Los	O
Angeles	O
Times	O
investigation	O
reported	O
that	O
in	O
many	O
people	O
OxyContin's	O
12-hour	O
schedule	O
does	O
not	O
adequately	O
control	O
pain,	O
resulting	O
withdrawal	O
symptoms	O
including	O
intense	O
craving	O
for	O
drug.	O
OxyContin	B-Drug

The	O
chillum	O
is	O
stuffed	O
with	O
the	O
Charas	O
and	O
tobacco	B-Drug
mixture	O
usually	O
smoked	O
in	O
a	O
group.	O

N-acetylcysteine	B-Drug
treatment	O
is	O
efficacious	O
in	O
dogs	O
when	O
administered	O
within	O
two	O
hours	O
of	O
paracetamol	B-Drug
ingestion.	O

Cimetidine	B-Drug
is	O
rapidly	O
eliminated,	O
with	O
an	O
elimination	O
half-life	O
of	O
123	O
minutes,	O
or	O
about	O
2	O
hours.	O

Other	O
SERMs,	O
like	O
raloxifene,	O
are	O
structurally	O
distinct	O
from	O
tamoxifen	B-Drug
and	O
other	O
triphenylethylenes.	O

Afghan	O
opium	B-Drug
kills	O
around	O
100,000	O
people	O
annually.	O

Studies	O
suggest	O
that	O
the	O
environment	O
in	O
which	O
a	O
child	O
grows	O
up	O
makes	O
more	O
important	O
contribution	O
to	O
outcome	O
cognitive,	O
behavioral	O
and	O
other	O
outcomes	O
than	O
does	O
cocaine	B-Drug
exposure	O
itself.	O

Progesterone	O
has	O
neurosteroid	O
activity	O
via	O
metabolism	O
into	O
allopregnanolone	B-Drug
and	O
pregnanolone,	O
potent	O
positive	O
allosteric	O
modulators	O
of	O
the	O
GABAA	O
receptor.	O

Overdoses	O
from	O
opioids	O
are	O
highest	O
among	O
individuals	O
who	O
between	O
the	O
ages	O
of	O
40	O
and	O
50,	O
in	O
contrast	O
to	O
heroin	B-Drug
overdoses,	O
which	O
20	O
30.	O

Dronabinol,	O
which	O
is	O
synthetic	O
THC,	O
has	O
shown	O
benefit	O
in	O
reducing	O
cravings	O
and	O
other	O
symptoms	O
of	O
withdrawal,	O
though	O
without	O
preventing	O
relapse	O
or	O
promoting	O
abstinence.	O
THC	B-Drug

A	O
less	O
expensive	O
alternative	O
is	O
dopamine	O
antagonists	O
such	O
as	O
domperidone	B-Drug
and	O
metoclopramide.	O
metoclopramide	B-Drug

CIBA	O
filed	O
for	O
a	O
U.S.	O
patent	O
in	O
1957,	O
and	O
began	O
marketing	O
the	O
drug	O
as	O
Dianabol	B-Drug
1958	O

According	O
to	O
United	O
Nations	O
(U.N.)	O
International	O
Narcotics	O
Control	O
Board	O
(INCB)	O
data,	O
China	O
produces	O
approximately	O
14	O
metric	O
tons	O
(31,000	O
lb)	O
of	O
legal	O
opium	B-Drug
per	O
year	O
for	O
use	O
in	O
the	O
domestic	O
pharmaceutical	O
industry.	O

N-Desmethylapalutamide	O
is	O
formed	O
from	O
apalutamide	B-Drug
in	O
the	O
liver	O
by	O
cytochrome	O
P450	O
enzymes	O
CYP2C8	O
and	O
CYP3A4.	O

MBDB	B-Drug
is	O
considered	O
a	O
Schedule	O
9	O
Prohibited	O
substance	O
in	O
Australia	O
under	O
the	O
Poisons	O
Standard	O
(October	O
2015).	O

The	O
pharmaceutical	O
division	O
of	O
ICI	O
was	O
split	O
out	O
into	O
an	O
independent	O
company	O
called	O
Zeneca	O
in	O
1993,	O
and	O
April	O
May	O
1995,	O
(now	O
AstraZeneca,	O
after	O
merging	O
with	O
Astra	O
AB	O
1999)	O
began	O
pre-approval	O
marketing	O
bicalutamide	B-Drug
for	O
the	O
treatment	O
prostate	O
cancer	O
U.S..	O

While	O
other	O
opioids	O
of	O
recreational	O
use	O
produce	O
only	O
morphine,	O
heroin	B-Drug
also	O
leaves	O
6-MAM,	O
a	O
psycho-active	O
metabolite.	O
morphine	B-Drug

Tetramethoxyamphetamine,	O
or	O
2,3,4,5-tetramethoxyamphetamine,	O
is	O
a	O
lesser-known	O
psychedelic	O
drug	O
and	O
substituted	O
amphetamine.	O
2,3,4,5-tetramethoxyamphetamine	B-Drug

Norboletone	B-Drug
(13-ethyl-17-hydroxy-18,	O
19-dinorpregn-4-en-3-one)	O

The	O
key	O
differences	O
between	O
the	O
two	O
patent	O
applications	O
were	O
that	O
1998	O
application	O
specified	O
counterion	O
(Gleevec	O
is	O
a	O
specific	O
salt	O
-	O
imatinib	B-Drug
mesylate)	O
while	O
1993	O
did	O
not	O
claim	O
any	O
salts	O
nor	O
it	O
mention	O
mesylate,	O
and	O
solid	O
form	O
of	O
Gleevec	B-Drug
way	O
individual	O
molecules	O
are	O
packed	O
together	O
into	O
when	O
drug	O
itself	O
manufactured	O
(this	O
separate	O
from	O
processes	O
by	O
which	O
formulated	O
pills	O
or	O
capsules)	O
not.	O
mesylate	I-Drug

Announcing	O
Owsley's	O
first	O
bust	O
in	O
1966,	O
The	O
San	O
Francisco	O
Chronicle's	O
headline	O
"LSD	O
Millionaire	O
Arrested"	O
inspired	O
the	O
rare	O
Grateful	O
Dead	O
song	O
"Alice	O
D.	O
Millionaire.	O
LSD	B-Drug

A	O
lab	O
in	O
Kent,	O
and	O
a	O
flat	O
London	O
were	O
raided	O
simultaneously	O
quantities	O
of	O
equipment	O
LSD	B-Drug
seized	O
along	O
with	O
the	O
two	O
men	O
who	O
had	O
been	O
making	O
LSD,	O
Quentin	O
Theobald	O
Peter	O
Simmons.	O

Paracetamol	B-Drug
is	O
the	O
active	O
metabolite	O
of	O
phenacetin	O
and	O
acetanilide,	O
both	O
once	O
popular	O
as	O
analgesics	O
antipyretics	O
in	O
their	O
own	O
right.	O

In	O
addition	O
to	O
serotonergic	O
activity,	O
tramadol	B-Drug
is	O
also	O
a	O
norepinephrine	O
reuptake	O
inhibitor.	O

Such	O
areas	O
are	O
chosen	O
for	O
coca	B-Drug
cultivation	O
due	O
to	O
their	O
remote	O
locations,	O
minimising	O
chances	O
of	O
detection.	O

Inducers	O
of	O
liver	O
enzymes	O
can	O
increase	O
the	O
metabolism	O
desogestrel	B-Drug
and	O
etonogestrel	B-Drug
reduce	O
their	O
circulating	O
levels.	O

In	O
the	O
United	O
States,	O
alprazolam	B-Drug
is	O
a	O
prescription	O
drug	O
and	O
assigned	O
to	O
Schedule	O
IV	O
of	O
Controlled	O
Substances	O
Act	O
by	O
Drug	O
Enforcement	O
Administration.	O

Medical	O
examiners	O
concluded	O
that	O
musician	O
Prince	O
died	O
on	O
April	O
21,	O
2016,	O
from	O
an	O
accidental	O
fentanyl	B-Drug
overdose.	O

THJ-2201	B-Drug
Tinabinol	O

However,	O
norketamine	B-Drug
is	O
about	O
1/5th	O
as	O
potent	O
ketamine	B-Drug
an	O
antidepressant	O
in	O
mice	O
per	O
the	O
forced	O
swim	O
test,	O
and	O
this	O
seems	O
also	O
to	O
be	O
accordance	O
with	O
its	O
35-fold	O
reduced	O
comparative	O
potency	O
vivo	O
NMDA	O
receptor	O
antagonist.	O

A	O
inhibitors,	O
since	O
both	O
MAOIs	O
and	O
amphetamine	B-Drug
increase	O
plasma	O
catecholamines	O
(i.e.,	O
norepinephrine	O
dopamine);	O
therefore,	O
concurrent	O
use	O
of	O
is	O
dangerous.	O

Fentanyl	B-Drug
has	O
been	O
discovered	O
for	O
sale	O
in	O
illicit	O
markets	O
Australia	O
2017	O
and	O
New	O
Zealand	O
2018.	O

However,	O
this	O
timing	O
cannot	O
be	O
recommended	O
for	O
enteric-coated	O
aspirin.	O
aspirin	B-Drug

Marijuana	O
or	O
marihuana	B-Drug
(herbal	O
cannabis)	O
consists	O
of	O
the	O
dried	O
flowers	O
and	O
fruits	O
subtending	O
leaves	O
stems	O
female	O
Cannabis	O
plant.	O

Fluticasone	B-Drug
propionate	I-Drug
is	O
broken	O
down	O
by	O
CYP3A4	O

Kratom	B-Drug
overdose	O
is	O
a	O
subject	O
of	O
concern	O
in	O
many	O
countries	O
because	O
the	O
rising	O
number	O
hospitalizations	O
and	O
deaths	O
which	O
chronic	O
kratom	B-Drug
abuse	O
contributing	O
factor.	O

For	O
instance,	O
warfarin	B-Drug
is	O
the	O
FDA	O
approved	O
oral	O
anticoagulant	O
commonly	O
prescribed	O
to	O
patients	O
with	O
blood	O
clots.	O

The	O
structure	O
of	O
DRD2	O
in	O
complex	O
with	O
the	O
atypical	O
antipsychotic	O
risperidone	B-Drug
has	O
been	O
determined.	O

Antagonism	O
of	O
the	O
NMDA	O
receptor	O
is	O
responsible	O
for	O
anesthetic,	O
analgesic,	O
and	O
psychotomimetic	O
effects	O
ketamine.	O
ketamine	B-Drug

The	O
four	O
variations	O
of	O
laudanum	B-Drug
listed	O
here	O
were	O
used	O
in	O
the	O
United	O
States	O
during	O
late	O
19th	O
century.	O

Decreased	O
plasma	O
levels	O
of	O
buspirone	B-Drug
Grapefruit:	O

Despite	O
this,	O
cases	O
of	O
thalidomide	B-Drug
embryopathy	O
continue,	O
with	O
at	O
least	O
100	O
identified	O
in	O
Brazil	O
between	O
2005	O
and	O
2010.	O

In	O
an	O
episode	O
of	O
Hannibal,	O
Dr.Lecter	O
administers	O
Naloxone	B-Drug
to	O
Jack	O
Crawford's	O
wife	O
after	O
she	O
tries	O
commit	O
suicide	O
by	O
overdosing	O
on	O
morphine.	O
morphine	B-Drug

E56K,	O
G178R,	O
S549R,	O
K1060T,	O
G1244E,	O
P67L,	O
E193K,	O
G551D,	O
A1067T,	O
S1251N,	O
R74W,	O
L206W,	O
G551S,	O
G1069R,	O
S1255P,	O
D110E,	O
R347H,	O
D579G,	O
R1070Q,	O
D1270N,	O
D110H,	O
R352Q,	O
S945L,	O
R1070W,	O
G1349D,	O
R117C,	O
A455E,	O
S977F,	O
F1074L,	O
R117H,	O
S549N,	O
F1052V,	O
D1152H.Ivacaftor	O
is	O
also	O
included	O
in	O
a	O
combination	O
product,	O
lumacaftor/ivacaftor,	O
single	O
pill,	O
which	O
used	O
to	O
treat	O
people	O
with	O
cystic	O
fibrosis	O
who	O
have	O
the	O
F508del	O
mutation	O
CFTR.Ivacaftor	O
product	O
tezacaftor/ivacaftor	O
ivacaftor	B-Drug
sold	O
as	O
Symdeko	O
and	O
Symkevi.	O
lumacaftor/ivacaftor	B-Drug
tezacaftor	B-Drug

While	O
officials	O
believe	O
that	O
this	O
cocaine	B-Drug
was	O
in	O
transit	O
to	O
Australia,	O
Philippine	O
Drug	O
Enforcement	O
Agency	O
believes	O
intended	O
be	O
a	O
diversion.	O

Stimulation	O
of	O
the	O
D1	O
receptor	O
by	O
dopaminergic	O
agonists	O
such	O
as	O
fenoldopam	B-Drug
is	O
used	O
intravenously	O
to	O
treat	O
hypertensive	O
crisis.	O

Although	O
it	O
is	O
a	O
prescription	O
medication	O
in	O
many	O
countries,	O
unauthorized	O
possession	O
and	O
distribution	O
of	O
amphetamine	B-Drug
often	O
tightly	O
controlled	O
due	O
to	O
the	O
significant	O
health	O
risks	O
associated	O
with	O
uncontrolled	O
or	O
heavy	O
use.	O

Spironolactone	B-Drug
can	O
be	O
considered	O
as	O
a	O
first-line	O
treatment	O
for	O
acne	O
in	O
those	O
who	O
have	O
failed	O
other	O
standard	O
treatments	O
such	O
topical	O
therapies	O
and	O
under	O
certain	O
circumstances,	O
although	O
this	O
is	O
controversial	O
due	O
to	O
the	O
side	O
effects	O
of	O
spironolactone	B-Drug
its	O
teratogenicity.	O

The	O
Sumerian,	O
Assyrian,	O
Egyptian,	O
Indian,	O
Minoan,	O
Greek,	O
Roman,	O
Persian	O
and	O
Arab	O
Empires	O
all	O
made	O
widespread	O
use	O
of	O
opium,	O
which	O
was	O
the	O
most	O
potent	O
form	O
pain	O
relief	O
then	O
available,	O
allowing	O
ancient	O
surgeons	O
to	O
perform	O
prolonged	O
surgical	O
procedures.	O
opium	B-Drug

Mescaline	B-Drug
is	O
biosynthesized	O
from	O
tyrosine	O
which,	O
in	O
turn,	O
derived	O
phenylalanine	O
by	O
the	O
enzyme	O
hydroxylase.	O

Fentanyl	B-Drug
is	O
a	O
synthetic	O
opioid	O
in	O
the	O
phenylpiperidine	O
family,	O
which	O
includes	O
sufentanil,	O
alfentanil,	O
remifentanil,	O
and	O
carfentanil.	O
sufentanil	B-Drug
alfentanil	B-Drug
remifentanil	B-Drug
carfentanil	B-Drug

For	O
one	O
of	O
our	O
tobacco	B-Drug
companies	O
to	O
commission	O
this	O
study	O
was	O
not	O
just	O
a	O
terrible	O
mistake,	O
it	O
wrong.	O

Thus,	O
with	O
both	O
higher	O
the	O
dosage	O
of	O
heroin	B-Drug
used	O
and	O
faster	O
route	O
administration	O
used,	O
potential	O
risk	O
for	O
psychological	O
dependence/addiction.	O

Its	O
dance	O
floor	O
was	O
decorated	O
with	O
an	O
image	O
of	O
the	O
"Man	O
in	O
Moon"	O
that	O
included	O
animated	O
cocaine	B-Drug
spoon.	O
spoon	I-Drug

The	O
movie	O
Fear	O
and	O
Loathing	O
in	O
Las	O
Vegas	O
(1998),	O
adapted	O
from	O
a	O
1971	O
novel	O
of	O
Hunter	O
S.	O
Thompson,	O
portrays	O
heavy	O
psychedelic	O
drug	O
use	O
mentions	O
Leary	O
when	O
the	O
protagonist	O
ponders	O
meaning	O
acid	B-Drug
wave	O
1960s	O

Cannabidiol	B-Drug
(CBD),	O
another	O
cannabinoid	O
found	O
in	O
cannabis	O
varying	O
amounts,	O
has	O
been	O
shown	O
to	O
ameliorate	O
the	O
adverse	O
effects	O
of	O
THC,	O
including	O
anxiety,	O
that	O
some	O
consumers	O
experience.	O
CBD	B-Drug
THC	B-Drug

para-Iodoamphetamine	O
(PIA),	O
also	O
known	O
as	O
4-iodoamphetamine	O
(4-IA),	O
is	O
a	O
research	O
chemical	O
of	O
the	O
phenethylamine	B-Drug
and	O
amphetamine	B-Drug
classes.	O

Lastly,	O
Vint,	O
Russian	O
for	O
"a	O
screw",	O
refers	O
to	O
a	O
very	O
impure	O
homemade	O
form	O
of	O
methamphetamine	B-Drug
in	O
Russia.	O

In	O
1987,	O
temazepam	B-Drug
was	O
the	O
most	O
widely	O
abused	O
legal	O
prescription	O
drug	O
in	O
United	O
Kingdom.	O

The	O
high	O
incidence	O
of	O
side	O
effects,	O
including	O
severe	O
cardiopulmonary	O
depression,	O
has	O
caused	O
etorphine	B-Drug
to	O
fall	O
into	O
disfavor	O
in	O
general	O
veterinary	O
practice.	O

Fentanyl	B-Drug
patches	O
for	O
cancer	O
pain	O
are	O
on	O
the	O
World	O
Health	O
Organization's	O
List	O
of	O
Essential	O
Medicines.	O

There	O
are	O
currently	O
no	O
medications	O
to	O
treat	O
MDMA	B-Drug
addiction.	O

Popular	O
treatments	O
include	O
kratom,	O
naloxone,	O
methadone,	O
and	O
buprenorphine,	O
which	O
are	O
more	O
effective	O
when	O
combined	O
with	O
a	O
form	O
of	O
behavioral	O
treatment.	O
kratom	B-Drug
naloxone	B-Drug
methadone	B-Drug
buprenorphine	B-Drug

Pregabalin	B-Drug
is	O
eliminated	O
by	O
the	O
kidneys	O
in	O
urine,	O
mainly	O
its	O
unchanged	O
form.	O

Butalbital	B-Drug
is	O
not	O
recommended	O
as	O
a	O
first-line	O
treatment	O
because	O
it	O
impairs	O
alertness,	O
brings	O
risk	O
of	O
dependence	O
and	O
addiction,	O
increases	O
the	O
that	O
episodic	O
headaches	O
will	O
become	O
chronic.	O

Dienogest	B-Drug
is	O
available	O
both	O
alone	O
and	O
in	O
combination	O
with	O
estrogens.	O

Cathinone	B-Drug
occurs	O
naturally	O
in	O
the	O
plant	O
khat	O
whose	O
leaves	O
are	O
chewed	O
as	O
a	O
recreational	O
drug.	O

For	O
instance,	O
chronic	O
methamphetamine	B-Drug
use	O
caused	O
methylation	O
of	O
the	O
lysine	O
in	O
position	O
4	O
histone	O
3	O
located	O
at	O
promoters	O
c-fos	O
and	O
C-C	O
chemokine	O
receptor	O
2	O
(ccr2)	O
genes,	O
activating	O
those	O
genes	O
nucleus	O
accumbens	O
(NAc).	O

Oral	O
doses	O
of	O
opium	B-Drug
tincture	O
are	O
rapidly	O
absorbed	O
in	O
the	O
gastrointestinal	O
tract	O
and	O
metabolized	O
liver.	O

As	O
of	O
August	O
2015,	O
25I-NBOMe	B-Drug
has	O
reportedly	O
led	O
to	O
at	O
least	O
19	O
overdose	O
deaths	O
in	O
the	O
United	O
States.	O

After	O
winning	O
the	O
100m	O
gold	O
at	O
1988	O
Summer	O
Olympics	O
in	O
Seoul,	O
Canadian	O
sprinter	O
Ben	O
Johnson	O
tested	O
positive	O
for	O
anabolic	O
steroid	O
Stanozolol,	O
was	O
later	O
stripped	O
of	O
his	O
medal,	O
and	O
banned	O
from	O
competition	O
two	O
years.	O
Stanozolol	B-Drug

There	O
are	O
case	O
reports	O
of	O
increased	O
liver	O
enzymes	O
involving	O
ketamine	B-Drug
treatment	O
chronic	O
pain.	O

Studies	O
have	O
shown	O
some	O
deterioration	O
of	O
the	O
brain's	O
white	O
matter	O
due	O
to	O
heroin	B-Drug
use,	O
which	O
may	O
affect	O
decision-making	O
abilities,	O
ability	O
regulate	O
behavior,	O
and	O
responses	O
stressful	O
situations.	O

From	O
2013	O
until	O
2016,	O
overdose	O
deaths	O
involving	O
fentanyl	B-Drug
increased	O
113%	O
per	O
year.	O

In	O
June	O
2013,	O
the	O
United	O
States	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
(CDC)	O
issued	O
a	O
health	O
advisory	O
to	O
emergency	O
departments	O
alerting	O
14	O
overdose	O
deaths	O
among	O
intravenous	O
drug	O
users	O
in	O
Rhode	O
Island	O
associated	O
with	O
acetylfentanyl,	O
synthetic	O
opioid	O
analog	O
of	O
fentanyl	B-Drug
that	O
has	O
never	O
been	O
licensed	O
medical	O
use.	O

Techniques	O
included	O
the	O
covert	O
administration	O
of	O
high	O
doses	O
psychoactive	O
drugs	O
(especially	O
LSD)	O
and	O
other	O
chemicals,	O
electroshocks,	O
hypnosis,	O
sensory	O
deprivation,	O
isolation,	O
verbal	O
sexual	O
abuse,	O
in	O
addition	O
to	O
forms	O
torture.	O
LSD	B-Drug

It	O
is	O
recommended	O
that,	O
to	O
avoid	O
becoming	O
a	O
victim	O
of	O
hyoscine,	O
person	O
should	O
never	O
accept	O
food	O
or	O
beverages	O
offered	O
by	O
strangers	O
new	O
acquaintances,	O
nor	O
leave	O
unattended	O
in	O
their	O
presence.	O
hyoscine	B-Drug

In	O
those	O
with	O
renal	O
impairment,	O
the	O
half-life	O
of	O
hydromorphone	B-Drug
may	O
increase	O
to	O
as	O
much	O
40	O
hours.	O

Her	O
two	O
autopsies	O
detected	O
more	O
than	O
11	O
drugs	O
in	O
her	O
bloodstream,	O
including	O
chloral	O
hydrate,	O
clonazepam,	O
lorazepam,	O
oxazepam,	O
diazepam,	O
diphenhydramine,	O
topiramate,	O
oseltamivir,	O
ciprofloxacin,	O
methocarbamol,	O
carisoprodol	B-Drug
and	O
others.	O
clonazepam	B-Drug
lorazepam	B-Drug
oxazepam	B-Drug
diazepam	B-Drug
diphenhydramine	B-Drug
topiramate	B-Drug
oseltamivir	B-Drug
ciprofloxacin	B-Drug
methocarbamol	B-Drug

The	O
final	O
class	O
of	O
barbiturates	O
are	O
known	O
as	O
long-acting	O
(the	O
most	O
notable	O
one	O
being	O
phenobarbital,	O
which	O
has	O
a	O
half-life	O
roughly	O
92	O
hours).	O
phenobarbital	B-Drug

Before	O
he	O
assumed	O
leadership	O
of	O
the	O
entire	O
cartel,	O
served	O
as	O
logistical	O
coordinator	O
for	O
its	O
Zambada-Garca	O
faction,	O
which	O
has	O
overseen	O
trafficking	O
cocaine	B-Drug
and	O
heroin	B-Drug
into	O
Chicago	O
other	O
US	O
cities	O
by	O
aircraft,	O
narcosubs,	O
container	O
ships,	O
go-fast	O
boats,	O
fishing	O
vessels,	O
buses,	O
rail	O
cars,	O
tractor	O
trailers,	O
automobiles.	O

heroin,	O
cannabis,	O
MDMA,	O
cocaine,	O
amphetamines,	O
barbiturates	O
Return	O
to	O
Paradise	O
(1998)	O
cannabis	O
resin	B-Drug
Revenge	O
of	O
the	O
Nerds	O
(1984)	O
heroin	B-Drug
MDMA	B-Drug
cocaine	B-Drug

The	O
likelihood	O
of	O
experiencing	O
adverse	O
effects	O
from	O
hyoscine	B-Drug
is	O
increased	O
in	O
the	O
elderly	O
relative	O
to	O
younger	O
people.	O

Desogestrel	B-Drug
is	O
marketed	O
under	O
a	O
variety	O
of	O
brand	O
names	O
throughout	O
the	O
world	O
including	O
Alenvona,	O
Apri,	O
Azalia,	O
Azurette,	O
Caziant,	O
Cerazette,	O
Cerelle,	O
Cesia,	O
Cyclessa,	O
Denise,	O
Desogen,	O
Desirett,	O
Diamilla,	O
Emoquette,	O
Feanolla,	O
Gedarel,	O
Gracial,	O
Kariva,	O
Laurina,	O
Linessa,	O
Marvelon,	O
Mercilon,	O
Mircette,	O
Mirvala,	O
Novynette,	O
Ortho-Cept,	O
Reclipsen,	O
Regulon,	O
Solia,	O
Velivet,	O
and	O
Viorele	O
among	O
others.	O
Kariva	B-Drug
Velivet	B-Drug

It	O
has	O
a	O
much	O
longer	O
elimination	O
half-life	O
via	O
intramuscular	O
injection	O
than	O
drostanolone.	O
drostanolone	B-Drug

Hemp,	O
which	O
had	O
been	O
grown	O
for	O
industrial	O
purposes,	O
not	O
affected	O
by	O
the	O
opium	B-Drug
conference	O
in	O
1925.	O

In	O
the	O
UK	O
GHB	B-Drug
was	O
made	O
a	O
class	O
C	O
drug	O
in	O
June	O
2003.	O

Since	O
1994,	O
the	O
production,	O
dispensing,	O
and	O
prescription	O
of	O
thalidomide	B-Drug
have	O
been	O
strictly	O
controlled,	O
requiring	O
women	O
to	O
use	O
two	O
forms	O
birth	O
control	O
submit	O
regular	O
pregnancy	O
tests.	O

Nortriptyline	B-Drug
is	O
a	O
secondary	O
amine	O
TCA,	O
with	O
its	O
N-methylated	O
parent	O
amitriptyline	B-Drug
being	O
tertiary	O
amine.	O

The	O
Melbourne,	O
Australia	O
inner-city	O
suburbs	O
of	O
Richmond	O
and	O
Abbotsford	O
are	O
locations	O
in	O
which	O
the	O
use	O
dealing	O
heroin	B-Drug
has	O
been	O
concentrated	O
for	O
a	O
protracted	O
time	O
period.	O

GHB	B-Drug
has	O
been	O
used	O
as	O
a	O
club	O
drug,	O
apparently	O
starting	O
in	O
the	O
1990s,	O
small	O
doses	O
of	O
can	O
act	O
euphoriant	O
and	O
are	O
believed	O
to	O
be	O
aphrodisiac.	O

The	O
severity	O
and	O
location	O
of	O
the	O
deformities	O
depended	O
on	O
how	O
many	O
days	O
into	O
pregnancy	O
mother	O
was	O
before	O
beginning	O
treatment;	O
thalidomide	B-Drug
taken	O
20th	O
day	O
caused	O
central	O
brain	O
damage,	O
21	O
would	O
damage	O
eyes,	O
22	O
ears	O
face,	O
24	O
arms,	O
leg	O
occur	O
if	O
up	O
to	O
28.	O

A	O
systematic	O
review	O
from	O
2014	O
found	O
that	O
low	O
doses	O
of	O
amphetamine	B-Drug
also	O
improve	O
memory	O
consolidation,	O
in	O
turn	O
leading	O
to	O
improved	O
recall	O
information.	O

Cannabicyclohexanol	B-Drug
is	O
not	O
listed	O
in	O
the	O
schedules	O
set	O
out	O
by	O
United	O
Nations'	O
Single	O
Convention	O
on	O
Narcotic	O
Drugs	O
from	O
1961	O
nor	O
their	O
Psychotropic	O
Substances	O
1971,	O
so	O
signatory	O
countries	O
to	O
these	O
international	O
drug	O
control	O
treaties	O
are	O
required	O
said	O
Cannabicyclohexanol.	O

Because	O
cocaine	B-Drug
is	O
hydrolyzed	O
and	O
rendered	O
inactive	O
in	O
the	O
acidic	O
stomach,	O
it	O
not	O
readily	O
absorbed	O
when	O
ingested	O
alone.	O

heroin	B-Drug
Enter	O
the	O
Void	O
(2009)	O

Hemodialysis	O
is	O
effective	O
in	O
removing	O
phenobarbital	B-Drug
from	O
the	O
body,	O
and	O
may	O
reduce	O
its	O
half-life	O
by	O
up	O
to	O
90%.	O

For	O
a	O
time,	O
the	O
Cali	O
Cartel	O
eventually	O
grew	O
big	O
enough	O
to	O
supply	O
70%	O
of	O
United	O
States	O
cocaine	B-Drug
demands	O
through	O
Jorge	O
Alberto	O
Rodriguez,	O
who	O
oversaw	O
all	O
major	O
shipments	O
entering	O
States,	O
and	O
were	O
able	O
meet	O
90%	O
European	O
market.	O

"In	O
connection	O
with	O
his	O
proposals	O
to	O
make	O
Salvia	O
divinorum	O
and	O
salvinorin	B-Drug
A	I-Drug
Schedule	O

The	O
duration	O
of	O
experience	O
varies	O
with	O
the	O
method	O
ingestion	O
and	O
amount	O
salvinorin	B-Drug
A	I-Drug
absorbed.	O

Darolutamide	B-Drug
and	O
ketodarolutamide	O
appear	O
to	O
negligibly	O
cross	O
the	O
bloodbrain	O
barrier	O
both	O
in	O
mice	O
humans.	O

CD4:	O
benzodiazepines,	O
e.g.	O
diazepam,	O
nitrazepam	B-Drug
diazepam	B-Drug

In	O
1992,	O
finasteride	B-Drug
(5	O
mg)	O
was	O
approved	O
by	O
the	O
U.S.	O
Food	O
and	O
Drug	O
Administration	O
(FDA)	O
for	O
treatment	O
of	O
BPH,	O
which	O
Merck	O
marketed	O
under	O
brand	O
name	O
Proscar.	O
Proscar	B-Drug

Pyrovalerone	B-Drug
(Centroton,	O
4-Methyl--keto-prolintane,	O
Thymergix,	O
O-2371)	O
is	O
a	O
psychoactive	O
drug	O
with	O
stimulant	O
effects	O
via	O
acting	O
as	O
norepinephrine-dopamine	O
reuptake	O
inhibitor	O
(NDRI),	O
and	O
used	O
for	O
the	O
clinical	O
treatment	O
of	O
chronic	O
fatigue	O
or	O
lethargy	O
an	O
anorectic	O
appetite	O
suppressant	O
weight	O
loss	O
purposes.	O

Other	O
prodrug	O
ester	O
forms	O
of	O
GHB	B-Drug
have	O
also	O
rarely	O
been	O
encountered	O
by	O
law	O
enforcement,	O
including	O
1,4-butanediol	O
diacetate	O
(BDDA/DABD),	O
methyl-4-acetoxybutanoate	O
(MAB),	O
and	O
ethyl-4-acetoxybutanoate	O
(EAB),	O
but	O
these	O
are,	O
in	O
general,	O
covered	O
analogue	O
laws	O
jurisdictions	O
where	O
is	O
illegal,	O
little	O
known	O
about	O
them	O
beyond	O
their	O
delayed	O
onset	O
longer	O
duration	O
action.	O

Bufotenin	B-Drug
is	O
a	O
constituent	O
of	O
the	O
seeds	O
Anadenanthera	O
colubrina	O
and	O
peregrina	O
trees.	O

By	O
1978,	O
buprenorphine	B-Drug
was	O
first	O
launched	O
in	O
the	O
UK	O
as	O
an	O
injection	O
to	O
treat	O
severe	O
pain,	O
with	O
a	O
sublingual	O
formulation	O
released	O
1982.	O

PCP	B-Drug
has	O
been	O
shown	O
to	O
produce	O
conditioned	O
place	O
aversion	O
and	O
preference	O
in	O
animal	O
studies.	O

While	O
experiences	O
of	O
apparent	O
entity	O
contact	O
may	O
occasionally	O
occur	O
under	O
the	O
influence	O
DPT,	O
perspective	O
is	O
more	O
as	O
an	O
observer	O
or	O
watcher,	O
contrasted	O
to	O
personal	O
and	O
realistic	O
experience	O
reported	O
with	O
DMT.	O
DPT	B-Drug

Further	O
research	O
is	O
therefore	O
needed	O
to	O
compare	O
nalbuphine	B-Drug
with	O
other	O
postoperative	O
opioids.	O

The	O
acute	O
toxicity	O
of	O
nandrolone	B-Drug
esters	O
in	O
animals	O
and	O
donkeys	O
is	O
very	O
low	O
there	O
are	O
no	O
reports	O
overdosage	O
with	O
decanoate	I-Drug
humans.	O

Unlike	O
opioid	O
inverse	O
agonists	O
such	O
as	O
naloxone	B-Drug
and	O
naltrexone	B-Drug
(which	O
are	O
often	O
dubbed	O
"antagonists"	O
for	O
simplicity's	O
sake),	O

Tranylcypromine	B-Drug
may	O
have	O
neuroprotective	O
properties	O
applicable	O
to	O
the	O
treatment	O
of	O
Parkinson's	O
disease,	O
similar	O
MAO-B	O
inhibitors	O
selegiline	B-Drug
and	O
rasagiline.	O
rasagiline	B-Drug

nicotine	B-Drug
(found	O
in	O
Nicotiana	O
spp.)	O

Black	O
tar	O
as	O
a	O
type	O
holds	O
variable	O
admixture	O
morphine	B-Drug
derivativespredominantly	O
6-MAM	O
(6-monoacetylmorphine),	O
which	O
is	O
another	O
result	O
of	O
crude	O
acetylation.	O
6-monoacetylmorphine	B-Drug

Etizolam	B-Drug
produces,	O
especially	O
at	O
higher	O
dosages,	O
a	O
reduction	O
in	O
time	O
taken	O
to	O
fall	O
asleep,	O
an	O
increase	O
total	O
sleep	O
time,	O
and	O
the	O
number	O
of	O
awakenings.	O

This	O
weaning	O
process	O
may	O
be	O
over	O
a	O
few	O
days	O
if	O
the	O
course	O
of	O
prednisone	B-Drug
was	O
short,	O
but	O
take	O
weeks	O
or	O
months	O
patient	O
had	O
been	O
on	O
long-term	O
treatment.	O

Though	O
the	O
laws	O
affected	O
use	O
and	O
distribution	O
of	O
opium	B-Drug
by	O
Chinese	O
immigrants,	O
no	O
action	O
was	O
taken	O
against	O
producers	O
such	O
products	O
as	O
laudanum,	O
a	O
tincture	O
alcohol,	O
commonly	O
panacea	O
white	O
Americans.	O
laudanum	B-Drug

Thalidomide	B-Drug
did	O
not	O
damage	O
the	O
fetus	O
if	O
taken	O
after	O
42	O
days	O
gestation.	O

The	O
exploration	O
of	O
the	O
antiangiogenic	O
and	O
immunomodulatory	O
activities	O
thalidomide	B-Drug
has	O
led	O
to	O
study	O
creation	O
analogs.	O

MDMA	B-Drug
(Methylenedioxymethamphetamine),	O
which	O
is	O
known	O
as	O
ecstasy.	O
Methylenedioxymethamphetamine	B-Drug
ecstasy	B-Drug

Heroin	B-Drug
trafficking	O
was	O
virtually	O
eliminated	O
in	O
the	O
US	O
during	O
World	O
War	O
II	O
because	O
of	O
temporary	O
trade	O
disruptions	O
caused	O
by	O
war.	O

Levorphanol,	O
similarly	O
to	O
certain	O
other	O
opioids,	O
also	O
acts	O
as	O
a	O
glycine	O
receptor	O
antagonist	O
and	O
GABA	O
at	O
very	O
high	O
concentrations.	O
Levorphanol	B-Drug

The	O
available	O
data	O
was	O
determined	O
to	O
be	O
insufficient	O
allow	O
reliable	O
conclusions	O
drawn	O
regarding	O
the	O
effectiveness	O
of	O
oral	O
cannabis	O
extract	O
or	O
THC	B-Drug
in	O
controlling	O
tics.	O

The	O
British	O
government	O
has	O
contradicted	O
the	O
Home	O
Office's	O
suggestion	O
that	O
opium	B-Drug
cultivation	O
can	O
be	O
legalized	O
in	O
Afghanistan	O
for	O
exports	O
to	O
United	O
Kingdom,	O
helping	O
lower	O
poverty	O
and	O
internal	O
fighting	O
while	O
NHS	O
meet	O
high	O
demand	O
morphine	B-Drug
heroin.	O
heroin	B-Drug

Trichocereus	O
pachanoi),	O
Mescaline	B-Drug
0.006-0.12%,	O
0.05%	O
Average;	O

Opium	O
tincture	O
is	O
indicated	O
for	O
the	O
treatment	O
of	O
severe	O
fulminant	O
(intense,	O
prolific)	O
diarrhea	O
that	O
does	O
not	O
respond	O
to	O
standard	O
therapy	O
(e.g.,	O
Imodium	B-Drug
or	O
Lomotil).	O
Lomotil	B-Drug

Subsequently,	O
gabapentin	B-Drug
was	O
approved	O
in	O
the	O
United	O
States	O
for	O
treatment	O
of	O
postherpetic	O
neuralgia	O
2002.	O

The	O
first	O
dose	O
for	O
patients	O
who	O
have	O
been	O
receiving	O
methadone	B-Drug
will	O
be	O
a	O
little	O
higher	O
than	O
the	O
amount	O
of	O
that	O
was	O
being	O
taken	O
every	O
day,	O
but	O
not	O
more	O
120	O
mg.	O

For	O
example,	O
in	O
the	O
United	O
Kingdom	O
formula	O
for	O
Paregoric,	O
B.P.	O
is	O
tincture	O
of	O
opium	B-Drug
5	O
ml,	O
benzoic	O
acid	O
500	O
mg,	O
camphor	O
300	O
anise	O
oil	O

It	O
is	O
also	O
one	O
of	O
the	O
most	O
common	O
medicines	O
used	O
in	O
rescue	O
inhalers	O
(short-term	O
bronchodilators	O
to	O
alleviate	O
asthma	O
attacks).As	O
a	O
2	O
agonist,	O
salbutamol	B-Drug
has	O
use	O
obstetrics.	O

MDMA	B-Drug
was	O
also	O
found	O
to	O
have	O
effects	O
on	O
blood	O
sugar	O
levels	O
comparable	O
high	O
doses	O
of	O
ephedrine.	O
ephedrine	B-Drug

There	O
was	O
low-	O
to	O
moderate-strength	O
evidence	O
of	O
no	O
benefit	O
for	O
most	O
the	O
other	O
medications	O
used	O
in	O
RCTs,	O
which	O
included	O
antidepressants	O
(bupropion,	O
mirtazapine,	O
sertraline),	O
antipsychotics	O
(aripiprazole),	O
anticonvulsants	O
(topiramate,	O
baclofen,	O
gabapentin),	O
naltrexone,	O
varenicline,	O
citicoline,	O
ondansetron,	O
prometa,	O
riluzole,	O
atomoxetine,	O
dextroamphetamine,	O
and	O
modafinil.	O
bupropion	B-Drug
mirtazapine	B-Drug
sertraline	B-Drug
aripiprazole	B-Drug
topiramate	B-Drug
baclofen	B-Drug
gabapentin	B-Drug
naltrexone	B-Drug
varenicline	B-Drug
ondansetron	B-Drug
riluzole	B-Drug
atomoxetine	B-Drug
dextroamphetamine	B-Drug
modafinil	B-Drug

In	O
general,	O
MDMA	B-Drug
users	O
report	O
feeling	O
the	O
onset	O
of	O
subjective	O
effects	O
within	O
30	O
to	O
60	O
minutes	O
oral	O
consumption	O
and	O
reaching	O
peak	O
effect	O
at	O
75	O
120	O
minutes,	O
which	O
then	O
plateaus	O
for	O
about	O
3.5	O
hours.	O

On	O
November	O
19,	O
2010,	O
the	O
FDA	O
requested	O
manufacturers	O
withdraw	O
propoxyphene	B-Drug
from	O
US	O
market,	O
citing	O
heart	O
arrhythmia	O
in	O
patients	O
who	O
took	O
drug	O
at	O
typical	O
doses.	O

As	O
of	O
2011,	O
levothyroxine	B-Drug
was	O
the	O
second-most	O
commonly	O
prescribed	O
medication	O
in	O
U.S.,	O
with	O
23.8	O
million	O
prescriptions	O
filled	O
each	O
year.	O

Carbamazepine	B-Drug
and	O
other	O
enzyme	O
inducers	O
may	O
reduce	O
plasma	O
levels	O
of	O
risperidone.	O
risperidone	B-Drug

Spironolactone	B-Drug
at	O
higher	O
doses	O
can	O
cause	O
menstrual	O
irregularities	O
as	O
a	O
side	O
effect	O
in	O
women.	O

Cannabis	O
impairs	O
a	O
person's	O
driving	O
ability,	O
and	O
THC	B-Drug
was	O
the	O
illicit	O
drug	O
most	O
frequently	O
found	O
in	O
blood	O
of	O
drivers	O
who	O
have	O
been	O
involved	O
vehicle	O
crashes.	O

All	O
other	O
cannabinoids	O
(including	O
but	O
not	O
limited	O
to	O
cannabis,	O
hashish,	O
marijuana,	O
and	O
THC)	O
are	O
prohibited	O
in-competition.	O
hashish	B-Drug
THC	B-Drug

Between	O
1992	O
and	O
1997	O
they	O
published	O
three	O
papers	O
on	O
the	O
effects	O
of	O
this	O
drug	O
in	O
rats	O
idea	O
that	O
it	O
could	O
potentially	O
be	O
used	O
treatment	O
depression	O
a	O
potential	O
replacement	O
for	O
Prozac.	O
Prozac	B-Drug

This	O
explains	O
why	O
one	O
lorazepam	B-Drug
dose,	O
despite	O
its	O
shorter	O
serum	O
half-life,	O
has	O
more	O
prolonged	O
peak	O
effects	O
than	O
an	O
equivalent	O
diazepam	B-Drug
dose.	O

Recent	O
studies	O
suggest	O
that	O
taking	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs)	O
antidepressants	O
paroxetine	B-Drug
(Paxil),	O
fluoxetine	B-Drug
(Prozac),	O
and	O
sertraline	B-Drug
(Zoloft)	O
can	O
decrease	O
effectiveness	O
of	O
tamoxifen,	O
as	O
these	O
drugs	O
compete	O
for	O
CYP2D6	O
enzyme	O
which	O
is	O
needed	O
to	O
metabolize	O
tamoxifen	B-Drug
into	O
its	O
active	O
forms.	O
Paxil	B-Drug
Prozac	B-Drug
Zoloft	B-Drug

As	O
a	O
result,	O
it	O
was	O
possible	O
for	O
Temmler	O
to	O
market	O
on	O
large	O
scale	O
as	O
nonprescription	O
drug	O
under	O
the	O
trade	O
name	O
Pervitin	B-Drug
(methamphetamine	O
hydrochloride).	O
methamphetamine	B-Drug
hydrochloride	I-Drug

Wyeth's	O
original	O
patent	O
on	O
lorazepam	B-Drug
is	O
expired	O
in	O
the	O
United	O
States.	O

This	O
is	O
based	O
in	O
part	O
on	O
a	O
2012	O
review	O
which	O
found	O
that	O
zolpidem's	O
effectiveness	O
nearly	O
as	O
much	O
due	O
to	O
psychological	O
effects	O
the	O
medication	O
itself.	O
zolpidem	B-Drug

Several	O
reviews	O
concluded	O
that	O
similar	O
results	O
concerning	O
effects	O
and	O
safety	O
were	O
obtained	O
using	O
either	O
bevacizumab	B-Drug
or	O
ranibizumab.	O
ranibizumab	B-Drug

In	O
the	O
role-playing	O
video-game	O
Darkest	O
Dungeon	O
(2016),	O
laudanum	B-Drug
is	O
a	O
provision	O
that	O
used	O
to	O
cure	O
Horror,	O
stress-over-time	O
negative	O
effect	O
Eleanor	O
Catton's	O
novel	O
The	O
Luminaries	O
(2013),	O
and	O
subsequent	O
TV	O
adaptation	O
(2020),	O
many	O
characters	O
are	O
addicted	O
it	O
murder	O
Crosbie	O
Wells.	O

Daclatasvir	B-Drug
Glecaprevir/pibrentasvir	O
Sofosbuvir	B-Drug
Sofosbuvir/velpatasvir	O
Dasabuvir	B-Drug
Ledipasvir/sofosbuvir	B-Drug
Ombitasvir/paritaprevir/ritonavir	O
Ribavirin	B-Drug
Pegylated	B-Drug
interferon-alpha-2a	I-Drug
or	O
pegylated	B-Drug
interferon-alpha-2b	I-Drug
velpatasvir	B-Drug
paritaprevir	B-Drug
ritonavir	B-Drug

Methyltestosterone	B-Drug
(17-hydroxy-17-methylandrost-4-en-3-one)	O

Long-term	O
use	O
of	O
benzodiazepines	O
such	O
as	O
diazepam	B-Drug
is	O
associated	O
with	O
drug	O
tolerance,	O
benzodiazepine	O
dependence,	O
and	O
withdrawal	O
syndrome.	O

Serotonergic	O
psychedelics	O
such	O
as	O
tryptamines	O
(e.g.,	O
psilocybin,	O
psilocin,	O
DMT,	O
5-MeO-DMT,	O
bufotenin),	O
lysergamides	O
LSD,	O
ergine	B-Drug
(LSA)),	O
phenethylamines	O
mescaline,	O
2C-B,	O
25I-NBOMe),	O
and	O
amphetamines	O
MDA,	O
DOM)	O
are	O
non-selective	O
agonists	O
of	O
serotonin	O
receptors.	O
psilocin	B-Drug
5-MeO-DMT	B-Drug
bufotenin	B-Drug
LSD	B-Drug
mescaline	B-Drug
2C-B	B-Drug
25I-NBOMe	B-Drug

particularly	O
methyltestosterone	B-Drug
show	O
a	O
high	O
risk	O
of	O
gynecomastia	O
at	O
sufficiently	O
dosages,	O
while	O
AAS	O
that	O
have	O
reduced	O
potential	O
for	O
aromatization	O
like	O
nandrolone	B-Drug
much	O
lower	O
(	O

There	O
may	O
be	O
an	O
increase	O
in	O
the	O
clearance	O
and	O
resultant	O
decrease	O
blood	O
concentration	O
of	O
lamotrigine,	O
phenytoin,	O
to	O
a	O
lesser	O
extent	O
carbamazepine,	O
possibly	O
decreases	O
level	O
levetiracetam	B-Drug
active	O
oxcarbazepine	B-Drug
metabolite,	O
monohydroxy	O
derivative.	O
lamotrigine	B-Drug
phenytoin	B-Drug
carbamazepine	B-Drug

Scopolamine	B-Drug
in	O
particular	O
has	O
been	O
implemented	O
scientific	O
models	O
used	O
to	O
study	O
the	O
cholinergic	O
hypothesis	O
for	O
Alzheimer's	O
disease	O
and	O
other	O
related	O
dementias.	O

Studies	O
have	O
found	O
that	O
Duloxetine	B-Drug
can	O
increase	O
liver	O
function	O
tests	O
three	O
times	O
above	O
their	O
upper	O
normal	O
limit.	O

Spironolactone	B-Drug
can	O
also	O
have	O
numerous	O
other	O
interactions,	O
most	O
commonly	O
with	O
cardiac	O
and	O
blood	O
pressure	O
medications,	O
for	O
instance	O
digoxin.	O
digoxin	B-Drug

"A	O
2012	O
review	O
found	O
that	O
the	O
THC	B-Drug
content	O
in	O
marijuana	O
had	O
increased	O
worldwide	O
from	O
1970	O
to	O
2009.	O

This	O
process	O
reduces	O
the	O
oil	O
yield,	O
but	O
resulting	O
is	O
less	O
acidic,	O
more	O
easily	O
digestible	O
and	O
much	O
potent	O
(almost	O
pure	O
THC).	O
THC	B-Drug

There	O
is	O
no	O
evidence	O
that	O
amphetamine	B-Drug
directly	O
neurotoxic	O
in	O
humans.	O

Feedstock	O
syrups	O
containing	O
medium	O
to	O
large	O
concentrations	O
of	O
fructose	O
(for	O
example,	O
cashew	O
apple	O
juice,	O
55%	O
fructose:	O
45%	O
glucose)	O
can	O
produce	O
yields	O
200	O
g	O
(7.1	O
oz)	O
mannitol	B-Drug
per	O
liter	O
feedstock.	O

the	O
separated	O
resin,	O
crude	O
or	O
purified,	O
obtained	O
from	O
cannabis	O
plantSemisynthetic	O
opioids:	O
acetorphine	B-Drug
desomorphine	B-Drug
etorphine	B-Drug
heroinSynthetic	O
opioids	O

Increased	O
levels	O
of	O
estradiol	O
with	O
spironolactone	B-Drug
may	O
be	O
involved	O
in	O
its	O
preservation	O
bone	O
density	O
and	O
side	O
effects	O
such	O
as	O
breast	O
tenderness,	O
enlargement,	O
gynecomastia	O
women	O
men.	O

"Many	O
users	O
of	O
ibogaine	B-Drug
report	O
experiencing	O
visual	O
phenomena	O
during	O
a	O
waking	O
dream	O
state,	O
such	O
as	O
instructive	O
replays	O
life	O
events	O
that	O
led	O
to	O
their	O
addiction,	O
while	O
others	O
therapeutic	O
shamanic	O
visions	O
help	O
them	O
conquer	O
the	O
fears	O
and	O
negative	O
emotions	O
might	O
drive	O
addiction.	O

In	O
return	O
for	O
their	O
efforts	O
towards	O
eradication	O
of	O
the	O
coca	B-Drug
plant,	O
countries	O
were	O
granted	O
U.S.	O
tariff	O
exemptions	O
on	O
certain	O
products,	O
such	O
as	O
types	O
fruit.	O

,	O
like	O
codeine,	O
is	O
a	O
weak	O
opioid,	O
known	O
to	O
cause	O
dependency	O
among	O
recreational	O
users.	O
codeine	B-Drug

LSD's	O
psychedelic	O
properties	O
were	O
discovered	O
5	O
years	O
later	O
when	O
Hofmann	O
himself	O
accidentally	O
ingested	O
an	O
unknown	O
quantity	O
of	O
the	O
chemical.	O
LSD	B-Drug

In	O
February	O
2020,	O
the	O
FDA	O
requested	O
that	O
manufacturer	O
lorcaserin	B-Drug
voluntarily	O
withdraw	O
drug	O
from	O
US	O
market	O
because	O
a	O
safety	O
clinical	O
trial	O
showed	O
an	O
increased	O
occurrence	O
of	O
cancer.	O

Prior	O
use	O
of	O
amiodarone	B-Drug
hydrochloride	O
Adams-Stokes	O
syndrome	O
Wolff-Parkinson-White	O
Lidocaine	B-Drug
viscous	O
is	O
not	O
recommended	O
by	O
the	O
FDA	O
to	O
treat	O
teething	O
pain	O
in	O
children	O
and	O
infants.	O

As	O
of	O
August	O
2020,	O
it	O
is	O
still	O
illegal	O
to	O
carry	O
cannabis	O
and	O
cannabis-derived	O
products	O
(including	O
containing	O
CBD)	O
across	O
the	O
Canadian	O
border.	O
CBD	B-Drug

Though	O
this	O
is	O
somewhat	O
controversial	O
among	O
proponents	O
of	O
a	O
zero-tolerance	O
drug	O
policy,	O
it	O
has	O
proven	O
superior	O
to	O
methadone	B-Drug
in	O
improving	O
the	O
social	O
and	O
health	O
situations	O
addicts.	O

Ammonia	O
gas	O
(amphetamine,	O
methamphetamine)	O
amphetamine	B-Drug
methamphetamine	B-Drug

generalized	O
to	O
aminorex	B-Drug
as	O
amphetamine	B-Drug
stimulus	O
but	O
not	O
fenfluramine.	O
fenfluramine	B-Drug

Suvorexant	B-Drug
exerts	O
its	O
therapeutic	O
effect	O
in	O
insomnia	O
through	O
antagonism	O
of	O
orexin	O
receptors.	O

The	O
formal	O
generic	O
names	O
of	O
nandrolone	B-Drug
esters	O
include	O
cyclohexylpropionate	O
(BANM),	O
cyclotate	O
(USAN),	O
decanoate	I-Drug
(USAN,	O
USP,	O
BANM,	O
JAN),	O
laurate	O
phenpropionate	I-Drug
(USP),	O
and	O
phenylpropionate	I-Drug
(BANM,	O
JAN).	O

In	O
Australia,	O
modafinil	B-Drug
is	O
considered	O
to	O
be	O
a	O
Schedule	O
4	O
prescription-only	O
medicine	O
or	O
prescription	O
animal	O
remedy.	O

For	O
accessing	O
sterile	O
injecting	O
equipment	O
clients	O
frequently	O
visit	O
NSP	O
outlets,	O
and	O
for	O
receiving	O
pharmacotherapy	O
(e.g.	O
methadone,	O
buprenorphine)	O
they	O
OST	O
clinics;	O
these	O
frequent	O
visits	O
are	O
used	O
opportunistically	O
to	O
offer	O
much	O
needed	O
health	O
care.	O
methadone	B-Drug
buprenorphine	B-Drug

There	O
soon	O
appeared	O
reports	O
of	O
abnormalities	O
in	O
children	O
being	O
born	O
to	O
mothers	O
using	O
thalidomide.	O
thalidomide	B-Drug

Moreover,	O
ketamine	B-Drug
was	O
discovered	O
and	O
better	O
tolerated	O
as	O
an	O
anesthetic.	O

Noscapine	B-Drug
is	O
a	O
marginal	O
case	O
as	O
it	O
does	O
have	O
CNS	O
effects	O
but	O
not	O
necessarily	O
similar	O
to	O
morphine,	O
and	O
probably	O
in	O
category	O
all	O
its	O
own.	O
morphine	B-Drug

In	O
1915,	O
Yamaigiwa	O
Katsusaburo	O
and	O
Koichi	O
Ichikawa	O
tested	O
the	O
carcinogenicity	O
of	O
coal	B-Drug
tar	I-Drug
using	O
inner	O
surface	O
rabbit's	O
ears.	O

Nandrolone	B-Drug
was	O
probably	O
among	O
the	O
first	O
AAS	O
to	O
be	O
used	O
as	O
a	O
doping	O
agent	O
in	O
sports	O
1960s.	O

Zopiclone	B-Drug
is	O
a	O
sedative.	O

Because	O
of	O
the	O
high	O
cost	O
per	O
volume,	O
heroin	B-Drug
is	O
easily	O
smuggled.	O

In	O
2016,	O
a	O
randomized	O
trial	O
provided	O
strong	O
evidence	O
that	O
treatment	O
with	O
celecoxib	B-Drug
is	O
not	O
more	O
likely	O
to	O
result	O
in	O
poor	O
cardiovascular	O
outcomes	O
than	O
naproxen	B-Drug
or	O
ibuprofen.	O
ibuprofen	B-Drug

However,	O
there	O
were	O
ultimately	O
some	O
concerns	O
raised	O
over	O
the	O
compounds	O
affinity	O
for	O
5HT2B	O
receptors,	O
since	O
of	O
more	O
serious	O
side	O
effects	O
serotonin	O
releasing	O
weight	O
loss	O
drug	O
fenfluramine	B-Drug
linked	O
to	O
an	O
activation	O
this	O
receptor.	O

25I-NBOMe	B-Drug
is	O
potent,	O
being	O
active	O
in	O
sub-milligram	O
doses.	O

Compared	O
with	O
other	O
ergot	O
alkaloids,	O
ergometrine	B-Drug
has	O
a	O
greater	O
selectivity	O
in	O
stimulating	O
the	O
uterus.	O

It	O
modifies	O
the	O
LSD	B-Drug
molecule	O
by	O
adding	O
a	O
propionyl	O
group	O
to	O
nitrogen	O
of	O
LSD's	O
indole.	O

L-tyrosine	O
and	O
its	O
derivatives	O
(L-DOPA,	O
melanin,	O
phenylpropanoids,	O
others)	O
are	O
used	O
in	O
pharmaceuticals,	O
dietary	O
supplements,	O
food	O
additives.	O
L-DOPA	B-Drug

Hundreds	O
of	O
cocaine	B-Drug
analogues	O
have	O
been	O
created,	O
all	O
them	O
usually	O
maintaining	O
a	O
benzyloxy	O
connected	O
to	O
the	O
3	O
carbon	O
tropane.	O

Of	O
these,	O
ethylmethylthiambutene	B-Drug
is	O
the	O
most	O
potent,	O
with	O
1.3x	O
potency	O
of	O
morphine,	O
pyrrolidinylthiambutene	O
least	O
potent	O
at	O
0.7x,	O
and	O
rest	O
are	O
all	O
around	O
same	O
as	O
morphine.	O
morphine	B-Drug

The	O
value	O
of	O
the	O
cocaine	B-Drug
trade	O
is	O
assessed	O
at	O
$10	O
billion	O
per	O
year	O
in	O
U.S.	O
dollars.	O

Recently,	O
analogs	O
of	O
GHB,	O
such	O
as	O
4-hydroxy-4-methylpentanoic	O
acid	O
(UMB68)	O
have	O
been	O
synthesised	O
and	O
tested	O
on	O
animals,	O
in	O
order	O
to	O
gain	O
a	O
better	O
understanding	O
GHB's	O
mode	O
action.	O
GHB	B-Drug

NMT	O
is	O
in	O
turn	O
transmethylated	O
by	O
the	O
same	O
process	O
(step	O
3)	O
to	O
form	O
end	O
product	O
N,N-dimethyltryptamine.	O
N,N-dimethyltryptamine	B-Drug

Flunitrazepam	B-Drug
is	O
classed	O
as	O
a	O
nitro-benzodiazepine.	O

In	O
1986,	O
Bristol-Myers	O
Squibb	O
gained	O
FDA	O
approval	O
for	O
buspirone	B-Drug
in	O
the	O
treatment	O
of	O
GAD.	O

Entactogens	O
are	O
sometimes	O
incorrectly	O
referred	O
to	O
as	O
hallucinogens	O
or	O
stimulants,	O
although	O
many	O
entactogens	O
such	O
ecstasy	B-Drug
exhibit	O
psychedelic	O
stimulant	O
properties	O
well.	O

In	O
premenopausal	O
women,	O
the	O
adrenal	O
glands	O
and	O
ovaries	O
each	O
produce	O
about	O
half	O
of	O
total	O
androstenedione	B-Drug
(about	O
3	O
mg/day).	O

Additionally	O
in	O
2018,	O
American	O
rapper	O
Mac	O
Miller	O
died	O
from	O
an	O
accidental	O
overdose	O
of	O
fentanyl,	O
cocaine	B-Drug
and	O
alcohol.	O
fentanyl	B-Drug

Alprazolam	B-Drug
is	O
covered	O
under	O
U.S.	O
Patent	O
3,987,052,	O
which	O
was	O
filed	O
on	O
29	O
October	O
1969,	O
granted	O
19	O
1976,	O
and	O
expired	O
in	O
September	O
1993.	O

The	O
contention	O
that	O
methylphenidate	B-Drug
acts	O
as	O
a	O
gateway	O
drug	O
has	O
been	O
discredited	O
by	O
multiple	O
sources,	O
according	O
to	O
which	O
abuse	O
is	O
statistically	O
very	O
low	O
and	O
"stimulant	O
therapy	O
in	O
childhood	O
does	O
not	O
increase	O
the	O
risk	O
for	O
subsequent	O
alcohol	O
disorders	O
later	O
life".	O

Etidocaine,	O
marketed	O
under	O
the	O
trade	O
name	O
Duranest,	O
is	O
an	O
amide-type	O
local	O
anesthetic	O
given	O
by	O
injection	O
during	O
surgical	O
procedures	O
and	O
labor	O
delivery.	O
Etidocaine	B-Drug

AL-LAD	B-Drug
is	O
illegal	O
in	O
Denmark.	O

Street	O
cocaine	B-Drug
is	O
often	O
adulterated	O
or	O
"cut"	O
with	O
talc,	O
lactose,	O
sucrose,	O
glucose,	O
mannitol,	O
inositol,	O
caffeine,	O
procaine,	O
phencyclidine,	O
phenytoin,	O
lignocaine,	O
strychnine,	O
amphetamine,	O
heroin.	O
mannitol	B-Drug
procaine	B-Drug
phencyclidine	B-Drug
phenytoin	B-Drug
lignocaine	B-Drug
amphetamine	B-Drug
heroin	B-Drug

However,	O
lacking	O
proper	O
equipment,	O
training,	O
and	O
testing	O
users	O
are	O
extremely	O
unlikely	O
to	O
produce	O
desomorphine	B-Drug
in	O
a	O
pure	O
form	O
at	O
home,	O
as	O
result	O
end	O
up	O
injecting	O
highly	O
impure	O
mixture	O
of	O
codeine,	O
desomorphine,	O
the	O
toxic	O
chemicals	O
used	O
crude	O
reaction	O
such	O
lye	O
or	O
acetone.	O
codeine	B-Drug

NIDA	O
has	O
drawn	O
criticism	O
for	O
continuing	O
to	O
provide	O
funding	O
George	O
Ricaurte,	O
who	O
in	O
2002	O
conducted	O
a	O
study	O
that	O
was	O
widely	O
touted	O
as	O
proving	O
MDMA	B-Drug
(ecstasy)	O
caused	O
dopaminergic	O
neurotoxicity	O
monkeys.	O
ecstasy	B-Drug

The	O
use	O
of	O
valproate	B-Drug
for	O
migraine	O
or	O
bipolar	O
disorder	O
during	O
pregnancy	O
is	O
contraindicated	O
in	O
the	O
European	O
Union,	O
and	O
medicines	O
are	O
not	O
recommended	O
epilepsy	O
unless	O
there	O
no	O
other	O
effective	O
treatment	O
available.	O

Due	O
to	O
tiredness	O
associated	O
with	O
the	O
body's	O
recovery	O
from	O
stimulants,	O
such	O
as	O
BZP,	O
it	O
is	O
uncommon	O
for	O
users	O
be	O
able	O
sustain	O
a	O
week-long	O
intake.	O
BZP	B-Drug

When	O
the	O
Controlled	O
Substances	O
Act	O
(CSA)	O
was	O
enacted	O
in	O
1971,	O
nalbuphine	B-Drug
placed	O
schedule	O
II.	O

When	O
the	O
FDA	O
requested	O
Endo	O
Pharmaceuticals	O
on	O
June	O
8,	O
2017,	O
to	O
remove	O
oxymorphone	B-Drug
hydrochloride	I-Drug
from	O
market,	O
it	O
was	O
first	O
such	O
request	O
in	O
history.	O

In	O
the	O
case	O
of	O
a	O
functional	O
neuroendocrine	O
tumor,	O
somatostatin	O
analogs	O
such	O
as	O
octreotide	B-Drug
are	O
used	O
to	O
reduce	O
production	O
serotonin	O
by	O
tumor	O
cells,	O
which	O
often	O
highly	O
express	O
inhibitory	O
receptors.	O

It	O
is	O
unclear	O
if	O
there	O
are	O
any	O
benefits	O
to	O
clobazam	B-Drug
over	O
other	O
seizure	O
medications	O
for	O
children	O
with	O
Rolandic	O
epilepsy	O
or	O
epileptic	O
syndromes.	O

This	O
research	O
was	O
of	O
notable	O
interest	O
in	O
those	O
countries	O
where	O
opium	B-Drug
poppy	O
an	O
important	O
oilseed	O
crop	O
but	O
due	O
to	O
high	O
labor	O
costs	O
the	O
harvesting	O
not	O
economic.	O

Rather,	O
the	O
prepared	O
opium	B-Drug
is	O
indirectly	O
heated	O
to	O
temperatures	O
at	O
which	O
active	O
alkaloids,	O
chiefly	O
morphine,	O
are	O
vaporized.	O
morphine	B-Drug

Apalutamide	B-Drug
is	O
provided	O
in	O
the	O
form	O
of	O
60	O
mg	O
oral	O
tablets.	O

The	O
color	O
of	O
"crack"	O
cocaine	B-Drug
depends	O
upon	O
several	O
factors	O
including	O
the	O
origin	O
used,	O
method	O
preparation	O
with	O
ammonia	O
or	O
baking	O
soda	O
and	O
presence	O
impurities.	O

In	O
this	O
case,	O
the	O
DEA	O
scheduled	O
MDMA	B-Drug
as	O
a	O
Schedule	O

In	O
vivo	O
studies	O
conducted	O
on	O
the	O
dentate	O
gyrus	O
of	O
hippocampus	O
noted	O
an	O
increase	O
in	O
proliferation	O
BrdU	O
positive	O
cells	O
response	O
to	O
100	O
g	O
5-MeO-DMT	B-Drug
injected	O
intravenously	O
adult	O
mouse	O
brain.	O

4-methylaminorex	B-Drug
phenylacetic	O
acid	O
phenyl-2-propanone	O
piperidine	O
phencyclidine	B-Drug
(PCP)	O
piperonal	O
(heliotropin)	O
PCP	B-Drug

Researchers	O
have	O
also	O
found	O
that	O
systemic	O
naltrexone	B-Drug
treatment	O
of	O
female	O
prairie	O
voles	O
during	O
initial	O
exposure	O
to	O
a	O
male	O
reduced	O
subsequent	O
mating	O
bouts	O
and	O
nonsexual	O
socialization	O
with	O
this	O
familiar	O
partner,	O
when	O
choice	O
test	O
including	O
novel	O
was	O
performed	O
afterwards.	O

The	O
opposite	O
is	O
true	O
of	O
CYP3A4	O
inhibitors	O
such	O
as	O
ketoconazole,	O
itraconazole	B-Drug
and	O
clarithromycin:	O
they	O
might	O
increase	O
etonogestrel	B-Drug
concentrations	O
in	O
the	O
body.	O
ketoconazole	B-Drug

He	O
also	O
had	O
close	O
social	O
connections	O
the	O
Grateful	O
Dead,	O
Jefferson	O
Airplane,	O
and	O
Big	O
Brother	O
The	O
Holding	O
Company,	O
regularly	O
supplying	O
them	O
with	O
LSD	B-Drug
working	O
as	O
their	O
live	O
sound	O
engineer,	O
creating	O
many	O
tapes	O
of	O
these	O
groups	O
in	O
concert.	O

Thus,	O
an	O
order	O
for	O
opium	B-Drug
tincture	O
containing	O
directions	O
in	O
teaspoons	O
is	O
almost	O
certainly	O
error.	O

It	O
is	O
formed	O
from	O
tilidine	B-Drug
by	O
demethylation	O
in	O
the	O
liver.	O

In	O
2003,	O
Roxane	O
Laboratories,	O
Inc.	O
discontinued	O
Orlaam	B-Drug
in	O
the	O
US.	O

Paranoia	O
and	O
anxiety	O
are	O
among	O
the	O
most	O
common	O
psychological	O
symptoms	O
of	O
crack	B-Drug
cocaine	I-Drug
use.	O

The	O
principal	O
clinical	O
indication	O
of	O
drostanolone	B-Drug
propionate	I-Drug
in	O
the	O
United	O
States	O
as	O
well	O
international	O
markets	O
was	O
treatment	O
advanced	O
inoperable	O
breast	O
cancer	O
women.	O

It	O
is	O
not	O
a	O
first	O
line	O
drug	O
such	O
as	O
few	O
beta	O
blockers,	O
calcium	O
channel	O
tricyclic	O
antidepressants,	O
and	O
some	O
anticonvulsants	O
divalproex,	O
but	O
rather	O
when	O
these	O
drugs	O
secondary	O
SSRIs,	O
angiotensin	O
II	O
receptor	O
antagonists,	O
etc.	O
fail	O
in	O
the	O
prophylaxis	O
of	O
migraines,	O
have	O
intolerable	O
side	O
effects	O
or	O
are	O
contraindicated.	O
divalproex	B-Drug

Androstenedione	B-Drug
is	O
the	O
common	O
precursor	O
of	O
androgen	O
and	O
estrogen	O
sex	O
hormones.	O

Synthetic	O
Ibogaine-Natural	O
Tramadol	B-Drug
Bufotenine:	O
Bufotenine	B-Drug

Heroin	B-Drug
1.5	O
grams	O

Fluticasone	B-Drug
propionate	I-Drug
in	O
a	O
topical	O
form	O
can	O
be	O
used	O
to	O
treat	O
skin	O
conditions	O
such	O
as	O
eczema,	O
psoriasis,	O
and	O
rashes.	O

tibolone	B-Drug
Moderate:	O

Absolute	O
contraindications	O
include:	O
Previous	O
hypersensitivity	O
(including	O
jaundice,	O
agranulocytosis,	O
etc.)	O
to	O
phenothiazines,	O
especially	O
chlorpromazine,	O
or	O
any	O
of	O
the	O
excipients	O
in	O
formulation	O
being	O
used.	O
chlorpromazine	B-Drug

However,	O
other	O
studies	O
have	O
found	O
that	O
the	O
analgesic	O
effects	O
of	O
tramadol	B-Drug
are	O
significantly	O
decreased	O
or	O
even	O
absent	O
in	O
CYP2D6	O
poor	O
metabolizers.	O

Two	O
much	O
more	O
potent	O
and	O
shorter-acting	O
agents,	O
carfentanil	B-Drug
(a	O
large	O
animal	O
tranquilizer)	O
remifentanil	B-Drug
surgical	O
painkiller),	O
were	O
found	O
in	O
the	O
samples.	O

The	O
elimination	O
half-life	O
of	O
darolutamide	O
is	O
far	O
shorter	O
than	O
that	O
enzalutamide	B-Drug
(e.g.,	O
1.6	O
hours	O
vs.	O
18.3	O
in	O
mice).	O

Respiratory	O
depression	O
is	O
a	O
potentially	O
serious	O
or	O
fatal	O
adverse	O
drug	O
reaction	O
associated	O
with	O
the	O
use	O
of	O
codeine,	O
but	O
mainly	O
danger	O
lies	O
in	O
much	O
more	O
potent	O
and	O
CNS-depressing	O
phenothiazine-related	O
antihistamine	O
promethazine.	O
codeine	B-Drug
promethazine	B-Drug

However,	O
possession	O
of	O
the	O
pure	O
compound	O
without	O
a	O
prescription	O
or	O
DEA	O
license	O
would	O
be	O
prosecuted,	O
as	O
ergine,	O
under	O
name	O
"lysergic	O
acid	I-Drug
amide",	O
is	O
listed	O
Schedule	O
III	O
Controlled	O
Substances	O
Act.	O
ergine	B-Drug
lysergic	B-Drug
amide	I-Drug

The	O
drug	O
was	O
found	O
to	O
have	O
20-fold	O
higher	O
affinity	O
for	O
the	O
AR	O
than	O
bicalutamide	B-Drug
in	O
MDA-MB-453	O
cells,	O
and	O
showed	O
3-	O
7-fold	O
antiandrogenic	O
activity	O
of	O
vitro.	O

Although	O
poisoning	O
by	O
hyoscine	B-Drug
appears	O
quite	O
often	O
in	O
the	O
media	O
as	O
an	O
aid	O
for	O
raping,	O
kidnapping,	O
killing,	O
or	O
robbery,	O
effects	O
of	O
this	O
drug	O
and	O
way	O
it	O
is	O
applied	O
criminals	O
(transdermal	O
injection,	O
on	O
playing	O
cards	O
papers,	O
etc.)	O
are	O
exaggerated,	O
especially	O
skin	O
exposure,	O
dose	O
that	O
can	O
be	O
absorbed	O
too	O
low	O
to	O
have	O
any	O
effect.	O

However,	O
large	O
doses	O
of	O
amphetamine	B-Drug
may	O
indirectly	O
cause	O
dopaminergic	O
neurotoxicity	O
as	O
a	O
result	O
hyperpyrexia,	O
the	O
excessive	O
formation	O
reactive	O
oxygen	O
species,	O
and	O
increased	O
autoxidation	O
dopamine.	O

Acrylfentanyl	B-Drug
(also	O
known	O
as	O
acryloylfentanyl	O
or	O
Egyptenyl)	O
is	O
a	O
highly	O
potent	O
opioid	O
analgesic	O
that	O
an	O
analog	O
of	O
fentanyl	B-Drug
and	O
has	O
been	O
sold	O
online	O
designer	O
drug.	O

A	O
forensic	O
standard	O
of	O
AM-2201	B-Drug
is	O
available,	O
and	O
the	O
compound	O
has	O
been	O
posted	O
on	O
Forendex	O
website	O
potential	O
drugs	O
abuse.	O

Estonia	O
in	O
known	O
to	O
have	O
been	O
home	O
the	O
world's	O
longest	O
documented	O
fentanyl	B-Drug
epidemic,	O
especially	O
following	O
Taliban	O
ban	O
on	O
opium	O
poppy	O
cultivation	O
Afghanistan.	O

Some	O
manufacturers	O
ship	O
cannabidiol	B-Drug
products	O
nationally,	O
an	O
illegal	O
action	O
which	O
the	O
FDA	O
did	O
not	O
enforce	O
in	O
2018,	O
with	O
CBD	B-Drug
remaining	O
subject	O
of	O
investigational	O
new	O
drug	O
evaluation,	O
and	O
is	O
considered	O
legal	O
as	O
a	O
dietary	O
supplement	O
or	O
food	O
ingredient,	O
October	O
2020.	O

Pregabalin	B-Drug
undergoes	O
little	O
or	O
no	O
metabolism.	O

Fentanyl	B-Drug
analogs	O
have	O
killed	O
hundreds	O
of	O
people	O
throughout	O
Europe	O
and	O
the	O
former	O
Soviet	O
republics	O
since	O
most	O
recent	O
resurgence	O
in	O
use	O
began	O
Estonia	O
early	O
2000s,	O
novel	O
derivatives	O
continue	O
to	O
appear.	O

In	O
Japan,	O
Sulpiride	B-Drug
is	O
both	O
approved	O
as	O
a	O
treatment	O
for	O
schizophrenia	O
and	O
major	O
depressive	O
disorder	O
(low	O
dose).	O

The	O
bioavailability	O
of	O
danazol	B-Drug
is	O
low.	O

For	O
comparison	O
to	O
progesterone,	O
a	O
200	O
mg	O
dose	O
of	O
oral	O
progesterone	O
is	O
considered	O
be	O
approximately	O
equivalent	O
in	O
antimineralocorticoid	O
effect	O
25	O
50	O
spironolactone.	O
spironolactone	B-Drug

The	O
potentiation	O
effect	O
is	O
also	O
useful	O
in	O
other	O
pain	O
situations	O
and	O
especially	O
with	O
opioids	O
of	O
the	O
open-chain	O
class,	O
such	O
as	O
methadone,	O
levomethadone,	O
ketobemidone,	O
phenadoxone	B-Drug
others.	O
methadone	B-Drug
levomethadone	B-Drug
ketobemidone	B-Drug

In	O
2019,	O
the	O
WHO	O
Expert	O
Committee	O
recommended	O
that	O
all	O
isomers	O
of	O
THC	B-Drug
be	O
withdrawn	O
from	O
Schedules	O
1971	O
Convention	O
and	O
included	O
in	O
1961	O
alongside	O
other	O
Cannabis-related	O
products	O
pharmaceutical	O
preparations.	O

Those	O
are	O
refined	O
into	O
drugs	O
like	O
oxycodone.	O
oxycodone	B-Drug

It	O
is	O
likely	O
that	O
the	O
higher	O
THC	B-Drug
content	O
allows	O
people	O
to	O
ingest	O
less	O
tar.	O

Cannabinol	B-Drug
(CBN)	O
is	O
the	O
primary	O
product	O
of	O
THC	B-Drug
degradation,	O
and	O
there	O
usually	O
little	O
it	O
in	O
a	O
fresh	O
plant.	O
CBN	B-Drug

Morphine-6-glucuronide	O
(M6G)	O
is	O
a	O
major	O
active	O
metabolite	O
of	O
morphine.	O
morphine	B-Drug

The	O
term	O
was	O
introduced	O
by	O
David	O
F.	O
Duncan	O
and	O
Robert	O
S.	O
Gold	O
to	O
distinguish	O
these	O
drugs	O
from	O
psychedelics	O
dissociatives,	O
such	O
as	O
LSD	B-Drug
ketamine	B-Drug
respectively,	O
due	O
their	O
primary	O
effect	O
of	O
causing	O
delirium,	O
opposed	O
the	O
more	O
lucid	O
states	O
produced	O
other	O
hallucinogens	O
those	O
represented	O
dissociatives.	O

Ligandrol	B-Drug
(VK5211,	O
LGD-4033)	O
is	O
a	O
novel	O
nonsteroidal	O
oral	O
selective	O
androgen	O
receptor	O
modulator	O
(SARM)	O
for	O
treatment	O
of	O
conditions	O
such	O
as	O
muscle	O
wasting	O
and	O
osteoporosis,	O
discovered	O
by	O
Ligand	O
Pharmaceuticals	O
currently	O
under	O
development	O
Viking	O
Therapeutics.	O
LGD-4033	B-Drug

Upon	O
oral	O
administration	O
and	O
during	O
first-pass	O
metabolism	O
in	O
the	O
liver,	O
etynodiol	O
diacetate	O
is	O
rapidly	O
converted	O
by	O
esterases	O
into	O
etynodiol,	O
which	O
followed	O
oxygenation	O
of	O
C3	O
hydroxyl	O
group	O
to	O
produce	O
norethisterone.	O
norethisterone	B-Drug

The	O
oil	O
available	O
on	O
the	O
U.S.	O
West	O
Coast	O
in	O
1974	O
averaged	O
about	O
15%	O
THC.	O
THC	B-Drug

In	O
contrast,	O
the	O
newer	O
NSAAs	O
nilutamide,	O
bicalutamide,	O
and	O
enzalutamide	B-Drug
all	O
have	O
much	O
longer	O
half-lives,	O
this	O
allows	O
for	O
once-daily	O
administration	O
in	O
their	O
cases.	O
bicalutamide	B-Drug

Crack	O
cocaine	O
may	O
be	O
combined	O
with	O
amphetamine	B-Drug
("croak");	O
tobacco	B-Drug
("coolie");	O
marijuana	O
("buddha";	O
"caviar";	O
"chronic";	O
"cocoa	O
puffs";	O
"fry	O
daddy";	O
"gimmie";	O
"gremmie";	O
"juice";	O
"primo";	O
"torpedo";	O
"turbo";	O
"woolie";	O
"woola");	O
heroin	B-Drug
("moon	O
rock");	O
and	O
phencyclidine	B-Drug
("clicker";	O
"p-funk";	O
"spacebase").	O

Traditionally,	O
processing	O
of	O
Afghan's	O
opium	B-Drug
into	O
heroin	B-Drug
has	O
taken	O
place	O
outside	O
Afghanistan;	O
however,	O
in	O
an	O
effort	O
to	O
reap	O
more	O
profits	O
internally,	O
Afghan	O
drug	O
kingpins	O
have	O
stepped	O
up	O
within	O
their	O
borders.	O

Veterinarians	O
often	O
use	O
ketamine	B-Drug
with	O
sedative	O
drugs	O
to	O
produce	O
balanced	O
anaesthesia	O
and	O
analgesia,	O
as	O
a	O
constant-rate	O
infusion	O
help	O
prevent	O
pain	O
wind-up.	O

According	O
to	O
psychiatrist	O
George	O
Greer,	O
therapists	O
who	O
used	O
MDMA	B-Drug
in	O
their	O
practice	O
were	O
impressed	O
by	O
the	O
results.	O

In	O
1999,	O
the	O
U.S.	O
Congress	O
added	O
a	O
provision	O
to	O
its	O
Plan	O
Colombia	O
aid	O
package	O
that	O
called	O
for	O
employment	O
of	O
mycoherbicides	O
against	O
coca	B-Drug
and	O
opium	B-Drug
crops.	O

JWH-018	B-Drug
is	O
one	O
of	O
these	O
compounds,	O
with	O
studies	O
showing	O
an	O
affinity	O
for	O
the	O
cannabinoid	O
(CB1)	O
receptor	O
five	O
times	O
greater	O
than	O
that	O
THC.	O
THC	B-Drug

Colistin	B-Drug
Fosfomycin	B-Drug
Linezolid	B-Drug
Meropenem/vaborbactam	O
Plazomicin	B-Drug
Polymyxin	O
B	O
Clofazimine	B-Drug
Dapsone	B-Drug
Rifampicin	B-Drug
Ethambutol	O
Ethambutol/isoniazid/pyrazinamide/rifampicin	B-Drug
(ethambutol	O
+	O
isoniazid	B-Drug
pyrazinamide	B-Drug
rifampicin)	O
Meropenem	B-Drug
rifampicin	B-Drug

Conversely,	O
it	O
was	O
found	O
to	O
decrease	O
sebum	O
DHT	O
levels	O
by	O
55%	O
in	O
men	O
versus	O
a	O
modest	O
reduction	O
of	O
only	O
15%	O
for	O
finasteride.	O
finasteride	B-Drug

In	O
emergency	O
medicine,	O
safe	O
administration	O
of	O
intranasal	O
fentanyl	B-Drug
with	O
a	O
low	O
rate	O
side	O
effects	O
and	O
promising	O
pain	O
reducing	O
effect	O
was	O
demonstrated	O
in	O
prospective	O
observational	O
study	O
about	O
900	O
out-of-hospital	O
patients.	O

This	O
makes	O
JWH-175	B-Drug
considerably	O
less	O
potent	O
than	O
most	O
synthetic	O
cannabinoid	O
drugs	O
used	O
in	O
cannabis	O
blends,	O
and	O
it	O
is	O
unclear	O
if	O
has	O
ever	O
been	O
for	O
this	O
purpose.	O

Patients	O
appear	O
twice	O
daily	O
at	O
a	O
treatment	O
center,	O
where	O
they	O
inject	O
their	O
dose	O
of	O
diamorphine	B-Drug
under	O
the	O
supervision	O
medical	O
staff.	O

Soon,	O
the	O
demand	O
for	O
cocaine	B-Drug
was	O
skyrocketing	O
in	O
United	O
States	O
and	O
Escobar	O
organized	O
more	O
smuggling	O
shipments,	O
routes,	O
distribution	O
networks	O
South	O
Florida,	O
California,	O
other	O
parts	O
of	O
States.	O

More	O
recent	O
research	O
has	O
found	O
zolpidem	B-Drug
treatment	O
to	O
be	O
effective	O
in	O
the	O
short	O
term,	O
but	O
only	O
a	O
small	O
proportion	O
of	O
cases	O
(estimated	O
at	O
around	O
5%)	O
and	O
when	O
brain	O
injury	O
is	O
specific	O
type.	O

Cocaine	B-Drug
has	O
a	O
similar	O
potential	O
to	O
induce	O
temporary	O
psychosis	O
with	O
more	O
than	O
half	O
of	O
cocaine	B-Drug
abusers	O
reporting	O
at	O
least	O
some	O
psychotic	O
symptoms	O
point.	O

Nandrolone	B-Drug
esters	O
are	O
used	O
for	O
physique-	O
and	O
performance-enhancing	O
purposes	O
by	O
competitive	O
athletes,	O
bodybuilders,	O
powerlifters.	O

The	O
prescription	O
heroin	B-Drug
can	O
be	O
accessed	O
by	O
doctors	O
through	O
Health	O
Canada's	O
Special	O
Access	O
Programme	O
(SAP)	O
for	O
"emergency	O
access	O
to	O
drugs	O
patients	O
with	O
serious	O
or	O
life-threatening	O
conditions	O
when	O
conventional	O
treatments	O
have	O
failed,	O
are	O
unsuitable,	O
unavailable."	O

Both	O
agents	O
show	O
much	O
higher	O
affinity	O
and	O
more	O
potent	O
inhibition	O
of	O
the	O
AR	O
relative	O
to	O
other	O
NSAAs	O
enzalutamide	B-Drug
apalutamide,	O
although	O
they	O
also	O
possess	O
shorter	O
comparatively	O
less	O
favorable	O
elimination	O
half-lives.	O
apalutamide	B-Drug

Sibutramine	B-Drug
should	O
not	O
be	O
taken	O
within	O
two	O
weeks	O
of	O
stopping	O
or	O
starting	O
an	O
MAOI.	O

The	O
resulting	O
compound	O
is	O
called	O
psilocin,	O
which	O
responsible	O
for	O
the	O
psychedelic	O
effects.	O
psilocin	B-Drug

Combining	O
nicotine	B-Drug
patch	O
use	O
with	O
a	O
faster	O
acting	O
replacement,	O
like	O
gum	O
or	O
spray,	O
improves	O
the	O
odds	O
of	O
treatment	O
success.	O

The	O
user	O
consumed	O
JWH-018	B-Drug
daily	O
for	O
eight	O
months.	O

In	O
addition	O
to	O
functioning	O
as	O
an	O
endogenous	O
prohormone,	O
androstenedione	B-Drug
also	O
has	O
weak	O
androgenic	O
activity	O
in	O
its	O
own	O
right.	O

After	O
cooling	O
the	O
acetic	O
acid	O
was	O
evaporated	O
and	O
precipitate	O
filtered,	O
washed	O
with	O
water	O
dried	O
to	O
give	O
paracetamol	B-Drug
as	O
a	O
white	O
solid.	O

Drowsiness	O
Dizziness	O
Somnolence	O
Physostigmine,	O
a	O
cholinergic	O
drug	O
that	O
readily	O
crosses	O
the	O
blood-brain	O
barrier,	O
has	O
been	O
used	O
as	O
an	O
antidote	O
to	O
treat	O
central	O
nervous	O
system	O
depression	O
symptoms	O
of	O
hyoscine	B-Drug
overdose.	O
Physostigmine	B-Drug

Relative	O
to	O
catecholaminergic	O
transmission,	O
MDMA	B-Drug
enhances	O
serotonergic	O
transmission	O
significantly	O
more,	O
when	O
compared	O
classical	O
stimulants	O
like	O
amphetamine.	O
amphetamine	B-Drug

If	O
consumed	O
with	O
alcohol,	O
cocaine	B-Drug
combines	O
alcohol	O
in	O
the	O
liver	O
to	O
form	O
cocaethylene.	O
cocaethylene	B-Drug

By	O
this	O
time,	O
Sandoz	O
LSD	B-Drug
was	O
hard	O
to	O
come	O
by,	O
and	O
"Owsley	O
Acid"	O
had	O
become	O
the	O
new	O
standard.	O

Methadone	B-Drug
is	O
used	O
as	O
an	O
analgesic	O
in	O
chronic	O
pain,	O
often	O
rotation	O
with	O
other	O
opioids.	O

The	O
weak	O
partial	O
agonist	O
effect	O
can	O
be	O
useful	O
for	O
some	O
purposes,	O
and	O
has	O
previously	O
been	O
used	O
purposes	O
such	O
as	O
long-term	O
maintenance	O
of	O
former	O
opioid	O
addicts	O
using	O
nalorphine,	O
however	O
it	O
also	O
have	O
disadvantages	O
worsening	O
respiratory	O
depression	O
in	O
patients	O
who	O
overdosed	O
on	O
non-opioid	O
sedatives	O
alcohol	O
or	O
barbiturates.	O
nalorphine	B-Drug

DMT	O
is	O
a	O
functional	O
analog	O
and	O
structural	O
of	O
other	O
psychedelic	O
tryptamines	O
such	O
as	O
O-acetylpsilocin	B-Drug
(4-AcO-DMT),	O
5-MeO-DMT,	O
psilocybin	O
(4-PO-DMT),	O
psilocin	B-Drug
(4-HO-DMT),	O
bufotenin	B-Drug
(5-HO-DMT).	O
4-AcO-DMT	B-Drug
5-MeO-DMT	B-Drug

Methamphetamine	B-Drug
was	O
discovered	O
in	O
1893	O
and	O
exists	O
as	O
two	O
enantiomers:	O
levo-methamphetamine	O
dextro-methamphetamine.	O

The	O
results	O
of	O
animal	O
experiments	O
conducted	O
with	O
this	O
drug	O
suggest	O
that	O
it	O
has	O
an	O
abuse	O
liability	O
similar	O
to	O
cocaine	B-Drug
and	O
amphetamine.	O
amphetamine	B-Drug

In	O
practice,	O
those	O
charged	O
with	O
cocaine	B-Drug
possession	O
will	O
in	O
most	O
cases	O
be	O
given	O
an	O
opportunity	O
to	O
plead	O
guilty	O
and	O
receive	O
no	O
jail	O
time	O
under	O
PC	O
1000,	O
Prop	O
36,	O
or	O
felony	O
supervised	O
probation.	O

The	O
reduced	O
ratio	O
of	O
anabolic	O
to	O
androgenic	O
activity	O
oxandrolone	B-Drug
often	O
motivates	O
its	O
medical	O
use	O
in	O
children	O
and	O
women	O
because	O
less	O
effect	O
implies	O
risk	O
virilization.	O

Due	O
to	O
concerns	O
about	O
the	O
potential	O
of	O
JWH-018	B-Drug
and	O
other	O
synthetic	O
cannabinoids	O
cause	O
psychosis	O
in	O
vulnerable	O
individuals,	O
it	O
has	O
been	O
recommended	O
that	O
people	O
with	O
risk	O
factors	O
for	O
psychotic	O
illnesses	O
(like	O
a	O
past	O
or	O
family	O
history	O
psychosis)	O
not	O
use	O
these	O
substances.	O

JWH-018	B-Drug
has	O
been	O
shown	O
to	O
cause	O
profound	O
changes	O
in	O
CB1	O
receptor	O
density	O
following	O
administration,	O
causing	O
desensitization	O
its	O
effects	O
more	O
rapidly	O
than	O
related	O
cannabinoids.	O

Nalbuphine	B-Drug
was	O
patented	O
in	O
1963	O
and	O
introduced	O
for	O
medical	O
use	O
the	O
United	O
States	O
1979.	O

Large	O
retail	O
pharmacy	O
chains	O
in	O
the	O
US	O
are	O
implementing	O
protocols,	O
guidelines,	O
and	O
initiatives	O
to	O
take	O
back	O
unused	O
opioids,	O
providing	O
naloxone	B-Drug
kits,	O
being	O
vigilant	O
for	O
suspicious	O
prescriptions.	O

Additionally,	O
there	O
is	O
no	O
evidence	O
that	O
hydrocodone	B-Drug
useful	O
in	O
children.	O

For	O
instance,	O
indometacin	B-Drug
inhibits	O
both	O
cyclooxygenase-1	O
and	O
cyclooxygenase-2,	O
which	O
then	O
the	O
production	O
of	O
prostaglandins	O
in	O
stomach	O
intestines	O
responsible	O
for	O
maintaining	O
mucous	O
lining	O
gastrointestinal	O
tract.	O

The	O
synthesis	O
of	O
exemestane	B-Drug
also	O
consists	O
three	O
steps,	O
as	O
shown	O
in	O
figure	O
3.	O

As	O
a	O
result	O
of	O
this	O
difference,	O
dutasteride	B-Drug
is	O
able	O
to	O
achieve	O
reduction	O
in	O
circulating	O
DHT	O
levels	O
up	O
98%,	O
whereas	O
finasteride	B-Drug
only	O
65	O
70%.	O

The	O
FDA	O
implemented	O
its	O
Drug	O
Efficacy	O
Study	O
Implementation	O
(DESI)	O
program	O
to	O
study	O
and	O
regulate	O
drugs,	O
including	O
stanozolol,	O
that	O
had	O
been	O
introduced	O
prior	O
the	O
amendment.	O
stanozolol	B-Drug

Several	O
randomized	O
trials	O
noted	O
improvement	O
in	O
the	O
area	O
of	O
lipodermatosclerosis,	O
reduced	O
skin	O
thickness,	O
and	O
possibly	O
faster	O
ulcer	O
healing	O
rates	O
with	O
stanozolol.	O
stanozolol	B-Drug

When	O
it	O
is	O
made	O
semi-synthetically	O
from	O
pseudo/ephedrine	O
as	O
a	O
starting	O
material,	O
then	O
only	O
single	O
enantiomer	O
produced.	O
ephedrine	B-Drug

,	O
a	O
close	O
analogue	O
of	O
the	O
benzodiazepine	O
antagonist	O
flumazenil	B-Drug
(Ro15-1788),	O
has	O
been	O
found	O
to	O
bind	O
same	O
site	O
as	O
ethanol	O
and	O
competitively	O
displace	O
it	O
in	O
saturable	O
manner.	O

Fentanyl	B-Drug
may	O
be	O
measured	O
in	O
blood	O
or	O
urine	O
to	O
monitor	O
for	O
abuse,	O
confirm	O
a	O
diagnosis	O
of	O
poisoning,	O
assist	O
medicolegal	O
death	O
investigation.	O

Starting	O
in	O
1983,	O
the	O
Texas	O
Group	O
mass-produced	O
MDMA	B-Drug
a	O
lab	O
or	O
imported	O
it	O
from	O
California	O
and	O
marketed	O
tablets	O
using	O
pyramid	O
sales	O
structures	O
toll-free	O
numbers.	O

Examples	O
include	O
GnRH	O
modulators	O
like	O
leuprorelin	B-Drug
(a	O
agonist)	O
and	O
cetrorelix	B-Drug
antagonist),	O
progestogens	O
allylestrenol,	O
chlormadinone	O
acetate,	O
cyproterone	O
gestonorone	O
caproate,	O
hydroxyprogesterone	O
medroxyprogesterone	B-Drug
megestrol	O
osaterone	O
acetate	I-Drug
(veterinary),	O
oxendolone,	O
estrogens	O
estradiol,	O
estradiol	O
esters,	O
ethinylestradiol,	O
conjugated	O
estrogens,	O
diethylstilbestrol.	O

Brand	O
names	O
include	O
Contergan,	O
Thalomid,	O
Talidex,	O
Talizer,	O
Neurosedyn,	O
Distaval	O
and	O
many	O
others.	O
Contergan	B-Drug
Thalomid	B-Drug
Neurosedyn	B-Drug

In	O
2017,	O
doctors	O
in	O
the	O
UK	O
began	O
first	O
clinical	O
study	O
of	O
MDMA	B-Drug
alcohol	O
use	O
disorder.	O

Oxycodone	B-Drug
is	O
a	O
restricted	O
drug	O
in	O
Japan.	O

When	O
enough	O
fentanyl	B-Drug
has	O
been	O
absorbed,	O
the	O
(sedated)	O
person	O
generally	O
lets	O
lollipop	O
fall	O
from	O
mouth,	O
indicating	O
sufficient	O
analgesia	O
and	O
somewhat	O
reducing	O
likelihood	O
of	O
overdose	O
associated	O
risks.	O

The	O
production	O
of	O
meth	B-Drug
further	O
produces	O
hydrogen	O
chloride	O
gas,	O
which	O
when	O
released	O
into	O
the	O
environment	O
cause	O
damage	O
metal	O
structures	O
and	O
buildings.	O

Israel	O
banned	O
25I-NBOMe	B-Drug
in	O
2013.	O

The	O
levonorgestrel	B-Drug
intrauterine	O
system	O
(LNG-IUS)	O
is	O
a	O
type	O
of	O
long-term	O
birth	O
control	O
that	O
releases	O
the	O
progestin	O
into	O
uterine	O
cavity.	O

but	O
"It	O
is	O
noteworthy	O
that,	O
unlike	O
the	O
other	O
analogs,	O
striatal	O
levels	O
of	O
5-HT	O
did	O
not	O
decline	O
with	O
TPH	O
activity	O
following	O
multiple	O
4-methylaminorex	B-Drug
treatment"	O

Efavirenz	B-Drug
was	O
approved	O
by	O
the	O
FDA	O
on	O
September	O
21,	O
1998On	O
February	O
17,	O
2016,	O
generic	O
tablet	O
formulation	O
to	O
be	O
produced	O
Mylan.	O

Mifepristone	B-Drug
alone	O
is	O
less	O
effective,	O
resulting	O
in	O
abortion	O
within	O
12	O
weeks	O
8%	O
to	O
46%	O
of	O
pregnancies.	O

Naloxone	B-Drug
comes	O
with	O
a	O
variety	O
of	O
delivery	O
systems,	O
including	O
nasal	O
spray,	O
intravenous	O
infusion,	O
as	O
well	O
subcutaneous	O
and	O
intramuscular	O
injection	O
(also	O
encompassing	O
auto-injection	O
pens).	O

Brivaracetam	B-Drug
(2016).	O

Barbital	B-Drug
(or	O
barbitone),	O
marketed	O
under	O
the	O
brand	O
names	O
Veronal	O
for	O
pure	O
acid	O
and	O
Medinal	O
sodium	O
salt,	O
was	O
first	O
commercially	O
available	O
barbiturate.	O
barbitone	B-Drug

A	O
variety	O
of	O
hydrocortisone	B-Drug
esters	O
exist	O
and	O
have	O
been	O
marketed	O
for	O
medical	O
use.	O

The	O
side	O
effects	O
of	O
Adderall	B-Drug
vary	O
widely	O
among	O
individuals,	O
but	O
most	O
commonly	O
include	O
insomnia,	O
dry	O
mouth,	O
loss	O
appetite,	O
and	O
weight	O
loss.	O

MDMA	B-Drug
and	O
metabolites	O
are	O
primarily	O
excreted	O
as	O
conjugates,	O
such	O
sulfates	O
glucuronides.	O

5-MAPDB	B-Drug
6-MAPDB,	O
its	O
psychedelic	O
activity	O
is	O
disputed	O
6-MAPB	B-Drug
6-MAPDB	B-Drug

December	O
2019,	O
the	O
UNODC	O
announced	O
scheduling	O
recommendations	O
placing	O
AB-FUBINACA	B-Drug
as	O
a	O
controlled	O
research	O
chemical	O
into	O
Schedule	O
II.	O

Most	O
of	O
the	O
cases	O
liver	O
injury	O
are	O
associated	O
with	O
use	O
paracetamol	B-Drug
at	O
doses	O
that	O
exceed	O
4000	O
milligrams	O
per	O
day,	O
and	O
often	O
involve	O
more	O
than	O
one	O
paracetamol-containing	O
product."	O

Pervitin	B-Drug
is	O
a	O
brand-name	O
for	O
methamphetamine,	O
drug	O
that	O
belongs	O
to	O
the	O
stimulant	O
class	O
of	O
drugs.	O
methamphetamine	B-Drug

As	O
of	O
October	O
31,	O
2016;	O
25C-NBOMe	B-Drug
is	O
a	O
controlled	O
substance	O
(Schedule	O
III)	O
in	O
Canada.	O

Albert	O
Hofmann	O
(11	O
January	O
1906	O
29	O
April	O
2008)	O
was	O
a	O
Swiss	O
chemist	O
known	O
best	O
for	O
being	O
the	O
first	O
person	O
to	O
synthesize,	O
ingest,	O
and	O
learn	O
of	O
psychedelic	O
effects	O
lysergic	O
acid	B-Drug
diethylamide	O
(LSD).	O

Fentanyl	B-Drug
is	O
used	O
orally,	O
smoked,	O
snorted,	O
or	O
injected.	O

Oxabolone	O
(4,17-dihydroxyestr-4-en-3-one)	O
Oxandrolone	B-Drug
(17-hydroxy-17-methyl-2-oxa-5-androstan-3-one)	O

Russian	O
Spetsnaz	O
security	O
forces	O
used	O
a	O
fentanyl	B-Drug
analogue	O
or	O
derivative	O
to	O
incapacitate	O
people	O
rapidly	O
in	O
the	O
Moscow	O
theater	O
hostage	O
crisis	O
2002.	O

Lysergic	O
acid	I-Drug
and	O
lysergic	B-Drug
amide,	O
LSD	O
precursors,	O
are	O
both	O
classified	O
in	O
Schedule	O
III	O
of	O
the	O
Controlled	O
Substances	O
Act.	O
amide	I-Drug

Perampanel	B-Drug
has	O
a	O
prolonged	O
terminal	O
half-life	O
in	O
humans	O
of	O
approximately	O
105	O
hours.	O

The	O
risk	O
of	O
gynecomastia	O
with	O
5-reductase	O
inhibitors	O
is	O
about	O
2.8%.The	O
FDA	O
has	O
added	O
a	O
warning	O
to	O
dutasteride	B-Drug
an	O
increased	O
high-grade	O
prostate	O
cancer.	O

Oxymorphone	B-Drug
extended-release	O
tablets	O
are	O
indicated	O
for	O
the	O
management	O
of	O
chronic	O
pain	O
and	O
only	O
people	O
already	O
on	O
a	O
regular	O
schedule	O
strong	O
opioids	O
prolonged	O
period.	O

Smart	O
shops	O
(often	O
webshops)	O
offer	O
prescription-free	O
pharmacy	O
products	O
such	O
as	O
Ritalin,	O
Adderall,	O
and	O
modafinil,	O
for	O
example.	O
Ritalin	B-Drug
Adderall	B-Drug
modafinil	B-Drug

Clinical	O
indications	O
for	O
indometacin	B-Drug
include:Joint	O
diseases	O
rheumatoid	O
arthritis	O
ankylosing	O
spondylitis	O
osteoarthritis	O
gouty	O
acute	O
painful	O
shoulder	O
bursitis	O
or	O
tendinitisHeadaches	O

psilocin	B-Drug
psilocybinStimulants:	O

JWH-018,	O
JWH-073,	O
CP	B-Drug
47,497	I-Drug
(and	O
its	O
homologues),	O
and	O
HU-210	B-Drug
as	O
well	O
leonotis	O
leonurus	O
have	O
been	O
all	O
banned	O
in	O
Latvia	O
since	O
2005.	O
JWH-018	B-Drug
JWH-073	B-Drug

As	O
of	O
October	O
31,	O
2016;	O
25I-NBOMe	B-Drug
is	O
a	O
controlled	O
substance	O
(Schedule	O
III)	O
in	O
Canada.	O

If	O
the	O
supply	O
of	O
drugs	O
such	O
as	O
ecstasy	B-Drug
came	O
from	O
legitimate	O
pharmaceutical	O
companies,	O
their	O
product	O
would	O
be	O
far	O
less	O
likely	O
to	O
contain	O
toxic	O
additives	O
or	O
varying	O
dosages.	O

Rifampicin	B-Drug
greatly	O
reduces	O
plasma	O
concentrations	O
of	O
oxycodone	B-Drug
due	O
to	O
strong	O
induction	O
CYP3A4.	O

The	O
website	O
Erowid	O
states	O
that	O
25I-NBOMe	B-Drug
is	O
extremely	O
potent	O
and	O
should	O
not	O
be	O
snorted,	O
the	O
drug	O
"appears	O
to	O
have	O
led	O
several	O
deaths	O
in	O
past	O
year."	O

Phencyclidine	B-Drug
is	O
an	O
NMDA	O
receptor	O
antagonist	O
that	O
blocks	O
the	O
activity	O
of	O
to	O
cause	O
anaesthesia	O
and	O
analgesia	O
without	O
causing	O
cardiorespiratory	O
depression.	O

It	O
is	O
several	O
times	O
less	O
potent	O
as	O
a	O
serotonin	O
agonist	O
than	O
5-MeO-DiPT	B-Drug
and	O
with	O
relatively	O
more	O
activity	O
at	O
5-HT1A,	O
but	O
still	O
shows	O
strongest	O
effects	O
the	O
5-HT2	O
family	O
of	O
receptors.	O

Opium,	O
and	O
after	O
1820,	O
morphine,	O
was	O
mixed	O
with	O
everything	O
imaginable:	O
mercury,	O
hashish,	O
cayenne	O
pepper,	O
ether,	O
chloroform,	O
belladonna,	O
whiskey,	O
wine	O
brandy."	O
morphine	B-Drug
hashish	B-Drug

Desogestrel	B-Drug
may	O
slightly	O
reduce	O
ethinylestradiol-induced	O
increases	O
in	O
SHBG	O
levels.	O

Fewer	O
than	O
30	O
different	O
analogs	O
of	O
PCP	B-Drug
were	O
reported	O
as	O
being	O
used	O
on	O
the	O
street	O
during	O
1970s	O
and	O
1980s,	O
mainly	O
in	O
United	O
States.	O

Tranylcypromine	B-Drug
has	O
also	O
been	O
shown	O
to	O
inhibit	O
the	O
histone	O
demethylase,	O
BHC110/LSD1.	O

Acetaminophen	B-Drug
treats	O
pain	O
mainly	O
by	O
blocking	O
COX-2	O
and	O
inhibiting	O
endocannabinoid	O
reuptake	O
almost	O
exclusively	O
within	O
the	O
brain,	O
but	O
not	O
much	O
in	O
rest	O
of	O
body.	O

Methylprednisolone	B-Drug
has	O
been	O
a	O
prescribed	O
therapy	O
amidst	O
the	O
COVID-19	O
pandemic	O

Due	O
to	O
the	O
effect	O
pH	O
has	O
on	O
absorption,	O
proton	O
pump	O
inhibitors,	O
which	O
reduce	O
gastric	O
acid,	O
are	O
known	O
interact	O
with	O
methamphetamine.	O
methamphetamine	B-Drug

In	O
the	O
US,	O
Harrison	O
Act	O
was	O
passed	O
in	O
1914,	O
and	O
required	O
sellers	O
of	O
opiates	O
cocaine	B-Drug
to	O
get	O
a	O
license.	O

In	O
2015,	O
Afghanistan	O
produced	O
about	O
66%	O
of	O
the	O
world's	O
opium.	O
opium	B-Drug

The	O
report	O
indicated	O
that	O
between	O
the	O
age	O
range	O
from	O
15	O
to	O
65,	O
tobacco	B-Drug
was	O
most	O
addictive	O
substance	O
with	O
62.3%	O
of	O
users	O
expressing	O
a	O
craving	O
for	O
it.	O

With	O
the	O
ability	O
to	O
detect	O
THG,	O
USADA	O
retested	O
550	O
existing	O
urine	O
samples	O
from	O
athletes,	O
of	O
which	O
several	O
proved	O
be	O
positive	O
for	O
THG.A	O
number	O
players	O
Oakland	O
Raiders	O
were	O
implicated	O
in	O
this	O
scandal,	O
including	O
Bill	O
Romanowski,	O
Tyrone	O
Wheatley,	O
Barrett	O
Robbins,	O
Chris	O
Cooper	O
and	O
Dana	O
Stubblefield.	O
THG	B-Drug

Quinine's	O
vinyl	O
group	O
is	O
then	O
constructed	O
by	O
Hofmann	O
elimination	O
with	O
sodium	O
hydroxide	O
in	O
water	O
at	O
140	O
C.	O
Quinine	B-Drug

In	O
the	O
United	O
Kingdom	O
use	O
of	O
LSD	B-Drug
was	O
pioneered	O
by	O
Dr.	O
Ronald	O
A.	O
Sandison	O
in	O
1952,	O
at	O
Powick	O
Hospital,	O
Worcestershire.	O

As	O
an	O
anti-inflammatory,	O
dapsone	B-Drug
inhibits	O
the	O
myeloperoxidase-H2O2-halide-mediated	O
cytotoxic	O
system	O
in	O
polymorphonucleocytes.	O

In	O
January	O
2009,	O
an	O
FDA	O
advisory	O
committee	O
voted	O
14	O
to	O
12	O
against	O
the	O
continued	O
marketing	O
of	O
propoxyphene	B-Drug
products,	O
based	O
on	O
its	O
weak	O
pain-killing	O
abilities,	O
addictiveness,	O
association	O
with	O
drug	O
deaths	O
and	O
possible	O
heart	O
problems,	O
including	O
arrhythmia.	O

The	O
officers	O
said	O
the	O
cups	O
and	O
bottle	O
all	O
emitted	O
"strong	O
odors	O
of	O
codeine"	O
even	O
though	O
codeine	B-Drug
is	O
odorless	O
according	O
to	O
National	O
Institutes	O
Health.	O

Acetothiolutamide	O
High-affinity	O
AR	O
full	O
agonist	O
in	O
vitro,	O
but	O
very	O
low	O
activity	O
vivo	O
due	O
to	O
poor	O
pharmacokinetics	O
Andarine	B-Drug
("	O

For	O
example,	O
SNRIs	O
such	O
as	O
venlafaxine	B-Drug
are	O
commonly	O
prescribed	O
to	O
treat	O
depression,	O
and	O
the	O
5-HT1A	O
agonist	O
buspirone	B-Drug
is	O
primarily	O
for	O
treatment	O
of	O
anxiety.	O

The	O
severity	O
of	O
gynecomastia	O
with	O
spironolactone	B-Drug
varies	O
considerably,	O
but	O
is	O
usually	O
mild.	O

Some	O
drugs,	O
such	O
as	O
amphetamine	B-Drug
and	O
cocaine,	O
give	O
the	O
dancer	O
hyperactivity	O
energy	O
to	O
dance	O
all	O
night.	O
cocaine	B-Drug

Hyoscine	B-Drug
is	O
reported	O
to	O
be	O
the	O
only	O
active	O
alkaloid	O
within	O
these	O
plants	O
that	O
can	O
effectively	O
absorbed	O
through	O
skin	O
cause	O
effects.	O

A	O
newspaper	O
headline	O
identifying	O
Stanley	O
as	O
an	O
"LSD	O
Millionaire"	O
ran	O
in	O
the	O
Los	O
Angeles	O
Times	O
day	O
before	O
state	O
of	O
California,	O
on	O
October	O
6,	O
1966,	O
criminalized	O
drug.	O
LSD	B-Drug

Buprenorphine	B-Drug
(21-Cyclopropyl-7--[(s)-1-hydroxy-1,2,2-trimethylpropyl]-6,	O
14-endo-ethano-6,7,8,	O

Additionally,	O
drugs	O
such	O
as	O
stimulants	O
and	O
sympathomimetics	O
should	O
not	O
be	O
taken	O
with	O
propylhexedrine,	O
this	O
can	O
lead	O
to	O
potentially	O
dangerous	O
spikes	O
in	O
blood	O
pressure	O
irregular	O
heart	O
rhythms.	O
propylhexedrine	B-Drug

Unofficial	O
estimates	O
put	O
the	O
number	O
of	O
annual	O
hyoscine	B-Drug
incidents	O
in	O
Colombia	O
at	O
approximately	O
50,000.	O

Though	O
not	O
an	O
approved	O
drug,	O
ligandrol	B-Drug
has	O
been	O
sold	O
on	O
the	O
black	O
market	O
in	O
countries	O
where	O
it	O
is	O
classified	O
as	O
illegal	O
substance.	O

5-MeO-MiPT	B-Drug
is	O
a	O
Class	O
A	O
drug	O
in	O
the	O
United	O
Kingdom	O
as	O
are	O
most	O
ethers	O
of	O
ring-hydroxy	O
tryptamines.	O

Several	O
explosion	O
and	O
fire	O
incidents	O
related	O
to	O
hash	B-Drug
oil	I-Drug
manufacturing	O
attempts	O
in	O
homes	O
have	O
been	O
reported.	O

Among	O
the	O
early	O
cultivators	O
of	O
cannabis	O
for	O
recreational	O
use	O
in	O
California	O
were	O
Arabs,	O
Armenians,	O
and	O
Turks	O
who	O
grew	O
as	O
1895	O
to	O
make	O
hashish	B-Drug
local	O
consumption.	O

Whether	O
NDMA	O
can	O
also	O
be	O
formed	O
from	O
ranitidine	B-Drug
inside	O
the	O
body	O
is	O
unclear.	O

Active	O
substance	O
abuse	O
(for	O
serial	O
ketamine	B-Drug
injections).	O

Little	O
further	O
work	O
was	O
done	O
with	O
thalidomide	B-Drug
in	O
cancer	O
until	O
the	O
1990s.	O

5-MeO-AMT	B-Drug
is	O
a	O
Schedule	O

Hyoscine	B-Drug
is	O
the	O
main	O
active	O
component	O
produced	O
by	O
certain	O
plants	O
of	O
nightshade	O
family,	O
which	O
historically	O
have	O
been	O
used	O
as	O
psychoactive	O
drugs	O
due	O
to	O
their	O
hallucinogenic	O
effects.	O

Crystal	O
methamphetamine	B-Drug
and	O
salts	O
of	O
amphetamine	B-Drug
are	O
sometimes	O
powdered	O
insufflated	O
by	O
recreational	O
users,	O
which	O
results	O
in	O
a	O
fairly	O
rapid	O
uptake	O
the	O
drug	O
through	O
nasal	O
epithelium;	O
with	O
regular	O
use,	O
or	O
insufflation	O
slowly	O
damages	O
eventually	O
destroys	O
septum	O
due	O
to	O
their	O
causticity	O
vasoconstrictive	O
effects.	O

Murray	O
said	O
through	O
his	O
attorney	O
that	O
he	O
did	O
not	O
prescribe	O
or	O
administer	O
pethidine	B-Drug
oxycodone	B-Drug
to	O
Jackson,	O
but	O
say	O
what,	O
if	O
anything,	O
administer.	O

Androstenedione	B-Drug

Research	O
during	O
this	O
time	O
was	O
focused	O
on	O
the	O
search	O
for	O
a	O
painkiller	O
that	O
did	O
not	O
have	O
addictive	O
character	O
or	O
overdose	O
risk	O
of	O
morphine.	O
morphine	B-Drug

heroin,	O
cannabis	O
Don't	O
Be	O
a	O
Menace	O
to	O
South	O
Central	O
heroin	B-Drug

Carisoprodol	B-Drug
has	O
a	O
rapid,	O
30-minute	O
onset	O
of	O
action,	O
with	O
the	O
aforementioned	O
effects	O
lasting	O
about	O
two	O
to	O
six	O
hours.	O

Side	O
effects	O
of	O
benzimidazole	O
derived	O
opioids	O
are	O
expected	O
to	O
be	O
similar	O
those	O
fentanyl,	O
which	O
include	O
itching,	O
nausea	O
and	O
potentially	O
serious	O
respiratory	O
depression,	O
can	O
life-threatening.	O
fentanyl	B-Drug

Adverse	O
effects	O
of	O
benzodiazepines	O
such	O
as	O
diazepam	B-Drug
include	O
anterograde	O
amnesia,	O
confusion	O
(especially	O
pronounced	O
in	O
higher	O
doses)	O
and	O
sedation.	O

Aside	O
from	O
discontinuation	O
of	O
glucocorticoid	O
medication,	O
potential	O
treatments	O
discussed	O
in	O
the	O
research	O
literature	O
include:	O
anti-glucocorticoids	O
psychoactive	O
drugs	O
that	O
up-regulate	O
GRII	O
receptor:tricyclic	O
antidepressants:	O
Desipramine,	O
Imipramine,	O
and	O
Amitriptyline	B-Drug
(SSRIs	O
Desipramine	B-Drug
Imipramine	B-Drug

Desogestrel	B-Drug
is	O
marketed	O
widely	O
throughout	O
the	O
world.	O

Using	O
formaldehyde	O
and	O
sulfuric	O
acid,	O
the	O
solution	O
will	O
turn	O
purple	O
when	O
introduced	O
to	O
opium	B-Drug
drugs.	O

Included	O
in	O
MAPS'	O
research	O
efforts	O
are	O
MDMA	B-Drug
(methylenedioxymethamphetamine)	O
for	O
the	O
treatment	O
of	O
posttraumatic	O
stress	O
disorder	O
(PTSD);	O
LSD	B-Drug
and	O
psilocybin	O
anxiety,	O
cluster	O
headaches,	O
depression	O
associated	O
with	O
end-of-life	O
issues;	O
ibogaine	B-Drug
opiate	O
addiction,	O
ayahuasca	O
drug	O
addiction	O
PTSD;	O
medical	O
cannabis	O
alternative	O
delivery	O
systems	O
such	O
as	O
vaporizers	O
water	O
pipes.	O
methylenedioxymethamphetamine	B-Drug

In	O
2004,	O
the	O
University	O
of	O
Texas	O
found	O
that	O
8.3%	O
secondary	O
school	O
students	O
in	O
had	O
taken	O
codeine	B-Drug
syrup	O
to	O
get	O
high.	O

Twelve-step	O
programs	O
such	O
as	O
Cocaine	O
Anonymous	O
(modeled	O
on	O
Alcoholics	O
Anonymous)	O
have	O
been	O
widely	O
used	O
to	O
help	O
those	O
with	O
cocaine	B-Drug
addiction.	O

In	O
2018	O
a	O
woman	O
died	O
in	O
London	O
after	O
getting	O
prescription	O
for	O
tramadol	B-Drug
from	O
an	O
online	O
doctor	O
based	O
Prague	O
who	O
had	O
not	O
considered	O
her	O
medical	O
history.	O

Fentanyl	B-Drug
is	O
sometimes	O
sold	O
as	O
heroin	B-Drug
or	O
oxycodone,	O
leading	O
to	O
overdoses.	O
oxycodone	B-Drug

Opium	O
prohibition	O
in	O
China	O
began	O
1729,	O
yet	O
was	O
followed	O
by	O
nearly	O
two	O
centuries	O
of	O
increasing	O
opium	B-Drug
use.	O

In	O
addition,	O
clonazepam	B-Drug
decreases	O
the	O
utilization	O
of	O
5-HT	O
(serotonin)	O
by	O
neurons	O
and	O
has	O
been	O
shown	O
to	O
bind	O
tightly	O
central-type	O
benzodiazepine	O
receptors.	O

Hence,	O
the	O
effects	O
of	O
bupropion	B-Drug
cannot	O
be	O
understood	O
unless	O
its	O
metabolism	O
is	O
also	O
considered.	O

5-MeO-AMT	B-Drug
is	O
not	O
scheduled	O
at	O
the	O
federal	O
level	O
in	O
United	O
States.	O

ADSB-FUB-187	B-Drug
is	O
an	O
indazole-based	O
synthetic	O
cannabinoid.	O

The	O
acetylation	O
of	O
THC	B-Drug
does	O
not	O
change	O
the	O
properties	O
compound	O
to	O
same	O
extent	O
as	O
with	O
other	O
acetate	O
esters	O
(e.g.	O
morphine	B-Drug
vs	O
heroin),	O
parent	O
(THC)	O
is	O
already	O
highly	O
lipophilic,	O
but	O
potency	O
nonetheless	O
increased	O
some	O
extent.	O
heroin	B-Drug

This	O
side	O
effect	O
led	O
to	O
the	O
withdrawal	O
of	O
fenfluramine	B-Drug
as	O
an	O
anorectic	O
agent	O
worldwide,	O
and	O
benfluorex	O
in	O
Europe,	O
both	O
form	O
norfenfluramine	O
active	O
metabolite.	O

Cimetidine,	O
rifampicin,	O
and	O
thioridazine	O
cause	O
interactions	O
with	O
zaleplon.	O
Cimetidine	B-Drug
rifampicin	B-Drug
zaleplon	B-Drug

Exemestane	B-Drug
went	O
through	O
clinical	O
trials	O
in	O
the	O
1990s	O
and	O
received	O
FDA	O
approval	O
1999,	O
marketed	O
as	O
Aromasin.	O

While	O
higher	O
CYP2D6	O
activity	O
increases	O
the	O
effects	O
of	O
oxycodone	B-Drug
(owing	O
to	O
increased	O
conversion	O
into	O
oxymorphone),	O
CYP3A4	O
has	O
opposite	O
effect	O
and	O
decreases	O
metabolism	O
noroxycodone	O
noroxymorphone).	O
oxymorphone	B-Drug
noroxymorphone	B-Drug

In	O
addition,	O
some	O
AAS,	O
such	O
as	O
19-nortestosterone	B-Drug
derivatives	O
like	O
nandrolone,	O
are	O
also	O
potent	O
progestogens,	O
and	O
activation	O
of	O
the	O
progesterone	O
receptor	O
(PR)	O
is	O
antigonadotropic	O
similarly	O
to	O
AR.	O
nandrolone	B-Drug

In	O
2004,	O
the	O
FDA	O
created	O
a	O
ban	O
on	O
ephedrine	B-Drug
alkaloids	O
marketed	O
for	O
reasons	O
other	O
than	O
asthma,	O
colds,	O
allergies,	O
disease,	O
or	O
traditional	O
Asian	O
use.	O

A	O
review	O
of	O
the	O
available	O
data	O
carried	O
out	O
in	O
2008	O
indicated	O
that	O
bupropion	B-Drug
is	O
safe	O
to	O
use	O
people	O
with	O
a	O
variety	O
serious	O
cardiac	O
conditions.	O

As	O
of	O
2017,	O
much	O
the	O
pharmacology	O
kratom	B-Drug
was	O
not	O
well	O
understood,	O
having	O
stimulant	O
effects	O
at	O
low	O
doses,	O
an	O
opioid-like	O
effect	O
higher	O
as	O
sedative	O
and	O
sensory-suppressive	O
effects.	O

Particular	O
care	O
should	O
be	O
taken	O
with	O
drugs	O
that	O
potentiate	O
the	O
effects	O
of	O
diazepam,	O
such	O
as	O
barbiturates,	O
phenothiazines,	O
opioids,	O
and	O
antidepressants.	O
diazepam	B-Drug

It	O
has	O
been	O
suggested	O
that	O
the	O
edema	O
occurs	O
in	O
some	O
people	O
following	O
use	O
of	O
aspirin-like	O
cyclo-oxygenase	O
inhibitors	O
such	O
as	O
ibuprofen	B-Drug
or	O
indomethacin	B-Drug
may	O
be	O
due	O
to	O
inhibition	O
lymph	O
heart	O
action.	O

Selegiline	B-Drug
delays	O
the	O
point	O
when	O
levodopa	B-Drug
treatment	O
becomes	O
necessary	O
from	O
about	O
11	O
months	O
to	O
18	O
after	O
diagnosis.	O

Fentanyl	B-Drug
was	O
first	O
synthesized	O
in	O
Belgium	O
by	O
Paul	O
Janssen	O
under	O
the	O
label	O
of	O
his	O
relatively	O
newly	O
formed	O
Pharmaceutica	O
1959.	O

GABAA	O
receptors	O
containing	O
the	O
1	O
subunit	O
mediate	O
sedative,	O
anterograde	O
amnesic,	O
and	O
partly	O
anticonvulsive	O
effects	O
of	O
diazepam.	O
diazepam	B-Drug

Chemically,	O
PCP	B-Drug
is	O
a	O
member	O
of	O
the	O
arylcyclohexylamine	O
class,	O
and	O
pharmacologically,	O
it	O
dissociative	O
anesthetic.	O

Under	O
the	O
generic	O
name	O
diamorphine,	O
heroin	B-Drug
is	O
prescribed	O
as	O
a	O
strong	O
pain	O
medication	O
in	O
United	O
Kingdom,	O
where	O
it	O
administered	O
via	O
oral,	O
subcutaneous,	O
intramuscular,	O
intrathecal,	O
intranasal	O
or	O
intravenous	O
routes.	O
diamorphine	B-Drug

Clonazepam	B-Drug
is	O
generally	O
not	O
recommended	O
for	O
use	O
in	O
elderly	O
people	O
insomnia	O
due	O
to	O
its	O
high	O
potency	O
relative	O
other	O
benzodiazepines.	O

This	O
led	O
to	O
the	O
development	O
of	O
fluoxetine,	O
first	O
SSRI.	O
fluoxetine	B-Drug

The	O
AGS	O
stated	O
the	O
strength	O
of	O
recommendation	O
that	O
older	O
adults	O
avoid	O
zolpidem	B-Drug
is	O
"strong"	O
and	O
quality	O
evidence	O
supporting	O
it	O
"moderate."	O

For	O
this	O
reason,	O
shorter	O
acting	O
agents	O
such	O
as	O
alfentanyl	O
or	O
remifentanil	B-Drug
may	O
be	O
more	O
suitable	O
in	O
the	O
context	O
of	O
inducing	O
general	O
anaesthesia.	O

Chinese	O
men	O
were	O
deported	O
for	O
playing	O
keno	O
and	O
sentenced	O
to	O
hard	O
labor	O
opium	B-Drug
possession.	O

Although	O
the	O
determination	O
of	O
psilocin	B-Drug
levels	O
in	O
urine	O
can	O
be	O
performed	O
without	O
sample	O
clean-up	O
(i.e.,	O
removing	O
potential	O
contaminants	O
that	O
make	O
it	O
difficult	O
to	O
accurately	O
assess	O
concentration),	O
analysis	O
plasma	O
or	O
serum	O
requires	O
a	O
preliminary	O
extraction,	O
followed	O
by	O
derivatization	O
extracts	O
case	O
GCMS.	O

One	O
case	O
of	O
serotonin	O
syndrome	O
has	O
been	O
reported,	O
where	O
the	O
patient	O
was	O
already	O
prescribed	O
fluoxetine	B-Drug
and	O
olanzapine,	O
then	O
took	O
40	O
tablets	O
containing	O
mephedrone	B-Drug
in	O
one	O
night.	O
olanzapine	B-Drug

The	O
UK	O
ACMD	O
recommended	O
that	O
generic	O
prohibition	O
legislation	O
be	O
extended	O
to	O
include	O
UR-144	B-Drug
in	O
October	O
2012.	O

Norgestrel	B-Drug
was	O
introduced	O
for	O
medical	O
use	O
as	O
a	O
combined	O
birth	O
control	O
pill	O
with	O
ethinylestradiol	O
under	O
the	O
brand	O
name	O
Eugynon	O
in	O
Germany	O
1966	O
and	O
Ovral	O
United	O
States	O
1968,	O
progestogen-only	O
Ovrette	B-Drug
1973.	O

The	O
effects	O
established	O
so	O
far	O
for	O
recreational	O
use	O
of	O
ecstasy	B-Drug
lie	O
in	O
the	O
range	O
moderate	O
to	O
severe	O
serotonin	O
transporter	O
reduction.	O

However,	O
based	O
on	O
the	O
reports	O
of	O
exposure	O
they	O
are	O
more	O
likely	O
to	O
resemble	O
hallucinogenic	O
effects	O
deliriants	O
than	O
serotonergic	O
psychedelics	O
such	O
as	O
LSD.	O
LSD	B-Drug

At	O
the	O
same	O
time,	O
CBD	B-Drug
levels	O
in	O
seized	O
samples	O
have	O
lowered,	O
part	O
because	O
of	O
desire	O
to	O
produce	O
higher	O
THC	B-Drug
and	O
more	O
illegal	O
growers	O
cultivate	O
indoors	O
using	O
artificial	O
lights.	O

Controlled-release	O
dihydrocodeine	B-Drug
is	O
a	O
non-prescription	O
item	O
in	O
some	O
places,	O
especially	O
the	O
60	O
mg	O
strength.	O

Nubain	B-Drug
was	O
approved	O
for	O
marketing	O
in	O
the	O
United	O
States	O
1978	O
and	O
remains	O
as	O
only	O
opioid	O
analgesic	O
of	O
this	O
type	O
(marketed	O
U.S.)	O
not	O
controlled	O
under	O
Controlled	O
Substances	O
Act	O
(CSA).	O

In	O
pure	O
form,	O
the	O
first	O
ergot	O
alkaloids,	O
ergotamine	B-Drug
and	O
its	O
isomer	O
ergotaminine	O
were	O
isolated	O
by	O
Arthur	O
Stoll	O
in	O
1918.	O

Similarly,	O
hypersensitivity	O
to	O
the	O
antiretroviral	O
drug	O
abacavir	B-Drug
is	O
strongly	O
associated	O
with	O
a	O
single-nucleotide	O
polymorphism	O
that	O
varies	O
in	O
frequency	O
between	O
populations.	O

In	O
dogs,	O
the	O
absorption	O
of	O
meloxicam	B-Drug
from	O
stomach	O
is	O
not	O
affected	O
by	O
presence	O
food,	O
with	O
peak	O
concentration	O
(Cmax)	O
occurring	O
in	O
blood	O
78	O
hours	O
after	O
administration.	O

Naloxone	B-Drug
should	O
be	O
stored	O
at	O
room	O
temperature	O
and	O
protected	O
from	O
light.	O

Brand	O
names	O
include	O
Sublimaze,	O
Actiq,	O
Durogesic,	O
Duragesic,	O
Fentora,	O
Matrifen,	O
Haldid,	O
Onsolis,	O
Instanyl,	O
Abstral,	O
Lazanda	B-Drug
and	O
others.	O
Actiq	B-Drug
Duragesic	B-Drug

The	O
plasma	O
protein-binding	O
of	O
zopiclone	B-Drug
has	O
been	O
reported	O
to	O
be	O
weak,	O
between	O
45	O
and	O
80%	O
(mean	O
5259%).	O

Sydenham's	O
laudanum	B-Drug
was	O
used	O
widely	O
in	O
both	O
Europe	O
and	O
the	O
Americas	O
until	O
20th	O
century.	O

Its	O
levorotary	O
enantiomer,	O
levacetylmethadol,	O
is	O
an	O
FDA-approved	O
treatment	O
for	O
opioid	O
addiction.	O
levacetylmethadol	B-Drug

That	O
year,	O
attorneys	O
general	O
in	O
Connecticut	O
and	O
Illinois	O
announced	O
that	O
Redux	O
Beverages	O
complied	O
to	O
not	O
market	O
Cocaine	B-Drug
their	O
respective	O
states.	O

blazed	O
Result	O
of	O
smoking	O
cannabis	O
with	O
high	O
THC	B-Drug
level.	O

Trade	O
in	O
opium	B-Drug
was	O
standardized,	O
with	O
production	O
of	O
balls	O
raw	O
opium,	O
1.11.6	O
kg	O
(2.43.5	O
lb),	O
30%	O
water	O
content,	O
wrapped	O
poppy	O
leaves	O
and	O
petals,	O
shipped	O
chests	O
6065	O
(132143	O
lb)	O
(one	O
picul).	O

Desocodeine	O
is	O
a	O
semi-synthetic	O
opioid	O
which	O
the	O
penultimate	O
intermediate	O
in	O
manufacture	O
of	O
desomorphine	B-Drug
from	O
codeine.	O
codeine	B-Drug

Using	O
formaldehyde	O
and	O
sulfuric	O
acid,	O
the	O
solution	O
will	O
turn	O
purple	O
when	O
introduced	O
to	O
opium	B-Drug
drugs.	O

Estradiol	O
is	O
converted	O
from	O
testosterone	O
directly	O
(in	O
males),	O
or	O
via	O
the	O
primary	O
pathway	O
DHEA	O
-	O
androstenedione	B-Drug
estrone	O
and	O
secondarily	O
females).	O

The	O
drug	O
was	O
approved	O
in	O
Israel	O
1999.Clinical	O
trials	O
of	O
mifepristone	B-Drug
China	O
began	O
1985.	O

It	O
is	O
unclear,	O
however,	O
whether	O
the	O
increase	O
in	O
THC	B-Drug
content	O
has	O
caused	O
people	O
to	O
consume	O
more	O
or	O
if	O
users	O
adjust	O
based	O
on	O
potency	O
of	O
cannabis.	O

They	O
were	O
primarily	O
involved	O
in	O
marijuana	O
trafficking,	O
but	O
the	O
1980s	O
they	O
branched	O
out	O
into	O
cocaine	B-Drug
trafficking.	O

MDMA	B-Drug
is	O
often	O
considered	O
the	O
drug	O
of	O
choice	O
within	O
rave	O
culture	O
and	O
also	O
used	O
at	O
clubs,	O
festivals,	O
house	O
parties.	O

Thus,	O
in	O
persons	O
with	O
diminished	O
kidney	O
function,	O
the	O
clearance	O
of	O
chlortalidone	B-Drug
is	O
reduced	O
and	O
elimination	O
half-life	O
increased.	O

On	O
insistence	O
of	O
Allen	O
Ginsberg,	O
Leary,	O
together	O
with	O
his	O
younger	O
colleague	O
Richard	O
Alpert	O
(Ram	O
Dass)	O
also	O
made	O
LSD	B-Drug
available	O
to	O
students.	O

March	O
20,	O
2014,	O
the	O
Florida	O
House	O
of	O
Representatives	O
Budget	O
Committee	O
passed	O
"so-called	O
Charlotte's	O
Web	O
measure	O
(CS/HB	O
843)"	O
designed	O
to	O
limit	O
prosecutors'	O
ability	O
prosecute	O
those	O
in	O
possession	O
low	O
THC/high	O
CBD	B-Drug
marijuana	O
("0.5	O
percent	O
or	O
less	O
tetrahydrocannabinol	B-Drug
and	O
more	O
than	O
15	O
cannabidiol")	O
used	O
for	O
treating	O
seizures.	O
THC	B-Drug
cannabidiol	B-Drug

The	O
use	O
of	O
crystal	B-Drug
methamphetamine	I-Drug
or	O
mephedrone	B-Drug
for	O
chemsex	O
is	O
associated	O
with	O
"high-risk	O
sexual	O
behaviour	O
little	O
regard	O
to	O
consequences,	O
poor	O
ARV	O
adherence	O
HIV,	O
condoms,	O
extended	O
episodes	O
(often	O
traumatic)	O
pursuits	O
(e.g.	O
fisting)	O
typically	O
lasting	O
two	O
three	O
days,	O
[and]	O
multiple	O
partners.	O

It	O
is	O
similar	O
in	O
effects	O
to	O
phencyclidine	B-Drug
but	O
slightly	O
less	O
potent	O
and	O
has	O
stimulant	O
instead	O
producing	O
a	O
sedative	O
effect	O
described	O
as	O
being	O
somewhat	O
barbiturate,	O
with	O
additional	O
PCP-like	O
dissociative,	O
anaesthetic	O
hallucinogenic	O
effects.	O

In	O
Australia,	O
as	O
of	O
February	O
1,	O
2016,	O
some	O
forms	O
naloxone	B-Drug
are	O
available	O
"over	O
the	O
counter"	O
in	O
pharmacies	O
without	O
a	O
prescription.	O

People	O
who	O
regularly	O
use	O
oxycodone	B-Drug
recreationally	O
or	O
at	O
higher	O
than	O
prescribed	O
doses	O
are	O
even	O
risk	O
of	O
severe	O
withdrawal	O
symptoms.	O

Simultaneous	O
use	O
of	O
hydromorphone	B-Drug
with	O
other	O
opioids,	O
muscle	O
relaxants,	O
tranquilizers,	O
sedatives,	O
and	O
general	O
anesthetics	O
may	O
cause	O
a	O
significant	O
increase	O
in	O
respiratory	O
depression,	O
progressing	O
to	O
coma	O
or	O
death.	O

JWH-018	B-Drug
is	O
a	O
full	O
agonist	O
of	O
both	O
the	O
CB1	O
and	O
CB2	O
cannabinoid	O
receptors,	O
with	O
reported	O
binding	O
affinity	O
9.00	O
5.00	O
nM	O
at	O
2.94	O
2.65	O
CB2.	O

In	O
Southeast	O
Asia,	O
the	O
consumption	O
of	O
mitragynine	B-Drug
from	O
whole	O
leaf	O
kratom	B-Drug
preparations	O
is	O
common	O
among	O
laborers	O
who	O
report	O
utilizing	O
kratom's	O
mild	O
stimulant	O
and	O
perceived	O
antinociceptive	O
properties	O
to	O
increase	O
endurance	O
ease	O
pain	O
while	O
working.	O

In	O
early	O
pregnancy,	O
nitrazepam	B-Drug
levels	O
are	O
lower	O
in	O
the	O
baby	O
than	O
mother,	O
and	O
later	O
stages	O
of	O
is	O
found	O
equal	O
both	O
mother	O
unborn	O
child.	O

Social	O
attachment	O
was	O
demonstrated	O
to	O
be	O
mediated	O
by	O
the	O
opioid	O
system	O
through	O
experiments	O
administering	O
morphine	B-Drug
and	O
naltrexone,	O
an	O
agonist	O
antagonist,	O
juvenile	O
guinea	O
pigs.	O
naltrexone	B-Drug

In	O
2010	O
the	O
FDA	O
noted	O
concerns	O
that	O
sibutramine	B-Drug
increases	O
risk	O
of	O
heart	O
attacks	O
and	O
strokes	O
in	O
patients	O
with	O
a	O
history	O
cardiovascular	O
disease.	O

Ethylestrenol	B-Drug
is	O
or	O
has	O
been	O
marketed	O
under	O
a	O
variety	O
of	O
brand	O
names	O
including	O
Durabolin	B-Drug
O,	O
Duraboral,	O
Fertabolin,	O
Maxibolin,	O
Maxibolin	O
Elixir,	O
Orabolin,	O
Orgabolin,	O
Orgaboral,	O
and	O
Virastine.	O

We	O
know	O
that	O
morphine,	O
which	O
so	O
far	O
has	O
been	O
thought	O
to	O
be	O
the	O
only	O
active	O
principle	O
of	O
opium,	O
does	O
not	O
account	O
for	O
all	O
effects	O
and	O
a	O
long	O
time	O
physiologists	O
are	O
claiming	O
there	O
is	O
gap	O
filled.	O
morphine	B-Drug
opium	B-Drug

This	O
elaborate	O
procedure,	O
requiring	O
the	O
maintenance	O
of	O
pots	O
opium	B-Drug
at	O
just	O
right	O
temperature	O
for	O
a	O
globule	O
to	O
be	O
scooped	O
up	O
with	O
needle-like	O
skewer	O
smoking,	O
formed	O
basis	O
craft	O
"paste-scooping"	O
by	O
which	O
servant	O
girls	O
could	O
become	O
prostitutes	O
as	O
opportunity	O
arose.	O

The	O
cognitive	O
enhancing	O
effects	O
of	O
pramipexole,	O
guanfacine,	O
clonidine,	O
and	O
fexofenadine	B-Drug
have	O
been	O
tested,	O
but	O
no	O
significant	O
cognition-enhancing	O
in	O
healthy	O
individuals	O
were	O
found.	O
pramipexole	B-Drug
guanfacine	B-Drug
clonidine	B-Drug

Oxycodone	B-Drug
can	O
be	O
administered	O
orally,	O
intranasally,	O
via	O
intravenous,	O
intramuscular,	O
or	O
subcutaneous	O
injection,	O
rectally.	O

The	O
CDC	O
presumes	O
that	O
a	O
large	O
proportion	O
of	O
the	O
increase	O
in	O
deaths	O
is	O
due	O
to	O
illegally-made	O
fentanyl;	O
as	O
statistics	O
on	O
overdose	O
(as	O
2015)	O
do	O
not	O
distinguish	O
pharmaceutical	O
fentanyl	B-Drug
from	O
fentanyl,	O
actual	O
death	O
rate	O
could,	O
therefore,	O
be	O
much	O
higher	O
than	O
reported.	O

Dienogest	B-Drug
is	O
used	O
primarily	O
in	O
birth	O
control	O
pills	O
combination	O
with	O
ethinylestradiol	O
under	O
the	O
brand	O
name	O
Valette.	O

Following	O
the	O
patch,	O
a	O
flavoured	O
lollipop	O
of	O
fentanyl	B-Drug
citrate	O
mixed	O
with	O
inert	O
fillers	O
was	O
introduced	O
in	O
1998	O
under	O
brand	O
name	O
Actiq,	O
becoming	O
first	O
quick-acting	O
formation	O
for	O
use	O
chronic	O
breakthrough	O
pain.	O
Actiq	B-Drug

Peak	O
concentrations	O
of	O
etonogestrel	B-Drug
occur	O
about	O
1.5	O
hours	O
after	O
a	O
dose	O
while	O
desogestrel	B-Drug
are	O
very	O
low	O
and	O
have	O
disappeared	O
by	O
3	O
dose.	O

Despite	O
this,	O
cases	O
of	O
thalidomide	B-Drug
embryopathy	O
continue,	O
with	O
at	O
least	O
100	O
identified	O
in	O
Brazil	O
between	O
2005	O
and	O
2010.	O

The	O
United	O
Nations	O
Office	O
on	O
Drugs	O
and	O
Crime	O
stated	O
in	O
its	O
2014	O
World	O
Drug	O
Report	O
that	O
US	O
ecstasy	B-Drug
retail	O
prices	O
range	O
from	O
US$1	O
to	O
$70	O
per	O
pill,	O
or	O
$15,000	O
$32,000	O
kilogram.	O

However,	O
PCP	B-Drug
has	O
little	O
affinity	O
for	O
the	O
human	O
monoamine	O
transporters,	O
including	O
dopamine	O
transporter	O
(DAT).	O

Nortriptyline	B-Drug
is	O
an	O
active	O
metabolite	O
of	O
amitriptyline	B-Drug
by	O
demethylation	O
in	O
the	O
liver.	O

NSAIDs	O
reduce	O
kidney	O
blood	O
flow	O
and	O
thereby	O
decrease	O
the	O
efficacy	O
of	O
diuretics,	O
inhibit	O
elimination	O
lithium	O
methotrexate.	O
methotrexate	B-Drug

This	O
study	O
has	O
since	O
been	O
used	O
as	O
the	O
foundation	O
for	O
idea	O
that	O
MDMA	B-Drug
neurotoxicity,	O
due	O
to	O
its	O
effect	O
on	O
serotonin	O
neurons,	O
could	O
influence	O
magnitude	O
of	O
TAE	O
in	O
individuals	O
who	O
use	O
MDMA.	O

The	O
use	O
of	O
ketamine	B-Drug
in	O
anesthesia	O
reflects	O
its	O
characteristics.	O

Tamoxifen	B-Drug
may	O
inhibit	O
its	O
own	O
metabolism.	O

EEG	O
tests	O
show	O
more	O
drowsiness	O
and	O
light	O
sleep	O
18	O
hours	O
after	O
nitrazepam	B-Drug
intake,	O
so	O
than	O
amylobarbitone.	O

In	O
dose-ranging	O
studies,	O
tamoxifen	B-Drug
was	O
administered	O
at	O
very	O
high	O
doses	O
in	O
women	O
(e.g.,	O
300	O
mg/m2)	O
and	O
found	O
to	O
produce	O
acute	O
neurotoxicity	O
including	O
tremor,	O
hyperreflexia,	O
unsteady	O
gait,	O
dizziness.	O

Nicotine	B-Drug
addiction	O
seems	O
to	O
worsen	O
mental	O
health	O
problems.	O

In	O
the	O
U.S.,	O
fentanyl	B-Drug
is	O
a	O
Schedule	O
II	O
controlled	O
substance	O
per	O
Controlled	O
Substance	O
Act.	O

They	O
encompass	O
a	O
variety	O
of	O
distinct	O
chemical	O
classes:	O
the	O
classical	O
cannabinoids	O
structurally	O
related	O
to	O
THC,	O
nonclassical	O
(cannabimimetics)	O
including	O
aminoalkylindoles,	O
1,5-diarylpyrazoles,	O
quinolines,	O
and	O
arylsulfonamides	O
as	O
well	O
eicosanoids	O
endocannabinoids.	O
THC	B-Drug

After	O
using	O
cocaine	B-Drug
on	O
a	O
regular	O
basis,	O
many	O
users	O
will	O
become	O
addicted.	O

Ibogaine	B-Drug
is	O
metabolized	O
in	O
the	O
human	O
body	O
by	O
cytochrome	O
P450	O
2D6	O
into	O
noribogaine	B-Drug
(more	O
correctly,	O
O-desmethylibogaine	O
or	O
12-hydroxyibogamine).	O

At	O
that	O
time,	O
Imitrex	B-Drug
sold	O
for	O
about	O
$25	O
a	O
pill.	O

"Obetrolling"	O
or	O
"doubling"	O
were	O
the	O
terms	O
used	O
by	O
character	O
to	O
refer	O
tripping	O
on	O
Obetrol,	O
which	O
increased	O
his	O
self-awareness	O
and	O
made	O
him	O
feel	O
alive.	O
Obetrol	B-Drug

If	O
sumatriptan	B-Drug
is	O
discontinued,	O
the	O
condition	O
reverses	O
within	O
a	O
few	O
weeks.	O

In	O
South	O
Carolina,	O
a	O
bill	O
was	O
introduced	O
in	O
the	O
state	O
House	O
that	O
would	O
require	O
doctors	O
and	O
other	O
medical	O
professionals	O
who	O
can	O
prescribe	O
medication	O
to	O
Narcan	B-Drug
(or	O
naloxone	B-Drug
generic)	O
patients	O
have	O
ever	O
overdosed	O
on	O
opioids,	O
history	O
of	O
drug	O
abuse,	O
or	O
are	O
being	O
prescribed	O
any	O
benzodiazepines	O
(such	O
as	O
Xanax)	O
while	O
opioids.	O
Xanax	B-Drug

Naloxone	B-Drug
is	O
a	O
non-selective	O
and	O
competitive	O
opioid	O
receptor	O
antagonist.	O

Other	O
related	O
indole-containing	O
psychedelic	O
compounds	O
include	O
dimethyltryptamine,	O
found	O
in	O
many	O
plant	O
species	O
and	O
trace	O
amounts	O
some	O
mammals,	O
bufotenine,	O
the	O
skin	O
of	O
psychoactive	O
toads.	O
dimethyltryptamine	B-Drug
bufotenine	B-Drug

Also,	O
in	O
MDPV-treated	O
mice,	O
a	O
priming-dose	O
of	O
cocaine	B-Drug
triggers	O
significant	O
neuroplasticity,	O
implying	O
high	O
vulnerability	O
to	O
its	O
abuse.	O

Substituted	O
indoles	O
are	O
structural	O
elements	O
of	O
(and	O
for	O
some	O
compounds,	O
the	O
synthetic	O
precursors	O
for)	O
tryptophan-derived	O
tryptamine	O
alkaloids,	O
which	O
includes	O
neurotransmitters	O
serotonin	O
and	O
melatonin,	O
as	O
well	O
naturally	O
occurring	O
psychedelic	O
drugs	O
dimethyltryptamine	B-Drug
psilocybin.	O
melatonin	B-Drug

The	O
risk	O
and	O
severity	O
of	O
the	O
withdrawal	O
syndrome	O
increases	O
higher	O
dose	O
longer	O
prazepam	B-Drug
is	O
taken	O
for.	O

Edible	O
CBD	B-Drug
products	O
were	O
scheduled	O
to	O
be	O
permitted	O
for	O
sale	O
in	O
Canada	O
on	O
October	O
17,	O
2019	O
human	O
consumption.	O

A	O
comprehensive	O
article	O
(Lotsof	O
1995)	O
on	O
the	O
subject	O
of	O
ibogaine	B-Drug
therapy	O
detailing	O
procedure,	O
effects,	O
and	O
aftereffects	O
is	O
found	O
in	O
"Ibogaine	O
Treatment	O
Chemical	O
Dependence	O
Disorders:	O
Clinical	O
Perspectives".	O
Ibogaine	B-Drug

Serious	O
breathing	O
suppression,	O
potentially	O
fatal,	O
may	O
occur	O
when	O
gabapentin	B-Drug
is	O
taken	O
together	O
with	O
opioids,	O
benzodiazepines,	O
or	O
other	O
depressants,	O
by	O
people	O
underlying	O
lung	O
problems	O
such	O
as	O
COPD.	O

Ottoman	O
and	O
European	O
testimonies	O
confirm	O
that	O
from	O
the	O
16th	O
to	O
19th	O
centuries	O
Anatolian	O
opium	B-Drug
was	O
eaten	O
in	O
Constantinople	O
as	O
much	O
it	O
exported	O
Europe.	O

After	O
four	O
weeks	O
of	O
incubation,	O
a	O
30%	O
loss	O
in	O
LSD	B-Drug
concentration	O
at	O
37	O
C	O
and	O
up	O
to	O
40%	O
45	O
were	O
observed.	O

A	O
2014	O
review	O
found	O
evidence	O
of	O
drug-seeking	O
behavior,	O
with	O
prescriptions	O
for	O
zolpidem	B-Drug
making	O
up	O
20%	O
falsified	O
or	O
forged	O
prescriptions.	O

Ethylestrenol	B-Drug
is	O
or	O
has	O
been	O
marketed	O
under	O
a	O
variety	O
of	O
brand	O
names	O
including	O
Durabolin	B-Drug
O,	O
Duraboral,	O
Fertabolin,	O
Maxibolin,	O
Maxibolin	O
Elixir,	O
Orabolin,	O
Orgabolin,	O
Orgaboral,	O
and	O
Virastine.	O

In	O
addition	O
to	O
its	O
medical	O
use,	O
ethylestrenol	B-Drug
has	O
been	O
used	O
improve	O
physique	O
and	O
performance.	O

In	O
the	O
largest	O
and	O
most	O
precisely	O
controlled	O
study	O
of	O
its	O
kind	O
carried	O
out	O
by	O
U.S.	O
Department	O
Transportation's	O
National	O
Highway	O
Traffic	O
Safety	O
Administration,	O
it	O
was	O
found	O
that	O
other	O
"studies	O
measure	O
presence	O
THC	B-Drug
in	O
drivers'	O
blood	O
or	O
oral	O
fluid,	O
rather	O
than	O
relying	O
on	O
self-report	O
tend	O
to	O
have	O
much	O
lower	O
(or	O
no)	O
elevated	O
crash	O
risk	O
estimates.	O

For	O
this	O
reason,	O
shorter	O
acting	O
agents	O
such	O
as	O
alfentanyl	O
or	O
remifentanil	B-Drug
may	O
be	O
more	O
suitable	O
in	O
the	O
context	O
of	O
inducing	O
general	O
anaesthesia.	O

The	O
treatment	O
was	O
attempted	O
despite	O
the	O
ban	O
on	O
thalidomide's	O
use,	O
and	O
results	O
were	O
favourable:	O
patient	O
slept	O
for	O
hours	O
able	O
to	O
get	O
out	O
of	O
bed	O
without	O
aid	O
upon	O
awakening.	O
thalidomide	B-Drug

Effects	O
of	O
oral	O
dosing	O
PEA	B-Drug
has	O
been	O
explored	O
in	O
humans,	O
and	O
include	O
clinical	O
trials	O
for	O
a	O
variety	O
pain	O
states,	O
inflammatory	O
syndromes.	O

This	O
may	O
play	O
a	O
role	O
in	O
chlordiazepoxide's	O
anticonvulsant	O
properties.	O
chlordiazepoxide	B-Drug

Other	O
antiestrogens,	O
such	O
as	O
ethamoxytriphetol	O
(MER-25)	O
and	O
clomifene	B-Drug
(MRL-41),	O
were	O
assessed	O
for	O
treatment	O
of	O
breast	O
cancer	O
found	O
to	O
be	O
effective	O
before	O
tamoxifen,	O
but	O
plagued	O
with	O
toxicity	O
issues.	O
tamoxifen	B-Drug

The	O
Committee	O
considered	O
that	O
the	O
abuse	O
liability	O
of	O
dronabinol	B-Drug
does	O
not	O
constitute	O
a	O
substantial	O
risk	O
to	O
public	O
health	O
and	O
society.	O

In	O
contrast,	O
the	O
current	O
version	O
of	O
Laudanum	B-Drug
contains	O
about	O
18%	O
alcohol.	O

Laudanum	B-Drug
remains	O
available	O
by	O
prescription	O
in	O
the	O
United	O
States	O
and	O
theoretically	O
Kingdom,	O
although	O
today	O
drug's	O
therapeutic	O
indications	O
are	O
generally	O
confined	O
to	O
controlling	O
diarrhea,	O
alleviating	O
pain,	O
easing	O
withdrawal	O
symptoms	O
infants	O
born	O
mothers	O
addicted	O
heroin	O
or	O
other	O
opioids.	O

The	O
Clinical	O
Pharmacogenetics	O
Implementation	O
Consortium	O
recommends	O
avoiding	O
nortriptyline	B-Drug
in	O
persons	O
who	O
are	O
CYP2D6	O
ultrarapid	O
or	O
poor	O
metabolizers,	O
due	O
to	O
the	O
risk	O
of	O
a	O
lack	O
efficacy	O
and	O
side	O
effects,	O
respectively.	O

Local	O
burning	O
or	O
itching	O
is	O
not	O
an	O
effect	O
of	O
alfatradiol,	O
but	O
the	O
ethanol	O
in	O
solvent.	O
alfatradiol	B-Drug

Ciclosporin	B-Drug
has	O
been	O
used	O
experimentally	O
to	O
treat	O
cardiac	O
hypertrophy	O
(an	O
increase	O
in	O
cell	O
volume).	O

If	O
non-pharmacological	O
measures	O
are	O
ineffective,	O
laxatives,	O
including	O
stool	O
softeners	O
(e.g.,	O
polyethylene	O
glycol),	O
bulk-forming	O
laxatives	O
fiber	O
supplements),	O
stimulant	O
bisacodyl,	O
senna),	O
and/or	O
enemas,	O
may	O
be	O
used.	O
senna	B-Drug

Apalutamide	B-Drug
is	O
used	O
in	O
conjunction	O
with	O
castration,	O
either	O
via	O
bilateral	O
orchiectomy	O
or	O
gonadotropin-releasing	O
hormone	O
analogue	O
(GnRH	O
analogue)	O
therapy,	O
as	O
a	O
method	O
of	O
androgen	O
deprivation	O
therapy	O
the	O
treatment	O
NM-CRPC.	O

that	O
bears	O
a	O
quaternary	O
amine,	O
alvimopan	B-Drug
owes	O
its	O
selectivity	O
for	O
peripheral	O
receptors	O
to	O
kinetics.	O

Hoffmann	O
was	O
working	O
at	O
Bayer	O
pharmaceutical	O
company	O
in	O
Elberfeld,	O
Germany,	O
and	O
his	O
supervisor	O
Heinrich	O
Dreser	O
instructed	O
him	O
to	O
acetylate	O
morphine	B-Drug
with	O
the	O
objective	O
of	O
producing	O
codeine,	O
a	O
constituent	O
opium	O
poppy	O
that	O
is	O
pharmacologically	O
similar	O
but	O
less	O
potent	O
addictive.	O
codeine	B-Drug

By	O
May	O
1985,	O
MDMA	B-Drug
use	O
was	O
widespread	O
in	O
California,	O
Texas,	O
southern	O
Florida,	O
and	O
the	O
northeastern	O
United	O
States.	O

The	O
carotenes	O
alpha-carotene,	O
beta-carotene,	O
gamma-carotene;	O
and	O
the	O
xanthophyll	O
beta-cryptoxanthin	O
(all	O
of	O
which	O
contain	O
beta-ionone	O
rings),	O
but	O
no	O
other	O
carotenoids,	O
function	O
as	O
provitamin	O
A	O
in	O
herbivores	O
omnivore	O
animals,	O
possess	O
enzyme	O
beta-carotene	O
15,15'-dioxygenase	O
intestinal	O
mucosa	O
to	O
cleave	O
convert	O
retinol.	O
retinol	B-Drug

Bill	O
Wilson,	O
the	O
founder	O
of	O
Alcoholics	O
Anonymous,	O
participated	O
in	O
medically	O
supervised	O
experiments	O
on	O
effects	O
LSD	B-Drug
alcoholism	O
and	O
believed	O
could	O
be	O
used	O
to	O
cure	O
alcoholics.	O

Because	O
the	O
FDA	O
prohibited	O
hexachlorophene,	O
a	O
compound	O
similar	O
to	O
triclosan,	O
Halden	O
and	O
others	O
argued	O
that	O
should	O
also	O
ban	O
triclosan.	O
hexachlorophene	B-Drug

Short-term	O
side	O
effects,	O
as	O
with	O
all	O
glucocorticoids,	O
include	O
high	O
blood	O
glucose	O
levels	O
(especially	O
in	O
patients	O
diabetes	O
mellitus	O
or	O
on	O
other	O
medications	O
that	O
increase	O
glucose,	O
such	O
tacrolimus)	O
and	O
mineralocorticoid	O
effects	O
fluid	O
retention.	O
tacrolimus	B-Drug

In	O
July	O
2014,	O
the	O
Medicines	O
and	O
Healthcare	O
products	O
Regulatory	O
Agency	O
(MHRA)	O
of	O
UK	O
issued	O
a	O
warning	O
about	O
potential	O
for	O
life-threatening	O
harm	O
from	O
accidental	O
exposure	O
to	O
transdermal	O
fentanyl	B-Drug
patches,	O
particularly	O
in	O
children,	O
advised	O
that	O
they	O
should	O
be	O
folded,	O
with	O
adhesive	O
side	O
in,	O
before	O
being	O
discarded.	O

The	O
FDA	O
required	O
that	O
Celgene	O
Corporation,	O
which	O
planned	O
to	O
market	O
thalidomide	B-Drug
under	O
the	O
brand	O
name	O
Thalomid,	O
establish	O
a	O
system	O
for	O
education	O
and	O
prescribing	O
safety	O
(STEPS)	O
oversight	O
program.	O
Thalomid	B-Drug

After	O
menopause,	O
androstenedione	B-Drug
production	O
is	O
about	O
halved,	O
due	O
primarily	O
to	O
the	O
reduction	O
of	O
steroid	O
secreted	O
by	O
ovary.	O

The	O
Medicines	O
Act	O
prevented	O
naphyrone	B-Drug
from	O
being	O
sold	O
for	O
human	O
consumption,	O
and	O
therefore	O
it	O
was	O
sometimes	O
as	O
'pond	O
cleaner'	O
or	O
another	O
substance	O
not	O
normally	O
consumed	O
by	O
humans.	O

heroin	B-Drug
Black's	O
Game	O
(2012)	O

It	O
has	O
been	O
alleged	O
that	O
a	O
non-conjugated	O
tetanus	B-Drug
vaccine	I-Drug
used	O
in	O
developing	O
countries	O
is	O
laced	O
with	O
human	O
chorionic	O
gonadotropin	O
based	O
anti-fertility	O
drug	O
and	O
distributed	O
as	O
means	O
of	O
mass	O
sterilization.	O

Illicit	O
methamphetamine	B-Drug
is	O
more	O
commonly	O
made	O
by	O
the	O
reduction	O
of	O
ephedrine	B-Drug
or	O
pseudoephedrine,	O
which	O
produces	O
active	O
d-methamphetamine	O
isomer.	O
pseudoephedrine	B-Drug

Desmethyldiazepam	B-Drug
is	O
responsible	O
for	O
most	O
of	O
the	O
therapeutic	O
effects	O
clorazepate.	O
clorazepate	B-Drug

Clorazepate	B-Drug
is	O
completely	O
metabolised	O
to	O
desmethyl-diazepam	B-Drug
in	O
the	O
gastrointestinal	O
tract	O
and	O
thus	O
pharmacological	O
properties	O
of	O
clorazepate	B-Drug
are	O
largely	O
due	O
desmethyldiazepam.	O
desmethyldiazepam	B-Drug

Reviews	O
of	O
clinical	O
stimulant	O
research	O
have	O
established	O
the	O
safety	O
and	O
effectiveness	O
long-term	O
continuous	O
amphetamine	B-Drug
use	O
for	O
treatment	O
ADHD.	O

As	O
the	O
19th	O
century	O
progressed	O
however,	O
doctor	O
Hamilton	O
Wright	O
worked	O
to	O
decrease	O
use	O
of	O
opium	B-Drug
in	O
US	O
by	O
submitting	O
Harrison	O
Act	O
congress.	O

In	O
some	O
cases,	O
switching	O
from	O
venlafaxine	B-Drug
to	O
fluoxetine,	O
a	O
long-acting	O
SSRI,	O
and	O
then	O
tapering	O
off	O
may	O
be	O
recommended	O
reduce	O
discontinuation	O
symptoms.	O
fluoxetine	B-Drug

One	O
of	O
the	O
first	O
mentions	O
this	O
drug	O
can	O
be	O
found	O
in	O
document	O
written	O
by	O
The	O
College	O
on	O
Problem	O
Drug	O
Dependence,	O
where	O
it	O
is	O
mentioned	O
as	O
N-butyramide	O
fentanyl	B-Drug
analog.	O

Delorazepam	B-Drug
is	O
available	O
in	O
tablet	O
and	O
liquid	O
drop	O
formulations.	O

In	O
people	O
with	O
shock,	O
including	O
septic,	O
cardiogenic,	O
hemorrhagic,	O
or	O
spinal	O
those	O
who	O
received	O
naloxone	B-Drug
had	O
improved	O
blood	O
flow.	O

An	O
ADHD	O
biomarker	O
review	O
also	O
indicated	O
that	O
urinary	O
phenethylamine	B-Drug
levels	O
could	O
be	O
a	O
diagnostic	O
for	O
ADHD.Thirty	O
minutes	O
of	O
moderate-	O
to	O
high-intensity	O
physical	O
exercise	O
has	O
been	O
shown	O
induce	O
an	O
increase	O
in	O
phenylacetic	O
acid,	O
the	O
primary	O
metabolite	O
phenethylamine.	O

Psilocin,	O
also	O
known	O
as	O
'4-HO-DMT';	O
another	O
active	O
constituent	O
of	O
the	O
Psilocybe	O
genus	O
mushrooms;	O
a	O
metabolite	O
psilocybin	O
and	O
psilacetin	O
Psilocybin,	O
'4-PO-DMT';	O
primary	O
its	O
effects	O
are	O
partially	O
attributed	O
to	O
psilocin,	O
which	O
it	O
is	O
prodrug	O
via	O
dephosphorylation	O
Bufotenin,	O
'5-HO-DMT'	O
dimethylserotonin;	O
skin	O
venom	O
psychoactive	O
toads,	O
psychedelic	O
activity	O
disputed;	O
5-MeO-DMT	B-Drug
Baeocystin,	O
'4-PO-NMT';	O
disputed	O
Aeruginascin,	O
'4-PO-N-TMT',	O
an	O
mushroom	O
Inocybe	O
aeruginascens	O
5-MeO-DMT,	O
bufotenin	B-Drug
demethylation	O
N,N-Dimethyltryptamine,	O
'DMT';	O
Amerindian	O
brew	O
ayahuasca;	O
endogenously	O
present	O
in	O
various	O
plants	O
animals,	O
including	O
humans,	O
possibly	O
trace	O
amine	O
neurotransmitter	O
5-Bromo-DMT,	O
was	O
found	O
marine	O
invertebrates	O
Smenospongia	O
aurea	O
echina,	O
well	O
Verongula	O
rigida	O
N-Methyl-	O
Psilocin	B-Drug
psilocin	B-Drug
Bufotenin	B-Drug
Baeocystin	B-Drug
Aeruginascin	B-Drug
N,N-Dimethyltryptamine	B-Drug
5-Bromo-DMT	B-Drug

Similarly	O
to	O
gabapentin	B-Drug
and	O
pregabalin,	O
baclofen,	O
a	O
close	O
analogue	O
of	O
phenibut	B-Drug
(baclofen	O
specifically	O
being	O
4-chlorophenibut),	O
is	O
transported	O
by	O
the	O
LAT1,	O
although	O
it	O
relatively	O
weak	O
substrate	O
for	O
transporter.	O
pregabalin	B-Drug
baclofen	B-Drug

The	O
first	O
study	O
of	O
finasteride	B-Drug
in	O
the	O
treatment	O
hirsutism	O
women	O
was	O
published	O
1994.	O

Dexamethasone	B-Drug
and	O
most	O
glucocorticoids	O
are	O
banned	O
by	O
sporting	O
bodies	O
including	O
the	O
World	O
Anti-Doping	O
Agency.	O

Desbutal	O
was	O
a	O
brand	O
name	O
drug	O
by	O
Abbott	O
containing	O
5mg	O
methamphetamine	B-Drug
hydrochloride	I-Drug
(Desoxyn)	O
and	O
30mg	O
pentobarbital	B-Drug
sodium	I-Drug
(Nembutal);	O
substituted	O
amphetamine	O
barbiturate	O
combined	O
within	O
the	O
same	O
pill.	O
Desoxyn	B-Drug
Nembutal	B-Drug

Ethylone,	O
also	O
known	O
as	O
3,4-methylenedioxy-N-ethylcathinone	O
(MDEC,	O
k-MDEA),	O
is	O
a	O
recreational	O
designer	O
drug	O
classified	O
an	O
entactogen,	O
stimulant,	O
and	O
psychedelic	O
of	O
the	O
phenethylamine,	O
amphetamine,	O
cathinone	O
chemical	O
classes.	O
Ethylone	B-Drug

Codeine,	O
clopidogrel,	O
tamoxifen,	O
and	O
warfarin	B-Drug
a	O
few	O
examples	O
of	O
medications	O
that	O
follow	O
the	O
above	O
metabolic	O
pathways.	O
Codeine	B-Drug
clopidogrel	B-Drug
tamoxifen	B-Drug

Medivation,	O
the	O
developer	O
of	O
enzalutamide,	O
conducted	O
an	O
international	O
phase	O
III	O
trial	O
that	O
began	O
in	O
September	O
2009	O
known	O
as	O
AFFIRM.	O
enzalutamide	B-Drug

heroin,	O
cocaine	B-Drug
heroin	B-Drug

DOET	B-Drug
is	O
in	O
a	O
class	O
of	O
compounds	O
commonly	O
known	O
as	O
substituted	O
amphetamines;	O
its	O
full	O
chemical	O
name	O
4-ethyl-2,5-dimethoxy-alpha-methylbenzeneethanamine,	O
or	O
1-(2,5-dimethoxy-4-ethylphenyl)propan-2-amine.	O

The	O
biosynthesis	O
begins	O
with	O
L-glutamine,	O
which	O
is	O
derived	O
from	O
L-ornithine	O
in	O
plants.	O
L-glutamine	B-Drug

Pregabalin	B-Drug
was	O
approved	O
for	O
medical	O
use	O
in	O
the	O
United	O
States	O
2004.	O

The	O
254	O
pounds	O
(115	O
kg)	O
of	O
fentanyl,	O
which	O
was	O
estimated	O
to	O
be	O
worth	O
US$3.5M,	O
concealed	O
in	O
a	O
compartment	O
under	O
false	O
floor	O
truck	O
transporting	O
cucumbers.	O
fentanyl	B-Drug

Tobacco	O
mixed	O
with	O
opium	B-Drug
was	O
called	O
madak	O
(or	O
madat)	O
and	O
became	O
popular	O
throughout	O
China	O
its	O
seafaring	O
trade	O
partners	O
(such	O
as	O
Taiwan,	O
Java,	O
the	O
Philippines)	O
in	O
17th	O
century.	O

Thus,	O
17,20-lyase	O
is	O
required	O
for	O
the	O
synthesis	O
of	O
androstenedione,	O
whether	O
immediately	O
or	O
one	O
step	O
removed.	O
androstenedione	B-Drug

There	O
is	O
no	O
good	O
evidence	O
that	O
trifluoperazine	B-Drug
more	O
effective	O
for	O
schizophrenia	O
than	O
lower-potency	O
antipsychotics	O
like	O
chlorpromazine,	O
chlorprothixene,	O
thioridazine	O
and	O
levomepromazine,	O
but	O
appears	O
to	O
cause	O
adverse	O
effects	O
these	O
drugs.	O
chlorpromazine	B-Drug
levomepromazine	B-Drug

as	O
well	O
Flupenthixol	B-Drug
binds	O
D1,	O
D2,	O
D3,	O
and	O
D5	O
is	O
also	O
used	O
an	O
antidepressant.	O

Use	O
of	O
ibuprofen	B-Drug
to	O
lower	O
the	O
risk	O
Parkinson's	O
disease	O
in	O
general	O
population	O
would	O
not	O
be	O
problem-free,	O
given	O
possibility	O
adverse	O
effects	O
on	O
urinary	O
and	O
digestive	O
systems.	O

These	O
include	O
acamprosate	B-Drug
or	O
naltrexone	B-Drug
in	O
the	O
treatment	O
of	O
alcoholism,	O
methadone	B-Drug
buprenorphine	B-Drug
maintenance	O
therapy	O
case	O
opioid	O
addiction.	O

The	O
items	O
affected	O
include	O
E-cigarettes,	O
Hookah	O
tobacco,	O
and	O
pipe	O
tobacco.	O
tobacco	B-Drug

Thalidomide	B-Drug
did	O
not	O
damage	O
the	O
fetus	O
if	O
taken	O
after	O
42	O
days	O
gestation.	O

Several	O
currently	O
marketed	O
amphetamine	B-Drug
formulations	O
contain	O
both	O
enantiomers,	O
including	O
those	O
under	O
the	O
brand	O
names	O
Adderall,	O
Adderall	B-Drug
XR,	O
Mydayis,	O
Adzenys	O
ER,	O
XR-ODT,	O
Dyanavel	O
Evekeo,	O
and	O
Evekeo	B-Drug
ODT.	O

Vaporizer,	O
which	O
heats	O
any	O
form	O
of	O
cannabis	O
to	O
165190	O
C	O
(329374	O
F),	O
causing	O
the	O
active	O
ingredients	O
evaporate	O
into	O
vapor	O
without	O
burning	O
plant	O
material	O
(the	O
boiling	O
point	O
THC	B-Drug
is	O
157	O
(315	O
F)	O
at	O
atmospheric	O
pressure).	O

These	O
successes,	O
however,	O
merely	O
pushed	O
coca	B-Drug
cultivation	O
increasingly	O
to	O
FARC-dominated	O
areas	O
while	O
weakening	O
many	O
of	O
the	O
FARC's	O
political-military	O
opponents.	O

As	O
a	O
hormone	O
precursor,	O
there	O
have	O
been	O
reports	O
of	O
side	O
effects	O
possibly	O
caused	O
by	O
the	O
metabolites	O
prasterone.	O
prasterone	B-Drug

In	O
response	O
to	O
the	O
ever-growing	O
number	O
of	O
Chinese	O
people	O
becoming	O
addicted	O
opium,	O
Qing	O
Daoguang	O
Emperor	O
took	O
strong	O
action	O
halt	O
smuggling	O
including	O
seizure	O
cargo.	O
opium	B-Drug

Alcohol	O
may	O
increase	O
the	O
drowsiness	O
caused	O
by	O
diphenhydramine.	O
diphenhydramine	B-Drug

Enzalutamide	B-Drug
is	O
first	O
introduced	O
for	O
medical	O
use,	O
to	O
treat	O
prostate	O
cancer	O
2018:	O

In	O
June	O
2004	O
5-MeO-DALT	B-Drug
became	O
available	O
from	O
internet	O
research	O
chemical	O
vendors	O
after	O
being	O
synthesized	O
by	O
commercial	O
laboratories	O
in	O
China.	O

Psilocybin	O
and	O
psilocin	B-Drug
create	O
short-term	O
increases	O
in	O
tolerance	O
of	O
users,	O
thus	O
making	O
it	O
difficult	O
to	O
misuse	O
them	O
because	O
the	O
more	O
often	O
they	O
are	O
taken	O
within	O
a	O
short	O
period	O
time,	O
weaker	O
resultant	O
effects	O
are.	O

Hashish	B-Drug
has	O
been	O
consumed	O
for	O
many	O
centuries,	O
though	O
there	O
is	O
no	O
clear	O
evidence	O
as	O
to	O
its	O
first	O
appearance.	O

Diphenhydramine	B-Drug
is	O
used	O
to	O
treat	O
akathisia	O
and	O
Parkinson's	O
diseaselike	O
extrapyramidal	O
symptoms	O
caused	O
by	O
antipsychotics.	O

In	O
February	O
2018,	O
the	O
U.S.	O
Drug	O
Enforcement	O
Administration	O
indicated	O
that	O
illicit	O
fentanyl	B-Drug
analogs	O
have	O
no	O
medically	O
valid	O
use,	O
and	O
thus	O
applied	O
a	O
"Schedule	O
I"	O
classification	O
to	O
them.	O

Ropivacaine	B-Drug
hydrochloride	O
is	O
commonly	O
marketed	O
by	O
AstraZeneca	O
under	O
the	O
brand	O
name	O
Naropin.	O

A	O
ring-opening	O
reaction	O
with	O
hydrogen	O
fluoride	O
in	O
tetrahydrofuran	O
gives	O
dexamethasone.	O
dexamethasone	B-Drug

Abuse	O
of	O
opium	B-Drug
in	O
the	O
United	O
States	O
began	O
late	O
19th	O
century	O
and	O
was	O
largely	O
associated	O
with	O
Chinese	O
immigrants.	O

As	O
so-called	O
"androgenic"	O
tissues	O
such	O
as	O
skin/hair	O
follicles	O
and	O
male	O
reproductive	O
are	O
very	O
high	O
in	O
5-reductase	O
expression,	O
while	O
skeletal	O
muscle	O
is	O
virtually	O
devoid	O
of	O
5-reductase,	O
this	O
may	O
primarily	O
explain	O
the	O
myotrophicandrogenic	O
ratio	O
dissociation	O
seen	O
with	O
nandrolone,	O
well	O
various	O
other	O
AAS.Aside	O
from	O
aromatase	O
inactivate	O
testosterone	O
signaling	O
adipose	O
tissue,	O
so	O
AAS	O
that	O
lack	O
affinity,	O
addition	O
to	O
being	O
free	O
potential	O
side	O
effect	O
gynecomastia,	O
might	O
be	O
expected	O
have	O
a	O
higher	O
comparison.	O
nandrolone	B-Drug

One	O
US	O
Department	O
of	O
Justice	O
publication	O
lists	O
"China	O
White"	O
as	O
a	O
synonym	O
for	O
number	O
fentanyl	B-Drug
analogues,	O
including	O
3-methylfentanyl	B-Drug
and	O
-methylfentanyl,	O
which	O
today	O
are	O
classified	O
Schedule	O
I	O
drugs	O
in	O
the	O
United	O
States.	O

Androstenedione	B-Drug

In	O
2010,	O
the	O
BBC	O
reported	O
that	O
use	O
of	O
MDMA	B-Drug
had	O
decreased	O
in	O
UK	O
previous	O
years.	O

Via	O
its	O
weak	O
progestogenic	O
and	O
androgenic	O
activity,	O
through	O
activation	O
of	O
the	O
PR	O
AR	O
in	O
pituitary	O
gland,	O
danazol	B-Drug
produces	O
antigonadotropic	O
effects.	O

Loperamide	B-Drug
is	O
often	O
compared	O
to	O
diphenoxylate.	O
diphenoxylate	B-Drug

Following	O
the	O
European	O
rule	O
from	O
2014,	O
25I-NBOMe	B-Drug
was	O
put	O
in	O
class	O
4	O
of	O
prohibited	O
substances.	O

Most	O
of	O
the	O
research	O
on	O
gene	O
regulation	O
and	O
addiction	O
is	O
based	O
upon	O
animal	O
studies	O
with	O
intravenous	O
amphetamine	B-Drug
administration	O
at	O
very	O
high	O
doses.	O

Vicks	O
Vatronol	O
nose	O
drops	O
(now	O
discontinued)	O
contained	O
ephedrine	B-Drug
sulfate	O
as	O
the	O
active	O
ingredient	O
for	O
rapid	O
nasal	O
decongestion.	O

Lisdexamfetamine	B-Drug
was	O
developed	O
with	O
the	O
goal	O
of	O
providing	O
a	O
long	O
duration	O
effect	O
that	O
is	O
consistent	O
throughout	O
day,	O
reduced	O
potential	O
for	O
abuse.	O

Compared	O
with	O
amphetamine,	O
MDMA	B-Drug
and	O
its	O
metabolite	O
MDA	O
are	O
less	O
reinforcing.	O
amphetamine	B-Drug

For	O
gastritis,	O
drinking	O
a	O
viscous	O
lidocaine	B-Drug
formulation	O
may	O
help	O
with	O
the	O
pain.	O

Enzalutamide	B-Drug
was	O
the	O
first	O
new	O
AR	O
antagonist	O
to	O
be	O
approved	O
for	O
treatment	O
of	O
prostate	O
cancer	O
in	O
over	O
15	O
years,	O
following	O
introduction	O
first-generation	O
NSAA	O
bicalutamide	B-Drug
1995.	O

When	O
enough	O
fentanyl	B-Drug
has	O
been	O
absorbed,	O
the	O
(sedated)	O
person	O
generally	O
lets	O
lollipop	O
fall	O
from	O
mouth,	O
indicating	O
sufficient	O
analgesia	O
and	O
somewhat	O
reducing	O
likelihood	O
of	O
overdose	O
associated	O
risks.	O

Ingesting	O
coca	B-Drug
leaves	O
generally	O
is	O
an	O
inefficient	O
means	O
of	O
administering	O
cocaine.	O
cocaine	B-Drug

Indication	O
for	O
exemestane	B-Drug
is	O
advanced	O
breast	O
cancer	O
in	O
postmenopausal	O
women,	O
where	O
the	O
has	O
progressed	O
following	O
tamoxifen	B-Drug
therapy.	O

As	O
of	O
2015,	O
the	O
Sinaloa	O
Cartel	O
is	O
most	O
active	O
drug	O
cartel	O
involved	O
in	O
smuggling	O
illicit	O
drugs	O
such	O
as	O
heroin	B-Drug
into	O
United	O
States	O
and	O
trafficking	O
them	O
throughout	O
States.	O

The	O
risk	O
of	O
pharmacological	O
dependence	O
on	O
diazepam	B-Drug
is	O
significant,	O
and	O
patients	O
experience	O
symptoms	O
benzodiazepine	O
withdrawal	O
syndrome	O
if	O
it	O
taken	O
for	O
six	O
weeks	O
or	O
longer.	O

A	O
common	O
problem	O
in	O
treating	O
methadone	B-Drug
overdoses	O
is	O
that,	O
given	O
the	O
short	O
action	O
of	O
naloxone	B-Drug
(versus	O
extremely	O
longer-acting	O
methadone),	O
a	O
dosage	O
to	O
methadone-overdosed	O
person	O
will	O
initially	O
work	O
bring	O
out	O
overdose,	O
but	O
once	O
wears	O
off,	O
if	O
no	O
further	O
administered,	O
can	O
go	O
right	O
back	O
into	O
overdose	O
(based	O
upon	O
time	O
and	O
ingested).	O

TFMPP	B-Drug
is	O
scheduled	O
in	O
Texas	O
under	O
Penalty	O
Group	O
2,	O
as	O
a	O
hallucinogenic	O
substance.	O

In	O
addition,	O
with	O
kidney	O
or	O
liver	O
impairment,	O
ranitidine	B-Drug
must	O
be	O
used	O
caution.	O

The	O
short	O
term	O
effects	O
of	O
cannabis	O
can	O
be	O
altered	O
if	O
it	O
has	O
been	O
laced	O
with	O
opioid	O
drugs	O
such	O
as	O
heroin	B-Drug
or	O
fentanyl.	O
fentanyl	B-Drug

Zopiclone	B-Drug
is	O
sometimes	O
used	O
as	O
a	O
method	O
of	O
suicide.	O

Both	O
Pickard	O
and	O
Apperson	O
were	O
eventually	O
found	O
guilty	O
at	O
trial	O
of	O
conspiring	O
to	O
manufacture,	O
distribute,	O
dispense	O
ten	O
grams	O
or	O
more	O
a	O
mixture	O
substance	O
containing	O
detectable	O
amount	O
lysergic	O
acid	B-Drug
diethylamide	O
(LSD);	O
received	O
two	O
life	O
sentences,	O
while	O
30	O
years'	O
imprisonment.	O
LSD	B-Drug

For	O
example,	O
phenylpropanolamine	B-Drug
was	O
removed	O
from	O
sale	O
in	O
the	O
United	O
States	O
over	O
concern	O
regarding	O
strokes	O
young	O
women.	O

Clomifene	B-Drug
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
malignant	O
melanomas	O
and	O
thyroid	O
cancer.	O

The	O
fructose	O
is	O
then	O
hydrogenated	O
over	O
a	O
nickel	O
catalyst	O
into	O
mixture	O
of	O
isomers	O
sorbitol	O
and	O
mannitol.	O
mannitol	B-Drug

Unlike	O
other	O
progestogens,	O
except	O
in	O
the	O
case	O
of	O
its	O
strong	O
effects	O
uterus,	O
dienogest	B-Drug
has	O
been	O
described	O
as	O
lacking	O
antiestrogenic	O
effects,	O
and	O
does	O
not	O
antagonize	O
beneficial	O
estradiol,	O
for	O
instance	O
metabolic	O
vascular	O
systems.	O

A	O
2014	O
review	O
of	O
the	O
safety	O
and	O
efficacy	O
MDMA	B-Drug
as	O
a	O
treatment	O
for	O
various	O
disorders,	O
particularly	O
PTSD,	O
indicated	O
that	O
has	O
therapeutic	O
in	O
some	O
patients;	O
however,	O
it	O
emphasized	O
issues	O
regarding	O
controlability	O
MDMA-induced	O
experiences	O
neurochemical	O
recovery	O
must	O
be	O
addressed.	O

Neonicotinoids,	O
which	O
are	O
derived	O
from	O
and	O
structurally	O
similar	O
to	O
nicotine,	O
widely	O
used	O
as	O
agricultural	O
veterinary	O
pesticides	O
of	O
2016.In	O
nicotine-producing	O
plants,	O
nicotine	B-Drug
functions	O
an	O
antiherbivory	O
chemical;	O
consequently,	O
has	O
been	O
insecticide,	O
neonicotinoids,	O
such	O
imidacloprid,	O
used.	O

On	O
June	O
30,	O
2009,	O
an	O
FDA	O
advisory	O
panel	O
recommended	O
that	O
Vicodin	B-Drug
and	O
another	O
painkiller,	O
Percocet,	O
be	O
removed	O
from	O
the	O
market	O
because	O
they	O
have	O
allegedly	O
caused	O
over	O
400	O
deaths	O
a	O
year.	O
Percocet	B-Drug

As	O
a	O
result	O
of	O
this	O
regulation,	O
130	O
drugs	O
have	O
been	O
withdrawn	O
from	O
the	O
market,	O
but	O
containing	O
multicomponent	O
dextromethorphan	B-Drug
can	O
be	O
sold	O
over	O
counter.	O

With	O
the	O
exception	O
of	O
naproxen,	O
nonselective	O
NSAIDs	O
increase	O
risk	O
having	O
a	O
heart	O
attack.	O
naproxen	B-Drug

The	O
nonsteroidal	O
antiandrogen	O
bicalutamide	B-Drug
is	O
an	O
alternative	O
option	O
to	O
flutamide	O
with	O
improved	O
safety.	O

Use	O
of	O
Pervitin	B-Drug
was	O
restricted	O
by	O
the	O
Wehrmacht	O
and	O
Nazi	O
Germany	O
as	O
a	O
whole	O
under	O
Opium	O
Law,	O
which	O
required	O
drug	O
be	O
obtained	O
through	O
physician's	O
prescription.	O

MBE	O
of	O
the	O
United	O
Kingdom,	O
born	O
with	O
phocomelia	O
both	O
arms	O
and	O
legs,	O
is	O
only	O
thalidomide	B-Drug
survivor	O
to	O
carry	O
Olympic	O
Torch.	O

Specifically,	O
the	O
FDA	O
found	O
a	O
lack	O
of	O
efficacy	O
for	O
stanozolol	B-Drug
as	O
"an	O
adjunct	O
to	O
promote	O
body	O
tissue-building	O
processes	O
and	O
reverse	O
tissue-depleting	O
in	O
such	O
conditions	O
malignant	O
diseases	O
chronic	O
nonmalignant	O
diseases;	O
debility	O
elderly	O
patients,	O
other	O
emaciating	O
gastrointestinal	O
disorders	O
resulting	O
alterations	O
normal	O
metabolism;	O
use	O
during	O
pre-operative	O
postoperative	O
periods	O
undernourished	O
patients	O
poor-risk	O
surgical	O
cases	O
due	O
traumatism;	O
infants,	O
children,	O
adolescents	O
who	O
do	O
not	O
reach	O
an	O
adequate	O
weight;	O
supportive	O
treatment	O
help	O
restore	O
or	O
maintain	O
favorable	O
metabolic	O
balance,	O
postsurgical,	O
postinfectious,	O
convalescent	O
patients;	O
value	O
pre-	O
operative	O
have	O
lost	O
tissue	O
from	O
disease	O
process	O
associated	O
symptoms,	O
anorexia;	O
retention	O
utilization	O
calcium;	O
applications;	O
disease,	O
malnourished	O
adults,	O
illness;	O
pediatric	O
nutritional	O
problems;	O
prostatic	O
carcinoma;	O
endocrine	O
deficiencies."	O

The	O
UN	O
states	O
that	O
the	O
leaves	O
can	O
contain	O
ten	O
times	O
less	O
THC	B-Drug
than	O
buds,	O
and	O
stalks	O
one	O
hundred	O
THC.After	O
revisions	O
to	O
cannabis	O
scheduling	O
in	O
UK,	O
government	O
moved	O
back	O
from	O
a	O
class	O
C	O
B	O
drug.	O

In	O
2010,	O
the	O
World	O
Health	O
Organization	O
(WHO)	O
stated	O
that	O
it	O
did	O
not	O
recommend	O
thalidomide	B-Drug
for	O
leprosy	O
due	O
to	O
difficulty	O
of	O
adequately	O
controlling	O
its	O
use,	O
and	O
availability	O
clofazimine.	O
clofazimine	B-Drug

It	O
may	O
also	O
be	O
mixed	O
with	O
cannabis	O
or	O
tobacco.	O
tobacco	B-Drug

When	O
the	O
level	O
of	O
harm	O
associated	O
with	O
other	O
drugs	O
includes	O
that	O
arises	O
solely	O
as	O
a	O
result	O
illegality	O
rather	O
than	O
merely	O
danger	O
which	O
is	O
actually	O
using	O
drugs,	O
only	O
heroin,	O
cocaine,	O
barbiturates	O
and	O
street	O
methadone	B-Drug
were	O
shown	O
to	O
be	O
more	O
harmful	O
legal	O
drug	O
alcohol.	O
heroin	B-Drug
cocaine	B-Drug

5-EAPB	B-Drug
6-EAPB	B-Drug

In	O
2018,	O
Epidiolex	B-Drug
(cannabidiol	O
as	O
the	O
therapeutic	O
ingredient)	O
oral	O
solution	O
was	O
approved	O
by	O
FDA	O
for	O
two	O
types	O
of	O
epilepsy.	O
cannabidiol	B-Drug

Since	O
2002,	O
a	O
topical	O
emulsion	O
of	O
ciclosporin	B-Drug
for	O
treating	O
inflammation	O
caused	O
by	O
keratoconjunctivitis	O
sicca	O
(dry	O
eye	O
syndrome)	O
has	O
been	O
marketed	O
under	O
the	O
trade	O
name	O
Restasis	B-Drug
(0.05%).	O

In	O
a	O
variety	O
of	O
animal	O
models,	O
PEA	B-Drug
seems	O
to	O
have	O
some	O
promise;	O
researchers	O
been	O
able	O
demonstrate	O
relevant	O
clinical	O
efficacy	O
in	O
disorders,	O
from	O
multiple	O
sclerosis	O
neuropathic	O
pain.	O

In	O
the	O
UK,	O
since	O
2016,	O
sale,	O
import,	O
and	O
export	O
of	O
kratom	B-Drug
are	O
prohibited	O
under	O
Psychoactive	O
Substances	O
Act.	O

Similarly,	O
the	O
United	O
States	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
describes	O
tobacco	B-Drug
use	O
as	O
"the	O
single	O
most	O
important	O
preventable	O
risk	O
to	O
human	O
health	O
in	O
developed	O
countries	O
an	O
cause	O
of	O
premature	O
death	O
worldwide."	O

Like	O
methamphetamine,	O
desomorphine	B-Drug
made	O
this	O
way	O
is	O
often	O
contaminated	O
with	O
various	O
agents.	O
methamphetamine	B-Drug

On	O
October	O
15,	O
2011,	O
Anderson	O
County	O
coroner	O
Greg	O
Shore	O
attributed	O
the	O
death	O
of	O
a	O
South	O
Carolina	O
college	O
basketball	O
player	O
to	O
"drug	O
toxicity	O
and	O
organ	O
failure"	O
caused	O
by	O
JWH-018.	O
JWH-018	B-Drug

The	O
rave-influenced	O
scene	O
is	O
widely	O
seen	O
as	O
heavily	O
influenced	O
by	O
drugs,	O
especially	O
ecstasy	B-Drug
(MDMA).	O
MDMA	B-Drug

2C-B	B-Drug
is	O
considered	O
both	O
a	O
psychedelic	O
and	O
mild	O
empathogen/entactogen.	O

Various	O
surveys	O
conducted	O
between	O
2015	O
and	O
2019	O
found	O
that	O
many	O
users	O
of	O
cannabis	O
substitute	O
it	O
for	O
prescription	O
drugs	O
(including	O
opioids),	O
alcohol,	O
tobacco;	O
most	O
those	O
who	O
used	O
in	O
place	O
alcohol	O
or	O
tobacco	B-Drug
either	O
reduced	O
stopped	O
their	O
intake	O
the	O
latter	O
substances.	O

Some	O
manufacturers	O
add	O
the	O
narcotic	O
antagonist	O
naloxone	B-Drug
or	O
anticholinergics	O
atropine	O
and	O
homatropine	O
(in	O
lower	O
than	O
therapeutic	O
doses)	O
to	O
their	O
pills	O
prevent	O
injection.	O

Androstenedione	B-Drug
is	O
banned	O
by	O
MLB,	O
the	O
NFL,	O
USOC,	O
NCAA,	O
and	O
NBA.On	O
March	O
12,	O
2004,	O
Anabolic	O
Steroid	O
Control	O
Act	O
of	O
2004	O
was	O
introduced	O
into	O
United	O
States	O
Senate.	O

Flutamide	O
has	O
far	O
lower	O
affinity	O
for	O
the	O
AR	O
than	O
do	O
steroidal	O
antiandrogens	O
like	O
spironolactone	B-Drug
and	O
cyproterone	O
acetate,	O
it	O
is	O
a	O
relatively	O
weak	O
antiandrogen	O
in	O
terms	O
of	O
potency	O
by	O
weight,	O
but	O
large	O
dosages	O
at	O
which	O
flutamide	O
used	O
appear	O
to	O
compensate	O
this.	O

Examples	O
of	O
OTC	O
substances	O
approved	O
in	O
the	O
United	O
States	O
are	O
sunscreens,	O
anti-microbial	O
and	O
anti-fungal	O
products,	O
external	O
internal	O
analgesics	O
such	O
as	O
lidocaine	B-Drug
aspirin,	O
psoriasis	O
eczema	O
topical	O
treatments	O
aspirin	B-Drug

Conversely,	O
bicalutamide	B-Drug
monotherapy	O
is	O
associated	O
with	O
much	O
higher	O
rates	O
of	O
breast	O
tenderness,	O
gynecomastia,	O
and	O
feminization	O
in	O
men	O
than	O
GnRH	O
analogues	O
CPA.	O

Venlafaxine	B-Drug
and	O
desvenlafaxine	B-Drug
contain	O
a	O
cycloalkanol	O
ethylamine	O
scaffold.	O

St	O
John's	O
wort	O
decreases	O
the	O
blood	O
levels	O
of	O
midazolam.	O
midazolam	B-Drug

Toxicology	O
reports	O
showed	O
the	O
teenagers	O
had	O
not	O
taken	O
any	O
mephedrone	B-Drug
and	O
died	O
as	O
a	O
result	O
of	O
consuming	O
alcohol	O
heroin	B-Drug
substitute	O
methadone.	O
methadone	B-Drug

The	O
majority	O
of	O
reports	O
indicate	O
people	O
with	O
PTSD	O
have	O
elevated	O
levels	O
corticotropin-releasing	O
hormone,	O
lower	O
basal	O
cortisol	O
levels,	O
and	O
enhanced	O
negative	O
feedback	O
suppression	O
the	O
HPA	O
axis	O
by	O
dexamethasone.	O
dexamethasone	B-Drug

Finasteride	B-Drug
results	O
in	O
a	O
decrease	O
of	O
circulating	O
DHT	O
levels	O
by	O
about	O
65	O
to	O
70%	O
with	O
an	O
oral	O
dosage	O
5	O
mg/day	O
and	O
the	O
prostate	O
gland	O
up	O
80	O
90%	O
1	O
or	O
mg/day.	O

This	O
gives	O
the	O
user	O
impression	O
of	O
high-quality	O
cocaine,	O
when	O
in	O
actuality	O
is	O
receiving	O
a	O
diluted	O
product.	O
cocaine	B-Drug

Hemp	O
CBD	B-Drug
products	O
may	O
not	O
be	O
sold	O
into	O
general	O
commerce,	O
but	O
rather	O
are	O
allowed	O
only	O
for	O
research.	O

Examples	O
include	O
amobarbital,	O
pentobarbital,	O
phenobarbital,	O
secobarbital,	O
and	O
sodium	B-Drug
thiopental.	O
amobarbital	B-Drug
pentobarbital	B-Drug
phenobarbital	B-Drug
secobarbital	B-Drug
thiopental	I-Drug

XLR-11	B-Drug
is	O
banned	O
in	O
the	O
Czech	O
Republic.	O

Properidine	B-Drug
is	O
an	O
opioid,	O
analgesic,	O
and	O
the	O
isopropyl	O
analog	O
of	O
pethidine.	O
pethidine	B-Drug

CBN	B-Drug
is	O
not	O
listed	O
in	O
the	O
schedules	O
set	O
out	O
by	O
United	O
Nations'	O
Single	O
Convention	O
on	O
Narcotic	O
Drugs	O
from	O
1961	O
nor	O
their	O
Psychotropic	O
Substances	O
1971,	O
so	O
signatory	O
countries	O
to	O
these	O
international	O
drug	O
control	O
treaties	O
are	O
required	O
CBN.	O

Since	O
2003,	O
TFMPP	B-Drug
and	O
BZP	B-Drug
became	O
illegal	O
in	O
Japan.	O

Reports	O
of	O
deaths	O
and	O
significant	O
injuries	O
have	O
been	O
attributed	O
to	O
the	O
use	O
25I-NBOMe,	O
prompting	O
some	O
governments	O
control	O
its	O
possession,	O
production,	O
sale.	O
25I-NBOMe	B-Drug

Withdrawal	O
from	O
diazepam	B-Drug
or	O
other	O
benzodiazepines	O
often	O
leads	O
to	O
withdrawal	O
symptoms	O
similar	O
those	O
seen	O
during	O
barbiturate	O
alcohol	O
withdrawal.	O

Tranylcypromine	B-Drug
is	O
used	O
to	O
treat	O
major	O
depressive	O
disorder,	O
including	O
atypical	O
depression,	O
especially	O
when	O
there	O
an	O
anxiety	O
component,	O
typically	O
as	O
a	O
second-line	O
treatment.	O

Specifically,	O
acidic	O
substances	O
will	O
reduce	O
the	O
absorption	O
of	O
methamphetamine	B-Drug
and	O
increase	O
urinary	O
excretion,	O
while	O
alkaline	O
do	O
opposite.	O

Unlike	O
dextromoramide,	O
which	O
is	O
a	O
potent	O
analgesic	O
with	O
high	O
abuse	O
potential,	O
levomoramide	B-Drug
virtually	O
without	O
activity.	O
dextromoramide	B-Drug

An	O
approach	O
to	O
the	O
trans-decalin	O
ring	O
system	O
of	O
salvinorin	B-Drug
A	I-Drug
used	O
an	O
intramolecular	O
Diels-Alder	O
reaction/Tsuji	O
allylation	O
strategy,	O
and	O
a	O
total	O
synthesis	O
was	O
achieved	O
using	O
/	O
Tsuji	O
approach,	O
combined	O
with	O
asymmetric	O
late-stage	O
addition	O
furan	O
moiety.	O

There	O
is	O
some	O
evidence	O
that	O
domperidone	B-Drug
has	O
antiemetic	O
activity.	O

Fentanyl,	O
also	O
spelled	O
fentanil,	O
is	O
an	O
opioid	O
used	O
as	O
a	O
pain	O
medication	O
and	O
together	O
with	O
other	O
medications	O
for	O
anesthesia.	O
Fentanyl	B-Drug

In	O
females,	O
synthesis	O
of	O
estrogens	O
starts	O
in	O
theca	O
interna	O
cells	O
the	O
ovary,	O
by	O
androstenedione	B-Drug
from	O
cholesterol.	O

As	O
an	O
example,	O
saquinavir	B-Drug
concentrations	O
can	O
decrease	O
by	O
half	O
when	O
given	O
with	O
loperamide.	O
loperamide	B-Drug

Afghanistan's	O
neighbors	O
are	O
either	O
accomplices	O
or	O
victims	O
in	O
the	O
opium	B-Drug
trade,	O
so	O
they	O
need	O
to	O
be	O
part	O
of	O
solution.	O

When	O
taken	O
orally,	O
heroin	B-Drug
undergoes	O
extensive	O
first-pass	O
metabolism	O
via	O
deacetylation,	O
making	O
it	O
a	O
prodrug	O
for	O
the	O
systemic	O
delivery	O
of	O
morphine.	O
morphine	B-Drug

Clomifene	B-Drug
was	O
studied	O
for	O
treatment	O
and	O
prevention	O
of	O
breast	O
cancer,	O
but	O
issues	O
with	O
toxicity	O
led	O
to	O
abandonment	O
this	O
indication,	O
as	O
did	O
the	O
discovery	O
tamoxifen.	O
tamoxifen	B-Drug

A	O
reduced	O
quality	O
of	O
life	O
is	O
associated	O
with	O
heavy	O
cannabis	O
use,	O
although	O
the	O
relationship	O
inconsistent	O
and	O
weaker	O
than	O
for	O
tobacco	B-Drug
other	O
substances.	O

Certainly,	O
by	O
c.	O
1870	O
or	O
earlier,	O
it	O
was	O
manifest	O
that	O
this	O
not	O
the	O
case	O
and	O
title	O
of	O
earliest	O
morphine	B-Drug
addict	O
as	O
term	O
is	O
currently	O
understood	O
often	O
given	O
to	O
Pravaz'	O
wife,	O
although	O
habituation	O
through	O
orally	O
ingesting	O
drug	O
known	O
before	O
time,	O
including	O
Friedrich	O
Sertrner	O
his	O
associates,	O
followers,	O
dog.	O

From	O
1880	O
to	O
the	O
beginning	O
of	O
Communist	O
era,	O
British	O
attempted	O
discourage	O
use	O
opium	B-Drug
in	O
China,	O
but	O
this	O
effectively	O
promoted	O
morphine,	O
heroin,	O
and	O
cocaine,	O
further	O
exacerbating	O
problem	O
addiction.	O
morphine	B-Drug
heroin	B-Drug
cocaine	B-Drug

Cocaine	B-Drug
traffickers	O
from	O
Colombia	O
and	O
Mexico	O
have	O
established	O
a	O
labyrinth	O
of	O
smuggling	O
routes	O
throughout	O
the	O
Caribbean,	O
Bahama	O
Island	O
chain,	O
South	O
Florida.	O

Despite	O
this	O
fact,	O
Nandrolone	O
decanoate	O
is	O
one	O
of	O
the	O
most	O
popular	O
injectable	O
AAS	O
worldwide,	O
and	O
nandrolone	B-Drug
esters	O
have	O
been	O
said	O
to	O
be	O
used	O
by	O
bodybuilders	O
in	O
sports.	O

Thalidomide	B-Drug
should	O
not	O
be	O
used	O
by	O
women	O
who	O
are	O
breastfeeding	O
or	O
pregnant,	O
trying	O
able	O
to	O
conceive	O
a	O
child,	O
cannot	O
will	O
follow	O
the	O
risk	O
management	O
program	O
prevent	O
pregnancies.	O

This	O
rise	O
in	O
androstenedione	B-Drug
and	O
DHEA	O
is	O
hypothesized	O
to	O
play	O
a	O
crucial	O
role	O
for	O
learning	O
social,	O
cultural	O
ecological	O
skills,	O
such	O
as	O
the	O
development	O
understanding	O
of	O
sexual	O
attraction.	O

Alvimopan	B-Drug
Methylnaltrexone	B-Drug
Naloxegol	B-Drug
6-Naltrexol	O

Nalmefene	B-Drug
in	O
pill	O
form,	O
which	O
is	O
used	O
to	O
treat	O
alcohol	O
dependence	O
and	O
other	O
addictive	O
behaviors,	O
has	O
never	O
been	O
sold	O
the	O
United	O
States.	O

Both	O
are	O
synthesized	O
from	O
opium	B-Drug
for	O
medicinal	O
use.	O

In	O
one	O
of	O
the	O
only	O
double-blind,	O
randomized	O
studies	O
to	O
date,	O
those	O
given	O
microdoses	O
LSD	B-Drug
did	O
not	O
perform	O
better	O
than	O
placebo	O
on	O
cognitive	O
tasks.	O

In	O
February	O
2020,	O
the	O
UK	O
FSA	O
advised	O
vulnerable	O
people,	O
such	O
as	O
pregnant	O
women,	O
breastfeeding	O
mothers,	O
and	O
those	O
already	O
taking	O
medication	O
for	O
other	O
medical	O
concerns	O
not	O
to	O
take	O
CBD.	O
CBD	B-Drug

Following	O
oral	O
administration,	O
amphetamine	B-Drug
appears	O
in	O
urine	O
within	O
3	O
hours.	O

Nandrolone	B-Drug
is	O
the	O
generic	O
name	O
of	O
drug	O
and	O
its	O
INN,	O
BAN,	O
DCF,	O
DCIT.	O

(minor)	O
Hydroxyzine	B-Drug
(Atarax)	O
(minor	O
effect)	O
Atarax	B-Drug

An	O
analysis	O
of	O
samples	O
acquired	O
four	O
weeks	O
after	O
the	O
German	O
prohibition	O
JWH-018	B-Drug
took	O
place	O
found	O
that	O
manufacturers	O
had	O
shortened	O
alkyl	O
chain	O
by	O
one	O
carbon	O
to	O
circumvent	O
ban.	O

Common	O
side	O
effects	O
of	O
lisdexamfetamine	B-Drug
include	O
loss	O
appetite,	O
anxiety,	O
diarrhea,	O
trouble	O
sleeping,	O
irritability,	O
and	O
nausea.	O

A	O
THC	B-Drug
breathalyzer	O
could	O
revolutionize	O
roadside	O
sobriety	O
testing	O
for	O
drivers	O
suspected	O
of	O
impairment.	O

Cimetidine	B-Drug
undergoes	O
relatively	O
little	O
metabolism,	O
with	O
56	O
to	O
85%	O
excreted	O
unchanged.	O

Hydrocodone	B-Drug
can	O
undergo	O
O-demethylation	O
via	O
CYP2D6	O

Chad	O
"J-Bo"	O
Brown,	O
supplied	O
him	O
with	O
cocaine	B-Drug
on	O
behalf	O
of	O
Demetrius.	O

Intravenous	O
diazepam	B-Drug
or	O
lorazepam	B-Drug
are	O
first-line	O
treatments	O
for	O
convulsive	O
status	O
epilepticus.	O

Although	O
Flow	O
was	O
involved	O
in	O
waterjet	O
cutting,	O
mainly	O
for	O
mining	O
and	O
limited	O
factory	O
applications,	O
it	O
wasn't	O
until	O
Hashish	B-Drug
invented	O
a	O
new	O
technique	O
to	O
add	O
abrasives	O
the	O
that	O
strongest	O
cutting	O
tool	O
world	O
realized.	O

But	O
at	O
doses	O
of	O
4-10	O
milligrams	O
users	O
find	O
5-MeO-MiPT	B-Drug
to	O
be	O
a	O
very	O
euphoric	O
and	O
tactile	O
chemical.	O

N-methylation	O
of	O
milnacipran	B-Drug
in	O
substituent	O
group	O
R4	O
and	O
R5	O
reduces	O
the	O
norepinephrine	O
serotonin	O
activity.	O

Tetrahydrocannabinol	B-Drug
(THC)	O
is	O
the	O
main	O
psychoactive	O
component	O
of	O
cannabis,	O
which	O
one	O
483	O
known	O
compounds	O
in	O
plant,	O
including	O
at	O
least	O
65	O
other	O
cannabinoids,	O
cannabidiol	B-Drug
(CBD).	O
THC	B-Drug
CBD	B-Drug

are	O
only	O
around	O
1/10	O
as	O
potent	O
LSD,	O
although	O
some	O
N-monoalkyl	O
lysergamides	O
such	O
the	O
sec-butyl	O
and	O
t-butyl	O
derivatives	O
were	O
also	O
found	O
to	O
show	O
an	O
activity	O
profile	O
potency	O
comparable	O
mono-isopropyl	O
derivative	O
is	O
slightly	O
weaker	O
than	O
MIPLA.	O
LSD	B-Drug

A	O
study	O
found	O
that	O
a	O
combination	O
of	O
60	O
g/day	O
EE	O
and	O
0.25	O
mg/day	O
levonorgestrel	B-Drug
in	O
women	O
men	O
resulted	O
peak	O
levels	O
495	O
pg/mL	O
251	O
pg/mL,	O
area-under-the-curve	O
6.216	O
pg/mL/hour	O
2.850	O
pg/mL/hour,	O
elimination	O
half-lives	O
16.5	O
hours	O
10.2	O
hours,	O
respectively.	O

It	O
is	O
used	O
in	O
veterinary	O
medicine	O
the	O
combination	O
product	O
Telazol	O
(tiletamine/zolazepam,	O
tiletamine	B-Drug
zolazepam	B-Drug

Before	O
the	O
development	O
of	O
duloxetine,	O
exploration	O
aryloxypropanamine	O
SAR	O
resulted	O
in	O
identification	O
fluoxetine	B-Drug
and	O
atomoxetine.	O
duloxetine	B-Drug
atomoxetine	B-Drug

A	O
cannabis	O
concentrate	O
(also	O
called	O
marijuana	O
concentrate,	O
extract,	O
or	O
extract)	O
is	O
a	O
highly	O
potent	O
tetrahydrocannabinol	B-Drug
(THC)	O
and/or	O
cannabidiol	B-Drug
(CBD)	O
concentrated	O
mass.	O
THC	B-Drug
CBD	B-Drug

Ibuprofen	B-Drug
is	O
commonly	O
available	O
in	O
the	O
United	O
States	O
up	O
to	O
FDA's	O
1984	O
dose	O
limit	O
OTC,	O
rarely	O
used	O
higher	O
by	O
prescription.	O

It	O
is	O
around	O
30x	O
more	O
potent	O
than	O
THC,	O
and	O
exhibits	O
antiemetic	O
analgesic	O
effects	O
via	O
activation	O
of	O
CB1	O
CB2	O
cannabinoid	O
receptors.	O
THC	B-Drug

Because	O
of	O
a	O
strong	O
vesicant	O
nature	O
bis(2-chloroethyl)methylamine	O
there	O
are	O
many	O
other	O
routes	O
developed	O
for	O
obtaining	O
ketobemidone.	O
ketobemidone	B-Drug

Internationally,	O
the	O
production,	O
distribution,	O
sale,	O
and	O
possession	O
of	O
methamphetamine	B-Drug
is	O
restricted	O
or	O
banned	O
in	O
many	O
countries,	O
due	O
to	O
its	O
placement	O
schedule	O
II	O
United	O
Nations	O
Convention	O
on	O
Psychotropic	O
Substances	O
treaty.	O

In	O
Hong	O
Kong,	O
methylphenidate	B-Drug
is	O
controlled	O
under	O
the	O
schedule	O
1	O
of	O
Dangerous	O
Drugs	O
Ordinance	O
(Cap.	O
134).	O

cannabis,	O
LSD,	O
and	O
opium	B-Drug
Around	O
the	O
Fire	O
(1999)	O
LSD	B-Drug

Gabapentin	B-Drug
concentration	O
in	O
cerebrospinal	O
fluid	O
is	O
approximately	O
9-14%	O
of	O
its	O
blood	O
plasma	O
concentration.	O

Prazepam	B-Drug
is	O
a	O
benzodiazepine	O
derivative	O
drug	O
developed	O
by	O
Warner-Lambert	O
in	O
the	O
1960s.	O

Therefore,	O
oxycodone	B-Drug
accumulates	O
in	O
patients	O
with	O
kidney	O
impairment.	O

Then	O
battery	O
acid	O
(weak	O
sulfuric	O
acid)	O
was	O
used,	O
one	O
bucket	O
per	O
55	O
lb	O
(25	O
kg)	O
of	O
leaves,	O
to	O
create	O
a	O
phase	O
separation	O
in	O
which	O
the	O
cocaine	B-Drug
free	O
base	O
gasoline	O
acidified	O
and	O
extracted	O
into	O
few	O
buckets	O
"murky-looking	O
smelly	O
liquid".	O

Long-acting	O
benzodiazepines	O
such	O
as	O
diazepam	B-Drug
are	O
not	O
recommended	O
for	O
the	O
elderly.	O

Salves	O
and	O
absorption	O
through	O
the	O
skin	O
(transdermal)	O
are	O
increasingly	O
common	O
in	O
medical	O
uses,	O
both	O
of	O
CBD,	O
THC,	O
other	O
cannabinoids.	O
CBD	B-Drug
THC	B-Drug

Bufotenin	B-Drug
is	O
found	O
in	O
the	O
skin	O
and	O
glands	O
of	O
Bufo	O
toads.	O

While	O
salvinorin	B-Drug
A	I-Drug
is	O
considered	O
a	O
hallucinogen,	O
its	O
effects	O
are	O
qualitatively	O
different	O
than	O
those	O
produced	O
by	O
the	O
classical	O
psychedelic	O
hallucinogens	O
such	O
as	O
lysergic	O
acid	B-Drug
diethylamide	O
(LSD),	O
psilocybin,	O
or	O
mescaline,	O
instead	O
being	O
much	O
more	O
akin	O
to	O
ibogaine,	O
which	O
also	O
KOR	O
agonist.	O
LSD	B-Drug
mescaline	B-Drug
ibogaine	B-Drug

It	O
is	O
sold	O
under	O
many	O
trade	O
names	O
worldwide	O
including	O
Aplenzin,	O
Budeprion	O
SR,	O
Bup,	O
Bupredol,	O
Buproban,	O
Bupropion	B-Drug
GSK,	O
BuPROPion	O
HCL	O
SR	O
Watson,	O
Hydrochloride	O
Anchen,	O
Apotex,	O
Cadista,	O
Mylan,	O
Sandoz,	O
buPROPion	O
actavis,	O
Sun	O
Pharma,	O
Torrent	O
Wockhardt,	O
XL	O
Sanis	O
Health,	O
Bupropionhydrochlorid	O
HEXAL,	O
Bupropionhydrochloride	O
Buprotrin,	O
Butrin,	O
Buxon,	O
Carmubine,	O
Depnox-SR,	O
Elontril,	O
Elontril	O
XL,	O
Forfivo	O
Funnix,	O
Aplenzin	B-Drug

25I-NBOMe,	O
25B-NBOMe	B-Drug
and	O
25C-NBOMe	B-Drug
are	O
currently	O
Schedule	O
1	O
Substances	O
according	O
to	O
21	O
CFR	O
1308.11(d)	O
25I-NBOMe	B-Drug

This	O
led	O
to	O
widespread	O
morphine	B-Drug
addiction	O
among	O
veterans	O
of	O
the	O
war.	O

This	O
was	O
particularly	O
significant	O
during	O
the	O
American	O
Civil	O
War,	O
when	O
wounded	O
soldiers	O
were	O
treated	O
with	O
morphine.	O
morphine	B-Drug

Although	O
herbal	O
cannabis	O
and	O
industrial	O
hemp	O
derive	O
from	O
the	O
same	O
species	O
contain	O
psychoactive	O
component	O
(THC),	O
they	O
are	O
distinct	O
strains	O
with	O
unique	O
biochemical	O
compositions	O
uses.	O
THC	B-Drug

A	O
kilogram	O
of	O
heroin	B-Drug
laced	O
with	O
fentanyl	B-Drug
may	O
sell	O
for	O
more	O
than	O
US$100,000,	O
but	O
the	O
itself	O
be	O
produced	O
far	O
cheaply	O
about	O
US$6,000	O
per	O
kilogram.	O

However,	O
in	O
2012,	O
racemic	O
amphetamine	B-Drug
sulfate	O
was	O
reintroduced	O
as	O
the	O
Evekeo	B-Drug
brandname.	O

Most	O
of	O
the	O
trials	O
which	O
compared	O
bupropion	B-Drug
to	O
other	O
drugs	O
for	O
depression	O
showed	O
similar	O
effectiveness,	O
but	O
this	O
finding	O
is	O
based	O
in	O
part	O
upon	O
low-quality	O
evidence.	O

Sleep	O
Older	O
age	O
Concomitant	O
use	O
of	O
CNS	O
depressants	O
like	O
benzodiazepines,	O
barbiturates,	O
alcohol,	O
and	O
inhaled	O
anesthetics	O
Hyperventilation	O
Decreased	O
CO2	O
levels	O
in	O
the	O
serum	O
Respiratory	O
acidosis	O
fentanyl	B-Drug
clearance	O
from	O
body	O
blood	O
flow	O
to	O
liver	O
Renal	O
insufficiencySustained	O
release	O
preparations,	O
such	O
as	O
patches,	O
may	O
also	O
produce	O
unexpected	O
delayed	O
respiratory	O
depression.	O

While	O
isotonitazene	B-Drug
was	O
not	O
compared	O
directly	O
to	O
morphine	B-Drug
in	O
this	O
assay,	O
it	O
found	O
be	O
around	O
2.5	O
times	O
more	O
potent	O
than	O
hydromorphone	B-Drug
and	O
slightly	O
fentanyl.	O
fentanyl	B-Drug

Codeine	B-Drug
was	O
once	O
viewed	O
as	O
the	O
"gold	O
standard"	O
in	O
cough	O
suppressants,	O
but	O
this	O
position	O
is	O
now	O
questioned.	O

Heroin	B-Drug
trafficking	O
was	O
virtually	O
eliminated	O
in	O
the	O
US	O
during	O
World	O
War	O
II	O
because	O
of	O
temporary	O
trade	O
disruptions	O
caused	O
by	O
war.	O

Ciclosporin's	O
main	O
effect	O
is	O
to	O
lower	O
the	O
activity	O
of	O
T-cells;	O
it	O
does	O
so	O
by	O
inhibiting	O
calcineurin	O
in	O
calcineurinphosphatase	O
pathway	O
and	O
preventing	O
mitochondrial	O
permeability	O
transition	O
pore	O
from	O
opening.	O
Ciclosporin	B-Drug

N,N-Dimethyltryptamine	B-Drug
(DMT	O
or	O
N,N-DMT)	O
is	O
a	O
chemical	O
substance	O
that	O
occurs	O
in	O
many	O
plants	O
and	O
animals	O
which	O
both	O
derivative	O
structural	O
analog	O
of	O
tryptamine.	O
N,N-DMT	B-Drug

Due	O
to	O
changes	O
that	O
the	O
brain	O
undergoes	O
during	O
and	O
following	O
MDMA	B-Drug
consumption,	O
various	O
consequences	O
have	O
been	O
noted.	O

According	O
to	O
David	O
Nutt,	O
when	O
safrole	O
was	O
restricted	O
by	O
the	O
United	O
Nations	O
in	O
order	O
reduce	O
supply	O
of	O
MDMA,	O
producers	O
China	O
began	O
using	O
anethole	O
instead,	O
but	O
this	O
gives	O
para-methoxyamphetamine	B-Drug
(PMA,	O
also	O
known	O
as	O
"Dr	O
Death"),	O
which	O
is	O
much	O
more	O
toxic	O
than	O
MDMA	B-Drug
and	O
can	O
cause	O
overheating,	O
muscle	O
spasms,	O
seizures,	O
unconsciousness,	O
death.	O
PMA	B-Drug

Excessive	O
glutamate	O
activity	O
is	O
believed	O
to	O
be	O
involved	O
in	O
catatonia;	O
when	O
first-line	O
treatment	O
options	O
fail,	O
NMDA	O
antagonists	O
such	O
as	O
amantadine	B-Drug
or	O
memantine	B-Drug
may	O
used.	O

In	O
contrast,	O
5-APDB	B-Drug
is	O
highly	O
selective	O
for	O
serotonin.	O

Metopon	B-Drug
(5-methylhydromorphone)	O
is	O
an	O
opioid	O
analogue	O
that	O
a	O
methylated	O
derivative	O
of	O
hydromorphone	B-Drug
which	O
was	O
invented	O
in	O
1929	O
as	O
analgesic.	O

This	O
may	O
be	O
due	O
to	O
increased	O
seizures	O
during	O
use	O
and	O
decreased	O
production	O
of	O
the	O
precursor	O
chemicals	O
used	O
manufacture	O
MDMA.	O
MDMA	B-Drug

There	O
is	O
a	O
tremendous	O
demand	O
for	O
cocaine	B-Drug
in	O
the	O
U.S.	O
market,	O
particularly	O
among	O
those	O
who	O
are	O
making	O
incomes	O
affording	O
luxury	O
spending,	O
such	O
as	O
single	O
adults	O
and	O
professionals	O
with	O
discretionary	O
income.	O

Etilamfetamine	B-Drug
Fenfluramine	B-Drug
(one	O
of	O
the	O
two	O
components	O
[the	O
other	O
being	O
phentermine]	O
Fen-phen.	O
phentermine	B-Drug
Fen-phen	B-Drug

The	O
pharmacological	O
effects	O
of	O
triazolam	B-Drug
are	O
similar	O
to	O
those	O
most	O
other	O
benzodiazepines.	O

Modafinil	B-Drug
is	O
a	O
mild	O
stimulant	O
designed	O
to	O
be	O
taken	O
right	O
before	O
competition	O
in	O
order	O
sharpen	O
an	O
athlete's	O
senses	O
and	O
performance.	O

Drugs	O
that	O
are	O
injected	O
include	O
morphine	B-Drug
and	O
heroin,	O
less	O
commonly	O
other	O
opioids.	O
heroin	B-Drug

Diazepam	B-Drug
in	O
doses	O
of	O
5	O
mg	O
or	O
more	O
causes	O
significant	O
deterioration	O
alertness	O
performance	O
combined	O
with	O
increased	O
feelings	O
sleepiness.	O

Owsley's	O
LSD	B-Drug
activities	O
immortalized	O
by	O
Steely	O
Dan	O
in	O
their	O
song	O
"Kid	O
Charlemagne"	O
ended	O
with	O
his	O
arrest	O
at	O
the	O
end	O
of	O
1967,	O
but	O
some	O
other	O
manufacturers	O
most	O
likely	O
operated	O
continuously	O
for	O
30	O
years	O
or	O
more.	O

Further,	O
many	O
undergraduate	O
students	O
who	O
were	O
not	O
part	O
of	O
Leary's	O
research	O
program	O
heard	O
the	O
profound	O
experiences	O
other	O
had	O
undergone	O
and	O
began	O
taking	O
LSD	B-Drug
for	O
recreational	O
purposes,	O
which	O
was	O
illegal	O
at	O
time	O
.	O

that	O
JWH-018	B-Drug
was	O
found	O
as	O
one	O
of	O
the	O
active	O
components	O
in	O
at	O
least	O
three	O
versions	O
grey	O
market	O
drug	O
Spice,	O
which	O
has	O
been	O
sold	O
an	O
incense	O
a	O
number	O
countries	O
around	O
world	O
since	O
2002.	O

Brazilian	O
footballer	O
assistant	O
Robson	O
Oliveira	O
was	O
arrested	O
in	O
2019	O
upon	O
arriving	O
Russia	O
with	O
methadone	B-Drug
tablets	O
sold	O
legally	O
other	O
countries	O
and	O
has	O
been	O
jail	O
since	O
then	O
for	O
what	O
considered	O
drug	O
trafficking	O
under	O
Russian	O
law.	O

O-demethylation	O
of	O
dextromethorphan	B-Drug
to	O
dextrorphan	B-Drug
contributes	O
at	O
least	O
80%	O
the	O
formed	O
during	O
metabolism.	O

Thalidomide	B-Drug
may	O
be	O
helpful	O
in	O
some	O
cases	O
where	O
standard	O
TB	O
drugs	O
and	O
corticosteroids	O
are	O
not	O
sufficient	O
to	O
resolve	O
severe	O
inflammation	O
the	O
brain.	O

MDMA's	O
toxicity	O
in	O
overdose	O
may	O
be	O
exacerbated	O
by	O
caffeine,	O
with	O
which	O
it	O
is	O
frequently	O
cut	O
order	O
to	O
increase	O
volume.	O
MDMA	B-Drug

Use	O
is	O
also	O
contraindicated	O
in	O
people	O
that	O
are	O
already	O
taking	O
potassium-sparing	O
drugs	O
(e.g.	O
spironolactone	B-Drug
and	O
triamterene)	O
or	O
whom	O
potassium	O
supplements	O
chloride)	O
most	O
circumstances.	O
triamterene	B-Drug

During	O
the	O
1960s,	O
this	O
second	O
group	O
of	O
casual	O
lysergic	O
acid	B-Drug
diethylamide	O

In	O
2012,	O
the	O
U.S.	O
Justice	O
Department	O
announced	O
that	O
GlaxoSmithKline	O
had	O
agreed	O
to	O
plead	O
guilty	O
and	O
pay	O
a	O
$3-billion	O
fine,	O
in	O
part	O
for	O
promoting	O
unapproved	O
use	O
of	O
Wellbutrin	B-Drug
weight	O
loss	O
sexual	O
dysfunction.	O

After	O
two	O
weeks	O
of	O
chronic	O
administration	O
(30	O
mg/day	O
in	O
both	O
cases),	O
the	O
increase	O
prolactin	O
levels	O
produced	O
by	O
domperidone	B-Drug
was	O
reduced	O
(53.2	O
ng/mL;	O
6.6-fold	O
above	O
baseline),	O
but	O
metoclopramide,	O
conversely,	O
heightened	O
(179.6	O
24.3-fold	O
baseline).	O
metoclopramide	B-Drug

Metabolism	O
of	O
JWH-018	B-Drug
was	O
assessed	O
using	O
Wistar	O
rats	O
which	O
had	O
been	O
administered	O
an	O
ethanolic	O
extract	O
containing	O
JWH-018.	O

One	O
study	O
found	O
that	O
only	O
10%	O
of	O
the	O
patient	O
population	O
presenting	O
with	O
a	O
benzodiazepine	O
overdose	O
are	O
suitable	O
candidates	O
for	O
flumazenil.	O
flumazenil	B-Drug

Naproxen	B-Drug
is	O
a	O
member	O
of	O
the	O
2-arylpropionic	O
acid	O
(profen)	O
family	O
NSAIDs.	O

It	O
was	O
approved	O
by	O
the	O
Food	O
and	O
Drug	O
Administration	O
on	O
23	O
March	O
1943	O
for	O
sale	O
in	O
United	O
States	O
Health	O
Canada	O
under	O
brand	O
name	O
Hycodan.	O
Hycodan	B-Drug

Deepak	O
Chopra	O
expressed	O
concern	O
that	O
Jackson	O
appears	O
to	O
have	O
been	O
given	O
no	O
naloxone,	O
a	O
drug	O
used	O
counteract	O
the	O
effects	O
of	O
an	O
Opiate	O
overdose,	O
but	O
opioids	O
were	O
not	O
major	O
factor	O
in	O
Jackson's	O
overdose.	O
naloxone	B-Drug

Ciclosporin	B-Drug
binds	O
to	O
the	O
cytosolic	O
protein	O
cyclophilin	O
(immunophilin)	O
of	O
lymphocytes,	O
especially	O
T	O
cells.	O

It	O
was	O
synthesised	O
because	O
of	O
the	O
observation	O
that	O
reverse	O
ester	O
pairs	O
several	O
structurally	O
related	O
substances	O
show	O
similar	O
activity	O
to	O
each	O
other	O
(see	O
e.g.	O
methylphenidate	B-Drug
vs	O
phacetoperane,	O
pethidine	B-Drug
desmethylprodine).	O
desmethylprodine	B-Drug

coastal	O
freighters	O
that	O
carry	O
an	O
average	O
cocaine	B-Drug
load	O
of	O
approximately	O
2.5	O
tonnes.	O

In	O
Thailand,	O
a	O
2007	O
survey	O
found	O
that	O
the	O
lifetime,	O
past	O
year,	O
and	O
30	O
days	O
kratom	B-Drug
usage	O
rates	O
were	O
2.32%,	O
0.81%	O
0.57%,	O
respectively,	O
among	O
respondents	O
aged	O
1265	O
years,	O
was	O
most	O
widely	O
used	O
drug	O
in	O
Thailand.	O

Powdered	O
MDMA	B-Drug
ranges	O
from	O
pure	O
to	O
crushed	O
tablets	O
with	O
3040%	O
purity.	O

He	O
claimed	O
he	O
received	O
a	O
tainted	O
vitamin	B-Drug
b12	I-Drug
shot	O
from	O
Miguel	O
Tejada.	O

Studies	O
have	O
found	O
after	O
controlling	O
for	O
other	O
factors	O
that	O
some	O
effects	O
are	O
present	O
in	O
pregnancies	O
involving	O
cocaine:	O
abruptio	O
placenta,	O
prematurity,	O
low	O
birth	O
weight,	O
and	O
small	O
size	O
compared	O
to	O
babies	O
of	O
the	O
same	O
gestational	O
time.	O
cocaine	B-Drug

For	O
this	O
reason,	O
SARMs	O
have	O
already	O
been	O
banned	O
by	O
the	O
World	O
Anti-Doping	O
Agency	O
since	O
January	O
2008	O
despite	O
no	O
drugs	O
from	O
class	O
yet	O
being	O
in	O
clinical	O
use,	O
and	O
blood	O
tests	O
for	O
all	O
known	O
are	O
currently	O
developed,	O
including	O
LGD-2226.	O
LGD-2226	B-Drug

Additional	O
reports	O
of	O
the	O
use	O
ergine	B-Drug
were	O
made	O
by	O
Don	O
Thomes	O
MacDougall.	O

An	O
important	O
difference	O
between	O
nalbuphine	B-Drug
and	O
the	O
pure	O
MOR	O
agonist	O
opioid	O
analgesic	O
drugs	O
is	O
ceiling	O
effect	O
on	O
respiration	O
(but	O
no	O
effect).	O

PCP	B-Drug
comes	O
in	O
both	O
powder	O
and	O
liquid	O
forms	O
(PCP	O
base	O
is	O
dissolved	O
most	O
often	O
ether),	O
but	O
typically	O
it	O
sprayed	O
onto	O
leafy	O
material	O
such	O
as	O
cannabis,	O
mint,	O
oregano,	O
tobacco,	O
parsley,	O
or	O
ginger	O
leaves,	O
then	O
smoked.	O
tobacco	B-Drug

Cannabichromene	O
(CBC)	O
is	O
non-psychoactive	O
and	O
does	O
not	O
affect	O
the	O
psychoactivity	O
of	O
THC.	O
THC	B-Drug

However,	O
as	O
of	O
2014,	O
it	O
remains	O
unclear	O
to	O
what	O
extent	O
is	O
covered	O
by	O
the	O
UK	O
phenylethylamine	B-Drug
catch-all	O
clause,	O
with	O
commentators	O
noting	O
both	O
structural	O
similarities	O
and	O
differences	O
class.	O

Nicodicodine	B-Drug
is	O
an	O
opioid	O
developed	O
as	O
a	O
cough	O
suppressant	O
and	O
analgesic.	O

5-MeO-MiPT	B-Drug
is	O
a	O
psychedelic	O
and	O
hallucinogenic	O
drug,	O
used	O
by	O
some	O
as	O
an	O
entheogen.	O

This	O
represents	O
the	O
equivalent	O
of	O
between	O
two	O
to	O
three	O
teaspoons	O
(1015	O
mL)	O
opium	B-Drug
tincture.	O

THC	B-Drug
in	O
low	O
levels	O
does	O
not	O
cause	O
a	O
"high".	O

The	O
accused	O
owned	O
a	O
tablet	O
press	O
and	O
ordered	O
fentanyl	B-Drug
in	O
powder	O
form	O
from	O
China.	O

Transdermal	O
(diffusion	O
through	O
the	O
intact	O
skin	O
for	O
systemic	O
rather	O
than	O
topical	O
distribution),	O
e.g.	O
transdermal	O
patches	O
such	O
as	O
fentanyl	B-Drug
in	O
pain	O
therapy,	O
nicotine	B-Drug
treatment	O
of	O
addiction	O
and	O
nitroglycerine	O
angina	O
pectoris.	O

In	O
June	O
2015,	O
then	O
federal	O
Minister	O
of	O
Health	O
Rona	O
Ambrose	O
announced	O
that	O
within	O
three	O
years	O
all	O
oxycodone	B-Drug
products	O
sold	O
in	O
Canada	O
would	O
need	O
to	O
be	O
tamper-resistant.	O

Ipratropium	B-Drug
bromide	I-Drug
was	O
patented	O
in	O
1966,	O
and	O
approved	O
for	O
medical	O
use	O
1974.	O

Although	O
overall	O
incidence	O
of	O
male	O
breast	O
cancer	O
in	O
clinical	O
trials	O
for	O
finasteride	B-Drug
5	O
mg	O
was	O
not	O
increased,	O
there	O
are	O
post-marketing	O
reports	O
association	O
with	O
its	O
use,	O
though	O
available	O
evidence	O
does	O
provide	O
clarity	O
as	O
to	O
whether	O
is	O
a	O
causative	O
relationship	O
between	O
and	O
these	O
cancers.	O

Chemical	O
syntheses	O
of	O
pregabalin	B-Drug
have	O
been	O
described.	O

Also	O
note;	O
IC50	O
/	O
pIC50	O
values	O
represent	O
binding	O
affinity	O
only	O
and	O
do	O
not	O
reflect	O
efficacy	O
or	O
pharmacokinetics,	O
some	O
compounds	O
listed	O
are	O
GABAA	O
antagonists	O
rather	O
than	O
agonists	O
(e.g.	O
flumazenil).	O
flumazenil	B-Drug

Cannabidiol	B-Drug
(CBD)	O
is	O
non-psychotropic.	O
CBD	B-Drug

Shulgin	O
later	O
characterized	O
the	O
substance	O
in	O
his	O
book	O
PiHKAL.In	O
United	O
States,	O
MDEA	O
was	O
introduced	O
recreationally	O
1985	O
as	O
a	O
legal	O
substitute	O
to	O
newly	O
banned	O
MDMA.	O
MDMA	B-Drug

The	O
risk	O
of	O
venous	O
thromboembolisms	O
with	O
thalidomide	B-Drug
seems	O
to	O
be	O
increased	O
when	O
patients	O
are	O
treated	O
oral	O
contraceptives	O
or	O
other	O
cytotoxic	O
agents	O
(including	O
doxorubicin	B-Drug
and	O
melphalan)	O
concurrently.	O

Following	O
the	O
passage	O
of	O
a	O
regional	O
law	O
in	O
1895,	O
Australia's	O
1897	O
Aboriginals	O
Protection	O
and	O
Restriction	O
Sale	O
Opium	O
Act	O
addressed	O
opium	B-Drug
addiction	O
among	O
Aborigines,	O
though	O
it	O
soon	O
became	O
general	O
vehicle	O
for	O
depriving	O
them	O
basic	O
rights	O
by	O
administrative	O
regulation.	O

Androstenedione	B-Drug
is	O
produced	O
in	O
the	O
adrenal	O
glands	O
and	O
gonads.	O

The	O
opioid	O
antagonist	O
activity	O
of	O
nalbuphine	B-Drug
is	O
one-fourth	O
as	O
potent	O
nalorphine	B-Drug
and	O
10	O
times	O
that	O
pentazocine.	O
pentazocine	B-Drug

The	O
illegal	O
possession	O
or	O
consumption	O
of	O
Nimetazepam	B-Drug
is	O
punishable	O
by	O
up	O
to	O
10	O
years	O
imprisonment,	O
a	O
fine	O
20,000	O
Singapore	O
dollars,	O
both.	O

The	O
use	O
of	O
clonazepam	B-Drug
during	O
pregnancy	O
should	O
only	O
occur	O
if	O
the	O
clinical	O
benefits	O
are	O
believed	O
to	O
outweigh	O
risks	O
fetus.	O

Ethocybin	B-Drug
is	O
probably	O
metabolized	O
mostly	O
in	O
the	O
liver	O
where	O
it	O
becomes	O
ethocin,	O
but	O
also	O
broken	O
down	O
by	O
enzyme	O
monoamine	O
oxidase.	O
ethocin	B-Drug

This	O
is	O
similar	O
to	O
how	O
isolated	O
THC	B-Drug
produces	O
very	O
different	O
effects	O
than	O
an	O
extract	O
that	O
retains	O
the	O
many	O
cannabinoids	O
of	O
plant	O
such	O
as	O
cannabidiol	B-Drug
and	O
cannabinol.	O
cannabinol	B-Drug

Methyldopa:	O
Methyldopa	B-Drug

Amphetamine	B-Drug
modulates	O
the	O
activity	O
of	O
most	O
psychoactive	O
drugs.	O

USAF	O
Pararescue	O
combat	O
medics	O
in	O
Afghanistan	O
use	O
fentanyl	B-Drug
lozenges	O
the	O
form	O
of	O
lollipops	O
on	O
casualties	O
from	O
IED	O
blasts	O
and	O
other	O
trauma.	O

The	O
device	O
delivers	O
a	O
subcutaneous	O
injection	O
of	O
6	O
mg	O
sumatriptan,	O
without	O
the	O
use	O
needle.	O
sumatriptan	B-Drug

Beta	O
blockade	O
with	O
propranolol	B-Drug
causes	O
a	O
rebound	O
in	O
airway	O
resistance	O
after	O
exercise	O
normal	O
subjects	O
over	O
the	O
same	O
time	O
course	O
as	O
bronchoconstriction	O
seen	O
induced	O
asthma.	O

It	O
is	O
structurally	O
distinct	O
from	O
other	O
naturally	O
occurring	O
hallucinogens	O
(such	O
as	O
DMT,	O
psilocybin,	O
and	O
mescaline)	O
because	O
it	O
contains	O
no	O
nitrogen	O
atoms;	O
hence,	O
not	O
an	O
alkaloid	O
(and	O
cannot	O
be	O
rendered	O
a	O
salt),	O
but	O
rather	O
terpenoid.	O
mescaline	B-Drug

It	O
has	O
also	O
shown	O
the	O
ability	O
to	O
reduce	O
testosterone,	O
androstenedione,	O
and	O
progesterone	O
in	O
androgen	O
stimulated	O
prostate	O
cell	O
lines	O
by	O
adenovirus	O
vectors.	O
androstenedione	B-Drug

MDMA	B-Drug
is	O
a	O
stimulating	O
psychedelic.	O

For	O
example,	O
the	O
Massachusetts	O
Department	O
of	O
Agricultural	O
Resources	O
issued	O
a	O
rule	O
in	O
June	O
2019	O
aligning	O
state	O
CBD	B-Drug
regulations	O
with	O
FDA	O
regulations.	O

opium;	O
considered	O
the	O
oldest	O
still	O
existing	O
motion	O
picture	O
to	O
contain	O
substance	O
abuse	O
opium	B-Drug

The	O
Controlled	O
Substances	O
Act	O
created	O
a	O
list	O
of	O
five	O
Schedules,	O
and	O
placed	O
cannabis	O
alongside	O
codeine	B-Drug
heroin	B-Drug
in	O
Schedule	O
I,	O
the	O
most	O
restrictive	O
classification.	O

CART	O
mRNA	O
increased	O
with	O
cocaine	B-Drug
administration.	O

It	O
has	O
recently	O
been	O
discovered	O
that	O
most	O
or	O
all	O
of	O
the	O
therapeutic	O
efficacy	O
paracetamol	B-Drug
is	O
due	O
to	O
a	O
metabolite,	O
AM404,	O
which	O
enhances	O
release	O
serotonin	O
and	O
inhibits	O
uptake	O
anandamide.	O

Tea	O
contains	O
small	O
amounts	O
of	O
theobromine	O
and	O
slightly	O
higher	O
levels	O
theophylline	B-Drug
than	O
coffee.	O

(5-(o-Fluorophenyl)-1,3-dihydro-1-methyl-7-nitro-2H-1,	O
4-benzodiazepin-2-one)	O
Ketamine	B-Drug
(Cyclohexanone,	O
2-(2-chlorophenyl)-2-(methylamino))	O

Metenolone	O
acetate,	O
or	O
methenolone	B-Drug
sold	O
under	O
the	O
brand	O
names	O
Primobolan	O
and	O
Nibal,	O
is	O
an	O
androgen	O
anabolic	O
steroid	O
(AAS)	O
medication	O
which	O
used	O
mainly	O
in	O
treatment	O
of	O
anemia	O
due	O
to	O
bone	O
marrow	O
failure.	O

These	O
drugs	O
often	O
included	O
picrotoxin,	O
amiphenazole	B-Drug
(Daptazile),	O
bemegride	B-Drug
(Megimide),	O
and	O
methamphetamine	B-Drug
sulfate	O
(Methedrine)	O
in	O
dosages	O
sometimes	O
exceeding	O
250mg	O
over	O
the	O
first	O
24	O
hour	O
period	O
of	O
being	O
admitted	O
into	O
an	O
intensive	O
care	O
unit	O
(ICU).	O
Megimide	B-Drug
Methedrine	B-Drug

The	O
UNODC	O
states	O
that	O
cannabis	O
often	O
contains	O
5%	O
THC	B-Drug
content,	O
resin	O
"can	O
contain	O
up	O
to	O
20%	O
content",	O
and	O
"Cannabis	O
oil	I-Drug
may	O
more	O
than	O
60%	O
content.	O
Cannabis	B-Drug

The	O
greatly	O
increased	O
potency	O
essentially	O
eliminates	O
the	O
toxic	O
effects	O
of	O
norpethidine	B-Drug
accumulation	O
which	O
are	O
seen	O
when	O
pethidine	B-Drug
is	O
administered	O
in	O
high	O
doses	O
or	O
for	O
long	O
periods	O
time.	O

In	O
those	O
days	O
70	O
per	O
cent	O
of	O
crime	O
was	O
not	O
associated	O
with	O
drug	O
prohibition:	O
It	O
did	O
exist	O
because	O
heroin	B-Drug
legal.	O

On	O
25	O
November	O
2014	O
two	O
British	O
tourists	O
aged	O
20	O
and	O
21	O
died	O
in	O
a	O
hotel	O
room	O
Amsterdam,	O
after	O
snorting	O
white	O
heroin	B-Drug
that	O
was	O
sold	O
as	O
cocaine	B-Drug
by	O
street	O
dealer.	O

Levothyroxine	B-Drug
is	O
safe	O
and	O
effective	O
for	O
children	O
with	O
hypothyroidism;	O
the	O
goal	O
of	O
treatment	O
hypothyroidism	O
to	O
reach	O
preserve	O
normal	O
intellectual	O
physical	O
development.	O

By	O
inhibiting	O
the	O
synthesis	O
of	O
prostaglandins,	O
indometacin	B-Drug
can	O
reduce	O
pain,	O
fever,	O
and	O
inflammation.	O

Acylation	O
of	O
4	O
with	O
phenylpropionyl	O
chloride	O
yields	O
nandrolone	B-Drug
phenpropionate.	O
phenpropionate	I-Drug

Coming	O
off	O
long-term	O
lorazepam	B-Drug
use	O
may	O
be	O
more	O
realistically	O
achieved	O
by	O
a	O
gradual	O
switch	O
to	O
an	O
equivalent	O
dose	O
of	O
diazepam	B-Drug
and	O
period	O
stabilization	O
on	O
this,	O
only	O
then	O
initiating	O
reductions.	O

Ibogaine	B-Drug
decreases	O
body	O
temperature.	O

Prepared	O
ipecacuanha,	O
10	O
g.,	O
powdered	O
opium	B-Drug
lactose	O
80	O
g.	O

A	O
Cochrane	O
review	O
on	O
the	O
treatment	O
of	O
ADHD	O
in	O
children	O
with	O
tic	O
disorders	O
such	O
as	O
Tourette	O
syndrome	O
indicated	O
that	O
stimulants	O
general	O
do	O
not	O
make	O
tics	O
worse,	O
but	O
high	O
doses	O
dextroamphetamine	B-Drug
could	O
exacerbate	O
some	O
individuals.	O

is	O
therefore	O
no	O
longer	O
preferred;	O
phenothiazines	O
are	O
particularly	O
risky,	O
as	O
they	O
may	O
lower	O
the	O
seizure	O
threshold,	O
worsen	O
hyperthermia,	O
and	O
boost	O
anticholinergic	O
effects	O
of	O
PCP.	O
PCP	B-Drug

The	O
first	O
20	O
years	O
of	O
licensed	O
measles	B-Drug
vaccination	I-Drug
in	O
the	O
U.S.	O
prevented	O
an	O
estimated	O
52	O
million	O
cases	O
disease,	O
17,400	O
mental	O
retardation,	O
and	O
5,200	O
deaths.	O

In	O
veterinary	O
medicine,	O
imipramine	B-Drug
is	O
used	O
with	O
xylazine	B-Drug
to	O
induce	O
pharmacologic	O
ejaculation	O
in	O
stallions.	O

Recent	O
research	O
points	O
to	O
an	O
important	O
role	O
of	O
circadian	O
mechanisms	O
and	O
clock	O
genes	O
in	O
behavioral	O
actions	O
cocaine.	O
cocaine	B-Drug

The	O
bioavailability	O
of	O
intranasal	O
fentanyl	B-Drug
is	O
about	O
7090%,	O
but	O
with	O
some	O
imprecision	O
due	O
to	O
clotted	O
nostrils,	O
pharyngeal	O
swallow	O
and	O
incorrect	O
administration.	O

The	O
potency	O
derives	O
from	O
the	O
fact	O
that	O
it	O
overlays	O
fentanyl.	O
fentanyl	B-Drug

In	O
early	O
20th-century	O
Memphis,	O
Tennessee,	O
cocaine	B-Drug
was	O
sold	O
in	O
neighborhood	O
drugstores	O
on	O
Beale	O
Street,	O
costing	O
five	O
or	O
ten	O
cents	O
for	O
a	O
small	O
boxful.	O

The	O
Netherlands	O
is	O
a	O
major	O
producer	O
and	O
leading	O
distributor	O
of	O
cannabis,	O
heroin,	O
cocaine,	O
amphetamines	O
other	O
synthetic	O
drugs,	O
medium	O
consumer	O
illicit	O
drugs.	O
heroin	B-Drug
cocaine	B-Drug

The	O
widespread	O
use	O
of	O
fentanyl	B-Drug
triggered	O
the	O
production	O
citrate	O
(the	O
salt	O
formed	O
by	O
combining	O
and	O
citric	O
acid	O
in	O
a	O
1:1	O
stoichiometric	O
ratio).	O

Tamoxifen's	O
further	O
development	O
may	O
have	O
been	O
bolstered	O
by	O
a	O
second	O
clinical	O
study	O
Harold	O
Tamoxifen	B-Drug

PX-2	B-Drug
(also	O
known	O
as	O
5F-APP-PINACA,	O
FU-PX	O
and	O
PPA(N)-2201)	O
is	O
an	O
indazole-based	O
synthetic	O
cannabinoid	O
that	O
has	O
been	O
sold	O
online	O
a	O
designer	O
drug.	O

According	O
to	O
Dan	O
Duchaine,	O
author	O
of	O
the	O
book	O
Underground	O
Steroid	O
Handbook	O
and	O
worked	O
with	O
countless	O
world-class	O
female	O
bodybuilders,	O
Greg	O
Zulak,	O
listed	O
following	O
performance-enhancing	O
drugs	O
that	O
bodybuilders	O
may	O
use:	O
oxymetholone	B-Drug
(Anadrol)	O
oxandrolone	B-Drug
(Anavar)	O
clenbuterol	B-Drug
nandrolone	B-Drug
decanoate	I-Drug
(Deca-Durabolin)	O
Anadrol	B-Drug
Deca-Durabolin	B-Drug

Inhibition	O
of	O
COX-1	O
(which	O
celecoxib	B-Drug
does	O
not	O
inhibit	O
at	O
therapeutic	O
concentrations)	O
inhibits	O
the	O
production	O
prostaglandins	O
and	O
thromboxane	O
A2,	O
a	O
platelet	O
activator.	O

It	O
is	O
the	O
indole	O
2-ethyl	O
derivative	O
of	O
related	O
compound	O
JWH-018.	O
JWH-018	B-Drug

marijuana,	O
cocaine,	O
LSD	B-Drug
and	O
methamphetamine	B-Drug
Thank	O
You	O
For	O
Smoking	O
(2006)	O
cocaine	B-Drug

Various	O
compounds	O
present	O
in	O
the	O
nut,	O
including	O
arecoline	O
(the	O
primary	O
psychoactive	O
ingredient	O
which	O
is	O
similar	O
to	O
nicotine),	O
contribute	O
histologic	O
changes	O
oral	O
mucosa.	O
nicotine	B-Drug

The	O
term	O
"morphine",	O
used	O
in	O
English	O
and	O
French,	O
was	O
given	O
by	O
the	O
French	O
physicist	O
Joseph	O
Louis	O
Gay-Lussac.	O
morphine	B-Drug

Bevacizumab	B-Drug
has	O
been	O
studied	O
as	O
a	O
treatment	O
for	O
cancers	O
that	O
grow	O
from	O
the	O
nerve	O
connecting	O
ear	O
and	O
brain.	O

The	O
possession	O
of	O
crystal	B-Drug
meth	I-Drug
can	O
result	O
in	O
a	O
punishment	O
varying	O
from	O
fine	O
to	O
jail	O
sentence.	O

In	O
the	O
U.S.,	O
fentanyl	B-Drug
is	O
a	O
Schedule	O
II	O
controlled	O
substance	O
per	O
Controlled	O
Substance	O
Act.	O

Updated	O
guidelines	O
published	O
by	O
Britain's	O
NHS	O
Migraine	O
Trust	O
in	O
2014	O
recommended	O
"Methysergide	O
medicines	O
are	O
now	O
only	O
to	O
be	O
used	O
for	O
preventing	O
severe	O
intractable	O
migraine	O
and	O
cluster	O
headache	O
when	O
standard	O
have	O
failed".	O
Methysergide	B-Drug

6-MAM	O
is	O
rarely	O
encountered	O
in	O
an	O
isolated	O
form	O
due	O
to	O
the	O
difficulty	O
selectively	O
acetylating	O
morphine	B-Drug
at	O
6-position	O
without	O
also	O
3-position.	O

Food	O
delays	O
the	O
median	O
time	O
to	O
peak	O
levels	O
of	O
apalutamide	B-Drug
by	O
approximately	O
2	O
hours,	O
with	O
no	O
significant	O
changes	O
in	O
themselves	O
or	O
area-under-curve	O
levels.	O

The	O
role	O
of	O
NMDAR	O
antagonism	O
in	O
the	O
effect	O
PCP,	O
ketamine,	O
and	O
related	O
dissociative	O
agents	O
was	O
first	O
published	O
early	O
1980s	O
by	O
David	O
Lodge	O
colleagues.	O
PCP	B-Drug
ketamine	B-Drug

On	O
July	O
5,	O
2010,	O
former	O
Oakland	O
Raiders	O
quarterback	O
JaMarcus	O
Russell	O
was	O
arrested	O
at	O
his	O
home	O
in	O
Mobile,	O
Alabama,	O
for	O
possession	O
of	O
codeine	B-Drug
syrup	O
without	O
a	O
prescription.	O

Since	O
the	O
mid-1990s,	O
MDMA	B-Drug
has	O
become	O
most	O
widely	O
used	O
amphetamine-type	O
drug	O
by	O
college	O
students	O
and	O
teenagers.	O

Buds	O
stored	O
in	O
sealed	O
non-plastic	O
container	O
and	O
left	O
dark	O
placeRipeness	O
is	O
defined	O
as	O
the	O
point	O
where	O
THC	B-Drug
other	O
cannabinoid	O
production	O
has	O
reached	O
maximum	O
levels,	O
but	O
before	O
cannabinoids	O
have	O
begun	O
to	O
degrade/breakdown.	O

Imidazenil	B-Drug
is	O
an	O
experimental	O
anxiolytic	O
drug	O
which	O
derived	O
from	O
the	O
benzodiazepine	O
family,	O
and	O
most	O
closely	O
related	O
to	O
other	O
imidazobenzodiazepines	O
such	O
as	O
midazolam,	O
flumazenil,	O
bretazenil.	O
midazolam	B-Drug
flumazenil	B-Drug

The	O
conversion	O
rate	O
between	O
lisdexamfetamine	B-Drug
dimesylate	I-Drug
(Vyvanse)	O
to	O
dextroamphetamine	B-Drug
base	O
is	O
29.5%.	O
Vyvanse	B-Drug

Haldol	B-Drug
(haloperidol)	O
typical	O
antipsychotic.	O
haloperidol	B-Drug

However,	O
from	O
2012	O
onwards,	O
heroin	B-Drug
and	O
fentanyl	B-Drug
have	O
become	O
more	O
common	O
causes	O
of	O
drug-related	O
deaths.	O

,	O
despite	O
being	O
inactive,	O
levomoramide	B-Drug
is	O
scheduled	O
by	O
UN	O
Single	O
Convention	O
on	O
Narcotic	O
Drugs.	O

The	O
other	O
drugs	O
included	O
diazepam	B-Drug
as	O
a	O
tranquilizer,	O
cisatracurium	B-Drug
besylate	O
muscle	O
relaxant,	O
and	O
potassium	O
chloride	O
to	O
stop	O
the	O
heart.	O

Some	O
countries,	O
such	O
as	O
Peru	O
and	O
Bolivia,	O
permit	O
the	O
cultivation	O
of	O
coca	B-Drug
leaf	O
for	O
traditional	O
consumption	O
by	O
local	O
indigenous	O
population,	O
but	O
nevertheless,	O
prohibit	O
production,	O
sale,	O
cocaine.	O
cocaine	B-Drug

Etizolam's	O
main	O
metabolites	O
in	O
humans	O
are	O
alpha-hydroxyetizolam	O
and	O
8-hydroxyetizolam.	O
Etizolam	B-Drug

Taken	O
together,	O
these	O
suggest	O
that	O
there	O
may	O
be	O
an	O
indirect	O
dopaminergic	O
contribution	O
to	O
psilocin's	O
psychotomimetic	O
effects.	O
psilocin	B-Drug

The	O
making	O
and	O
use	O
of	O
opium	B-Drug
was	O
known	O
to	O
the	O
ancient	O
Minoans.	O

In	O
addition,	O
aripiprazole	B-Drug
treats	O
schizophrenia,	O
bipolar	O
disorder	O
(mania),	O
depression,	O
and	O
tic	O
disorders	O
Clozapine	B-Drug
binds	O
D1	O
D4	O
with	O
the	O
highest	O
affinity	O
but	O
still	O
D2	O
D3.	O

The	O
former	O
chemistry	O
student	O
set	O
up	O
a	O
private	O
LSD	B-Drug
lab	O
in	O
the	O
mid-60s	O
San	O
Francisco	O
and	O
supplied	O
consumed	O
at	O
famous	O
Acid	O
Test	O
parties	O
held	O
by	O
Ken	O
Kesey	O
his	O
Merry	O
Pranksters,	O
as	O
well	O
Human	O
Be-In	O
January	O
1967	O
Monterey	O
International	O
Pop	O
Festival	O
June	O
1967.	O

Sveriges	O
riksdags	O
health	O
ministry	O
Statens	O
folkhlsoinstitut	O
classified	O
5-MeO-MT	O
as	O
"health	O
hazard"	O
under	O
the	O
act	O
Lagen	O
om	O
frbud	O
mot	O
vissa	O
hlsofarliga	O
varor	O
(translated	O
Act	O
on	O
Prohibition	O
of	O
Certain	O
Goods	O
Dangerous	O
to	O
Health)	O
Oct	O
1,	O
2004,	O
in	O
their	O
regulation	O
SFS	O
2004:696	O
listed	O
5-metoxi-alfametyltryptamin	O
(5-MeO-AMT),	O
making	O
it	O
illegal	O
sell	O
or	O
possess.	O
5-MeO-AMT	B-Drug

Oxycodone	B-Drug
can	O
produce	O
drug	O
dependence	O
of	O
the	O
morphine	B-Drug
type	O
and,	O
therefore,	O
has	O
potential	O
for	O
being	O
addictive.	O

PCP	B-Drug
may	O
cause	O
hallucinations,	O
distorted	O
perceptions	O
of	O
sounds,	O
and	O
violent	O
behavior.	O

After	O
prolonged	O
use,	O
the	O
body	O
can	O
become	O
accustomed	O
to	O
effects	O
of	O
zopiclone.	O
zopiclone	B-Drug

Ecstasy,	O
like	O
LSD,	O
has	O
had	O
a	O
tangible	O
influence	O
on	O
culture	O
and	O
aesthetics,	O
particularly	O
the	O
aesthetics	O
of	O
rave	O
culture.	O
LSD	B-Drug

Particular	O
problems	O
arose	O
with	O
the	O
trafficking	O
and	O
abuse	O
of	O
nimetazepam	B-Drug
temazepam	B-Drug
within	O
that	O
same	O
year	O
in	O
1991.	O

For	O
comparison	O
to	O
testosterone,	O
methyltestosterone	B-Drug
is	O
at	O
least	O
as	O
potent	O
an	O
AAS.	O

An	O
antidote	O
to	O
ondansetron	B-Drug
is	O
not	O
known.	O

Symptoms	O
associated	O
with	O
hydromorphone	B-Drug
withdrawal	O
include:	O
Abdominal	O
pain	O
Anxiety	O
or	O
panic	O
attacks	O
Depression	O
Goose	O
bump	O
skin	O
Inability	O
to	O
enjoy	O
daily	O
activities	O
Muscle	O
and	O
joint	O
Nausea	O
Runny	O
nose	O
excessive	O
secretion	O
of	O
tears	O
Sweating	O
VomitingIn	O
the	O
clinical	O
setting,	O
tears,	O
yawning,	O
dilation	O
pupils	O
are	O
helpful	O
presentations	O
in	O
diagnosing	O
opioid	O
withdrawal.	O

Noscapine	B-Drug
(also	O
known	O
as	O
Narcotine,	O
Nectodon,	O
Nospen,	O
Anarcotine	O
and	O
(archaic)	O
Opiane)	O
is	O
a	O
benzylisoquinoline	O
alkaloid,	O
of	O
the	O
phthalideisoquinoline	O
structural	O
subgroup,	O
which	O
has	O
been	O
isolated	O
from	O
numerous	O
species	O
family	O
Papaveraceae.	O
Narcotine	B-Drug

In	O
March	O
2009,	O
a	O
DEA	O
agent	O
who	O
gained	O
access	O
to	O
the	O
site	O
successfully	O
purchased	O
25	O
hits	O
of	O
LSD,	O
sending	O
money	O
Budapest	O
and	O
receiving	O
drugs	O
in	O
Los	O
Angeles.	O
LSD	B-Drug

Its	O
levorotary	O
enantiomer,	O
levacetylmethadol,	O
is	O
an	O
FDA-approved	O
treatment	O
for	O
opioid	O
addiction.	O
levacetylmethadol	B-Drug

Activation	O
of	O
the	O
5-HT2A	O
receptor	O
is	O
necessary	O
for	O
effects	O
"classic"	O
psychedelics	O
like	O
LSD,	O
psilocin	B-Drug
and	O
mescaline,	O
which	O
act	O
as	O
full	O
or	O
partial	O
agonists	O
at	O
this	O
receptor,	O
represent	O
three	O
main	O
classes	O
agonists,	O
ergolines,	O
tryptamines	O
phenethylamines,	O
respectively.	O
LSD	B-Drug
mescaline	B-Drug

A	O
case	O
report	O
has	O
shown	O
that	O
an	O
intravenous	O
bolus	O
dose	O
of	O
indometacin	B-Drug
given	O
with	O
2	O
hours	O
continuous	O
infusion	O
is	O
able	O
to	O
reduce	O
intracranial	O
pressure	O
by	O
37%	O
in	O
10	O
15	O
minutes	O
and	O
increases	O
cerebral	O
perfusion	O
30%	O
at	O
the	O
same	O
time.	O

NM-2201	B-Drug
is	O
specifically	O
banned	O
in	O
Sweden,	O
Germany	O
(Anlage	O
II),	O
and	O
Japan	O
but	O
also	O
controlled	O
many	O
other	O
jurisdictions	O
under	O
analogue	O
laws.	O

This	O
treaty	O
has	O
since	O
been	O
supplemented	O
by	O
the	O
Convention	O
on	O
Psychotropic	O
Substances,	O
which	O
controls	O
LSD,	O
MDMA,	O
and	O
other	O
psychoactive	O
pharmaceuticals,	O
United	O
Nations	O
Against	O
Illicit	O
Traffic	O
in	O
Narcotic	O
Drugs	O
strengthens	O
provisions	O
against	O
money	O
laundering	O
drug-related	O
offenses.	O
LSD	B-Drug
MDMA	B-Drug

The	O
Russian	O
Health	O
Minister	O
later	O
stated	O
that	O
the	O
gas	O
was	O
based	O
on	O
fentanyl,	O
but	O
exact	O
chemical	O
agent	O
has	O
not	O
been	O
identified.	O
fentanyl	B-Drug

The	O
Supreme	O
Court	O
decided	O
that	O
the	O
substance	O
Novartis	O
sought	O
to	O
patent	O
was	O
indeed	O
a	O
modification	O
of	O
known	O
drug	O
(the	O
raw	O
form	O
imatinib,	O
which	O
publicly	O
disclosed	O
in	O
1993	O
application	O
and	O
scientific	O
articles),	O
did	O
not	O
present	O
evidence	O
difference	O
therapeutic	O
efficacy	O
between	O
final	O
Gleevec	B-Drug
therefore	O
properly	O
rejected	O
by	O
office	O
lower	O
courts.	O
imatinib	B-Drug

When	O
the	O
nasal	O
decongestant	O
is	O
taken	O
in	O
excess,	O
levomethamphetamine	B-Drug
has	O
potential	O
side	O
effects	O
resembling	O
those	O
of	O
other	O
sympathomimetic	O
drugs;	O
these	O
include	O
hypertension	O
(elevated	O
blood	O
pressure),	O
tachycardia	O
(rapid	O
heart	O
rate),	O
nausea,	O
stomach	O
cramps,	O
dizziness,	O
headache,	O
sweating,	O
muscle	O
tension,	O
and	O
tremors.	O

They	O
concluded	O
that	O
the	O
agent	O
used	O
in	O
Moscow	O
theater	O
hostage	O
crisis	O
contained	O
two	O
fentanyl	B-Drug
derivatives	O
much	O
stronger	O
than	O
itself,	O
sprayed	O
an	O
aerosol	O
mist.	O

However,	O
this	O
activation	O
is	O
unlikely	O
to	O
be	O
the	O
dominant	O
mechanism	O
of	O
gabapentin's	O
therapeutic	O
effects.	O
gabapentin	B-Drug

Specifically,	O
nociceptin	O
acts	O
to	O
inhibit	O
neural	O
rewards	O
induced	O
by	O
drugs	O
such	O
as	O
amphetamines,	O
morphine,	O
cocaine,	O
and	O
especially	O
alcohol	O
in	O
animal	O
models,	O
though	O
the	O
exact	O
mechanism	O
of	O
this	O
has	O
not	O
yet	O
been	O
proven.	O
morphine	B-Drug
cocaine	B-Drug

In	O
the	O
Northeast	O
in	O
particular,	O
cocaine	B-Drug
became	O
popular	O
amongst	O
workers	O
factories,	O
textile	O
mills,	O
and	O
on	O
railroads.	O

The	O
treatment	O
was	O
attempted	O
despite	O
the	O
ban	O
on	O
thalidomide's	O
use,	O
and	O
results	O
were	O
favourable:	O
patient	O
slept	O
for	O
hours	O
able	O
to	O
get	O
out	O
of	O
bed	O
without	O
aid	O
upon	O
awakening.	O
thalidomide	B-Drug

The	O
proposed	O
changes	O
included	O
other	O
similar	O
blanket	O
bans	O
for	O
substances,	O
such	O
as	O
a	O
ban	O
on	O
any	O
and	O
all	O
plants	O
containing	O
Mescaline	B-Drug
or	O
Ephedrine.	O
Ephedrine	B-Drug

The	O
patients,	O
who	O
were	O
rigid	O
and	O
almost	O
completely	O
immobile,	O
responded	O
to	O
levodopa	B-Drug
treatment.	O

Phenampromide	B-Drug
is	O
in	O
Schedule	O
I	O
of	O
the	O
Controlled	O
Substances	O
Act	O
1970	O
United	O
States	O
as	O
a	O
Narcotic	O
with	O
ACSCN	O
9638	O
zero	O
aggregate	O
manufacturing	O
quota	O
2014.	O

Phenibut,	O
also,	O
is	O
taken	O
3	O
times	O
per	O
day.	O
Phenibut	B-Drug

Relapses	O
fell	O
from	O
an	O
average	O
of	O
four	O
times	O
per	O
month	O
before	O
treatment	O
with	O
coca	B-Drug
tea	O
to	O
one	O
during	O
the	O
treatment.	O

Amitriptyline	B-Drug
is	O
a	O
highly	O
lipophilic	O
molecule	O
having	O
an	O
octanol-water	O
partition	O
coefficient	O
(pH	O
7.4)	O
of	O
3.0,	O
while	O
the	O
log	O
P	O
free	O
base	O
was	O
reported	O
as	O
4.92.	O

Side	O
effects	O
of	O
etonogestrel	B-Drug
include	O
menstrual	O
irregularities,	O
breast	O
tenderness,	O
mood	O
changes,	O
acne,	O
headaches,	O
vaginitis,	O
and	O
others.	O

Apalutamide	B-Drug
is	O
the	O
generic	O
name	O
of	O
drug	O
and	O
its	O
INN.	O

In	O
South	O
America,	O
coca	B-Drug
paste,	O
also	O
known	O
as	O
cocaine	B-Drug
base	O
or	O
basuco	O
and,	O
therefore,	O
often	O
confused	O
with	O
freebase	O
in	O
North	O
is	O
relatively	O
inexpensive	O
and	O
widely	O
used	O
by	O
low-income	O
populations.	O

In	O
1981,	O
Clegg	O
had	O
coined	O
"Ecstasy"	O
as	O
a	O
slang	O
term	O
for	O
MDMA	B-Drug
to	O
increase	O
its	O
marketability.	O

In	O
June	O
2017	O
the	O
price	O
of	O
methamphetamine	B-Drug
on	O
streets	O
Manila	O
was	O
lower	O
than	O
it	O
had	O
been	O
at	O
start	O
Duterte's	O
presidency,	O
according	O
to	O
Philippine	O
Drug	O
Enforcement	O
Agency	O
data.	O

PCP	B-Drug
is	O
a	O
Schedule	O
II	O
substance	O
in	O
the	O
United	O
States	O
and	O
its	O
ACSCN	O
7471.	O

methamphetamine,	O
also	O
known	O
as	O
"ice",	O
"crystal"	O
and	O
"crank".	O
methamphetamine	B-Drug
crank	B-Drug

Step	O
2	O
is	O
hydroxylation	O
of	O
androst-4-ene-3,17-dione	B-Drug
with	O
OsO4	O
followed	O
by	O
step	O
3	O
alkaline	O
dehydration	O
the	O
resultant	O
diols	O
to	O
give	O
formestane.	O

Mifepristone	B-Drug
showed	O
no	O
detectable	O
anti-HIV	O
activity	O
in	O
clinical	O
trials.	O

At	O
dosages	O
of	O
50	O
mg	O
or	O
100	O
per	O
day,	O
androstenedione	B-Drug
had	O
no	O
effect	O
on	O
muscle	O
strength	O
size,	O
body	O
fat	O
levels.	O

In	O
the	O
United	O
States,	O
illicit	O
methamphetamine	B-Drug
comes	O
in	O
a	O
variety	O
of	O
forms	O
with	O
prices	O
varying	O
widely	O
over	O
time.	O

AB-PICA	B-Drug
is	O
a	O
potent	O
agonist	O
for	O
the	O
CB1	O
receptor	O

In	O
the	O
US,	O
Food	O
and	O
Drug	O
Act	O
of	O
1906	O
required	O
that	O
certain	O
specified	O
drugs,	O
including	O
alcohol,	O
cocaine,	O
heroin,	O
morphine,	O
cannabis,	O
be	O
accurately	O
labeled	O
with	O
contents	O
dosage.	O
cocaine	B-Drug
heroin	B-Drug
morphine	B-Drug

Some	O
of	O
the	O
trichomes	O
are	O
packaged	O
as-is,	O
or	O
they	O
can	O
be	O
repeatedly	O
pressed	O
and	O
heated	O
to	O
form	O
dense	O
slabs	O
hashish.	O
hashish	B-Drug

On	O
discontinuation,	O
lorazepam	B-Drug
serum	O
levels	O
become	O
negligible	O
after	O
three	O
days	O
and	O
undetectable	O
about	O
a	O
week.	O

In	O
2010,	O
the	O
World	O
Health	O
Organization	O
(WHO)	O
stated	O
that	O
it	O
did	O
not	O
recommend	O
thalidomide	B-Drug
for	O
leprosy	O
due	O
to	O
difficulty	O
of	O
adequately	O
controlling	O
its	O
use,	O
and	O
availability	O
clofazimine.	O
clofazimine	B-Drug

After	O
7	O
days	O
of	O
nicotine	B-Drug
treatment	O
mice,	O
the	O
post-translational	O
modifications	O
consisting	O
acetylation	O
both	O
histone	O
H3	O
and	O
H4	O
was	O
increased	O
at	O
FosB	O
promoter	O
in	O
nucleus	O
accumbens	O
brain,	O
causing	O
a	O
61%	O
increase	O
expression.	O

Nicotine's	O
selectivity	O
is	O
thought	O
to	O
be	O
due	O
a	O
particular	O
amino	O
acid	O
difference	O
on	O
these	O
receptor	O
subtypes.	O
Nicotine	B-Drug

The	O
recreational	O
use	O
is	O
not	O
particularly	O
widespread	O
in	O
the	O
EU	O
with	O
exception	O
of	O
Tallinn,	O
Estonia,	O
where	O
it	O
has	O
largely	O
replaced	O
heroin.	O
heroin	B-Drug

It	O
can	O
also	O
be	O
produced	O
by	O
oxidising	O
the	O
ephedrine	B-Drug
analogue	O
4-methylephedrine	O
using	O
potassium	O
permanganate	O
dissolved	O
in	O
sulfuric	O
acid.	O

Following	O
further	O
FDA	O
pressure,	O
CIBA	O
withdrew	O
Dianabol	B-Drug
from	O
the	O
U.S.	O
market	O
in	O
1983.	O

While	O
cocaine	B-Drug
production	O
in	O
Colombia	O
initially	O
decreased	O
with	O
the	O
onset	O
of	O
Plan	O
Colombia,	O
United	O
Nations	O
declared	O
that	O
2005,	O
despite	O
record	O
levels	O
eradication	O
by	O
U.S.,	O
coca	B-Drug
increased	O
to	O
about	O
330	O
square	O
miles	O
(850	O
km2).	O

Illicitly	O
produced	O
desomorphine	B-Drug
is	O
typically	O
far	O
from	O
pure	O
and	O
often	O
contains	O
large	O
amounts	O
of	O
toxic	O
substances	O
contaminants	O
as	O
a	O
result	O
the	O
drug	O
producers	O
neglecting	O
to	O
remove	O
highly	O
reactants	O
solvents	O
left	O
over	O
synthesis.	O

The	O
maximum	O
conversion	O
rate	O
for	O
ephedrine	B-Drug
and	O
pseudoephedrine	B-Drug
is	O
92%,	O
although	O
typically,	O
illicit	O
methamphetamine	B-Drug
laboratories	O
convert	O
at	O
a	O
of	O
50%	O
to	O
75%.	O

The	O
FDA	O
reported	O
in	O
April	O
2012	O
that	O
twelve	O
young	O
children	O
had	O
died	O
and	O
more	O
made	O
seriously	O
ill	O
from	O
separate	O
accidental	O
exposures	O
to	O
fentanyl	B-Drug
skin	O
patches.	O

The	O
metabolite	O
N-(3-hydroxypentyl)	O
JWH-018	B-Drug
was	O
found	O
to	O
have	O
toxic	O
effects	O
that	O
its	O
parent	O
compound	O
does	O
not.	O

The	O
stalks	O
and	O
seeds	O
have	O
"much	O
lower	O
THC	B-Drug
levels".	O

Studies	O
suggest	O
treatment	O
of	O
ATS-induced	O
psychosis	O
by	O
risperidone	B-Drug
and	O
olanzapine.	O
olanzapine	B-Drug

Temazepam	B-Drug
abuse	O
and	O
seizures	O
have	O
been	O
falling	O
in	O
the	O
UK	O
probably	O
due	O
to	O
its	O
reclassification	O
as	O
Schedule	O
3	O
controlled	O
drug	O
with	O
tighter	O
prescribing	O
restrictions	O
resultant	O
reduction	O
availability.	O

Cocaine	B-Drug
overdose	O
may	O
result	O
in	O
hyperthermia	O
as	O
stimulation	O
and	O
increased	O
muscular	O
activity	O
cause	O
greater	O
heat	O
production.	O

Naloxone	B-Drug
is	O
increasingly	O
available	O
to	O
the	O
public.	O

Illicitly	O
synthesized	O
fentanyl	B-Drug
powder	O
has	O
also	O
appeared	O
on	O
the	O
United	O
States	O
market.	O

Depression,	O
substance	O
use	O
disorders,	O
relationship	O
problems,	O
premenstrual	O
syndrome,	O
and	O
autism	O
were	O
among	O
several	O
psychiatric	O
disorders	O
MDMA	B-Drug
assisted	O
therapy	O
was	O
reported	O
to	O
treat.	O

One	O
of	O
these	O
compounds	O
was	O
active,	O
chlordiazepoxide.	O
chlordiazepoxide	B-Drug

Some	O
of	O
the	O
cases	O
were	O
due	O
to	O
overdoses	O
acetaminophen	B-Drug
component,	O
resulting	O
in	O
fatal	O
liver	O
damage.	O

The	O
SAR	O
of	O
milnacipran	B-Drug
derivatives	O
at	O
transporter	O
level	O
is	O
still	O
largely	O
unclear	O
and	O
based	O
on	O
in	O
vivo	O
efficacy	O
that	O
was	O
reported	O
1987.	O

This	O
drug	O
is	O
10,000-times	O
more	O
lipid	O
soluble	O
than	O
the	O
short	O
acting	O
beta-2	O
adrenoceptor	O
agonist,	O
albuterol.	O
albuterol	B-Drug

Purdue	O
strongly	O
discouraged	O
the	O
practice:	O
Purdue's	O
medical	O
director	O
Robert	O
Reder	O
wrote	O
to	O
one	O
doctor	O
in	O
1995	O
that	O
"OxyContin	O
has	O
been	O
developed	O
for	O
[12-hour]	O
dosing...	O
OxyContin	B-Drug

From	O
2015	O
to	O
December	O
2020,	O
the	O
FDA	O
issued	O
dozens	O
of	O
warning	O
letters	O
American	O
manufacturers	O
CBD	B-Drug
products	O
for	O
false	O
advertising	O
and	O
illegal	O
interstate	O
marketing	O
as	O
an	O
unapproved	O
drug	O
treat	O
diseases,	O
such	O
cancer,	O
osteoarthritis,	O
symptoms	O
opioid	O
withdrawal,	O
Alzheimer's	O
disease,	O
pet	O
disorders.	O

Anxiety	O
associated	O
with	O
depression	O
is	O
responsive	O
to	O
alprazolam.	O
alprazolam	B-Drug

Amphetamine	B-Drug
systematic	O
reviews	O
and	O
meta-analyses	O
report	O
that	O
low-dose	O
amphetamine	B-Drug
improves	O
cognitive	O
functions	O
(e.g.,	O
inhibitory	O
control,	O
episodic	O
memory,	O
working	O
aspects	O
of	O
attention)	O
in	O
healthy	O
people	O
individuals	O
with	O
ADHD.	O

However,	O
there	O
is	O
also	O
a	O
response	O
from	O
the	O
Ministry	O
of	O
Health	O
Russian	O
Federation	O
indicating	O
that	O
CBD	B-Drug
can	O
be	O
considered	O
as	O
an	O
isomer	O
restricted	O
THC.	O
THC	B-Drug

the	O
following	O
phenethylamine	B-Drug
derivatives,	O
namely:	O
(c)	O

MDMA	B-Drug
could	O
be	O
purchased	O
via	O
credit	O
card	O
and	O
taxes	O
were	O
paid	O
on	O
sales.	O

Because	O
of	O
the	O
low	O
social	O
status	O
immigrant	O
workers,	O
contemporary	O
writers	O
and	O
media	O
had	O
little	O
trouble	O
portraying	O
opium	B-Drug
dens	O
as	O
seats	O
vice,	O
white	O
slavery,	O
gambling,	O
knife-	O
revolver-fights,	O
a	O
source	O
for	O
drugs	O
causing	O
deadly	O
overdoses,	O
with	O
potential	O
to	O
addict	O
corrupt	O
population.	O

Initially,	O
Cocaine	B-Drug
was	O
a	O
personal	O
project	O
for	O
Sibiryov.	O

One	O
unpublished	O
study	O
by	O
Frank	O
Sharp	O
reportedly	O
showed	O
no	O
damage	O
the	O
NDMA	O
antagonist	O
ketamine,	O
a	O
structurally	O
similar	O
drug,	O
far	O
beyond	O
recreational	O
doses,	O
but	O
due	O
to	O
never	O
having	O
been	O
published,	O
its	O
validity	O
is	O
controversial.	O
ketamine	B-Drug

Estonia	O
has	O
the	O
highest	O
rate	O
of	O
3-methylfentanyl	B-Drug
overdose	O
deaths	O
in	O
EU,	O
due	O
to	O
its	O
high	O
recreational	O
use.	O

There	O
is	O
no	O
data	O
on	O
the	O
use	O
of	O
amiloride	B-Drug
in	O
women	O
that	O
are	O
breastfeeding.	O

In	O
September	O
2019,	O
the	O
U.S.	O
Food	O
and	O
Drug	O
Administration	O
(FDA)	O
learned	O
that	O
some	O
ranitidine	B-Drug
medicines,	O
including	O
products	O
sold	O
under	O
brand	O
name	O
Zantac,	O
contained	O
a	O
nitrosamine	O
impurity	O
called	O
N-nitrosodimethylamine	O
(NDMA),	O
classified	O
as	O
probable	O
human	O
carcinogen,	O
at	O
low	O
levels.	O
Zantac	B-Drug

Chlortalidone	B-Drug
is	O
superior	O
to	O
angiotensin	O
converting	O
enzyme	O
Inhibitors	O
or	O
II	O
receptor	O
blockers	O
for	O
inducing	O
regression	O
of	O
enlargement	O
the	O
left	O
ventricle,	O
which	O
main	O
pumping	O
chamber	O
heart.	O

The	O
biological	O
changes	O
in	O
mice	O
correspond	O
to	O
the	O
epidemiological	O
observations	O
humans	O
that	O
nicotine	B-Drug
consumption	O
is	O
coupled	O
an	O
increased	O
probability	O
of	O
later	O
use	O
cannabis	O
and	O
cocaine,	O
as	O
well	O
other	O
drugs.	O
cocaine	B-Drug

Research	O
in	O
these	O
events	O
is	O
complicated	O
because	O
cannabis	O
often	O
used	O
conjunction	O
with	O
tobacco,	O
and	O
drugs	O
such	O
as	O
alcohol	O
cocaine.	O
tobacco	B-Drug
cocaine	B-Drug

Dextroamphetamine	B-Drug
is	O
the	O
active	O
metabolite	O
of	O
prodrug	O
lisdexamfetamine	B-Drug
(L-lysine-dextroamphetamine),	O
available	O
by	O
brand	O
name	O
Vyvanse	B-Drug
(Elvanse	O
in	O
European	O
market)	O
(lisdexamfetamine	O
dimesylate).	O
dimesylate	I-Drug

Side	O
effects	O
of	O
testosterone	B-Drug
propionate	I-Drug
include	O
virilization	O
among	O
others.	O

In	O
September	O
2020,	O
the	O
WHO	O
released	O
updated	O
guidance	O
on	O
using	O
corticosteroids	O
for	O
COVID19.In	O
July	O
European	O
Medicines	O
Agency	O
(EMA)	O
started	O
reviewing	O
results	O
from	O
RECOVERY	O
study	O
arm	O
that	O
involved	O
use	O
of	O
dexamethasone	B-Drug
in	O
treatment	O
patients	O
with	O
COVID19	O
admitted	O
to	O
hospital	O
provide	O
an	O
opinion	O
and	O
particular	O
potential	O
adults	O
COVID-19.	O

People	O
who	O
intravenously	O
inject	O
black	O
tar	O
heroin	B-Drug
are	O
at	O
higher	O
risk	O
of	O
venous	O
sclerosis	O
than	O
those	O
injecting	O
powder	O
heroin.	O

On	O
decarboxylation	O
the	O
following	O
major	O
cannabinoids	O
THC,	O
CBD,	O
CBC,	O
CBCV,	O
CBDV,	O
CBGV,	O
THCV	O
are	O
formed.	O
THC	B-Drug
CBD	B-Drug

Lorazepam	B-Drug
has	O
anxiolytic,	O
sedative,	O
hypnotic,	O
amnesic,	O
anticonvulsant,	O
and	O
muscle	O
relaxant	O
properties.	O

In	O
children,	O
intranasal	O
fentanyl	B-Drug
is	O
useful	O
for	O
the	O
treatment	O
of	O
moderate	O
and	O
severe	O
pain	O
well	O
tolerated.	O

Some	O
studies	O
found	O
that	O
the	O
abrupt	O
substitution	O
of	O
substitutive	O
pharmacotherapy	O
was	O
actually	O
less	O
effective	O
than	O
gradual	O
dose	O
reduction	O
alone,	O
and	O
only	O
three	O
benefits	O
adding	O
melatonin,	O
paroxetine,	O
trazodone,	O
or	O
valproate	B-Drug
in	O
conjunction	O
with	O
a	O
reduction.	O
melatonin	B-Drug
paroxetine	B-Drug
trazodone	B-Drug

It	O
is	O
around	O
100	O
times	O
stronger	O
than	O
morphine,	O
about	O
50	O
heroin.	O
morphine	B-Drug
heroin	B-Drug

Bonnie	O
Parker	O
(Emily	O
Brobst)	O
of	O
and	O
Clyde	O
Fame	O
is	O
addicted	O
to	O
laudanum.	O
laudanum	B-Drug

Twelve	O
reported	O
fatalities	O
have	O
been	O
attributed	O
to	O
mirtazapine	B-Drug
overdose.	O

A	O
related	O
AAS	O
is	O
boldenone	B-Drug
undecylenate	I-Drug
(1-testosterone	O
17-undec-10-enoate).	O
1-testosterone	B-Drug

One	O
involved	O
Eli	O
Lilly's	O
antipsychotic	O
Zyprexa,	O
and	O
the	O
other	O
Bextra.	O
Zyprexa	B-Drug
Bextra	B-Drug

However,	O
propranolol	B-Drug
is	O
highly	O
bound	O
to	O
proteins	O
in	O
the	O
bloodstream	O
and	O
distributed	O
into	O
breast	O
milk	O
at	O
very	O
low	O
levels.	O

This	O
study	O
suggested	O
that	O
25I-NBOMe	B-Drug
is	O
approximately	O
14-fold	O
more	O
potent	O
than	O
2C-I	O
in-vivo.	O

Initial	O
research	O
with	O
mice	O
shows	O
the	O
compound	O
has	O
a	O
painkilling	O
effect	O
greater	O
than	O
that	O
of	O
morphine.	O
morphine	B-Drug

In	O
Europe	O
addicts	O
use	O
mostly	O
heroin	B-Drug
from	O
Western	O
Asia	O
(from	O
Afghanistan	O
and	O
neighboring	O
countries)	O

Cocaine	B-Drug

The	O
strategy	O
suggests	O
regulations	O
that	O
are	O
encompassed	O
under	O
three	O
main	O
categories:	O
(1)	O
to	O
promote	O
the	O
responsible	O
use	O
of	O
opioids,	O
(2)	O
reduce	O
supply	O
and	O
(3)	O
support	O
overdose	O
prevention	O
expand	O
access	O
naloxone.	O
naloxone	B-Drug

Naltrexone	B-Drug
is	O
also	O
a	O
partial	O
inverse	O
agonist,	O
and	O
this	O
property	O
exploited	O
in	O
treatment	O
of	O
opioid	O
addiction,	O
as	O
sustained	O
course	O
low-dose	O
naltrexone	O
can	O
reverse	O
the	O
altered	O
homeostasis	O
which	O
results	O
from	O
long-term	O
abuse	O
agonist	O
drugs.	O

The	O
effect	O
of	O
ketamine	B-Drug
on	O
the	O
respiratory	O
and	O
circulatory	O
systems	O
is	O
different	O
from	O
that	O
other	O
anesthetics.	O

Medical	O
and	O
scientific	O
research	O
with	O
LSD	B-Drug
in	O
humans	O
is	O
permitted	O
under	O
the	O
1971	O
UN	O
Convention.	O

The	O
contributions	O
of	O
these	O
metabolites	O
to	O
the	O
psychoactive	O
and	O
toxic	O
effects	O
MDMA	B-Drug
are	O
an	O
area	O
active	O
research.	O

In	O
contrast,	O
much	O
larger	O
doses	O
of	O
Adderall	B-Drug
can	O
impair	O
cognitive	O
control,	O
cause	O
rapid	O
muscle	O
breakdown,	O
provoke	O
panic	O
attacks,	O
or	O
induce	O
a	O
psychosis	O
(e.g.,	O
paranoia,	O
delusions,	O
hallucinations).	O

All	O
drugs	O
in	O
the	O
NBOMe	O
series,	O
including	O
25I-NBOMe,	O
became	O
illegal	O
Russia	O
October	O
2011.	O
25I-NBOMe	B-Drug

The	O
user	O
allows	O
the	O
heroin	B-Drug
to	O
completely	O
dissolve	O
into	O
water	O
and	O
solution	O
is	O
dropped	O
nose.	O

Various	O
surveys	O
conducted	O
between	O
2015	O
and	O
2019	O
found	O
that	O
many	O
users	O
of	O
cannabis	O
substitute	O
it	O
for	O
prescription	O
drugs	O
(including	O
opioids),	O
alcohol,	O
tobacco;	O
most	O
those	O
who	O
used	O
in	O
place	O
alcohol	O
or	O
tobacco	B-Drug
either	O
reduced	O
stopped	O
their	O
intake	O
the	O
latter	O
substances.	O

Generic	O
production	O
shut	O
down	O
two	O
years	O
later,	O
when	O
the	O
FDA	O
revoked	O
metandienone's	O
approval	O
entirely	O
in	O
1985.	O
metandienone	B-Drug

Testosterone	B-Drug
propionate	I-Drug
is	O
mentioned	O
in	O
a	O
letter	O
to	O
the	O
editor	O
of	O
Strength	O
and	O
Health	O
magazine	O
1938;	O
this	O
earliest	O
known	O
reference	O
an	O
AAS	O
U.S.	O
weightlifting	O
or	O
bodybuilding	O
magazine.	O

Alcohol	O
and	O
caffeine	O
are	O
ingested	O
in	O
beverage	O
form;	O
nicotine	B-Drug
cannabis	O
smoked	O
or	O
vaporized;	O
peyote	O
psilocybin	O
mushrooms	O
botanical	O
form	O
dried;	O
crystalline	O
drugs	O
such	O
as	O
cocaine	B-Drug
methamphetamine	B-Drug
usually	O
insufflated	O
(inhaled	O
"snorted").	O

cannabis,	O
LSD	B-Drug
Head,	O
Heart	O
and	O
Balls...	O
or	O

In	O
the	O
United	O
States,	O
deaths	O
linked	O
to	O
methadone	B-Drug
more	O
than	O
quadrupled	O
in	O
five-year	O
period	O
between	O
1999	O
and	O
2004.	O

Both	O
exhibit	O
optical	O
isomerism	O
and	O
alphaprodine	B-Drug
betaprodine	B-Drug
are	O
racemates.	O

Cocaine	B-Drug
is	O
a	O
powerful	O
stimulant	O
known	O
to	O
make	O
users	O
feel	O
energetic,	O
cheerful,	O
talkative,	O
etc.	O

Thalidomide	B-Drug
is	O
provided	O
as	O
a	O
racemic	O
mixture	O
of	O
two	O
enantiomers;	O
while	O
there	O
are	O
reports	O
that	O
only	O
one	O
the	O
enantiomers	O
may	O
cause	O
birth	O
defects,	O
body	O
converts	O
each	O
enantiomer	O
into	O
other	O
through	O
mechanisms	O
not	O
well	O
understood.	O

Less	O
frequently,	O
in	O
3-10%	O
of	O
people,	O
fentanyl	B-Drug
can	O
cause	O
abdominal	O
pain,	O
headache,	O
fatigue,	O
anorexia	O
and	O
weight	O
loss,	O
dizziness,	O
nervousness,	O
hallucinations,	O
anxiety,	O
depression,	O
flu-like	O
symptoms,	O
dyspepsia	O
(indigestion),	O
shortness	O
breath,	O
hypoventilation,	O
apnoea,	O
urinary	O
retention.	O

In	O
2006,	O
the	O
U.S.	O
Food	O
and	O
Drug	O
Administration	O
(FDA)	O
began	O
investigating	O
several	O
respiratory	O
deaths,	O
but	O
doctors	O
in	O
United	O
Kingdom	O
were	O
not	O
warned	O
of	O
risks	O
with	O
fentanyl	B-Drug
until	O
September	O
2008.	O

Schedule	O
III:	O
substances	O
that	O
are	O
turned	O
into	O
morphine	B-Drug
once	O
in	O
the	O
human	O
body	O
such	O
as	O
codeine	B-Drug
and	O
dextropropoxyphene.	O
dextropropoxyphene	B-Drug

Prior	O
to	O
the	O
compounds	O
being	O
made	O
illegal,	O
mephedrone,	O
methylone,	O
and	O
MDPV	B-Drug
were	O
marketed	O
as	O
bath	O
salts.	O
mephedrone	B-Drug
methylone	B-Drug

It	O
is	O
unclear	O
if	O
fentanyl	B-Drug
gives	O
long-term	O
pain	O
relief	O
to	O
people	O
with	O
neuropathic	O
pain.	O

Long-acting	O
injectable	O
naltrexone	B-Drug
decreases	O
heroin	B-Drug
use	O
more	O
than	O
placebo.	O

MDMA	B-Drug
may	O
have	O
been	O
in	O
non-medical	O
use	O
the	O
western	O
United	O
States	O
1968.	O

A	O
combination	O
of	O
paracetamol,	O
codeine,	O
and	O
the	O
calmative	O
doxylamine	O
succinate	O
is	O
also	O
available.	O
paracetamol	B-Drug
codeine	B-Drug

Thalidomide	B-Drug
may	O
be	O
helpful	O
in	O
some	O
cases	O
where	O
standard	O
TB	O
drugs	O
and	O
corticosteroids	O
are	O
not	O
sufficient	O
to	O
resolve	O
severe	O
inflammation	O
the	O
brain.	O

It	O
is	O
a	O
substrate	O
for	O
5-reductase	O
like	O
testosterone,	O
and	O
so	O
potentiated	O
analogously	O
in	O
so-called	O
"androgenic"	O
tissues	O
the	O
skin,	O
hair	O
follicles,	O
prostate	O
gland	O
via	O
transformation	O
into	O
more	O
potent	O
AR	O
agonist	O
mestanolone	B-Drug
(17-methyl-DHT).	O

The	O
amount	O
of	O
cocaine	B-Drug
in	O
a	O
line	O
varies	O
widely	O
from	O
person	O
to	O
and	O
occasion	O

In	O
accordance,	O
modafinil	B-Drug
increases	O
locomotor	O
activity	O
and	O
extracellular	O
dopamine	O
concentrations	O
in	O
animals	O
a	O
manner	O
similar	O
to	O
the	O
selective	O
DRI	O
vanoxerine	B-Drug
(GBR-12909),	O
also	O
inhibits	O
methamphetamine-induced	O
release	O
(a	O
common	O
property	O
of	O
DRIs,	O
since	O
DAT	O
transport	O
facilitates	O
methamphetamine's	O
access	O
its	O
intracellular	O
targets).	O
methamphetamine	B-Drug

It	O
is	O
also	O
used	O
as	O
a	O
recreational	O
drug,	O
often	O
mixed	O
with	O
heroin	B-Drug
or	O
cocaine.	O
cocaine	B-Drug

The	O
former	O
compound,	O
L--methadol,	O
is	O
an	O
important	O
active	O
metabolite	O
of	O
levacetylmethadol	B-Drug
(LAAM),	O
opioid	O
substitute	O
drug	O
that	O
used	O
clinically.	O
methadol	B-Drug

Loperamide	B-Drug
taken	O
with	O
quinidine	B-Drug
was	O
found	O
to	O
produce	O
respiratory	O
depression,	O
indicative	O
of	O
central	O
opioid	O
action.	O

5-MeO-EiPT	B-Drug
is	O
illegal	O
in	O
Italy.	O

Desmetramadol	O
(INN),	O
also	O
known	O
as	O
O-desmethyltramadol	O
(O-DSMT),	O
is	O
an	O
opioid	O
analgesic	O
and	O
the	O
main	O
active	O
metabolite	O
of	O
tramadol.	O
tramadol	B-Drug

During	O
the	O
18th	O
century,	O
opium	B-Drug
was	O
found	O
to	O
be	O
a	O
good	O
remedy	O
for	O
nervous	O
disorders.	O

The	O
oral	O
bioavailability	O
of	O
amphetamine	B-Drug
varies	O
with	O
gastrointestinal	O
pH;	O
it	O
is	O
well	O
absorbed	O
from	O
the	O
gut,	O
and	O
typically	O
over	O
75%	O
for	O
dextroamphetamine.	O
dextroamphetamine	B-Drug

Elliot	O
Borin's	O
article	O
"The	O
U.S.	O
Military	O
Needs	O
its	O
Speed"published	O
in	O
Wired	O
on	O
February	O
10,	O
2003reports:	O
But	O
the	O
Defense	O
Department,	O
which	O
distributed	O
millions	O
of	O
amphetamine	B-Drug
tablets	O
to	O
troops	O
during	O
World	O
War	O
II,	O
Vietnam	O
and	O
Gulf	O
War,	O
soldiers	O
on,	O
insisting	O
that	O
they	O
are	O
not	O
only	O
harmless	O
but	O
beneficial.	O

In	O
recent	O
years	O
fentanyl	B-Drug
has	O
disrupted	O
the	O
North	O
American	O
drug	O
market,	O
capitalizing	O
on	O
pre-existing	O
demand	O
for	O
opiates	O
such	O
as	O
heroin	B-Drug
and	O
prescription	O
pharmaceuticals.	O

Nine	O
percent	O
of	O
ingested	O
PCP	B-Drug
is	O
excreted	O
in	O
its	O
unchanged	O
form.	O

In	O
July	O
2014,	O
Gilead	O
Sciences	O
filed	O
a	O
patent	O
for	O
sofosbuvir	B-Drug
in	O
India.	O

The	O
images	O
produced	O
are	O
similar	O
to	O
those	O
for	O
labelled	O
flumazenil,	O
though	O
the	O
distribution	O
varies	O
especially	O
in	O
regions	O
such	O
as	O
occipital	O
lobe,	O
cerebellum,	O
and	O
basal	O
ganglia,	O
it	O
does	O
not	O
selectively	O
label	O
GABRA1	O
subtype.	O
flumazenil	B-Drug

These	O
toxic	O
reactions	O
may	O
also	O
occur	O
as	O
part	O
of	O
the	O
dapsone	B-Drug
hypersensitivity	I-Drug
syndrome	I-Drug
(a	O
form	O
SCARs-see	O
above)	O
or	O
(see	O
below).	O

Tolerance	O
to	O
LSD	B-Drug
builds	O
up	O
with	O
consistent	O
use	O
and	O
cross-tolerance	O
has	O
been	O
demonstrated	O
between	O
LSD,	O
mescaline,	O
psilocybin.	O
mescaline	B-Drug

As	O
of	O
February	O
2016,	O
pharmacies	O
across	O
Alberta	O
and	O
some	O
other	O
Canadian	O
jurisdictions	O
are	O
allowed	O
to	O
distribute	O
take-home	O
naloxone	B-Drug
kits.	O

The	O
S(+)	O
and	O
R()	O
stereoisomers	O
of	O
ketamine	B-Drug
bind	O
to	O
the	O
dizocilpine	O
site	O
NMDA	O
receptor	O
with	O
different	O
affinities,	O
former	O
showing	O
approximately	O
2-	O
3-fold	O
greater	O
affinity	O
for	O
than	O
latter.	O

Betaprodine	B-Drug
is	O
some	O
five	O
times	O
more	O
potent	O
than	O
alphaprodine,	O
but	O
metabolized	O
rapidly,	O
and	O
only	O
alphaprodine	B-Drug
was	O
developed	O
for	O
medicinal	O
use.	O

By	O
blocking	O
sodium	O
ion	O
resorption	O
in	O
the	O
distal	O
convoluted	O
tubule,	O
chlortalidone	B-Drug
induces	O
an	O
increase	O
excretion	O
of	O
urine	O
(natriuresis).	O

A	O
survey	O
conducted	O
by	O
the	O
UK	O
National	O
Addiction	O
Centre	O
found	O
67%	O
of	O
mephedrone	B-Drug
users	O
experienced	O
sweating,	O
51%	O
suffered	O
from	O
headaches,	O
43%	O
heart	O
palpitations,	O
27%	O
nausea	O
and	O
15%	O
cold	O
or	O
blue	O
fingers,	O
indicative	O
vasoconstriction	O
occurring.	O

Dienogest	B-Drug
does	O
not	O
inhibit	O
or	O
induce	O
CYP3A4,	O
unlike	O
many	O
other	O
related	O
progestins.	O

Animal	O
research	O
suggests	O
that	O
monoamine	O
oxidase	O
inhibitors	O
present	O
in	O
tobacco	O
smoke	O
may	O
enhance	O
nicotine's	O
addictive	O
properties	O
.	O
nicotine	B-Drug

Diazepam	B-Drug
has	O
a	O
range	O
of	O
side	O
effects	O
common	O
to	O
most	O
benzodiazepines,	O
including:	O
Suppression	O
REM	O
sleep	O
and	O
Slow	O
wave	O

Meperidine	B-Drug
is	O
a	O
fully	O
synthetic	O
opioid,	O
and	O
other	O
members	O
of	O
the	O
phenylpiperidine	O
family	O
like	O
alfentanil	B-Drug
sufentanil	B-Drug
are	O
complex	O
versions	O
this	O
structure.	O

More	O
recently,	O
a	O
participant	O
in	O
an	O
endurance	O
walking	O
race	O
Britain,	O
Abraham	O
Wood,	O
said	O
1807	O
that	O
he	O
had	O
used	O
laudanum	B-Drug
(which	O
contains	O
opiates)	O
to	O
keep	O
him	O
awake	O
for	O
24	O
hours	O
while	O
competing	O
against	O
Robert	O
Barclay	O
Allardyce.	O

Amphetamine	B-Drug
also	O
inhibits	O
monoamine	O
oxidases	O
at	O
very	O
high	O
doses,	O
resulting	O
in	O
less	O
and	O
trace	O
amine	O
metabolism	O
consequently	O
higher	O
concentrations	O
of	O
synaptic	O
monoamines.	O

Major	O
examples	O
include	O
the	O
pregnanes	O
pregnenolone	O
sulfate	O
(PS),	O
epipregnanolone,	O
and	O
isopregnanolone	O
(sepranolone),	O
androstanes	O
dehydroepiandrosterone	B-Drug
(DHEA;	O
prasterone),	O
(DHEA-S;	O
prasterone	B-Drug
sulfate),	O
cholestane	O
24(S)-hydroxycholesterol	O
(NMDA	O
receptor-selective;	O
very	O
potent).	O

An	O
estimated	O
19416	O
individuals	O
died	O
of	O
a	O
drug	O
overdose	O
in	O
the	O
United	O
States	O
first	O
3	O
months	O
2020	O
compared	O
with	O
16682	O
same	O
3-month	O
period	O
2019;	O
this	O
trend	O
was	O
fueled	O
by	O
synthetic	O
opioids	O
(especially	O
illicitly	O
manufactured	O
fentanyl	B-Drug
and	O
analogs),	O
while	O
continental	O
Europe	O
has	O
seen	O
decrease	O
from	O
heroin	B-Drug
overdoses,	O
practical	O
absence	O
illicit,	O
opioids.	O

As	O
of	O
January	O
2015,	O
kratom	B-Drug
was	O
controlled	O
as	O
a	O
narcotic	O
in	O
Australia	O
and	O
under	O
Medicines	O
Regulations	O
1985	O
(Amended	O
August	O
6,	O
2015)	O
New	O
Zealand.	O

Ergot	O
alkaloids	O
ergometrine	B-Drug
(ergobazin,	O
ergonovine),	O
ergotamine	B-Drug
and	O
their	O
synthetic	O
derivatives	O
(methylergometrine)	O
are	O
applied	O
against	O
uterine	O
bleeding,	O
bisindole	O
vinblastine	B-Drug
vincristine	B-Drug
antitumor	O
agents.	O
ergonovine	B-Drug

Since	O
amphetamine	B-Drug
use	O
is	O
illicit	O
in	O
most	O
countries,	O
the	O
off-label	O
by	O
students	O
often	O
regarded	O
as	O
a	O
major	O
issue	O
governmental	O
regulation	O
institutions.	O

Notably,	O
with	O
the	O
sole	O
exception	O
of	O
amineptine,	O
TCAs	O
have	O
negligible	O
affinity	O
for	O
dopamine	O
transporter	O
(DAT),	O
and	O
therefore	O
no	O
efficacy	O
as	O
reuptake	O
inhibitors	O
(DRIs).	O
amineptine	B-Drug

The	O
alkaloid	O
profiles	O
of	O
poppy	O
straw	O
and	O
opium	B-Drug
are	O
similar,	O
but	O
preliminary	O
research	O
suggests	O
they	O
can	O
be	O
distinguished	O
by	O
relative	O
quantities	O
alkaloids.	O

Merck	O
was	O
awarded	O
a	O
separate	O
patent	O
for	O
the	O
use	O
of	O
finasteride	B-Drug
to	O
treat	O
pattern	O
hair	O
loss	O
and	O
it	O
expired	O
in	O
November	O
2013.	O

In	O
order	O
to	O
curb	O
misuse,	O
many	O
health	O
insurers	O
have	O
begun	O
require	O
precertification	O
and/or	O
quantity	O
limits	O
for	O
Actiq	B-Drug
prescriptions.	O

More	O
than	O
33,000	O
people	O
died	O
from	O
overdoses	O
in	O
2015,	O
nearly	O
equal	O
to	O
the	O
number	O
of	O
deaths	O
car	O
crashes	O
with	O
heroin	B-Drug
alone	O
more	O
gun	O
homicides.	O

Ethylestrenol	B-Drug
was	O
first	O
described	O
in	O
1959	O
and	O
introduced	O
for	O
medical	O
use	O
1961.	O

In	O
2004,	O
the	O
National	O
Institute	O
for	O
Health	O
and	O
Clinical	O
Excellence	O
produced	O
guidance	O
on	O
management	O
of	O
caesarean	O
section,	O
which	O
recommended	O
use	O
intrathecal	O
or	O
epidural	O
diamorphine	B-Drug
post-operative	O
pain	O
relief.	O

Additionally,	O
because	O
cocaine	B-Drug
is	O
a	O
vasoconstrictor,	O
and	O
usage	O
often	O
entails	O
multiple	O
injections	O
within	O
several	O
hours	O
or	O
less,	O
subsequent	O
are	O
progressively	O
more	O
difficult	O
to	O
administer,	O
which	O
in	O
turn	O
may	O
lead	O
injection	O
attempts	O
consequences	O
from	O
improperly	O
performed	O
injection.	O

Hydrolysis	O
of	O
the	O
enamine	O
function	O
then	O
affords	O
mibolerone	B-Drug
(6).	O

Maintenance	O
treatment	O
with	O
bevacizumab/pemetrexed	O
did	O
not	O
confer	O
a	O
significant	O
increase	O
in	O
overall	O
survival	O
vs	O
bevacizumab	B-Drug
alone	O
on	O
follow	O
up	O
analysis.	O
pemetrexed	B-Drug

it	O
is	O
illegal	O
to	O
sell	O
tobacco	B-Drug
products	O
people	O
under	O
the	O
age	O
of	O
16.	O

25I-NBOMe	B-Drug
is	O
potent,	O
being	O
active	O
in	O
sub-milligram	O
doses.	O

Hence,	O
it	O
appears	O
most	O
conventional	O
antidepressants	O
can	O
be	O
safely	O
combined	O
with	O
ketamine.	O
ketamine	B-Drug

Zopiclone	B-Drug
is	O
therefore	O
very	O
similar	O
pharmacologically	O
to	O
benzodiazepines.	O

Different	O
plants	O
of	O
the	O
genus	O
Cannabis	O
contain	O
different	O
and	O
often	O
unpredictable	O
concentrations	O
THC	B-Drug
other	O
cannabinoids	O
hundreds	O
molecules	O
that	O
have	O
a	O
pharmacological	O
effect,	O
so	O
final	O
net	O
effect	O
cannot	O
reliably	O
be	O
foreseen.	O

Members	O
of	O
the	O
team	O
later	O
claimed	O
they	O
had	O
been	O
injected	O
glucose,	O
and	O
physician	O
Franz	O
Loogen	O
said	O
in	O
2004	O
that	O
players	O
only	O
given	O
Vitamin	B-Drug
C	I-Drug
before	O
game.	O

About	O
1,200,	O
or	O
0.1%	O
of	O
bicalutamide	B-Drug
prescriptions	O
were	O
dispensed	O
to	O
pediatric	O
patients	O
(age	O
016).	O

The	O
additional	O
carbon	O
atoms	O
required	O
for	O
the	O
synthesis	O
of	O
cocaine	B-Drug
are	O
derived	O
from	O
acetyl-CoA,	O
by	O
addition	O
two	O
acetyl-CoA	O
units	O
to	O
N-methyl-1-pyrrolinium	O
cation.	O

Diphenhydramine	B-Drug
is	O
also	O
an	O
anticholinergic.	O

In	O
accordance	O
with	O
the	O
very	O
weak	O
nature	O
of	O
its	O
AR	O
antagonistic	O
activity,	O
cimetidine	B-Drug
has	O
shown	O
minimal	O
effectiveness	O
in	O
treatment	O
androgen-dependent	O
conditions	O
such	O
as	O
acne,	O
hirsutism	O
(excessive	O
hair	O
growth),	O
and	O
hyperandrogenism	O
(high	O
androgen	O
levels)	O
women.	O

inhibitorTramadol	O
acts	O
on	O
the	O
opioid	O
receptors	O
through	O
its	O
major	O
active	O
metabolite	O
desmetramadol,	O
which	O
has	O
as	O
much	O
700-fold	O
higher	O
affinity	O
for	O
MOR	O
relative	O
to	O
tramadol.	O
tramadol	B-Drug

Black	O
tar	O
heroin	O
is	O
impure	O
diamorphine.	O
diamorphine	B-Drug

Similarly	O
to	O
nilutamide,	O
bicalutamide,	O
and	O
enzalutamide,	O
flutamide	O
crosses	O
the	O
bloodbrain	O
barrier	O
exerts	O
central	O
antiandrogen	O
actions.	O
bicalutamide	B-Drug
enzalutamide	B-Drug

Interdiction	O
efforts,	O
using	O
current	O
armed	O
forces	O
resources,	O
would	O
have	O
almost	O
no	O
effect	O
on	O
cocaine	B-Drug
importation	O
into	O
the	O
United	O
States,	O
report	O
concluded.	O

In	O
the	O
United	O
States,	O
MDMA	B-Drug
is	O
currently	O
placed	O
in	O
Schedule	O
I	O
of	O
Controlled	O
Substances	O
Act.	O

Methylphenidate's	O
mechanism	O
of	O
action	O
in	O
the	O
release	O
dopamine	O
and	O
norepinephrine	O
is	O
fundamentally	O
different	O
from	O
most	O
other	O
phenethylamine	O
derivatives,	O
as	O
methylphenidate	B-Drug
thought	O
to	O
increase	O
neuronal	O
firing	O
rate,	O
whereas	O
amphetamine	B-Drug
reduces	O
but	O
causes	O
monoamine	O
by	O
reversing	O
flow	O
monoamines	O
through	O
transporters	O
via	O
a	O
diverse	O
set	O
mechanisms,	O
including	O
TAAR1	O
activation	O
modulation	O
VMAT2	O
function,	O
among	O
mechanisms.	O
Methylphenidate	B-Drug

The	O
development	O
of	O
synthetic	O
quinine	B-Drug
is	O
considered	O
a	O
milestone	O
in	O
organic	O
chemistry	O
although	O
it	O
has	O
never	O
been	O
produced	O
industrially	O
as	O
substitute	O
for	O
natural	O
occurring	O
quinine.	O

In	O
addition,	O
the	O
C7	O
substitution	O
appears	O
to	O
be	O
responsible	O
for	O
loss	O
of	O
progestogenic	O
activity	O
and	O
good	O
oral	O
bioavailability	O
spironolactone,	O
as	O
SC-5233,	O
analogue	O
spironolactone	B-Drug
without	O
a	O
substitution,	O
has	O
potent	O
but	O
very	O
poor	O
similarly	O
progesterone.	O

The	O
aftermath	O
of	O
World	O
War	O
II	O
saw	O
an	O
explosion	O
in	O
the	O
discovery	O
new	O
classes	O
antibacterial	O
drugs	O
including	O
cephalosporins	O
(developed	O
by	O
Eli	O
Lilly	O
based	O
on	O
seminal	O
work	O
Giuseppe	O
Brotzu	O
and	O
Edward	O
Abraham),	O
streptomycin	B-Drug
(discovered	O
during	O
a	O
Merck-funded	O
research	O
program	O
Selman	O
Waksman's	O
laboratory),	O
tetracyclines	O
at	O
Lederle	O
Laboratories,	O
now	O
part	O
Pfizer),	O
erythromycin	B-Drug
Co.)	O
their	O
extension	O
to	O
increasingly	O
wide	O
range	O
bacterial	O
pathogens.	O

Cannabis	O
produces	O
CBD-carboxylic	O
acid	O
through	O
the	O
same	O
metabolic	O
pathway	O
as	O
THC,	O
until	O
next	O
to	O
last	O
step,	O
where	O
CBDA	O
synthase	O
performs	O
catalysis	O
instead	O
of	O
THCA	O
synthase.	O
THC	B-Drug

MDMA	B-Drug
and	O
MDA	O
may	O
be	O
quantitated	O
in	O
blood,	O
plasma	O
or	O
urine	O
to	O
monitor	O
for	O
use,	O
confirm	O
a	O
diagnosis	O
of	O
poisoning	O
assist	O
the	O
forensic	O
investigation	O
traffic	O
other	O
criminal	O
violation	O
sudden	O
death.	O

Oxymetholone	B-Drug
is	O
the	O
generic	O
name	O
of	O
drug	O
and	O
its	O
INN,	O
USAN,	O
USP,	O
BAN,	O
JAN,	O
while	O
oxymtholone	O
DCF.	O

In	O
addition	O
to	O
its	O
medical	O
use,	O
oxandrolone	B-Drug
is	O
used	O
improve	O
physique	O
and	O
performance.	O

If	O
vasoconstriction	O
is	O
desired	O
for	O
a	O
procedure	O
(as	O
it	O
reduces	O
bleeding),	O
the	O
anesthetic	B-Drug
combined	O
with	O
vasoconstrictor	O
such	O
as	O
phenylephrine	B-Drug
or	O
epinephrine.	O

The	O
report	O
found	O
that	O
alprazolam	B-Drug
is	O
the	O
most	O
common	O
benzodiazepine	O
for	O
recreational	O
use,	O
followed	O
by	O
clonazepam,	O
lorazepam,	O
and	O
diazepam.	O
clonazepam	B-Drug
lorazepam	B-Drug
diazepam	B-Drug

In	O
a	O
deal	O
expected	O
to	O
take	O
effect	O
in	O
2012,	O
GlaxoSmithKline	O
sold	O
Tagamet	B-Drug
and	O
16	O
other	O
brands	O
Prestige	O
Brands.	O

In	O
the	O
United	O
Kingdom,	O
all	O
but	O
phenethylamine	B-Drug
are	O
illegal.	O

Fentanyl	B-Drug
was	O
first	O
synthesized	O
in	O
Belgium	O
by	O
Paul	O
Janssen	O
under	O
the	O
label	O
of	O
his	O
relatively	O
newly	O
formed	O
Pharmaceutica	O
1959.	O

Most	O
cloud-chasers	O
do	O
not	O
use	O
nicotine.	O
nicotine	B-Drug

However,	O
its	O
high	O
potency,	O
combined	O
with	O
the	O
rapid	O
action	O
of	O
both	O
etorphine	B-Drug
and	O
antagonist,	O
diprenorphine,	O
means	O
that	O
it	O
has	O
found	O
a	O
place	O
for	O
use	O
in	O
capture	O
large	O
mammals	O
such	O
as	O
rhinoceroses	O
elephants,	O
where	O
onset	O
recovery	O
are	O
very	O
important.	O

Various	O
physical	O
and	O
psychological	O
adverse	O
effects	O
have	O
been	O
reported	O
from	O
JWH-018	B-Drug
use.	O

Zonisamide	B-Drug
(2000).	O

This	O
effect	O
of	O
nociceptin	O
may	O
lead	O
to	O
its	O
future	O
use	O
as	O
a	O
method	O
reduce	O
morphine	B-Drug
dosage	O
and	O
decrease	O
the	O
development	O
tolerance	O
dependence.	O

In	O
1868,	O
as	O
a	O
result	O
of	O
the	O
increased	O
use	O
opium,	O
UK	O
restricted	O
sale	O
opium	B-Drug
in	O
Britain	O
by	O
implementing	O
1868	O
Pharmacy	O
Act.	O

Swallowing	O
has	O
been	O
used	O
for	O
the	O
transportation	O
of	O
heroin,	O
cocaine,	O
and	O
MDMA/Ecstasy.	O
heroin	B-Drug
cocaine	B-Drug
MDMA	B-Drug

By	O
binding	O
to	O
the	O
NMDA	O
receptor	O
with	O
a	O
higher	O
affinity	O
than	O
Mg2+	O
ions,	O
memantine	B-Drug
is	O
able	O
inhibit	O
prolonged	O
influx	O
of	O
Ca2+	O
particularly	O
from	O
extrasynaptic	O
receptors,	O
which	O
forms	O
basis	O
neuronal	O
excitotoxicity.	O

At	O
the	O
same	O
time,	O
CBD	B-Drug
levels	O
in	O
seized	O
samples	O
have	O
lowered,	O
part	O
because	O
of	O
desire	O
to	O
produce	O
higher	O
THC	B-Drug
and	O
more	O
illegal	O
growers	O
cultivate	O
indoors	O
using	O
artificial	O
lights.	O

In	O
utero	O
exposure	O
to	O
MDMA	B-Drug
is	O
associated	O
with	O
a	O
neuro-	O
and	O
cardiotoxicity	O
impaired	O
motor	O
functioning.	O

Mescaline	B-Drug
appears	O
not	O
to	O
be	O
subject	O
metabolism	O
by	O
CYP2D6	O
and	O
between	O
20%	O
50%	O
of	O
mescaline	B-Drug
is	O
excreted	O
in	O
the	O
urine	O
unchanged,	O
rest	O
being	O
as	O
carboxylic	O
acid	O
form	O
mescaline,	O
a	O
likely	O
result	O
MAO	O
degradation.	O

Major	O
members	O
of	O
this	O
class	O
include	O
MDMA,	O
MDA,	O
MDEA,	O
MDOH,	O
MBDB,	O
6-APB,	O
methylone,	O
mephedrone,	O
MT,	O
and	O
ET,	O
MDAI	B-Drug
among	O
others.	O
MDMA	B-Drug
MDOH	B-Drug
MBDB	B-Drug
6-APB	B-Drug
methylone	B-Drug
mephedrone	B-Drug

Buspirone	B-Drug
is	O
the	O
INN,	O
BAN,	O
DCF,	O
and	O
DCIT	O
of	O
buspirone,	O
while	O
buspirone	B-Drug
hydrochloride	I-Drug
its	O
USAN,	O
BANM,	O
JAN.	O

While	O
loop	O
diuretics	O
remain	O
first-line	O
for	O
most	O
people	O
with	O
heart	O
failure,	O
spironolactone	B-Drug
has	O
shown	O
to	O
reduce	O
both	O
morbidity	O
and	O
mortality	O
in	O
numerous	O
studies	O
remains	O
an	O
important	O
agent	O
treating	O
fluid	O
retention,	O
edema,	O
symptoms	O
of	O
failure.	O

Raw	O
materials	O
for	O
the	O
manufacture	O
of	O
ephedrine	B-Drug
and	O
traditional	O
Chinese	O
medicines	O
are	O
produced	O
in	O
China	O
on	O
a	O
large	O
scale.	O

For	O
example,	O
the	O
main	O
metabolites	O
of	O
JWH-018,	O
which	O
there	O
are	O
over	O
20,	O
include	O
carboxylated,	O
monohydroxylated,	O
dihydroxylated,	O
and	O
trihydroxylated	O
metabolites,	O
but	O
they	O
mostly	O
excreted	O
in	O
urine	O
as	O
glucuronide	O
conjugates.	O
JWH-018	B-Drug

Prednisolone	B-Drug
can	O
also	O
be	O
used	O
for	O
allergic	O
reactions	O
ranging	O
from	O
seasonal	O
allergies	O
to	O
drug	O
reactions.	O

Two	O
of	O
the	O
most	O
used	O
and	O
valuable	O
illegal	O
drugs	O
in	O
country	O
are	O
methamphetamine	B-Drug
hydrochloride	I-Drug
(known	O
locally	O
as	O
shabu)	O
marijuana.	O
shabu	B-Drug

This	O
created	O
harsher	O
penalties	O
for	O
drug	O
offenders	O
and	O
also	O
expanded	O
the	O
list	O
of	O
prohibited	O
drugs	O
to	O
include	O
morphine	B-Drug
cocaine,	O
while	O
cannabis	O
was	O
included	O
in	O
1923.	O
cocaine	B-Drug

Levomethadone	B-Drug
has	O
been	O
sold	O
under	O
brand	O
names	O
including	O
L-Polaflux,	O
L-Polamidon,	O
L-Polamivet,	O
Levadone,	O
Levo-Methasan,	O
Levothyl,	O
Mevodict,	O
and	O
Vistadict,	O
among	O
others.	O

Phenaridine	B-Drug
has	O
similar	O
effects	O
to	O
fentanyl.	O
fentanyl	B-Drug

Phenytoin	B-Drug
was	O
first	O
made	O
in	O
1908	O
by	O
the	O
German	O
chemist	O
Heinrich	O
Biltz	O
and	O
found	O
useful	O
for	O
seizures	O
1936.	O

Heroin	B-Drug
addicts	O
used	O
such	O
tablets	O
(crushed	O
and	O
mixed	O
with	O
heroin)	O
to	O
prolong	O
the	O
effect	O
of	O
narcotic	O
ease	O
withdrawal	O
symptoms.	O
heroin	B-Drug

The	O
report	O
stated	O
that	O
not	O
enough	O
was	O
being	O
done	O
about	O
alcohol	O
and	O
tobacco	B-Drug
usage	O
the	O
Misuse	O
of	O
Drugs	O
Act	O
should	O
be	O
reviewed.	O

Large	O
retail	O
pharmacy	O
chains	O
in	O
the	O
US	O
are	O
implementing	O
protocols,	O
guidelines,	O
and	O
initiatives	O
to	O
take	O
back	O
unused	O
opioids,	O
providing	O
naloxone	B-Drug
kits,	O
being	O
vigilant	O
for	O
suspicious	O
prescriptions.	O

Propranolol,	O
sold	O
under	O
the	O
brand	O
name	O
Inderal	B-Drug
among	O
others,	O
is	O
a	O
medication	O
of	O
beta	O
blocker	O
class.	O
Propranolol	B-Drug

This	O
provides	O
an	O
explanation	O
for	O
why	O
some	O
people	O
resort	O
to	O
substances	O
that	O
enhance	O
serotonin	O
activity	O
such	O
as	O
nicotine,	O
alcohol,	O
and	O
cannabis	O
when	O
their	O
progesterone	O
levels	O
fall	O
below	O
optimal	O
levels.	O
nicotine	B-Drug

As	O
of	O
August	O
2015,	O
25I-NBOMe	B-Drug
has	O
reportedly	O
led	O
to	O
at	O
least	O
19	O
overdose	O
deaths	O
in	O
the	O
United	O
States.	O

Mefloquine:	O
may	O
increase	O
valproate	B-Drug
metabolism	O
combined	O
with	O
the	O
direct	O
epileptogenic	O
effects	O
of	O
mefloquine.	O
Mefloquine	B-Drug
mefloquine	B-Drug

Laudanum	B-Drug
is	O
prescribed	O
in	O
Glendon	O
Swarthout's	O
novel	O
The	O
Shootist	O
(1975)	O
to	O
the	O
character	O
J.B.	O
Books,	O
played	O
by	O
John	O
Wayne	O
Don	O
Siegel's	O
movie	O
adaptation	O
(1976).	O

The	O
documentary	O
was	O
presented	O
by	O
Christian	O
Jessen	O
and	O
Jon	O
Snow,	O
included	O
debate	O
on	O
the	O
harms	O
of	O
MDMA,	O
as	O
well	O
exhibiting	O
findings	O
study.	O
MDMA	B-Drug

Simone	O
Courvoisier	O
conducted	O
behavioural	O
tests	O
and	O
found	O
chlorpromazine	B-Drug
produced	O
indifference	O
to	O
aversive	O
stimuli	O
in	O
rats.	O

Some	O
studies	O
found	O
that,	O
like	O
other	O
NMDA	O
receptor	O
antagonists,	O
PCP	B-Drug
can	O
cause	O
a	O
kind	O
of	O
brain	O
damage	O
called	O
Olney's	O
lesions	O
in	O
rats.	O

JWH-018	B-Drug
may	O
cause	O
intense	O
anxiety,	O
agitation,	O
and,	O
in	O
rare	O
cases	O
(generally	O
with	O
non-regular	O
JWH	O
users),	O
has	O
been	O
assumed	O
to	O
have	O
the	O
of	O
seizures	O
and	O
convulsions	O
by	O
inhibiting	O
GABA	O
neurotransmission	O
more	O
effectively	O
than	O
THC.	O
THC	B-Drug

Drugs	O
in	O
this	O
schedule	O
include:	O
Amphetamine	B-Drug
drugs	O
including	O
Adderall,	O
Dextroamphetamine	B-Drug
(Dexedrine),	O
Lisdexamfetamine	B-Drug
(Vyvanse):	O
treatment	O
of	O
ADHD,	O
narcolepsy,	O
severe	O
obesity	O
(limited	O
use,	O
dextroamphetamine	B-Drug
only),	O
binge	O
eating	O
disorder	O
(lisdexamfetamine	O
only).	O
Adderall	B-Drug
Dexedrine	B-Drug
Vyvanse	B-Drug
lisdexamfetamine	B-Drug

There	O
are	O
no	O
expected	O
pharmacokinetic	O
interactions	O
between	O
thalidomide	B-Drug
and	O
other	O
medicines	O
due	O
to	O
its	O
neutral	O
effects	O
on	O
P-glycoprotein	O
the	O
cytochrome	O
P450	O
family.	O

However,	O
drugs	O
sometimes	O
falsely	O
represented	O
by	O
sellers	O
as	O
LSD	B-Drug
in	O
the	O
1970s	O

Phencyclidine	B-Drug
is	O
an	O
NMDA	O
receptor	O
antagonist	O
that	O
blocks	O
the	O
activity	O
of	O
to	O
cause	O
anaesthesia	O
and	O
analgesia	O
without	O
causing	O
cardiorespiratory	O
depression.	O

As	O
an	O
AAS,	O
ethylestrenol	B-Drug
is	O
agonist	O
of	O
the	O
androgen	O
receptor	O
(AR),	O
similarly	O
to	O
androgens	O
like	O
testosterone	O
and	O
dihydrotestosterone	O
(DHT).	O

While	O
the	O
predominant	O
drugs	O
of	O
abuse	O
examined	O
have	O
been	O
cocaine	B-Drug
(44%),	O
ethanol	O
(35%),	O
and	O
opioids	O
(24%).	O

As	O
of	O
October	O
2015	O
Ethylone	B-Drug
is	O
a	O
controlled	O
substance	O
in	O
China.	O

Thus,	O
progesterone	O
was	O
suggested	O
as	O
an	O
agent	O
that	O
decreases	O
cocaine	B-Drug
craving	O
by	O
reducing	O
the	O
dopaminergic	O
properties	O
of	O
drug.	O

While	O
metoclopramide	B-Drug
is	O
used	O
to	O
try	O
increase	O
breast	O
milk	O
production,	O
evidence	O
that	O
it	O
effective	O
for	O
this	O
poor.	O

It	O
also	O
bypasses	O
first-pass	O
metabolism	O
in	O
the	O
liver,	O
resulting	O
higher	O
bioavailability	O
and	O
efficiency	O
for	O
many	O
drugs	O
(such	O
as	O
morphine	B-Drug
or	O
diacetylmorphine/heroin;	O
roughly	O
two-thirds	O
of	O
which	O
is	O
destroyed	O
liver	O
when	O
consumed	O
orally)	O
than	O
oral	O
ingestion	O
would.	O
diacetylmorphine	B-Drug
heroin	B-Drug

The	O
regulatory	O
authorities	O
in	O
East	O
Germany	O
did	O
not	O
approve	O
thalidomide.	O
thalidomide	B-Drug

In	O
poppies	O
subjected	O
to	O
mutagenesis	O
and	O
selection	O
on	O
a	O
mass	O
scale,	O
researchers	O
have	O
been	O
able	O
use	O
poppy	O
straw	O
obtain	O
large	O
quantities	O
of	O
oripavine,	O
precursor	O
opioids	O
antagonists	O
such	O
as	O
naltrexone.	O
naltrexone	B-Drug

Fencamfamin	B-Drug
is	O
well	O
tolerated	O
and	O
causes	O
minimal	O
circulatory	O
effects.	O

The	O
study	O
also	O
found	O
that	O
up	O
to	O
20%	O
of	O
gay	O
men	O
from	O
central	O
London	O
gyms	O
had	O
tried	O
methamphetamine,	O
the	O
drug	O
most	O
associated	O
with	O
PNPing.	O
methamphetamine	B-Drug

Methylnaphthidate	B-Drug
(methyl	O
2-(naphthalen-2-yl)-2-(piperidin-2-yl)acetate)	O

Mary	O
Todd	O
Lincoln,	O
for	O
example,	O
the	O
wife	O
of	O
US	O
president	O
Abraham	O
was	O
a	O
laudanum	B-Drug
addict,	O
as	O
English	O
poet	O
Samuel	O
Taylor	O
Coleridge,	O
who	O
famously	O
interrupted	O
in	O
middle	O
an	O
opium-induced	O
writing	O
session	O
Kubla	O
Khan	O
by	O
"person	O
from	O
Porlock".	O

The	O
pharmacodynamics	O
of	O
spironolactone	B-Drug
are	O
characterized	O
by	O
high	O
antimineralocorticoid	O
activity,	O
moderate	O
antiandrogenic	O
and	O
weak	O
steroidogenesis	O
inhibition,	O
among	O
other	O
more	O
minor	O
activities.	O

Crack	O
cocaine	B-Drug
can	O
also	O
be	O
injected	O
intravenously	O
with	O
the	O
same	O
effect	O
as	O
powder	O
cocaine.	O

5-MeO-MiPT	B-Drug
is	O
a	O
controlled	O
substance	O
in	O
China.	O

Thorazine	B-Drug
(chlorpromazine)	O
the	O
first	O
antipsychotic	O
although	O
highly	O
effective,	O
it	O
is	O
rarely	O
used	O
nowadays	O
because	O
of	O
high	O
rate	O
serious	O
side	O
effects.	O
chlorpromazine	B-Drug

Schedule	O
V:	O
dextrometorphan	O
as	O
well	O
the	O
sleeping	O
agents	O
zopiclone	B-Drug
and	O
zolpidem,	O
among	O
others.	O
zolpidem	B-Drug

The	O
spiritual	O
use	O
of	O
caffeine	O
and	O
nicotine	B-Drug
as	O
stimulants	O
is	O
well	O
known	O
in	O
the	O
Hasidic	O
communities.	O

One	O
of	O
the	O
substances	O
was	O
ligandrol.	O
ligandrol	B-Drug

As	O
of	O
2013	O
in	O
the	O
US,	O
there	O
was	O
a	O
significant	O
increase	O
prescription	O
opioid	O
abuse	O
compared	O
to	O
illegal	O
opiates	O
like	O
heroin.	O
heroin	B-Drug

Sensational	O
media	O
attention	O
was	O
given	O
to	O
the	O
proposed	O
criminalization	O
and	O
reaction	O
of	O
MDMA	B-Drug
proponents,	O
effectively	O
advertising	O
drug.	O

Through	O
computer	O
simulation,	O
scientists	O
found	O
a	O
way	O
to	O
make	O
the	O
fentanyl	B-Drug
analog	O
only	O
affect	O
inflamed	O
tissue	O
via	O
addition	O
of	O
fluorine	O
chemical	O
structure.	O

Chlorodehydromethyltestosterone	B-Drug
(CDMT;	O
brand	O
name	O
Oral	B-Drug
Turinabol),	O
also	O
known	O
as	O
4-chloro-17-hydroxy17-methylandrosta-1,4-dien-3-one,	O
is	O
an	O
anabolicandrogenic	O
steroid	O
(AAS).	O
Turinabol	I-Drug

Thebacon	B-Drug
is	O
indicated	O
for	O
moderate	O
to	O
moderately	O
severe	O
pain	O
and	O
dry	O
painful	O
coughing,	O
like	O
hydrocodone.	O
hydrocodone	B-Drug

The	O
ratio	O
of	O
progestogenic	O
to	O
androgenic	O
activity	O
appears	O
be	O
much	O
lower	O
for	O
norgestrienone	O
that	O
it	O
is	O
other	O
19-nortestosterone	B-Drug
progestins	O
such	O
as	O
norethisterone	B-Drug
and	O
levonorgestrel.	O
levonorgestrel	B-Drug

Vaporizer,	O
which	O
heats	O
any	O
form	O
of	O
cannabis	O
to	O
165190	O
C	O
(329374	O
F),	O
causing	O
the	O
active	O
ingredients	O
evaporate	O
into	O
vapor	O
without	O
burning	O
plant	O
material	O
(the	O
boiling	O
point	O
THC	B-Drug
is	O
157	O
(315	O
F)	O
at	O
atmospheric	O
pressure).	O

In	O
addition,	O
it	O
tends	O
to	O
cause	O
less	O
vomiting	O
and	O
regurgitation	O
than	O
other	O
pure-opiate	O
(codeine,	O
morphine)	O
synthetic	O
pure-opioid	O
agonists	O
(oxycodone,	O
hydromorphone)	O
when	O
given	O
as	O
a	O
continuous	O
post-operative	O
infusion.	O
codeine	B-Drug
morphine	B-Drug
oxycodone	B-Drug
hydromorphone	B-Drug

Thus,	O
with	O
both	O
higher	O
the	O
dosage	O
of	O
heroin	B-Drug
used	O
and	O
faster	O
route	O
administration	O
used,	O
potential	O
risk	O
for	O
psychological	O
dependence/addiction.	O

Apalutamide	B-Drug
was	O
originated	O
by	O
the	O
University	O
of	O
California	O
system	O
and	O
developed	O
primarily	O
Janssen	O
Research	O
&	O
Development,	O
a	O
division	O
Johnson	O
Johnson.	O

While	O
Suboxone	B-Drug
is	O
indicated	O
for	O
the	O
treatment	O
of	O
opioid	O
dependence,	O
it	O
does	O
contain	O
an	O
which	O
means	O
a	O
person	O
may	O
be	O
at	O
risk	O
developing	O
dependence	O
to	O
as	O
well.	O

In	O
these	O
coffeeshops,	O
they	O
sell	O
cannabis,	O
which	O
is	O
considered	O
to	O
be	O
soft	O
drugs	O
in	O
comparison	O
hard	O
drugs;	O
such	O
as	O
heroin.	O
heroin	B-Drug

Because	O
THC	B-Drug
production	O
drops	O
off	O
once	O
pollination	O
occurs,	O
the	O
male	O
plants	O
(which	O
produce	O
little	O
themselves)	O
are	O
eliminated	O
before	O
they	O
shed	O
pollen	O
to	O
prevent	O
pollination,	O
thus	O
inducing	O
development	O
of	O
parthenocarpic	O
fruits	O
gathered	O
in	O
dense	O
infructescences.	O

Chinese	O
officials	O
are	O
becoming	O
increasingly	O
concerned	O
about	O
the	O
abuse	O
of	O
methamphetamine	B-Drug
and	O
other	O
amphetamine-type	O
stimulants.	O

The	O
company's	O
breakthrough	O
came	O
in	O
the	O
middle	O
of	O
2012	O
when	O
it	O
was	O
able	O
to	O
develop	O
a	O
unique	O
strain	O
medical	O
marijuana	O
that	O
does	O
not	O
contain	O
psychoactive	O
substance	O
THC,	O
producing	O
no	O
sense	O
intoxication,	O
and	O
yet	O
had	O
anti-inflammatory	O
properties	O
plant	O
called	O
cannabidiol,	O
or	O
CBD.	O
THC	B-Drug
cannabidiol	B-Drug
CBD	B-Drug

Quinbolone	B-Drug
(17-(1-cyclopenten-1-yloxy)	O

In	O
similar	O
manner,	O
older	O
dopamine	O
agonists	O
used	O
for	O
Parkinson's	O
disease	O
such	O
as	O
bromocriptine	B-Drug
and	O
cabergoline	B-Drug
are	O
poorly	O
selective	O
one	O
receptor	O
over	O
another,	O
and,	O
although	O
most	O
of	O
these	O
agents	O
do	O
act	O
D2	O
agonists,	O
they	O
affect	O
other	O
subtypes	O
well.	O

PCP	B-Drug
not	O
only	O
produced	O
symptoms	O
similar	O
to	O
schizophrenia,	O
it	O
also	O
yielded	O
electroencephalogram	O
changes	O
in	O
the	O
thalamocortical	O
pathway	O
(increased	O
delta	O
decreased	O
alpha)	O
and	O
hippocampus	O
(increase	O
theta	O
bursts)	O
that	O
were	O
those	O
schizophrenia.	O

Other	O
related	O
compounds	O
with	O
equivalent	O
activity	O
where	O
the	O
piperidine	O
ring	O
has	O
been	O
replaced	O
by	O
other	O
groups,	O
include	O
morpholine	O
derivative	O
phenadoxone,	O
as	O
well	O
corresponding	O
pyrrolidine	O
derivative.	O
phenadoxone	B-Drug

MAM-2201	B-Drug
MDA-7	O
MDA-19	B-Drug
MDA-77	O

Recreational	O
use	O
of	O
telazol	B-Drug
has	O
been	O
documented.	O

Phenobarbital	B-Drug
is	O
one	O
of	O
the	O
initial	O
drugs	O
choice	O
to	O
treat	O
epilepsy	O
in	O
dogs,	O
and	O
drug	O
cats.	O

Hyoscine	B-Drug
enters	O
breast	O
milk	O
by	O
secretion.	O

Tapentadol	B-Drug
is	O
used	O
for	O
the	O
treatment	O
of	O
moderate	O
to	O
severe	O
pain	O
both	O
acute	O
(following	O
injury,	O
surgery,	O
etc.)	O
and	O
chronic	O
musculoskeletal	O
pain.	O

Paracetamol	B-Drug
(acetaminophen)	O
is	O
not	O
considered	O
an	O
NSAID	O
because	O
it	O
has	O
little	O
anti-inflammatory	O
activity.	O
acetaminophen	B-Drug

At	O
the	O
height	O
of	O
its	O
operations,	O
Medelln	O
Cartel	O
smuggled	O
multiple	O
tons	O
cocaine	B-Drug
each	O
week	O
into	O
countries	O
around	O
world	O
and	O
brought	O
in	O
up	O
to	O
US$60	O
million	O
daily	O
drug	O
profits.	O

An	O
extension	O
of	O
this	O
legend	O
is	O
that	O
a	O
person	O
who	O
does	O
LSD	B-Drug
more	O
than	O
"	O

muscaria,	O
are	O
noted	O
for	O
their	O
hallucinogenic	O
properties,	O
with	O
the	O
main	O
psychoactive	O
constituents	O
being	O
neurotoxins	O
ibotenic	O
acid	B-Drug
and	O
muscimol.	O

Ketorolac	B-Drug
is	O
contraindicated	O
in	O
those	O
with	O
hypersensitivity,	O
allergies	O
to	O
the	O
medication,	O
cross-sensitivity	O
other	O
NSAIDs,	O
prior	O
surgery,	O
history	O
of	O
peptic	O
ulcer	O
disease,	O
gastrointestinal	O
bleeding,	O
alcohol	O
intolerance,	O
renal	O
impairment,	O
cerebrovascular	O
nasal	O
polyps,	O
angioedema,	O
and	O
asthma.	O

Psilocybin	O
is	O
about	O
100	O
times	O
less	O
potent	O
than	O
LSD	B-Drug
on	O
a	O
weight	O
per	O
basis,	O
and	O
the	O
physiological	O
effects	O
last	O
half	O
as	O
long.	O

Patents	O
on	O
paracetamol	B-Drug
have	O
long	O
expired,	O
and	O
generic	O
versions	O
of	O
the	O
drug	O
are	O
widely	O
available.	O

Ethylmorphine	B-Drug
(also	O
known	O
as	O
codethyline,	O
dionine,	O
and	O
ethyl	O
morphine)	O
is	O
an	O
opioid	O
analgesic	O
antitussive.	O
dionine	B-Drug
morphine	B-Drug

Isomethadone	B-Drug
was	O
used	O
as	O
both	O
an	O
analgesic	O
and	O
antitussive.	O

Treatment	O
had	O
reduced	O
the	O
number	O
of	O
cocaine	B-Drug
abusers	O
by	O
two-thirds.	O

Levodopa	B-Drug
(commonly	O
referred	O
to	O
as	O
L-DOPA),	O
the	O
dopamine	O
precursor,	O
is	O
most	O
commonly	O
prescribed	O
medication	O
for	O
Parkinson's	O
disease,	O
despite	O
controversy	O
concerning	O
neurotoxicity	O
of	O
and	O
L-DOPA.	O
L-DOPA	B-Drug

crack,	O
cannabis,	O
morphine	B-Drug
Ghost	O
in	O
the	O
Shell	O
(2017)	O

Methadone	B-Drug
is	O
made	O
by	O
chemical	O
synthesis	O
and	O
acts	O
on	O
opioid	O
receptors.	O

In	O
the	O
U.S.,	O
clostebol	B-Drug
is	O
listed	O
as	O
a	O
Schedule	O
III	O
substance.	O

At	O
least	O
some	O
of	O
the	O
LSD	B-Drug
that	O
his	O
labs	O
made	O
was	O
not	O
pure."	O

Orally	O
administered	O
methylphenidate	B-Drug
is	O
subject	O
to	O
first-pass	O
metabolism,	O
by	O
which	O
the	O
levo-isomer	O
extensively	O
metabolized.	O

"Illicit	O
fentanyl	B-Drug
is	O
commonly	O
made	O
in	O
Mexico	O
and	O
trafficked	O
by	O
cartels.	O

The	O
effects,	O
beginning	O
around	O
45	O
to	O
120	O
minutes	O
after	O
consumption,	O
are	O
similar	O
dextromethorphan	B-Drug
and	O
alcohol	O
intoxication.	O

Tamoxifen	B-Drug
is	O
a	O
nonsteroidal	O
SERM	O
of	O
the	O
triphenylethylene	O
family	O
and	O
was	O
structurally	O
derived	O
from	O
diethylstilbestrol-like	O
estrogens	O
antiestrogens	O
such	O
as	O
chlorotrianisene	O
ethamoxytriphetol.	O

Fentanyl	B-Drug
was	O
first	O
made	O
by	O
Paul	O
Janssen	O
in	O
1960	O
and	O
approved	O
for	O
medical	O
use	O
the	O
United	O
States	O
1968.	O

Domperidone	B-Drug
use	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
sudden	O
cardiac	O
death	O
(by	O
70%)	O
most	O
likely	O
through	O
its	O
prolonging	O
effect	O
the	O
QT	O
interval	O
and	O
ventricular	O
arrhythmias.	O

According	O
to	O
some	O
estimates	O
as	O
of	O
2004,	O
only	O
marijuana	O
attracts	O
more	O
first	O
time	O
users	O
in	O
the	O
US.After	O
MDMA	B-Drug
was	O
criminalized,	O
most	O
medical	O
use	O
stopped,	O
although	O
therapists	O
continued	O
prescribe	O
drug	O
illegally.	O

Adderall	B-Drug
and	O
Mydayis	O
are	O
trade	O
names	O
for	O
a	O
combination	O
drug	O
containing	O
four	O
salts	O
of	O
amphetamine.	O
amphetamine	B-Drug

Contains	O
109	O
positions,	O
generalization	O
clause	O
(with	O
2	O
exclusions)	O
and	O
specific	O
generalizations	O
(1	O
for	O
ecgonine	O
1	O
pentavalent	O
nitrogen	O
morphine	B-Drug
derivatives).	O

The	O
patches	O
work	O
by	O
slowly	O
releasing	O
fentanyl	B-Drug
through	O
the	O
skin	O
into	O
bloodstream	O
over	O
48	O
to	O
72	O
hours,	O
allowing	O
for	O
long-lasting	O
pain	O
management.	O

This	O
association	O
of	O
opium	B-Drug
with	O
sex	O
continued	O
in	O
China	O
until	O
the	O
end	O
19th	O
century.	O

The	O
usual	O
dose	O
of	O
350	O
mg	O
is	O
unlikely	O
to	O
engender	O
prominent	O
side	O
effects	O
other	O
than	O
somnolence,	O
and	O
mild	O
significant	O
euphoria	O
or	O
dysphoria,	O
but	O
the	O
generally	O
short-lived	O
due	O
fast	O
metabolism	O
carisoprodol	B-Drug
into	O
meprobamate	B-Drug
metabolites;	O
derived	O
is,	O
according	O
new	O
research,	O
most	O
likely	O
carisoprodol's	O
inherent,	O
potent	O
anxiolytic	O
that	O
are	O
far	O
stronger	O
those	O
produced	O
by	O
its	O
primary	O
metabolite,	O
meprobamate,	O
which	O
often	O
misblamed	O
for	O
drug-seeking	O
associated	O
with	O
carisoprodol,	O
as	O
itself	O
responsible	O
significantly	O
more	O
intense	O
central	O
nervous	O
system	O
alone.	O

Metabolism/excretion:	O
Paracetamol	B-Drug
is	O
metabolized	O
primarily	O
in	O
the	O
liver	O
via	O
glucuronidation	O
and	O
sulfation	O
to	O
mostly	O
non-toxic	O
metabolites	O
some	O
highly	O
reactive	O
metabolites,	O
which	O
inactivated	O
by	O
glutathione.	O

Fluoxymesterone,	O
sold	O
under	O
the	O
brand	O
names	O
Halotestin	O
and	O
Ultandren	O
among	O
others,	O
is	O
an	O
androgen	O
anabolic	O
steroid	O
(AAS)	O
medication	O
which	O
used	O
in	O
treatment	O
of	O
low	O
testosterone	O
levels	O
men,	O
delayed	O
puberty	O
boys,	O
breast	O
cancer	O
women,	O
anemia.	O
Fluoxymesterone	B-Drug

Cocaine	B-Drug
is	O
smoked	O
by	O
inhaling	O
the	O
vapor	O
produced	O
when	O
solid	O
cocaine	B-Drug
heated	O
to	O
point	O
that	O
it	O
sublimates.	O

MDMA	B-Drug
also	O
interacts	O
with	O
drugs	O
which	O
inhibit	O
CYP450	O
enzymes,	O
like	O
ritonavir	B-Drug
(Norvir),	O
particularly	O
CYP2D6	O
inhibitors.	O
Norvir	B-Drug

This	O
was	O
easily	O
accomplished	O
because	O
Mexico	O
had	O
long	O
been	O
a	O
major	O
source	O
of	O
heroin	B-Drug
and	O
cannabis,	O
drug	O
traffickers	O
from	O
already	O
established	O
an	O
infrastructure	O
that	O
stood	O
ready	O
to	O
serve	O
the	O
Colombia-based	O
traffickers.	O

About	O
448	O
tons	O
of	O
heroin	B-Drug
were	O
made	O
in	O
2016.	O

The	O
addition	O
of	O
abiraterone	O
acetate	O
to	O
castration	O
was	O
found	O
reduce	O
levels	O
DHT	O
by	O
85%,	O
DHEA	O
97	O
98%,	O
and	O
androstenedione	B-Drug
77	O
78%	O
relative	O
alone.	O

In	O
the	O
Netflix	O
adaptation	O
of	O
Julia	O
Quinn's	O
novels,	O
Bridgerton	O
(2020),	O
when	O
Baron	O
Featherington,	O
Featherington	O
patriarch	O
is	O
ambushed	O
by	O
gambling	O
bookies,	O
a	O
bottle	O
laudanum	B-Drug
poison	O
shown	O
on	O
table	O
and	O
later	O
family	O
learns	O
his	O
off-screen	O
death,	O
presumably	O
murdered.	O

Rates	O
of	O
kratom	B-Drug
use	O
appear	O
to	O
be	O
increasing	O
among	O
those	O
who	O
have	O
been	O
self-managing	O
chronic	O
pain	O
with	O
opioids	O
purchased	O
without	O
a	O
prescription	O
and	O
are	O
cycling	O
(but	O
not	O
quitting)	O
their	O
use.	O

Depending	O
on	O
the	O
pharmacy,	O
a	O
pharmacist	O
may	O
have	O
to	O
write	O
prescription	O
or	O
not	O
be	O
able	O
give	O
naloxone	B-Drug
comply	O
with	O
accounting	O
rules	O
regarding	O
medications,	O
as	O
is	O
still	O
considered	O
only	O
medication	O
under	O
FDA	O
rules.	O

The	O
amphetamine	B-Drug
metabolite	O
peaks	O
at	O
1024	O
hours.	O

Zolpidem,	O
a	O
GABA-A	O
receptor	O
agonist	O
and	O
"Z-hypnotic"	O
medication,	O
has	O
shown	O
some	O
efficacy	O
in	O
treating	O
insomnia	O
due	O
to	O
cannabis	O
withdrawal,	O
though	O
there	O
is	O
potential	O
for	O
misuse.	O
Zolpidem	B-Drug

On	O
April	O
19,	O
2011,	O
he	O
released	O
his	O
fifth	O
solo	O
mixtape	O
Cocaine	B-Drug
Riot,	O
featuring	O
guest	O
appearances	O
from	O
the	O
various	O
members	O
of	O
Coke	O
Boys.	O

This	O
combination	O
was	O
sold	O
under	O
the	O
brand	O
name	O
Jatrosom	O
N.	O
Likewise	O
a	O
with	O
amobarbital	B-Drug
(potent	O
sedative/hypnotic	O
agent)	O
for	O
amelioration	O
of	O
psychoneurosis	O
and	O
insomnia	O
existed	O
Jalonac.	O

Conversely,	O
buprenorphine	B-Drug
behaves	O
like	O
a	O
partial	O
agonist	O
of	O
the	O
MOR	O
with	O
respect	O
to	O
respiratory	O
depression.	O

Delorazepam	B-Drug
is	O
also	O
used	O
as	O
a	O
premedication	O
for	O
dental	O
phobia	O
its	O
anxiolytic	O
properties.	O

Increased	O
heart	O
rate,	O
a	O
steep	O
increase	O
in	O
body	O
temperature,	O
blood	O
pressure,	O
spasms	O
and	O
dehydration	O
are	O
all	O
common	O
side	O
effects	O
of	O
MDMA	B-Drug
methamphetamine.	O
methamphetamine	B-Drug

agaric	O
(Amanita	O
muscaria)	O
and	O
zolpidem	B-Drug
(Ambien)	O
Ambien	B-Drug

Lysergic	B-Drug
acid	B-Drug
diethylamide	I-Drug
(LSD),	O
also	O
known	O
colloquially	O
as	O
acid,	O
is	O
a	O
hallucinogenic	O
drug.	O
LSD	B-Drug

Hours	O
after	O
dextromethorphan	B-Drug
therapy,	O
(in	O
humans)	O
the	O
metabolites	O
(+)	O

In	O
August	O
2018,	O
the	O
United	O
States	O
used	O
fentanyl	B-Drug
for	O
first	O
time	O
to	O
execute	O
a	O
prisoner.	O

Israeli	O
scientists	O
have	O
conducted	O
research	O
into	O
the	O
properties	O
and	O
medical	O
applications	O
of	O
cannabis	O
since	O
1960s,	O
with	O
notable	O
discoveries	O
first	O
made	O
by	O
Raphael	O
Mechoulam	O
Yechiel	O
Gaoni	O
Hebrew	O
University	O
Jerusalem,	O
who	O
isolated	O
THC	B-Drug
from	O
in	O
1964	O
later	O
discovered	O
anandamide,	O
has	O
been	O
legal	O
to	O
use	O
for	O
purposes	O
1990s.	O

25I-NBOMe	B-Drug
(2C-I-NBOMe,	O
Cimbi-5,	O
also	O
shortened	O
to	O
"25I")	O
is	O
a	O
synthetic	O
hallucinogen	O
that	O
used	O
in	O
biochemistry	O
research	O
for	O
mapping	O
the	O
brain's	O
usage	O
of	O
type	O
2A	O
serotonin	O
receptor;	O
it	O
sometimes	O
recreational	O
purposes.	O
2C-I-NBOMe	B-Drug

Some	O
of	O
the	O
off-label	O
indications	O
methylprednisolone	B-Drug
include	O
acute	O
spinal	O
cord	O
injury,	O
respiratory	O
distress	O
syndrome,	O
alcoholic	O
hepatitis,	O
hormonal	O
resuscitation	O
in	O
cadaveric	O
organ	O
recovery,	O
and	O
chronic	O
obstructive	O
pulmonary	O
disease.	O

Mescaline	B-Drug
elicits	O
a	O
pattern	O
of	O
sympathetic	O
arousal,	O
with	O
the	O
peripheral	O
nervous	O
system	O
being	O
major	O
target	O
for	O
this	O
substance.	O

The	O
clinical	O
trial	O
did	O
show	O
that	O
bevacizumab	B-Drug
reduced	O
tumor	O
volumes	O
and	O
showed	O
an	O
increase	O
in	O
progression	O
free	O
survival	O
time.	O

Other	O
factors	O
that	O
increase	O
the	O
risk	O
of	O
respiratory	O
depression	O
are:	O
High	O
fentanyl	B-Drug
doses	O

Celecoxib	B-Drug
and	O
other	O
COX-2	O

Cannabidiol	B-Drug
has	O
low	O
affinity	O
for	O
the	O
cannabinoid	O
CB1	O
and	O
CB2	O
receptors,	O
although	O
it	O
can	O
act	O
as	O
an	O
antagonist	O
of	O
CB1/CB2	O
agonists	O
despite	O
this	O
affinity.	O

The	O
northern	O
soul	O
and	O
mod	O
subcultures	O
in	O
England	O
were	O
known	O
for	O
their	O
characteristic	O
amphetamine	B-Drug
use.	O

This	O
is	O
in	O
accordance	O
with	O
the	O
fact	O
that	O
sebum	O
secretion	O
appears	O
to	O
be	O
entirely	O
under	O
control	O
of	O
5-reductase	O
type	O
I.	O
5-Reductase	O
inhibitors	O
like	O
finasteride	B-Drug
and	O
dutasteride	B-Drug
inhibit	O
II	O
and/or	O
other	O
isoforms	O
are	O
able	O
decrease	O
circulating	O
DHT	O
levels	O
by	O
65	O
98%	O
depending	O
on	O
inhibitor	O
question.	O

Metoclopramide	B-Drug
is	O
a	O
substituted	O
benzamide;	O
cisapride	B-Drug
and	O
mosapride	O
are	O
structurally	O
related.	O

Phencyclidine	B-Drug
or	O
phenylcyclohexyl	O
piperidine	O
(PCP),	O
also	O
known	O
as	O
angel	B-Drug
dust	I-Drug
among	O
other	O
names,	O
is	O
a	O
drug	O
used	O
for	O
its	O
mind-altering	O
effects.	O
PCP	B-Drug

Opioids	O
include	O
substances	O
such	O
as	O
heroin,	O
morphine,	O
fentanyl,	O
codeine,	O
dihydrocodeine,	O
oxycodone,	O
and	O
hydrocodone.	O
heroin	B-Drug
morphine	B-Drug
fentanyl	B-Drug
codeine	B-Drug
dihydrocodeine	B-Drug
oxycodone	B-Drug
hydrocodone	B-Drug

Mannitol	B-Drug
is	O
used	O
intravenously	O
to	O
reduce	O
acutely	O
raised	O
intracranial	O
pressure	O
until	O
more	O
definitive	O
treatment	O
can	O
be	O
applied,	O
e.g.,	O
after	O
head	O
trauma.	O

The	O
allegations	O
include	O
that	O
Johnson	O
&	O
and	O
Janssen	O
were	O
warned	O
by	O
the	O
U.S.	O
Food	O
Drug	O
Administration	O
(FDA)	O
not	O
to	O
promote	O
Risperdal	B-Drug
as	O
effective	O
safe	O
for	O
elderly	O
patients	O
when	O
in	O
fact	O
it	O
is	O
associated	O
with	O
early	O
death,	O
but	O
they	O
did	O
so;	O
bribed	O
Omnicare	O
pharmacists	O
tens	O
of	O
millions	O
dollars	O
drug	O
care	O
home	O
physicians	O
this	O
unapproved	O
use.	O

Lofentanil	B-Drug
can	O
be	O
described	O
as	O
3-methylcarfentanil,	O
or	O
3-methyl-4-carbomethoxyfentanyl.	O

Concentrations	O
of	O
4-methylaminorex	B-Drug
were:	O
in	O
blood	O
21.3	O
mg/L;	O
urine	O
12.3	O
mg/	O

Gynecomastia	O
induced	O
by	O
spironolactone	B-Drug
usually	O
regresses	O
after	O
a	O
few	O
weeks	O
following	O
discontinuation	O
of	O
the	O
medication.	O

Likewise	O
CYP2D6	O
inhibitors	O
such	O
as	O
paroxetine	B-Drug
or	O
fluoxetine	B-Drug
can	O
reduce	O
chlorpromazine	B-Drug
clearance	O
and	O
hence	O
increase	O
serum	O
levels	O
of	O
potentially	O
also	O
its	O
adverse	O
effects.	O

When	O
LSD	B-Drug
became	O
illegal	O
in	O
California	O
on	O
October	O
6,	O
1966,	O
Scully	O
decided	O
to	O
set	O
up	O
a	O
new	O
lab	O
Denver,	O
Colorado.	O

This	O
class	O
of	O
drugs	O
can	O
be	O
highly	O
addictive,	O
and	O
includes	O
opiate	O
narcotics,	O
like	O
morphine	B-Drug
codeine.	O
codeine	B-Drug

Desmethyldiazepam	B-Drug
has	O
a	O
half-life	O
of	O
36200	O
hours,	O
and	O
flurazepam,	O
with	O
the	O
main	O
active	O
metabolite	O
desalkylflurazepam,	O
40250	O
hours.	O
flurazepam	B-Drug
desalkylflurazepam	B-Drug

The	O
primary	O
safety	O
concerns	O
with	O
pholcodine	B-Drug
revolve	O
around	O
death	O
during	O
general	O
anaesthesia.	O

Absorption	O
by	O
any	O
administered	O
route	O
and	O
the	O
risk	O
of	O
accumulation	O
is	O
significantly	O
increased	O
in	O
neonate,	O
withdrawal	O
diazepam	B-Drug
during	O
pregnancy	O
breast	O
feeding	O
clinically	O
justified.	O

He	O
is	O
accused	O
of	O
producing	O
cocaine	B-Drug
in	O
Colombia,	O
storing	O
it	O
Apure,	O
and	O
then	O
transporting	O
to	O
Central	O
America	O
Mexico	O
before	O
smuggling	O
into	O
the	O
United	O
States.	O

Toxicity	O
from	O
propylene	O
glycol	O
has	O
been	O
reported	O
in	O
the	O
case	O
of	O
a	O
person	O
receiving	O
continuous	O
lorazepam	B-Drug
infusion.	O

Narcan	B-Drug
Nasal	O
Spray	O
was	O
approved	O
in	O
2015	O
and	O
the	O
first	O
FDA-approved	O
nasal	O
spray	O
for	O
emergency	O
treatment	O
or	O
suspected	O
overdose.	O

In	O
cases	O
where	O
pharmacists	O
have	O
misinterpreted	O
DTO,	O
and	O
given	O
"deodorized	O
tincture	O
of	O
opium"	O
when	O
"diluted	O
was	O
meant,	O
infants	O
received	O
a	O
massive	O
25-fold	O
overdose	O
morphine,	O
sometimes	O
resulting	O
in	O
fatalities.	O
opium	B-Drug
morphine	B-Drug

It	O
is	O
the	O
indazole	O
analogue	O
of	O
XLR-11.	O
XLR-11	B-Drug

This	O
page	O
provides	O
supplementary	O
chemical	O
data	O
on	O
Cocaine	B-Drug
in	O
free	O
base	O
form.	O

In	O
1958,	O
Chemie	O
Grnenthal	O
reached	O
an	O
agreement	O
with	O
William	O
S	O
Merrell	O
Company	O
in	O
Cincinnati,	O
Ohio,	O
(later	O
Richardson-Merrell,	O
now	O
part	O
of	O
Sanofi),	O
to	O
market	O
and	O
distribute	O
thalidomide	B-Drug
throughout	O
the	O
USThe	O
US	O
FDA	O
refused	O
approve	O
for	O
marketing	O
distribution.	O

In	O
1-5	O
minutes	O
after	O
inducing	O
anesthesia	O
by	O
a	O
rapid	O
intravenous	O
injection	O
of	O
ketamine,	O
its	O
plasma	O
concentration	O
reaches	O
as	O
high	O
60110	O
M.	O
When	O
the	O
was	O
maintained	O
using	O
nitrous	O
oxide	O
together	O
with	O
continuous	O
ketamine	B-Drug
stabilized	O
at	O
about	O
9.3	O
an	O
experiment	O
purely	O
anesthesia,	O
patients	O
began	O
to	O
awaken	O
once	O
level	O
decreased	O
2,600	O
ng/mL	O
(11	O
M)	O
and	O
became	O
oriented	O
in	O
place	O
time	O
when	O
down	O
1,000	O
(4	O
M).	O

In	O
addition,	O
another	O
2009	O
study	O
found	O
that	O
the	O
estrogenic	O
effects	O
of	O
tibolone	B-Drug
on	O
adiposity	O
in	O
rats	O
do	O
not	O
require	O
aromatization	O
(as	O
indicated	O
by	O
use	O
aromatase	O
knockout	O
mice),	O
further	O
support	O
3-hydroxytibolone	O
and	O
are	O
indeed	O
responsible	O
for	O
such	O
effects.	O

It	O
is	O
a	O
prescription	O
drug,	O
but	O
it	O
not	O
available	O
to	O
the	O
public	O
through	O
pharmacies;	O
its	O
distribution	O
restricted	O
specially	O
qualified	O
licensed	O
physicians,	O
sold	O
by	O
Danco	O
Laboratories	O
under	O
trade	O
name	O
Mifeprex.	O
Mifeprex	B-Drug

Specifically,	O
25I-NBOMe	B-Drug
is	O
an	O
N-benzyl	O
derivative	O
of	O
the	O
phenethylamine	B-Drug
molecule	O
2C-I,	O
formed	O
by	O
adding	O
a	O
2-methoxybenzyl	O
(BnOMe)	O
onto	O
nitrogen	O
(N)	O
backbone.	O

Cocaine	B-Drug
increases	O
alertness,	O
feelings	O
of	O
well-being	O
and	O
euphoria,	O
energy	O
motor	O
activity,	O
competence	O
sexuality.	O

In	O
2016,	O
deaths	O
from	O
fatal	O
fentanyl	B-Drug
overdoses	O
in	O
the	O
province	O
of	O
British	O
Columbia	O
averaged	O
two	O
persons	O
per	O
day.	O

Nicotine,	O
however,	O
is	O
treated	O
separately	O
psychiatrically	O
under	O
tobacco	B-Drug
use	O
disorder.	O
Nicotine	B-Drug

Taking	O
this	O
concession	O
as	O
a	O
basis,	O
the	O
European	O
Commission	O
has	O
decided	O
to	O
ask	O
Council	O
place	O
BZP	B-Drug
under	O
control	O
of	O
UN	O
Convention	O
on	O
Psychotropic	O
Substances.	O

MDMA	B-Drug
likely	O
emerged	O
as	O
a	O
substitute	O
for	O
its	O
analog	O
methylenedioxyamphetamine	O
(MDA),	O
drug	O
at	O
the	O
time	O
popular	O
among	O
users	O
of	O
psychedelics	O
which	O
was	O
made	O
Schedule	O
1	O
substance	O
in	O
United	O
States	O
1970.	O

After	O
inhalation,	O
the	O
user	O
usually	O
experiences	O
a	O
warm	O
sensation,	O
euphoria,	O
and	O
strong	O
visual	O
auditory	O
hallucinations,	O
due	O
to	O
5-MeO-DMT's	O
high	O
affinity	O
for	O
5-HT2	O
5-HT1A	O
serotonin	O
receptor	O
subtypes.	O
5-MeO-DMT	B-Drug

Excessive	O
consumption	O
of	O
alcohol	O
in	O
combination	O
with	O
nortriptyline	B-Drug
therapy	O
may	O
have	O
a	O
potentiating	O
effect,	O
which	O
lead	O
to	O
the	O
danger	O
increased	O
suicidal	O
attempts	O
or	O
overdosage,	O
especially	O
patients	O
histories	O
emotional	O
disturbances	O
ideation.	O

JWH-307	B-Drug

The	O
main	O
difference	O
relative	O
to	O
pure	O
diphenhydramine	B-Drug
is	O
a	O
lower	O
potency	O
due	O
being	O
combined	O
with	O
8-chlorotheophylline.	O

lorazepam,	O
lormetazepam,	O
oxazepam,	O
temazepam7-nitro	O
compounds:clonazepam,	O
flunitrazepam,	O
nimetazepam	B-Drug
lorazepam	B-Drug
lormetazepam	B-Drug
oxazepam	B-Drug
clonazepam	B-Drug
flunitrazepam	B-Drug

Methohexital	B-Drug
or	O
methohexitone	O

25I-NBOMe	B-Drug
was	O
explicitly	O
scheduled	O
in	O
Queensland	O
drug	O
law	O
April	O
2012,	O
and	O
New	O
South	O
Wales	O
October	O
2013,	O
as	O
were	O
some	O
related	O
compounds	O
such	O
25B-NBOMe.	O
25B-NBOMe	B-Drug

All	O
of	O
the	O
victims	O
were	O
described	O
by	O
by-standers	O
as	O
zombielike	O
and	O
cause	O
was	O
attributed	O
to	O
use	O
AMB-FUBINACA	B-Drug
demethylated	O
metabolite	O
found	O
in	O
blood	O
urine	O
eight	O
hospitalized	O
patients	O
that	O
had	O
been	O
sent	O
for	O
testing	O
DEA.	O

In	O
palliative	O
care,	O
transdermal	O
fentanyl	B-Drug
patches	O
have	O
a	O
definitive,	O
but	O
limited	O
role	O
for:	O

Narcotic	O
drugs	O
and	O
psychotropic	O
substances,	O
etc.,	O
not	O
liable	O
to	O
distress	O
or	O
attachmentNotwithstanding	O
anything	O
the	O
contrary	O
contained	O
in	O
any	O
law	O
contract,	O
no	O
narcotic	O
drug,	O
substance,	O
coca	B-Drug
plant,	O
opium	O
poppy	O
cannabis	O
plant	O
shall	O
be	O
detained	O
attached	O
by	O
person	O
for	O
recovery	O
of	O
money	O
under	O
order	O
decree	O
court	O
authority	O
otherwise.	O

Illicit	O
manufacturing	O
of	O
nimetazepam	B-Drug
(sold	O
as	O
Erimin-5)	O
is	O
prevalent	O
in	O
the	O
region.	O

Rabe	O
and	O
Kindler	O
re	O
investigate	O
a	O
sample	O
left	O
over	O
from	O
their	O
1918	O
experiments	O
identify	O
isolate	O
quinine	B-Drug
(again)	O
together	O
with	O
diastereomers	O
quinidine,	O
epi-quinine	O
epi-quinidine.	O
quinidine	B-Drug

Thalidomide	B-Drug
is	O
racemic;	O
while	O
R-thalidomide	O
the	O
bioactive	O
form	O
of	O
molecule,	O
individual	O
enantiomers	O
can	O
racemize	O
to	O
each	O
other	O
due	O
acidic	O
hydrogen	O
at	O
chiral	O
centre,	O
which	O
carbon	O
glutarimide	O
ring	O
bonded	O
phthalimide	O
substituent.	O

Mercdes	O
Benegbi,	O
born	O
with	O
phocomelia	O
of	O
both	O
arms,	O
drove	O
the	O
successful	O
campaign	O
for	O
compensation	O
from	O
her	O
government	O
Canadians	O
who	O
were	O
affected	O
by	O
thalidomide.	O
thalidomide	B-Drug

Piperazines,	O
especially	O
BZP	B-Drug
and	O
TFMPP	B-Drug
were	O
extremely	O
common	O
adulterants	O
in	O
the	O
club	O
rave	O
scene,	O
often	O
being	O
passed	O
off	O
as	O
MDMA,	O
although	O
they	O
do	O
not	O
share	O
many	O
similarities	O
their	O
effects.	O
MDMA	B-Drug

For	O
both	O
emergency	O
and	O
palliative	O
use,	O
intranasal	O
fentanyl	B-Drug
is	O
available	O
in	O
doses	O
of	O
50,	O
100,	O
200	O
g.	O

The	O
treatment	O
of	O
overdose	O
is	O
mostly	O
supportive	O
as	O
no	O
specific	O
antidote	O
for	O
amitriptyline	B-Drug
available.	O

5-APDB	B-Drug
(3-Desoxy-MDA)	O
is	O
an	O
analogue	O
of	O
6-APDB	B-Drug
where	O
the	O
3-position	O
oxygen	O
has	O
been	O
replaced	O
with	O
a	O
methylene	O
instead.	O

Butorphanol	B-Drug
is	O
available	O
as	O
the	O
tartrate	O
salt	O
in	O
injectable,	O
tablet,	O
and	O
intranasal	O
spray	O
formulations.	O

Syrup	O
Depakene	B-Drug
by	O
Abbott	O
Laboratories.	O

Pyroglutamyl-histidyl-glycine	O
SibutramineOther	O
compounds	O
with	O
known	O
appetite	O
suppressant	O
activity	O
include:	O
Amphetamine	B-Drug
sulfate	O
(also	O
as	O
amfetamine)	O
USFDA-approved	O
for	O
the	O
treatment	O
of	O
exogenous	O
obesity	O
under	O
brand	O
name	O
"Evekeo".	O
amfetamine	B-Drug
Evekeo	B-Drug

Cocaine	B-Drug
is	O
known	O
to	O
have	O
a	O
number	O
of	O
deleterious	O
effects	O
during	O
pregnancy.	O

Ligand	O
Pharmaceutics	O
has	O
disclosed	O
that	O
its	O
royalty	O
fee	O
incurred	O
upon	O
Viking	O
Therapeutics	O
for	O
production	O
and	O
sale	O
of	O
ligandrol	B-Drug
would	O
be	O
7.25-9.25%	O
the	O
product	O
revenue.	O

The	O
ovulation-inhibiting	O
dosage	O
of	O
both	O
oral	O
norethisterone	B-Drug
and	O
NETA	O
is	O
about	O
0.5	O
mg/day	O
in	O
women.	O

Baclofen	B-Drug
was	O
first	O
suggested	O
as	O
an	O
adjunct	O
because	O
benzodiazepines	O
do	O
not	O
affect	O
GABAB	O
receptors	O
and	O
therefore	O
have	O
no	O
cross-tolerance	O
with	O
GHB	B-Drug
while	O
baclofen,	O
which	O
works	O
via	O
receptors,	O
is	O
cross-tolerant	O
may	O
be	O
more	O
effective	O
in	O
alleviating	O
withdrawal	O
effects	O
of	O
GHB.GHB	O
widely	O
discussed	O
textbooks	O
some	O
psychiatrists,	O
general	O
practitioners,	O
even	O
hospital	O
emergency	O
physicians	O
familiar	O
this	O
syndrome.	O
baclofen	B-Drug

Withdrawal	O
symptoms	O
have	O
also	O
been	O
reported	O
in	O
newborns	O
whose	O
mothers	O
had	O
either	O
injecting	O
or	O
orally	O
taking	O
oxycodone	B-Drug
during	O
pregnancy.	O

Pan	O
masala	O
with	O
a	O
small	O
quantity	O
of	O
tobacco	B-Drug
is	O
called	O
gutka.	O

Morphine	B-Drug
in	O
particular	O
was	O
used	O
much	O
more	O
widely	O
after	O
the	O
invention	O
of	O
hypodermic	O
syringe,	O
and	O
practise	O
local	O
anaesthesia	O
by	O
infiltration	O
another	O
step	O
forward	O
medicine	O
resulting	O
from	O
needle,	O
discovered	O
at	O
around	O
same	O
time	O
that	O
it	O
determined	O
cocaine	B-Drug
produced	O
useful	O
numbing	O
mucous	O
membranes	O
eye.	O

Historically,	O
LSD	B-Drug
solutions	O
were	O
first	O
sold	O
on	O
sugar	O
cubes,	O
but	O
practical	O
considerations	O
forced	O
a	O
change	O
to	O
tablet	O
form.	O

With	O
the	O
reemergence	O
of	O
Taliban	O
and	O
virtual	O
absence	O
rule	O
law	O
in	O
countryside,	O
opium	B-Drug
production	O
heroin	B-Drug
processing	O
have	O
dramatically	O
increased,	O
especially	O
southern	O
province	O
Helmand.	O

In	O
contrast	O
to	O
psilocin,	O
1-methylpsilocin	O
did	O
not	O
activate	O
5-HT1A	O
receptors	O
in	O
mice.	O
psilocin	B-Drug

While	O
many	O
pharmacies	O
will	O
dispense	O
Narcan	B-Drug
or	O
naloxone	B-Drug
without	O
a	O
prescription,	O
prescription	O
is	O
usually	O
required	O
for	O
health	O
insurance	O
reimbursement.	O

The	O
early	O
twentieth	O
century	O
brought	O
increased	O
regulation	O
of	O
all	O
manner	O
narcotics,	O
including	O
paregoric,	O
as	O
the	O
addictive	O
properties	O
opium	B-Drug
became	O
more	O
widely	O
understood,	O
and	O
"patent	O
medicines	O
came	O
under	O
fire	O
largely	O
because	O
their	O
mysterious	O
compositions".	O

It	O
is	O
unclear	O
if	O
Fruhstorfer	O
investigated	O
the	O
effects	O
of	O
MDMA	B-Drug
in	O
humans.	O

Police	O
found	O
43	O
grams	O
of	O
crystalline	O
LSD	B-Drug
at	O
Sand's	O
lab,	O
approximately	O
430,000	O
doses	O
LSD.	O

Alternative	O
rock	O
band	O
Chumbawamba	O
responded	O
with	O
their	O
own	O
'anti-poster'	O
reading	O
"Distorted:	O
you	O
are	O
just	O
as	O
likely	O
to	O
die	O
from	O
eating	O
a	O
bay	O
leaf	O
an	O
ecstasy	B-Drug
tablet".	O

Bicalutamide	B-Drug
does	O
not	O
inhibit	O
5-reductase	O
nor	O
is	O
known	O
to	O
other	O
enzymes	O
involved	O
in	O
androgen	O
steroidogenesis	O
(e.g.,	O
CYP17A1).	O

Treatment	O
mirrors	O
that	O
of	O
barbiturate	O
overdoses	O
and	O
is	O
generally	O
supportive,	O
including	O
the	O
administration	O
mechanical	O
respiration	O
pressors	O
as	O
implicated	O
(and	O
in	O
rare	O
cases,	O
bemegride).	O
bemegride	B-Drug

Due	O
to	O
the	O
COVID-19	O
pandemic,	O
safe	O
access	O
mifepristone	B-Drug
was	O
a	O
concern,	O
and	O
American	O
College	O
of	O
Obstetricians	O
Gynecologists	O
among	O
other	O
groups	O
files	O
lawsuit	O
relax	O
FDA's	O
rule	O
as	O
allow	O
be	O
acquired	O
from	O
mail-order	O
retail	O
pharmacies.	O

This	O
indicates	O
that	O
increasing	O
CREB	O
reverses	O
the	O
positive	O
effects	O
of	O
cocaine.	O
cocaine	B-Drug

The	O
common	O
side	O
effects	O
from	O
nicotine	B-Drug
exposure	O
are	O
listed	O
in	O
the	O
table	O
below.	O

Tetrahydrocannabinol	B-Drug
(THC)	O
is	O
the	O
main	O
psychoactive	O
component	O
of	O
cannabis,	O
which	O
one	O
483	O
known	O
compounds	O
in	O
plant,	O
including	O
at	O
least	O
65	O
other	O
cannabinoids,	O
cannabidiol	B-Drug
(CBD).	O
THC	B-Drug
CBD	B-Drug

As	O
an	O
example,	O
the	O
17-alkylated	O
AAS	O
methyltestosterone	B-Drug
and	O
metandienone	B-Drug
are	O
converted	O
by	O
aromatase	O
into	O
methylestradiol.	O

Unlike	O
most	O
other	O
NSAIDs,	O
ibuprofen	B-Drug
also	O
acts	O
as	O
an	O
inhibitor	O
of	O
Rho	O
kinase,	O
and	O
may	O
be	O
useful	O
in	O
recovery	O
from	O
spinal	O
cord	O
injury.	O

MDA	O
is	O
rarely	O
sought	O
after	O
as	O
a	O
recreational	O
drug	O
compared	O
to	O
other	O
drugs	O
in	O
the	O
amphetamine	B-Drug
family;	O
however,	O
it	O
remains	O
an	O
important	O
and	O
widely	O
used	O
due	O
being	O
primary	O
metabolite,	O
product	O
of	O
hepatic	O
N-dealkylation,	O
MDMA	B-Drug
(ecstasy),	O
In	O
addition,	O
common	O
find	O
adulterant	O
illicitly	O
produced	O
MDMA.	O
ecstasy	B-Drug

Methamphetamine	B-Drug
neurotoxicity	O
causes	O
adverse	O
changes	O
in	O
brain	O
structure	O
and	O
function,	O
such	O
as	O
reductions	O
grey	O
matter	O
volume	O
several	O
regions,	O
well	O
markers	O
of	O
metabolic	O
integrity.	O

Clonazepam	B-Drug
(1974).	O

Thalidomide	B-Drug
has	O
been	O
used	O
by	O
Brazilian	O
physicians	O
as	O
the	O
drug	O
of	O
choice	O
for	O
treatment	O
severe	O
ENL	O
since	O
1965,	O
and	O
1996,	O
at	O
least	O
33	O
cases	O
thalidomide	B-Drug
embryopathy	O
were	O
recorded	O
in	O
people	O
born	O
Brazil	O
after	O
1965.	O

Hence,	O
the	O
metabolites	O
of	O
finasteride	B-Drug
are	O
not	O
particularly	O
active.	O

Treatment	O
admissions	O
for	O
illicit	O
prescription	O
drugs	O
increased	O
332%	O
from	O
1998	O
to	O
2008,	O
surpassing	O
cocaine	B-Drug
in	O
2005.	O

Whereas	O
opioids	O
like	O
codeine,	O
hydrocodone,	O
oxycodone,	O
and	O
hydromorphone	B-Drug
are	O
synthesized	O
by	O
simple	O
modifications	O
of	O
morphine,	O
fentanyl	B-Drug
its	O
relatives	O
meperidine.	O
codeine	B-Drug
hydrocodone	B-Drug
oxycodone	B-Drug
morphine	B-Drug
meperidine	B-Drug

Oxycodone	B-Drug
is	O
eliminated	O
in	O
the	O
urine	O
10%	O
as	O
unchanged	O
oxycodone,	O
45%	O
21%	O
N-demethylated	O
metabolites	O
(noroxycodone,	O
noroxymorphone,	O
noroxycodols),	O
11	O
6%	O
O-demethylated	O
(oxymorphone,	O
oxymorphols),	O
and	O
8%	O
6-keto-reduced	O
(oxycodols).	O
oxycodone	B-Drug
noroxymorphone	B-Drug
oxymorphone	B-Drug

A	O
1991	O
study	O
indicated	O
that	O
diazepam,	O
in	O
particular,	O
had	O
a	O
greater	O
abuse	O
liability	O
among	O
people	O
who	O
were	O
drug	O
abusers	O
than	O
did	O
many	O
of	O
the	O
other	O
benzodiazepines.	O
diazepam	B-Drug

Side-effect	O
profile	O
of	O
modafinil	B-Drug
is	O
generally	O
benign	O
(e.g.	O
headache,	O
trouble	O
sleeping,	O
and	O
nausea).	O

Formoterol	B-Drug
has	O
been	O
demonstrated	O
to	O
have	O
a	O
faster	O
onset	O
of	O
action	O
than	O
salmeterol	B-Drug
as	O
result	O
lower	O
lipophilicity,	O
and	O
also	O
be	O
more	O
potenta	O

However,	O
the	O
following	O
year	O
detection	O
method	O
for	O
nandrolone	B-Drug
at	O
time	O
was	O
proved	O
to	O
be	O
faulty.	O

Cannabis	O
users	O
can	O
develop	O
tolerance	O
to	O
the	O
effects	O
of	O
THC.	O
THC	B-Drug

Pharmacological	O
data	O
on	O
bupropion	B-Drug
and	O
its	O
metabolites	O
are	O
shown	O
in	O
the	O
table.	O

According	O
to	O
the	O
model	O
proposed	O
by	O
Carlezon	O
et	O
al.,	O
use	O
of	O
cocaine	B-Drug
increases	O
expression	O
cAMP	O
and	O
cAMP-dependent	O
protein	O
kinase	O
(PKA).	O

MGA	O
also	O
reaches	O
steady-state	O
levels	O
more	O
quickly	O
than	O
medroxyprogesterone	B-Drug
acetate.	O
acetate	I-Drug

If	O
intravenous	O
midazolam	B-Drug
is	O
given	O
too	O
quickly,	O
hypotension	O
may	O
occur.	O

Tramadol	B-Drug
undergoes	O
hepatic	O
metabolism	O
via	O
the	O
cytochrome	O
P450	O
isozyme	O
CYP2B6,	O

Midazolam	B-Drug

The	O
situation	O
was	O
exacerbated	O
by	O
his	O
disdain	O
for	O
the	O
coarse	O
language	O
and	O
deleterious	O
drugs	O
(most	O
notably	O
alcohol	O
cocaine)	O
favored	O
band's	O
physically	O
imposing	O
roadies,	O
many	O
of	O
whom	O
perceived	O
themselves	O
as	O
"macho	O
cowboys"	O
in	O
contrast	O
to	O
Stanley's	O
diminutive	O
stature	O
erudite	O
mien.	O
cocaine	B-Drug

Like	O
zaleplon,	O
zolpidem	B-Drug
may	O
increase	O
slow	O
wave	O
sleep	O
but	O
cause	O
no	O
effect	O
on	O
stage	O
2	O
sleep.	O
zaleplon	B-Drug

Risperidone	B-Drug
has	O
been	O
classified	O
as	O
a	O
"qualitatively	O
atypical"	O
antipsychotic	O
agent	O
with	O
relatively	O
low	O
incidence	O
of	O
extrapyramidal	O
side	O
effects	O
(when	O
given	O
at	O
doses)	O
that	O
more	O
pronounced	O
serotonin	O
antagonism	O
than	O
dopamine	O
antagonism.	O

Persons	O
with	O
a	O
history	O
of	O
ulcers	O
or	O
inflammatory	O
bowel	O
disease	O
should	O
consult	O
doctor	O
before	O
taking	O
naproxen.	O
naproxen	B-Drug

For	O
example,	O
the	O
retail	O
price	O
of	O
cocaine	B-Drug
in	O
US	O
2007	O
was	O
less	O
than	O
half	O
1984,	O
despite	O
massive	O
investments	O
by	O
government	O
supply	O
reduction	O
strategies.	O

THC	B-Drug
was	O
first	O
isolated	O
and	O
elucidated	O
in	O
1969	O
by	O
Raphael	O
Mechoulam	O
Yechiel	O
Gaoni	O
at	O
the	O
Weizmann	O
Institute	O
of	O
Science	O
Israel.	O

However,	O
when	O
GHB	B-Drug
is	O
consumed	O
for	O
recreational	O
or	O
health	O
promotion	O
purposes,	O
its	O
concentration	O
in	O
the	O
body	O
much	O
higher	O
than	O
normal,	O
which	O
changes	O
enzyme	O
kinetics	O
so	O
that	O
these	O
pathways	O
operate	O
to	O
metabolise	O
rather	O
producing	O
it.	O

It	O
is	O
also	O
used	O
as	O
a	O
recreational	O
drug,	O
often	O
mixed	O
with	O
heroin	B-Drug
or	O
cocaine.	O
cocaine	B-Drug

A	O
study	O
consisting	O
of	O
1,081	O
U.S.	O
residents	O
who	O
had	O
first	O
used	O
cocaine	B-Drug
within	O
the	O
previous	O
24	O
months	O
was	O
conducted.	O

The	O
effects	O
of	O
PCE	O
later	O
in	O
a	O
child's	O
life	O
are	O
poorly	O
understood;	O
there	O
is	O
little	O
information	O
about	O
the	O
utero	O
cocaine	B-Drug
exposure	O
on	O
children	O
over	O
age	O
five	O
years	O
old.	O

Due	O
to	O
the	O
high	O
cost	O
of	O
production	O
in	O
countries	O
where	O
cultivation	O
is	O
undertaken	O
on	O
small	O
landholdings,	O
such	O
as	O
India	O
and	O
Turkey,	O
licit	O
requires	O
market	O
support	O
(the	O
costs	O
for	O
equivalent	O
1	O
kg	O
morphine	B-Drug
1999	O
was	O
US$56	O
Australia,	O
US$159.77	O
US$250	O
Turkey).	O

Fighting	O
to	O
End	O
the	O
American	O
Drug	O
Overdose	O
Epidemic	O
interviews	O
people	O
involved	O
in	O
naloxone	B-Drug
programs	O
aiming	O
make	O
available	O
opioid	O
users	O
and	O
with	O
chronic	O
pain.	O

Natural	O
genetic	O
variation	O
in	O
these	O
enzymes	O
can	O
also	O
influence	O
the	O
clearance	O
of	O
oxycodone,	O
which	O
may	O
be	O
related	O
to	O
wide	O
inter-individual	O
variability	O
its	O
half-life	O
and	O
potency.	O
oxycodone	B-Drug

muscaria,	O
are	O
noted	O
for	O
their	O
hallucinogenic	O
properties,	O
with	O
the	O
main	O
psychoactive	O
constituents	O
being	O
neurotoxins	O
ibotenic	O
acid	B-Drug
and	O
muscimol.	O

Nabiximols	B-Drug
(as	O
Sativex)	O
is	O
available	O
as	O
a	O
prescription	O
drug	O
in	O
Canada.	O
Sativex	B-Drug

The	O
dose	O
of	O
THC	B-Drug
needed	O
to	O
kill	O
50%	O
tested	O
rodents	O
is	O
extremely	O
high.	O

The	O
study	O
tested	O
and	O
compared	O
the	O
abuse	O
liability	O
of	O
temazepam,	O
triazolam,	O
diazepam,	O
lorazepam,	O
oxazepam,	O
flurazepam,	O
alprazolam,	O
chlordiazepoxide,	O
clonazepam,	O
nitrazepam,	O
flunitrazepam,	O
bromazepam,	O
clorazepate.	O
temazepam	B-Drug
triazolam	B-Drug
diazepam	B-Drug
lorazepam	B-Drug
oxazepam	B-Drug
flurazepam	B-Drug
alprazolam	B-Drug
chlordiazepoxide	B-Drug
clonazepam	B-Drug
nitrazepam	B-Drug
flunitrazepam	B-Drug
bromazepam	B-Drug
clorazepate	B-Drug

6-MAPDB	B-Drug
(1-(2,3-dihydrobenzofuran-6-yl)-N-methylpropan-2-amine)	O
is	O
a	O
chemical	O
compound	O
which	O
might	O
be	O
an	O
entactogenic	O
drug.	O

A	O
former	O
heroin	B-Drug
addict	O
realizes	O
that	O
he	O
wants	O
to	O
help	O
other	O
addicts	O
kick	O
their	O
habits.	O

Its	O
formation	O
can	O
be	O
blocked	O
by	O
the	O
coadministration	O
of	O
dutasteride,	O
a	O
potent	O
and	O
selective	O
5-reductase	O
inhibitor.	O
dutasteride	B-Drug

(2009)	O
cannabis,	O
crack/cocaine	O
cocaine	B-Drug

Vicoprofen	O
tablets	O
were	O
initially	O
formulated	O
and	O
packaged	O
by	O
Knoll,	O
with	O
ibuprofen	B-Drug
supplied	O
Albemarle	O
Corporation	O
hydrocodone	B-Drug
Mallinckrodt	O
Pharmaceuticals.	O

The	O
structures	O
at	O
right	O
illustrate	O
baeocystin	B-Drug
in	O
its	O
zwitterionic	O
form.	O

While	O
PMA	B-Drug
alone	O
may	O
cause	O
significant	O
toxicity,	O
the	O
combination	O
of	O
with	O
MDMA	B-Drug
has	O
a	O
synergistic	O
effect	O
that	O
seems	O
to	O
be	O
particularly	O
hazardous.	O

In	O
2017,	O
Joakim	O
Noah	O
was	O
banned	O
for	O
twenty	O
games	O
by	O
the	O
NBA	O
testing	O
positive	O
Ligandrol.	O
Ligandrol	B-Drug

Nicocodeine	B-Drug
(Lyopect,	O
Tusscodin)	O
is	O
an	O
opioid	O
analgesic	O
and	O
cough	O
suppressant,	O
ester	O
of	O
codeine	B-Drug
closely	O
related	O
to	O
dihydrocodeine	B-Drug
the	O
analogue	O
nicomorphine.	O
nicomorphine	B-Drug

Cannabidiol	B-Drug
was	O
studied	O
in	O
1940	O
from	O
Minnesota	O
wild	O
hemp	O
and	O
Egyptian	O
Cannabis	O
indica	O
resin.	O
resin	B-Drug

Metazocine	B-Drug
is	O
an	O
opioid	O
analgesic	O
related	O
to	O
pentazocine.	O
pentazocine	B-Drug

Increasing	O
prescription	O
of	O
opioids	O
fueled	O
a	O
growing	O
black	O
market	O
for	O
heroin.	O
heroin	B-Drug

As	O
of	O
2017	O
in	O
the	O
United	O
States	O
about	O
1%	O
people	O
grade	O
12	O
reported	O
using	O
PCP	B-Drug
prior	O
year	O
while	O
2.9%	O
those	O
over	O
age	O
25	O
it	O
at	O
some	O
point	O
their	O
lives.	O

Sophisticated	O
drug	O
subs	O
are	O
the	O
latest	O
tool	O
runners	O
using	O
to	O
bring	O
cocaine	B-Drug
north	O
from	O
Colombia,	O
it	O
was	O
reported	O
on	O
20	O
March	O
2008.	O

The	O
drug	O
of	O
choice	O
is	O
typically	O
methamphetamine,	O
known	O
as	O
tina	O
or	O
T,	O
but	O
other	O
drugs	O
are	O
also	O
used,	O
such	O
mephedrone,	O
GHB,	O
GBL	O
and	O
alkyl	O
nitrites	O
(known	O
poppers).	O
methamphetamine	B-Drug
mephedrone	B-Drug
GHB	B-Drug

In	O
PiHKAL,	O
Shulgin	O
lists	O
the	O
dosage	O
of	O
DOET	B-Drug
as	O
being	O
27	O
mg	O
orally,	O
with	O
67	O
for	O
full,	O
desired	O
effects.	O

A	O
consumer	O
report	O
noted	O
that	O
ibuprofen,	O
naproxen,	O
and	O
salsalate	B-Drug
are	O
less	O
expensive	O
than	O
other	O
NSAIDs,	O
essentially	O
as	O
effective	O
safe	O
when	O
used	O
appropriately	O
to	O
treat	O
osteoarthritis	O
pain.	O
ibuprofen	B-Drug
naproxen	B-Drug

Side	O
effects	O
of	O
nandrolone	B-Drug
esters	O
include	O
masculinization	O
among	O
others.	O

Salbutamol	B-Drug
is	O
usually	O
used	O
with	O
an	O
inhaler	O
or	O
nebulizer,	O
but	O
it	O
also	O
available	O
in	O
a	O
pill,	O
liquid,	O
and	O
intravenous	O
solution.	O

Clenbuterol	B-Drug
is	O
a	O
growth-promoting	O
drug	O
in	O
the	O
agonist	O
class	O
of	O
compounds.	O

At	O
the	O
same	O
time,	O
research	O
on	O
use	O
of	O
GHB	B-Drug
in	O
form	O
sodium	B-Drug
oxybate	I-Drug
had	O
formalized,	O
as	O
a	O
company	O
called	O
Orphan	O
Medical	O
filed	O
an	O
investigational	O
new	O
drug	O
application	O
and	O
was	O
running	O
clinical	O
trials	O
with	O
intention	O
gaining	O
regulatory	O
approval	O
for	O
to	O
treat	O
narcolepsy.	O

As	O
of	O
2001,	O
the	O
RDA	O
for	O
adult	O
males	O
is	O
900	O
RAE	O
(900	O
g	O
or	O
3000	O
IU	O
retinol).	O
retinol	B-Drug

As	O
of	O
2016,	O
the	O
combination	O
efavirenz,	O
tenofovir,	O
and	O
lamivudine	B-Drug
is	O
marketed	O
under	O
brand	O
name	O
Eflaten.	O
efavirenz	B-Drug
tenofovir	B-Drug

That	O
bill	O
was	O
withdrawn	O
in	O
favor	O
of	O
one	O
specifically	O
aimed	O
at	O
opium,	O
though	O
further	O
bills	O
including	O
hemp-based	O
drugs	O
were	O
introduced	O
1885	O
and	O
1889.	O
opium	B-Drug

Methamphetamine	B-Drug
is	O
illegal	O
for	O
possession	O
under	O
Health	O
and	O
Safety	O
Code	O
11377.	O

Potassium	O
sparing	O
diuretics:	O
Dyazide	B-Drug
and	O
Maxzide	O
triamterene	B-Drug
Use	O
of	O
hydrochlorothiazide	B-Drug
is	O
prohibited	O
by	O
the	O
World	O
Anti-Doping	O
Agency	O
for	O
its	O
ability	O
to	O
mask	O
use	O
performance-enhancing	O
drugs.	O

Androstenedione	B-Drug
can	O
be	O
biosynthesized	O
in	O
one	O
of	O
two	O
ways.	O

Some	O
Australian	O
cities	O
(such	O
as	O
Sydney)	O
have	O
instituted	O
legal	O
diamorphine	B-Drug
supervised	O
injecting	O
centers,	O
in	O
line	O
with	O
other	O
wider	O
harm	O
minimization	O
programs.	O

For	O
example,	O
ephedrine	B-Drug
and	O
pseudoephedrine	B-Drug
are	O
used	O
to	O
produce	O
methcathinone	B-Drug
methamphetamine.	O
methamphetamine	B-Drug

This	O
compound	O
is	O
however	O
occasionally	O
encountered	O
as	O
an	O
impurity	O
in	O
3,4-methylenedioxy-N-methylamphetamine	B-Drug
(MDMA)	O
which	O
has	O
been	O
synthesized	O
by	O
methylation	O
of	O
MDA	O
using	O
methylating	O
reagents	O
such	O
methyl	O
iodide.	O
MDMA	B-Drug

He	O
also	O
mentioned	O
several	O
negative	O
side	O
effects	O
seen	O
with	O
MDMA	B-Drug
("Ecstasy")	O
such	O
as	O
difficulty	O
urinating	O
and	O
internal	O
dryness.	O

The	O
reduction	O
of	O
the	O
ketone	O
group	O
in	O
cathinone	B-Drug
will	O
produce	O
cathine.	O
cathine	B-Drug

Bretazenil	O
has	O
also	O
been	O
found	O
to	O
have	O
less	O
abuse	O
potential	O
than	O
benzodiazepine	O
full	O
agonists	O
such	O
as	O
diazepam	B-Drug
and	O
alprazolam,	O
however	O
long-term	O
use	O
of	O
bretazenil	O
would	O
still	O
be	O
expected	O
result	O
in	O
dependence	O
addiction.	O
alprazolam	B-Drug

In	O
low	O
to	O
moderate	O
doses,	O
methamphetamine	B-Drug
can	O
elevate	O
mood,	O
increase	O
alertness,	O
concentration	O
and	O
energy	O
in	O
fatigued	O
individuals,	O
reduce	O
appetite,	O
promote	O
weight	O
loss.	O

Treatment	O
with	O
finasteride	B-Drug
slows	O
further	O
hair	O
loss	O
and	O
provides	O
about	O
30%	O
improvement	O
in	O
after	O
six	O
months	O
of	O
treatment,	O
effectiveness	O
persisting	O
as	O
long	O
the	O
drug	O
is	O
taken.	O

CsA	B-Drug
also	O
inhibits	O
the	O
phosphatase	O
calcineurin	O
pathway	O
(14).	O

The	O
FDA	O
issued	O
a	O
warning	O
in	O
November	O
1990	O
that	O
sale	O
of	O
GHB	B-Drug
was	O
illegal.	O

The	O
origin	O
of	O
the	O
name	O
"crack"	O
comes	O
from	O
"crackling"	O
sound	O
(and	O
hence	O
onomatopoeic	O
moniker	O
"crack")	O
that	O
is	O
produced	O
when	O
cocaine	B-Drug
and	O
its	O
impurities	O
(i.e.	O
water,	O
sodium	O
bicarbonate)	O
are	O
heated	O
past	O
point	O
vaporization.	O

Butorphanol	B-Drug
(17-(cyclobutymethyl)	O
morphinan	O
3,	O

Specifically,	O
nociceptin	O
acts	O
to	O
inhibit	O
neural	O
rewards	O
induced	O
by	O
drugs	O
such	O
as	O
amphetamines,	O
morphine,	O
cocaine,	O
and	O
especially	O
alcohol	O
in	O
animal	O
models,	O
though	O
the	O
exact	O
mechanism	O
of	O
this	O
has	O
not	O
yet	O
been	O
proven.	O
morphine	B-Drug
cocaine	B-Drug

Bupropion	B-Drug
inhibits	O
the	O
re-uptake	O
of	O
nor-epinephrine	O
and	O
dopamine	O
has	O
been	O
FDA	O
approved	O
for	O
smoking	O
cessation,	O
while	O
nortriptyline	B-Drug
is	O
a	O
tricyclic	O
antidepressant	O
which	O
used	O
to	O
aid	O
in	O
cessation	O
it	O
not	O
this	O
indication.	O

Early	O
carbon	O
dioxide	O
retention	O
causing	O
cutaneous	O
vasodilation	O
(releasing	O
more	O
fentanyl),	O
together	O
with	O
acidosis,	O
which	O
reduces	O
protein	O
binding	O
of	O
fentanyl,	O
releasing	O
yet	O
fentanyl.	O
fentanyl	B-Drug

Selegiline	B-Drug
is	O
the	O
levorotatory	O
enantiomer	O
of	O
racemic	O
mixture	O
deprenyl.	O
deprenyl	B-Drug

6-EAPB	B-Drug

Since	O
metolazone	O
(as	O
well	O
as	O
other	O
drugs	O
like	O
indapamide)	O
acts	O
on	O
the	O
same	O
target	O
thiazides	O
and	O
behave	O
in	O
a	O
similar	O
pharmacologic	O
fashion,	O
it	O
is,	O
however,	O
considered	O
"thiazide-like	O
diuretic."	O
indapamide	B-Drug

Fentanyl	B-Drug
is	O
a	O
highly	O
lipophilic	O
compound,	O
which	O
well	O
absorbed	O
sublingually	O
and	O
generally	O
tolerated.	O

Lorazepam	B-Drug
has	O
pupil-dilating	O
effects,	O
which	O
may	O
further	O
interfere	O
with	O
the	O
drainage	O
of	O
aqueous	O
humor	O
from	O
anterior	O
chamber	O
eye,	O
thus	O
worsening	O
narrow-angle	O
glaucoma.	O

Finasteride	B-Drug
has	O
also	O
been	O
tested	O
for	O
pattern	O
hair	O
loss	O
in	O
women;	O
however,	O
the	O
results	O
were	O
no	O
better	O
than	O
placebo.	O

Omeprazole	B-Drug
Ranitidine	B-Drug
Dexamethasone	B-Drug
Metoclopramide	B-Drug
Ondansetron	B-Drug
Aprepitant	B-Drug
Sulfasalazine	B-Drug
Hydrocortisone	B-Drug
Senna	O
Oral	O
rehydration	O
salts	O
+	O
zinc	O
sulfate	O
(Co-packaged)	O

THC	B-Drug
appears	O
to	O
alter	O
mood	O
and	O
cognition	O
through	O
its	O
agonist	O
actions	O
on	O
the	O
CB1	O
receptors,	O
which	O
inhibit	O
a	O
secondary	O
messenger	O
system	O
(adenylate	O
cyclase)	O
in	O
dose-dependent	O
manner.	O

Another	O
form	O
of	O
fentanyl	B-Drug
that	O
has	O
appeared	O
on	O
the	O
streets	O
is	O
Actiq	B-Drug
lollipop	O
formulation.	O

Mestanolone,	O
also	O
known	O
as	O
methylandrostanolone	O
and	O
sold	O
under	O
the	O
brand	O
names	O
Androstalone	O
Ermalone	O
among	O
others,	O
is	O
an	O
androgen	O
anabolic	O
steroid	O
(AAS)	O
medication	O
which	O
mostly	O
no	O
longer	O
used.	O
Mestanolone	B-Drug

If	O
withdrawal	O
occurs,	O
naltrexone	B-Drug
should	O
not	O
be	O
started.	O

When	O
given	O
by	O
injection	O
into	O
a	O
vein,	O
heroin	B-Drug
has	O
two	O
to	O
three	O
times	O
the	O
effect	O
of	O
similar	O
dose	O
morphine.	O
morphine	B-Drug

According	O
to	O
Abdelelah	O
Mohammed	O
Al-Sharif,	O
secretary	O
general	O
of	O
the	O
National	O
Committee	O
for	O
Narcotics	O
Control	O
and	O
assistant	O
director	O
Anti-Drug	O
Preventative	O
Affairs,	O
40%	O
drug	O
users	O
who	O
fall	O
in	O
1222	O
age	O
group	O
Saudi	O
Arabia	O
are	O
addicted	O
fenethylline.	O
fenethylline	B-Drug

Widely	O
known	O
drugs	O
such	O
as	O
ganja,	O
cocaine,	O
heroin	B-Drug
etc.	O
are	O
mentioned	O
by	O
those	O
names.	O
cocaine	B-Drug

When	O
entheogenic	O
preparations	O
of	O
these	O
plants	O
were	O
used,	O
hyoscine	B-Drug
was	O
considered	O
to	O
be	O
the	O
main	O
psychoactive	O
compound	O
and	O
largely	O
responsible	O
for	O
hallucinogenic	O
effects,	O
particularly	O
when	O
preparation	O
made	O
into	O
a	O
topical	O
ointment	O
(most	O
notably	O
flying	O
ointment).	O

It	O
produces	O
effects	O
in	O
animals	O
similar	O
to	O
those	O
of	O
tetrahydrocannabinol	B-Drug
(THC),	O
a	O
cannabinoid	O
naturally	O
present	O
cannabis,	O
leading	O
its	O
use	O
synthetic	O
cannabis	O
products	O
that	O
some	O
countries	O
are	O
sold	O
legally	O
as	O
"incense	O
blends".	O
THC	B-Drug

Methadone	B-Drug
maintenance	O
treatment	O

Isomethadone	B-Drug

Butorphanol	B-Drug
is	O
a	O
morphinan-type	O
synthetic	O
agonistantagonist	O
opioid	O
analgesic	O
developed	O
by	O
Bristol-Myers.	O

Side	O
effects	O
of	O
fentanyl	B-Drug
analogs	O
are	O
similar	O
to	O
those	O
itself,	O
which	O
include	O
itching,	O
nausea	O
and	O
potentially	O
serious	O
respiratory	O
depression,	O
can	O
be	O
life-threatening.	O

Nothing	O
is	O
known	O
about	O
the	O
use	O
of	O
alfatradiol	B-Drug
during	O
pregnancy	O
or	O
lactation,	O
in	O
patients	O
under	O
18	O
years	O
age.	O

According	O
to	O
the	O
DEA,	O
majority	O
of	O
heroin	B-Drug
consumed	O
in	O
United	O
States	O
comes	O
from	O
Mexico	O
(50%)	O
and	O
Colombia	O
(43-45%)	O
via	O
Mexican	O
criminal	O
cartels	O
such	O
as	O
Sinaloa	O
Cartel.	O

Buprenorphine	B-Drug
has	O
shown	O
antidepressant	O
effects	O
in	O
some	O
human	O
studies,	O
thought	O
to	O
be	O
because	O
of	O
its	O
antagonist	O
at	O
the	O
KOR,	O
but	O
not	O
been	O
further	O
developed	O
for	O
this	O
application	O
MOR	O
agonist	O
and	O
consequent	O
abuse	O
potential.	O

Chlortalidone	B-Drug
reduces	O
the	O
volume	O
and	O
thereby	O
pressure	O
in	O
inner	O
ear	O
chambers;	O
elevated	O
endolymph	O
is	O
thought	O
to	O
be	O
cause	O
of	O
Mnire's	O
disease	O
or	O
Endolymphatic	O
hydrops.	O

Indicated	O
as	O
a	O
short-term	O
secondary	O
treatment	O
for	O
exogenous	O
obesity,	O
phendimetrazine	B-Drug

Deliberate	O
overdoses	O
with	O
250	O
mg	O
and	O
up	O
to	O
300	O
buspirone	B-Drug
have	O
resulted	O
in	O
drowsiness	O
about	O
50%	O
of	O
individuals.	O

Research	O
in	O
these	O
events	O
is	O
complicated	O
because	O
cannabis	O
often	O
used	O
conjunction	O
with	O
tobacco,	O
and	O
drugs	O
such	O
as	O
alcohol	O
cocaine.	O
tobacco	B-Drug
cocaine	B-Drug

Some	O
states	O
have	O
restricted	O
the	O
sale	O
of	O
dextromethorphan	B-Drug
to	O
adults	O
or	O
put	O
other	O
restrictions	O
on	O
its	O
purchase	O
in	O
place,	O
similar	O
those	O
for	O
pseudoephedrine.	O
pseudoephedrine	B-Drug

Strassman's	O
interest	O
in	O
the	O
human	O
biology	O
of	O
altered	O
states	O
consciousness	O
led	O
him	O
to	O
study	O
pineal	O
gland	O
hormone	O
melatonin	B-Drug
1980s,	O
at	O
which	O
time	O
there	O
were	O
suggestive	O
data	O
regarding	O
its	O
psychoactive	O
effects.	O

inhibitor	O
ketoconazole	B-Drug
elevates	O
amitriptyline	B-Drug
level	O
by	O
about	O
a	O
quarter.	O

PCP	B-Drug
can	O
be	O
ingested	O
through	O
smoking.	O

In	O
the	O
United	O
States	O
in	O
1937,	O
Marihuana	B-Drug
Tax	O
Act	O
was	O
passed,	O
and	O
prohibited	O
production	O
of	O
hemp	O
addition	O
to	O
cannabis.	O

Roughly	O
90%	O
of	O
ingested	O
amphetamine	B-Drug
is	O
eliminated	O
3	O
days	O
after	O
the	O
last	O
oral	O
dose.	O

Instead,	O
norpethidine	B-Drug
acts	O
as	O
a	O
stimulant	O
and	O
causes	O
convulsions.	O

Listed	O
as	O
a	O
Schedule	O
1	O
it	O
is	O
an	O
analogue	O
of	O
amphetamine.	O
amphetamine	B-Drug

Bromadoline	O
is	O
related	O
to	O
AH-7921	O
and	O
U-47700.	O
U-47700	B-Drug

desomorphine,	O
acetylpropionylmorphine,	O
dibenzoylmorphine,	O
diacetyldihydromorphine;	O
Semi-synthetic	O
opioids:	O
created	O
from	O
either	O
the	O
natural	O
opiates	O
or	O
morphine	B-Drug
esters,	O
such	O
as	O
hydromorphone,	O
hydrocodone,	O
oxycodone,	O
oxymorphone,	O
ethylmorphine	B-Drug
and	O
buprenorphine;	O
Fully	O
synthetic	O
fentanyl,	O
pethidine,	O
levorphanol,	O
methadone,	O
tramadol,	O
tapentadol,	O
dextropropoxyphene;	O
Endogenous	O
opioid	O
peptides,	O
produced	O
naturally	O
in	O
body,	O
endorphins,	O
enkephalins,	O
dynorphins,	O
endomorphins.	O
desomorphine	B-Drug
acetylpropionylmorphine	B-Drug
diacetyldihydromorphine	B-Drug
hydromorphone	B-Drug
hydrocodone	B-Drug
oxycodone	B-Drug
oxymorphone	B-Drug
buprenorphine	B-Drug
fentanyl	B-Drug
pethidine	B-Drug
levorphanol	B-Drug
methadone	B-Drug
tramadol	B-Drug
tapentadol	B-Drug
dextropropoxyphene	B-Drug

"	O
Tramadol	B-Drug
is	O
also	O
used	O
as	O
a	O
coping	O
mechanism	O
in	O
the	O
Gaza	O
Strip.	O

The	O
idea	O
that	O
ergine	B-Drug
is	O
the	O
main	O
psychedelic	O
component	O
in	O
containing	O
seeds	O
(morning	O
glory,	O
Hawaiian	O
baby	O
woodrose)	O
well	O
debated,	O
as	O
effects	O
of	O
isolated	O
synthetic	O
are	O
reported	O
to	O
be	O
only	O
mildly	O
psychedelic.	O

Research	O
during	O
this	O
time	O
was	O
focused	O
on	O
the	O
search	O
for	O
a	O
painkiller	O
that	O
did	O
not	O
have	O
addictive	O
character	O
or	O
overdose	O
risk	O
of	O
morphine.	O
morphine	B-Drug

Benzodiazepine	O
drugs	O
including	O
medazepam	B-Drug
increase	O
the	O
inhibitory	O
processes	O
in	O
cerebral	O
cortex	O
by	O
allosteric	O
modulation	O
of	O
GABA	O
receptor.	O

Unlike	O
NSAIDs	O
such	O
as	O
aspirin,	O
paracetamol	B-Drug
does	O
not	O
appear	O
to	O
inhibit	O
the	O
function	O
of	O
any	O
cyclooxygenase	O
(COX)	O
aspirin	B-Drug

Another	O
claim	O
about	O
cannabis	O
is	O
that	O
impairment	O
due	O
to	O
smoking	O
it	O
lasts	O
many	O
days	O
after	O
using	O
it,	O
since	O
THC	B-Drug
stored	O
in	O
the	O
fat	O
cells,	O
leading	O
a	O
low-grade	O
haze	O
long	O
primary	O
high	O
gone.	O

During	O
the	O
time	O
major	O
traffickers	O
like	O
Falcon	O
brothers	O
and	O
Sal	O
Magluta	O
smuggled	O
in	O
around	O
2	O
billion	O
dollars	O
of	O
cocaine	B-Drug
from	O
Colombia.	O

Through	O
using	O
cocaine,	O
he	O
feels	O
on	O
top	O
of	O
the	O
world,	O
and	O
finds	O
confidence	O
to	O
act	O
like	O
a	O
salesman	O
again.	O
cocaine	B-Drug

As	O
such,	O
PCP	B-Drug
is	O
an	O
NMDA	O
receptor	O
antagonist.	O

The	O
seeds	O
of	O
this	O
powerful	O
narcotic,	O
termed	O
"passion	O
seeds"	O
(candabija),	O
are	O
the	O
strongest	O
elements	O
and	O
contain	O
alkaloids	O
hyoscine,	O
hyoscyamine,	O
atropine	O
in	O
forms	O
that	O
survive	O
burning	O
or	O
boiling.	O
hyoscine	B-Drug
hyoscyamine	B-Drug

Generic	O
versions	O
of	O
extended-release	O
oxymorphone,	O
such	O
as	O
those	O
manufactured	O
by	O
Amneal	O
Pharmaceuticals,	O
are	O
still	O
available	O
in	O
the	O
US.	O
oxymorphone	B-Drug

They	O
may	O
be	O
the	O
endogenous	O
ligands	O
of	O
2	O
subunit,	O
and	O
they	O
competitively	O
antagonize	O
effects	O
gabapentin.	O
gabapentin	B-Drug

This	O
elaborate	O
procedure,	O
requiring	O
the	O
maintenance	O
of	O
pots	O
opium	B-Drug
at	O
just	O
right	O
temperature	O
for	O
a	O
globule	O
to	O
be	O
scooped	O
up	O
with	O
needle-like	O
skewer	O
smoking,	O
formed	O
basis	O
craft	O
"paste-scooping"	O
by	O
which	O
servant	O
girls	O
could	O
become	O
prostitutes	O
as	O
opportunity	O
arose.	O

The	O
mixture	O
is	O
composed	O
of	O
equal	O
parts	O
racemic	O
amphetamine	B-Drug
and	O
dextroamphetamine,	O
which	O
produces	O
a	O
(3:1)	O
ratio	O
between	O
dextroamphetamine	B-Drug
levoamphetamine,	O
the	O
two	O
enantiomers	O
amphetamine.	O

Danish	O
pharmaceutical	O
company	O
Lundbeck	O
has	O
licensed	O
nalmefene	B-Drug
from	O
Biotie	O
Therapies	O
and	O
performed	O
clinical	O
trials	O
with	O
for	O
treatment	O
of	O
alcohol	O
dependence.	O

Recreational	O
use	O
of	O
Adderall	B-Drug
generally	O
involves	O
far	O
larger	O
doses	O
and	O
is	O
therefore	O
significantly	O
more	O
dangerous,	O
involving	O
a	O
much	O
greater	O
risk	O
serious	O
adverse	O
drug	O
effects	O
than	O
dosages	O
used	O
for	O
therapeutic	O
purposes.	O

Chlorpromazine	B-Drug
is	O
in	O
the	O
typical	O
antipsychotic	O
class,	O
and,	O
chemically,	O
one	O
of	O
phenothiazines.	O

It	O
inactivates	O
the	O
cobalamin	B-Drug
form	O
of	O
vitamin	B-Drug
B12	I-Drug
by	O
oxidation.	O

Due	O
to	O
the	O
effect	O
pH	O
has	O
on	O
absorption,	O
amphetamine	B-Drug
also	O
interacts	O
with	O
gastric	O
acid	O
reducers	O
such	O
as	O
proton	O
pump	O
inhibitors	O
and	O
H2	O
antihistamines,	O
which	O
increase	O
gastrointestinal	O
(i.e.,	O
make	O
it	O
less	O
acidic).	O

Three-quarters	O
of	O
the	O
world's	O
annual	O
yield	O
cocaine	B-Drug
has	O
been	O
produced	O
in	O
Colombia,	O
both	O
from	O
base	O
imported	O
Peru	O
(primarily	O
Huallaga	O
Valley)	O
and	O
Bolivia,	O
locally	O
grown	O
coca.	O
coca	B-Drug

Generic	O
ciclosporin	B-Drug
preparations	O
have	O
been	O
marketed	O
under	O
various	O
trade	O
names,	O
including	O
Cicloral	O
(Sandoz/Hexal),	O
Gengraf	O
(Abbott)	O
and	O
Deximune	O
(Dexcel	O
Pharma).	O

The	O
evolution	O
of	O
resistance	O
to	O
first-generation	O
drugs	O
(e.g.	O
chloroquine)	O
and	O
insecticides	O
exacerbated	O
the	O
situation.	O
chloroquine	B-Drug

Those	O
taking	O
fentanyl-laced	O
heroin	B-Drug
are	O
more	O
likely	O
to	O
overdose	O
because	O
they	O
do	O
not	O
know	O
also	O
ingesting	O
the	O
powerful	O
drug.	O

It	O
is	O
the	O
beta-methoxy	O
derivative	O
of	O
mescaline.	O
mescaline	B-Drug

Prior	O
to	O
infusion,	O
a	O
lymphodepleting	O
preparative	O
regimen	O
is	O
undergone,	O
typically	O
60	O
mg/kg	O
cyclophosphamide	B-Drug
for	O
2	O
days	O
and	O
25	O
mg/m2	O
fludarabine	B-Drug
administered	O
5	O
days.	O

Nicodicodeine	B-Drug
is	O
a	O
similar	O
drug	O
which	O
to	O
nicocodeine	B-Drug
as	O
dihydrocodeine	B-Drug
codeine.	O
codeine	B-Drug

The	O
short-term	O
benefits	O
and	O
cost	O
effectiveness	O
of	O
methylphenidate	B-Drug
are	O
well	O
established.	O

China	O
ceased	O
producing	O
licit	O
opium	B-Drug
after	O
2001.	O

Examples:	O
noretynodrel,	O
norethisterone	B-Drug
(norethindrone),	O
lynestrenol,	O
levonorgestrel.	O
levonorgestrel	B-Drug

In	O
early	O
20th-century	O
Memphis,	O
Tennessee,	O
cocaine	B-Drug
was	O
sold	O
in	O
neighborhood	O
drugstores	O
on	O
Beale	O
Street,	O
costing	O
five	O
or	O
ten	O
cents	O
for	O
a	O
small	O
boxful.	O

Metabolism	O
of	O
JWH-018	B-Drug
was	O
assessed	O
using	O
Wistar	O
rats	O
which	O
had	O
been	O
administered	O
an	O
ethanolic	O
extract	O
containing	O
JWH-018.	O

Boldenone	B-Drug
has	O
strong	O
anabolic	O
effects	O
and	O
moderate	O
androgenic	O
effects.	O

Milnacipran	B-Drug
has	O
a	O
half-life	O
of	O
about	O
6	O
to	O
8	O
hours,	O
and	O
steady-state	O
levels	O
are	O
reached	O
within	O
36	O
48	O
hours.	O

Sultiame.	O
Sultiame	B-Drug

Most	O
commercial	O
opiate	O
immunoassay	O
screening	O
tests	O
do	O
not	O
cross-react	O
significantly	O
with	O
tramadol	B-Drug
or	O
its	O
major	O
metabolites,	O
so	O
chromatographic	O
techniques	O
must	O
be	O
used	O
to	O
detect	O
and	O
quantitate	O
these	O
substances.	O

Marijuana	O
or	O
marihuana	B-Drug
(herbal	O
cannabis)	O
consists	O
of	O
the	O
dried	O
flowers	O
and	O
fruits	O
subtending	O
leaves	O
stems	O
female	O
Cannabis	O
plant.	O

The	O
main	O
active	O
constituent	O
of	O
vilca	O
is	O
bufotenin;	O
to	O
a	O
much	O
lesser	O
degree	O
DMT	O
and	O
5-MeO-DMT	B-Drug
are	O
also	O
present.	O
bufotenin	B-Drug

On	O
the	O
other	O
hand,	O
although	O
there	O
is	O
also	O
a	O
relative	O
decrease	O
in	O
pseudocholinesterase	O
enzymes	O
those	O
with	O
liver	O
disease,	O
kidney	O
anemia,	O
pregnancy,	O
chronic	O
cocaine	B-Drug
use,	O
amphetamine	B-Drug
abuse,	O
increased	O
age,	O
and	O
connective	O
tissue	O
succinylcholine	B-Drug
effect	O
minimal	O
dose	O
reduction	O
not	O
needed.	O

Since	O
PMA	B-Drug
has	O
a	O
slow	O
onset	O
of	O
effects,	O
several	O
deaths	O
have	O
occurred	O
where	O
individuals	O
taken	O
pill	O
containing	O
PMA,	O
followed	O
by	O
MDMA	B-Drug
some	O
time	O
afterwards	O
due	O
to	O
thinking	O
that	O
the	O
first	O
was	O
not	O
active.	O

Despite	O
showing	O
some	O
advantages	O
over	O
etorphine,	O
for	O
instance	O
producing	O
less	O
toxic	O
side	O
effects	O
in	O
giraffes,	O
acetorphine	B-Drug
was	O
never	O
widely	O
adopted	O
veterinary	O
use,	O
and	O
etorphine	B-Drug
(along	O
with	O
other	O
tranquilizers	O
such	O
as	O
carfentanil	B-Drug
azaperone)	O
remains	O
the	O
drug	O
of	O
choice	O
this	O
application.	O

The	O
recommendation	O
applying	O
to	O
CBD	B-Drug
extracts,	O
synthesized	O
CBD,	O
and	O
all	O
products,	O
including	O
oil	I-Drug
was	O
scheduled	O
for	O
a	O
final	O
ruling	O
by	O
the	O
European	O
Commission	O
in	O
March	O
2019.	O

5-MeO-DMT	B-Drug
was	O
first	O
synthesized	O
in	O
1936,	O
and	O
1959	O
it	O
isolated	O
as	O
one	O
of	O
the	O
psychoactive	O
ingredients	O
Anadenanthera	O
peregrina	O
seeds	O
used	O
preparing	O
Yopo	O
snuff.	O
snuff	B-Drug

In	O
1989,	O
John	O
Olney	O
discovered	O
that	O
neuronal	O
vacuolation	O
and	O
other	O
cytotoxic	O
changes	O
("lesions")	O
occurred	O
in	O
brains	O
of	O
rats	O
administered	O
NMDA	O
antagonists,	O
including	O
PCP	B-Drug
ketamine.	O
ketamine	B-Drug

There	O
is	O
also	O
evidence	O
that	O
this	O
type	O
of	O
treatment	O
works	O
with	O
LSD,	O
which	O
has	O
been	O
shown	O
to	O
have	O
a	O
therapeutic	O
effect	O
on	O
alcoholism.	O
LSD	B-Drug

25CN-NBOMe	O
(2C-CN-NBOMe,	O
NBOMe-2C-CN)	O
is	O
a	O
derivative	O
of	O
the	O
phenethylamine	B-Drug
2C-CN.	O

The	O
toxicity	O
of	O
GHB	B-Drug
has	O
been	O
an	O
issue	O
in	O
criminal	O
trials,	O
as	O
the	O
death	O
Felicia	O
Tang,	O
where	O
defense	O
argued	O
that	O
was	O
due	O
to	O
GHB,	O
not	O
murder.	O

No	O
decline	O
in	O
renal	O
excretory	O
function	O
was	O
observed	O
when	O
meloxicam	B-Drug
administered	O
to	O
cats	O
with	O
chronic	O
kidney	O
disease.	O

Tramadol	B-Drug
has	O
also	O
been	O
shown	O
to	O
act	O
as	O
a	O
serotonin	O
releasing	O
agent.	O

Therapeutic	O
doses	O
of	O
amphetamine	B-Drug
also	O
enhance	O
cortical	O
network	O
efficiency,	O
an	O
effect	O
which	O
mediates	O
improvements	O
in	O
working	O
memory	O
all	O
individuals.	O

It	O
is	O
closely	O
related	O
on	O
a	O
structural	O
level	O
to	O
number	O
of	O
other	O
stimulants,	O
such	O
as	O
MDPV	B-Drug
and	O
prolintane	O
(Promotil,	O
Katovit).	O

Commercial	O
cannabinoid	O
immunoassays,	O
often	O
employed	O
as	O
the	O
initial	O
screening	O
method	O
when	O
testing	O
physiological	O
specimens	O
for	O
marijuana	O
presence,	O
have	O
different	O
degrees	O
of	O
cross-reactivity	O
with	O
THC	B-Drug
and	O
its	O
metabolites.	O

Ketoprofen	B-Drug
topical	O
patches	O
are	O
being	O
used	O
for	O
treatment	O
of	O
musculoskeletal	O
pain.	O

In	O
1899,	O
a	O
Dr.	O
Schneiderlin	O
recommended	O
the	O
use	O
of	O
hyoscine	B-Drug
and	O
morphine	B-Drug
for	O
surgical	O
anaesthesia,	O
it	O
started	O
to	O
be	O
used	O
sporadically	O
that	O
purpose.	O

The	O
empathogen-entactogen	O
MDMA	B-Drug
releases	O
serotonin	O
from	O
synaptic	O
vesicles	O
of	O
neurons.	O

It	O
is	O
primarily	O
known	O
as	O
a	O
metabolite	O
of	O
the	O
better	O
psychoactive	O
drug	O
5-MeO-DiPT,	O
but	O
5-HO-DiPT	O
has	O
also	O
rarely	O
been	O
encountered	O
designer	O
in	O
its	O
own	O
right.	O
5-MeO-DiPT	B-Drug

Extracellular	O
MDMA	B-Drug
binds	O
to	O
presynaptic	O
serotonin	O
(SERT),	O
norepinephrine	O
(NET)	O
and	O
dopamine	O
transporters	O
(DAT)	O
as	O
a	O
reuptake	O
inhibitor,	O
so	O
that	O
they	O
uptake	O
less	O
of	O
their	O
namesake	O
monoamine	O
neurotransmitters.	O

Heroin	B-Drug
is	O
especially	O
lethal	O
because	O
it	O
depresses	O
the	O
central	O
nervous	O
system,	O
unlike	O
cocaine	B-Drug
and	O
meth	B-Drug
which	O
are	O
stimulants.	O

The	O
peripheral	O
site	O
of	O
action	O
alvimopan	B-Drug
suggests	O
that	O
such	O
a	O
heightened	O
sensitivity	O
would	O
precipitate	O
gastrointestinal	O
effects	O
beyond	O
dyspepsia.	O

Ranitidine	B-Drug
was	O
introduced	O
in	O
1981,	O
and	O
the	O
world's	O
biggest-selling	O
prescription	O
drug	O
by	O
1987.	O

After	O
a	O
single	O
dose	O
of	O
apalutamide,	O
its	O
clearance	O
rate	O
(CL/F)	O
was	O
1.3	O
L/h,	O
while	O
increased	O
to	O
2.0	O
L/h	O
at	O
steady-state.	O
apalutamide	B-Drug

Cocaine	B-Drug
has	O
been	O
demonstrated	O
to	O
bind	O
as	O
directly	O
stabilize	O
the	O
DAT	O
transporter	O
on	O
open	O
outward-facing	O
conformation.	O

In	O
1965,	O
Sandoz	O
laboratories	O
stopped	O
its	O
still	O
legal	O
shipments	O
of	O
LSD	B-Drug
to	O
the	O
United	O
States	O
for	O
research	O
and	O
psychiatric	O
use,	O
after	O
a	O
request	O
from	O
US	O
government	O
concerned	O
about	O
use.	O

Among	O
the	O
marijuana	O
community	O
however,	O
sativa	O
rather	O
refers	O
to	O
equatorial	O
varieties	O
producing	O
stimulating	O
psychoactive	O
effects	O
(THC:CBD	O
[almost	O
equal	O
to]	O
1),	O
whereas	O
indica-type	O
plants	O
from	O
Central	O
Asia	O
are	O
used	O
for	O
relaxing	O
and	O
sedative	O
drugs	O
>	O
1)	O
[8].	O
THC	B-Drug
CBD	B-Drug

In	O
February	O
2018,	O
the	O
U.S.	O
Drug	O
Enforcement	O
Administration	O
indicated	O
that	O
illicit	O
fentanyl	B-Drug
analogs	O
have	O
no	O
medically	O
valid	O
use,	O
and	O
thus	O
applied	O
a	O
"Schedule	O
I"	O
classification	O
to	O
them.	O

The	O
International	O
Nonproprietary	O
Name	O
Dronabinol,	O
also	O
known	O
as	O
Marinol,	O
Syndros,	O
REDUVO	O
and	O
Adversa,	O
is	O
a	O
trade	O
name	O
for	O
specific	O
form	O
of	O
tetrahydrocannabinol,	O
sold	O
an	O
appetite	O
stimulant,	O
antiemetic,	O
sleep	O
apnea	O
reliever.	O
tetrahydrocannabinol	B-Drug

This	O
was	O
particularly	O
significant	O
during	O
the	O
American	O
Civil	O
War,	O
when	O
wounded	O
soldiers	O
were	O
treated	O
with	O
morphine.	O
morphine	B-Drug

In	O
October	O
2019,	O
the	O
FDA	O
issued	O
an	O
advisory	O
warning	O
that	O
effects	O
of	O
CBD	B-Drug
during	O
pregnancy	O
or	O
breastfeeding	O
are	O
unknown,	O
indicating	O
safety,	O
doses,	O
interactions	O
with	O
other	O
drugs	O
foods,	O
and	O
side	O
not	O
clinically	O
defined,	O
may	O
pose	O
a	O
risk	O
to	O
mother	O
infant.	O

Durrani	O
then	O
arranged	O
for	O
hashish	B-Drug
to	O
be	O
smuggled	O
in	O
the	O
furniture	O
of	O
Pakistani	O
diplomats	O
who	O
were	O
moving	O
London;	O
Marks	O
would	O
intercept	O
find	O
drugs	O
this	O
arrangement	O
netted	O
him	O
a	O
profit	O
7,500.	O

Distillers	O
Co.	O
Ltd	O
(now	O
part	O
of	O
Diageo	O
plc),	O
marketed	O
thalidomide	B-Drug
throughout	O
the	O
UK,	O
Australia	O
and	O
New	O
Zealand,	O
under	O
brand	O
name	O
Distaval,	O
as	O
a	O
remedy	O
for	O
morning	O
sickness.	O

MDMA	B-Drug
has	O
become	O
widely	O
known	O
as	O
ecstasy	B-Drug
(shortened	O
"E",	O
"X",	O
or	O
"XTC"),	O
usually	O
referring	O
to	O
its	O
tablet	O
form,	O
although	O
this	O
term	O
may	O
also	O
include	O
the	O
presence	O
of	O
possible	O
adulterants	O
diluents.	O
XTC	B-Drug

Stiripentol.	O
Stiripentol	B-Drug

In	O
2011,	O
the	O
Indian	O
Air	O
Force	O
announced	O
that	O
modafinil	B-Drug
was	O
included	O
in	O
contingency	O
plans.	O

Withdrawal	O
symptoms	O
which	O
can	O
occur	O
from	O
stopping	O
benzodiazepines	O
such	O
as	O
lormetazepam	B-Drug
include:	O
rebound	O
insomnia	O
and	O
nightmares	O
anxiety,	O
panic	O
attacks,	O
agoraphobia	O
clinical	O
depression	O
malaise	O
lack	O
of	O
concentration	O
abdominal	O
discomfort	O
depersonalisation	O
feelings	O
unreality	O
emotional	O
lability	O
cognitive	O
impairment	O
tinnitus	O
paraesthesiae,	O
tingling,	O
numbness,	O
pain	O
muscle	O
pain,	O
weakness,	O
tension,	O
painful	O
tremor,	O
shaking	O
jerks,	O
blepharospasm	O
excitability,	O
jumpiness,	O
restlessness	O
stiffness	O
sweatsAbrupt	O
or	O
over	O
rapid	O
withdrawal	O
high	O
doses	O
provoke:	O
epileptic	O
seizures	O
hallucinations	O
(visual,	O
auditory)	O
misperceptionsWithdrawal	O
typically	O
subside	O
after	O
48	O
weeks	O
but	O
in	O
approximately	O
10-15%	O
individuals	O
persist	O
for	O
many	O
months	O
rare	O
cases	O
years.	O

In	O
the	O
United	O
States,	O
amphetamine	B-Drug
is	O
a	O
Schedule	O
II	O
prescription	O
drug,	O
classified	O
as	O
CNS	O
stimulant.	O

Phencyclidine	B-Drug

Morphine	B-Drug
itself,	O
in	O
trials	O
with	O
rats,	O
is	O
1122	O
times	O
more	O
potent	O
than	O
morphine-N-oxide	O
subcutaneously	O
and	O
3989	O
intraperitoneally.	O

Morpheridine	B-Drug
is	O
not	O
currently	O
used	O
in	O
medicine	O
and	O
a	O
Schedule	O

The	O
following	O
BischlerNapieralski	O
reaction	O
produces	O
papaverine.	O
papaverine	B-Drug

The	O
family	O
of	O
drugs	O
typified	O
by	O
MDMA	B-Drug
produce	O
their	O
effects	O
through	O
multiple	O
mechanisms	O
action	O
in	O
the	O
body,	O
and	O
consequently	O
three	O
distinct	O
cues	O
which	O
animals	O
can	O
be	O
trained	O
to	O
respond	O
to:	O
a	O
stimulant	O
cue	O
such	O
as	O
methamphetamine,	O
psychedelic	O
LSD	B-Drug
DOM,	O
an	O
"entactogen-like"	O
is	O
produced	O
MDAI	B-Drug
MBDB.	O
methamphetamine	B-Drug
MBDB	B-Drug

Cigarette	O
smokers	O
(about	O
21%	O
of	O
the	O
US	O
population	O
in	O
2013))	O
are	O
usually	O
addicted	O
to	O
nicotine.	O
nicotine	B-Drug

Longer-acting	O
benzodiazepines	O
such	O
as	O
nitrazepam	B-Drug
and	O
diazepam	B-Drug
have	O
residual	O
effects	O
that	O
may	O
persist	O
into	O
the	O
next	O
day	O
are,	O
in	O
general,	O
not	O
recommended.	O

5F-ADB	B-Drug
is	O
a	O
potent	O
agonist	O
of	O
the	O
CB1	O
receptor,	O
though	O
it	O
unclear	O
whether	O
selective	O
for	O
this	O
target.	O

Phenytoin,	O
reduces	O
phenytoin	B-Drug
excretion,	O
hence	O
increasing	O
the	O
potential	O
for	O
toxicity.	O
Phenytoin	B-Drug

LSD	B-Drug
art	O
is	O
any	O
or	O
visual	O
displays	O
inspired	O
by	O
psychedelic	O
experiences	O
and	O
hallucinations	O
known	O
to	O
follow	O
the	O
ingestion	O
of	O
(lysergic	O
acid	B-Drug
diethylamide,	O
also	O
colloquially	O
as	O
acid).	O

A	O
related	O
claim,	O
especially	O
in	O
the	O
UK,	O
is	O
that	O
cannabidiol/THC	O
ratio	O
has	O
decreased	O
over	O
past	O
few	O
decades,	O
resulting	O
a	O
new	O
and	O
presumably	O
more	O
dangerous	O
form	O
of	O
cannabis	O
never	O
existed	O
before	O
(since	O
CBD	B-Drug
thought	O
to	O
attenuate	O
some	O
negative	O
side	O
effects	O
THC).	O
cannabidiol	B-Drug
THC	B-Drug

the	O
Netherlands,	O
fentanyl	B-Drug
is	O
a	O
List	O

In	O
1959,	O
Wolfgang	O
Fruhstorfer	O
synthesized	O
MDMA	B-Drug
for	O
pharmacological	O
testing	O
while	O
researching	O
stimulants.	O

In	O
turn,	O
Phenytoin	B-Drug
may	O
lower	O
clonazepam	B-Drug
plasma	O
levels	O
by	O
increasing	O
the	O
speed	O
of	O
clearance	O
approximately	O
50%	O
and	O
decreasing	O
its	O
half-life	O
31%.	O

Paracelsus,	O
a	O
16th-century	O
Swiss-German	O
alchemist,	O
experimented	O
with	O
various	O
opium	B-Drug
concoctions,	O
and	O
recommended	O
for	O
reducing	O
pain.	O

Novel	O
with	O
Cocaine,	O
or	O
sometimes	O
Cocain	O
Romance	O
(Russian:	O
-	O
Roman	O
s	O
kokainom),	O
is	O
a	O
mysterious	O
Russian	O
novel	O
first	O
published	O
in	O
1934	O
Parisian	O
migr	O
publication,	O
Numbers,	O
and	O
subtitled	O
"Confessions	O
of	O
opium-eater".	O
Cocaine	B-Drug

Modafinil	B-Drug
is	O
sold	O
under	O
a	O
wide	O
variety	O
of	O
brand	O
names	O
worldwide,	O
including	O
Alertec,	O
Alertex,	O
Altasomil,	O
Aspendos,	O
Forcilin,	O
Intensit,	O
Mentix,	O
Modafinil,	O
Modafinilo,	O
Modalert,	O
Modanil,	O
Modasomil,	O
Modvigil,	O
Modiodal,	O
Modiwake,	O
Movigil,	O
Provigil,	O
Resotyl,	O
Stavigile,	O
Vigia,	O
Vigicer,	O
Vigil,	O
Vigimax,	O
Wakelert	O
and	O
Zalux.	O
Provigil	B-Drug

Mifepristone	B-Drug
followed	O
by	O
a	O
prostaglandin	O
analog	O
(misoprostol	O
or	O
gemeprost)	O
is	O
used	O
for	O
medical	O
abortion.	O
misoprostol	B-Drug
gemeprost	B-Drug

It	O
may	O
also	O
be	O
mixed	O
with	O
cannabis	O
or	O
tobacco.	O
tobacco	B-Drug

Conversely,	O
hydrocodone	B-Drug
inhibits	O
adrenocorticotropic	O
hormone	O
(ACTH),	O
cortisol	O
and	O
luteinizing	O
(LH)	O
secretion.	O

This	O
can	O
have	O
effects	O
on	O
other	O
areas	O
such	O
as	O
brain	O
development,	O
being	O
exposed	O
to	O
a	O
stimulant	O
cocaine	B-Drug
cause	O
damage	O
and	O
issues	O
in	O
development	O
over	O
time.	O

The	O
accused	O
owned	O
a	O
tablet	O
press	O
and	O
ordered	O
fentanyl	B-Drug
in	O
powder	O
form	O
from	O
China.	O

5-MeO-DALT	B-Drug
is	O
not	O
scheduled	O
at	O
the	O
federal	O
level	O
in	O
United	O
States,	O
but	O
it	O
likely	O
that	O
could	O
be	O
considered	O
an	O
analog	O
of	O
5-Meo-DiPT	B-Drug

(Indomethacin	O
morpholinylamide)	O
is	O
a	O
drug	O
used	O
in	O
scientific	O
research	O
that	O
acts	O
as	O
selective	O
CB2	O
inverse	O
agonist.	O
Indomethacin	B-Drug

The	O
research	O
team	O
of	O
Merck	O
Sharp	O
and	O
Dohme	O
Research	O
Laboratories	O
Beyer,	O
Sprague,	O
Baer,	O
Novello	O
created	O
a	O
new	O
series	O
medications,	O
the	O
thiazide	O
diuretics,	O
which	O
includes	O
chlorothiazide.	O
chlorothiazide	B-Drug

Side	O
effects	O
of	O
ethylestrenol	B-Drug
include	O
virilization	O
among	O
others.	O

The	O
combination	O
of	O
30	O
g/day	O
EE	O
and	O
150	O
desogestrel,	O
a	O
progestin	O
with	O
relatively	O
weak	O
androgenicity	O
than	O
levonorgestrel,	O
increases	O
SHBG	O
levels	O
by	O
200%,	O
while	O
the	O
35	O
2	O
mg/day	O
cyproterone	O
acetate,	O
potent	O
antiandrogenic	O
activity,	O
400%.	O
desogestrel	B-Drug
levonorgestrel	B-Drug

As	O
an	O
N-alkyl	O
derivative	O
of	O
lysergamide,	O
ergometrine	B-Drug
is	O
also	O
covered	O
by	O
the	O
Misuse	O
Drugs	O
Act	O
1971,	O
effectively	O
rendering	O
it	O
illegal	O
in	O
United	O
Kingdom.	O

Afghanistan	O
first	O
began	O
producing	O
opium	B-Drug
in	O
significant	O
quantities	O
the	O
mid-1950s,	O
to	O
supply	O
its	O
neighbor	O
Iran	O
after	O
poppy	O
cultivation	O
was	O
banned	O
there.	O

"Dex",	O
"Robo",	O
"Cough	O
Syrup",	O
"DXM")	O
"	O
DXM	B-Drug

Cannabis	O
strains	O
with	O
relatively	O
high	O
CBD:	O
CBD	B-Drug

It	O
was	O
also	O
used	O
for	O
smoking	O
cessationOther	O
notable	O
synthetic	O
cannabinoids	O
include:	O
JWH-018,	O
a	O
potent	O
cannabinoid	O
agonist	O
discovered	O
by	O
John	O
W.	O
Huffman	O
at	O
Clemson	O
University.	O
JWH-018	B-Drug

Similar	O
to	O
the	O
loss	O
of	O
cognitive	O
enhancement	O
when	O
using	O
large	O
amounts,	O
doses	O
methylphenidate	B-Drug
can	O
induce	O
side	O
effects	O
that	O
impair	O
athletic	O
performance,	O
such	O
as	O
rhabdomyolysis	O
and	O
hyperthermia.	O

Gabapentin	B-Drug
is	O
absorbed	O
from	O
the	O
intestines	O
by	O
an	O
active	O
transport	O
process	O
mediated	O
via	O
amino	O
acid	O
transporter,	O
presumably,	O
LAT2.	O

The	O
LAT1	O
is	O
easily	O
saturable,	O
so	O
the	O
pharmacokinetics	O
of	O
gabapentin	B-Drug
are	O
dose-dependent,	O
with	O
diminished	O
bioavailability	O
and	O
delayed	O
peak	O
levels	O
at	O
higher	O
doses.	O

The	O
toxicity	O
of	O
bromazepam	B-Drug
in	O
overdosage	O
increases	O
when	O
combined	O
with	O
other	O
CNS	O
depressant	O
drugs	O
such	O
as	O
alcohol	O
or	O
sedative	O
hypnotic	O
drugs.	O

The	O
estimated	O
U.S.	O
cocaine	B-Drug
market	O
exceeded	O
US$70	O
billion	O
in	O
street	O
value	O
for	O
the	O
year	O
2005,	O
exceeding	O
revenues	O
by	O
corporations	O
such	O
as	O
Starbucks.	O

Methasterone	B-Drug
was	O
therefore	O
being	O
sold	O
as	O
an	O
over-the-counter	O
dietary	O
supplement.	O

Imidazenil	B-Drug
has	O
not	O
yet	O
been	O
developed	O
commercially	O
for	O
use	O
in	O
humans,	O
however	O
it	O
suggested	O
as	O
a	O
safe	O
and	O
effective	O
treatment	O
anxiety,	O
potent	O
non-sedating	O
anticonvulsant	O
which	O
might	O
be	O
particularly	O
useful	O
the	O
of	O
poisoning	O
with	O
organophosphate	O
nerve	O
agents,	O
novel	O
schizophrenia.	O

The	O
"China	O
White"	O
form	O
of	O
fentanyl	B-Drug
refers	O
to	O
any	O
a	O
number	O
clandestinely	O
produced	O
analogues,	O
especially	O
-methylfentanyl	O
(AMF).	O

Taking	O
ethocybin	B-Drug
more	O
than	O
three	O
or	O
four	O
times	O
in	O
a	O
week	O
(especially	O
two	O
days	O
row)	O
can	O
result	O
diminished	O
effects.	O

The	O
drug	O
is	O
usually	O
manufactured	O
and	O
distributed	O
as	O
the	O
sulfate	O
salt	O
(salbutamol	O
sulfate).	O
salbutamol	B-Drug

MDMA	B-Drug
and	O
MDA	O
may	O
be	O
quantitated	O
in	O
blood,	O
plasma	O
or	O
urine	O
to	O
monitor	O
for	O
use,	O
confirm	O
a	O
diagnosis	O
of	O
poisoning	O
assist	O
the	O
forensic	O
investigation	O
traffic	O
other	O
criminal	O
violation	O
sudden	O
death.	O

Naloxone	B-Drug
is	O
increasingly	O
available	O
to	O
the	O
public.	O

Nevertheless,	O
the	O
number	O
of	O
cocaine	B-Drug
users	O
remain	O
high,	O
with	O
a	O
large	O
concentration	O
among	O
urban	O
youth.	O

Opium	O
tincture	O
is	O
used	O
to	O
treat	O
neonatal	O
opioid	O
withdrawal	O
syndrome	O
(NOWS)	O
when	O
diluted	O
1:25	O
(one	O
part	O
opium	B-Drug
25	O
parts	O
water).	O

Nicotine	B-Drug
acetylcholine	O
stimulation	O
is	O
not	O
directly	O
addictive.	O

(may	O
be	O
used	O
to	O
manufacture	O
temazepam)	O
also	O
known	O
as	O
9-chloro-6-(2-chlorophenyl)-4-hydroxy-2-methyl-2,5-diazabicyclo[5.4.0]undeca-5,8,10,12-tetraen-3-one	O
temazepam	B-Drug

Dying	O
from	O
cancer,	O
he	O
asked	O
his	O
wife	O
on	O
22	O
November	O
1963	O
to	O
inject	O
him	O
with	O
100	O
g	O
of	O
LSD.	O
LSD	B-Drug

In	O
September	O
2014	O
the	O
European	O
Union	O
implemented	O
a	O
ban	O
of	O
25I-NBOMe	B-Drug
in	O
all	O
its	O
member	O
states.	O

Isbell	O
and	O
Logan	O
(1957)	O
reported	O
that	O
chlorpromazine	B-Drug
(Thorazine)	O
could	O
either	O
block	O
or	O
reverse	O
the	O
effects	O
of	O
LSD.	O
Thorazine	B-Drug
LSD	B-Drug

Alvimopan's	O
high	O
affinity	O
for	O
the	O
peripheral	O
-receptor	O
results	O
in	O
an	O
absolute	O
bioavailability	O
less	O
than	O
7%.	O
Alvimopan	B-Drug

Acetylcholine	O
projections	O
in	O
hippocampal	O
neurons,	O
which	O
are	O
vital	O
mediating	O
long-term	O
potentiation,	O
inhibited	O
by	O
scopolamine.	O
scopolamine	B-Drug

There	O
is	O
also	O
a	O
high	O
risk	O
that	O
thalidomide	B-Drug
can	O
interfere	O
with	O
formation	O
of	O
various	O
kinds	O
new	O
blood	O
cells,	O
creating	O
infection	O
via	O
neutropenia,	O
leukopenia,	O
and	O
lymphopenia,	O
risks	O
will	O
not	O
clot	O
thrombocytopenia.	O

Note	O
that	O
four	O
of	O
the	O
above	O
compounds	O
(cathinone,	O
methcathinone,	O
diethylpropion	B-Drug
and	O
pyrovalerone)	O
were	O
already	O
illegal	O
in	O
UK	O
at	O
time	O
ACMD	O
report	O
was	O
issued.	O
cathinone	B-Drug
methcathinone	B-Drug
pyrovalerone	B-Drug

When	O
multiple	O
doses	O
of	O
etizolam,	O
or	O
lorazepam,	O
were	O
administered	O
to	O
rat	O
neurons,	O
lorazepam	B-Drug
caused	O
downregulation	O
alpha-1	O
benzodiazepine	O
binding	O
sites	O
(tolerance/dependence),	O
while	O
etizolam	B-Drug
an	O
increase	O
in	O
alpha-2	O
(reverse	O
tolerance	O
anti-anxiety	O
effects).	O

AMB-FUBINACA	B-Drug
was	O
the	O
most	O
common	O
synthetic	O
cannabinoid	O
identified	O
in	O
drug	O
seizures	O
by	O
Drug	O
Enforcement	O
Administration	O
2017	O
and	O
first	O
half	O
of	O
2018.	O

As	O
an	O
antibacterial,	O
dapsone	B-Drug
inhibits	O
bacterial	O
synthesis	O
of	O
dihydrofolic	O
acid,	O
via	O
competition	O
with	O
para-aminobenzoate	O
for	O
the	O
active	O
site	O
dihydropteroate	O
synthase,	O
thereby	O
inhibiting	O
nucleic	O
acid	O
synthesis.	O

USAF	O
Pararescue	O
combat	O
medics	O
in	O
Afghanistan	O
use	O
fentanyl	B-Drug
lozenges	O
the	O
form	O
of	O
lollipops	O
on	O
casualties	O
from	O
IED	O
blasts	O
and	O
other	O
trauma.	O

High	O
concentrations	O
of	O
tamoxifen	B-Drug
have	O
been	O
found	O
in	O
breast,	O
uterus,	O
liver,	O
kidney,	O
lung,	O
pancreas,	O
and	O
ovary	O
tissue	O
animals	O
humans.	O

The	O
fenfluramine	B-Drug
REMS	O
requires	O
health	O
care	O
professionals	O
who	O
prescribe	O
and	O
pharmacies	O
that	O
dispense	O
to	O
be	O
specially	O
certified	O
in	O
the	O
patients	O
enrolled	O
REMS.	O

Methyltestosterone	B-Drug
is	O
available	O
in	O
the	O
form	O
of	O
2,	O
5,	O
10,	O
and	O
25	O
mg	O
oral	O
tablets.	O

Phenobarbital	B-Drug
causes	O
a	O
depression	O
of	O
the	O
body's	O
systems,	O
mainly	O
central	O
and	O
peripheral	O
nervous	O
systems.	O

Some	O
formulations	O
of	O
buprenorphine	B-Drug
incorporate	O
the	O
opiate	O
antagonist	O
naloxone	B-Drug
during	O
production	O
pill	O
form	O
to	O
prevent	O
people	O
from	O
crushing	O
tablets	O
and	O
injecting	O
them,	O
instead	O
using	O
sublingual	O
(under	O
tongue)	O
route	O
administration.	O

Etizolam	B-Drug
has	O
an	O
anxiolytic	O
action	O
about	O
6	O
times	O
greater	O
than	O
that	O
of	O
diazepam.	O
diazepam	B-Drug

Aside	O
from	O
the	O
toxic	O
effects	O
of	O
cocaine,	O
there	O
is	O
also	O
danger	O
circulatory	O
emboli	O
insoluble	O
substances	O
that	O
may	O
be	O
used	O
to	O
cut	O
drug.	O
cocaine	B-Drug

Fentanyl	B-Drug
was	O
first	O
made	O
by	O
Paul	O
Janssen	O
in	O
1960	O
and	O
approved	O
for	O
medical	O
use	O
the	O
United	O
States	O
1968.	O

The	O
new	O
formulation	O
simply	O
replaced	O
the	O
two	O
methamphetamine	B-Drug
components	O
with	O
dextroamphetamine	B-Drug
and	O
amphetamine	B-Drug
of	O
same	O
weight	O
(the	O
other	O
original	O
were	O
preserved),	O
preserved	O
Obetrol	B-Drug
branding,	O
despite	O
it	O
utterly	O
lacking	O
FDA	O
approval,	O
still	O
made	O
onto	O
market	O
was	O
marketed	O
sold	O
by	O
Rexar	O
for	O
a	O
number	O
years.	O

Chemically,	O
levorphanol	B-Drug
belongs	O
to	O
the	O
morphinan	O
class	O
and	O
is	O
()	O

From	O
Cuba,	O
cocaine	B-Drug
would	O
be	O
transported	O
to	O
Miami,	O
Florida;	O
and	O
Union	O
City,	O
New	O
Jersey.	O

If	O
consumed	O
with	O
alcohol,	O
cocaine	B-Drug
combines	O
alcohol	O
in	O
the	O
liver	O
to	O
form	O
cocaethylene.	O
cocaethylene	B-Drug

Unsteadiness	O
after	O
taking	O
bromazepam	B-Drug
is,	O
however,	O
less	O
pronounced	O
than	O
other	O
benzodiazepines	O
such	O
as	O
lorazepam.	O
lorazepam	B-Drug

In	O
addition	O
to	O
its	O
well	O
explored	O
interactions	O
with	O
NMDA	O
receptors,	O
PCP	B-Drug
has	O
also	O
been	O
shown	O
inhibit	O
dopamine	O
reuptake,	O
and	O
thereby	O
leads	O
increased	O
extracellular	O
levels	O
of	O
hence	O
dopaminergic	O
neurotransmission.	O

Fentanyl	B-Drug
analogs	O
such	O
as	O
-methylfentanyl	O
and	O
3-methylfentanyl	B-Drug
are	O
often	O
used	O
the	O
"cut"	O
in	O
small	O
amounts	O
normal	O
heroin	B-Drug
stamps	O
bags,	O
making	O
them	O
more	O
potent	O
profitable	O
than	O
when	O
sold	O
alone	O
due	O
to	O
advantage	O
of	O
raising	O
retail	O
price	O
potency	O
per	O
unit	O
sold.	O

After	O
a	O
set	O
of	O
successful	O
clinical	O
trials,	O
Duragesic	B-Drug
fentanyl	B-Drug
patches	O
were	O
introduced	O
into	O
medical	O
practice.	O

cannabis,	O
LSD,	O
opium	B-Drug
Human	O
Traffic	O
(1999)	O
LSD	B-Drug

This	O
group	O
is	O
divided	O
by	O
chemical	O
structure	O
into	O
the	O
estranes	O
(derivatives	O
of	O
norethisterone)	O
and	O
gonanes	O
(18-methylgonanes	O
or	O
13-ethylestranes;	O
derivatives	O
levonorgestrel)	O
includes	O
following	O
marketed	O
medications:	O
Several	O
these	O
act	O
as	O
prodrugs	O
norethisterone,	O
including	O
NETA,	O
NETE,	O
etynodiol	O
diacetate,	O
lynestrenol,	O
quingestanol	O
acetate.	O
norethisterone	B-Drug
levonorgestrel	B-Drug

Unwitting	O
substitution	O
with	O
other	O
drugs,	O
such	O
as	O
mephedrone	B-Drug
and	O
methamphetamine,	O
well	O
legal	O
alternatives	O
to	O
MDMA,	O
BZP,	O
MDPV,	O
methylone,	O
are	O
also	O
thought	O
have	O
contributed	O
its	O
decrease	O
in	O
popularity.	O
methamphetamine	B-Drug
MDMA	B-Drug
BZP	B-Drug
MDPV	B-Drug
methylone	B-Drug

A	O
review	O
comparing	O
ethanol	O
to	O
GHB	B-Drug
concluded	O
that	O
the	O
dangers	O
of	O
two	O
drugs	O
were	O
similar.	O

Ondansetron	B-Drug
was	O
patented	O
in	O
1984	O
and	O
approved	O
for	O
medical	O
use	O
1990.	O

According	O
to	O
U.S.	O
Senator	O
Dick	O
Durbin,	O
"The	O
sentencing	O
disparity	O
between	O
crack	O
and	O
powder	O
cocaine	B-Drug
has	O
contributed	O
the	O
imprisonment	O
of	O
African	O
Americans	O
at	O
six	O
times	O
rate	O
Whites	O
United	O
States'	O
position	O
as	O
world's	O
leader	O
in	O
incarcerations."	O

Compared	O
to	O
heroin,	O
it	O
is	O
more	O
potent,	O
has	O
higher	O
profit	O
margins	O
and,	O
because	O
compact,	O
simpler	O
logistics.	O
heroin	B-Drug

The	O
claim	O
that	O
cocaine	B-Drug
is	O
much	O
more	O
addictive	O
when	O
smoked	O
must	O
be	O
reexamined."	O

Equianalgesic	O
tables	O
typically	O
list	O
drug	O
half-lives,	O
and	O
sometimes	O
equianalgesic	O
doses	O
of	O
the	O
same	O
by	O
means	O
administration,	O
such	O
as	O
morphine:	O
oral	O
intravenous.	O
morphine	B-Drug

The	O
combination	O
of	O
fenfluramine	B-Drug
with	O
phentermine,	O
a	O
norepinephrinedopamine	O
releasing	O
agent	O
acting	O
primarily	O
on	O
norepinephrine,	O
results	O
in	O
well-balanced	O
serotoninnorepinephrine	O
weaker	O
effects	O
dopamine	O
release.	O
phentermine	B-Drug

The	O
potential	O
selectivity	O
and	O
favorable	O
side	O
effect	O
profile	O
of	O
desmetramadol	O
compared	O
to	O
its	O
prodrug,	O
tramadol,	O
makes	O
it	O
more	O
suitable	O
for	O
clinical	O
use,	O
although	O
no	O
such	O
large	O
scale	O
controlled	O
trials	O
have	O
been	O
conducted	O
with	O
patients.	O
tramadol	B-Drug

The	O
same	O
concerns	O
do	O
not	O
apply	O
to	O
psychedelics	O
that	O
release	O
neurotransmitters,	O
such	O
as	O
LSD,	O
nor	O
dissociatives	O
or	O
deliriants.	O
LSD	B-Drug

As	O
with	O
most	O
barbiturates,	O
butalbital	B-Drug
is	O
a	O
general	O
inducer	O
of	O
P450	O
enzymes	O
in	O
both	O
rodents	O
and	O
humans,	O
particularly	O
CYP3A4	O

campylacantha,	O
Less	O
than	O
0.2%	O
DMT	O
in	O
leaf,	O
NMT;	O
and	O
other	O
tryptamines	O
bark	O
Acacia	O
rigidula,	O
DMT,	O
NMT,	O
tryptamine,	O
traces	O
of	O
amphetamines,	O
mescaline,	O
nicotine	B-Drug
others	O
sassa,	O
Psychoactive	O
schaffneri,	O
-methyl-phenethylamine,	O
Phenethylamine	B-Drug
Amphetamines	B-Drug
mescaline	B-Drug
also	O
found.	O
amphetamines	B-Drug

Recreational	O
use	O
of	O
25I-NBOMe	B-Drug
carries	O
a	O
significant	O
risk	O
both	O
pharmacological	O
and	O
behavioral	O
toxicity.	O

Ro4-1539	B-Drug

However,	O
whereas	O
powder	O
cocaine	B-Drug
dissolves	O
in	O
water,	O
crack	O
must	O
be	O
dissolved	O
an	O
acidic	O
solution	O
such	O
as	O
lemon	O
juice	O
(containing	O
citric	O
acid)	O
or	O
white	O
vinegar	O
acetic	O
acid),	O
a	O
process	O
that	O
effectively	O
reverses	O
the	O
original	O
conversion	O
of	O
to	O
crack.	O

A	O
clinically	O
relevant	O
lorazepam	B-Drug
dose	O
will	O
normally	O
be	O
effective	O
for	O
six	O
to	O
12	O
hours,	O
making	O
it	O
unsuitable	O
regular	O
once-daily	O
administration,	O
so	O
is	O
usually	O
prescribed	O
as	O
two	O
four	O
daily	O
doses	O
when	O
taken	O
regularly,	O
but	O
this	O
may	O
extended	O
five	O
or	O
six,	O
especially	O
in	O
the	O
case	O
of	O
elderly	O
people	O
who	O
could	O
not	O
handle	O
large	O
at	O
once.	O

Heroin	B-Drug
overdoses	O
can	O
occur	O
because	O
of	O
an	O
unexpected	O
increase	O
in	O
the	O
dose	O
or	O
purity	O
diminished	O
opioid	O
tolerance.	O

Some	O
people	O
are	O
fast	O
metabolizers	O
of	O
oxycodone,	O
resulting	O
in	O
reduced	O
effects,	O
while	O
others	O
slow	O
metabolizers,	O
increased	O
effects	O
and	O
toxicity.	O
oxycodone	B-Drug

Tetrahydrocannabinol	B-Drug
(THC)	O
is	O
the	O
main	O
psychoactive	O
component	O
of	O
cannabis,	O
which	O
one	O
483	O
known	O
compounds	O
in	O
plant,	O
including	O
at	O
least	O
65	O
other	O
cannabinoids,	O
cannabidiol	B-Drug
(CBD).	O
THC	B-Drug
CBD	B-Drug

Cannabidiol	B-Drug
has	O
been	O
used	O
by	O
professional	O
and	O
amateur	O
athletes	O
across	O
disciplines	O
countries,	O
with	O
the	O
World	O
Anti-Doping	O
Agency	O
removing	O
CBD	B-Drug
from	O
its	O
banned	O
substances	O
list.	O

After	O
90	O
days	O
to	O
6	O
months	O
(depending	O
on	O
the	O
clinic),	O
if	O
patients	O
have	O
met	O
clinic's	O
criteria,	O
they	O
are	O
typically	O
eligible	O
for	O
take-home	O
doses	O
of	O
methadone.	O
methadone	B-Drug

Fentanyl,	O
also	O
spelled	O
fentanil,	O
is	O
an	O
opioid	O
used	O
as	O
a	O
pain	O
medication	O
and	O
together	O
with	O
other	O
medications	O
for	O
anesthesia.	O
Fentanyl	B-Drug

Benzodiazepines,	O
including	O
lorazepam,	O
may	O
depress	O
central	O
nervous	O
system	O
respiratory	O
drive	O
and	O
are	O
contraindicated	O
in	O
severe	O
failure.	O
lorazepam	B-Drug

Diazepam	B-Drug
does	O
not	O
increase	O
or	O
decrease	O
hepatic	O
enzyme	O
activity,	O
and	O
alter	O
the	O
metabolism	O
of	O
other	O
compounds.	O

Metenolone,	O
as	O
its	O
esters,	O
is	O
used	O
almost	O
exclusively	O
in	O
the	O
treatment	O
of	O
anemia	O
due	O
to	O
bone	O
marrow	O
failure.	O
Metenolone	B-Drug

Cannabis	O
is	O
consumed	O
in	O
many	O
different	O
ways,	O
all	O
of	O
which	O
involve	O
heating	O
to	O
decarboxylate	O
THCA	O
the	O
plant	O
into	O
THC.	O
THC	B-Drug

It	O
is	O
an	O
epimer	O
of	O
codeine	B-Drug
that	O
can	O
be	O
prepared	O
from	O
it	O
by	O
a	O
Mitsunobu	O
reaction.	O

Another	O
harm	O
reduction	O
measure	O
employed	O
for	O
example	O
in	O
Europe,	O
Canada,	O
and	O
Australia	O
are	O
safe	O
injection	O
sites	O
where	O
users	O
can	O
inject	O
diamorphine	B-Drug
cocaine	B-Drug
under	O
the	O
supervision	O
of	O
medically	O
trained	O
staff.	O

In	O
turn,	O
alcohol	O
and	O
tobacco	B-Drug
are	O
typically	O
easier	O
to	O
obtain	O
at	O
an	O
earlier	O
age	O
than	O
is	O
cannabis	O
(though	O
the	O
reverse	O
may	O
be	O
true	O
in	O
some	O
areas),	O
thus	O
leading	O
"gateway	O
sequence"	O
those	O
individuals,	O
since	O
they	O
most	O
likely	O
experiment	O
with	O
any	O
drug	O
offered.	O

The	O
modern	O
era	O
really	O
began	O
with	O
Edward	O
Jenner's	O
discovery	O
of	O
the	O
smallpox	B-Drug
vaccine	I-Drug
at	O
end	O
18th	O
century	O
(inspired	O
by	O
method	O
inoculation	B-Drug
earlier	O
practiced	O
in	O
Asia),	O
Robert	O
Koch's	O
discoveries	O
around	O
1880	O
transmission	O
disease	O
bacteria,	O
and	O
then	O
antibiotics	O
1900.	O

Trenbolone	O
enanthate	O
is	O
also	O
a	O
very	O
commonly	O
used	O
AAS	O
and	O
lasts	O
much	O
longer	O
than	O
trenbolone	B-Drug
acetate	O
with	O
intramuscular	O
injection.	O

The	O
International	O
Olympic	O
Committee	O
in	O
1997	O
banned	O
androstenedione	B-Drug
and	O
placed	O
it	O
under	O
the	O
category	O
of	O
androgenic-anabolic	O
steroids.	O

Cocaine	B-Drug
and	O
various	O
opiates	O
were	O
subsequently	O
mass-produced	O
sold	O
openly	O
legally	O
in	O
the	O
Western	O
world,	O
resulting	O
widespread	O
misuse	O
addiction.	O

The	O
Expert	O
Committee	O
on	O
Drug	O
Dependence	O
cautiously	O
began	O
investigating	O
ketamine	B-Drug
at	O
its	O
thirty-third	O
meeting,	O
noting,	O
"Its	O
use	O
in	O
veterinary	O
medicine	O
must	O
also	O
be	O
considered	O
relation	O
to	O
control".	O

Morphine	B-Drug
was	O
the	O
first	O
chemical	O
shown	O
to	O
bind	O
"mu"	O
receptors.	O

The	O
changes	O
included	O
a	O
new	O
roadside	O
testing	O
kit,	O
which	O
could	O
detect	O
the	O
presence	O
of	O
cocaine	B-Drug
and	O
cannabis	O
in	O
suspect's	O
saliva	O
zero	O
tolerance	O
limits	O
for	O
number	O
illegal	O
drugs.	O

In	O
late	O
1967,	O
Stanley's	O
La	O
Espiral,	O
Orinda,	O
lab	O
was	O
raided	O
by	O
police;	O
he	O
found	O
in	O
possession	O
of	O
350,000	O
doses	O
LSD	B-Drug
and	O
1,500	O
STP.	O

Opiates	O
such	O
as	O
morphine	B-Drug
have	O
been	O
used	O
for	O
pain	O
relief	O
in	O
the	O
United	O
States	O
since	O
1800s,	O
and	O
were	O
during	O
American	O
Civil	O
War.	O

Cocaine	B-Drug
and	O
its	O
major	O
metabolites	O
may	O
be	O
quantified	O
in	O
blood,	O
plasma,	O
or	O
urine	O
to	O
monitor	O
for	O
use,	O
confirm	O
a	O
diagnosis	O
of	O
poisoning,	O
assist	O
the	O
forensic	O
investigation	O
traffic	O
other	O
criminal	O
violation	O
sudden	O
death.	O

Participation	O
in	O
methadone	B-Drug
and	O
buprenorphine	B-Drug
treatment	O
reduces	O
the	O
risk	O
of	O
mortality	O
due	O
to	O
overdose.	O

BZP	B-Drug
(benzylpiperazine),	O
a	O
synthetic	O
stimulant	O
once	O
sold	O
as	O
designer	O
drug.	O
benzylpiperazine	B-Drug

Cocaine	B-Drug
is	O
readily	O
available	O
in	O
all	O
major	O
countries'	O
metropolitan	O
areas.	O

This	O
study	O
analyzed	O
users	O
who	O
answered	O
mood	O
questionnaires	O
and	O
performed	O
behavioral	O
tests	O
after	O
taking	O
a	O
range	O
of	O
microdoses	O
from	O
026	O
ug	O
LSD.	O
LSD	B-Drug

This	O
prolonged	O
action	O
of	O
chlortalidone	B-Drug
despite	O
missing	O
doses	O
may	O
account	O
for	O
the	O
higher	O
efficacy	O
compared	O
to	O
shorter	O
half-life	O
medication,	O
hydrochlorothiazide.	O
hydrochlorothiazide	B-Drug

The	O
coca	B-Drug
eradication	O
policy	O
has	O
been	O
criticised	O
for	O
its	O
negative	O
impact	O
on	O
the	O
livelihood	O
of	O
growers	O
in	O
South	O
America.	O

Research	O
efforts	O
have	O
been	O
focused	O
on	O
determining	O
how	O
thalidomide	B-Drug
causes	O
birth	O
defects	O
and	O
its	O
other	O
activities	O
in	O
the	O
human	O
body,	O
to	O
develop	O
safer	O
analogs,	O
find	O
further	O
uses	O
for	O
thalidomide.	O

Dr.	O
Gandhi's	O
bill	O
would	O
legalise	O
marijuana	O
and	O
opium.	O
opium	B-Drug

PCP	B-Drug
may	O
induce	O
feelings	O
of	O
strength,	O
power,	O
and	O
invulnerability	O
as	O
well	O
a	O
numbing	O
effect	O
on	O
the	O
mind.	O

In	O
Thailand,	O
a	O
one-month	O
supply	O
of	O
efavirenz	B-Drug
+	O
Truvada,	O
as	O
June	O
2012,	O
cost	O
2,900	O
baht	O
(US$90),	O
and	O
there	O
is	O
social	O
program	O
for	O
patients	O
who	O
cannot	O
afford	O
the	O
medication.	O
Truvada	B-Drug

In	O
vitro	O
assessment	O
of	O
endomorphins	O
as	O
analgesics	O
reveals	O
similar	O
behavior	O
to	O
morphine	B-Drug
and	O
other	O
opiates,	O
where	O
drug	O
tolerance	O
leads	O
dependence	O
addiction.	O

Metabolism	O
of	O
JWH-018	B-Drug
was	O
assessed	O
using	O
Wistar	O
rats	O
which	O
had	O
been	O
administered	O
an	O
ethanolic	O
extract	O
containing	O
JWH-018.	O

Psilocybin	O
and	O
its	O
metabolized	O
counterpart	O
psilocin	B-Drug
are	O
Schedule	O
1	O
on	O
the	O
California	O
Uniform	O
Controlled	O
Substances	O
Act.	O

Some	O
3.3	O
million	O
Afghans	O
are	O
involved	O
in	O
producing	O
opium.	O
opium	B-Drug

Concurrent	O
to	O
the	O
rave	O
movement,	O
and	O
in	O
key	O
respects	O
integral	O
it,	O
are	O
development	O
of	O
new	O
mind-altering	O
drugs,	O
most	O
notably,	O
MDMA	B-Drug
(Ecstasy).	O

Canrenone	O
is	O
reportedly	O
more	O
potent	O
as	O
an	O
antimineralocorticoid	O
relative	O
to	O
spironolactone,	O
but	O
considerably	O
less	O
and	O
effective	O
antiandrogen.	O
spironolactone	B-Drug

There	O
are	O
a	O
variety	O
of	O
known	O
cases	O
doping	O
in	O
sports	O
with	O
enobosarm	B-Drug
by	O
professional	O
athletes.	O

Oral	O
benzodiazepines,	O
including	O
lorazepam,	O
are	O
occasionally	O
used	O
as	O
long-term	O
prophylactic	O
treatment	O
of	O
resistant	O
absence	O
seizures;	O
because	O
gradual	O
tolerance	O
to	O
their	O
anti-seizure	O
effects,	O
benzodiazepines	O
such	O
lorazepam	B-Drug
not	O
considered	O
first-line	O
therapies.	O

Stimulation	O
of	O
the	O
D1	O
receptor	O
by	O
dopaminergic	O
agonists	O
such	O
as	O
fenoldopam	B-Drug
is	O
used	O
intravenously	O
to	O
treat	O
hypertensive	O
crisis.	O

The	O
Salton	O
Sea	O
(2002)	O
methamphetamine	B-Drug
Sample	O
People	O
(2000)	O
fictional	O
drug	O
"glow"	O
and	O
cocaine	B-Drug
Sausage	O
Party	O
(2016)	O

Typically,	O
the	O
base	O
for	O
lean	O
has	O
been	O
prescription	O
cold	O
medicine,	O
specifically	O
cough	O
syrup,	O
one	O
that	O
contains	O
both	O
promethazine	B-Drug
and	O
codeine,	O
but	O
over-the-counter	O
medicine	O
lists	O
dextromethorphan	B-Drug
as	O
active	O
ingredient	O
also	O
used,	O
it	O
can	O
produce	O
similar	O
effects	O
eliminate	O
need	O
a	O
doctor's	O
visit.	O
codeine	B-Drug

It	O
is	O
the	O
N-methylated	O
derivative	O
of	O
MDAT,	O
similarly	O
to	O
relationship	O
MDMA	B-Drug
MDA	O
or	O
MDMAI	B-Drug
MDAI.	O
MDAI	B-Drug

It	O
is	O
sometimes	O
thought	O
that	O
heroin	B-Drug
users	O
can	O
walk	O
into	O
a	O
clinic	O
and	O
out	O
with	O
prescription,	O
but	O
the	O
process	O
takes	O
many	O
weeks	O
before	O
prescription	O
for	O
diamorphine	B-Drug
issued.	O

The	O
former	O
synonym	O
should	O
not	O
be	O
confused	O
with	O
methylandrostenolone,	O
which	O
is	O
another	O
name	O
for	O
a	O
different	O
AAS	O
known	O
as	O
metenolone.	O
metenolone	B-Drug

The	O
combined	O
data	O
from	O
four	O
different	O
clinical	O
trials	O
showed	O
that	O
bevacizumab	B-Drug
neither	O
prolonged	O
overall	O
survival	O
nor	O
slowed	O
disease	O
progression	O
sufficiently	O
to	O
outweigh	O
the	O
risk	O
it	O
presents	O
patients.	O

cannabis,	O
MDMA,	O
cocaine,	O
crack,	O
heroin,	O
amphetamine,	O
Viagra	B-Drug
The	O
Boys	O
in	O
the	O
Band	O
(1970)	O
MDMA	B-Drug
cocaine	B-Drug
heroin	B-Drug
amphetamine	B-Drug

The	O
medication	O
is	O
a	O
prodrug	O
of	O
norethisterone	B-Drug
in	O
the	O
body,	O
with	O
quingestanol	O
and	O
acetate	O
occurring	O
as	O
intermediates.	O

The	O
user	O
allows	O
the	O
heroin	B-Drug
to	O
completely	O
dissolve	O
into	O
water	O
and	O
solution	O
is	O
dropped	O
nose.	O

Amphetamine	B-Drug
type	O
stimulants	O
are	O
also	O
known	O
for	O
their	O
addictive	O
property	O
and	O
widespread	O
problem	O
of	O
substance	O
abuse.	O

The	O
patent	O
application	O
claimed	O
the	O
final	O
form	O
of	O
Gleevec	B-Drug
(the	O
beta	O
crystalline	O
imatinib	B-Drug
mesylate).	O
mesylate	I-Drug

Metandienone	B-Drug
is	O
subject	O
to	O
extensive	O
hepatic	O
biotransformation	O
by	O
a	O
variety	O
of	O
enzymatic	O
pathways.	O

Fludrocortisone	B-Drug
is	O
marketed	O
in	O
Austria,	O
Croatia,	O
Denmark,	O
Germany,	O
Luxembourg,	O
Romania,	O
and	O
Spain,	O
whereas	O
fludrocortisone	B-Drug
acetate	I-Drug
more	O
widely	O
available	O
throughout	O
the	O
world	O
United	O
States,	O
Canada,	O
Kingdom,	O
various	O
other	O
European	O
countries,	O
Australia,	O
Japan,	O
China,	O
Brazil,	O
many	O
countries.	O

Nortriptyline	B-Drug
is	O
a	O
tricyclic	O
compound,	O
specifically	O
dibenzocycloheptadiene,	O
and	O
possesses	O
three	O
rings	O
fused	O
together	O
with	O
side	O
chain	O
attached	O
in	O
its	O
chemical	O
structure.	O

After	O
receiving	O
a	O
bolus	O
dose	O
of	O
fentanyl,	O
people	O
can	O
also	O
experience	O
paradoxical	O
coughing,	O
which	O
is	O
phenomenon	O
that	O
not	O
well	O
understood.	O
fentanyl	B-Drug

Intravenous	O
fentanyl	B-Drug
is	O
often	O
used	O
for	O
anesthesia	O
and	O
to	O
treat	O
pain.	O

In	O
the	O
early	O
1980s,	O
prasterone	B-Drug
became	O
available	O
and	O
was	O
widely	O
sold	O
over-the-counter	O
as	O
a	O
non-prescription	O
supplement	O
in	O
United	O
States,	O
primarily	O
weight	O
loss	O
aid.	O

Cannabis	O
impairs	O
a	O
person's	O
driving	O
ability,	O
and	O
THC	B-Drug
was	O
the	O
illicit	O
drug	O
most	O
frequently	O
found	O
in	O
blood	O
of	O
drivers	O
who	O
have	O
been	O
involved	O
vehicle	O
crashes.	O

Some	O
athletes	O
who	O
were	O
found	O
to	O
have	O
used	O
modafinil	B-Drug
protested	O
as	O
the	O
drug	O
was	O
not	O
on	O
prohibited	O
list	O
at	O
time	O
of	O
their	O
offence,	O
however,	O
World	O
Anti-Doping	O
Agency	O
(WADA)	O
maintains	O
it	O
is	O
a	O
substance	O
related	O
those	O
already	O
banned,	O
so	O
decisions	O
stand.	O

Dienogest	B-Drug
produces	O
no	O
androgenic	O
side	O
effects	O
and	O
has	O
little	O
effect	O
on	O
metabolic	O
lipid	O
hemostatic	O
parameters.	O

As	O
of	O
October	O
2020,	O
CBD	B-Drug
was	O
not	O
an	O
FDA-approved	O
drug	O
eligible	O
for	O
interstate	O
commerce,	O
and	O
the	O
FDA	O
encouraged	O
manufacturers	O
to	O
follow	O
procedures	O
approval.	O

This	O
effect	O
of	O
nociceptin	O
may	O
lead	O
to	O
its	O
future	O
use	O
as	O
a	O
method	O
reduce	O
morphine	B-Drug
dosage	O
and	O
decrease	O
the	O
development	O
tolerance	O
dependence.	O

On	O
June	O
11,	O
2013,	O
just	O
days	O
after	O
being	O
robbed	O
at	O
gunpoint	O
in	O
San	O
Francisco,	O
rapper	O
2	O
Chainz	O
was	O
arrested	O
Los	O
Angeles	O
International	O
Airport	O
on	O
charges	O
of	O
possessing	O
promethazine	B-Drug
and	O
codeine	B-Drug
(the	O
primary	O
ingredients	O
lean)	O
along	O
with	O
marijuana.	O

In	O
July	O
2015,	O
the	O
FDA	O
approved	O
alirocumab	B-Drug
as	O
a	O
second	O
line	O
treatment	O
to	O
lower	O
LDL	O
cholesterol	O
for	O
adults	O
who	O
have	O
hereditary	O
high	O
and	O
people	O
with	O
atherosclerosis	O
require	O
additional	O
lowering	O
of	O
when	O
diet	O
statin	O
not	O
worked.	O

The	O
UK	O
ACMD	O
recommended	O
that	O
generic	O
prohibition	O
legislation	O
be	O
extended	O
to	O
include	O
UR-144	B-Drug
in	O
October	O
2012.	O

Nicocodine	B-Drug
(6-nicotinylcodeine)	O

This	O
epidemic	O
caused	O
the	O
risk	O
of	O
acquiring	O
a	O
blood	O
borne	O
infection	O
with	O
use	O
injectable	O
opioids	O
to	O
increase	O
in	O
comparison	O
an	O
when	O
using	O
heroin	B-Drug
or	O
cocaine.	O
cocaine	B-Drug

Aeruginascin	B-Drug
or	O
N,N,N-trimethyl-4-phosphoryloxytryptamine	O
is	O
an	O
indoleamine	O
derivative	O
which	O
occurs	O
naturally	O
within	O
the	O
mushroom	O
Inocybe	O
aeruginascens	O
and	O
Pholiotina	O
cyanopus.	O

L-dopa	B-Drug
is	O
a	O
precursor	O
for	O
dopamine,	O
the	O
neurotransmitter	O
whose	O
lack	O
produces	O
Parkinson's	O
symptoms.	O

However,	O
high	O
amphetamine	B-Drug
doses	O
that	O
are	O
above	O
the	O
therapeutic	O
range	O
can	O
interfere	O
with	O
working	O
memory	O
and	O
other	O
aspects	O
of	O
cognitive	O
control.	O

Fentanyl	B-Drug
decreases	O
the	O
heart	O
rate	O
by	O
increasing	O
vagal	O
nerve	O
tone	O
in	O
brainstem,	O
which	O
increases	O
parasympathetic	O
drive.	O

Salvinorin	B-Drug
A	I-Drug
is	O
found	O
with	O
several	O
other	O
structurally	O
related	O
salvinorins.	O

It	O
can	O
be	O
cut	O
into,	O
or	O
even	O
replace	O
entirely,	O
the	O
supply	O
of	O
heroin	B-Drug
and	O
other	O
opiates.	O

Fry"	O
or	O
"sherm"	O
are	O
street	O
terms	O
for	O
marijuana	O
tobacco	B-Drug
cigarettes	O
that	O
dipped	O
in	O
PCP	B-Drug
and	O
then	O
dried.	O

In	O
one	O
study	O
on	O
252	O
Americans,	O
84.3%	O
were	O
found	O
to	O
be	O
"fast"	O
(extensive)	O
metabolizers,	O
6.8%	O
"intermediate"	O
and	O
8.8%	O
"slow"	O
metabolizers	O
of	O
dextromethorphan.	O
dextromethorphan	B-Drug

Conversely,	O
endogeneous	O
GHB	B-Drug
production	O
in	O
those	O
taking	O
valproic	O
acid	O
will	O
be	O
inhibited	O
via	O
inhibition	O
of	O
the	O
conversion	O
from	O
succinic	O
semialdehyde	O
to	O
GHB.	O

Born	O
in	O
Armenia,	O
Colombia,	O
Lehder	O
eventually	O
ran	O
a	O
cocaine	B-Drug
transport	O
empire	O
on	O
Norman's	O
Cay	O
island,	O
210	O
miles	O
(340	O
km)	O
off	O
the	O
Florida	O
coast	O
central	O
Bahamas.	O

Cannabis	O
impairs	O
a	O
person's	O
driving	O
ability,	O
and	O
THC	B-Drug
was	O
the	O
illicit	O
drug	O
most	O
frequently	O
found	O
in	O
blood	O
of	O
drivers	O
who	O
have	O
been	O
involved	O
vehicle	O
crashes.	O

"	O
At	O
first	O
Coleridge	O
welcomed	O
the	O
relief	O
from	O
pain	O
provided	O
by	O
Kendal	O
Black	O
Drop,	O
but	O
was	O
later	O
to	O
say	O
that	O
his	O
"eyes	O
had	O
been	O
opened	O
true	O
nature	O
of	O
habit	O
into	O
which	O
I	O
ignorantly	O
deluded	O
seeming	O
magic	O
effects	O
opium".	O
opium	B-Drug

Increased	O
dosages	O
may	O
be	O
required	O
to	O
achieve	O
desired	O
effect	O
of	O
methylprednisolone.	O
methylprednisolone	B-Drug

In	O
another	O
study,	O
100	O
mg	O
mesterolone	B-Drug
cipionate	O
was	O
administered	O
twice	O
monthly.	O

Resistance	O
to	O
trimethoprim	B-Drug
is	O
increasing,	O
but	O
it	O
still	O
a	O
first	O
line	O
antibiotic	O
in	O
many	O
countries.	O

Memantine	B-Drug
has	O
a	O
more	O
targeted	O
pharmacological	O
profile	O
for	O
the	O
glutamate	O
system,	O
reduced	O
incidence	O
of	O
psychosis	O
and	O
may	O
therefore	O
be	O
preferred	O
individuals	O
who	O
cannot	O
tolerate	O
amantadine.	O
amantadine	B-Drug

Side	O
effects	O
of	O
pyrovalerone	B-Drug
include	O
anorexia	O
or	O
loss	O
appetite,	O
anxiety,	O
fragmented	O
sleep	O
insomnia,	O
and	O
trembling,	O
shaking,	O
muscle	O
tremors.	O

(1959c)	O
investigated	O
the	O
psychological	O
and	O
physical	O
effects	O
of	O
13	O
different	O
congeners	O
LSD,	O
correlated	O
these	O
with	O
their	O
potency	O
as	O
a	O
serotonin	O
antagonist	O
in	O
smooth	O
muscle.	O
LSD	B-Drug

Ketoconazole	B-Drug
can	O
achieve	O
similar	O
decreases	O
in	O
steroid	O
hormone	O
levels	O
as	O
AG	O
but	O
is	O
more	O
effective	O
promoting	O
tumor	O
regression	O
and	O
moderately	O
less	O
toxic	O
comparison.	O

Gepefrine	O
(INN;	O
trade	O
names	O
Pressionorm	O
and	O
Wintonin),	O
also	O
known	O
as	O
3-hydroxyamphetamine,	O
meta-hydroxyamphetamine,	O
-methyl-meta-tyramine,	O
is	O
an	O
antihypotensive	O
or	O
sympathomimetic	O
agent	O
of	O
the	O
amphetamine	B-Drug
family	O
that	O
marketed	O
in	O
certain	O
European	O
countries.	O

Butalbital	B-Drug
is	O
a	O
barbiturate	O
with	O
an	O
intermediate	O
duration	O
of	O
action.	O

Thalidomide	B-Drug
may	O
be	O
helpful	O
in	O
some	O
cases	O
where	O
standard	O
TB	O
drugs	O
and	O
corticosteroids	O
are	O
not	O
sufficient	O
to	O
resolve	O
severe	O
inflammation	O
the	O
brain.	O

To	O
manage	O
sexual	O
dysfunction,	O
studies	O
have	O
shown	O
that	O
switching	O
to	O
or	O
augmenting	O
with	O
bupropion	B-Drug
adding	O
a	O
PDE5	O
Inhibitor	O
decreased	O
symptoms	O
of	O
dysfunction.	O

A	O
2019	O
review	O
found	O
that	O
the	O
transition	O
rate	O
from	O
a	O
diagnosis	O
of	O
hallucinogen-induced	O
psychosis	O
(which	O
included	O
PCP)	O
to	O
schizophrenia	O
was	O
26%.	O
PCP	B-Drug

JWH-018	B-Drug
is	O
one	O
of	O
these	O
compounds,	O
with	O
studies	O
showing	O
an	O
affinity	O
for	O
the	O
cannabinoid	O
(CB1)	O
receptor	O
five	O
times	O
greater	O
than	O
that	O
THC.	O
THC	B-Drug

Ephedrine	B-Drug
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
inadequate	O
fluid	O
replacement,	O
impaired	O
adrenal	O
function,	O
hypoxia,	O
hypercapnia,	O
acidosis,	O
hypertension,	O
hyperthyroidism,	O
prostatic	O
hypertrophy,	O
diabetes	O
mellitus,	O
cardiovascular	O
disease,	O
during	O
delivery	O
if	O
maternal	O
blood	O
pressure	O
is	O

In	O
the	O
United	O
Kingdom	O
1926	O
report	O
of	O
Departmental	O
Committee	O
on	O
Morphine	B-Drug
and	O
Heroin	B-Drug
Addiction	O
under	O
Chairmanship	O
President	O
Royal	O
College	O
Physicians	O
reasserted	O
medical	O
control	O
established	O
"British	O
system"	O
controlwhich	O
lasted	O
until	O
1960s.	O

Phenobarbital	B-Drug
is	O
occasionally	O
prescribed	O
in	O
low	O
doses	O
to	O
aid	O
the	O
conjugation	O
of	O
bilirubin	O
people	O
with	O
CriglerNajjar	O
syndrome,	O
type	O
II,	O
or	O
patients	O
Gilbert's	O
syndrome.	O

Therefore,	O
there	O
is	O
a	O
need	O
for	O
the	O
development	O
of	O
high	O
opium	B-Drug
yielding	O
varieties.	O

-two	O
percent	O
of	O
counties	O
in	O
the	O
United	O
States	O
have	O
no	O
buprenorphine	B-Drug
prescribers.	O

the	O
use	O
of	O
ibogaine	B-Drug
spread,	O
its	O
administration	O
varied	O
widely;	O
some	O
groups	O
administered	O
it	O
systematically	O
using	O
well-developed	O
methods	O
and	O
medical	O
personnel,	O
while	O
others	O
employed	O
haphazard	O
possibly	O
dangerous	O
methodology.	O

Tolerance	O
to	O
some	O
of	O
the	O
desired	O
and	O
adverse	O
effects	O
MDMA	B-Drug
is	O
expected	O
occur	O
with	O
consistent	O
use.	O

Historically,	O
aryl	O
methyl	O
ethers,	O
including	O
natural	O
products	O
such	O
as	O
codeine	B-Drug
(O-methylmorphine),	O
have	O
been	O
demethylated	O
by	O
heating	O
the	O
substance	O
in	O
molten	O
pyridine	O
hydrochloride	O
(m.p.	O
144	O
C)	O
at	O
180	O
to	O
220	O
C,	O
sometimes	O
with	O
excess	O
hydrogen	O
chloride,	O
a	O
process	O
known	O
ZeiselPrey	O
ether	O
cleavage.	O

Bupropion	B-Drug
has	O
shown	O
no	O
effectiveness	O
in	O
the	O
treatment	O
of	O
cocaine	O
dependence,	O
but	O
there	O
is	O
weak	O
evidence	O
that	O
it	O
may	O
be	O
useful	O
treating	O
methamphetamine	B-Drug
dependence.	O

Celgene	O
Corporation	O
originally	O
synthesized	O
thalidomide	B-Drug
using	O
a	O
three-step	O
sequence	O
starting	O
with	O
L-glutamic	O
acid	O
treatment,	O
but	O
this	O
has	O
since	O
been	O
reformed	O
by	O
the	O
use	O
of	O
L-glutamine.	O
L-glutamine	B-Drug

3C-E	B-Drug
is	O
a	O
psychedelic	O
of	O
the	O
amphetamine	B-Drug
class.	O

cigarettes,	O
nicotine	B-Drug
(patches)	O

Brazilian	O
footballer	O
assistant	O
Robson	O
Oliveira	O
was	O
arrested	O
in	O
2019	O
upon	O
arriving	O
Russia	O
with	O
methadone	B-Drug
tablets	O
sold	O
legally	O
other	O
countries	O
and	O
has	O
been	O
jail	O
since	O
then	O
for	O
what	O
considered	O
drug	O
trafficking	O
under	O
Russian	O
law.	O

Midazolam	B-Drug
is	O
available	O
as	O
a	O
generic	O
medication.	O

With	O
the	O
establishment	O
of	O
poppy	O
straw	O
as	O
source	O
majority	O
natural	O
morphine	B-Drug
and	O
other	O
opiates,	O
much	O
world	O
production	O
opium	B-Drug
is	O
destined	O
for	O
illicit	O
uses.	O

Lidocaine	B-Drug
should	O
be	O
given	O
for	O
this	O
indication	O
after	O
defibrillation,	O
CPR,	O
and	O
vasopressors	O
have	O
been	O
initiated.	O

On	O
October	O
31,	O
2017,	O
the	O
FDA	O
sent	O
warning	O
letters	O
to	O
four	O
CBD	B-Drug
marketers,	O
including	O
Stanley	O
Brothers	O
Social	O
Enterprises,	O
LLC	O
(d/b/a	O
CW	O
Hemp),	O
producer	O
of	O
Charlotte's	O
Web.	O

Subcutaneous	O
implants	O
of	O
levonorgestrel	B-Drug
have	O
been	O
marketed	O
as	O
birth	O
control	O
under	O
the	O
brand	O
names	O
Norplant	O
and	O
Jadelle	O
are	O
available	O
for	O
use	O
in	O
some	O
countries.	O

However,	O
from	O
2012	O
onwards,	O
heroin	B-Drug
and	O
fentanyl	B-Drug
have	O
become	O
more	O
common	O
causes	O
of	O
drug-related	O
deaths.	O

At	O
the	O
same	O
time,	O
prevalence	O
of	O
abuse	O
shifted	O
from	O
organic	O
solvents	O
back	O
to	O
methamphetamine	B-Drug
abuse,	O
with	O
a	O
sharp	O
decline	O
in	O
solvent-related	O
arrests.	O

While	O
THC	B-Drug
remains	O
illegal,	O
cannabidiol	B-Drug
is	O
not	O
subject	O
to	O
the	O
Swiss	O
Narcotic	O
Acts	O
because	O
this	O
substance	O
does	O
produce	O
a	O
comparable	O
psychoactive	O
effect.	O

One	O
of	O
the	O
biggest	O
disadvantages	O
using	O
dipipanone	B-Drug
is	O
that	O
it	O
only	O
produced	O
in	O
one	O
dosage	O
form	O
mixed	O
with	O
anti-emetic	O
cyclizine	B-Drug
at	O
a	O
ratio	O
25%	O
to	O
75%	O
which	O
limits	O
dose	O
an	O
absolute	O
maximum	O
3	O
tablets	O
per	O
up	O
4-6	O
times	O
day.	O

It	O
was	O
found	O
that	O
newer	O
agents	O
with	O
novel	O
mechanisms	O
of	O
action	O
and	O
improved	O
safety	O
profiles,	O
such	O
as	O
the	O
melatonin	B-Drug
agonists,	O
hold	O
promise	O
for	O
management	O
chronic	O
insomnia	O
in	O
elderly	O
people.	O

Some	O
accumulation	O
of	O
tramadol	B-Drug
occurs	O
with	O
chronic	O
administration;	O
peak	O

Levonorgestrel	B-Drug
is	O
released	O
at	O
a	O
constant,	O
gradual	O
rate	O
of	O
0.02	O
mg	O
per	O
day	O
by	O
the	O
polydimethylsiloxane	O
membrane	O
device,	O
which	O
renders	O
it	O
effective	O
for	O
up	O
to	O
5	O
years.	O

At	O
low	O
doses,	O
levonorgestrel	B-Drug
is	O
used	O
in	O
monophasic	O
and	O
triphasic	O
formulations	O
of	O
combined	O
oral	O
contraceptive	O
pills,	O
with	O
available	O
doses	O
ranging	O
from	O
100	O
to	O
250	O
g,	O
50	O
g/75	O
g/125	O
g.	O

J&J	O
has	O
faced	O
numerous	O
civil	O
lawsuits	O
on	O
behalf	O
of	O
children	O
who	O
were	O
prescribed	O
risperidone	B-Drug
grew	O
breasts	O
(a	O
condition	O
called	O
gynecomastia);	O
as	O
July	O
2016	O
there	O
about	O
1,500	O
cases	O
in	O
Pennsylvania	O
state	O
court	O
Philadelphia,	O
and	O
had	O
been	O
a	O
February	O
2015	O
verdict	O
against	O
with	O
$2.5	O
million	O
awarded	O
to	O
man	O
from	O
Alabama,	O
$1.75M	O
that	O
November,	O
$70	O

crack,	O
heroin	B-Drug
Dream	O
with	O
the	O
Fishes	O
(1997)	O

Bupropion	B-Drug
treatment	O
also	O
is	O
not	O
associated	O
with	O
the	O
sleepiness	O
or	O
weight	O
gain	O
that	O
may	O
be	O
produced	O
by	O
other	O
antidepressants.	O

However,	O
thalidomide	B-Drug
is	O
a	O
teratogenic	O
substance,	O
and	O
proportion	O
of	O
children	O
born	O
during	O
the	O
1960s	O
were	O
afflicted	O
with	O
syndrome	O
known	O
as	O
embryopathy	O
(TE).	O

JWH-018	B-Drug
may	O
cause	O
intense	O
anxiety,	O
agitation,	O
and,	O
in	O
rare	O
cases	O
(generally	O
with	O
non-regular	O
JWH	O
users),	O
has	O
been	O
assumed	O
to	O
have	O
the	O
of	O
seizures	O
and	O
convulsions	O
by	O
inhibiting	O
GABA	O
neurotransmission	O
more	O
effectively	O
than	O
THC.	O
THC	B-Drug

There	O
is	O
evidence	O
that	O
suggests	O
the	O
molecular	O
target	O
of	O
amiloride,	O
ENaC,	O
also	O
implicated	O
in	O
cystic	O
fibrosis	O
due	O
to	O
its	O
effects	O
on	O
mucus	O
lungs.	O
amiloride	B-Drug

Cocaine,	O
caffeine,	O
and	O
cathinone	B-Drug
are	O
stimulants	O
of	O
the	O
central	O
nervous	O
system.	O
Cocaine	B-Drug

They	O
self-administer	O
cocaine	B-Drug
at	O
lower	O
doses	O
than	O
control,	O
but	O
have	O
a	O
greater	O
likelihood	O
of	O
relapse	O
when	O
the	O
drug	O
is	O
withheld.	O

A	O
national	O
referendum	O
in	O
November	O
2008	O
showed	O
68%	O
of	O
voters	O
supported	O
the	O
plan,	O
introducing	O
diamorphine	B-Drug
prescription	O
into	O
federal	O
law.	O

According	O
to	O
federal	O
laws,	O
methadone	B-Drug
cannot	O
be	O
prescribed	O
by	O
a	O
doctor	O
and	O
obtained	O
from	O
pharmacy	O
in	O
order	O
treat	O
addiction.	O

Fentanyl	B-Drug
patches	O
for	O
cancer	O
pain	O
are	O
on	O
the	O
World	O
Health	O
Organization's	O
List	O
of	O
Essential	O
Medicines.	O

Etizolam	B-Drug
overdose	O
deaths	O
are	O
rising	O
-	O
for	O
instance,	O
the	O
National	O
Records	O
of	O
Scotland	O
report	O
on	O
drug-related	O
deaths,	O
implicated	O
548	O
from	O
'street'	O
in	O
2018,	O
almost	O
double	O
number	O
2017	O
(299)	O
and	O
only	O
six	O
years	O
first	O
recorded	O
death	O
(in	O
2012).	O

Though	O
it	O
is	O
labeled	O
for	O
dog	O
use	O
only,	O
selegiline	B-Drug
has	O
been	O
used	O
off-label	O
geriatric	O
cats	O
with	O
cognitive	O
dysfunction.	O

It	O
is	O
likely	O
that	O
the	O
higher	O
THC	B-Drug
content	O
allows	O
people	O
to	O
ingest	O
less	O
tar.	O

Decreased	O
plasma	O
levels	O
of	O
buspirone	B-Drug
Nefazodone:	O
Nefazodone	B-Drug

Studies	O
have	O
found	O
that	O
children	O
exposed	O
to	O
cocaine	B-Drug
during	O
fetal	O
development	O
experience	O
problems	O
with	O
language,	O
behavior,	O
development,	O
and	O
attention.	O

Androstenedione	B-Drug
is	O
a	O
substrate	O
for	O
estrogen	O
production	O
in	O
granulosa	O
cells	O
which	O
produce	O
aromatase.	O

The	O
wall	O
is	O
thickened,	O
and	O
the	O
functional	O
bladder	O
capacity	O
as	O
low	O
10150	O
mL.Management	O
of	O
ketamine-induced	O
cystitis	O
involves	O
ketamine	B-Drug
cessation	O
first	O
step.	O

Chinese	O
emigrants	O
to	O
cities	O
such	O
as	O
San	O
Francisco,	O
London,	O
and	O
New	O
York	O
brought	O
with	O
them	O
the	O
manner	O
of	O
opium	B-Drug
smoking,	O
social	O
traditions	O
den.	O

Etonogestrel	B-Drug
has	O
about	O
20%	O
of	O
the	O
affinity	O
metribolone	O
and	O
50%	O
levonorgestrel	B-Drug
for	O
androgen	O
receptor	O
(AR)	O
while	O
desogestrel	B-Drug
no	O
this	O
receptor.	O

Furthermore,	O
some	O
testing	O
procedures	O
employ	O
a	O
hydrolysis	O
step	O
before	O
quantitation	O
that	O
converts	O
many	O
of	O
the	O
metabolic	O
products	O
to	O
morphine,	O
yielding	O
result	O
may	O
be	O
2	O
times	O
larger	O
than	O
with	O
method	O
examines	O
each	O
product	O
individually.	O
morphine	B-Drug

He	O
was	O
indicted	O
in	O
2007	O
for	O
possession	O
with	O
intent	O
to	O
distribute	O
cocaine.	O
cocaine	B-Drug

Bevacizumab	B-Drug
inhibits	O
the	O
growth	O
of	O
blood	O
vessels,	O
which	O
is	O
part	O
body's	O
normal	O
healing	O
and	O
maintenance.	O

Rodent	O
studies	O
of	O
the	O
tolerance-inducing	O
properties	O
have	O
shown	O
that	O
zolpidem	B-Drug
has	O
less	O
tolerance-producing	O
potential	O
than	O
benzodiazepines,	O
but	O
in	O
primates,	O
was	O
same	O
as	O
seen	O
with	O
benzodiazepines.	O

Methadone	B-Drug
has	O
a	O
typical	O
elimination	O
half-life	O
of	O
15	O
to	O
60	O
hours	O
with	O
mean	O
around	O
22.	O

It	O
works	O
by	O
blocking	O
the	O
effects	O
of	O
progesterone,	O
making	O
cervix	O
easier	O
to	O
open,	O
and	O
promoting	O
contraction	O
uterus	O
when	O
exposed	O
misoprostol.	O
misoprostol	B-Drug

cocaine,	O
alcohol,	O
methamphetamine,	O
zidovudine,	O
zalcitabine,	O
peptide	O
T	O
Danger	O
Diabolik	O
(1968)	O
cocaine	B-Drug
methamphetamine	B-Drug
zidovudine	B-Drug
zalcitabine	B-Drug

Later,	O
on	O
a	O
trip	O
to	O
Panama	O
launder	O
money,	O
Sito	O
contacts	O
traffickers	O
who	O
want	O
introduce	O
cocaine	B-Drug
into	O
Europe	O
through	O
Galicia.	O

It	O
is	O
recommended	O
that	O
alternatives	O
to	O
spironolactone	B-Drug
be	O
considered	O
if	O
serum	O
creatinine	O
greater	O
than	O
2.5	O
mg/dL	O

Butorphanol	B-Drug
is	O
a	O
commonly	O
used	O
narcotic	O
for	O
pain	O
relief	O
in	O
horses.	O

About	O
448	O
tons	O
of	O
heroin	B-Drug
were	O
made	O
in	O
2016.	O

Unlike	O
morphine	B-Drug
and	O
like	O
codeine,	O
oxycodone	B-Drug
has	O
a	O
good	O
oral	O
potency.	O
codeine	B-Drug

The	O
abuse	O
of	O
oxycodone	B-Drug
in	O
Canada	O
became	O
a	O
problem.	O

Grof	O
observed	O
four	O
levels	O
of	O
the	O
LSD	B-Drug
experience,	O
which	O
for	O
him	O
correspond	O
to	O
areas	O
human	O
unconscious:	O
(1)	O
Abstract	O
and	O
aesthetic	O
experiences	O
(2)	O

Also,	O
that	O
marijuana	O
legalization	O
would	O
yield	O
tax	O
revenue	O
of	O
$2.4	O
billion	O
annually	O
if	O
it	O
were	O
taxed	O
like	O
all	O
other	O
goods	O
and	O
$6.2	O
at	O
rates	O
comparable	O
to	O
those	O
on	O
alcohol	O
tobacco.	O
tobacco	B-Drug

This	O
causes	O
confounding	O
factors,	O
where	O
questions	O
arise	O
as	O
to	O
whether	O
the	O
tobacco,	O
cannabis,	O
or	O
both	O
that	O
have	O
caused	O
a	O
cancer.	O
tobacco	B-Drug

TRV734	O
is	O
an	O
oral	O
follow-up	O
to	O
the	O
injected	O
TRV130	B-Drug
mu-opioid	O
biased	O
ligand	O
program.	O

Sibutramine	B-Drug
and	O
its	O
two	O
active	O
N-demethylated	O
metabolites	O
may	O
be	O
measured	O
in	O
biofluids	O
by	O
liquid	O
chromatography-mass	O
spectrometry.	O

Diclofenac	B-Drug
eye	O
drops	O
have	O
also	O
been	O
used	O
to	O
manage	O
pain	O
for	O
traumatic	O
corneal	O
abrasion.	O

Her	O
death	O
was	O
caused	O
by	O
some	O
combination	O
of	O
burns,	O
phenobarbital,	O
and	O
carbon	O
monoxide	O
poisoning;	O
many	O
theories	O
about	O
her	O
have	O
been	O
posited,	O
it	O
is	O
believed	O
that	O
she	O
may	O
a	O
spy.	O
phenobarbital	B-Drug

UR-144	B-Drug
was	O
detected	O
in	O
Korea,	O
2012.	O

The	O
FDA	O
reported	O
in	O
April	O
2012	O
that	O
twelve	O
young	O
children	O
had	O
died	O
and	O
more	O
made	O
seriously	O
ill	O
from	O
separate	O
accidental	O
exposures	O
to	O
fentanyl	B-Drug
skin	O
patches.	O

Patients	O
already	O
prescribed	O
oxycodone	B-Drug
will	O
receive	O
coverage	O
for	O
an	O
additional	O
year	O
OxyNeo,	O
and	O
after	O
that,	O
it	O
be	O
disallowed	O
unless	O
designated	O
under	O
the	O
exceptional	O
access	O
program.	O

With	O
alprazolam	B-Drug
a	O
short-acting	O
benzodiazepine	O
taken	O
for	O
8	O
weeks,	O
65%	O
of	O
patients	O
experienced	O
significant	O
rebound	O
anxiety.	O

There	O
is	O
no	O
known	O
documentation	O
of	O
death	O
attributed	O
to	O
the	O
use	O
5-MeO-MiPT	B-Drug
alone.	O

